UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
40-F/A
(Amendment No. 1)
[X] Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934
or
[ ] Annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934
For the fiscal year ended __________________ Commission File Number __________________
THE FLOWR
CORPORATION
(Exact name of Registrant as specified in its
charter)
Ontario, Canada | 2833 | N/A |
(Province or other jurisdiction of | (Primary Standard Industrial Classification | (I.R.S. Employer |
incorporation or organization) | Code Number) | Identification Number) |
461 King Street West
Toronto, Ontario M5V
1K4
Canada
(647) 483-7065
(Address and
telephone number of Registrants principal executive offices)
DL Services Inc.
701 Fifth Avenue, Suite
6100
Seattle, Washington 98104-7043
(206)
903-8800
(Name, address (including zip code) and telephone number
(including
area code) of agent for service in the United States)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class | Name of each exchange on which registered |
Common Shares, no par value | The NASDAQ Stock Market LLC |
Securities registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
For annual reports, indicate by check mark the information filed with this Form:
[ ] Annual information form | [ ] Audited annual financial statements |
Indicate the number of outstanding shares of each of the registrants classes of capital or common stock as of the close of the period covered by the annual report: N/A
Indicate by check mark whether the registrant: (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Exchange Act
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports); and (2) has been subject to such filing
requirements for the past 90 days.
[ ]
Yes [X] No
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit
such files).
[ ]
Yes [ ] No
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 12b-2 of the Exchange Act.
[X]
Yes [ ] No
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
EXPLANATORY NOTE
The Flowr Corporation (the Company or the Registrant) is a Canadian public company whose common shares are listed on the TSX Venture Exchange (the Exchange). The Company is a foreign private issuer as defined in Rule 405 under Securities Exchange Act of 1934, as amended (the Exchange Act), and is eligible to file this registration statement on Form 40-F (the Registration Statement) pursuant to the Canada/United States multi-jurisdictional disclosure system (the MJDS). The Company filed a Registration Statement on Form 40-F (the Registration Statement) on February 5, 2019.
The Company is filing this Amendment No. 1 to the Registration Statement for the purposes of furnishing additional Exhibit No. 99.54 through Exhibit No. 99.85 thereto and providing the financial information for the year ended December 31, 2018. No other amendment to the Registrants Registration Statement is being effected hereby.
PRINCIPAL DOCUMENTS
In accordance with General Instruction B.(1) of Form 40-F, the Company hereby incorporates by reference Exhibits 99.1 through 99.85 , as set forth in the Exhibit Index attached hereto. In accordance with General Instruction D.(5) of Form 40-F, the Company hereby incorporates by reference Exhibit 99.53 , as set forth in the Exhibit Index attached hereto. In accordance with General Instruction D.(9) of Form 40-F, the Company has filed a consent of MNP, LLP as Exhibit 99.54.
TAX MATTERS
Purchasing, holding, or disposing of securities of the Company may have tax consequences under the laws of the United States and Canada that are not described in this registration statement on Form 40-F.
DESCRIPTION OF COMMON SHARES
The common shares of the Company have the following rights, privileges, restrictions and conditions:
1. |
Voting Rights. The holders of the common shares shall be entitled to receive notice of and to attend all meetings of the shareholders of the Company and shall confer the right to one (1) vote for each common share held at all meetings of the shareholders of the Company, except for meetings at which only holders of another class or series of shares of the Company are entitled to vote separately as a class or series. | |
2. |
Dividends. The holders of the common shares shall be entitled to receive, as and when properly declared by the board of directors of the Company dividends on the common shares at any time outstanding which the directors may determine to declare and pay in any fiscal year of the Company, provided that the directors shall declare dividends on the preferred shares, or on any other class of shares without being obliged to declare any dividends on the common shares of the Company. | |
3. |
Liquidation, Dissolution and Winding-up. In the event of the liquidation, dissolution or winding up of the Company, whether voluntary of involuntary, or any other distribution of assets of the Company among its shareholders for the purpose of winding up its affairs, subject to the prior rights of the holders of the preferred shares and to any other shares ranking equal to the common shares, the holders of the common shares shall be entitled to receive the remaining property and assets of the Company. |
FORWARD-LOOKING STATEMENTS
Certain statements contained or incorporated by reference in this document constitute forward-looking statements. When used in this document, the words may, would, could, will, intend, plan, propose, anticipate, believe, used by any of the Companys management, are intended to identify forward-looking statements. Such statements reflect the Companys forecasts, estimates and expectations, as they relate to the Companys current views based on their experience and expertise with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Companys actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. There can be no assurance that it will be completed as proposed or at all. The Company does not intend, and does not assume any obligation, to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments unless required by law.
2
OFF-BALANCE SHEET ARRANGEMENTS
The Company has no off-balance sheet arrangements.
CONTRACTUAL OBLIGATIONS
The following table lists, as of December 31, 2018, information with respect to the Companys known contractual obligations in Canadian dollars.
Payments due by period | |||||||||||||||
Less than | More than | ||||||||||||||
Contractual Obligations | Total | 1 year | 1-3 years | 3-5 years | 5 years | ||||||||||
Long-Term Debt Obligations | 1,592 | 288 | 1,304 | - | - | ||||||||||
Capital (Finance) Lease Obligations | - | - | - | - | - | ||||||||||
Operating Lease Obligations | 7,864 | 455 | 990 | 565 | 5,854 | ||||||||||
Purchase Obligations | 2,002 | 2,002 | - | - | - | ||||||||||
Other Long-Term Liabilities Reflected on the Companys | - | - | - | - | - | ||||||||||
Balance Sheet under IFRS of the primary financial statements | |||||||||||||||
Total | 11,458 | 2,745 | 2,294 | 565 | 5,854 |
NASDAQ CORPORATE GOVERNANCE
A foreign private issuer that follows home country practices in lieu of certain provisions of the NASDAQ Stock Market Rules must disclose the ways in which its corporate governance practices differ from those followed by domestic companies. As required by NASDAQ Rule 5615(a)(3), the Company will disclose on its website, as of the listing date, each requirement of the NASDAQ Stock Market Rules that it does not follow and describe the home country practice followed in lieu of such requirements.
UNDERTAKING
Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to: the securities registered pursuant to Form 40-F; the securities in relation to which the obligation to file an annual report on Form 40-F arises; or transactions in said securities.
CONSENT TO SERVICE OF PROCESS
The Company has previously filed a Form F-X in connection with the class of securities to which this Registration Statement relates.
Any change to the name or address of the Companys agent for service shall be communicated promptly to the Commission by amendment to the Form F-X referencing the file number of the Company.
3
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Company certifies that it meets all of the requirements for filing on Form 40-F/A and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized.
THE FLOWR CORPORATION | ||
By: | /s/ Alex Dann | |
Name: Alex Dann | ||
Title: Chief Financial Officer |
Date: May 28, 2019
4
EXHIBIT INDEX
The following documents are being filed with the Commission as Exhibits to this Registration Statement:
Exhibit |
Description |
99.1* |
Certification of Annual Filings by CFO dated August 29, 2017 |
99.2* |
Certification of Annual Filings by CEO dated August 29, 2017 |
99.3* |
Material change report filed September 18, 2017 |
99.4* |
Managements Discussion and Analysis of The Needle Capital Corporation for the three and nine months ended September 30, 2017 |
99.5* |
Certification of Interim Filings by CFO dated November 29, 2017 |
99.6* |
Certification of Interim Filings by CEO dated November 29, 2017 |
99.7* |
Interim Consolidated Financial Statements of The Needle Capital Corporation for the three months ended September 30, 2017 |
99.8* |
Managements Discussion and Analysis of The Needle Capital Corporation for the three and six months ended December 31, 2017 |
99.9* |
Certification of Interim Filings by CFO dated February 23, 2018 |
99.10* |
Certification of Interim Filings by CEO dated February 23, 2018 |
99.11* |
Management Information Circular dated March 9, 2018 in connection with the April 13, 2018 Annual and Special Meeting of Shareholders |
99.12* |
Form of proxy dated March 9, 2018 |
99.13* |
Certification of Interim Filings by CFO dated May 30, 2018 |
99.14* |
Certification of Interim Filings by CEO dated May 30, 2018 |
99.15* |
Interim Consolidated Financial Statements of The Needle Capital Corporation for the three and nine months ended March 31, 2018 |
99.16* |
Filing statement dated September 19, 2018 |
99.17* |
Material change report filed September 26, 2018 |
99.18* |
Articles of Amendment dated September 20, 2018 |
99.19* |
Business Combination Agreement dated August 27, 2018 among The Flowr Corporation, The Needle Capital Corp. and 262253 Ontario Inc. |
99.20* |
Amendment to Business Combination Agreement dated September 10, 2018 |
99.21* |
Articles of Continuance dated September 25, 2018 |
99.22* |
Press release dated October 3, 2018 |
99.23* |
Press release dated October 4, 2018 |
99.24* |
Press release dated October 10, 2018 |
99.25* |
Press release dated October 11, 2018 |
99.26* |
Press release dated October 12, 2018 |
99.27* |
Press release dated October 25, 2018 |
99.28* |
Code of conduct (employee handbook) filed October 26, 2018 |
99.29* |
Notice filed October 31, 2018 of change in corporate structure |
99.30* |
Audited Financial Statements of The Needle Corporation for the year ended June 30, 2018 and the period from June 1, 2016 to June 30, 2017 |
99.31* |
Managements Discussion and Analysis of The Needle Corporation for the year ended June 30, 2018 |
99.32* |
Certification of Annual Filings by CFO dated November 2, 2018 |
99.33* |
Certification of Annual Filings by CEO dated November 2, 2018 |
99.34* |
Press release dated November 9, 2018 |
99.35* |
Press release dated November 26, 2018 |
99.36* |
Condensed Interim Consolidated Financial Statements of the Company for the three and nine month period ended September 2018 and 2017 |
99.37* |
Managements Discussion and Analysis of the Company for the three and nine months ended September 30, 2018 and 2017 |
99.38* |
Certification of Interim Filings by CFO dated November 28, 2018 |
99.39* |
Certification of Interim Filings by CEO dated November 28, 2018 |
99.40* |
Press release dated November 28, 2018 |
99.41* |
Press release dated November 30, 2018 |
5
*Previously filed
6
Consent of Independent Registered Public Accounting Firm
The Board of Directors
The Flowr Corporation
We consent to the use in this Registration Statement on Form 40-F/A of:
1. | our report, dated October 26, 2018, on the financial statements of The Needle Capital Corp. which comprise the statements of financial position as at June 30, 2018 and June 30, 2017, and the statements of loss and other comprehensive loss, changes in shareholders equity and cash flows for the year ended June 30, 2018 and the period from June 1, 2016 (date of incorporation) to June 30, 2017 and notes, comprising a summary of significant accounting policies and other explanatory information, |
|
|
||
2. | our report, dated April 4, 2019, on the consolidated financial statements of The Flowr Corporation, which comprise the consolidated statements of financial position as at December 31, 2018 and 2017, and the consolidated statements of loss, changes in shareholders equity and cash flows for the years ended December 31, 2018 and December 31, 2017, and a summary of significant accounting policies and other explanatory information. |
which is included in this Registration Statement on Form 40-F/A being filed by The Flowr Corporation with the United States Securities and Exchange Commission.
Mississauga, Ontario | Chartered Professional Accountants |
May 28, 2019 | Licensed Public Accountants |
Flowr Applies for NASDAQ Listing
TORONTO, FEBRUARY 5, 2019 The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF) (Flowr or the Company), a Canadian licenced producer of premium cannabis products, announced today that it has submitted an application to list its common shares on The NASDAQ Capital Market (NASDAQ) and has filed a Form 40-F Registration Statement with the U.S. Securities and Exchange Commission (SEC).
The listing of Flowrs shares on the NASDAQ will be subject to a number of regulatory requirements, including registration of the common shares with the SEC and a determination by the NASDAQ that Flowr has satisfied all applicable listing requirements. Subject to approval for listing, the common shares will continue to trade on the TSX Venture Exchange (TSXV) under FLWR. A trading date will be made public once all regulatory formalities are satisfied.
"Flowr has made tremendous progress executing on its business plan since becoming a public company last year and we believe the Company is well positioned to pursue additional growth opportunities," said Vinay Tolia, Flowrs Co-CEO. "A NASDAQ listing is an important step forward for Flowr because we believe it will broaden our access to international investors as we become a truly global company."
About Flowr
The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF), through its subsidiaries, holds a cannabis production and sales licence granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own patented growing systems. Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Vinay
Tolia
Co-CEO
Contacts
Media |
Jim Walsh: +1.607.275.7141, jwalsh@flowr.ca |
Bruce Dunbar: +1.917.756.4065, bdunbar@flowr.ca |
Investors |
Bram Judd: +1.905.940.3993 ext.1520, bram@flowr.ca |
Notice Regarding Forward-Looking Information
This press release includes forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws. Any statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Often, but not always, forward-looking information can be identified by the use of words such as plans, expects, scheduled, intends, contemplates, anticipates, believes, proposes or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results may, could, should, would, might or will be taken, occur or be achieved. Forward-looking statements regarding Flowr and its business include, but are not limited to, statements with respect to: the potential listing of Flowrs common shares on NASDAQ, the timing thereof, the benefits to be provided to the Company by a NASDAQ listing, opportunities for Flowrs growth, Flowr becoming a truly global company, Flowrs exposure to international investors and the liquidity of Flowrs securities, Flowrs facilities being designed and constructed to GMP standards, Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market and other factors. Such statements are based on the current expectations of Flowrs management and are based on assumptions and subject to risks and uncertainties. Although Flowrs management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks relating to the listing of Flowrs securities on the NASDAQ, the failure to obtain necessary approvals to list and register Flowrs securities in the United States, a shutdown of the United States government, the NASDAQ listing not providing Flowr with broadened access to international investors or enhance Flowrs liquidity, the Company not expanding globally, which could result in the Company not having a diversified business platform for growth, the Company not being well positioned to pursue additional opportunities for growth, or such opportunities no longer being available to Flowr, the inability of Flowr to construct or maintain its facilities at GMP standards, which could significantly impact sales of Flowrs products, Flowrs cultivation team not employing exacting protocols throughout the growing and curing process, which could impact the quality of the products and the experience for customers, Flowr not being able to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market, demand for cannabis products decreasing, including with respect to Flowrs products, the inability of Flowr to provide what it perceives to be much-needed, high quality product to the market, the inability of Flowr to control the growing environment in its facilities, which could result in loss of products or the need to irradiate products, thus impacting the supply and demand for and/or quality of the products, Flowr requiring additional financing from time to time in order to continue its operations and construct its facilities and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Companys business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowrs products to be high quality, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, which could result in significant penalties or costs being imposed on Flowr, Flowrs securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowrs products, the cannabis industry an d the regulation thereof, the failure to comply with applicable laws, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowrs products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowrs filings with the Securities and Exchange Commission and Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
- ends -
Flowr Partners with Celebrated Canadian Chef Ryan Reed to Develop Premium Edibles and Engages ICR
Chef Ryan will join Flowrs world-class R&D team to research and develop high-quality edible products
KELOWNA, March 1, 2019 - The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF) (Flowr or the Company), a Canadian Licensed Producer of premium cannabis products, today announced the hiring of celebrated Canadian Chef Ryan Reed to develop signature edible cannabis products for the Flowr brand. Chef Ryan, a past winner of Iron Chef and Chopped and Victorias 2011 Chef of the Year, will collaborate closely with Flowr's R&D Team to research and develop high-quality edibles. Like the brands existing product, it is the Companys intention to target the needs of a premium client with this new line. Flowr expects that customers will be able to purchase these unique, gourmet products once launched following the anticipated legalization of edibles and infused products in Q4 2019.
The hiring of Chef Ryan complements Flowrs already significant investment in research and development, said Tom Flow, Flowrs Co-CEO. This includes our dedicated, state-of-the-art cannabis R&D facility, a North American first, our exclusive partnership with Hawthorne Gardening Company, a subsidiary of The Scotts Company, a world leader in lawn and garden products, and the recent hiring of Deron Caplan, North Americas First Cannabis Cultivation Ph.D., said Flow.
One POV in the analyst report published by Jefferies Financial earlier this week is that investment in R&D, including strategic hires, creates value for cannabis companies.1 That has always been Flowrs belief. Bringing Chef Ryan into the fold is the next step in a focused R&D strategy that has created a competitive advantage for Flowr and will keep us on the cutting edge of cannabis innovation, added Dr. Lyle Oberg, Chief Policy and Medical Officer of Flowr and a former Finance Minister of Alberta.
"Im thrilled to join the Flowr Family. Its an honour and a pleasure to join a company that is ride or die on technique, quality and innovation, said Chef Ryan.
A kitchen and a cultivation facility both require leaders with technical mastery to truly innovate. Tom Flow spent years mastering the craft of growing fine cannabis. Like Tom, Ive put in the time. Ive been a garde manger, a saucier, an entremetier as well as a head chef. Now I look forward to working with Tom and the team to bring gourmet, sophisticated edibles that are intended to cater to the needs of a premium customer to market, he added.
Flowr Engages ICR to Enhance Investor Relations, Media Relations, and Corporate Communications
Separately, Flowr also announced that it has engaged ICR, a leading strategic communications and advisory firm, to enhance the Company’s investor relations, media relations and corporate communications program.
“ICR’s capital markets and financial media expertise, combined with its significant experience in the cannabis, CPG and retail sectors is expected to enhance our communications to all of our stakeholders, broaden exposure to investors, and deepen the financial communities’ understanding of Flowr’s differentiated business model, growth strategy and market opportunity. We are excited to partner with ICR,” concluded Mr. Flow.
Flowr has engaged ICR to provide comprehensive investor relations and corporate communications services for a six-month period at an agreed upon monthly retainer fee, with the total cost of such fees being not more than US$150,000. Neither ICR nor any of its principals have an ownership interest, directly or indirectly, in Flowr or its securities, and the Company has not granted ICR or its principals any right to acquire such interests.
About ICR
Established in 1998, ICR partners with companies to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 650 clients in approximately 20 industries. ICR’s healthcare practice operates under the Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Francisco, San Diego and Beijing. ICR also advises on capital markets transactions through ICR Capital, LLC.
Learn more at www.icrinc.com. Follow ICR on Twitter at @ICRPR.
About Flowr
Flowr, through its subsidiaries, holds a cannabis production and sales licence granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own patented growing systems. Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Tom Flow
Co-CEO
Notice Regarding Forward-Looking Information
This press release includes forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws. Any statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements regarding Flowr and its business include, but are not limited to, statements with respect to: Flowr’s intention to develop edible cannabis products, Chef Ryan collaborating closely with Flowr’s R&D team to research and develop high-quality edibles, Chef Ryan working closely with Tom Flow and others at the Company to bring edible products to market, the Company’s intention to target the needs of premium clients with a new line of edibles, the Company’s expectation for when customers will be able to purchase any edible and/or infused products, Flowr’s belief that investment in R&D, including strategic hires, creates value for cannabis companies, any next steps in Flowr’s R&D Strategy and the ability of those steps to create a competitive advantage for the Company, Flowr continuing to be on the cutting edge of cannabis innovation, ICR enhancing the Company’s investor relations, media relations, and corporate communications program, ICR’s ability to enhance communications to the Company’s stakeholders, broaden exposure to investors and deepen the financial communities’ understanding of Flowr’s differentiated business model, growth strategy and market opportunity, Flowr’s facilities being designed and constructed to GMP standards, Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market and other factors. Such statements are based on the current expectations of Flowr’s management and are based on assumptions and subject to risks and uncertainties. Although Flowr’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks relating to the inability of the Company to develop edible products, the inability of the Company to bring edible products to market, the anticipated legalization of edible and infused products failing to occur and/or a legal market for edible and infused products not developing, investment in R&D, including strategic hires not creating value for the Company, Flowr’s R&D strategy failing to create a competitive advantage for the Company, the Company’s inability to remain on the cutting edge of cannabis innovation, , ICR being unable to enhance the Company’s investor relations, media relations, and corporate communications program, ICR’s inability to enhance communications to the Company’s stakeholders, broaden exposure to investors and deepen the financial communities’ understanding of Flowr’s differentiated business model, growth strategy and market opportunity, the inability of Flowr to construct or maintain its facilities at GMP standards, which could significantly impact sales of Flowr’s products, Flowr’s cultivation team not employing exacting protocols throughout the growing and curing process, which could impact the quality of the products and the experience for customers, Flowr not being able to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market, demand for cannabis products decreasing, including with respect to Flowrs products, the inability of Flowr to provide what it perceives to be much-needed, high quality product to the market, the inability of Flowr to control the growing environment in its facilities, which could result in loss of products or the need to irradiate products, thus impacting the supply and demand for and/or quality of the products, Flowr requiring additional financing from time to time in order to continue its operations and construct its facilities and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Companys business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowrs products to be high quality, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, which could result in significant penalties or costs being imposed on Flowr, Flowrs securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowrs products, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowrs products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowrs filings with the Securities and Exchange Commission and Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
The information contained or referred to in this press release relating to ICR under the heading About ICR has been provided by ICR. Although Flowr has no knowledge that would indicate that any statements contained herein concerning ICR are untrue or incomplete, neither Flowr nor any of its directors or officers assumes any responsibility for the accuracy or completeness of such information or for any failure by ICR to ensure disclosure of events or facts that may have occurred which may affect the significance or accuracy of any such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
1The Flowr Corporation (Flowr) is not affiliated with Jeffries Financial, and Flowr has not endorsed the contents of the Jeffries Financial analyst report. Any opinions, forecasts or estimates about Flowrs performance made by Jeffries Financial are theirs alone. They do not represent opinions, predictions or forecasts of Flowr or its management. By its reference in this press release, Flowr does not imply its endorsement of, or agreement with such information, recommendations or conclusions. In addition, Flowr has not independently verified the accuracy or completeness of the information contained in the report.
- ends -
Contacts |
Media |
Rebecca Brown: +1.647.456.5599, rebecca@crowns.agency |
Investors |
Bram Judd: +1.905.940.3993 ext.1520, bram@flowr.ca |
FLOWR PROMOTES JASON BROOME M.SC. TO CHIEF RESEARCH AND INNOVATION OFFICER
Mr. Broome will lead the development of premium cannabis products for the global market
KELOWNA, BC, March 6, 2019 - The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF) (Flowr or the Company), a Canadian licensed producer of premium cannabis products, today announced the promotion of Jason Broome to the role of Chief Research and Innovation Officer (CRIO). Mr. Broome previously served as Senior Vice President of Operations.
As CRIO, Mr. Broome will develop new high-quality products and lead Flowrs research into cultivars, form factors and delivery systems for the global markets. He will also oversee Flowrs state-of-the-art R&D facility, part of an exclusive partnership with Hawthorne Canada, a subsidiary of The Scott's Miracle-Gro Corporation (NYSE: SMG).
Flowrs product innovation portfolio must meet the world-class standards of our cultivation, said Tom Flow, Flowr's Co-CEO. Its an unusually demanding ask, but Jasons expertise across all aspects of product development, from molecule to market, is unique and yet totally in keeping with Flowrs high-performance, high-creativity culture.
Over a 15-year career in the pharmaceutical industry, Mr. Broome led the commercialization of major pharmaceutical brands and built, operated and sold several healthcare-related companies, bringing disruptive technologies and systems to market. Within the cannabis sector, he was co-founder of the first company licensed to cultivate and extract hemp in the state of Kentucky and COO of a Colorado manufacturer of CBD oil. He holds a masters degree in Molecular Genetics from the University of Ottawa.
Mr. Broomes appointment is a natural and dynamic step forward for Flowr, working closely with Dr. Lyle Oberg, Chief Policy and Medical Officer, and in line with the recent hiring of Dr. Deron Caplan, North Americas first cannabis cultivation Ph.D., and Chef Ryan Reed, both to the Companys R&D department.
About Flowr
Flowr, through its subsidiaries, holds a cannabis production and sales licence granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own patented growing systems. Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation
On behalf of The Flowr Corporation:
Tom Flow
Co-CEO and Director
Contacts
Media
Rebecca Brown: +1.647.456.5599, rebecca@crowns.agency
Investors
Bram Judd: +1.905.940.3993 ext.1520, bram@flowr.ca
Forward-Looking Information
This press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr and its business, which may include, but are not limited to: the facilities described herein, including, without limitation, the timing of construction and completion thereof, the expertise and experience of Mr. Broome, Mr. Broome developing new high-quality products, Mr. Broome leading Flowr’s research into cultivars, form factors and delivery systems, Mr. Broome overseeing Flowr’s state-of-the-art R&D facility, Flowr’s vision to be on the cutting edge of cultivation, Flowr’s world class standards in cultivation, Flowr developing new products for global markets, Flowr’s R&D program and its focus on improving cultivation techniques and systems and developing cannabis plants that produce the highest quality flower and address specific needs in the medical and recreational markets, Flowr’s focus on producing premium quality cannabis at scale, the addition of Mr. Broome and the alliance with Hawthorne Canada strengthening Flowr’s position at the forefront of understanding the tools and techniques needed to grow great cannabis, the belief that Flowr’s R&D team and its partnership with Hawthorne uniquely positions Flowr to address genetic intricacies that drive the unique consumer experience produced by each strain and to cultivate a strain to maximize the natural expression of those genetics through its chemical components, Flowr’s intention to develop and test Hawthorne cultivation systems in the R&D facility, Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of Flowr’s management and are based on assumptions and subject to risks and uncertainties. Although Flowr’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks relating to Flowr’s inability to construct the facilities described herein, or in the time anticipated, Flowr’s inability to grow cannabis at scale, which could adversely impact revenues, the fact that the facilities described herein may not include all the elements described in this press release, which could adversely impact the partnership with Hawthorne, Flowr’s R&D strategy and/or Flowr’s revenues, the inability of Flowr to test Hawthorne’s cultivation systems, which could adversely impact the partnership described herein and future R&D initiatives of Flowr, Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities described herein or otherwise, Flowr’s inability to research genetics and cultivation data analytic systems, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Mr. Broome not bringing the experience or expertise described herein, Mr. Broome being unable to develop new high-quality products, Mr. Broome being unable to lead Flowr’s research into cultivars, form factors and delivery systems, Mr. Broome being unable to oversee Flowr’s state-of-the-art R&D facility, Flowr not being able to remain at the cutting edge of cultivation or maintain world-class standards for cultivation, Flowr’s R&D program not improving cultivation techniques and systems and not developing cannabis plants that produce the highest quality flower and address specific needs in the medical and recreational markets, which could result in Flowr losing its competitive edge and/or sales, the addition of Mr. Broome and the alliance with Hawthorne Canada not strengthening Flowr’s position at the forefront of understanding the tools and techniques needed to grow great cannabis or bring new products to market, which could significantly impact Flowr’s competitive edge with respect to cultivation, Flowr requiring additional financing from time to time in order to continue its operations and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Company’s business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowr’s products to be high quality, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowr’s securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowr’s products, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements, possible failure to realize the anticipated benefits of partnership arrangements, product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowr’s products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowr’s filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
-ends -
Amended and Restated Agreement
Among
The Flowr Group (Okanagan) Inc.
(Formerly known as
Cannatech Plant Systems Inc.)
And
The Flowr Canada Holdings ULC (Formerly known as The Flowr Cannabis ULC)
And
Hawthorne Canada Limited
This Amended and Restated Agreement (Agreement) is made this 14th day of December, 2018 (the Effective Date) by and between The Flowr Canada Holdings ULC (Formerly known as The Flowr Cannabis ULC), an unlimited liability company existing under the laws of the Province of British Columbia having a place of business at 100 Allstate Parkway, Suite 201, Markham, ON L3R 9R9 (hereinafter Flowr), The Flowr Group (Okanagan) Inc. (Formerly known as Cannatech Plant Systems Inc.), a British Columbia corporation having a place of business at Kelowna BC (hereinafter The LP), and Hawthorne Canada Limited, a Canadian corporation having a place of business at 2000 Argentia Road, Plaza 2, Suite 300, Mississauga, ON L5N 1V8 (hereinafter Hawthorne).
Whereas The LP has received a license, authorizing it as a licensed producer of cannabis, from Health Canada under the Cannabis Act (the Producer License);
Whereas The LP and Flowr have expertise in designing and building cannabis cultivation facilities and growing high quality cannabis;
Whereas Hawthorne is a subsidiary of The Scotts Miracle-Gro Company (SMG) and is focused on selling products and developing systems for cultivating a variety of plants and is interested in performing research, development and testing of its products, including the scientific exploration of various inputs, processes and products such as fertilizers, lights, nutrients, and pesticides (the Hawthorne R&D) on cannabis, solely in Canada pursuant to all applicable laws, regulatory policies, practices, protocols, guidelines and directives concerning the research, development, production, storage, possession, use, sale, handling, shipping, transportation, delivery and destruction of cannabis in Canada (collectively, the Cannabis Laws);
Whereas the parties previously entered into an Agreement dated January 25, 2018 (the Original Agreement) whereby Hawthorne retained The LP to oversee the construction of a research facility and provide certain research and development services, as further described herein; and
Whereas the design, budget and timeframe for the construction of the facility have evolved and the parties wish to amend and restate the Original Agreement.
NOW, THEREFORE, in consideration of the promises and mutual obligations contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, The LP, Flowr and Hawthorne agree as follows:
1
1. |
Responsibilities: |
a. |
The LP and Flowr will work with Hawthorne to design a research and development facility at the Kelowna Property, which will include ten (10) growing rooms dedicated to the research and development activities described herein of equal size to conduct the Hawthorne R&D (the Facility), as more particularly described in Section 3. | |
b. |
The Facility will be built on land owned by The LP that is civically known as 9580 McCarthy Road, Kelowna, BC (the Kelowna Property). The Facility and the Kelowna Property will be owned by The LP. | |
c. |
The LP will ensure that all operations at the Facility will be conducted in accordance with and under the authority of The LPs Producer License. | |
d. |
The LP agrees to obtain any other license or governmental approval required to carry out research and development at the Facility (the Other Licenses) in the event that 1) The LPs existing Producer License is deemed inadequate by a regulatory authority to conduct the Hawthorne R&D at the Facility; or 2) Other Licenses become necessary under applicable law to conduct the Hawthorne R&D at the Facility. | |
e. |
The parties agree that the structure of the research and development arrangements described in this Agreement, the Hawthorne R&D and the Facility will be designed to comply with all Health Canada and other relevant government regulations and Cannabis Laws. | |
f. |
As more particularly described in Sections 3 and 5 and Schedule 1, as consideration for The LPs provision of research and development services hereunder, Hawthorne will provide the following funding to The LP: |
a. |
a Loan (as defined in Section 3(j))for the design and construction of the Facility, up to a maximum aggregate amount of CAD $11,500,000 (the Cap).The Loan includes all costs and expenses incurred by The LP as of the Effective Date with respect to the design and construction of the Facility, as set forth in Schedule 2 hereof (the Reimbursable Expenses); | |
b. |
the Design and Construction Fee (as defined herein); and | |
c. |
the fees set forth in Schedule 1. |
g. |
The LP will supervise and manage the design and construction of the Facility as more particularly described in Section 3 and the staffing, operations and maintenance of the Facility as more particularly described in Section 5. | |
h. |
The LP will manage the day-to-day operations of the Facility including the Additional Employees (as defined in Section 11). |
2. |
Term: |
a. |
The term of this Agreement (the Term) shall commence on the Effective Date and expire twenty (20) years less one day after the first date on which the Hawthorne R&D can be conducted on the first floor of the Facility (the Opening Date). Notwithstanding the foregoing, provided Hawthorne is not in breach of this Agreement and, if in breach, such breach has not been cured by Hawthorne within thirty (30) days of the date of such breach, Hawthorne shall have the right to terminate this Agreement with or without cause on the date that is ten (10) years after the Opening Date and the date that is fifteen (15) years after the Opening Date without penalty. Provided that Hawthorne is not in breach of this Agreement and, if in breach, such breach has not been cured by Hawthorne within thirty (30) days of the date of such breach, Hawthorne shall also have the right to terminate this Agreement with or without cause on the date that is eight (8) years after the Opening Date, as set forth in further detail in Section 16 of this Agreement. |
2
3. |
Design and Build Out of the Facility: |
a. |
The LP agrees to manage and administer the design, development and construction of the Facility in accordance with the Approved Plans (as defined below), the Approved Development Budget (as defined below), the Approved Development Schedule (as defined below), all applicable zoning, building and construction laws, Cannabis Laws, regulatory policy, practice, protocol, guideline or directive, including, but not limited to, those concerning storage and physical security requirements for cannabis facilities (the Cannabis-Specific Requirements) and in accordance with and as otherwise provided in this Agreement and, in connection therewith, shall exercise that degree of care, diligence and skill that a reasonable and prudent development manager of a comparable property would exercise in comparable circumstances. Other than the Design and Construction Fee and the fees set forth in Schedule 1, no design, development management, construction management or other fees shall be paid to The LP or Flowr in connection with the management and administration of the design, development and construction of the Facility. The façade of the Facility shall be designed and constructed by The LP, provided that Hawthorne shall approve such design and construction, which approval shall not be unreasonably withheld, conditioned or delayed. In addition, the name of The LP or Flowr and Hawthorne Canada, a subsidiary of The Scotts Miracle- Gro Company, shall be placed on the front of the Facility during the Term of this Agreement, with the cost of such signage to be paid for by The LP and Hawthorne in equal proportion. In addition, should the parties agree to change the façade of the Facility (Façade Change), outside the scope of the façade included in the budget, any increase in the costs of the façade resulting from such Façade Change shall be paid for by The LP and Hawthorne in equal proportion. | |
b. |
The LP and Hawthorne, each acting reasonably and in good faith, will work together to complete the design of the Facility, provided that in the event of a disagreement as to the design of the Facility, the decision of Hawthorne shall be final and binding so long as it is commercially reasonable and complies with all Cannabis-Specific Requirements. The first floor of the Facility, when finished, is expected to total approximately 20,000 sq. ft. of indoor space. The design and construction of the Facility shall include the shell for a second floor and rooftop greenhouse (the Additional Floors), and the structural and other improvements (the Reinforcement Improvements) required to construct such Additional Floors. The Additional Floors shall not be used or be accessible to Hawthorne under the terms of this Agreement. |
c. |
The: |
a. |
schedule for the development and construction of the Facility agreed to by the parties is attached hereto as Exhibit C (the Approved Development Schedule); |
3
b. |
budget for the development and construction of the Facility agreed to by the parties is attached hereto as Exhibit A (the Approved Development Budget); and | |
c. |
design plans, specifications and drawings for the Facility agreed to by the parties is attached hereto as Exhibit B (the Approved Plans). |
d. |
Hawthorne shall have the right to review, comment and approve any changes to the Approved Plans, which approval shall not be unreasonably delayed, conditioned or withheld. |
e. |
As more particularly described in the Approved Development Budget, the anticipated cost to develop and construct the Facility, including, without limitation, the initial costs of the Reinforcement Improvements and the Design and Construction Fee is , which may be adjusted upon the mutual agreement of the parties as described in this Agreement. Notwithstanding anything to the contrary contained in this Agreement: |
a. |
the maximum aggregate amount of the development and construction costs relating to the Facility which Hawthorne is responsible to fund from the Loan shall not exceed the Cap; | |
b. |
within 30 days following the execution and delivery of this Agreement by all parties, Hawthorne shall pay to Flowr an amount equal to (the Design and Construction Fee), which amount shall not be included the Loan; and | |
c. |
upon execution of this Agreement, Hawthorne shall pay Flowr the Reimbursable Expenses, which amount shall be included in the Loan. |
For the avoidance of doubt, in no event will Hawthorne be responsible for development and construction-related costs and expenses in excess of those set forth directly above, provided that the parties shall discuss in good faith additional consideration that may be provided to The LP as a result of costs and expenses incurred by The LP in connection with the development and construction of the Facility resulting from the occurrence of an event of Force Majeure (as defined herein).
The Approved Development Budget does not include the cost of the Facility Equipment, which shall be the responsibility of Hawthorne (with the exception of the Facility Equipment that is included in or exclusively services the Flowr Rooms as set forth in Section 4) and will not be deducted from the amount of the Loan.
f. |
As more particularly set out in the Approved Development
Schedule, the parties have agreed to the following milestones (the
Milestones) and milestone dates (the Milestone Dates) in
connection with the development and construction of the
Facility: |
g. |
Any delay, amendment, alteration or other change proposed by Flowr which: |
a. |
has the effect of impacting any one or more of the Milestone Dates set out in the Approved Development Schedule by three days or more; or |
Redacted:
Commercially Sensitive Information
4
b. |
results in an increase or decrease to the Approved Development Budget by CAD $10,000 or more, |
will require Hawthornes prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed, provided that Hawthorne approves such delay, amendment, alteration or other change within 3 business days of receipt of a notice of such delay, amendment, alteration or change. If Hawthorne does not approve or reject such delay, amendment, alteration or change within such period, than such delay, amendment, alteration or change shall be deemed to be approved.
h. |
Any delay, amendment, alteration or other change which has not been approved or deemed to be approved by Hawthorne and that delays the occurrence of one or more of the Milestones by seven (7) business days or more (as compared to the Milestone Dates) and does not arise as a result of: |
a. |
an event of Force Majeure; | |
b. |
delays caused directly (whether by action or failure to act) by Hawthorne, including without limitation, changes to the design requested by Hawthorne which result in an extension to the Approved Development Schedule, |
will result in Hawthornes responsibility to advance funds under the Loan for the costs and expenses associated with the development and construction of the Facility being reduced by CAD $5,000 for each seven (7) business day period of delay (the Reduction Amount). The Reduction Amount shall not in any event exceed CAD $1,500,000. The Reduction Amount shall:
c. |
be the responsibility of Flowr and The LP; and | |
d. |
reduce the Cap by an equal amount. |
i. |
The LP will be responsible to tender and enter into the construction, material and supply contract(s) required in connection with the development and construction of the Facility with independent, qualified and experienced contractors and suppliers. With respect to any contract which is anticipated to be greater than CAD $100,000.00 in value, The LP must notify Hawthorne and will solicit a minimum of 2 bids. Prior to entering into any contract in connection with the development and construction of the Facility which is greater than CAD $100,000.00 in value or is in excess of the amount specified for such contract in the then-current Approved Development Budget or is with a person at non- arms length to Flowr or The LP, Flowr shall obtain the approval of Hawthorne, which approval shall not be unreasonably delayed, conditioned or withheld. Schedule 3 hereof contains a list of all contracts entered into by The LP that exceed CAD $100,000.00 in value or that are with a person at non-arms length to Flowr or The LP, and upon execution of this Agreement Hawthorne shall be deemed to have ap proved such contracts. |
j. |
All costs and expenses incurred in connection with the development and construction of the Facility, other than: |
a. |
the Design and Construction Fee; and | |
b. |
costs and expenses incurred in connection with the Reinforcement Improvements, |
up to the maximum amount of the Cap (as same may be adjusted in accordance with this Agreement) will be advanced by Hawthorne to The LP as a loan with interest charged at a rate of 4% per annum commencing on the Opening Date (the Loan). During the Term, the Loan and accrued interest will be repaid on a monthly basis commencing on the first payment date that the management fee included in Schedule 1 is paid to The LP (the Loan Repayments), with payment due within 15 (fifteen) days of month-end. Any amount due and payable by Hawthorne to The LP in respect of the SR&ED Services Fees (as defined in Section 5(j) may be offset in whole or in part against a Loan Repayment which is then due and payable. For the avoidance of doubt, Flowr will be responsible for the cost of the Reinforcement Improvements as well as all design and construction expenses above the Cap.
5
Hawthorne will be responsible to lend to The LP, in advance, cash for all soft and hard costs and expenses reasonably incurred in connection with the design and construction of the Facility (expressly excluding Direct Costs, the Design and Construction Fee and the costs and expenses incurred in connection with the Reinforcement Improvements) up to the amount of the Cap (collectively, the Approved Development Expenses) provided:
i. |
that such expenses are included in the then-current Approved Development Budget; | |
ii. |
with respect to expenses included in the then-current Approved Development Budget but exceeding the amount set out in the then-current Approved Development Budget, the aggregate amount of any such expense and the aggregate amount of all other expenditures of a similar category, type or nature in the Approved Development Budget, would be increased by less than 10% and the aggregate amount of the Approved Development Budget would be increased by less than 5% provided in no event shall Hawthorne be responsible to fund an amount under the Loan in excess of the Cap (as same may be adjusted in accordance with this Agreement); and | |
iii. |
with respect to any expense not included in the then-current Approved Development Budget, such expense was/will be incurred in connection with an emergency situation affecting the Facility or was approved in advance, in writing, by Hawthorne acting reasonably provided in no event shall Hawthorne be responsible to fund an amount under the Loan in excess of the Cap. |
On or prior to the fifteenth (15th) business day of each month, The LP shall deliver to Hawthorne a statement for a requested Loan draw in connection with the Approved Development Expenses to be incurred in the immediately following month together with reasonable evidence thereof. Subject to the immediately following sentences, Hawthorne shall pay The LP in advance for all such Approved Development Expenses within ten (10) business days after receipt of the statement. The parties acknowledge and agree that any request for a Loan draw in connection with Approved Development Expenses will include applicable provincial sales tax and not include any federal sales tax with respect to such Approved Development Expenses, and as a result The LP shall be entitled to any tax credits as a result of the payment or remittance of such federal sales tax to the applicable government authority. The parties also acknowledge and agree that the payment of provincial sales tax is not subject to a tax credit, and therefore in no event will either party be entitled to any tax credit as a result of the payment of provincial sales tax. Hawthorne has the right to request, and The LP shall promptly deliver, additional reasonable information relating to the Approved Development Expenses. Hawthorne shall not be required to lend funds to The LP for any Approved Development Expenses contained in a statement (1) for which Hawthorne has not received commercially reasonable supporting information; and (2) which Hawthorne, acting reasonably, disputes as an expense which is not an Approved Development Expense unless and until it has been finally determined or mutually agreed that such expense is an Approved Development Expense.
6
On a quarterly basis, The LP and Flowr will each provide to Hawthorne financial information including The LPs profit and loss statement, balance sheet, cash flow statement and any other documentation that Hawthorne reasonably requests.
k. |
The LP shall provide Hawthorne with a weekly update on development and construction progress as compared to the Approved Development Schedule and a reasonable explanation relating to any delays. | |
l. |
In every case where The LP requests Hawthornes review, approval or consent, Hawthorne will respond in a commercially reasonable timeframe not to exceed three (3) business days where Hawthorne, acting reasonably, is of the opinion that the review, approval or consent relates to a matter which is not material to the development, construction or budget for the Facility. In the case of a review, approval or consent which Hawthorne, acting reasonably, is of the opinion is material to the development, construction or budget for the Facility, Hawthorne shall have five (5) days to review. In the event Hawthorne exceeds the response times set forth in this Section 3(l), the timing set forth in the Approved Development Schedule and Milestone Dates, as applicable, will toll until Hawthorne delivers its review, approval or consent to The LP. | |
m. |
At any time after the date that is ninety (90) days after the Effective Date, Flowr and The LP shall have a right to elect to complete the design, development and construction of the Additional Floors (the Election). Flowr and The LP agree to provide Hawthorne with prior written notice of the Election. In the event that Hawthorne wishes to participate in completing the design, development and construction of the Additional Floors, it shall deliver written notice to Flowr and The LP within fifteen (15) business days of the receipt of the Election that it wishes to participate (the Participation Notice). If Hawthorne provides the Participation Notice to Flowr and The LP, then the parties will negotiate in good faith for a period of sixty (60) days a further agreement to complete the design, development and construction of the Additional Floors. Flowr shall be permitted to proceed with the completion of the design, development and construction of the Additional Floors without the participation of Hawthorne, if (i) Hawthorne does not submit a Participation Notice within the timeframes described herein, (ii) an agreement as described herein is not executed within the timeframes described herein, or (iii) Hawthorne elects not to participate in such completion of the design, development and construction of the Additional Floors, provided that: |
a. |
the completion of the development and construction of the Additional Floors will not materially interfere or disrupt the day-to-day operations of the Facility; and | |
b. |
prior to the commencement of the completion of the construction of the Additional Floors, the parties shall agree on the manner in which the completion of the construction of the Additional Floors shall proceed to ensure that the day-to-day operations of the Facility are not materially interfered with or disrupted. |
4. |
Acquisition of Equipment for the Facility: Hawthorne will be responsible for selecting and purchasing the equipment needed for operation of the Facility (the Facility Equipment). Hawthorne shall be required to directly pay the vendors of the Facility Equipment. Hawthorne shall own the Facility Equipment, other than any equipment that is included in or exclusively services the Flowr Rooms. Hawthorne shall be responsible for the repair and replacement costs associated with the Facility Equipment. Notwithstanding the foregoing, Hawthorne will be responsible solely for the purchase and maintenance of the Facility Equipment used in connection with the Hawthorne R&D. Flowr will be responsible for the purchase and maintenance of the Facility Equipment that is included in or exclusively services the Flowr Rooms. |
7
5. |
Operation of the Facility: |
a. |
The LP will be responsible for staffing and running the day-to-day operations of the Facility (including without limitation maintenance and repair of the Facility Equipment), honestly and in good faith and, in connection therewith, shall exercise that degree of care, diligence and skill that The LP exercises in comparable circumstances in connection with its own operations and pursuant to the Research Plan (as defined in section 12(a) of this Agreement), all applicable laws, rules and regulations including, without limitation, all applicable Cannabis Laws, rules and regulations concerning the required personnel, production, use, sale, handling, shipping, transportation, delivery and destruction of cannabis in Canada and any other Cannabis Specific Requirements. In that regard, The LP will only utilize employees at the Facility with suitable training, experience and skill necessary to perform the services to Hawthorne to the standard set forth in this Section. | |
b. |
The employees and contractors employed at the Facility will not be employees of Hawthorne and shall at all times remain employees or contractors of The LP. The LP and Hawthorne shall promptly notify each other of any job performance related issues concerning such employees. The LP shall be responsible for all aspects of the proper and lawful employment, management, communication, supervision, direction, evaluation, well-being, discipline, and termination of employment of the employees at the Facility, in accordance with applicable laws, and will ensure that all services provided by them will be performed in a professional and workmanlike manner, subject to reasonable disclosure to, consultation with and direction from Hawthorne; and without limiting the foregoing, The LP shall use commercially reasonable processes and procedures of at least the standard that Hawthorne uses in its own R&D facilities as disclosed by Hawthorne from time to time. | |
c. |
The LP and Hawthorne have each appointed an employee/employees to serve as the primary contact(s) with respect to this Agreement who shall respond reasonably promptly to any request from either party to provide direction, information, approvals, authorizations or decisions that are reasonably necessary for The LP to conduct the Hawthorne R&D in accordance with the requirements of this Agreement. The appointed employee(s) shall have the authority to act on behalf of The LP and Hawthorne, respectively, with respect to matters pertaining to this Agreement. | |
d. |
Currently the appointed employee for The LP is and the employee for Hawthorne is . Either party may change their appointed employee at any time by giving written notice to the other. I | |
e. |
Unless prohibited by applicable law, The LP shall promptly inform Hawthorne of any non-routine audits or inspections of the Facility by regulatory authorities and will involve Hawthorne in the preparation of any proposed response to any such audits or inspections by regulatory authorities including proposed corrective action, voluntary or involuntary, in relation to the Facility, as well as the Producer License or the Other Licenses insofar as it may impact the Facility and/or the Hawthorne R&D. |
Redacted:
Commercially Sensitive Information
8
f. |
Hawthorne shall have the right to conduct an audit of the Facility during business hours upon five (5) days prior written notice to The LP but not more than three times per calendar year during the Term of this Agreement, unless either party, any governmental authority or any third party raises any questions about the Facility, which could have a material and detrimental effect on Hawthorne, in which case Hawthornes audit right shall not be subject to the foregoing annual limitation until the specific issue in question has been resolved, and The LP shall promptly supply to Hawthorne, unless prohibited by applicable law, all records, reports, regulatory correspondence, and complaints in connection with the issue in question. | |
g. |
Subject to compliance with applicable laws, Hawthorne shall at all times have reasonable access to the Facility. | |
h. |
The LP shall provide to Hawthorne no later than 60 days prior to the anticipated Opening Date, and annually thereafter, no later than 60 days prior to each anniversary of the Opening Date, for review and approval by Hawthorne, which approval shall not be unreasonably delayed: |
i. |
A 12 month operating budget for the staffing, operation, insurance and maintenance of the Facility and the maintenance and insurance of the Facility Equipment; and | |
ii. |
a 2-year forecasted plan for capital or major improvements required for the Facility or the Facility Equipment which plan shall include the cost of such improvements and the timing of the completion of such improvements. |
Once approved by Hawthorne, the operating budget for the subject year is the Approved Annual Operating Budget and the forecasted plan is the Approved Annual Capital Budget.
Notwithstanding anything to the contrary contained in this Agreement, in no event shall the following costs and expenses be included in the operating budget for the Facility or the forecasted plan for capital or major improvements for the Facility (collectively, the Initial Cost Deficiencies):
i. |
the correction of initial construction faults, faulty design or inferior or deficient materials or workmanship in the Facility; and/or | |
ii. |
initial maladjustments in generating equipment installed in the Facility; and/or | |
iii. |
structural defects or weaknesses in the initial design or construction of the Facility. |
All Initial Cost Deficiencies incurred by The LP shall be the responsibility of The LP and shall not be reimbursed by Hawthorne.
i. |
Subject to the parameters set forth in Section 7(b), for no consideration, The LP will be entitled to unlimited full use of two out of the ten rooms in the Facility, with the choice of rooms to be mutually agreed upon by The LP and Hawthorne (the Flowr Rooms). In addition, The LP will be entitled to use the Common Facility Equipment 20% of the time for its own purposes and not for providing research and development services to Hawthorne. Common Facility Equipment means all equipment located in the common areas of the Facility (i.e., not located exclusively in the Flowr Rooms or exclusively in the eight (8) rooms dedicated to the Hawthorne R&D). The LP and Flowr shall be responsible for payment of 20% of the Direct Costs (the The LP Direct Costs), provided that The LP Direct Costs shall not include staffing costs relating to staff dedicated to the Hawthorne R&D. For the avoidance of doubt, at least 80% of the use of the Facility and the Common Facility Equipment will be dedicated to use in connection with the Hawthorne R&D. |
9
j. |
From and after the Opening Date, and subject to Section 5(i), as consideration for The LPs provision of the research and development services, Hawthorne will pay to The LP a SR&ED Services Fee computed as the aggregate of the following amounts: (i) per month (adjusted beginning in the 11th year following the Opening Date by an amount equal to the lesser of 3% and the annual inflation rate for Canada (based on the Statistics Canada Consumer Price Index), in either case, over the prior year; and (ii) a monthly amount that equates to the monthly principal and interest payments set forth in Schedule 1 (which may be amended from time to time); and the Direct Costs, which include the following: staffing, operation, insurance, maintenance and repair costs and expenses relating to the operation, maintenance and repair of the Facility, net of The LP Direct Costs, provided (the Direct Costs): |
i. |
that such costs and expenses are included in the then-current Approved Annual Operating Budget or Approved Annual Capital Budget; | |
ii. |
with respect to costs and expenses included in the then-current Approved Annual Operating Budget or Approved Annual Capital Budget but exceeding the amount set out in the then-current Approved Annual Operating Budget or Approved Annual Capital Budget, as applicable, the aggregate amount of any such expense and the aggregate amount of all other expenditures of a similar category, type or nature in the applicable approved budget, would be increased by less than 10% and the aggregate amount of the Approved Annual Operating Budget or Approved Annual Capital Budget, as applicable, would be increased by less than 5%; | |
iii. |
with respect to any expense not included in the then-current Approved Annual Operating Budget or Approved Annual Capital Budget, as applicable, such expense was incurred in connection with an emergency situation affecting the Facility or was approved in advance, in writing, by Hawthorne. |
For the avoidance of doubt, depreciation of the Facility and the cost to acquire the Facility Equipment is not a Direct Cost. Further, The LP shall not be entitled to any separate or additional fee or compensation for cooperation, information and assistance related to the Investment Tax Credits as defined in Subsection 127(9) of the ITA (Investment Tax Credits), however the Direct Costs shall include the lesser of the expense directly related to an administrative worker needed to track all of the information necessary for taking advantage of the Investment Tax Credits and CAD $250.00 per month.
Redacted:
Commercially Sensitive Information
10
On the fifth business day of each month, The LP shall deliver to Hawthorne an invoice in connection with the Direct Costs anticipated to be incurred in the next calendar month. The invoice shall set out any tax payable as a separate line item and shall include The LPs registration numbers under the ETA (as defined below) for purposes of the goods and services/harmonized sales tax (GST). Subject to the following sentences, Hawthorne shall pay The LP for all such Direct Costs within ten business days after receipt of the invoice.
Within 30 days of the end of each calendar quarter, The LP shall deliver a statement to Hawthorne showing the Direct Costs invoiced by month for the prior quarter versus the actual Direct Costs incurred by The LP along with commercially reasonable documentation. Hawthorne has the right to request, and The LP shall promptly deliver, additional commercially reasonable information relating to the Direct Costs.
If Hawthorne has paid more in Direct Costs for the quarter than actually incurred, Hawthorne will receive a credit on the next monthly invoice. If Hawthorne has paid less than the Direct Costs actually incurred in the quarter, the underpayment will be added to the next monthly invoice. Within five business days following the date on which the Term of this Agreement expires or is terminated, any payment owing to Hawthorne in connection with this paragraph shall be paid by The LP and any payment owing to The LP in connection this paragraph shall be paid by Hawthorne. This paragraph shall survive termination of this Agreement.
Hawthorne shall not be required to pay The LP for any Direct Costs contained in an invoice (1) until Hawthorne has received commercially reasonable supporting information; and (2) which Hawthorne, acting reasonably, disputes as an expense which is not a Direct Costs unless and until it has been finally determined or mutually agreed that such expense is a Direct Cost.
Hawthorne shall receive a credit for any Direct Costs, but not including a credit with respect to The LP Direct Costs, for which The LP actually receives a refund or credit (including, for greater certainty, any GST).
k. |
The LP shall submit to Hawthorne, on a regular basis, all paid invoices, subcontractor lien waivers or partial lien waivers and other receipts related to the construction, purchase and maintenance, as applicable, of the Facility and the Facility Equipment owned by Hawthorne. The LP hereby represents that they will fully pay all subcontractors in a timely manner subject to The LPs right, acting reasonably, to dispute the amounts owed to any subcontractor in a commercially reasonable manner and provided that any such dispute does not adversely affect the operations being conducted at the Facility. |
6. |
Scientific Research and Experimental Development: |
Hawthorne and The LP acknowledge and agree that the Hawthorne R&D may require the performance of scientific research and experimental development (SR&ED) as defined in subsection 248(1) of the Income Tax Act (Canada) (the ITA). Hawthorne and The LP further agree that, to the extent SR&ED is required, (i) the SR&ED done in respect of the Hawthorne R&D will be carried on in Canada by The LP and directly undertaken on behalf of Hawthorne; (ii) all or a portion of each relevant payment to be made by Hawthorne will be for SR&ED performed by The LP, as the case may be, that is related to a business of Hawthorne; (iii) Hawthorne is entitled to exploit the Intellectual Property resulting from the SR&ED, in the manner set out in this Agreement; (iv) The LP is a taxable supplier as defined in subsection 127(9) of the ITA; and (v) Hawthorne will be entitled to include the amounts paid for SR&ED in computing the amounts described in subsection 37(1) of the ITA. The LP shall cooperate fully with, provide scientific, technical and financial information to, and assist Hawthorne to determine what activities of The LP under this Agreement qualify as SR&ED and what expenditures qualify for the Investment Tax Credits and to allow Hawthorne and its tax advisors to complete Hawthornes claims for the Investment Tax Credits (including for greater certainty separately identifying certain costs (including facility design costs and overhead costs) with sufficient detail as reasonably requested by Hawthorne).
11
7. |
Use of Facility Equipment and Discrete Space at the Facility: |
a. |
The LP shall have the right to use the Common Testing Equipment in the Facility 20% of the time for its own purposes provided that, in Hawthornes reasonable discretion, the testing will not adversely impact the execution of the Hawthorne R&D. Common Testing Equipment means all equipment located in the common areas of the Facility (i.e., not located exclusively in the Flowr Rooms or exclusively in the eight (8) rooms dedicated to the Hawthorne R&D). | |
b. |
In addition, The LP will be allocated the Flowr Rooms at the Facility in a location of the Facility which has been mutually agreed upon by the parties, each acting reasonably (the Dedicated LP Area), for its own, discrete unlimited full use. For the avoidance of doubt, 80% of the floor space at the Facility (which shall not include the Additional Floors) shall be dedicated to the conduct of the Hawthorne R&D. |
8. |
Intellectual Property and Joint Development: |
a. |
In this Agreement: |
i. Intellectual Property means (i) all trade secrets, Know-How, confidential information, standard operating procedures, processes, proprietary formulas, intellectual tools, techniques, specifications, designs and industrial designs, works of authorship, trademarks (whether registered or unregistered), inventions and improvements and modifications thereto (including all related designs, technical information, models, drawings, specifications, formulas, schemas, prototypes, and architectural plans), patents, copyrights, advertising, financial, commercial, or sales materials, equipment configurations, written materials, compositions, drawings, diagrams, studies, works in progress, visual demonstrations, and all other related material and data, (ii) all vested, contingent and future rights, in any jurisdiction, to all of the foregoing under any applicable statutory provision or common law principle, and all rights of action, powers and benefits relating thereto, including the right to bring proceedings and claim or recover damages or other remedies in relation to any infringement;
ii. Know-How means all information not publicly known or not independently developed by a third party that is used or required to be used in or in connection with any product existing in any form (including, but not limited to that comprised in or derived from engineering, chemical and other data, specifications, formulae, experience, drawings, manuals, component lists, instructions, designs and circuit diagrams, brochures, catalogues and other descriptions) and relating to:
1. |
the design, development, manufacture or production of or materials or equipment for any products or the optimization of design, development, manufacture or production of or materials or equipment for any products; |
12
2. |
the operation of any process; | |
3. |
the provision of any services; | |
4. |
the selection, procurement, construction, installation, maintenance or use of raw materials, plant, machinery or other equipment or processes; | |
5. |
the rectification, repair or service or maintenance of products, plant, machinery or other equipment; | |
6. |
the supply, storage, assembly or packing of raw materials, components or partly manufactured or finished products; or | |
7. |
quality control, testing or certification. |
However, Know-How does not include the Excluded Information.
iii. |
Excluded Information means information that the recipient proves: (i) was lawfully in its possession before receiving it from the discloser, or (ii) was provided in good faith to the recipient by a third party without breaching any of the disclosers rights or any rights of a third party, or (iii) is or becomes generally available to the public through no fault of the recipient or (iv) or was developed independently by the recipient without access or reference to the confidential information of the other party. |
b. |
The LP and Flowr each agree that Hawthorne is the sole and exclusive owner of all right, title and interest in and to all Hawthornes Intellectual Property provided to The LP by Hawthorne (the Hawthorne IP), for the purposes of conducting the Hawthorne R&D. Neither The LP nor Flowr shall have a right or license to use the Hawthorne IP except solely during the Term of the Agreement and to the extent necessary to conduct the Hawthorne R&D. | |
c. |
Hawthorne agrees it has no right or license to use the The LP IP except solely during the Term of the Agreement and only to the extent necessary to perform the Hawtho rne R&D at the Facility. | |
d. |
Neither The LP nor Flowr shall have a right or license to use any products or materials owned by Hawthorne and provided to The LP for the purposes of conducting the Hawthorne R&D, including, but not limited to, nutrients, growing media, fertilizers, and pesticides (the Hawthorne Materials) except solely during the Term of the Agreement and to the extent necessary to conduct the Hawthorne R&D. All other rights in and to the Hawthorne Materials are expressly reserved by Hawthorne. | |
e. |
Hawthorne shall have no right or license to use any intellectual property designs, products or materials owned by Flowr or The LP and provided to Hawthorne under this Agreement (the The LP IP) except solely during the Term of the Agreement and to the extent necessary to perform the Hawthorne R&D at the Facility. All other rights in and to the The LP Materials are expressly reserved by Flowr and The LP. | |
f. |
Subject to Sections 8d and 8e, neither Hawthorne nor The LP has any obligation to share Intellectual Property with the other and will respect each others Intellectual Property. |
13
g. |
The LP and Flowr each acknowledge and agree that (i) all work completed pursuant to this Agreement, and (ii) any Intellectual Property developed, created, derived or reduced to practice arising from the Hawthorne R&D and the Hawthorne Materials, including 1) any products or materials, will be exclusively owned by Hawthorne (the Hawthorne R&D IP). | |
h. |
The LP and Flowr each agree that Hawthorne is the sole and exclusive owner of all right, title and interest in and to all Hawthorne R&D IP, Hawthorne Materials and any products or materials arising from the Hawthorne R&D. | |
i. |
For greater certainty, the Hawthorne R&D IP shall not include any Intellectual Property developed, created, derived or reduced to practice by Flowr or The LP or any Intellectual Property arising from the research and development conducted by Flowr or The LP (The LP R&D) in the Dedicated LP Area (collectively, the The LP R&D IP). The LP and Flowr shall be the sole owner of all right, title and interest in and to all The LP R&D IP. | |
j. |
Each of The LP and Flowr acknowledges and agrees that, upon termination or expiry of this Agreement, Hawthorne shall continue to be the sole and exclusive owner of all right, title and interest in and to all Hawthorne R&D IP, Hawthorne Materials and any products or materials arising from the Hawthorne R&D. | |
k. |
Hawthorne acknowledges and agrees that, upon termination or expiry of this Agreement, The LP shall continue to be the sole and exclusive owner of all right, title and interest in and to all The LP IP and The LP R&D IP. | |
l. |
For purposes of Sections 8a through 8k only, each of The LP, Flowr and Hawthorne shall also refer to all affiliates, parents, subsidiaries and entities under common control with or by it. | |
m. |
If the parties mutually agree to explore joint development opportunities, they shall negotiate in good faith a more detailed, comprehensive joint development agreement covering additional aspects of a joint development relationship including any Intellectual Property issues. |
9. |
Non-Disclosure: |
a. |
The parties remain bound by that Mutual Confidentiality Agreement signed by them or their affiliates on September 13, 2017, which is hereby extended until the termination of this Agreement (the CA) . | |
b. |
Nothing in the CA or herein withstanding, the parties are permitted to publicly disclose the existence and general purpose, but not the specific terms, of this Agreement. Flowr and The LP will describe the relationship as being an exclusive strategic R&D alliance with Hawthorne Canada, a subsidiary of The Scotts Miracle-Gro Company, to construct and operate the only Hawthorne funded state-of-the-art facility to conduct research and development activities on all aspects of growing cannabis in Canada. In the event that Hawthorne enters into a relationship that it reasonably believes makes the relationship in this Agreement non-exclusive (a Relationship), it can give written notice to The LP, and The LP and Flowr will cease referring to the relationship as exclusive. For the avoidance of doubt, Hawthorne may enter into a Relationship freely and without the consent of The LP. |
14
Hawthorne will describe the relationship as being with Flowr or The LP and The LP will specifically advise on which is to be used before any public announcement is made. Any written publicity by either party naming the other party, any of its affiliates, and/or The Scotts Miracle-Gro Company shall be pre-approved in writing (for purposes of this paragraph email is acceptable written approval) by both parties before publishing.
10. |
Non-Solicitation: |
Each of the parties agree that they will not, without the prior written consent of the party employing such employee, contractor or former employee (which consent may be withheld in such parties sole, absolute and subjective discretion), hire or attempt to hire, directly or indirectly, any of the other parties employees, contractors or former employees, during the Term of this Agreement and within one year from the date of the termination or expiry of the Term of this Agreement. Without limiting the generality of the foregoing, Hawthorne agrees that neither it nor any of its affiliates shall, without the prior consent of The LP, hire or attempt to hire For purposes of this Agreement, attempt to hire shall mean the direct targeting and seeking out of one partys employees and shall not include general public solicitations (e.g., advertisements, job boards, etc.) or circumstances in which employees of one party seek employment or another relationship with another party. For the purpose of this Agreement, former employee means any employee who resigned their employment in the preceding twelve (12) months.
11. |
Additional Employees: |
a. |
(the Additional Employees and each an Additional Employee) to provide services exclusively for Hawthornes benefit at the Facility under and during the Term of this Agreement. | |
b. |
Where any such Additional Employee ceases employment for any reason during the Term of this Agreement, Hawthorne may require The LP to employ a replacement employee, either promptly upon such cessation or at such later time as Hawthorne may advise, as Hawthorne may determine in its sole discretion. In all instances, The LP shall have a commercially reasonable time to fill any vacant positions. So long as The LP is using commercially reasonable efforts to replace an employee, as requested by Hawthorne and subject to this Section 11, the failure to find and hire suitable candidates will not be considered a default. |
Although The LP will consult with Hawthorne as to the selection and hiring of each of the Additional Employees (including their terms and conditions of employment), The LP (subject to the prior approval of Hawthorne) will be responsible for selecting the employees and ensuring that each of them has suitable training, experience and skill necessary to perform the services hereunder (including, without limitation, by conducting appropriate diligence and background checks in the hiring process).
Redacted:
Commercially Sensitive Information
15
c. |
The LP shall be responsible for all aspects of the proper and lawful employment, management, communication, supervision, direction, evaluation, wellbeing, discipline, and termination of employment of the Additional Employees, in accordance with applicable laws, and will ensure that all services provided by them will be performed in a professional and workmanlike manner. | |
d. |
The LP shall be responsible, in consultation with Hawthorne, for the determination of the rate and manner of compensation (and for the payment of compensation, applicable employee and fringe benefits and all employment-related taxes and premiums), evaluation, discipline and termination of employment of the Additional Employees; provided, however, that in no event shall The LP increase any payments or benefits to such Additional Employees in a manner which would increase the costs of employing the Additional Employees, except for (i) changes made with the prior written consent of Hawthorne, which consent shall not be unreasonably withheld, conditioned or delayed, (ii) compensation increases and bonuses calculated in accordance with the current written plans of The LP awarded in the ordinary course of business, and (iii) changes in benefits, and costs related thereto, which are provided under an employee benefit plan in the ordinary course of business. | |
e. |
The Additional Employees will not be employees of Hawthorne and shall at all times remain exclusively employees or contractors of The LP. The LP and Hawthorne shall promptly notify each other of any job performance related issues concerning the Additional Employees. Requests for time off or vacations for Additional Employees must be approved by The LP and Hawthorne, in each case acting reasonably. | |
f. |
Pursuant to the process described in Section 5j, The LP shall invoice Hawthorne for an amount equal to the total cost of the wages and benefits, including but not limited to the salary, hourly rates, overtime pay, vacation pay, statutory holiday pay, insurance premiums, sick pay, termination pay , pay in lieu of notice of termination and severance pay, provided to the Additional Employees including the cost to The LP of Employment Insurance, Canada Pension Plan and workers compensation premiums and any other related or required statutory payments, deductions or withholdings for the Additional Employees, so long as such amounts are paid in accordance with the terms of this Agreement or mutually agreed upon by the parties on or prior to the hire date of the Additional Employees. Notwithstanding the foregoing, The LP and Hawthorne will mutually agree on the salaries and benefits provided to the Additional Employees. | |
g. |
Notwithstanding Section 10 hereof, at any time during the Term of this Agreement or thereafter, Hawthorne may hire or attempt to hire the Additional Employees or any of them, at its sole discretion, without any obligation to The LP or any of its affiliates. |
12. |
Research Plan and Testing R&D in Production: |
a. |
Subject to the terms of this Section 12, The LP shall conduct the Hawthorne R&D pursuant to the written instructions of Hawthorne (the Research Plan). | |
b. |
Hawthorne will provide reasonably sufficient detail in the Research Plan to allow The LP to perform the testing and analysis, provide interim and final reports on the status of the testing and analysis and provide the deliverables, as applicable, within a reasonable timeframe. Hawthorne will provide the necessary materials in connection with the Hawthorne R&D to be performed, if applicable. |
16
c. |
It is understood that under no circumstances will The LP agree to any test, analysis or activity requested by Hawthorne that The LP believes could reasonably present a risk of non-compliance with any applicable laws, including, but not limited to, Cannabis Laws, regulatory policy or directives or jeopardize the good standing of The LPs Producer License or Other Licenses. | |
d. |
The LP will present Hawthorne with a written response to the Hawthorne instructions confirming the details of the testing, the timing of the deliverable and outlining all incremental expenses for such testing including the changeover of any Facility Equipment, and the replacement of original Facility Equipment, if required. All such additional expenses shall be approved by Hawthorne prior to the start of any testing pursuant to the instructions in question. Once approved by Hawthorne, The LP shall promptly update the then-current Approved Annual Operating Budget to include such additional expenses and such additional expenses will be included within Direct Costs, subject to Section 4. | |
e. |
Hawthorne shall remain responsible for any and all fees, disbursements and other costs that may be incurred by The LP prior to or arising from the receipt of any requested changes from Hawthorne. Such fees, disbursements and other costs shall form part of Direct Costs and The LP shall promptly update the then-current Approved Annual Operating Budget to include such fees, disbursements and other costs. |
f. |
|
g. |
If the parties mutually agree that any portion of the Hawthorne R&D will take place at The LPs commercial facility, Hawthorne will be responsible for the incremental costs of testing and will have no claim on any cannabis grown in The LPs commercial facility. |
13. |
Pesticides and Pests |
Hawthorne hereby acknowledges and agrees that the Hawthorne R&D will not use pests or pesticides not approved by Health Canada and that the Facility has not been designed for such purpose. In the event that Hawthorne desires to use pesticides that are not approved by Health Canada, Hawthorne shall notify The LP of the pesticides it desires to use and The LP shall have the right, at its sole discretion, to approve Hawthornes use of such pesticides, such approval which may withheld.
14. |
Mutual Warranties and Representations: |
Redacted:
Commercially Sensitive Information
17
Each party represents and warrants to the other party, which representations and warranties shall remain true and accurate throughout the Term, that:
a. |
it is duly organized, validly existing and in good standing as a corporation or other entity as represented herein under the laws and regulations of its jurisdiction of incorporation or organization; | |
b. |
it has the full right and capacity to enter into this Agreement, to grant the rights and licenses granted hereunder and to perform its obligations hereunder; | |
c. |
the execution and delivery of this Agreement by such party and the performance of its obligations hereunder shall not result in either a breach or violation of any of the provisions of, or constitute a default under, or conflict with or cause the acceleration of any of the such partys obligations under: |
i. |
any of the terms and provisions of its governing documents or by-laws, or resolutions of the board of directors (or any committee thereof) or its general partner or limited partners; | |
ii. |
any judgment, decree, order or award of any court, governmental body or arbitrator having jurisdiction over it; | |
iii. |
any license, permit, approval, consent or authorization held by it; or | |
iv. |
any applicable Law, statute, ordinance, regulation or rule; |
d. |
the execution of this Agreement by its representative whose signature is set forth at the end hereof has been duly authorized by all necessary corporate or other action of the party; | |
e. |
when executed and delivered by such party, this Agreement will constitute the legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms. |
Each of the parties respectively, warrants that it has no agreements with any third party or commitments or obligations that conflicts with its obligations under this Agreement. During the Term of this Agreement, no party will enter into any agreement, commitment or obligation that materially conflicts with its obligations under this Agreement.
15. |
Representations and Warranties of The LP |
Each of Flowr and The LP covenants, represents and warrants, which representations and warranties shall remain true and accurate throughout the Term, to Hawthorne that:
a. |
it shall perform its responsibilities and obligations under this Agreement using personnel of required skill, experience and qualifications and in a professional and workmanlike manner in accordance with best industry standards for similar services and shall devote adequate resources to meet its responsibilities and obligations under this Agreement; |
18
b. |
it is in compliance with, and shall perform its responsibilities and obligations under this Agreement in compliance with, all applicable laws, including, but not limited to, all Cannabis Laws and all applicable privacy laws; | |
c. |
it shall perform its responsibilities and obligations under this Agreement in compliance with all applicable laws concerning the research, development, production, storage, possession, transportation, shipping, delivery, use, handling and destruction of cannabis in Canada, including Cannabis Laws, and maintain its Producer License and Other Licenses, if applicable, in good standing and in full force and effect; | |
d. |
The LP shall maintain its Producer License and Other Licenses, if applicable, in good standing and in full force and effect as well as any other applicable permits, licenses and approvals of any governmental entity relating to its responsibilities and obligations hereunder and/or business operations of it; | |
e. |
The LP is the registered and beneficial owner of the Kelowna Property free and clear of all financial encumbrances; and | |
f. |
it is a person resident in Canada for purposes of the ITA. |
16. |
Termination Rights: |
a. |
Hawthorne, in its sole discretion, may terminate this Agreement, on written notice to The LP, with a thirty-day cure period if capable of cure (with the exception of Section 16(a)(iii) below), if: |
i. |
The LP does not secure Other Licenses, as required, and described in Section 1d; | |
ii. |
The LP fails to amend, in a commercially reasonable period of time, its Producer License to include the Facility; | |
iii. |
The LP has ceased to maintain its Producer License or any Other License in good standing and in full force and effect; | |
iv. |
The LP makes a material change to the Producer License or Other Licenses or directly or indirectly, licenses, sub-licenses, sells, transfers, pledges or otherwise disposes of the Producer License or Other Licenses, in each case only in the event that such change has a material, negative impact on Hawthorne, in Hawthornes reasonable opinion; | |
v. |
The LP does not obtain and maintain the insurance policies required pursuant to Section 17; | |
vi. |
The LP makes an application to affect any material, fundamental change in the purpose or scope of the Producer License or Other Licenses or any other action which will, directly or indirectly, license, sub-license, sell, transfer, pledge or otherwise dispose of the Producer License or Other Licenses, in each case only in the event that such change has a material, negative impact on Hawthorne, in Hawthornes reasonable opinion; |
19
vii. |
The LP is subject to censure for misconduct or non-compliance with any regulatory obligations, applicable law or regulatory directive, including, but not limited to, regulatory actions against The LP in relation to its Producer License or Other Licenses in each case only in the event that such change has a material, negative impact on Hawthorne, in Hawthornes reasonable opinion. |
b. |
Either Hawthorne, on the one hand, or The LP, on the other hand, may terminate this Agreement, effective upon written notice to the other (the Defaulting Party), if the Defaulting Party: |
i. |
materially breaches this Agreement (other than a breach described elsewhere in this Section 16), and such breach is incapable of cure, or with respect to a material breach capable of cure, the Defaulting Party does not cure such breach within thirty (30) days after receipt of written notice of such breach; or | |
ii. |
(1) becomes insolvent or admits its inability to pay its debts generally as they become due; (2) becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which is not fully stayed within seven Business Days or is not dismissed or vacated within 45 days after filing; (3) is dissolved or liquidated or takes any corporate action for such purpose; (4) makes a general assignment for the benefit of creditors; or (5) has a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business. |
c. |
If an event of default specified in Section 16(b)(ii) occurs, The LP and Flowr shall, at the request of Hawthorne, use commercially reasonable efforts to assist Hawthorne to obtain all required prior approvals and consents to the direct transfer, where permissible, of any Producer License or Other Licenses which exclusively apply to the Facility, including all approvals and consents required by any Cannabis Laws or regulatory directive. | |
If the Producer License or Other Licenses under which the Facility operates also apply to the commercial properties of The LP and/or cannot be directly transferred to Hawthorne for legal reasons, then The LP will cooperate with Hawthorne and assist Hawthorne in identifying the licenses and approvals required to own, maintain, and operate the Facility from and after the event of default specified in Section 16(b)(ii) (except in the case of a solvent debt restructuring), and use commercially reasonable efforts to assist Hawthorne with obtaining new licenses and approvals which will allow them to own, maintain and operate the Facility independently. Such efforts, cooperation and assistance shall include, but is not limited to, the use of the knowledge, expertise and information of The LP and their respective agents, experts and employees, as well as the use of any documentation, including but not limited to audit reports, technical documents, standard operating procedures, and regulatory dossier relating only to the Facility that will assist Hawthorne in expediting its application for a regulatory license or approval. Nothing in this Section 16c shall require Flowr or The LP to undertake anything that would be a breach of applicable laws, including relating to preferences or conveyances under applicable bankruptcy laws. |
20
d. |
In the event that this Agreement : |
i. |
has been terminated by Hawthorne pursuant to Sections 16(a) or 16(b) of this Agreement on or prior to the Opening Date, within 30 business days following the date of termination, The LP shall pay to Hawthorne an amount equal to 100% of all costs and expenses advanced by Hawthorne under the Loan to The LP pursuant to Sections 3 and 5 of this Agreement and liquidated damages equal to CAD$1,500,000. | |
ii. |
terminates pursuant to the expiration of the Term or has been terminated by Hawthorne pursuant to Section 2 or 16(a) or by The LP pursuant to Section 16(b) following the Opening Date, then Hawthorne shall pay a termination fee (Termination Fee) equal to 10% of the then-outstanding principal balance of the Loan based on the Loan Amortization Schedule set forth in Schedule 1. The Termination Fee payable to The LP may be offset in whole or in part against the Loan at Hawthornes discretion. Notwithstanding the foregoing, Hawthorne will not owe a Termination Fee to The LP if Hawthorne terminates the Agreement pursuant to Sections 16(a)(i), 16(a)(iii), 16(a)(iv), 16(a)(vi) or 16(a)(vii). | |
iii. |
has been terminated by Hawthorne pursuant to Sections 16(a) or 16(b) following the Opening Date, The LP shall pay to Hawthorne an amount equal to the then outstanding principal balance of the Loan as of the termination date (as set forth in Schedule 1, the Remaining Loan Balance) and any accrued interest owing. The LP shall pay the Remaining Loan Balance to Hawthorne over a period of two years, in two equal installments, with each installment payable on the first and second anniversary of the termination date. | |
iv. |
[Reserved.] | |
v. |
[Reserved.] | |
vi. |
has been terminated by Hawthorne as set forth in Section 2 hereof at the date that is eight (8) years after the Opening Date (Year 8), Hawthorne will pay the Termination Fee and an additional termination fee (Additional Termination Fee) equal to the difference between the Remaining Loan Balance at the end of Year 8 and the Remaining Loan Balance at the end of the tenth year after the Opening Date as if Hawthorne terminated this Agreement at the date that is ten (10) years after the Opening Date. The Additional Termination Fee payable to The LP shall be offset in whole or in part against the Loan. In the event of such termination by Hawthorne as described in this Section 16(d)(vi), beginning on the date that is eleven (11) years after the Opening Date, The LP will pay the Remaining Loan Balance to Hawthorne pursuant to Schedule 1 over a period of three years, in three equal installments, with each installment payable on the first, second and third anniversary of the termination date. |
21
vii. |
is terminated for any reason permitted by this Agreement or upon expiry of the Term, for the Facility Equipment owned by Hawthorne, Hawthorne will give to The LP a written list of each article and its then current book value within 30 Business Days of the termination date or expiry date and The LP will respond in writing within 30 Business Days with a list of the Facility Equipment it wishes to purchase from Hawthorne. The LP will pay Hawthorne the Book Value for all Facility Equipment it wishes to purchase concurrent with the transfer of title to such equipment (the Equipment Payment). Any Facility Equipment The LP does not wish to purchase will be removed by Hawthorne upon termination or expiration of this Agreement. |
e. |
To secure The LPs obligation to make the Remaining Loan Balance and the Equipment Payment, The LP shall grant a first ranking mortgage and security interest over the Facility on the terms and conditions set out in Exhibit E to this Agreement. | |
f. |
Upon termination or expiry of this Agreement, each party shall immediately, or within an agreed upon timeframe: |
i. |
cease all activities related to the Hawthorne R&D; | |
ii. |
in the case of The LP, deliver up to Hawthorne or destroy all copies of all manuals, instructional materials and other technical information, records and instructions relating to the Hawthorne R&D and Hawthorne R&D IP, respectively, in any media or form, without retaining any copies other than necessary for government or internal corporate document retention policies; | |
iii. |
in the case of Hawthorne, deliver up to The LP or destroy all copies of all manuals, instructional materials and other technical information, records and instructions relating to The LP IP and The LP R&D IP, respectively, in any media or form, without retaining any copies other than necessary for government or internal corporate document retention policies; and | |
iv. |
deliver up to the other party or destroy all copies of all confidential information of the other party, and all summaries, copies and excerpts of confidential information and all electronic media or records containing or derived from confidential information, without retaining any copies other than necessary for government or internal corporate document retention policies. |
g. |
The provisions of this Section 16 shall survive termination of this Agreement. In addition, each Party expressly acknowledges and agrees that this Section 16 and Section 2 set forth the only rights of each party to terminate this Agreement. |
22
17. |
Insurance: |
a. |
At all times during the Term of this Agreement (including any renewal thereof), The LP shall procure and include within the applicable budget, at least the following types and amounts of insurance coverage: |
i. |
during construction of the Facility and until the Opening Date, All Risks property insurance including boiler and machinery (if applicable) covering all risks of physical loss or damage to the Facility during construction covering the full insurable replacement cost of the Facility. Such insurance shall cover as named insureds The LP, Hawthorne and any other entity that The LP or Hawthorne may reasonably require who shall be added as named or additional insured from time to time having an insurable interest. At the written direction of Hawthorne, insurance proceeds shall be: |
1. |
applied toward the repair or replacement of the insured property; or | |
2. |
paid directly to Hawthorne in which case this Agreement shall automatically be terminated. |
ii. |
from and after the Opening Date, all risk form insurance in respect of fire and such other perils as are from time to time defined in a standard all risks insurance policy, covering leasehold improvements, trade fixtures, the Facility Equipment and furniture located in the Facility, for not less than the full replacement cost thereof, and which insurance proceeds shall be applied toward the repair or replacement of the insured property. Insurance proceeds shall be applied toward the repair or replacement of the insured property unless the Facility has been substantially damaged (as determined by The LP and Hawthorne each acting reasonably) in which case Hawthorne shall receive: (A) 90% of the book value of the Facility; and (B) 100% of the book value of the Facility Equipment owned by Hawthorne, to be paid to Hawthorne and this Agreement shall immediately be terminated; | |
iii. |
business interruption coverage for no less than 12 months; | |
iv. |
if applicable, boiler and machinery insurance covering heat, air conditioning and other electrical equipment for the full replacement cost of such equipment; | |
v. |
Commercial General Liability with limits no less than per occurrence and in the aggregate, including bodily injury and property damage and products and completed operations and advertising liability, which policy will include contractual liability coverage insuring the activities of The LP and Flowr under this Agreement; |
Redacted:
Commercially Sensitive Information
23
vi. | Worker's compensation insurance for the personnel of The LP, in accordance with applicable law; | ||
vii. | Professional liability (errors and omissions) insurance in an amount of not less than per occurrence; and | ||
viii. | such other insurance as Hawthorne may from time to time request, acting reasonably. |
b. |
All non-statutory insurance policies required pursuant to this Section 17 shall: |
i. |
be issued by insurance companies acceptable to Hawthorne, acting reasonably; | |
ii. |
provide that such insurance carriers give Hawthorne at least 30 days prior written notice of cancellation or non-renewal of policy coverage; provided that, prior to such cancellation, The LP shall have new insurance policies in place that meet the requirements of this Section 17; | |
iii. |
waive any right of subrogation of the insurers against Hawthorne or any of its affiliates; | |
iv. |
provide that such insurance be primary insurance and any similar insurance in the name of and/or for the benefit of Hawthorne shall be excess and non-contributory; and | |
v. |
name Hawthorne and Hawthornes affiliates, including, in each case, all successors and permitted assigns, as additional insureds. |
On the date on which construction commences on the Facility, on the Opening Date and on an annual basis thereafter, The LP shall provide Hawthorne with copies of the certificates of insurance and policy endorsements for all applicable insurance coverage required by this Section 17, including The LP workers compensation registration numbers, and shall not do anything to invalidate such insurance. This Section 17 shall not be construed in any manner as waiving, restricting or limiting the liability of either party for any obligations imposed under this Agreement (including but not limited to, any provisions requiring a party hereto to indemnify, defend and hold the other harmless under this Agreement). Hawthorne does not in any way represent or warrant that the coverage or limits of insurance specified in this Section 17 are sufficient or adequate to protect The LP interests or liabilities.
If The LP fails to take out, renew or keep in force the insurance described in this Section 17, or if the certificates submitted to Hawthorne pursuant to the preceding paragraph are unacceptable to Hawthorne, acting reasonably (or no such certificates are submitted within a reasonable period after request therefor by Hawthorne), then Hawthorne may give to The LP written notice requiring compliance with this Section and specifying the respects in which The LP is not then in compliance with this Section. If The LP does not, within five (5) business days (or a lesser period if there is an urgency of the situation), provide appropriate evidence of compliance with this Section, Hawthorne may (but shall not be obligated to) obtain some or all of the additional coverage or other insurance which The LP shall have failed to obtain, without prejudice to any other rights of Hawthorne under this Agreement or otherwise.
Redacted:
Commercially Sensitive Information
24
It shall be the responsibility of The LP not to violate nor permit to be violated any conditions of the policies maintained according to the provisions of this Section 17.
In the event of an insured claim, the cost of the deductible under the applicable insurance policy shall be included in Approved Development Expenses or Direct Costs unless caused by the negligence or willful misconduct of The LP, Flowr or anyone under either of their supervision or a breach by The LP or Flowr of its obligations and liabilities under this Agreement.
18. |
Indemnification: |
a. |
The parties shall each defend, indemnify and hold each other, and each others affiliates and their respective directors, officers, employees and agents, successors and permitted assigns (each, an Indemnitee) harmless from and against any and all losses that may, directly or indirectly, result from, arise out of or be in relation to (i) the performance by the other party or by any of their respective employees, subcontractors or other persons for whom either is responsible, of the services performed hereunder; (ii) any breach, violation or non-performance by the other party, or by any of their respective employees, subcontractors or other persons for whom either is responsible, of any term, condition, representation, warranty or covenant contained in this Agreement; (iii) any failure or delay by a party to make or maintain any registration, permit, coverage or payments or file any return or information required by any applicable law (including, all applicable Cannabis Laws); (iv) any negligent act or omission of a party or any of their respective employees, subcontractors or other persons for whom either is responsible at law or in equity; and/or (v) any claim that the services or deliverables provided by a party hereunder, or their use by the other party, directly or indirectly, violate or infringe any intellectual property right or other proprietary right of any person. | |
b. |
Hawthorne shall defend, indemnify and hold harmless The LP and its affiliates and its and its affiliates respective officers, directors, employees, agents, successors and permitted assigns from and against all losses awarded against The LP or its affiliates in a final judgment arising out of or resulting from: |
i. |
bodily injury, death of any person or damage to real or tangible, personal property resulting from the gross negligence or willful acts or omissions of Hawthorne or any of its affiliates; and | |
ii. |
Hawthornes (including, any of its affiliates) material breach of any representation, warranty or obligation of Hawthorne in this Agreement. |
c. |
The LP shall defend, indemnify and hold harmless Hawthorne and its respective officers, directors, employees, agents, successors and permitted assigns from and against all losses awarded against Hawthorne in a final judgment arising out of or resulting from: |
i. |
bodily injury, death of any person or damage to real or tangible, personal property resulting from the gross negligence or willful acts or omissions of The LP, Flowr or any of their affiliates; and |
25
ii. |
The LPs, Flowrs (including, any of their affiliates) material breach of any representation, warranty or obligation of The LP or Flowr in this Agreement. |
d. |
The party seeking indemnification hereunder shall promptly notify the indemnifying party in writing of any third party action and cooperate with the indemnifying party at the indemnifying party's sole cost and expense. The indemnifying party shall immediately take control of the defense and investigation of such action and shall employ counsel of its choice to handle and defend the same, at the indemnifying party's sole cost and expense. The indemnifying party shall not settle any action in a manner that adversely affects the rights of the indemnified party without the indemnified party's prior written consent. The indemnified party's failure to perform any obligations under this Section 18d shall not relieve the indemnifying party of its obligations under this Section 18d except to the extent that the indemnifying party can demonstrate th at it has been materially prejudiced as a result of such failure. The indemnified party may participate in and observe the proceedings at its own cost and expense. | |
e. |
The provisions of this Section 18 shall survive and remain in full force and effect following any termination or expiry of this Agreement. |
19. |
Dealing With Officials: Each of Flowr and The LP represents and warrants that: (a) neither it nor any of its employees or officers is an official, employee, or active member of the armed services of any government; an official or employee of any government, an official of a political party, or a candidate for political office; and (b) as of the Effective Date and during the Term of this Agreement, no government official, and no official of any government agency or instrumentality, is or will become associated with, or will own or presently owns an interest, whether direct or indirect, in The LP or Flowr or has or will have any legal or beneficial interest in this Agreement. The LP further agrees to inform Hawthorne of any change in such status or representation. The LP and Flowr each warrant that, in connection with its performance under this Agreement, it has not and will not make or authorize any payments or gifts or any offers or promises of payments or gifts of any kind, directly or indirectly, to any official of any government or any agency or instrumentality thereof for the purpose of influencing any act or decision of such official or to induce such official to use his/her influence with the government. Each of The LP and Flowr further agree that it will not make any payment to any person or entity if Hawthorne knows or has reason to know that all or any portion of such payment will be offered or given directly or indirectly to any official of a government or political party, or any candidate for governmental or political party office, for the purpose of influencing or inducing any official to use his/her influence with the government or any instrumentality thereof. Each of The LP and Flowr warrants that it has not and will not pay, offer or tender, directly or indirectly, any political contributions or donations, or any commission or finders or referral fee to any person or firm in connection with its activities under this Agreement. Each of The LP and Flowr is in compliance with and will continue to comply in all material respects with all applicable anti-bribery laws. Each of The LP and Flowr hereby acknowledge receipt of a copy of Hawthornes Foreign Corrupt Practices Act Policy (FCPA Policy) and by execution of this Agreement, each of The LP and Flowr warrants and certifies that it will do nothing in the performance of its obligations under this Agreement which will be in conflict with Hawthornes FCPA Policy. |
20. |
Miscellaneous: |
26
a. |
This Agreement may not be modified, amended, or discharged except by a written agreement signed by an authorized representative of each party. | |
b. |
The provisions of this Agreement shall be deemed separable. If any provision in this Agreement shall be found or be held to be invalid or unenforceable, then the meaning of that provision shall be construed, to the extent feasible, to render the provision enforceable, and if no feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement, which shall remain in full force and effect unless the provisions that are invalid or unenforceable substantially impair the value of the entire Agreement to either party. In such event, the parties shall use their respective reasonable efforts to negotiate a substitute, valid, and enforceable provision which mo st nearly effects the parties intent in entering into this Agreement. | |
c. |
No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any one or more instances shall be deemed to be or construed as a further or continuing waiver of such term, provision or condition or of any other term, provision or condition of this Agreement. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. | |
d. |
This Agreement shall bind the parties, their successors, trustee in bankruptcy, and permitted assigns. The parties acknowledge and agree that HGCI, Inc. (an affiliate of Hawthorne) is an intended third-party beneficiary of this Agreement with respect to the Hawthorne R&D IP. During the Term of this Agreement neither The LP nor Flowr shall be permitted to sell, transfer, assign, lease, financially encumber or otherwise dispose of its right, title and interest in the Kelowna Property, the Facility or the Facility Equipment (other than Facility Equipment owned by The LP or Flowr) without the prior written consent of Hawthorne, which consent may not be unreasonably withheld or delayed provided that neither The LP nor Flowr shall need the consent of Hawthorne (and nothing herein shall in any way limit The LP or Flowrs right) to complete an internal corporate reorganization if: (1) such reorganization does not have and is not likely to have, in the opinion of Hawthorne acting reasonably, an adverse effect on the Hawthorne R&D or The LPs and Flowrs obligations under this Agreement; and (2) any successor to The LP or Flowr under this Agreement is a resident of Canada. | |
e. |
No party shall be considered in default or be liable to the other party for any delay in performance or nonperformance caused by circumstances beyond the reasonable control of such party (expressly excluding any financial inability of such party), including but not limited to acts of God, explosion, fire, flood, war, whether or not declared, accident, labor strike or labor disturbances, inability to procure supplies from third party vendors, sabotage, order or decrees of any court, or action of government authority or the inability to obtain any permission from any government, government authority or agency or department or other body having jurisdiction (each such event being a Force Majeure event) provided that (a) the affected party shall not in any material way have caused or contributed to such Force Majeure event, (b) the Force Majeure event could not have been prevented by reasonable and ordinary precautions (as would be employed by a reasonably prudent person in the position of the affected party), and (c) the Force Majeure event could not reasonably have been circumvented by the affected party by reasonable and ordinary commercial means, such as the use of alternate suppliers or subcontractors. Notwithstanding the foregoing: |
27
i. |
the existence or occurrence of a Force Majeure event shall excuse a breach of this Agreement only for such period of time as the Force Majeure event remains in existence and only to the extent that such Force Majeure event has caused in whole or in part the breach of this Agreement; and | |
ii. |
the existence of a Force Majeure event that has caused a breach of this Agreement shall not prevent a party from asserting and acting upon a breach of this Agreement that has not been caused by a Force Majeure event. |
f. |
The relationship between the parties is that of independent contractors. Nothing contained in this Agreement shall be construed as creating any agency, partnership, joint venture or other form of joint enterprise, employment or fiduciary relationship between the parties, and neither party shall have authority to contract for or bind the other party in any manner whatsoever. | |
g. |
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement. | |
h. |
In this Agreement, all references to dollar amounts are in Canadian currency unless expressly stated to the contrary. | |
i. |
The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement. | |
j. |
This Agreement, together with all Schedules and Exhibits and any other documents incorporated herein by reference, constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter, including the Original Agreement. | |
k. |
Each party shall, upon the reasonable request of the other party, promptly execute such documents and perform such acts as may be necessary to give full effect to the terms of this Agreement. | |
l. |
All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by email (with confirmation of transmission) if sent on or prior to 5:00 pm (PST), and on the next business day if sent after 5:00 pm (PST); provided any such email notice is promptly followed by notice by hand, registered mail or overnight delivery service, or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the addresses indicated below (or at such other address for a party as shall be specified in a notice given in accordance with this Section 20). |
28
If to The LP: | 9590 McCarthy Rd. |
Lake Country, BC V4V 1S5 | |
Email: Tom@flowr.ca | |
Attention: Tom Flow | |
If to Flowr: | Suite 201 |
100 Allstate Parkway | |
Markham, Ontario | |
L3R 6H3 | |
Email: vinay@flowr.ca | |
Attention: Vinay Tolia | |
If to Hawthorne: | 2000 Argentia Road, Plaza 2, Suite 300 |
Mississauga, ON L5N 1V8 | |
Attention: Adam Hanscom | |
Email: adam.hanscom@genhydro.com | |
with a copy to (which shall not constitute | |
notice): | |
800 Port Washington Blvd. | |
Port Washington, NY 11050 | |
Attention: Chris Hagedorn | |
Email: chagedorn@hawthornegc.com | |
and | |
c/o The Scotts Company LLC | |
14111 Scottslawn Rd. | |
Marysville, OH 43041 USA | |
Email: kwiles@hawthornegc.com | |
Attention: Katy Wiles |
21. |
Governing Law and Waiver of Jury Trial: |
a. |
This Agreement shall be governed by and construed in accordance with the laws of the Province of British Columbia and the federal laws of Canada applicable in that Province, without giving effect to any choice or conflict of law provision or rule (whether of the Province of British Columbia or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than those of the Province of British Columbia. Any legal suit, action or proceeding arising out of or related to this Agreement or the services provided hereunder shall be instituted exclusively in the courts of the Province of British Columbia, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of process, summons, notice or other document by mail to such party's address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court. |
29
b. |
Each party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement or the transactions contemplated hereby. |
[Remainder of Page Intentionally Left Blank]
30
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
The Flowr Group (Okanagan) Inc. | ||
(Formerly known as Cannatech Plant Systems, Inc.) | ||
By: | Thomas Flow | |
Name: | Thomas Flow | |
Title | Co-CEO | |
Hawthorne Canada Limited | ||
By: | Albert Messina | |
Name: | Albert Messina | |
Title | Treasurer | |
The Flowr Canada Holdings ULC | ||
By: | Thomas Flow | |
Name: | Thomas Flow | |
Title | Co-CEO |
[Agreement Signature Page]
Redacted:
Commercially Sensitive Information
Exhibit A
Redacted:
Commercially Sensitive Information
Exhibit B
Redacted:
Commercially Sensitive Information
Exhibit C
Redacted:
Commercially Sensitive Information
Redacted:
Commercially Sensitive Information
Redacted:
Commercially Sensitive Information
Redacted:
Commercially Sensitive Information
Exhibit E
Redacted:
Commercially Sensitive Information
Exhibit E
Flowr Medical Cannabis Now Available to Qualified Patients Online at Shoppers Drug Mart
Toronto, Ontario, March 18th, 2019 The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (Flowr or the Company) today announced its FlowrRx products are now available for purchase through Shoppers Drug Marts online medical cannabis site, shoppersdrugmart.ca/cannabis.
On January 9, 2019, the two companies confirmed a sales agreement. This new relationship represents a major milestone in the de-stigmatization of medical cannabis place in mainstream medicine, and in simplifying cannabis delivery in Canada. Medical Cannabis by Shoppers Drug Mart is currently available only to patients in Ontario.
Were pleased to provide patients with the high quality and consistent products they seek, now with access to the world class patient care team that Shoppers Drug Mart has assembled, said Vinay Tolia, Flowrs Co-CEO. Flowrs premium medical cannabis is grown in what we believe is the industrys most advanced GMP designed cultivation facility. This relationship is testament to our commitment to ultra-high-quality cannabis cultivation and further solidifies Flowrs role in Canadas medical cannabis landscape.
Flowr announced in January that it had entered into an agreement to supply medical cannabis to Shoppers Drug Mart, creating the opportunity to significantly increase sales of Flowrs medical cannabis products in Canada. Under the agreement, Shoppers Drug Mart will be the exclusive direct-to-patient online provider of FlowrRx products. Previously FlowrRx products were available online to patients registered via Flowrs website.
To make an order, patients must submit a completed medical document from a health care practitioner to Shoppers Drug Mart directly to begin the process. Advisers will then contact the referring HCP to verify, then approve the patient who will be able to order immediately.
About The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and sales license granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own growing systems. Flowr's investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of the Flowr Corporation:
Vinay Tolia
Co-CEO and Director
CONTACT INFORMATION:
U.S. MEDIA: |
Tim Streeb |
+1.646.677.1800 |
Tim.Streeb@icrinc.com |
CANADIAN MEDIA: |
Rebecca Brown |
+1.647.456.5599 |
rebecca@crowns.agency |
FOR INVESTORS ONLY: |
Bram Judd |
+1.647.483.7065 ext. 1520 |
bram@flowr.ca |
Raphael Gross |
+1.203.682.8253 |
Raphael.Gross@icrinc.com |
Forward-Looking Information
This press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr and its business, which may include, but are not limited to: the Shoppers partnership being a major milestone in the de-stigmatization of medical cannabis place in mainstream medicine and in simplifying cannabis delivery in Canada, Shoppers planning to expand online nationwide and in-store in the near future, Shoppers providing access to a world class patient care team, Flowrs products being grown in what it believes is the industrys most advanced GMP designed cultivation facility, the Shoppers partnership solidifying Flowrs role in Canadas medical cannabis landscape, the Shoppers partnership creating the opportunity to significantly increase sales of Flowrs medical cannabis products in Canada, Flowrs facilities being designed in a way that should enable it to provide patients with both high quality products and consistent benefits, Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as plans, is expected, expects, scheduled, intends, contemplates, anticipates, believes, proposes or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results may, could, would, might or will be taken, occur or be achieved. Such statements are based on the current expectations of Flowrs management and are based on assumptions and subject to risks and uncertainties. Although Flowrs management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks relating to the inability to continue to supply patients online, the inability of the Flowr products providing Shoppers’ clients with a premium option, Flowr’s cultivation team failing to achieve the standards or level of products described herein, including with respect to quality and consistency of product offerings, the supply agreement with Shoppers not providing Flowr with the benefits described herein, including, without limitation, not increasing sales of Flowr’s medical products, the inability of Flowr to capture any portion of the expected Canadian medical cannabis market, the inability of Flowr to maintain its facilities at the standards described herein and using strict processes to enable it to provide patients with high quality and consistent products, which could significantly impact sales of Flowr’s products, the Shoppers partnership not de-stigmatization medical cannabis’ place in mainstream medicine and in simplifying cannabis delivery in Canada, Shoppers not expanding its product offerings online nationwide and in-store in the near future or at all, which could have a material adverse effect on sales of Flowr’s products, Shoppers not providing patients with access to a world class patient care team, Flowr’s facility failing to be the industry’s most advanced GMP designed cultivation facility, which could significantly impact the quality and safety of Flowr’s products, the Shoppers partnership not solidifying Flowr’s role in Canada’s medical cannabis landscape, Flowr not being able to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market, Flowr’s inability to excel at cultivating premium cannabis, Flowr’s inability to construct its facilities, or in the time anticipated, Flowr requiring additional financing from time to time in order to continue its operations and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Company’s business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowr’s products to be high quality, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, which could result in significant penalties or costs being imposed on Flowr, Flowr’s securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowr’s products, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements, possible failure to realize the anticipated benefits of partnership arrangements, including those described herein, product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowr’s products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowr’s filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
The Flowr Corporation Announces Fourth Quarter
2018
Conference Call and
Webcast
Engages Proactive Investors
Toronto, Ontario March 28, 2019 The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (Flowr or the Company), a Canadian Licensed Producer and global leader in premium cannabis R&D, innovation, and cultivation, today announced that it will release its fourth quarter 2018 results after the close of the financial markets on Thursday, April 4, 2019.
The Company will also host a conference call and webcast to review these results. A question-and-answer session will follow.
Fourth Quarter 2018 Conference Call and Webcast:
Thursday, April 4, 2019
5:00 p.m. Eastern Time
Toll Free:
1-877-705-6003
Toll/International: 1-201-493-6725
Webcast:
www.flowr.ca/investors
A telephonic replay of the call will be available later that same day through Thursday, April 18, 2019. To listen to the archived call, dial Toll Free 1-844-512-2921 or Toll/International 1-412-317-6671 and enter replay pin number 13689126, or access the webcast replay via Flowrs website.
Separately, Flowr also announced that it has engaged Proactive Investors (www.proactiveinvestors.com), a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London. The group operates investor forums where three or four companies present to an audience of high net worth sophisticated investors, fund managers, hedge funds, private client brokers and analysts.
Flowr has engaged Proactive Investors for one year beginning April 1, 2019 with an agreed upon annual retainer fee of US$25,000. Neither Proactive Investors nor any of its principals have an ownership interest, directly or indirectly, in Flowr or its securities, and the Company has not granted Proactive Investors or its principals any right to acquire such interests.
The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and sales license granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own patented growing systems. Flowr's investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
Forward-Looking Information
This press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr and its business, which may include, but are not limited to: statements with respect to the release date of Flowr's financial results, Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and address specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of Flowr’s management and are based on assumptions and subject to risks and uncertainties. Although Flowr’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks associated with a delay in releasing Flowr’s financial statements (which could result in a violation of applicable laws), Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities or otherwise, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Flowr requiring additional financing from time to time in order to continue its operations and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Company’s business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowr’s products to be high quality, the inability of Flowr’s products to appeal to the adult-use recreational market and address specific patient needs in the medicinal market, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowr’s securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowr’s products to treat certain conditions, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements, possible failure to realize the anticipated benefits of partnership arrangements, product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowr’s products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowr’s filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
CONTACT INFORMATION: |
U.S. MEDIA: |
Tim Streeb, ICR |
1-646-677-1800 |
Tim.Streeb@icrinc.com |
CANADIAN MEDIA: |
Rebecca Brown, Crowns Agency |
1-647-456-5599 |
rebecca@crowns.agency |
IR: |
Raphael Gross, ICR |
1-203-682-8253 |
Raphael.Gross@icrinc.com |
The Flowr Corporation Announces Results for
the
Fourth Quarter and Full Year
2018
Records Revenues on First Sales of
Cannabis
Company to Host Conference Call and Webcast Today at
5PM ET
Toronto, Ontario April 4, 2019 The Flowr Corporation (TSXV: FLWR; OTC: FLWPF) (Flowr or the Company), a Canadian Licensed Producer and global leader in premium cannabis R&D, innovation, and cultivation, today announced its results for the fourth quarter and full year ended December 31, 2018. The Companys financial statements and managements discussion and analysis for the periods are available on SEDAR at www.sedar.com. All results are reported in Canadian Dollars.
The following table summarizes the Companys key financial and operational results:
In thousands of CAD dollars, | Three months ended | Year ended | ||||||||||
(except loss per share and grams produced) | December 31, | December 31, | ||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Grams produced* | 259,091 | | 617,85 | | ||||||||
9 | ||||||||||||
Grams sold | 405,584 | | 405,58 | | ||||||||
4 | ||||||||||||
Average net realized price per gram | 7.08 | | 7.08 | | ||||||||
Gross revenue | 3,270 | | 3,270 | | ||||||||
Net revenue | 2,870 | | 2,870 | | ||||||||
Gross profit (loss) before fair value adjustments | 252 | (104 | ) | (390 | ) | (258 | ) | |||||
SG&A | 4,286 | 1,412 | 8,531 | 2,289 | ||||||||
Share-based compensation | 3,356 | 602 | 7,208 | 602 | ||||||||
Listing expense | | | 1,803 | | ||||||||
Net loss | 6,059 | 1,887 | 17,907 | 2,805 | ||||||||
Loss per share (basic and diluted) | (0.10 | ) | (0.04 | ) | (0.22 | ) | (0.05 | ) | ||||
Cash used in investing activities | (10,609 | ) | (5,116 | ) | (21,670 | ) | (8,132 | ) | ||||
Cash from financing activities | 2,267 | 13,614 | 51,296 | 17,363 |
*Grams produced refers to the grams of dried cannabis harvested from plants in the period. The Company calculates grams produced based on the final recorded weight of dried harvested buds that have completed the drying stage net of any weight loss during the drying process for the period.
Management Commentary
2018 was an incredibly eventful year at Flowr and we are only just getting started. As a global leader in the premium cannabis industry, our design and cultivation expertise along with our superior IP know-how enables us to grow high quality cannabis on a large scale at what we believe will be industry-leading yields. The revenue numbers reflect our ability to grow and process high quality product with only a fraction of our facility and packaging area complete. Once our Kelowna 1 facility is completed in Q3 2019, our operational efficiency will only improve.
Flowr Co-CEO Vinay Tolia continued, The fourth quarter of 2018 marked a major milestone for Flowr, as we launched our medicinal and recreational sales channels after receiving our licenses in August 2018, and sold nearly 406 kilograms of premium cannabis, despite having only 20% of our grow rooms in Kelowna 1 operational during the quarter itself. As of today, we have 10 grow rooms in Kelowna 1 licensed for use and expect to have all 20 grow rooms fully constructed in the third quarter of 2019. Completion of Kelowna 1 should enable us to begin capitalizing on strategic growth opportunities for medicinal and recreational use with approximately 10,000 kilograms of capacity for premium cannabis flower on an annualized basis.
Results of Operations Three Months Ended December 31, 2018, and December 31, 2017
Net loss in Q4 2018 totaled $6,059,002 which was $4,171,257 higher than the net loss in Q4 2017. The increase is mainly driven by the ramp up of the activities related to cultivation operations, harvests and sales. Key costs in Q4 2018 were cost of sales, selling, general and administrative expenses and share-based compensation partially offset by unrealized gains on changes in fair value of biological assets.
Selling, general and administrative expenditures, consisting primarily of salaries and professional fees, were $4,286,622 in Q4 2018 compared to $1,411,933 in Q4 2017. Share-based compensation was $3,356,823 in Q4 2018 compared to $601,536 in Q4 2017. Share-based compensation expense in Q4 2018 resulted from the issuance of stock options in the latter half of 2018 primarily to officers and directors of the Company.
Adjusted EBITDA (Non-IFRS Measure)
Adjusted EBITDA is net loss, plus (minus) income taxes (recovery), plus (minus) interest income (expense), net, plus depreciation and amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on biological assets and inventory sold, plus listing expense costs and plus (minus) loss (gain) on investments. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash used by operations.
In thousands of CAD dollars | Three months ended | Year ended | ||||||||||
December 31, | December 31, | |||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Net loss | (6,059 | ) | (1,887 | ) | (17,907 | ) | (2,805 | ) | ||||
Depreciation and amortization | 620 | | 640 | | ||||||||
Unrealized (gains) losses on fair value adjustments of biological assets | (165 | ) | | 420 | | |||||||
Fair value adjustments on inventory sold | (500 | ) | | (500 | ) | | ||||||
Share-based compensation | 3,356 | 602 | 7,208 | 602 | ||||||||
Listing expense | | | 1,803 | | ||||||||
Net gains on valuation of warrant investment | (489 | ) | (224 | ) | (153 | ) | (336 | ) | ||||
Interest (income) expense | (104 | ) | | (102 | ) | 1 | ||||||
Adjusted EBITDA | (3,341 | ) | (1,509 | ) | (8,591 | ) | (2,538 | ) |
Adjusted EBITDA losses were higher for the three and twelve months ended December 31, 2018 compared to 2017 by $1,832,000 and $6,053,000, respectively, due to the ramp up of cultivation, operating activities and sales in 2018.
Recent Business Developments
Recent Leadership Developments
Growth Opportunities
Conference Call and Webcast
Flowr will host a conference call and webcast today at 5:00 p.m. Eastern Time. A question-and-answer session will follow.
Toll Free: 1-877-705-6003
Toll/International: 1-201-493-6725
Webcast: www.flowr.ca/investors
A telephonic replay of the call will be available later that same day through Thursday, April 18, 2019. To listen to the archived call, dial Toll Free 1-844-512-2921 or Toll/International 1-412-317-6671 and enter replay pin number 13689126, or access the webcast replay via Flowr’s website.
About The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and sales license granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities. Flowr's investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Vinay Tolia
Co-CEO and Director
Non-IFRS Financial Measures
This press release makes reference to certain measures that are not recognized measures under International Financial Reporting Standards (“IFRS”). These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS, and are therefore unlikely to be comparable to similar measures presented by other companies. When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure. These measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective. Accordingly, they should not be considered in isolation nor as a substitute to the Company’s financial information reported under IFRS. Management uses non-IFRS measures such as Adjusted EBITDA to provide investors with supplemental information of the Company’s operating performance and thus highlight trends in the Company’s core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, to assess its ability to meet future debt service requirements, in making capital expenditures, and to consider the business’s working capital requirements. Readers are cautioned that the non-IFRS measures contained herein may not be appropriate for any other purpose.
Forward-Looking Information
This press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr and its business, which may include, but are not limited to: statements with respect to Holigen, including the closing of the acquisition, facilities Holigen is proposing to complete, the products it proposes to produce and sell, and the markets it proposes to operate and distribute its products in, Holigen potentially being among the lowest cost producers in the world, Flowr intending to use the Flowr Forest for greenhouse and outdoor production of cannabis and extraction of such other form factors, the Company initiating its licensing process with Health Canada and obtaining its license for Flowr Forest, the Company planning to begin construction and growing the Flowr Forest in 2019 and beyond, the products cultivated from the Flowr Forest being used for extraction in developing edibles and concentrates, the number of greenhouses, size of greenhouses, and size of the outdoor grow at the Flowr Forest, the Company intending to develop Kelowna 2, the planned size of Kelowna 2 and the number of grow rooms expected in Kelowna 2, Flowr only getting started with its planned operations and strategic direction, Flowr’s design and cultivation expertise and superior IP know-how enabling it to grow high quality cannabis on a large scale at industry leading yields, Flowr’s operational efficiency improving with the completion of the Kelowna 1 facility, Flowr having 20 grow rooms fully constructed in the third quarter of 2019, the completion of the Kelowna 1 facility enabling Flowr to begin to capitalize on strategic growth opportunities, the number of kilograms of capacity on an annualized basis, Flowr beginning to sell a wide selection of cannabis cultivars in both seed and clone form in the timeframe disclosed herein, the Company’s cultivation process allowing it to produce high quality clones, the number of clones that Flowr expects to produce on an annualized basis upon completion of the Kelowna 1 facility, the clones being incremental to the Company’s cultivation process and in excess of what it needs for its retail and medical production, the completion and timing of completion of the Kelowna 1 facility, the additional grow rooms that will become available upon completion of the Kelowna 1 facility, the listing of the Company’s common shares on the NASDAQ, the timing thereof and trading of the common shares being approved for listing, Chef Reed developing signature edible cannabis products and high quality edibles that are expected to address the needs of a premium client, the timing of the availability of edible products, Mr. Broome developing high quality products and leading Flowr’s research into cultivars, form factors and delivery systems for the global markets, Flowr being well positioned to complete its facilities build-out and ramp-up production in 2019 and capitalize on its strategic growth opportunities globally, Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeal to the adult-use recreational market and address specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of Flowr’s management and are based on assumptions and subject to risks and uncertainties. Although Flowr’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.
The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including, but not limited to, Flowr being delayed in closing the acquisition of Holigen or such acquisition not being completed, Holigen being unable to complete construction of its proposed facilities or being unable to get the required licenses to operate such facilities, Holigen not being able to produce and/or sell the products described herein or in the markets it proposes to sell such products, Holigen not being among the lowest cost producers in the world, resulting in decreased margins, higher costs and additional financing requirements, the inability of Flowr to use the Flowr Forest for greenhouse and outdoor production of cannabis and extraction of such other form factors, as result of the inability to receive required approvals and licenses, which could have a material adverse impact on Flowr’s results of operations, financial condition and business, the number of greenhouses, size of greenhouses and/or size of outdoor production being materially less than the numbers described herein, which could materially adversely impact the products to be cultivated and produced out of the Flowr Forest and the Company’s forecasts, the Company failing to initiate its licensing process with Health Canada and/or being unable to obtain its Health Canada license for the Flowr Forest, the Company being delayed in initiating its licensing process or Health Canada not approving the license for the Flowr Forest, which could have a material adverse impact on its financial condition, results of operations and business, the Company being delayed in constructing the Flowr Forest or not being able to construct or plant the Flowr Forest at all for any reason, including as a result of not receiving required approvals or due to weather conditions, which could have a material adverse impact on Flowr’s financial condition, results of operations, business, and/or ability to compete in the other form factor markets, the products cultivated from the Flowr Forest not being used or the inability to use such products for extraction in developing edibles and concentrates, any delay in the timing that edibles and concentrates are expected to be legally sold in Canada, which could materially adversely impact Flowr’s future cash-flows and forecasts, Flowr not being in a position to launch cannabis oils and vape technologies in 2019 or not launching them at all, which could have a material adverse impact on Flowr financial results, operations and financial condition, including losing competitive advantages over other licensed producers, the Company not being able to construct the Kelowna 2 facility, which would reduce Flowr’s capacity and have an impact on future financial results, Kelowna 2 being smaller and/or containing fewer grow rooms than as described herein, which could materially reduce the Company’s future planned capacity and forecasts, Flowr not being well positioned to execute on its planned operational and strategic direction, the inability of Flowr’s design and cultivation expertise and superior IP know-how enabling it to grow high quality cannabis on a large scale at industry leading yields, Flowr’s operational efficiency not improving as a result of the completion of the Kelowna 1 facility, Flowr failing to complete the 20 grow rooms or such rooms not being fully operational on the timing described herein, which could have a material adverse impact on Flowr’s business, financial condition and results of operations, the completion of the Kelowna 1 facility not allowing Flowr to begin to capitalize on strategic growth opportunities, Flowr not achieving or producing the number of kilograms of capacity on an annualized basis as set forth herein, which could have a material adverse effect on Flowr’s business, financial condition and results of operations, Flowr not being able to or being delayed in selling a wide selection of cannabis cultivars in both seed and clone form in 2019, which could have a material adverse impact on Flowr’s business, financial condition and results of operations, the Company’s cultivation process not enabling it to produce high quality clones, Flowr not being able to produce the number of clones set forth herein or at all on annualized basis upon completion of the Kelowna 1 facility, which could have a material adverse impact on Flowr’s business, financial condition and results of operations, the clones that Flowr produces not being incremental to the Company’s cultivation process and in excess of what it needs for its retail and medical production, which could have a material adverse impact on Flowr’s business, financial condition and results of operations, the Kelowna 1 facility not being completed or completed in time, the additional grow rooms that will become available upon completion of the Kelowna 1 facility not becoming available on time or at all, which could have a material adverse impact on Flowr’s business, financial condition and results of operations, the listing of the Company’s common shares on the NASDAQ not being approved or further delayed, which could impact the liquidity of the Company’s common shares or cause a significant decline in the price of the common shares, Chef Reed not being able to develop signature edible cannabis products and high quality edibles that are expected to addre ss the needs of a premium client, any delay in the timing of the availability of edible products, which could materially adversely impact additional revenue streams for Flowr, Mr. Broome not being able to lead and develop high quality products and Flowr’s research into cultivars, form factors and delivery systems for the global markets, which could have a material impact on Flowr’s growth and share of an addressable market, the steps taken by Flowr not preparing it financially and/or operationally for the recreational use market and/or to execute on its business strategy, Flowr not completing the build out and/or ramp-up of production in 2019, which could materially adversely impact Flowr’s financial condition, results of operations and business, Flowr not being able to execute on growth strategies, including international opportunities, which could adversely impact Flowrs growth and future prospects, Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities or otherwise, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Flowr requiring additional financing from time to time in order to continue its operations or expand domestically or globally and such financing not being available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Companys business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowrs products to be high quality, the inability of Flowrs products to appeal to the adult-use recreational market and address specific patient needs in the medicinal market, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowrs securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowrs products to treat certain conditions, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements (including the Hawthorne partnership), possible failure to realize the anticipated benefits of partnership arrangements (including the Hawthorne partnership), product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowrs products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowrs filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr.
Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
CONTACT INFORMATION: |
U.S. MEDIA: |
Tim Streeb, ICR |
1-646-677-1800 |
tim.streeb@icrinc.com |
CANADIAN MEDIA: |
Rebecca Brown, Crowns Agency |
1-647-456-5599 |
rebecca@crowns.agency |
INVESTOR RELATONS: |
Raphael Gross, ICR |
1-203-682-8253 |
raphael.Gross@icrinc.com |
Bram Judd |
The Flowr Corporation |
1-647-483-7065 ext. 1520 |
bram@flowr.ca |
2018 Annual Information Form April 3, 2019 |
TABLE OF CONTENTS
EXPLANATORY NOTES
Unless otherwise stated, the information in this Annual Information Form is stated as of December 31, 2018, and all references to the Corporation's fiscal year are to the year ended December 31, 2018. In this Annual Information Form, the Corporation and its subsidiaries, The Flowr Canada Holdings ULC and The Flowr Group (Okanagan) Inc., are collectively referred to as the "Corporation" or "Flowr", unless the context otherwise requires.
Information contained on, or otherwise accessed through, the website of the Corporation, www.flowr.ca, shall not be deemed to be a part of this Annual Information Form and such information is not incorporated by reference herein and should not be relied upon by readers for the purpose of determining whether to invest in the Common Shares (as defined herein) or any other securities of the Corporation.
Unless otherwise indicated, all charts, graphs, tables and figures are prepared by the Corporation's management.
Glossary
Attached as Appendix "A" to this Annual Information Form is a comprehensive glossary of terms. Capitalized terms not otherwise defined in the body of this Annual Information Form shall have the meanings ascribed to such terms in the glossary.
Trademarks
This Annual Information Form includes trademarks that are protected under applicable intellectual property laws and are the property of the Corporation or its affiliates or licensors. Solely for convenience, the trademarks of the Corporation or its affiliates and/or licensors referred to in this Annual Information Form may appear with or without the ® or ™ symbol, but such references or the absence thereof are not intended to indicate, in any way, that the Corporation or its affiliates or licensors will not assert, to the fullest extent under applicable law, their respective rights to these trademarks. Any other trademarks used in this Annual Information Form are the property of their respective owners.
Currency
All references to "$" in this Annual Information Form refer to Canadian dollars, unless otherwise indicated.
Market Data
This Annual Information Form contains certain statistical data, market research and industry forecasts that were obtained, unless otherwise indicated, from independent industry and government publications and reports or are based on estimates derived from such publications and reports and management's knowledge of, and experience in, the markets in which the Corporation operates. Industry and government publications and reports generally indicate that they have obtained their information from sources believed to be reliable, but do not guarantee the accuracy and completeness of their information. While the Corporation believes this data to be reliable, market and industry data is subject to variation and cannot be verified due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. The Corporation has not independently verified the accuracy or completeness of such information contained herein. In addition, projections, assumptions and estimates of the Corporation's future performance and the future performance of the industry in which the Corporation operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described under the heading "Risk Factors" in this Annual Information Form.
3 |
2018 Annual Information Form |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
Certain statements contained in this Annual Information Form constitute "forward-looking information" and "forward looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "forward-looking statements"), which are based upon the Corporation's current internal expectations, estimates, projections, assumptions and beliefs. Statements concerning the Corporation's objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and the business, operations, future financial performance and condition of the Corporation are forward-looking statements. The words "believe", "expect", "anticipate", "estimate", "intend", "may", "will", "would" and similar expressions, including the negative and grammatical variations of such expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking statements. In addition, this Annual Information Form, may contain forward-looking statements attributed to third-party industry sources.
By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts and projections that constitute forward-looking statements will not occur. Such forward-looking statements in this Annual Information Form speak only as of the date of this Annual Information Form. Forward-looking statements in this Annual Information Form include, but are not limited to, statements with respect to:
• the performance of the Corporation's business and operations;
• the Corporation's capital expenditure programs;
• the future development of the Corporation, its growth strategy and the timing thereof;
• the construction and expected completion of the facilities and projects in Kelowna;
• the acquisition strategy of the Corporation;
• the estimated future contractual obligations of the Corporation;
• the Corporation's future liquidity and financial capacity;
• the Corporation's ability to satisfy its financial obligations in future periods;
• the supply and demand for cannabis products and services similar to the Corporation's products and services;
• cost and/or pricing of the Corporation's products;
• expectations regarding the Corporation's ability to raise capital;
• the Corporation's treatment under government regulatory and taxation regimes; and
• the Corporation's net sales of all or any one of its products.
With respect to the forward-looking statements contained in this Annual Information Form, the Corporation has made assumptions regarding, among other things:
• the ability to develop and market future products;
• timing to launch new products;
• cost to develop and/or manufacture products;
• operating cost estimates and yield trends for the Corporation;
• inventory levels;
• pricing for the Corporation's products;
• future market demand/trends;
• gross profitability for products;
4 |
2018 Annual Information Form |
• the ability of the Corporation to comply with its contractual obligations, including, without limitation, its obligations under debt arrangements;
• the successful sale of products to third parties on terms favorable to the Corporation;
• the ability of the Corporation to maintain key strategic alliances, and licensing and partnering arrangements, now and in the future;
• the ability of the Corporation to complete construction of its facilities on time or at all;
• any delay in the construction and/or licencing of the facilities of the Corporation not being material;
• the ability of the Corporation to maintain its distribution networks and distribute its products effectively;
• the general regulatory environment in which the Corporation operates, including the areas of taxation, environmental protection, consumer safety and health regulation;
• the timely receipt of any required regulatory approvals;
• the general economic, financial, market and political conditions impacting the industry in which the Corporation operates;
• the tax treatment of the Corporation and the materiality of legal proceedings;
• the ability of the Corporation to achieve or increase profitability, fund its operations with existing capital, and/or raise additional capital to fund future acquisitions and/or development, including construction and licencing of the facilities of the Corporation;
• the ability of the Corporation to acquire any necessary technology, products or businesses and effectively integrate such acquisitions;
• reliance on third party suppliers to supply the Corporation with products required for its business on favourable terms;
• the ability of the Corporation to generate sufficient cash flow from operations;
• the availability of raw materials and finished products necessary for the Corporation's products;
• the impact of increasing competition;
• the ability of the Corporation to obtain and retain qualified staff, equipment and services in a timely and efficient manner;
• the ability of the Corporation to maintain and enforce the protection afforded by trade secrets or other intellectual property rights;
• the ability of the Corporation to conduct operations in a safe, efficient and effective manner;
• the results of continuing and future safety and efficacy studies by industry and government agencies related to the Corporation's products; and
• the ability of the Corporation to successfully market its products and services.
Forward-looking statements contained in this Annual Information Form are based on the key assumptions described herein. Readers are cautioned that such assumptions, although considered reasonable by the Corporation, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided in this Annual Information Form as a result of numerous known and unknown risks and uncertainties and other factors. The Corporation cannot guarantee future results.
Risks related to forward-looking statements include those risks referenced herein and in the Corporation's other filings with the Canadian Securities Regulators. Some of the risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking statements contained in this Annual Information Form include, but are not limited to, the risk factors described above and included under the heading "Risk Factors" in this Annual Information Form.
Forward-looking statements contained in this Annual Information Form are based on the Corporation's current plans, expectations, estimates, projections, beliefs and opinions and the assumptions relating to those plans, expectations, estimates, projections, beliefs and opinions may change. Management has included the summary of assumptions and risks related to forward-looking statements included in this Annual Information Form for the purpose of assisting the reader in understanding management's current views regarding those future outcomes. Readers are cautioned that this information may not be appropriate for other purposes. Readers are cautioned that the lists of assumptions and risk factors contained herein are not exhaustive. Neither the Corporation nor any other person assumes responsibility for the accuracy or completeness of the forward-looking statements contained herein.
5 |
2018 Annual Information Form |
Such forward-looking statements are made as of the date of this Annual Information Form and the Corporation disclaims any intention or obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
All of the forward-looking statements made in this Annual Information Form are expressly qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Corporation.
Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking statement in this Annual Information Form, and, accordingly, investors should not place undue reliance on any such forward-looking statement. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for the Corporation's management to predict all of such factors, or changes in such factors, or to assess in advance the impact of each such factors on the business of the Corporation or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement contained in this Annual Information Form.
6 |
2018 Annual Information Form |
CORPORATE STRUCTURE
Name, Address and Incorporation
The Flowr Corporation was incorporated under the Business Corporations Act (Alberta) on June 1, 2016. In connection with the completion of the Qualifying Transaction (as defined below), the Corporation continued from being governed under the Business Corporations Act (Alberta) to being governed under the Business Corporations Act (Ontario) on September 25, 2018 and amalgamated on January 1, 2019 with a subsidiary of the Corporation, The Flowr Group Inc. The head office of Flowr is located at 461 King Street West, Floor 2, Toronto, Ontario M5V 1K4. The registered office of the Corporation is located at 100 Allstate Parkway, Suite 201, Markham, Ontario L3R 6H3. The Corporation's shares are listed on the TSX-V under the symbol "FLWR".
The Corporation, formerly known as The Needle Capital Corp. ("Needle") was previously classified as a Capital Pool Company as defined in Policy 2.4 of TSX-V. On September 21, 2018, the Corporation completed a qualifying transaction under the TSX-V rules pursuant to a business combination agreement between The Flowr Corporation ("Flowr Privateco"), Needle and 2652253 Ontario Inc. ("Needle Subco") which resulted in a reverse takeover of Needle by the shareholders of Flowr Privateco (the "Qualifying Transaction"). In connection with the Qualifying Transaction, Flowr Privateco and Needle Subco amalgamated and the name of the amalgamated company was changed to The Flowr Group Inc. On January 1, 2019, the Corporation and The Flowr Group Inc. amalgamated with the name of the amalgamated company being "The Flowr Corporation".
7 |
2018 Annual Information Form |
GENERAL DEVELOPMENT OF THE BUSINESS
Company History
The Corporation, formerly known as Needle, was previously classified as a Capital Pool Company as defined in Policy 2.4 of the TSX-V. The principal business of Needle was to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein in a manner that would constitute a qualifying transaction under TSX-V rules.
On September 21, 2018, the Corporation completed the Qualifying Transaction pursuant to a business combination agreement between Flowr Privateco, Needle and Needle Subco, which resulted in a reverse takeover of Needle by the shareholders of Flowr Privateco. In connection with the Qualifying Transaction, Flowr Privateco and Needle Subco amalgamated and the name of the amalgamated company was changed to The Flowr Group Inc. On January 1, 2019, the Corporation and The Flowr Group Inc. amalgamated with the name of the amalgamated company being "The Flowr Corporation".
Prior to December 1, 2017, the business of the Corporation was originally undertaken solely by Cannatech Plant Systems Inc. ("Cannatech"), a British Columbia corporation. On December 1, 2017, a reorganization was completed that resulted in the limited partners of Flowco Services LP and Flowco Investments LP becoming shareholders of Flowr Privateco and Flowr Privateco having one direct subsidiary, The Flowr Canada Holdings ULC ("Flowr ULC"), a British Columbia corporation, and two indirect subsidiaries, The Flowr Group (Okanagan) Inc., formerly known as Cannatech ("Flowr Okanagan") and Flowco Advisory LP (organized in Ontario). Flowco Advisory LP is a dormant entity with no assets at this time. For a further description of the reorganization, see the Corporation's consolidated financial statements for the years ended December 31, 2018 and 2017 under the heading "Corporate Information".
The Corporation owns 100% of the issued and outstanding common shares of Flowr ULC and two U.S. shareholders own 100% of the issued and outstanding class A preferred shares in the capital of Flowr ULC (the "Flowr ULC Class A Shares"). The Corporation's interest in Flowr Okanagan is held through Flowr ULC, which owns 100% of the issued and outstanding shares in Flowr Okanagan.
8 |
2018 Annual Information Form |
DESCRIPTION OF THE BUSINESS
General Description of the Business
Flowr operates in the high growth cannabis industry and is focused on producing high-yield, premium cannabis for both medical patients and adult-use throughout Canada, through its indoor growing operations located in the Okanagan Valley of British Columbia (the "Kelowna Campus"). The Corporation's production launch plan is to continue to focus on dried flower products (i.e. dried flower jars and pre-rolls) and strategically enter adjacent verticals including cultivar sales, cannabis oils, vape technology, edibles, beverages and topical products as demand patterns evolve. In light of this expected market demand, on February 12, 2019 Flowr purchased a parcel of land across the street from its current operations, which it plans to use for greenhouse production of cannabis and extraction of such other form factors (the "Flowr Forest"). The Corporation believes that a small subset of such form factors, such as "live resin" vape products, will be best produced using its indoor cultivated premium dried flower. However, the Corporation believes that high quality versions of many of these form factors can be produced using lower-cost biomass from greenhouse and outdoor growing formats such as the Flowr Forest.
In addition, commencing in the second quarter of 2019, Flowr plans to sell a wide selection of cannabis cultivars in both clone and seed form. Flowr expects its efficient cultivation process will allow it to produce more than 3.2 million high quality clones on an annualized basis once the first facility in the Kelowna Campus is completed. These clones will be incremental to Flowr's cultivation process and therefore will be in excess of the Corporation's requirements to support its retail and medical production. Flowr believes that the current demand for high-quality clones exceeds supply given the rapid expansion of cultivation facilities commencing construction in Canada and globally.
The Corporation's operational team is comprised of individuals with significant experience in facility design, construction and cultivation. This operational team includes co-founders and employees of MedReleaf, which was sold to Aurora in a transaction valued at $3.2 billion when announced in May 2018. Having constructed 17 facilities under various regulatory regimes in Canada, the expertise of the Flowr operational team is unparalleled in the Canadian industry. As at December 31, 2018, the Corporation had 121 employees (78 full-time and 43 part-time).
Products
Flowr's branding strategy is focused on two distinct brands: (1) FlowrRx®, for the medical market; and (2) Flowr®, for the Canadian legalized adult-use market. FlowrRx® targets the wellness, health and alternative treatment market capturing revenue through regular patient use. The Flowr® brand is well positioned for the fast-growing adult-use cannabis markets, seeking to produce consistent, non-irradiated product to provide customers with premium product, with robust terpene profiles. Management believes premium, quality flower is difficult to grow and many consumers are willing to pay premium prices for premium product. The Corporation believes that Flowr's ability to grow premium products has allowed it to realize prices that exceed the Canadian national average price per gram by approximately 49%, based on sales data provided by the OCS and in becoming a leading brand in pre-roll products in Ontario.
The Corporation currently has the following cultivars available for sale in the adult use and medical markets in Canada:
Medical Market:
9 |
2018 Annual Information Form |
Recreational Market:
Key Markets
Premium Indoor Grown Products Market
Adult-use dried flower sales in markets continue to experience strong growth, even as these markets mature and new product formats are introduced. Flowr believes that high product quality, as defined by sensory experience, THC content, and robust terpene profiles, is extremely important to frequent consumers' purchasing decisions.
Through its purpose-built indoor growing facility in the Okanagan Valley, which is being designed to GMP standards, the Corporation is able to control key growing variables to cultivation, including lighting, temperature, irrigation and pest control. Key insights developed by designing and developing multiple growing facilities have allowed Flowr to design systems intended to optimize yield, number of harvests per year, quality of product and product consistency.
Flowr believes that through exerting a high degree of control over the environment in which cannabis is grown using its state-of-the-art indoor facilities, it can achieve a high degree of product consistency with respect to the chemical composition and terpene profiles of the cultivars it grows, as well as the cleanliness of the end product distributed to consumers.
Cultivars
Flowr's strategy for growing and supplying premium cannabis products starts with the selection of seeds with the desired genetics. In addition to the cultivars available for sale, as described above, Flowr has another twenty (20) cultivars being tested for potential future production. Flowr typically selects plant genetics based on several factors including optimal growth characteristics, cannabinoid levels, terpene profiles, and anticipated distinctiveness in the market in order to curate a suitably complete product mix. Flowr plans to continue to develop new genetic varieties offering distinctive cannabinoid profiles and therapeutic effects. The Corporation is dedicated to the research of cannabis, and has assembled a team of experts to use genetics, breeding and cultivation data to create better and more resilient cultivars.
Flowr's PhD-led plant genetics research and development program is aimed at breeding new varieties of plants to meet the needs of specific customer preferences based on the success of the cultivars it sells. The Corporation's development team includes leading product development and scientific executives, including the first North American recipient of a PhD in research focused on cannabis production.
In addition, an objective of the Corporation is to develop new and/or improved cannabis cultivars with genetics intended to optimize levels of production. Accordingly, Flowr has entered into an agreement pursuant to which Flowr is building along with the Hawthorne Gardening Company ("Hawthorne"), a subsidiary of The Scotts Miracle-Gro Company, a 50,000 square foot research and development facility located at the Kelowna Campus. Flowr believes that this practical commercial laboratory will allow the Corporation to develop and refine new products and cultivation techniques, leveraging Hawthorne's decades of experience with growing techniques and growing products.
10 |
2018 Annual Information Form |
Terpene Profiles and Irradiation
As part of strain selection, and in its overall approach to producing premium cannabis, the Corporation focuses on achieving industry-leading terpene levels responsible for producing rich tastes and aromas. Terpenes are also thought to be important for the "entourage effect" by which multiple components of cannabis interact to create a psychoactive effect. The Corporation, therefore, believes that preserving the terpene profile of its products is an important differentiating factor in producing premium products.
Like other licensed producers, in order to comply with Health Canada's stringent requirements the Corporation treats some of its products with irradiation, a "kill step" used to eliminate microbial contamination. However, unlike its peers - the vast majority of whom, according to MJ Observer, routinely use irradiation to comply - the Corporation has a strategic focus on reducing and ultimately eliminating the need for irradiation, because of the negative effect of irradiation on terpenes and the potential for residual mycotoxins. A 2016 study conducted by the peer-reviewed journal Frontiers in Pharmacology found that the use of irradiation on cannabis measurably reduced multiple terpenes, in some cases by as much as 38%, potentially compromising its efficacy for medical customers, and its psychoactive effect, tastes and aromas for recreational customers.
Through exercising a high degree of control over the environment in which it grows its cannabis at the K1 Facility (as defined below), Flowr has been able to produce certain batches of products without the use of irradiation. Through continued refinement of its design and construction capability, through the experiences of the Flowr operational team, the Corporation intends to reduce and potentially eliminate the use of irradiation. Moreover, in designing its current facility to GMP standards (see "The Facility" below), Flowr believes that the cleanliness of such operations can further improve the ability of the Corporation to produce cannabis that is not affected by the growth of pests and bacteria, and thus not requiring irradiation.
The Facility
Flowr Okanagan is a holder of a Standard Cultivation, Standard Processing and Sale for Medical Purposes licence to produce and sell cannabis products (the "Licence") under the Cannabis Act and the Cannabis Regulations under the Cannabis Act (the "Cannabis Regulations") and operates, what the Corporation expects upon completion to be, an 85,000-square-foot GMP designed cultivation facility in Kelowna, British Columbia (the "K1 Facility"). Flowr carries on its current cultivation operations from the K1 Facility.
Flowr's operational team has significant experience in designing and building cannabis cultivation facilities and in cultivating cannabis plants, which has allowed the Flowr team to design and control the K1 Facility's cultivation environment. Accordingly, the K1 Facility features industry-leading security systems, climate control, lighting, cultivation systems, and other proprietary cultivation equipment to realize operational efficiencies.
Flowr leases the K1 Facility pursuant to a lease expiring November 30, 2041, with an option to extend the term of the lease as well as an option to purchase the K1 Facility pursuant to the terms of the lease.
Flowr expects to complete construction of the K1 Facility by the end of the third quarter of 2019. When complete, Flowr expects the K1 Facility to produce in excess of 10,000 kilograms of premium cannabis flower on an annualized basis. To the extent the Corporation has available working capital, the Corporation also anticipates beginning construction of its larger Kelowna 2 facility (the "K2 Facility") during the second half of 2019 and projects that facility to produce in excess of 40,000 kilograms on an annualized basis after its completion, which completion is targeted for the end of 2021 assuming that such project is fully funded in the near term. In the first quarter of 2019, Flowr commenced construction of the Flowr Forest, and is targeting the second half of 2019 to begin cultivation of the Flowr Forest, assuming it receives all necessary licences and approvals to commence cultivation, including, without limitation, Health Canada and permitting approvals. As described below, the Corporation believes that it can produce product for extraction into other form factors using lower-cost biomass from greenhouse and outdoor growing formats such as the Flowr Forest. In addition, Flowr has a right of first refusal on two additional parcels of land adjacent to the Flowr Forest. See "Extraction Market".
11 |
2018 Annual Information Form |
Manufacturing Certifications
The K1 Facility is designed to be compliant with GMP, including the requirements of the ICH. ICH Good Manufacturing Practices are the standards and procedures that pharmaceutical companies must adhere to in manufacturing products in North America. The ICH Good Manufacturing Practices exceed the good pharmacy practice standards required by Health Canada for growing and cultivating medical cannabis. The K1 Facility was assessed by Orion GMP Solutions to determine whether its production processes meet the ICH Good Manufacturing Practices requirements. Based on the results of Orion GMP Solutions' audit, Flowr expects that the ICH Good Manufacturing Practices certification will be received by the end of 2019 after completion of the K1 Facility. If obtained, this certification will signify that Flowr's production practices meet stringent pharmaceutical manufacturing requirements that are internationally harmonized in 17 countries including the United States, Canada, Singapore, Japan, Australia and several European nations. The Corporation expects that such certification, if obtained, will provide the Corporation with a competitive advantage relative to other producers that do not produce cannabis in compliance with these standards, in particular with respect to the export of products to jurisdictions, such as Germany and Australia, that require product to be manufactured in accordance with GMP standards.
Extraction Market
Flowr is planning to begin planting the Flowr Forest upon receipt of Health Canada and other required approvals. The products cultivated from the Flowr Forest will be used for extraction in developing edibles and concentrates. The Corporation expects extracts for vaping, cannabis oils, active pharmaceutical ingredients, edibles, capsules, tinctures and beverages to be brought to market in both psychoactive (THC-focused) and non-psychoactive (CBD-focused) varieties. The Corporation's development team that will lead its efforts on extraction includes leading product development and scientific executives with PhD holders, including the first North American recipient of a PhD in research focused on cannabis production. The Corporation believes that the addition of these new consumer-friendly formats will significantly expand the size of the addressable market for the Corporation, as convenient, discreet and precisely dosage-metered products such as vape pens, capsules and edibles, bring in new consumers less familiar with cannabis and less accustomed to smoking or vaping dried flower. Flowr expects that its cost of production at the Flowr Forest will be significantly less than its current cost of production at the K1 Facility, thus enabling it to compete in the mass market with a lower cost product that benefits from Flowr's reputation as a premium provider of indoor grown premium flower.
Cultivar Market
Commencing in the second quarter of 2019, Flowr plans to sell a wide selection of cannabis cultivars in both clone and seed form. Flowr expects that its highly efficient cultivation process will allow it to produce more than 3.2 million high quality clones on an annualized basis once the K1 Facility is completed. Flowr believes there is an opportunity to sell cultivars in four key markets: Canadian licence holders seeking high quality genetics as they expand production; micro-cultivators, a new Health Canada licence subclass that can operate small "craft" cultivation facilities; export to producers in international markets; and, individuals purchasing through provincial or licenced private retailers for personal use.
Marketing
The Corporation's marketing strategies to promote Flowr's brands are primarily carried out through consumer education and in-person engagement at local events. Branding and marketing is also conducted through a digital component that consists of on-going website, blog and social channel content creation. Given the constraints imposed under the Cannabis Act and Cannabis Regulations related to marketing, the Corporation intends to use "guerilla" marketing techniques to market its products. The Corporation is in the process of building out its marketing function, and expects to manage most of its marketing functions internally.
Competitive Environment
In addition to other licensed producers currently operating, the Corporation expects that Health Canada will continue to grant new licenses to process, cultivate and sell cannabis and, therefore, the total number of licensed producers will increase. As such, the Corporation believes that it will face ongoing and increased competition from other licensed producers. Further, as the number of licensed producers increases, the supply of cannabis from licensed producers may exceed demand. The Cannabis Act also permits individuals to grow a limited number of cannabis plants for personal use. For further details on how cannabis may be produced and distributed in Canada see "Regulatory Framework - Canada" of this AIF.
12 |
2018 Annual Information Form |
Key Distribution Channels
Recreational Market
Flowr has key distribution agreements with some of the largest Canadian provincial boards including Ontario and British Columbia and distribution arrangements in Saskatchewan, Nova Scotia and Manitoba. The Corporation will continue to optimize its distribution network to enhance the brand value of its products while selecting retail partners as regulations change in individual provinces.
In October 2018, Flowr also entered into a strategic partnership with AV Cannabis Inc. ("Ace Valley") to create a new brand of cannabis products for the adult-use market with the team that developed Ace Hill Beer. Ace Valley's curated product portfolio of pre-rolled joints and premium dried flower applies the Ace Hill Beer team's understanding of consumer values and trends to the cannabis market, while leveraging Flowr's expertise in cultivation. Ace Valley's flagship products are pre-rolled joints available in two cultivars: Ace Valley Sativa and Ace Valley CBD, both grown and craft-cured by Flowr's cultivators in the K1 Facility. The Ace Valley partnership has provided Flowr with insights in identifying and capitalizing on consumer values and trends.
Medical Market
In January 2019, Flowr announced that it had entered into an agreement to supply medical cannabis to Shoppers on a purchase order basis, with a term of three (3) years, and a two (2) year renewal option. In addition, in Q1 of 2019, Shoppers' new e-commerce site became the direct-to-patient online provider of FlowrRx® products in Canada. Flowr believes that this opportunity could significantly increase its sales of medical cannabis products in Canada, given Shoppers reach and access to patients in Canada. This agreement will also enable Flowr to have a low cost distribution channel for its medical products.
Yield
Unique insights developed by designing and developing multiple growing facilities have allowed Flowr to design systems intended to optimize yield, number of harvests per year and product consistency. Flowr's current annual production capacity of 4,500 kg at the K1 Facility is expected to expand to over 10,000 kg of production by the end of 2019 with the additional grow rooms coming on stream.
Management believes that Flowr's business strategy will allow the Corporation to generate strong growth and free cash flow. Growth will be driven by (i) increased domestic production and product breadth, (ii) international growth and (iii) continued operational efficiencies. As Flowr continues to expand its production, such expansion provides economics of scale and reduced production costs. The Corporation is targeting yields of 275 g/sq. ft by Q4 of 2019. The Corporation believes its cultivation design, careful selection of cultivars to develop and lowering costs of production, such as packaging efficiencies and certain automation, will allow Flowr to achieve greater yields per square foot. This focus on high yields and lower costs is expected to generate a strong, attractive free cash flow profile and strong EBITDA margins, as Flowr continues to seek to price its premium products at premium pricing.
Recent Events
On November 19, 2018, the Corporation entered into a binding term sheet with Holigen Holdings Limited ("Holigen"), pursuant to which the Corporation agreed to lend $6,000,000 to Holigen. The proceeds received from Flowr are being used by Holigen to purchase land and obtain certain cannabis related licenses in certain jurisdictions including Portugal. As of December 31, 2018, $6,000,000 had been advanced to Holigen. Flowr has the right to convert all debt owing under the loan facility into the same class of shares held by the shareholders of Holigen, or a subsidiary thereof, that would result in a 19.8% equity interest in Holigen, or a subsidiary thereof.
The Corporation's Filing Statement dated September 19, 2018 included information related to the Corporation's use of proceeds from the RTO Financing. As a result of the foregoing, the Corporation has committed $6,000,000 from the RTO Financing to advance this loan to Holigen.
13 |
2018 Annual Information Form |
On December 19, 2018, the Corporation entered into the Holigen Agreement which effectively exercises the Corporation's option to convert the loan receivable into shares of Holigen, or a subsidiary thereof. In addition, on December 19, 2018, the Corporation entered into a license agreement with Holigen, whereby the Corporation agreed to provide certain intellectual property to Holigen to accelerate the completion of Holigen's construction and licensing projects. The closing of the acquisition of the 19.8% equity interest with Holigen, or a subsidiary thereof, is subject to certain closing conditions.
14 |
2018 Annual Information Form |
EQUITY TRANSACTIONS
The Corporation completed the following equity transactions during the past three years:
On September 30, 2016 Needle completed a private placement of 4,200,000 Needle Shares at a price of $0.05 per share for aggregate gross proceeds of $210,000.
On September 15, 2017, Needle completed its initial public offering of 3,000,000 Needle Shares at a price of $0.10 per share pursuant to a prospectus dated June 16, 2017.
On January 9, 2018, Flowr Privateco completed a non-brokered private placement of 15,000,000 Flowr Class A Shares at a price of $1.00 per share, for aggregate gross proceeds of $15,000,000. The private placement closed in two tranches, as follows:
On December 28, 2017, 14,185,000 Flowr Class A Shares were issued for aggregate gross proceeds of $14,185,000; and
On January 9, 2018, 815,000 Flowr Class A Shares were issued for aggregate gross proceeds of $815,000.
Between April 11, 2018 and July 18, 2018, Flowr Privateco completed a non-brokered private placement, in five tranches, of 5,309,361 Flowr Common Shares at a price of $2.60 per share, for aggregate gross proceeds of $13,804,339.
As part of the Qualifying Transaction, Flowr Privateco completed a brokered and non-brokered private placement on August 28, 2018 of an aggregate of 13,807,734 Subscription Receipts at a price of $2.60 per Subscription Receipt for aggregate gross proceeds of $35,900,108 (the "RTO Financing").
15 |
2018 Annual Information Form |
REGULATORY FRAMEWORK
The following summary addresses the primary laws and regulations of Canada, Australia and Portugal that are associated with the production and distribution of legal cannabis and related products. It does not address the laws and regulations of any other jurisdiction. The Corporation believes that, as of the date of this Annual Information Form, it is in material compliance with all laws and regulations summarized below.
Canada
Background
On October 17, 2018, the Cannabis Act and the Cannabis Regulations came into force, legalizing the sale of cannabis for adult-use. Prior to the Cannabis Act and the Cannabis Regulations coming into force, only the sale of medical cannabis was legal and was regulated by the ACMPR made under the CDSA. The Cannabis Act and the Cannabis Regulations replaced the CDSA and the ACMPR as the governing laws and regulations in respect of the production, sale and distribution of medical cannabis and related oil extract. Given that the Cannabis Act and the Cannabis Regulations are very new, the impact of such regulatory changes on the Corporation's business is unknown. See "Risk Factors - Changes in Laws, Regulations and Guidelines".
The Cannabis Act provides a licensing and permitting scheme for the production, importation, exportation, testing, packaging, labelling, sending, delivery, transportation, sale, possession and disposal of cannabis for non-medical (i.e., adult use) use, to be implemented by regulations made under the Cannabis Act. The Cannabis Act maintains separate access to cannabis for medical purposes, including providing that import and export licences and permits will only be issued in respect of cannabis for medical or scientific purposes or in respect of industrial hemp.
The Cannabis Regulations, among other things, set out regulations relating to the following matters: (1) Licences, Permits and Authorizations; (2) Security Clearances; (3) Cannabis Tracking System; (4) Cannabis Products; (5) Packaging and Labelling; (6) Cannabis for Medical Purposes; and (7) Drugs Containing Cannabis.
Transitional provisions of the Cannabis Act provide that every licence issued under Section 35 of the ACMPR that was in force immediately before the day on which the Cannabis Act came into force (being October 17, 2018) was deemed to be a licence issued under the Cannabis Act, and that such licence will continue in force until it is revoked or expires.
Licences, Permits and Authorizations
The Cannabis Regulations establish six classes of licences under the Cannabis Act: cultivation licences; processing licences; analytical testing licences; sales for medical purposes licences; research licences; and cannabis drug licences. The Cannabis Regulations also create subclasses for cultivation licences (standard cultivation, micro-cultivation and nursery) and processing licences (standard processing and micro-processing). Different licences and each subclass therein, carry differing rules and requirements that are intended to be proportional to the public health and safety risks posed by each licence category and each subclass. The Cannabis Regulations provide that all licences issued under the Cannabis Act will be valid for a period of no more than five years.
Security Clearances
Certain people associated with cannabis licensees, including individuals occupying a "key position" such as directors, officers, large shareholders and individuals identified by the Minister, must hold a valid security clearance issued by the Minister. Under the Cannabis Regulations, the Minister may refuse to grant security clearances to individuals with associations to organized crime or with past convictions for, or an association with, drug trafficking, corruption or violent offences. This was largely the approach in place under the ACMPR and other related regulations governing the licenced production of cannabis for medical purposes. Individuals who have histories of non-violent, lower-risk criminal activity (for example, simple possession of cannabis, or small-scale cultivation of cannabis plants) are not precluded from participating in the legal cannabis industry, and the grant of security clearance to such individuals is at the discretion of the Minister and such applications will be reviewed on a case-by-case basis. See "Risk Factors - Dependence on Skilled Labour and Suppliers".
16 |
2018 Annual Information Form |
Cannabis Tracking System
Under the Cannabis Act, the Minister is authorized to establish and maintain a national cannabis tracking system. The purpose of this system will be to track cannabis throughout the supply chain to help prevent diversion of cannabis into, and out of, the legal market. The Cannabis Regulations provide the Minister with the authority to make a ministerial order that would require certain persons named in such order to report specific information about their authorized activities with cannabis, in the form and manner specified by the Minister. The Minister has introduced the Cannabis Tracking and Licensing System, and licence holders are required to use this system to submit monthly reports to the Minister, among other things.
Cannabis Products
The Cannabis Regulations set out the requirements for the sale of cannabis products at the retail level and permit the sale of dried cannabis, cannabis oil, fresh cannabis, cannabis plants, and cannabis seeds, including in such forms as "pre-rolled" and capsule products. The THC content and serving size of cannabis products is limited by the Cannabis Regulations. The sale of edible cannabis products and concentrates (such as hashish, wax and vaping products) are currently prohibited but expected to be permitted within one year following the Cannabis Act coming into force. The Cannabis Regulations acknowledge that a range of product forms should be enabled to help the legal industry displace the illegal market. Additional product forms that are mentioned under the Cannabis Regulations include vaporization cartridges manufactured with dried cannabis. Specific details related to these new products are set out in a separate regulatory proposal issued after the coming into force of the Cannabis Act.
Packaging and Labelling
The Cannabis Regulations set out requirements pertaining to the packaging and labelling of cannabis products which are intended to promote informed consumer choice and allow for the safe handling and transportation of cannabis, while also reducing the appeal of cannabis to youth and promoting safe consumption. These requirements require plain packaging for cannabis products, including strict requirements for logos, colours and branding, as well as packaging that is tamper-proof and child-resistant. The Cannabis Regulations further require mandatory health warnings, standardized cannabis symbols and specific product information. Cannabis package labels must include specific information, such as: (i) product source information, including the class of cannabis and the name, phone number and email of the cultivator; (ii) a mandatory health warning, rotating between Heath Canada's list of standard health warnings; (iii) the Health Canada standardized cannabis symbol; and (iv) information specifying THC and CBD content. The Cannabis Regulations provided a six-month transitional period to allow licenced holders to sell cannabis products labelled in accordance with the ACMPR.
Advertising
The Cannabis Act introduces restrictions regarding the promotion of cannabis products. Subject to a few exceptions, all promotions of cannabis products are prohibited unless authorized by the Cannabis Act.
Health Products and Cosmetics Containing Cannabis
Health Canada has taken a scientific, evidenced-based approach for the oversight of health products with cannabis that are approved with health claims, including prescription and non-prescription drugs, natural health products, veterinary drugs and veterinary health products, and medical devices. Under the Cannabis Regulations, the use of cannabis-derived ingredients (other than certain hemp seed derivatives containing no more than 10 parts per million THC) in cosmetics is permitted and will be subject to the provisions of the Cannabis Act.
Cannabis for Medical Purposes
With the Cannabis Act and the Cannabis Regulations coming into force on October 17, 2018, the medical cannabis regime migrated from the CDSA and the ACMPR to the Cannabis Act and the Cannabis Regulations. The medical cannabis regulatory framework under the Cannabis Act and the Cannabis Regulations remains substantively the same as it existed under the CDSA and the ACMPR, with adjustments to create consistency with rules for non-medical use, improve patient access, and reduce the risk of abuse within the medical access system. Under Part 14 of the Cannabis Regulations, patients have three options for obtaining cannabis for medical purposes: (i) they can continue to access cannabis by registering with licenced producers; (ii) they can register with Health Canada to produce a limited amount of cannabis for their own medical purposes; or (iii) they can designate someone else to produce cannabis for them. With respect to (ii) and (iii), starting materials, such as cannabis plants or seeds, must be obtained from licenced producers. It is possible that (ii) and (iii) could significantly reduce the addressable market for the Corporation's products and could materially and adversely affect the business, financial condition and results of operations of the Corporation. However, management of the Corporation believes that many patients may be deterred from opting to proceed with options (ii) or (iii) since such steps require applying for and obtaining registration from Health Canada to grow cannabis, as well as the up-front costs of obtaining equipment and materials to produce such cannabis.
17 |
2018 Annual Information Form |
Provincial Regulatory Framework
While the Cannabis Act provides for the regulation of the commercial production of cannabis for adult-use purposes and related matters by the federal government, the Cannabis Act provides that the provinces and territories of Canada have authority to regulate other aspects of adult-use cannabis (similar to what is currently the case for liquor and tobacco products), such as sale and distribution, minimum age requirements, places where cannabis can be consumed, and a range of other matters. At present, the Corporation has entered into supply agreements or arrangements with distributors in the provinces of Ontario, Manitoba, Saskatchewan, Nova Scotia and British Columbia. All Canadian provinces and territories have announced regulatory regimes for the distribution and sale of cannabis for adult-use purposes within those jurisdictions. There are essentially three general frameworks that the provinces and territories have proposed and/or enacted: (i) private cannabis retailers licenced by the province; (ii) government run retail stores; or (iii) a combination of both frameworks (e.g., privately licenced bricks and mortar retail stores, while online retail stores are operated by the applicable provincial government). Regardless of the framework, the adult-use cannabis market is ultimately supplied by federally licenced cultivators and processors. In many cases, the provinces and territories that have or propose to have privately licenced retailers will have a government run wholesaler. Such privately licenced retail stores are or will be required to obtain their cannabis products from the wholesalers, while the wholesalers, in turn, acquire the cannabis products from the federally licenced cultivators and processors. In addition, each of these Canadian jurisdictions has established a minimum age of 19 years old, except for Québec and Alberta, where the minimum age is 18.
Québec: In Québec, all adult-use cannabis must be managed and sold through outlets of the Société québécoise du cannabis, a subsidiary of the Société des alcools du Québec, and its online site.
Ontario: In Ontario, the distribution and retail sale of adult-use cannabis is to be conducted through the Ontario Cannabis Retail Corporation ("OCRS"), a subsidiary of the Liquor Control Board of Ontario, while adult-use cannabis is sold online through the OCS platform. Ontario allowed the sale of adult-use cannabis by private retailers commencing on April 1, 2019. In addition, the regulatory regime in Ontario:
requires private retailers to obtain both a retail operator licence and a retail store authorization. Retail store authorizations are only to be issued to persons holding a retail operator licence. Separate retail store authorizations are to be required for each cannabis retail store, but a licenced retail operator may hold more than one retail store authorization and operate multiple stores. Private retailers are not permitted to sell cannabis on-line, but may only sell cannabis in person at an authorized retail store;
requires anyone who supervises employees, oversees cannabis sales, manages compliance or has signing authority to purchase cannabis, enters into contracts or hires employees to have a cannabis retail manager licence;
limits licensed producers and their "affiliates" from holding more than one retail location between them, and requiring that such retail location be located on or within the premises licensed by the Cannabis Act. The term "affiliate" is broadly defined and includes, among other things: (i) a corporation of which licenced producers own or control (directly or indirectly) or have the right to acquire shares (or convertible securities) to which 9.9% or more of the voting rights attach; (ii) a partner in the same partnership as the licensed producer; and (iii) member of the same joint venture, unincorporated association, unincorporated syndicate or unincorporated organization as the licensed producer;
prohibits federally licenced producers from promoting their products by way of providing any material inducement to cannabis retailers;
permits municipalities and reserve band councils to opt out of the retail cannabis market by resolution. Municipalities had until January 22, 2019 to pass such by-laws. Municipalities that opt out may later lift the prohibition on retail cannabis stores by subsequent resolution. Municipalities may not pass a by-law providing for a further system of licensing over the retail sale of cannabis; and
18 |
2018 Annual Information Form |
imposes further restrictions through future regulation. Cannabis retail store operators are only permitted to purchase cannabis from the OCRS, which may set a minimum price for cannabis or classes of cannabis.
British Columbia: In British Columbia, adult-use cannabis is to be sold through both public and privately operated stores, with the provincial Liquor Distribution Branch handling wholesale distribution.
Alberta: In Alberta, cannabis products are sold by private retailers that receive their products from a government-regulated distributor, similar to the distribution system currently in place for alcohol in the province. Only licenced retail outlets are to be permitted to sell cannabis with online sales run by the Alberta Gaming and Liquor Commission.
Saskatchewan: In Saskatchewan, adult-use cannabis is sold by private retailers. The Saskatchewan Liquor and Gaming Authority is to issue approximately 50 retail permits to private stores located across the province, with municipalities having the option of opting out of having a cannabis store if they choose.
Manitoba: In Manitoba, a "hybrid model" for cannabis distribution applies where the supply of cannabis is secured and tracked by the Manitoba Liquor and Lotteries Corp.; however, licenced private retail stores will be permitted to sell adult-use cannabis.
New Brunswick: In New Brunswick, adult-use cannabis is sold through a network of tightly-controlled, stand-alone stores through the New Brunswick Liquor Corporation.
Nova Scotia: In Nova Scotia, the Nova Scotia Liquor Corporation is responsible for the regulation of cannabis in the province, and adult-use cannabis is only to be sold publicly through government-operated storefronts and online sales.
Prince Edward Island: In Prince Edward Island, similar to Nova Scotia, cannabis must be sold publicly, through government stores and online.
Newfoundland and Labrador: In Newfoundland and Labrador, adult-use cannabis must be sold through licenced private stores, with its crown-owned liquor corporation, the Newfoundland and Labrador Liquor Corp. (the "NLC"), overseeing the distribution to private sellers who may sell to consumers. The NLC controls the possession, sale and delivery of cannabis, and sets prices. It is also the initial online retailer, although licences may later be issued to private interests. The Government of Newfoundland and Labrador has issued a request for proposals for private retailers.
Yukon: The Yukon limits the initial distribution and sale of adult-use cannabis to government outlets and government-run online stores, and allows for the later licensing of private retailers.
Northwest Territories: The Northwest Territories relies on the N.W.T. Liquor Commission to control the importation and distribution of cannabis, whether through retail outlets or by mail order service run by the liquor commission. Communities in the Northwest Territories will be able to hold a plebiscite to prohibit cannabis, similar to options currently available to restrict alcohol in the Northwest Territories.
Nunavut: In Nunavut, the Nunavut Liquor and Cannabis Commission is responsible for the sale of cannabis remotely (both online and by phone), in physical stores, and through private third party agents.
Australia
Australia's federal, state and territorial regulatory framework is relatively new, as Australia transitions from a prohibition-based framework to a framework in which certain medical cannabis activities are permitted, but strictly regulated.
The cultivation, production, manufacturing, distribution and use of cannabis and cannabis products in Australia is governed by the Narcotic Drugs Act 1967 (Cth) (the "Narcotics Act"). Further, Australia's federal laws must adhere to the country's treaty obligations, including the Single Convention on Narcotic Drugs which restricts the possession, use, trade, distribution, import, export, manufacture and production of narcotic drugs (including cannabis) to medical and scientific purposes.
The Australian Government Department of Health regulates medical cannabis products through the Office of Drug Control (the "ODC"), which oversees controlled substances, including cannabis. The ODC is responsible for granting licences and permits for the cultivation and production, manufacture and importation of cannabis and cannabis products for medical and scientific purposes. In addition, the Therapeutic Goods Administration (the "TGA") also regulates the manufacture, registration and supply of medical cannabis. Under the Narcotics Act, cultivation and production, manufacturing and import licences are subject to screening by the ODC, and must satisfy certain "fit and proper person" requirements which take into account: (i) any convictions or civil penalties under the laws of the Commonwealth, states or territories; (ii) the associations of the directors and officers of the licensee; (iii) previous business experience of the directors and officers of the licensee; (iv) whether the directors and officers of the licensee are of good repute, having regard to their character, honesty and integrity; (v) the financial capacity and circumstances of the licensee; and (vi) and the ability of the licensee to meet the conditions of the licence.
19 |
2018 Annual Information Form |
State and territorial governments are responsible for the prescription, storage and supply of medical cannabis and medical cannabis products.
Cultivation and Production
Cultivation, including production, requires a cultivation licence issued by the ODC. A cultivation licence allows the licensee to cultivate cannabis plants to produce dried cannabis and cannabis resin. Cultivation licences must be renewed every two years. Before starting cultivation and/or production, licensees must also obtain a cultivation permit and/or production permit from the ODC. Cultivation permits authorize specific activities relating to the cultivation of cannabis, and include restrictions on the types and strains of plants that may be cultivated, the maximum number of plants that may be cultivated, and limitations on the concentrations of THC and CBD that cannabis products may contain. Production permits authorise specific activities relating to the production of cannabis products, and include restrictions on the maximum quantity of dried cannabis or cannabis resin to be produced, the maximum quantity of dried cannabis and cannabis resin the licensee may hold, and the time period during which cultivation activities may occur. Both cultivation and production permits expire after three months.
Manufacturing
Similarly, manufacturing of cannabis products also requires a manufacturing licence and permits issued by the ODC. Manufacturing licences allow the licensee to manufacture cannabis products and to engage in certain related activities such as packaging, transport, storage, supply and destruction. Manufacturing licences must be renewed every two years. A manufacturing permit must also be obtained before starting to manufacture cannabis products. Manufacturing permits authorize certain activities and prescribe the maximum quantity of cannabis products that may be manufactured, the maximum quantity of cannabis products the licensee may hold, and the period during which manufacturing may occur. Like cultivation and production permits, manufacturing permits expire after three months.
Manufacturers of cannabis products must also comply with GMP in order to satisfy the requirements of the TGA. Manufacturing must occur at facilities inspected and approved by the TGA. Further, the TGA has also issued a Therapeutic Goods Order which imposes certain standards relating to decontamination, identification, chemical testing, adulteration and quality testing for medical cannabis and cannabis products in Australia.
Import
The ODC is also responsible for the issuance of import licences and permits, which are required to import "finished" medical cannabis products (products which are ready for supply to patients) and nursery stock for cannabis cultivation activities. Prospective import licensees must submit to an ODC inspection of their storage and security measures. Import licensees must obtain an import permit prior to each shipment, which discloses the details of the substance to be imported. Once cannabis products are imported, the licensee must comply with a number of record-keeping obligations, including maintaining records of the quantity of cannabis held and supplied. To import nursery stock, an additional permit is also required from the Department of Agriculture and Water Resources. Any plant material, including cannabis, imported into Australia is subject to biosecurity screening before entering the country as well as quarantine requirements before being released for cultivation.
Prescription, Supply and Storage
The prescription and supply of cannabis and cannabis products requires approval by the TGA, either in the form of the Special Access Scheme ("SAS") or Authorised Prescriber Scheme ("APS"). Both schemes permit medical practitioners to prescribe cannabis and cannabis products to patients; however, under the SAS, medical practitioners must seek approval from the TGA prior to writing each prescription on an individual patient basis, whereas the APS allows approved medical practitioners to prescribe cannabis to specific classes of patients with defined illnesses or which meet certain criteria. Medical practitioners that wish to prescribe cannabis, must first be approved by a Human Research and Ethics Committee, and must obtain approval from the applicable state or territory Health Departments.
20 |
2018 Annual Information Form |
The supply of medical cannabis products by retail, other than by a pharmacist on prescription, is prohibited in Australia. Cannabis may only be supplied to certain parties expressly named in the applicable statutes, which are typically limited to medical practitioners and pharmacists. Each state and territory has specific requirements for companies that wish to supply medical cannabis products. Medical cannabis suppliers must first obtain a licence from the applicable state or territory Department of Health. A supply licence is generally only required in the state or territory in which the supplier will store products.
Subject to minor variations between jurisdictions, state and territorial laws impose mandatory standards for the storage of cannabis and cannabis products, which typically include that cannabis and cannabis products are stored in a lockable vault of specified thickness with specific locking mechanisms and securely attached to either a floor or wall. Cannabis and cannabis products must be kept under the control of the supplier, and supplied only in accordance with a relevant approval, such as the SAS or APS.
Portugal
Decree-Law no. 15/93, of January 1993 ("DL 15/93") provides the legal framework in Portugal for the cultivation, production, manufacture, distribution, wholesale trade, import, export, transit, transportation, possession by any title and use of narcotic drugs and psychotropic substances, including certain cannabis substances. DL 15/93, is regulated by Regulatory-Decree 61/94 ("RD 61/94"), which among other things, sets out regulations relating to: (i) cultivation and production; (ii) wholesale trade; (iii) delivery conditions; (iv) record keeping; (v) packaging and labelling; (vi) licensing requirements; and (vi) reporting obligations.
In July 2018, Law 33/2018, of 18 July ("Law 33/2018") was published, and subsequently came into effect, providing for the use of drugs, preparations and substances based on the cannabis plant, for medicinal use. New regulations were published on January 15, 2019 (Decree-Law 8/2019) and came into effect in February 2019, which provide that the sale authorization for placing the Cannabis-based drugs for medicinal use in the market can be issued for a period of five years and be renewed. In addition, these new regulations will: (i) require that licensees annually update the information provided in their initial licence application; (ii) provide that licensees must follow a system of good practices in the activities of cultivation, manufacture and distribution of Cannabis-based drugs for medicinal use, which must follow the European guidelines; and (iii) impose regulations on the prescription of cannabis-based drugs by doctors, which must follow the lists and regulations of the National Institute of Pharmacy and Medicine ("INFARMED") for the conditions cannabis-based drugs may be prescribed to treat.
INFARMED is authorized to regulate and supervise activities relating to the cultivation, production, extraction and manufacture, wholesale trade, distribution to pharmacies, import and export, transit, purchase, sale and delivery of drugs, preparations and substances based on the cannabis plant, for medicinal purposes, as provided for in the applicable laws. INFARMED is also responsible for Portugal's cannabis licensing regime.
21 |
2018 Annual Information Form |
DESCRIPTION OF CAPITAL STRUCTURE
The authorized capital of the Corporation consists of an unlimited number of Common Shares and an unlimited number of preferred shares issuable in series without nominal or par value (the "Preferred Shares"). As at December 31, 2018, 86,700,306 Common Shares were issued and outstanding. As at April 3, 2019 86,895,352 Common Shares were issued and outstanding. As at December 31, 2018, and as at the date hereof, there were and are no preferred shares issued and outstanding.
Common Shares
There are no special rights or restrictions attached to the Common Shares. The Common Shares rank equally as to all benefits which might accrue to the holders thereof, including the right to receive dividends out of monies of the Corporation properly applicable to the payment of dividends if and when declared by the Board provided that the Board shall declare dividends on the Preferred Shares (as defined below), or any other class of shares without being obliged to declare any dividends on the Common Shares of the Corporation. There are no provisions restricting the issuance of Common Shares or any other material restrictions. In the event of a liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, or any other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, subject to the prior rights of the holders of the Preferred Shares (as defined below) and to any other shares ranking equal to the Common Shares, the holders of the Common Shares shall be entitled to receive the remaining property and assets of the Corporation.
The holders of Common Shares are entitled to receive notice of, and attend, all meetings of shareholders to be convened by the Corporation. At any general meeting, on a show of hands every shareholder who is present in person or by proxy and entitled to vote has one vote, and on a poll, every shareholder who is entitled to vote has one vote for each Common Share held and may exercise such vote either in person or by proxy, except for meetings at which only holders of another class or series of shares of the Corporation are entitled to vote separately as a class or series.
Preferred Shares
The Board may fix from time to time before each issuance of a series of Preferred Shares, the number of Preferred Shares comprising each series and the designation, rights, privileges, restrictions and conditions attaching to each series of Preferred Shares including, any voting rights, the rate or amount of dividends or the method of calculating dividends, the dates of payment thereof, the terms and conditions of redemption, purchase and conversion, if any, and any sinking fund or other provisions.
The Preferred Shares of each series is entitled, with respect to the payment of dividends and the distribution of assets or return of capital in the event of liquidation, dissolution or winding-up of the Corporation, or any other return of capital or distribution, to a preference over the Common Shares and over any other shares of the Corporation ranking by their terms junior to the Preferred Shares of that series.
As at December 31, 2018, and as at the date hereof, there were and are no preferred shares issued and outstanding.
Flowr ULC Shares
In addition, there are currently 44,100,000 Flowr ULC Class A Shares, exchangeable at no additional consideration for Common Shares on a one for one basis at any time at the option of the holders thereof pursuant to the share exchange agreement dated August 2018 among the Corporation, Flowr ULC and certain shareholders of the Corporation.
Stock Option Plan
The Corporation's stock option plan (the "SOP") was approved by the TSX-V in connection with the Qualifying Transaction. Effective as of November 26, 2018, the SOP was amended. Such amendment was of a "house-keeping" nature to address certain United States securities laws matters, to reflect the adoption of the LTIP and to make certain administrative changes to reflect the total number of securities that may be issued pursuant to the SOP. The amended SOP was approved by the shareholders of the Corporation at the special meeting of shareholders held on December 28, 2018 and was approved by the TSX-V on January 16, 2019.
Summary of the Stock Option Plan
The following is a summary of the principal provisions of the SOP and is qualified in its entirety by the full text of the SOP which is attached to the Corporation's management information circular dated November 26, 2018, available on SEDAR, online at www.sedar.com.
Stock options ("Options") to purchase Common Shares may be granted to full-time and part-time employees of the Corporation or its subsidiaries, and Directors, officers, consultants or advisors of the Corporation or its subsidiaries; provided, however, that a consultant or advisor shall not be an eligible participant of the SOP unless such consultant or advisor is an individual that provides bona fide services to the Corporation and such services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for Corporation's securities.
22 |
2018 Annual Information Form |
Pursuant to the SOP, the exercise price of any Option cannot be less than the market price of the Common Shares at the time the Option is granted. Market price is deemed to be the closing price of the Common Shares on the TSX-V on the last trading day immediately preceding the day upon which the Option is granted, subject to any discounts that may be granted in accordance with the policies of the TSX-V. Options shall vest on the dates specified in the option agreement between the Corporation and the participant optionee. The exercise period of the Options cannot exceed ten (10) years. In the event that a participant ceases to be eligible under the SOP due to death or incapacity, Options that are exercisable will terminate 180 days after the date at which a participant ceases to be eligible, or in the case of retirement, 120 days after the date at which a participant ceases to be eligible. Subject to the provisions of any employment contract as it relates to exercise and vesting conditions, where a participant is terminated without good cause, the Options that are exercisable at the termination date will be exercisable until the earlier of (i) 30 days after that date, (ii) the date determined by the Board and (iii) the date at which the Option expires pursuant to the SOP. Where a participant is terminated by reason of good cause or resignation, any Options held by the participant will expire immediately and are cancelled at such time as may be determined by the Board.
The Board may grant Options, in accordance with the SOP, at any time they deem to be appropriate. The maximum number of Common Shares reserved for issuance under the SOP shall not exceed, in the aggregate, 10% of the issued and outstanding (a) Common Shares and (b) Flowr ULC Class A Shares (which are exchangeable for Common Shares at any time at the option of the holder), from time to time, provided that the Board shall have the right, from time to time, to increase such percentage subject to the approval of shareholders and such regulatory authorities, stock exchanges or over-the-counter markets having jurisdiction over the affairs of the Corporation. For purposes of clarity, the maximum number of Common Shares reserved and set aside for issue under the SOP and under LTIP shall not exceed 20% of the Common Shares and Flowr ULC Class A Shares.
The maximum number of Common Shares reserved for issuance in any 12 month period to any individual employee, officer, Director, consultant or advisor shall not exceed 5% of the issued and outstanding Common Shares and Flowr ULC Class A Shares, and to any consultant or person providing investor relation activities shall not exceed 2% of the issued and outstanding Common Shares and Flowr ULC Class A Shares. The aggregate number of Common Shares that can be granted to insiders of the Corporation as a group shall not exceed 10% of the issued and outstanding Common Shares and Flowr ULC Class A Shares.
Common Shares that were the subject of Options that have expired, been surrendered, lapsed, cancelled or terminated shall thereupon no longer be in reserve and may once again be subject to an Option granted under the SOP, effectively resulting in a replenishing of the number of Options available for grant under the SOP.
Long Term Incentive Plan
As part of an ongoing review of the Corporation's compensation strategies, effective as of November 26, 2018 the Board approved the long term incentive plan (the "LTIP"). The LTIP was approved by the shareholders of the Corporation at the special meeting of shareholders held on December 28, 2018 and was approved by the TSX-V on January 16, 2019.
Under the terms of the LTIP the Board or, if authorized by the Board, a committee of the Board may grant units ("Units"), which may be either restricted share units ("RSUs") or deferred share units ("DSUs") to officers, Directors, employees or consultants of the Corporation; provided, however, that a consultant or advisor shall not be an eligible participant of the LTIP unless such consultant or advisor is an individual that provides bona fide services to the Corporation and such services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the Corporation's securities. The purpose of the LTIP is to advance the interests of the Corporation: (a) through the motivation, attraction and retention of key employees and Directors of the Corporation; (b) by aligning the interests of eligible participants with the interests of shareholders generally; and (c) by furnishing eligible participants with an additional incentive in their efforts on behalf of the Corporation.
There are no RSUs or DSUs issued and outstanding as at the date of this Annual Information Form.
Summary of the Long Term Incentive Plan
The following is a summary of the principal provisions of the LTIP and is qualified in its entirety by the full text of the LTIP which is attached to the Corporation's management information circular dated November 26, 2018, available on SEDAR, online at www.sedar.com.
23 |
2018 Annual Information Form |
Pursuant to the terms of the LTIP each Unit represents the right to receive one Common Share. Participation in the LTIP is voluntary and, if an eligible participant agrees to participate, the grant of Units is evidenced by an agreement between the Corporation and the participant. The interest of any participant in any Unit may not be transferred or assigned except by testamentary disposition or in accordance with the laws governing the devolution of property upon death.
The maximum number of Common Shares which may be reserved and set aside for issue under the LTIP in respect of awards of DSUs to DSU participants and for payments in respect of awards of RSUs to RSU participants, shall not exceed 10% of the (a) Common Shares and (b) Flowr ULC Class A Shares (which are exchangeable for Common Shares at any time at the option of the holder), being 13,057,421 Common Shares, provided that the Board shall have the right, from time to time, to increase such number of Common Shares subject to the approval of shareholders and such regulatory authorities, stock exchanges or over-the-counter markets having jurisdiction over the affairs of the Corporation. For purposes of clarity, the maximum number of Common Shares reserved and set aside for issue under the LTIP and under the SOP shall not exceed 20% of the Common Shares and Flowr ULC Class A Shares. Common Shares that were the subject of awards that have expired, been surrendered, lapsed, cancelled or terminated shall thereupon no longer be in reserve and may once again be subject to an award granted under the LTIP, effectively resulting in a replenishing of the number of RSUs and DSUs available for grant under the LTIP.
The LTIP, together with all other previously established or proposed security-based compensation arrangements of the Corporation, including the SOP, may not result in:
(a) the number of Common Shares reserved for issuance to insiders at any time exceeding 10% of the issued and outstanding Common Shares and Flowr ULC Class A Shares;
(b) the issuance to insiders of the Corporation of a number of Common Shares exceeding, within a one year period, 10% of the issued and outstanding Common Shares and Flowr ULC Class A Shares; or
(c) the issuance to any one insider of the Corporation, within a one year period, of a number of Common Shares exceeding 5% of the issued and outstanding Common Shares and Flowr ULC Class A Shares.
Restricted Share Units
An officer, Director, employee or consultant of the Corporation who has been designated by the Corporation for participation in the LTIP and who agrees to participate in the LTIP is an eligible participant to receive RSUs under the LTIP (an "RSU Participant").
Unless otherwise approved by the Board, an RSU will vest as to 33 1/3% on each of the first, second and third anniversary dates of the grant date, provided that all RSUs granted under a particular award shall vest on or before December 31st of the calendar year which is 3 years following the calendar year in which the service was performed in respect of which the particular award was made (the "Final Vesting Date"), provided further that all payments under a particular award of a U.S. taxpayer shall be made on or before December 31st of the year in which the scheduled RSU vesting date (determined without regard to Section 3.2.2 of the LTIP) occurs or, if later, by the date that is two and one-half (2 ½) months after such scheduled RSU vesting date. In the event that a vesting date occurs within a blackout period or within 5 business days thereafter, the vesting date shall be 10 business days after the blackout period ends (the "Extension Period"). If an additional blackout period is subsequently imposed during the Extension Period, then the Extension Period will commence following the end of such additional blackout period. Despite the foregoing, a vesting date will not be extended beyond the Final Vesting Date.
On each vesting date, the Corporation decides, in its sole discretion, whether to make all payments in respect of vested RSUs to the RSU Participant in cash, Common Shares issued from treasury or a combination thereof based on the fair market value of the Common Shares as at such date. For the purposes of the LTIP, the fair market value of a Common Share is the weighted average trading price of the Common Shares on the TSX-V for the 5 trading days immediately preceding the vesting date for a RSU or DSU Termination Date (as defined below) in respect of DSUs, as applicable.
If an RSU Participant ceases to be an eligible participant under the LTIP due to termination with cause or voluntary termination by the RSU Participant, all unvested RSUs previously credited to the participant's account are terminated and forfeited as of the termination date. If an RSU Participant ceases to be an eligible participant under the LTIP due to termination without cause, death, total or permanent long-term disability or retirement, any unvested RSUs previously credited to the participant's account will continue to vest in accordance with their terms or, at the discretion of the Board, be terminated and forfeited as of the termination date, subject to the provisions of any RSU Participant's employment contract. In the event the Corporation pays a dividend on the Common Shares subsequent to the granting of an RSU award, the number of RSUs relating to such award shall be increased to reflect the amount of the dividend.
24 |
2018 Annual Information Form |
Deferred Share Units
A Director of the Corporation who has been designated by the Corporation for participation in the LTIP and who agrees to participate in the LTIP is an eligible participant to receive DSUs under the LTIP (a "DSU Participant").
All DSUs awarded to a DSU Participant vest on the date on which the DSU Participant ceases to be a Director of the Corporation (the "DSU Termination Date"). Notwithstanding the foregoing, any payments under a particular award of a U.S. taxpayer shall be made as soon as practicable following a DSU Termination Date in accordance with the LTIP, but in no case later than December 31st of the year in which such DSU Termination Date occurs or, if later, by the date that is two and one-half (2 ½) months after such DSU Termination Date.
On the DSU Termination Date, payment in respect of a DSU Participant's DSUs becomes payable and the Corporation decides, in its sole discretion, whether to make the payment in cash, Common Shares issued from treasury or a combination thereof based on the fair market value of the Common Shares as at the DSU Termination Date.
In the event the Corporation pays a dividend on the Common Shares subsequent to the granting of a DSU award, the number of DSUs relating to such award shall be increased to reflect the amount of the dividend.
Amendments
The Corporation retains the right without the approval of shareholders:
(a) to amend the LTIP or any RSUs or DSUs to:
i. make amendments of a grammatical, typographical, clerical and administrative nature and any amendments required by a regulatory authority or to comply or conform with applicable laws;
ii. change vesting provisions of the LTIP or any RSUs or DSUs;
iii. make any other amendments of a non-material nature;
iv. make amendments to the definition of "DSU Participant" and/or "RSU Participant" or the eligibility requirements of participating in the LTIP, where such amendment would not have the potential of broadening or increasing insider participation;
v. make amendments to the manner in which eligible participants may elect to participate in the LTIP;
vi. make any amendments to the provisions concerning the effect of the termination of a participant's employment or services on such participant's status under the LTIP; or
vii. make any amendment which is intended to facilitate the administration of the LTIP; or
(b) to suspend, terminate or discontinue the terms and conditions of the LTIP and the RSUs and DSUs granted under the LTIP by resolution of the Board, provided that:
i. no such amendment to the LTIP shall cause the LTIP in respect of RSUs to cease to be a plan described in paragraph (k) of the definition of "salary deferral arrangement" in subsection 248(1) of the Income Tax Act (Canada) (the "ITA") or any successor to such provision;
ii. no such amendment to the LTIP shall cause the LTIP in respect of DSUs to cease to be a plan described in regulation 6801(d) of the ITA or any successor to such provision; and
iii. any amendment shall be subject to the prior consent of any applicable regulatory bodies, including the TSX-V, as may be required.
Any amendment to the LTIP which changes the vesting provisions of the LTIP or any RSUs or DSUs, or any suspension, termination or discontinuance of the terms and conditions of the LTIP and the RSUs and DSUs granted under the LTIP, shall take effect only with respect to awards granted after the effective date of such amendment, provided that it may apply to any outstanding award with the mutual consent of the Corporation and the participants to whom such awards have been granted.
Any amendment to the LTIP other than as described above shall require the approval of shareholders given by the affirmative vote of a simple majority of the Common Shares (or, where required, "disinterested" shareholder approval) represented at a meeting of shareholders at which a motion to approve the LTIP or an amendment to the LTIP is presented. Specific amendments requiring shareholder approval include:
25 |
2018 Annual Information Form |
(a) to increase the number of Common Shares reserved under the LTIP;
(b) to change the definition of RSU Participants or DSU Participants or the eligibility requirements of participating in the LTIP, where such amendment would have the potential of broadening or increasing insider participation;
(c) the extension of any right of a participant under the LTIP beyond the date on which such right would originally have expired;
(d) to permit RSUs or DSUs to be transferred other than by testamentary disposition or in accordance with the laws governing the devolution of property in the event of death;
(e) to permit awards other than RSUs and DSUs under the LTIP; and
(f) to amend the amendment provisions of the LTIP so as to increase the ability of the Board to amend the LTIP without Shareholder approval.
In accordance with the policies of the TSX-V, to the extent that the Corporation grants RSUs, DSUs or Options to eligible participants under the LTIP and SOP, as applicable, which are agreed to be settled in cash on the grant date, such RSUs, DSUs and Options will not reduce the pool of securities available for grant under the SOP and LTIP, respectively.
26 |
2018 Annual Information Form |
DIVIDEND POLICY
There are no restrictions in the Corporation's articles preventing the Corporation from paying dividends. All of the Common Shares are entitled to an equal share in any dividends declared and paid. The Preferred Shares are entitled to any dividends declared and paid, and are entitled to preference over the Common Shares. The Board will determine if, and when, dividends will be declared and paid in the future from funds properly applicable to the payment of dividends based on the Corporation's financial position at the relevant time. In the future, the Corporation may enter into certain financing arrangements which may contain restrictions on the Corporation's ability to issue dividends.
MARKET FOR SECURITIES
Trading Price and Volume
The Common Shares are currently listed on the TSX-V under the trading symbol FLWR. The following table sets forth the reported intraday high and low prices and the trading volume for the Common Shares on the TSX-V, the Canadian marketplace on which the greatest volume of trading or quotation generally occurs, for the periods indicated.
TSX-V | |||
Month | High | Low | Volume |
($) | ($) | ||
2019 | |||
April 1 April 3 | 6.34 | 5.85 | 258,333 |
March | 8.42 | 5.33 | 11,221,170 |
February | 5.50 | 3.90 | 3,475,066 |
January | 4.70 | 3.58 | 1,648,595 |
2018 | |||
December | 4.39 | 2.74 | 1,799,895 |
November | 3.94 | 2.96 | 1,099,260 |
October | 7.19 | 3.11 | 3,350,790 |
September | 8.00 | 4.00 | 2,438,254 |
Prior Sales
Common Shares the following table summarizes details of the Common Shares issued by the Corporation during the Corporations most recently completed financial year:
Date | Type of Security Issued | Issuance Price per Security | Number of Securities Issued |
September 21, 2018 | Common Shares(1) | $2.60(2) | 86,282.864(3) |
November 10, 2018 | Common Shares(4) | $0.05(4) | 162,500 |
November 10, 2018 | Common Shares(5) | $1.30(5) | 18,461 |
December 7, 2018 | Common Shares(6) | $0.05(6) | 225,000 |
October 2018 January 2019(7) | Common Shares(7) | $1.30(7) | 16,587 |
(1) |
Issued to former shareholders of Flowr Privateco pursuant to the Business Combination Agreement. Pursuant to the private placement of Subscription Receipts completed prior to the closing of the Qualifying Transaction, Flowr Privateco issued 13,807,754 Subscription Receipts, which were exchanged for one common share of Flowr Privateco, which common shares were then exchanged for Common Shares on a one-for- one basis pursuant to the Qualifying Transaction. This figure includes the Common Shares issued to holders of such Subscription Receipts and 36,923 stock options exercised by former officers of Needle. |
(2) |
Deemed price on a post-Consolidation basis, completed prior to the closing of the Qualifying Transaction. |
(3) |
See Equity Transactions in this Annual Information Form for financings completed by Needle and Flowr Privateco prior to the completion of the Qualifying Transaction. |
(4) |
Issued upon exercise of 162,500 stock options by former employees of Flowr Privateco. These stock options were granted on October 30, 2017 with each option having an exercise price of $0.05. |
27 |
2018 Annual Information Form |
(5) Issued upon exercise of 18,461 stock options by a former director of Needle. These stock options were granted in connection with Needle's initial public offering completed on September 15, 2017 with each option having an exercise price of $0.10 for each share (or an exercise price of $1.30 on a post-Consolidation basis).
(6) Issued upon exercise of 225,500 stock options by a former officer/employee of the Corporation. These stock options were granted on October 30, 2017 with each option having an exercise price of $0.05.
(7) Issued upon exercise of 16,587 warrants held by agents of Needle between October 3, 2018 and January 23, 2019. These warrants were issued in connection with Needle's initial public offering completed on September 15, 2017 with each warrant having an exercise price of $0.10 for each share (or an exercise price of $1.30 on a post-Consolidation basis).
On October 26, 2018, the Board approved a grant of 325,000 Options to an employee effective on that employee's first day of employment on January 7, 2019. As this individual was under a blackout period imposed by the Corporation at the time of commencing his employment, and continues to be in a blackout period as at the date of this Annual Information Form, these Options will not be issued until 24 hours after the expiration of the then imposed blackout period.
On February 6, 2019, the Board approved (i) an aggregate grant of 60,000 Options to certain Directors; and (ii) an aggregate grant of 794,885 Options to certain employees and an employee who is also a Director. As these individuals were under a blackout period imposed by the Corporation at the time of the approval, and continue to be in a blackout period as at the date of this Annual Information Form, these Options will not be issued until 24 hours after the expiration of the then imposed blackout period.
On April 3, 2019, the Board approved (i) an aggregate grant of 492,000 Options to certain employees and (ii) up to 650,000 Options that may be granted to potential new hires subject to those individuals entering into employment agreements with the Corporation. As these individuals were under a blackout period imposed by the Corporation at the time of the approval, and continue to be in a blackout period as at the date of this Annual Information Form, these Options will not be issued until 24 hours after the expiration of the then imposed blackout period.
28 |
2018 Annual Information Form |
Stock Options/Warrants - the following table summarizes details of the issuances of stock options and warrants by the Corporation issued during the Corporation's most recently completed financial year:
Date |
Type of Security Issued |
Issuance Price per Security |
Number of Securities Issued |
September - October 2018(1) |
Stock Options(1) |
0.05(1) |
4,000,000 |
September 21, 2018 |
Stock Options(2) |
$2.60(2) |
8,035,530 |
September 21, 2018 |
Stock Options(3) |
$1.30(3) |
18,461 |
September 21, 2018 |
Warrants(4) |
$2.60(4) |
441,720 |
September 21, 2018 |
Warrants(5) |
$1.30(5) |
23,077 |
October 2, 2018 |
Stock Options(6) |
$5.24(6) |
325,000 |
October 23, 2018 |
Stock Options(7) |
$3.43(7) |
20,000 |
November 6, 2018 |
Stock Options(8) |
$3.60(8) |
20,000 |
(1) Pursuant to the Business Combination Agreement and the Qualifying Transaction, these stock options were re-issued on September 10, 2018 and October 1, 2018 to employees and former employees in connection with the exchange of the stock options of Flowr Privateco that were originally issued on October 30, 2017 at a price of $0.05 per share. These options expire on October 30, 2022.
(2) Pursuant to the Business Combination Agreement and the Qualifying Transaction, these stock options were issued to employees, directors and an agent in connection with the exchange of the stock options of Flowr Privateco held by such employees, directors and an agent that were originally issued between June 1, 2018 and September 14, 2018 at a price of $2.60 per share. These options expire between May 31, 2023 and September 14, 2023.
(3) These stock options were issued to a former director of Needle that were originally granted in connection with Needle's initial public offering completed on September 15, 2017 with each option having an exercise price of $0.10 for each share (or an exercise price of $1.30 on a post-Consolidation basis). These options were fully exercised on November 10, 2018 in exchange for Common Shares.
(4) These warrants were issued to certain agents of the Corporation in connection with the financing completed concurrently with the Qualifying Transaction and expire on September 20, 2021.
(5) These warrants were issued to agents in connection with Needle's initial public offering completed on September 15, 2017 with each warrant having an exercise price of $0.10 for each share (or an exercise price of $1.30 on a post-Consolidation basis).
(6) Stock options granted to an officer of the Corporation expiring on October 2, 2023.
(7) Stock options granted to an employee of the Corporation expiring on October 23, 2023.
(8) Stock options granted to an employee of the Corporation expiring on November 6, 2023.
29 |
2018 Annual Information Form |
Escrowed Securities and Securities Subject to Contractual Restriction on Transfer - except as otherwise described below, as of April 3, 2019, to the Corporation's knowledge, there are no other securities in escrow or that are subject to a contractual restriction on transfer:
Designation of class |
Number of securities held in escrow or that are subject to a contractual restriction on transfer |
Percentage of class |
Common Shares |
37,022,622 |
42.6% |
Notes:
30 |
2018 Annual Information Form |
DIRECTORS AND EXECUTIVE OFFICERS OF THE CORPORATION
Directors and Executive Officers, Positions and Security Holdings
The following table sets out the name; city, state/province and country of residence and position with the Corporation. The table also sets out the principal occupation of each Director and executive officer of the Corporation for the five preceding years.
Name, Province or State and Country of Residence |
Position with the Corporation(1) |
Principal Occupation During the Past Five Years |
Karen Basian(2)(3)(4)(5) Toronto, Ontario Canada
|
Director (appointed to the Board December 2018) |
|
Jason Broome Kelowna, British Columbia Canada |
Chief Research and Innovation Officer |
|
Alexander Dann Toronto, Ontario Canada |
Chief Financial Officer |
|
Lance Emanuel Toronto, Ontario Canada
|
President |
|
Thomas Flow Kelowna, British Columbia Canada |
Co-Chief Executive Officer and a Director (appointed to the Board September 2018) |
|
Steven Klein(6) Port Washington, New York United States of America
|
Director (appointed to the Board September 2018) |
|
Maurice Levesque(2)(3)(4)(5) Edmonton, Alberta Canada |
Director (appointed to the Board December 2018) |
|
David Miller Bernardsville, New Jersey United States of America
|
Director (appointed to the Board September 2018) |
|
Lyle Oberg Kelowna, British Columbia Canada
|
Chief Policy and Medical Officer and a Director (appointed to the Board September 2018)
|
|
Rishi Shah(2)(3)(4)(5)(7) Chicago, Illinois United States of America |
Director (appointed to the Board September 2018) |
|
31 |
2018 Annual Information Form |
Francesco Tallarico Mississauga, Ontario Canada |
General Counsel and Corporate Secretary |
|
J. André de Barros Teixeira(4) Alcabideche, Portugal |
Director (appointed to the Board December 2018) |
|
Vinay Tolia Toronto, Ontario Canada
|
Co-Chief Executive Officer and a Director (appointed to the Board October 2018)
|
|
Notes:
(1) Each Director listed will hold his or her position as a Director of the Corporation until the next annual meeting of shareholders or until their respective successors are elected or appointed in accordance with applicable law or the Corporation's by-laws.
(2) Member of the Nominating and Corporate Governance Committee of the Corporation.
(3) Member of the Human Resources and Compensation Committee of the Corporation.
(4) Independent Director.
(5) Member of the Audit Committee of the Corporation.
(6) Non-Executive Chairman of the Board.
(7) Lead Independent Director.
32 |
2018 Annual Information Form |
Shareholdings of Directors and Executive Officers
To the knowledge of the Corporation, as at March 11, 2019, the Directors and executive officers of the Corporation as a group beneficially own, directly or indirectly, or exercise control or direction over an aggregate of 39,235,317 Common Shares, representing approximately 45% of the issued and outstanding Common Shares on that date.
Biographies
The following are brief profiles of the Directors and the executive officers of the Corporation.
Executive Officers
Jason Broome, Chief Research and Innovation Officer - Mr. Broome has 15 years' experience in the pharmaceutical industry with roles in: sales, marketing, business, unit management, government affairs and global advisory boards. Jason has established, operated and sold several healthcare-related companies. With a master's degree in Molecular Genetics, Jason's expertise spans all aspects of development. From molecule to market, Jason has led the commercialization of several key pharmaceutical brands.
Alexander Dann, Chief Financial Officer - Mr. Dann is a bilingual CPA, CA with over 25 years of experience leading financial operations and strategic planning for multinational public companies, primarily in the mining and manufacturing sectors. Alex was most recently CFO of Era Resources Inc., prior to its acquisition by The Sentient Group. He has held senior positions including CFO of Avion Gold Corporation prior to its acquisition by Endeavour Mining Ltd., CFO of Goldbelt Resources Ltd. prior to its acquisition by Wega Mining ASA and Group Controller of Litens Automotive Partnership, a division within Magna International Inc.
Lance Emanuel, President - Mr. Emanuel co-founded QuarterSpot, Inc., an online lending platform. As President and COO, Mr. Emanuel built the company into an industry leader by overseeing the issuance of 8,500 loans and $670 million in financing in 6 years. He also led LASO, Inc., the company's intellectual property arm and formed a distribution partnership with one of the top 3 credit bureaus in the U.S. Previously, Mr. Emanuel served as General Counsel and COO at GotCoders, Inc, a software development consultancy. Mr. Emanuel holds a BBA, with distinction, from the University of Michigan's Ross School of Business and received his Juris Doctor from the Benjamin N. Cardozo School of Law in New York City.
Tom Flow, Co-Chief Executive Officer and a Director - Mr. Flow is globally recognized for his cannabis thought leadership and expertise in building and operating cannabis cultivation facilities. Over the past five years and in addition to his role at Flowr, Mr. Flow was a co- founder and Chief Operating Officer at MedReleaf from January 2013-April 2015. Mr. Flow sits on the board and advisory committees of several cannabis-related companies.
Dr. Lyle Oberg, Chief Policy and Medical Officer and a Director - Dr. Oberg received his MD degree from the University of Alberta in 1983. Dr. Oberg was a member of the Alberta Legislature from 1993 to 2008, and was the former Alberta Minister of Finance. Dr. Oberg was also formerly a medical doctor practising in Alberta. For the previous five years, Dr. Oberg was an independent consultant.
Francesco Tallarico, General Counsel and Corporate Secretary - Mr. Tallarico is Flowr's General Counsel and Corporate Secretary, overseeing all aspects of Flowr's legal needs, and providing leadership of Flowr's M&A and corporate finance strategy. Prior to joining Flowr, Mr. Tallarico served as Chief Legal Officer and Corporate Secretary at Concordia International Corp. (now Advanz Pharma Corp.), a specialty pharmaceutical company listed on the TSX. At Concordia, Mr. Tallarico led Concordia's global legal and compliance functions, M&A transactions valued at over USD$4.5 billion and a USD$2.4 billion corporate debt restructuring. Before joining Concordia, Mr. Tallarico practiced law in the corporate and securities group of Fasken in Toronto. Mr. Tallarico holds a BA from the University of Toronto and a JD from the University of Windsor.
Vinay Tolia, Co-Chief Executive Officer and a Director - Mr. Tolia attended the University of Michigan where he obtained a BA in economics and BSE in Industrial and Operations Engineering. Prior to his role with the Corporation, and over the past five years, Mr. Tolia was the managing member of Bengal Capital Trading LLC, a derivatives trading firm with a focus on listed equity options, and previously held roles with investment banking firms Peter J. Solomon Company and hedge fund Midtown Capital.
Directors
Karen Basian - Ms. Basian has over 25 years' in the consumer products, financial services and technology sectors. Karen is President of KB Capital Management Inc. (Strategy and Advisory Services). Karen also serves on the Board of Directors of goeasy (TSE:GSY) where she chairs the HR and Compensation Committee; BookJane (on-demand healthcare staffing software) where she Chairs the Audit Committee; Kognitiv (collaborative commerce) and was Managing Director of Newtopia, an innovative personalised health company. Previously, Karen was Chief Global Strategy and Business Development Officer for McCain Foods Ltd. An innovative thinker with deep financial acumen, Karen was recognized, in 2000 as one of Canada's 'Top 40 Under 40' for her work as the CFO & SVP, Corporate Services for 724 Solutions (NASDAQ/TSX). Prior roles include SVP Strategy for Frito-Lay North America; Manager with Bain and Company; and International Tax Specialist with Deloitte. Karen's community and philanthropic efforts include her advisory work with Baycrest, UHN, Robarts Research Institute and FINCA Canada; and the founding of the Jewish Womens Venture Philanthropy Fund. Karen is a CPA,CA; an MBA from IMEDE, Lausanne, Switzerland and Honors Business Administration from the University of Western Ontario.
33 |
2018 Annual Information Form |
Steven Klein - Mr. Klein received his J.D., Magna Cum Laude, from Boston University Law School and a Master's Degree in tax law from New York University Law School. He received his Bachelor of Science in business from the State University of New York in Albany. Mr. Klein is currently, and has been over the past five years, the Chief Executive Officer of Apple Core Holdings, which owns and operates hotels and event spaces, and provides seed capital to hedge funds, venture capital funds, and private equity funds. Previously, Mr. Klein was an attorney at Skadden, Arps, Slate, Meagher & Flom LLP.
Maurice Levesque - Mr. Levesque is a founder, Chairman, and Chief Executive Officer of Qwest Investment Management Corp. ("QIM"), an investment management firm specializing in identifying emerging trend opportunities, managing merchant banking transactions and structuring investment products in those sectors of the capital markets in which it has experience and expertise. Mr. Levesque is the Chairman, CEO and Chief Compliance Officer of Qwest Investment Fund Management Ltd., and Chairman, President and director of Heritage Bancorp Ltd. (both companies a subsidiary of QIM). Mr. Levesque has 30 years of experience in the Canadian financial industry and is recognized for his broad knowledge, skills and experience in the venture capital industry, financial services industry and for his leadership skills in new business formation and development. Mr. Levesque is a founder and/or a director of several private and publicly traded companies which operate in a variety of industries. Mr. Levesque graduated from The Northern Alberta Institute of Technology with a diploma in Administration Management.
David Miller - Mr. Miller studied accounting at The Wharton School of Business and received his law degree from Duke University. Over the past five years, Mr. Miller has been the Chief Financial Officer and General Counsel of Apple Core Holdings, which owns and operates hotels and event spaces, and provides seed capital to hedge funds, venture capital funds, and private equity funds.
Rishi Shah - Mr. Shah is Chairman and Managing Director of JumpStart Ventures, which helps early stage technology companies achieve traction at critical inflection points by offering advice on market and product strategy, supported with rapidly executed tactical marketing services. Previous to Jumpstart Ventures, in 2006 Mr. Shah founded Outcome Health and acted as Chairman and Chief Executive Officer of the company which worked to improve health outcomes by serving actionable health information to chronic disease patients at the point of care. In addition to his work at Jumpstart Ventures, Mr. Shah serves on the Board of Directors of many civic organizations including Young Presidents Organization (YPO), 1871, and MATTER, a community of healthcare innovators and incubator for ideas. Mr. Shah also serves as a mentor for numerous technology start-up accelerator/incubator programs including TechStars Chicago, HealthBox and Blueprint Health in New York City. Mr. Shah has had direct oversight over compensation related matters in many of these organizations where he has made compensation recommendations to the board or served on a compensation committee.
Dr. J. André de Barros Teixeira - Dr. André Teixeira is an Associate Partner and member of the Advisory Board of Globalpraxis, a consulting firm in Barcelona, Spain; Executive Professor at the Antwerp Management School, University of Antwerp, Belgium; Partner at Keiryo Packaging, a technology start-up in Luxembourg; Advisor and partner at Wine With Spirit, an award winning wine start-up in Lisbon, Portugal; Visiting Professor at CEIBS-Zurich Institute of Business, Switzerland; Member of the project funding evaluation panel of FIAL, Food Innovation Australia, Sydney, Australia, and Visiting Professor and consultant at the University of Fortaleza, Brazil. He is also a consultant in the areas of innovation, business development, multiculturalism in business, global development, motivation, story-telling, ideation, and mentor of CEOs and executives. Dr. Teixeira holds graduate and post-graduate degrees (BSc, MSc, MBA, PhD) in Philosophy, Industrial Chemistry, Food Science and Business Administration from the universities of Cambridge, Reading and Oxford in the UK.
34 |
2018 Annual Information Form |
Corporate Cease Trade Orders or Bankruptcies
Except as described below, no individual who is a Director, officer or promoter of or a securityholder anticipated to hold sufficient securities of the Corporation to affect materially the control of the Corporation, is, or has been within the past ten years, a director, officer or promoter of any other person or company that, while such person was acting in that capacity, was:
(a) the subject of a cease trade or similar order or an order that denied the person or company access to any exemptions under applicable securities law for a period of more than 30 consecutive days; or
(b) declared bankrupt or made a proposal under any legislation relating to bankruptcy or insolvency or been subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold the assets of that person.
Mr. Tallarico was formerly the Chief Legal Officer of Concordia International Corp. ("Concordia"). In October 2017, Concordia commenced proceedings under the Canada Business Corporations Act ("CBCA") to restructure its balance sheet. The CBCA is a Canadian corporate statute that, among other things, allows Canadian corporations to restructure certain debt obligations. In most cases, a corporation working through a CBCA process will be able to complete a recapitalization transaction in a more efficient manner based on time, cost and other key factors. The CBCA is not a bankruptcy or insolvency statute. On September 6, 2018, Concordia completed its restructuring and continues to operate its business. Concordia is listed on the TSX and is now known as ADVANZ Pharma Corp.
Mr. Levesque has been the President and a director of Knightswood Financial Corp. ("KFC") since December 1996. KFC was a publicly listed company on the TSX-V until mid 2017, and prior to December 1998 was known as First Venture Developments Ltd. Trading in the shares of KFC was halted on June 11, 2001, pending clarification of the company's affairs. On July 20, 2001, trading in the securities of KFC resumed under the "Inactive" designation pending completion of the review of the company's reorganization as per Canadian Venture Exchange (now the TSX-V) Policy 2.6. This review resulted in KFC no longer being deemed inactive as per Policy 2.6.
Penalties or Sanctions
Except as described below, no Director, officer or promoter of the Corporation or a securityholder holding sufficient securities of the Corporation to affect materially the control of the Corporation, has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority or been subject to any other penalties or sanctions imposed by a court or regulatory body, including a self-regulatory body, that would be likely to be considered important to a reasonable securityholder making an investment decision.
Messrs. Klein and Miller are former members of the board of directors of CNC Development, Ltd. ("CNC"). During the tenure of Messrs. Klein and Miller, CNC exhausted its liquidity and was unable to pay the necessary accounting and legal fees to fulfill its requirements as a publicly listed company in the United States to file periodic reports with the SEC. Trading in the shares of CNC was suspended and the SEC took administrative action to delist CNC in 2013.
In November 2017, certain shareholders of Outcome Health, of which Rishi Shah is a managing member, filed a claim against the company, its subsidiaries, and its owners, in the State Court of New York that included allegations of fraud. Further, a claim was filed against Gravitas Holdings, a subsidiary of the company, in the Chancery Court in Delaware. These claims were dismissed without prejudice in January 2018 and the matter was settled without admission of any wrongdoing by the company, its subsidiaries or its owners.
Individual Bankruptcies
Except as described below, no Director, officer or promoter of the Corporation or a securityholder holding sufficient securities of the Corporation to affect materially the control of the Corporation, or a personal holding company of any such person, has, within the ten years before the date of this Annual Information Form, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or been subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of that individual.
Thomas Flow was declared bankrupt on April 6, 2011. On January 7, 2012, Mr. Flow was discharged pursuant to subsection 168.1(1) of the Bankruptcy and Insolvency Act, (Canada) from all debts, except those matters referred to in subsection 178(1) of the Bankruptcy and Insolvency Act, (Canada).
Conflicts of Interest
There are no known existing or potential conflicts of interest between the Corporation or a subsidiary of the Corporation and a Director or officer of the Corporation or a subsidiary of the Corporation.
35 |
2018 Annual Information Form |
LEGAL PROCEEDINGS AND REGULATORY MATTERS
Other than as discussed herein, to the knowledge of the Corporation, there are no material legal proceedings or regulatory actions known or known to be contemplated against the Corporation or to which any of its property is or may be subject in respect of which the claim for damages, exclusive of interest and costs, exceeds ten percent (10%) of the current assets of the Corporation. No penalties or sanctions have been imposed against the Corporation by a court relating to securities legislation or by a securities regulatory authority and no settlement agreements have been entered into by the Corporation before a court relating to securities legislation or with a securities regulatory authority.
INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS
Other than as disclosed herein, to the knowledge of the Corporation, none of: (i) the Directors, executive officers or persons that beneficially own, or control or direct, directly or indirectly, more than 10% of the outstanding securities of the Corporation; or (ii) any associate or affiliate of the persons referred to in (i), has or has had any material interest, direct or indirect, in any transaction within the three most recently completed financial years or during the current financial year that has materially affected or will materially affect the Corporation or any of its subsidiaries.
PROMOTER
As of March 11, 2019: (i) Tom Flow beneficially owns, or controls or directs, directly or indirectly, a total of 26,025,000 Common Shares, representing approximately 18.4% of the equity of the Corporation on a fully diluted basis; and (ii) Steven Klein, through Core Flow Canada Holdings Inc., beneficially owns, or controls or directs, directly or indirectly, a total of 7,893,054 Common Shares and 41,598,000 Flowr ULC Class A Shares that are convertible into Common Shares, representing approximately 5.5% of the equity of the Corporation on a fully diluted basis. Other than as disclosed in this section or elsewhere in this Annual Information Form, no person who was a promoter of the Corporation:
Mr. Flow assigned certain patent applications to the Corporation for no consideration. The Corporation is now seeking these patents.
RELATED PARTIES
The Corporation and its subsidiaries are considered related parties under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as a result of Core Flow Canada Holdings Inc.'s deemed beneficial ownership of the Common Shares underlying the Flowr ULC Class A Shares it holds, and also on the basis that Core Flow Holdings Canada Inc. is controlled by Steve Klein (a Director).
As a result, the Corporation does not benefit from the exemption of the application of the related party transaction rules in section 5.1 of MI 61-101 for transactions with Flowr ULC or Flowr Okanagan on the basis that: (i) it is not a downstream transaction, because Core Flow Canada Holdings Inc. is a related party of the Corporation and Core Flow Canada Holdings Inc. has more than 5% of the voting rights in Flowr ULC; and (ii) neither Flowr ULC nor Flowr Okanagan are wholly owned subsidiaries of the Corporation.
36 |
2018 Annual Information Form |
The Corporation does from time to time enter into related party transactions with Flowr ULC and Flowr Okanagan primarily related to cash management transactions, intercompany loans and the issuances of shares from the Flowr ULC to the Corporation in accordance with the Share Exchange Agreement.
AUDIT COMMITTEE
The Board has established an audit committee comprised of three directors (the "Audit Committee"). As at December 31, 2018, the Audit Committee was chaired by Karen Basian and the other committee members included Rishi Shah and Maurice Levesque. Each member of the Audit Committee is independent of management of the Corporation and is financially literate in that each has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation's financial statements. The relevant education and experience of each member of the Audit Committee is provided above, under the heading "Directors and Executive Officers of the Corporation - Biographies".
The mandate of the Audit Committee is set out in the written Charter of the Audit Committee. A copy of the Audit Committee charter is included as Appendix "B" attached hereto.
Reliance on Certain Exemptions
The Corporation is a "venture issuer" as defined in NI 52-110 and, during the Corporation's most recently completed financial year, it relied on the exemption in section 6.1 of NI 52-110 relating to Parts 3 (Composition of Audit Committee) and 5 (Reporting Obligations). In addition, as a result of the resignation of Mr. David Towill from the Board on October 26, 2018, the Corporation relied on the exemption in subsection 6.1.1(6) of NI 52-110.
Audit Committee Oversight
At no time since the commencement of the Corporation's most recently completed financial year was a recommendation of the Audit Committee to nominate or compensate an external auditor not adopted by the Board.
Pre-Approval Policies and Procedures
The Audit Committee is authorized by the Board to review the performance of the Corporation's external auditors and approve in advance the provision of services other than auditing and to consider the independence of the external auditors, including reviewing the range of services provided. The Audit Committee may delegate to any independent member of the Audit Committee the authority to pre-approve any non-audit services.
External Auditor Service Fees
A summary of the external auditor service fees and billings paid or payable to the Corporation's external auditors in respect of the last two fiscal years ended December 31 is set out below:
Fiscal Year | Audit Fees | Audit-Related Fees | Tax Fees | All Other Fees | Total | ||||||||||
2018 | $ | 81,000 | $ | 38,500 | $ | 27,000 | $ | 21,950 | $ | 162,450 | |||||
20171 | $ | 51,000 | $ | 7,500 | $ | 27,000 | $ | 110,501 | $ | 196,001 |
Notes:
(1) These are the fees incurred by Needle prior to the completion of the Qualifying Transaction and also include fees incurred by Flowr Privateco, the private corporation that completed the Qualifying Transaction with Needle, as MNP LLP acted as auditor for both entities.
37 |
2018 Annual Information Form |
MATERIAL CONTRACTS
The Corporation and/or its subsidiaries, as applicable, have entered into the following material contracts since the beginning of the Corporation's most recently completed financial year or before the Corporation's most recently completed financial year if any such contract is still in effect, and which are outside of the ordinary course of the Corporation's business. A description and summary for each material contract is provided below or has been cross-referenced in this Annual Information Form.
1. Holigen Agreement: On November 19, 2018, the Company entered into a binding term sheet with Holigen pursuant to which the Company agreed to lend $6,000,000 to Holigen. On December 19, 2018, the Company entered into the Holigen Agreement which (i) entitled the Company to convert the $6,000,000 loan into shares of Holigen, or a subsidiary thereof, and (ii) the Company purchased additional shares of Holigen, or a subsidiary thereof. The closing of the Company's acquisition of the shares of Holigen, or a subsidiary thereof, is subject to certain conditions. Upon closing, the Company will own 19.8% of the issued and outstanding shares of Holigen, or a subsidiary thereof.
2. Hawthorne Agreement: On December 14, 2018, Flowr ULC, Flowr Okanagan and Hawthorne entered into an amended and restated agreement pursuant to which Hawthorne retained Flowr Okanagan to oversee the construction of a research and development facility and provide certain research and development services. Pursuant to the Hawthorne Agreement, Flowr Okanagan and Flowr ULC will work with Hawthorne to design a research and development facility on property owned by Flowr Okanagan. Hawthorne agreed to loan Flowr Okanagan up to a maximum amount of $11,500,000 to construct the research and development facility. Flowr Okanagan will be the owner of the research and development facility.
3. The License: See "Description of the Business - The Facility".
4. The Lease: On December 1, 2016, 0954717 B.C. Limited and Cannatech Plant Systems Inc. (now Flowr Okanagan), entered into a lease for the K1 Facility. The Lease expires on November 30, 2041 and contains (i) a right of first refusal in favour of Flowr Okanagan to purchase the land if 0954717 B.C. Limited receives a third-party offer to purchase the land and (ii) an option to purchase the land.
5. Share Exchange Agreement: Needle, Flowr Privateco, Flowr ULC and Flowco US Partners entered into a share exchange agreement which sets out the rights of the Flowco US Partners to exchange their Flowr ULC Class A Shares for Common Shares, for no additional consideration, following the completion of the Qualifying Transaction and the mechanism by which additional Flowr ULC Common Shares will be issued to the Corporation in the event that the Corporation issues additional Common Shares.
6. Business Combination Agreement: On August 27, 2018, Needle entered into the Business Combination Agreement, pursuant to which the parties thereto agreed to: (i) the completion of the consolidation of all Needle Shares; (ii) change the name of Needle to "The Flowr Corporation"; (iii) a brokered private placement and a non-brokered private placement of up to 13,807,734 Subscription Receipts for aggregate gross proceeds of up to $35,900,108.40; (iv) the reconstitution of the board of directors of Needle to consist of five (5) directors nominated by Flowr Privateco; (v) the continuance of Needle from the ABCA to the OBCA; (vi) the amalgamation of Flowr Privateco and Needle Subco; and (vii) the issuance of 85,692,095 Common Shares at a deemed issue price of $2.60 per Common Share (post-consolidation).
7. Amalgamation Agreement: On August 27, 2018, Needle, Flowr Privateco and Needle Subco entered into the Amalgamation Agreement, as amended by an amending agreement dated September 10, 2018, pursuant to which Flowr Privateco was amalgamated with Needle Subco under section 174 of the OBA which resulted in the indirect acquisition by Needle of all of the issued and outstanding securities of Flowr Privateco.
Copies of the above listed material contracts are available on the Corporation's profile on SEDAR at www.sedar.com or upon request from the Corporation at 461 King Street W., Floor 2, Toronto, ON M5V 1K4.
38 |
2018 Annual Information Form |
INTEREST OF EXPERTS
The auditors of the Corporation are MNP, LLP, Chartered Professional Accountants, 50 Burnhamthorpe Road West, Suite 900, Mississauga, Ontario L5B 3C2. MNP LLP, Calgary, Alberta was first appointed auditors of Needle on November 3, 2016 and MNP, Mississauga, Ontario were appointed auditors of the Corporation on January 24, 2018. MNP was the auditor in respect of the consolidated financial statements of the Corporation for the year ended December 31, 2018. MNP has confirmed that they are independent within the meaning of the relevant rules and related interpretations prescribed by the relevant professional bodies in Canada and any applicable legislation or regulations. As of the date hereof, MNP LLP and its partners and associates, beneficially own, directly or indirectly, in their respective groups, less than 1% of any class of outstanding securities of the Corporation. No director, officer or employee of MNP, is or is expected to be elected, appointed or employed as a Director, officer or employee of the Corporation or any associate or affiliate of the Corporation.
TRANSFER AGENT AND REGISTRAR
The transfer agent and registrar for the Common Shares is Computershare Investor Services Inc. at its principal offices in Toronto, Ontario.
39 |
2018 Annual Information Form |
RISK FACTORS
The following sets forth certain risks and uncertainties that could have a material adverse effect on the Corporation's business, financial condition and results of operations and the trading price of the Common Shares, which could decline, and investors may lose all or part of their investment. Additional risks and uncertainties of which the Corporation currently is unaware or that are unknown or that it currently deems to be immaterial could have a material adverse effect on the Corporation's business, financial condition and results of operations. The Corporation cannot assure you that it will successfully address any or all of these risks. The risks described below describe certain currently known material factors, any of which could have a material adverse effect on the Corporation's business, financial condition and results of operations. There is no assurance that any risk management steps taken will avoid future loss due to the occurrence of the risks described below or other unforeseen risks.
Risks Related to the Business
Limited Operating History and Uncertainty of Future Revenues
The Corporation has a limited operating history and, accordingly, potential investors will have a limited basis on which to evaluate the Corporation's ability to achieve its business objectives. The future success of the Corporation is dependent on management's ability to implement its strategy. Although management is optimistic about the Corporation's prospects, there is no certainty that anticipated outcomes and sustainable revenue streams will be achieved and there is no certainty that the Corporation will successfully produce commercial cannabis or establish a market for its products. The Corporation faces risks frequently encountered by early-stage companies. In particular, its future growth and prospects will depend on its ability to expand its operations and gain additional revenue streams whilst at the same time maintaining effective cost controls. Any failure to expand is likely to have a material adverse effect on the Corporation's business, financial condition and results of operations.
Future Funding Requirements
To date, the Corporation has had negative cash flow from operating activities. To fund its current operations and anticipated capacity expansions, additional funds will be required. If the Corporation continues to have negative cash flow into the future, the Corporation may need to allocate additional financing proceeds to funding this negative cash flow in addition to its operational expenses and planned capital expansions. Flowr may require additional financing to fund its operations to the point where it is generating positive cash flows. Continued negative cash flow may restrict the Corporation's ability to pursue its business objectives which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
The building and operation of the Corporation's facilities and business are capital intensive. In order to execute the anticipated growth strategy, the Corporation will require additional equity and/or debt financing to support on-going operations, to undertake capital expenditures or to undertake additional acquisitions or other business combination transactions. There can be no assurance that additional financing will be available to the Corporation when needed or on terms which are acceptable to the Corporation. The Corporation's inability to raise financing to support on-going operations or to fund capital expenditures or acquisitions could limit the Corporation's growth and may have a material adverse effect upon future profitability. The Corporation may require additional financing to fund its operations to the point where it is generating positive cash flows.
If additional funds are raised through further issuances of equity or debt securities, existing shareholders (including prospective investors) could suffer significant dilution, and any new equity securities issued could have rights, preferences and privileges superior to those of holders of the Common Shares. In addition, from time to time, the Corporation may enter into transactions to acquire assets or the shares of other corporations. These transactions may be financed wholly or partially with debt and/or equity issuances, which may temporarily increase the Corporation's debt levels above industry standards and/or further dilute shareholders significantly. Any debt financing secured in the future could involve restrictive covenants relating to the Corporation's capital raising activities and other financial and operational matters, which may make it more difficult for the Corporation to obtain additional capital and to pursue business opportunities, including potential acquisitions.
40 |
2018 Annual Information Form |
Reliance of the Corporation on Licensing
The Corporation's business operations, including its ability to grow, store and sell medical and adult-use cannabis in Canada and any other jurisdiction, are dependent on the Licence, and other applicable licences in applicable jurisdictions. The Licence, and other applicable licences in applicable jurisdictions, are subject to ongoing compliance and reporting requirements. In addition, all licences must be renewed from time to time. The Licence expires on December 1, 2020. Prior to expiry of the Licence, the Corporation must submit to Health Canada an application for renewal of the Licence containing information prescribed by the Cannabis Act.
Although the Corporation believes that it is complying in all material respects with the terms of the Licence, failure to comply with the requirements of the Licence or any failure to maintain the Licence would have a material adverse effect on the Corporation's business, financial condition and results of operations.
Although the Corporation believes it will meet the requirements of the Cannabis Act for future extensions or renewals of the Licence, there can be no guarantee that Health Canada will extend or renew the Licence or, if extended or renewed, that it will be extended or renewed on the same or similar terms. Should Health Canada not extend or renew the Licence or should they renew the Licence on different terms, it would have a material adverse effect on the Corporation's business, financial condition and results of operations. There are also various licensing requirements which the Corporation and certain of its directors and employees would need to satisfy for future extensions or renewals. There is no guarantee that the Corporation and/or such persons will satisfy the licensing requirements nor that Health Canada will extend or renew the License, or, if extended or renewed, that they will be extended or renewed on the same or similar terms. In addition, the expansion of the Corporation's operations and facilities may require new licences to be issued. Any failure or delay in obtaining such licences could have a material impact on the Corporation's ability to increase its revenue which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
The Corporation may not be able to obtain or maintain the necessary licences, permits, certificates, authorizations or accreditations, or may only be able to do so at great cost, to operate its business in Canada. The Corporation may not be able to comply fully with the wide variety of laws and regulations applicable to the cannabis industry in the jurisdictions in which the Corporation operates. Failure to comply with or to obtain the necessary licences, permits, certificates, authorizations or accreditations could result in restrictions on the Corporation's ability to operate in the cannabis industry in any jurisdiction, which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Regulatory Risks Generally Applicable to the Cannabis Industry
The laws, regulations and guidelines generally applicable to the cannabis industry domestically and internationally may change in ways currently unforeseen by the Corporation. The Corporation's operations are subject to a variety of laws, regulations and guidelines relating to the manufacture, extraction, management, transportation, storage, sale, health, import, export and safety and disposal of cannabis (including the Cannabis Act), as well as those relating to taxes, labour standards and occupational health, toxic substances, land use, water use, and other matters.
The commercial medical and adult-use cannabis industry is a new industry in Canada and in other jurisdictions. The ACMPR was established in August 2016 which was replaced by the Cannabis Act in October 2018. This industry and market may not continue to exist or grow as anticipated or Flowr may ultimately be unable to succeed in this industry and market.
The Corporation anticipates that regulations governing the industry will be subject to change as the Government of Canada, the governments of individual provinces and territories and other governments, monitor operating licenced producers. The operations of the Corporation will be subject to a variety of laws, regulations, guidelines and policies relating to the manufacture, processing, extraction, import, export, management, packaging/labelling, advertising, sale, transportation, storage and disposal of cannabis but also laws and regulations relating to drugs, controlled substances, health and safety, land use, the conduct of operations and the protection of the environment. While to the knowledge of management, the Corporation is currently in material compliance with all such laws, any changes to such laws, regulations, guidelines and policies may have a material adverse effect on its business, financial condition and results of operations, including with respect to the ability of the Corporation to leverage its cultivation data for expansion of operations in jurisdictions outside of Canada, including, without limitation, where genetic material is required by partners and/or affiliates in foreign jurisdictions for licensing purposes. No assurance can be given that new rules and regulations will not be enacted or that existing rules and regulations will not be applied in a manner which could limit or curtail the Corporation's ability to distribute or produce cannabis, or the ability of its affiliates and/or partners to complete their licensing process as a result of not being able to import genetic material. Amendments to current laws and regulations governing the distribution, transportation and/or production of cannabis, or more stringent implementation thereof, could cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development, which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
41 |
2018 Annual Information Form |
Changes in Laws, Regulations and Guidelines
The Cannabis Act and Cannabis Regulations came into force on October 17, 2018. The Cannabis Act and Cannabis Regulations prohibit testimonials, lifestyle branding and packaging that is appealing to youth. The restrictions on advertising, marketing and the use of logos and brand names could have a material adverse effect on the Corporation's business, financial condition and results of operations. The legislative framework pertaining to the Canadian adult-use cannabis market is uncertain.
The legislative and operational framework of the provinces and territories and international governments pertaining to the distribution of cannabis varies among jurisdictions and has resulted in additional regulations, creating additional compliance and other costs and/or limitations on the Corporation's ability to participate in such markets. There is no guarantee that jurisdictional legislation regulating the distribution and sale of cannabis for adult-use or medical purposes, as applicable, will be enacted according to all the terms announced by such jurisdictions, or at all, or that any such legislation, if enacted, will create the growth opportunities that the Corporation currently anticipates. While the impact of any new legislative framework for the regulation of the adult-use cannabis market or medical market, as applicable, is uncertain, any of the foregoing could result in a material adverse effect on the Corporation's business, financial condition and results of operations. The asymmetrical regulatory and market environment for cannabis in each of the provinces and territories of Canada could have a material adverse effect on the Corporation's business, financial condition and results of operations. In addition, although the Canadian government has proposed October 2019 as the timeline for legalization of edible and other concentrate sales, to the extent such timeline is delayed or such legislative proposals do not become laws, additional revenue from such products will be lost, which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
The governments of every Canadian province and territory have, to varying degrees, announced or implemented regulatory regimes for the distribution and sale of cannabis for adult-use purposes within those jurisdictions. There can be no assurance that the legalization of adult-use cannabis by each of the provinces and territories will occur as announced or at all.
Regional Overcapacity
The adult-use cannabis market in Canada may become oversupplied in the future and many analysts and commentators are predicting over-supply to occur.
Since the implementation of the Cannabis Act, demand for cannabis has increased. To date, licensed producers in Canada have not been able to produce sufficient amounts of cannabis product to satisfy demand, which has led to an undersupplied market. However, as the Corporation and other licensed producers in Canada produce more cannabis than is needed to satisfy the collective demand of the Canadian medical and adult-use markets, and should the Corporation be unable to export that oversupply into other markets where cannabis use is fully legal under all federal and state or provincial laws, the available supply of cannabis could exceed demand, resulting in a significant decline in the market price for cannabis. If this were to occur, there is no assurance that the Corporation would be able to generate sufficient revenue from the sale of adult-use cannabis to result in profitability which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Market Development and Continued Legalization
Development of the cannabis industry may be slower or less than originally anticipated due to a variety of factors that are out of the Corporation's control, including: (i) delayed approvals for legalization of both medical and adult-use cannabis in international markets; (ii) supply chain issues with delivery of cannabis to end users; (iii) delayed or cancelled approvals for additional cannabis products not yet legalized in Canada and other jurisdictions such as edibles, beverages, etc.; or (iv) lack of successful R&D for other cannabis products (beverages, creams, etc.). Any of these could have a material adverse effect on the Corporation's business, financial condition and results of operations.
42 |
2018 Annual Information Form |
Management of Growth and Capacity Constraints
The Corporation may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Corporation to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Corporation to deal with this growth may have a material adverse effect on the Corporation's business, financial condition and results of operations.
History of Net Losses and Achieving or Maintaining Profitability
The Corporation has incurred losses in recent periods. The unaudited condensed interim consolidated financial statements of the Corporation for the three and nine months ended September 30, 2018, and the audited annual consolidated financial statement for the year ended December 31, 2018, the only historical financial statements prepared after the completion of the Qualifying Transaction, only include public company costs since the completion of the Qualifying Transaction on September 21, 2018. It is possible that the Corporation's losses would have been higher for those periods as a public company. The Corporation may not be able to achieve or maintain profitability and may continue to incur significant losses in the future. In addition, the Corporation expects to continue to increase operating expenses as it implements initiatives to continue to grow its business. If the Corporation's revenues do not increase to offset these expected increases in costs and operating expenses, the Corporation will not be profitable.
Competition within the Cannabis Industry
The market in which the Corporation operates is competitive and fast moving and may become even more competitive. The Corporation faces intense competition from other companies, some of which can be expected to have a longer operating history and more financial resources and cultivation, processing, distribution and marketing experience than the Corporation. Increased competition by larger and better financed competitors could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Because the industry in which the Corporation operates is at an early stage, the Corporation may face additional competition from new entrants. Currently, the cannabis industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies who also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of larger operations and cultivation facilities. In doing so, these larger competitors could establish price setting and cost controls which would effectively "price out" many of the individuals and small to medium-sized entities who currently make up the bulk of the participants in the varied businesses operating within and in support of the medical and adult-use cannabis industry. While the trend in most laws and regulations seemingly deters this type of takeover, this industry remains quite nascent, so what the landscape will be in the future remains largely unknown, which in itself is a risk.
The number of licences granted and the number of licenced producers ultimately authorized by Health Canada, and other applicable regulatory bodies in the markets in which the Corporation operates, could have an impact on the operations of the Corporation. To date over 163 licences have been authorized within Canada. The Corporation expects to face additional competition from new market entrants that are granted licences under the Cannabis Act or existing licence holders which are not yet active in the industry. If a significant number of new licences are granted by Health Canada, or other applicable regulatory bodies in the markets in which the Corporation operates, in the near term future, the Corporation may experience increased competition for market share within the medical market and adult-use markets, which could negatively impact the Corporation's market share and demand for products.
If the national demand of medical and adult-use cannabis in Canada, and other applicable jurisdictions, increases, along with an increased number of licenced producers, the Corporation expects that competition will become more intense, as current and future competitors begin to offer an increasing number of diversified products. To remain competitive, the Corporation will require a continued high level of investment in research and development, marketing, sales and client support. The Corporation may not have sufficient resources to maintain research and development, marketing, sales and client support efforts on a competitive basis which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
The Corporation expects to be a leader in technologies related to cannabis. However, as various forms of technologies in the cultivation, processing, manufacturing and research and development of cannabis are being explored, there is potential for third party competitors to be in possession of superior technology that would reduce the relative competitiveness of the Corporation.
Finally, the Cannabis Regulations permit cultivation licence holders to conduct both outdoor and indoor cultivation of cannabis, however no licenced activities (except for destruction, antimicrobial treatment and distribution) can take place in a "dwelling-house". The implications of the proposal to allow outdoor cultivation are not yet known, but such a development could be significant as it may reduce start-up capital required for new entrants in the cannabis industry. It may also ultimately lower prices as capital expenditure requirements related to growing outside are typically much lower than those associated with indoor growing.
43 |
2018 Annual Information Form |
Strategic Acquisitions and Partnerships
The Corporation currently has, and may in the future enter into further, strategic acquisitions, partnerships or similar relationships that it believes will complement or augment its existing business. The Corporation's ability to complete such strategic acquisitions or partnerships is dependent upon, and may be limited by, the availability of suitable candidates and capital. There can be no assurance that the Corporation will be able to identify acquisition or partnership opportunities that meet its strategic objectives, or to the extent such opportunities are identified, that it will be able to negotiate terms that are acceptable to it. In addition, strategic acquisitions or partnerships could present unforeseen integration obstacles or costs, may not enhance the Corporation's business, and may involve risks that could adversely affect the ongoing business of the Corporation, including significant amounts of management time that may be diverted from operations to pursue and complete such transactions or maintain such strategic partnerships. Future strategic acquisitions or partnerships could result in the incurrence of additional debt, costs and contingent liabilities, and there can be no assurance that future strategic acquisitions or partnerships will achieve, or that the Corporation's existing strategic partnerships will continue to achieve, the expected benefits to the Corporation's business or that the Corporation will be able to consummate future strategic partnerships on satisfactory terms, or at all. The Corporation may also experience negative reactions from the financial markets, which could cause a decrease in the market price of the Corporation's securities, particularly if the market price reflects market assumptions that acquisitions or partnerships will be completed or completed on certain terms.
Further, some strategic partnerships involve master supply agreements entered with certain provinces in Canada, such as Ontario and British Columbia, whereby the provinces are not obligated to order any particular volume of cannabis or order at all. Additionally, some of the master supply agreements, such as those with such as Ontario and British Columbia, can be terminated by the provinces for any reason and at any time with 60 or 90 days' notice. Additionally, certain strategic partnerships may include restrictions on Flowr's ability to sell its products. For example, the supply agreement with Shoppers prohibits Flowr from selling medical cannabis directly to consumers in Canada or selling its medical cannabis brand into non-medical sales channels in Canada.
Any of the foregoing risks and uncertainties could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Competition from Illegal Dispensaries and the Black Market
The Corporation also faces competition from illegal dispensaries and the black market that are unlicensed and unregulated, and that are selling cannabis and cannabis products, including products with higher concentrations of active ingredients, and using delivery methods that the Corporation is prohibited from offering to individuals as they are not currently permitted by law. Various Canadian cities have seen an influx in the number of illegal dispensaries. Any inability or unwillingness of law enforcement authorities to enforce existing laws prohibiting the unlicensed cultivation and sale of cannabis and cannabis-based products could result in the perpetuation of the black market for cannabis and/or have a material adverse effect on the perception of cannabis use. Any or all these events could have a material adverse effect on the Corporation's business, financial condition and results of operations.
The Corporation May Fail to Retain Existing Clients or Acquire New Clients
The Corporation's success depends on its ability to attract and retain clients. There are many factors which could affect the Corporation's ability to attract and retain clients, including but not limited to its ability to continually produce desirable and effective product, the successful implementation of its marketing plan and the continued growth in the aggregate number of cannabis users. Moreover, even if the Corporation is successful at attracting a new client, there is no guarantee that such client will continue to purchase product from Flowr. The Corporation's failure to acquire and retain clients would have a material adverse effect on its business, financial condition and results of operations.
Competition from Synthetic Products
The pharmaceutical industry may attempt to dominate the cannabis industry, and in particular, legal cannabis, through the development and distribution of synthetic products which emulate the effects and treatment of organic cannabis. If they are successful, the widespread popularity of such synthetic products could change the demand, volume and profitability of the cannabis industry. This could adversely affect the ability of the Corporation to secure long-term profitability and success through the sustainable and profitable operation of the anticipated businesses and investment targets, and could have a material adverse effect on the Corporation's business, financial condition or results of operations.
44 |
2018 Annual Information Form |
Reputational Risk and Negative Public Opinion
Damage to the Corporation's reputation can result from the actual or perceived occurrence of any number of events, including any negative publicity, whether true or not. As a producer and distributor of cannabis, which is a controlled substance in Canada that has previously been commonly associated with various other narcotics, violence and criminal activities, there is a risk that the Corporation's business might attract negative publicity. There is also a risk that the actions of other licenced producers or of other companies and service providers in the cannabis industry may negatively affect the reputation of the industry as a whole and thereby negatively impact the Corporation's reputation. The increased usage of social media and other web-based tools used to generate, publish and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share negative opinions and views in regards to the Corporation's activities and the medical cannabis industry in general, whether true or not. The Corporation does not ultimately have direct control over how the Corporation or the cannabis industry is perceived by others. Reputational issues may result in decreased investor confidence, increased challenges in developing and maintaining community relations and present an impediment to the Corporation's overall ability to advance its business strategy and realize on its growth prospects, which could have a material adverse effect on the Corporation's business, financial condition or results of operations.
Reliance on the Expertise of the Board of Directors and Key Executives
The successful ongoing operation of the Corporation requires substantial expertise. The Board and management will have authority to make decisions and to exercise investment acquisition discretion on behalf of the Corporation. The success of the Corporation will depend to a great extent upon the expertise of the Board and management. The loss of the services of any member of the Board or one or more members of management, including as a result of the failure of such persons to be granted security clearances under the Cannabis Regulations, could have a material adverse effect on the Corporation's business, financial condition or results of operations. In particular, given the significant operation, design and construction expertise of Flowr's management, the loss of such expertise by way of resignation, termination and/or death could have a material adverse effect on the Corporation's business, financial condition or results of operations.
Reliance on the K1 Facility, and Other Proposed Facilities
The Corporation's activities and resources are focused on the construction and development of the K1 Facility, and other proposed facilities. Adverse changes or developments affecting the K1 Facility, or other proposed facilities, including but not limited to a natural disaster, calamity, act of war or terrorism or other major disturbance or breach of security, could have a material and adverse effect on the Corporation's business, financial condition or results of operations. Any breach of the security measures and other facility requirements, including any failure to comply with recommendations or requirements arising from inspections by Health Canada could also have an adverse impact on the Corporation's ability to continue operating under, or each entity's prospects of renewing, the applicable licences necessary to cultivate, manufacture, extract, grow, process and/or produce cannabis at the K1 Facility, or other proposed facilities, as applicable.
All facilities continue to operate with routine maintenance however, the buildings do have components that require replacement or repair. The Corporation will bear the costs of maintenance and upkeep at the K1 Facility, and other proposed facilities. If the Corporation is not able to keep up with such maintenance requirements it could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Certain contemplated capital expenditures of the Corporation, including expansion and/or renovation of the K1 Facility, and other proposed facilities, may require approval of Health Canada, or the applicable regulatory authorities in other applicable jurisdictions where the facilities are located. There is no guarantee that Health Canada, or the applicable regulatory authorities in other applicable jurisdictions where the facilities are located, will approve any contemplated capital expenditure on a timely basis or at all, which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
In addition, there is no guarantee that, even if approved by Health Canada, or the applicable regulatory authorities in other applicable jurisdictions where the facilities are located, the Corporation will have the funds necessary to complete any capital expenditures or that any capital projects will be completed on time or in accordance with budgetary projections.
If the Corporation cannot complete construction of the K1 Facility, or other proposed facilities, or is delayed in completing construction of these facilities, such events could have a material adverse effect on the Corporation's business, financial condition and results of operations, including reputational damage and loss of sales. Further, there is no guarantee that the Corporation can achieve the anticipated buildout and ramp up of the K1 Facility's, or other proposed facilities, expected capacity in the timeframe as forecasted, or at all. Even when fully built, the growing capacity of the K1 Facility, and other proposed facilities may be less than originally anticipated. The Corporation may not be able to achieve its expected capacity due to delays in construction, project cost overruns, the inability to raise capital to fund development efforts, unanticipated crop failures and other circumstances beyond its control which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
45 |
2018 Annual Information Form |
Breaches of Security at the Facilities or in Respect of Electronic Documents and Data Storage and Risks Related to Breaches of Applicable Privacy Laws
Given the nature of the Corporation's product and its lack of legal availability outside of channels approved by the Government of Canada and the individual Canadian provinces and territories, and notwithstanding meeting or exceeding Health Canada's security requirements, there remains a risk of theft. Given that the Corporation is permitted to store significant quantities of product as a licenced producer, a security breach at the Corporation's facility could expose the Corporation to additional liability and to potentially costly litigation, increased expenses relating to the resolution and future prevention of these breaches and may deter potential customers from choosing the Corporation's products.
In addition, as a licenced producer, the Corporation is expected to collect and store personal information about its clients and is responsible for protecting that information from privacy breaches. In addition, when the Corporation sells its products through third parties, such as Shoppers, such third parties are also required to protect such information. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized intrusions. Theft of data for competitive purposes, particularly patient lists and preferences, is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such theft or privacy breach involving the Corporation and/or its partners would have a material adverse effect on the Corporation's business, financial condition and results of operations. Moreover, there are a number of federal, provincial and territorial laws protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure of that protected information. In particular, the privacy rules under the Personal Information Protection and Electronic Documents Act ("PIPEDA"), protect medical records and other personal health information by limiting their use and disclosure of health information to the minimum level reasonably necessary to accomplish the intended purpose. If the Corporation or any of its partners was found to be in violation of the privacy or security rules under PIPEDA or other laws protecting the confidentiality of patient health information, such person could be subject to sanctions and civil or criminal penalties, which could increase the Corporation's liabilities, harm its reputation and have a material adverse effect on the Corporation's business, financial condition and results of operations.
Fraudulent or Illegal Activity by Employees, Contractors and Consultants
The Corporation is exposed to the risk that any of their employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to the Corporation that violates, (i) government regulations, (ii) manufacturing standards, (iii) federal, state and provincial healthcare fraud and abuse laws and regulations, or (iv) laws that require the true, complete and accurate reporting of financial information or data. It may not always be possible for the Corporation to identify and deter misconduct by its employees and other third parties, and the precautions taken by the Corporation to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Corporation from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against the Corporation, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on the business of the Corporation, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of the operations of the Corporation, any of which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Product Liability due to the Nature of the Products
As a distributor of products designed to be ingested by humans, the Corporation faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the sale of the Corporation's products involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of the Corporation's products alone or in combination with other medications or substances could occur. The Corporation may be subject to various product liability claims, including, among others, that the Corporation's products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against the Corporation could result in increased costs, could adversely affect the Corporation's reputation with its clients and consumers generally, and could have a material adverse effect on the business, financial condition and results of operations of the Corporation. There can be no assurances that the Corporation will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Corporation's products and could have a material adverse effect on the business, financial condition and results of operations of the Corporation.
46 |
2018 Annual Information Form |
Product Recalls including Contamination and Unintended Harmful Side effects
Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If the Corporation's products are recalled due to an alleged product defect or for any other reason, the Corporation could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Corporation may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Corporation has procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. A recall for any of the foregoing reasons could lead to decreased demand for the Corporation's products and could have a material adverse effect on the business, financial condition and results of operations of the Corporation. Additionally, product recalls may lead to increased scrutiny of the Corporation's operations by Health Canada or other regulatory agencies, requiring further management attention and potential legal fees and other expenses.
Inability to Maintain Pricing Premium for Premium Products
As the medical and adult-use cannabis industry is in its relative infancy both in Canada and internationally, the anticipated pricing spread between premium and non-premium products may not be as significant as originally forecasted. The Corporation's strategy is, to a certain extent, reliant on the development of a premium and super premium segment of the adult-use cannabis market and the ability to charge more for such product. A premium segment may not develop in the market and even if it does, premium pricing may be volatile. The Corporation's business model is susceptible to erosion of profitability should the actual pricing premium for high grade products be less than expected.
Operational Risks including Labour Disputes, Accidents, Fires, etc.
The Corporation may be affected by a number of operational risks and may not be adequately insured for certain risks, including: labour disputes; catastrophic accidents; fires; blockades or other acts of social activism; equipment defects, malfunction and failures; changes in the regulatory environment; impact of non-compliance with laws and regulations; natural phenomena, such as inclement weather conditions, floods, earthquakes, ground movements, accidents and explosions that can cause personal injury, loss of life, suspension of operations, damage to facilities, business interruption and damage to or destruction of property, equipment and the environment. There is no assurance that the foregoing risks and hazards will not result in damage to, or destruction of, the Corporation's properties, facilities, grow facilities and extraction facilities, personal injury or death, environmental damage, or have an adverse impact on the Corporation's operations, costs, monetary losses, potential legal liability and adverse governmental action, any of which could have a material adverse effect on the business, financial condition or results of operations of the Corporation. This lack of insurance coverage could have a material adverse effect on the Corporation's business, financial condition or results of operations.
The Corporation will continuously monitor its operations for quality control and safety. However, there are no assurances that the Corporation's safety procedures will always prevent such damages and the Corporation may be affected by liability or sustain loss in respect of certain risks and hazards. Although the Corporation will maintain insurance coverage that it believes to be adequate and customary in the industry, there can be no assurance that such insurance will be adequate to cover its liabilities. In addition, there can be no assurance that the Corporation will be able to maintain adequate insurance in the future at rates it considers reasonable and commercially justifiable. The Corporation may elect not to insure against certain risks due to cost or ease of procuring such insurance. The occurrence of a significant uninsured claim, a claim in excess of the insurance coverage limits then maintained by the Corporation, or a claim at a time when it is not able to obtain liability insurance, could have a material adverse effect on the Corporation's business, financial condition or results of operations.
47 |
2018 Annual Information Form |
In addition, many insurance providers are not insuring companies that operate in the cannabis industry or require significant premiums in order to provide coverage. The Corporation may not be able to obtain coverage, including directors and officers liability coverage, at reasonable rates or at all as a result of such circumstances. In addition, the Corporation may choose to access lower limits of insurance. As a result, the Corporation may not have adequate insurance for covering its risks, which could have a material adverse effect on the Corporation's business, financial condition or results of operations.
Proprietary Protection in respect of the Corporation's Ideas and Technology
The success of the Corporation's business depends in part on its ability to protect its ideas and technology. The Corporation has applied to register a number of patents and trademarks in Canada and elsewhere.
Even where the Corporation has taken steps to protect its technology with trademarks, patents, copyrights or by other means, the Corporation is not assured that competitors will not develop similar technology, business methods or that the Corporation will be able to exercise its legal rights to protect and maintain its intellectual property.
In addition, other countries may not protect intellectual property rights to the same standards as does Canada. Actions taken to protect or preserve intellectual property rights may require significant financial and other resources which may have a material adverse effect on the business, financial condition and results of operations of the Corporation.
The Corporation's intellectual property also consists of certain know-how in the design and construction of its facilities. Such know-how may not be protected by applicable laws, and although the Corporation enters into confidentiality and non-use agreements to protect such intellectual property, there is no assurance that such intellectual property may not be used by a third party or employee to the Corporation's detriment.
Conflicts of Interest in respect of Directors and Officers of the Corporation
All decisions to be made by the Directors and officers involving the Corporation are required to be made in accordance with their duties and obligations to act honestly and in good faith with a view to the best interests of the Corporation. In addition, such Directors and officers are required to declare their interests in, and such Directors are required to refrain from voting on, any matter in which they may have a material conflict of interest. However, certain of the Directors and officers of the Corporation are also directors and officers of other companies or are engaged and will continue to be engaged in activities that may put them in conflict with the business strategy of the Corporation. Consequently, there exists the possibility for such Directors and officers to be in a position of conflict with their duties to the Corporation and their decisions may not be in the best interests of the Corporation and its shareholders.
Constraints on Marketing Products due to Statutory Prohibitions
The Corporation intends to develop brand/product differentiation strategies to retain and/or grow brand market share. The potential for success of these strategies is uncertain, dependent on various factors, and subject to various challenges.
The development of the Corporation's business and operating results may be hindered by applicable regulatory restrictions on sales and marketing activities. Under the Cannabis Act, marketing and advertising for adult-use cannabis is significantly limited. More specifically, the Cannabis Act prohibits the marketing and advertising of products to individuals less than 18 years of age or in forums in which such individuals may be present or exposed to such advertising or publicity. Accordingly, the regulatory environment in Canada limits the Corporation's ability to compete for market share in a manner similar to other industries.
If the Corporation is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, it could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Risks Inherent in an Agricultural Business
Medical and adult-use cannabis is an agricultural product. There are risks inherent in an agricultural business, such as insects, plant diseases, crop failure and similar agricultural risks. Although the products are usually grown indoors or in green houses under climate-controlled conditions, with conditions monitored, there can be no assurance that natural elements will not have a material adverse effect on the production of the Corporation's products and, consequentially, on the Corporation's business, financial condition and results of operations. In addition, the Corporation intends on growing cannabis outdoors, in environments that are not controlled. As a result, the risk of crop failures and the loss of its crops is significantly more profound.
48 |
2018 Annual Information Form |
Although the Corporation aims to produce high quality products without the use of irradiation, the Corporation has used, and may in the future be required to use, irradiation on its products. Such irradiation is likely to impact the quality of the products, which could have a material adverse effect on the Corporation's sales, reputation as a high-quality cannabis producer and/or selling price, and, consequentially, on the Corporation's business, financial condition and results of operations.
Valuation of Biological Assets
Pursuant to IFRS, the Corporation measures the value of its biological assets consisting of cannabis plants using the income approach at fair value less costs to sell up to the point of harvest. As market prices are generally not available for biological assets while they are growing, the Corporation is required to make assumptions and estimates relating to, among other things, future agricultural commodity yields, prices and production costs. The assumptions and estimates used to determine the fair value of biological assets, and any changes to such prior estimates, directly affect the Corporation's reported results of operations. If actual yields, prices, costs, market conditions or other results differ from the Corporation's estimates and assumptions, there could be material adjustments to the Corporation's results of operations. In addition, the use of these future estimated metrics differs from generally accepted accounting principles in the United States. As a result, the Corporation's financial statements and reported earnings are not directly comparable to those of similar companies in the United States.
Environmental Regulation and Risks
The Corporation's operations are subject to environmental regulation in the various jurisdictions in which it operates. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Corporation's operations.
Government approvals and permits are currently, and may in the future be, required in connection with the Corporation's operations. To the extent such approvals are required and not obtained, the Corporation may be curtailed or prohibited from its production and/or distribution of cannabis or from proceeding with the development of its operations as currently proposed.
Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Corporation may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.
Results of Future Clinical Research
Research in Canada, the United States and internationally regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages. There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Although the Corporation believes that the articles, reports and studies support its beliefs regarding the effects of cannabis, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Further, the Corporation believes the cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the cannabis produced. Consumer perception can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of cannabis products. There can be no assurance that future scientific research or findings, regulatory investigations, litigation, media attention or other publicity will be favorable to the cannabis market or any particular product, or consistent with earlier publicity.
Future research studies and clinical trials may reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to cannabis, which could have a material adverse effect on the demand for the Corporation's products with the potential to lead to a material adverse effect on the Corporation's business, financial condition and results of operations. There is no assurance that such adverse publicity reports or other media attention will not arise.
49 |
2018 Annual Information Form |
Transportation Disruptions related to an Agricultural Product
As a business revolving mainly around the growth of an agricultural product, the ability to obtain speedy, cost-effective and efficient transport services will be essential to the prolonged operations of the Corporation's business. Should such transportation become unavailable for prolonged periods of time, it could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Due to the nature of the Corporation's products, security of the product during transportation to and from its facilities is of the utmost concern. A breach of security during transport or delivery could have a material adverse effect on the Corporation's business, financial condition and results of operations. Any breach of the security measures during transport or delivery, including any failure to comply with recommendations or requirements of Health Canada, could also have an impact on the Corporation's ability to continue operating under its licences or the prospect of renewing its licences.
Vulnerability to Rising Energy Costs
The Corporation's cannabis growing operations consume considerable energy, which makes the Corporation vulnerable to rising energy costs and/or the availability of stable energy sources. Accordingly, rising or volatile energy costs or the inability to access stable energy sources may have a material adverse effect on the Corporation's business, financial condition and results of operations.
Reliance on Key Inputs
The Corporation's business is dependent on a number of key inputs and their related costs including raw materials and supplies related to its growing operations, as well as electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Corporation. Some of these inputs may only be available from a single supplier or a limited group of suppliers, including access to the electricity grid. If a sole source supplier was to go out of business, the Corporation might be unable to find a replacement for such source in a timely manner or at all. If a sole source supplier were to be acquired by a competitor, that competitor may elect not to sell to the Corporation in the future. Any inability to secure required supplies and services or to do so on appropriate terms could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Dependence on Skilled Labour and Suppliers
The ability of the Corporation to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labour, equipment, parts and components. No assurances can be given that the Corporation will be successful in maintaining its required supply of skilled labour, equipment, parts and components. Qualified individuals are in high demand, and the Corporation may incur significant costs to attract and retain them. It is also possible that the final costs of the major equipment and materials, including packaging materials, contemplated by the Corporation's capital expenditure program may be significantly greater than anticipated by the Corporation's management, and may be greater than funds available to the Corporation, in which circumstance the Corporation may curtail, or extend the timeframes for completing, its capital expenditure plans. This could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Further, certain employees, including certain executive officers, are subject to a security clearance by Health Canada. There is no assurance that any of the Corporation's existing personnel who presently or may in the future require a security clearance will be able to obtain or renew such clearances or that new personnel who require a security clearance will be able to obtain one. Licenced producers were experiencing delays in Health Canada security clearances and any similar delays under the Cannabis Regulations could have an adverse effect on the Corporation's business and results of operations. A failure by an employee to maintain or renew his or her security clearance would result in a material adverse effect on the Corporation's business, financial condition and results of operations. In addition, if an employee with security clearance leaves and Flowr is unable to find a suitable replacement that has a security clearance in a timely manner, or at all, there could occur a material adverse effect on the Corporation's business, financial condition and results of operations.
50 |
2018 Annual Information Form |
Security Clearance of Individuals Occupying a "Key Position" in the Corporation
Certain people associated with cannabis licensees, including individuals occupying a "key position" such as directors, officers, large shareholders and other individuals identified by the Minister, must hold a valid security clearance issued by the Minister. Certain of Flowr's Directors and officers have applied to the Minister for their security clearance and are currently waiting for a response. Under the Cannabis Regulations, the Minister may refuse to grant security under certain circumstances. There is no assurance that any of the individuals occupying a "key position" who presently or may in the future require a security clearance will be able to obtain or renew such clearances or that new individuals occupying a "key position" who require a security clearance will be able to obtain one. A failure by such individuals to maintain or renew his or her security clearance would result in a material adverse effect on the Corporation's business, financial condition and results of operations. In addition, if such an individual with security clearance leaves and Flowr is unable to find a suitable replacement that has a security clearance in a timely manner, or at all, there could occur a material adverse effect on the Corporation's business, financial condition and results of operations.
Third Parties with Whom the Corporation Does Business May Perceive Themselves as Being Exposed to Reputational Risk as a Result of Their Relationship with the Corporation and May, as a Result, Refuse to Do Business with the Corporation
The parties with whom the Corporation does business, or would like to do business with, may perceive that they are exposed to reputational risk as a result of the Corporation's business activities relating to cannabis, which could hinder the Corporation's ability to establish or maintain business relationships. These perceptions relating to the cannabis industry may interfere with the Corporation's relationship with service providers in Canada and other countries, particularly in the financial services industry.
The Ability to Continuously Maintain and Retain a Competitive Talent Pool
As the Corporation grows, it will need to hire additional human resources to continue to develop its businesses. However, experienced talent in the areas of cannabis research and development, growing cannabis and extraction, as well as senior management, are difficult to source, and there can be no assurance that the appropriate individuals will be available or affordable. Without adequate personnel and expertise, the growth of the business of the Corporation may suffer. There can be no assurance that the Corporation will be able to identify, attract, hire and retain qualified personnel and expertise in the future, and any failure to do so could have a material adverse effect on the Corporation's business, financial condition or results of operations.
Management of Growth in Respect of Staff Resources
As the Corporation grows, the Corporation will also be required to hire, train, supervise and manage new employees. The Corporation may experience a period of significant growth in the number of personnel that will place a strain upon its management systems and resources. Its future will depend in part on the ability of its officers and other key employees to implement and improve financial and management controls, reporting systems and procedures on a timely basis and to expand, train, motivate and manage the workforce. The Corporation's current and planned personnel, systems, procedures and controls may be inadequate to support its future operations. Failure to effectively manage any future growth could have a material adverse effect on the Corporation's business, financial condition or results of operations.
Internal Controls Over Financial Reporting
Effective internal controls are necessary for the Corporation to provide reliable financial reports and to help prevent fraud. Although the Corporation will undertake a number of procedures and will implement a number of safeguards, in each case, in order to help ensure the reliability of its financial reports, including those imposed on the Corporation under Canadian and United States securities law, the Corporation cannot be certain that such measures will ensure that the Corporation will maintain adequate control over financial processes and reporting. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Corporation's results of operations or cause it to fail to meet its reporting obligations. If the Corporation or its auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market's confidence in the Corporation's consolidated financial statements and materially adversely affect the trading price of the Common Shares. In addition, as a TSX-V issuer, the Corporation is not required to establish and maintain disclosure controls and protocols and internal controls over financial reporting which may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided by the Corporation under applicable securities legislation.
51 |
2018 Annual Information Form |
Difficulty to Forecast Sales and Other Business Metrics
The Corporation must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the cannabis industry. In addition to inherent risks and difficulties forecasting sales, anticipated costs and yields are also challenging to predict with certainty as the cannabis industry is in its relative infancy and rapidly evolving. If Flowr makes capital investments based on flawed sales forecasts, the Corporation may not achieve its expected, or any, return on invested capital. Failure to realize forecasted sales, costs and yields could have a material adverse effect on the Corporation's business, results of operations and financial condition.
The Corporation May Become a Party to Litigation
The Corporation may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Corporation becomes involved be determined against the Corporation such a decision could adversely affect the Corporation's ability to continue operating and the market price for the Common Shares and could use significant resources and demand significant time and attention by management. Even if the Corporation is involved in litigation and wins, litigation can redirect significant resources.
The Corporation May Become Involved in Regulatory or Agency Proceedings, Investigations and Audits
Health Canada inspectors routinely assess the Corporation for compliance with applicable regulatory requirements. The Corporation's facilities will be inspected by Health Canada. Furthermore, the import of the Corporation's products into other jurisdictions, is subject to the regulatory requirements of the respective jurisdiction. Any failure by the Corporation to comply with the applicable regulatory requirements could require extensive changes to the Corporation's operations; result in regulatory or agency proceedings or investigations, increased compliance costs, damage awards, civil or criminal fines or penalties or restrictions on the Corporation's operations; harm the Corporation's reputation or give rise to material liabilities or a revocation of the Corporation's licences and other permits. There can be no assurance that any pending or future regulatory or agency proceedings, investigations or audits will not result in substantial costs, a diversion of management's attention and resources or other adverse consequences to the Corporation and its business.
There Can Be No Assurance That the Corporation May Not Be Treated as a "Passive Foreign Investment Company" ("PFIC") Under the U.S. Internal Revenue Code. If the Corporation Were Treated as a PFIC, Such Treatment Could Result in Adverse Tax Consequences for Investors in the United States
There can be no assurance that the Corporation may not be treated as a PFIC under the U.S. Internal Revenue Code. If the Corporation were treated as a PFIC, such treatment could result in adverse tax consequences for investors in the United States. Certain adverse tax consequences could apply to a U.S. holder if the Corporation were treated as a PFIC for any taxable year during which the U.S. holder owns Common Shares. The Corporation believes that it is not currently a PFIC and is not likely to become a PFIC in the foreseeable future. The determination of whether it is a PFIC, however, is made annually as of the close of each taxable year. Because the determination whether a foreign corporation is a PFIC is primarily factual and there is little administrative or judicial authority on which to rely to make a determination, the IRS might not agree that the Corporation is not a PFIC. Moreover, no assurance can be given that the Corporation would not become a PFIC for any future taxable year if there were to be changes in the Corporation's assets, income or operations.
The Corporation Is Subject to Certain Restrictions of the TSX-V Which May Constrain Its Ability to Expand Its Business Internationally
The TSX-V required, as a condition to listing, that the Corporation deliver an undertaking (the "Undertaking") confirming that, while listed on the TSX-V, the Corporation will only conduct the business of cannabis related business as described in the Filing Statement and/or the business of the production, sale and distribution of cannabis for medical and recreational purposes in Canada as permitted under the Corporation's licences with Health Canada. The Undertaking could have an adverse effect on the Corporation's ability to export cannabis from Canada and on its ability to expand its business into other areas while it is still listed on the TSX-V and subject to the Undertaking. The Undertaking may prevent the Corporation from expanding into new areas of business when its competitors have no such restrictions. All such restrictions could materially and adversely affect the Corporation's growth, business, financial condition and results of operations.
Risks Relating to International Activities
The Corporation's Operations in Foreign Countries May Be Subject to a Higher Degree of Political, Social and Economic Risk Than Jurisdictions in Which It Currently Operates
A number of risks are inherent in international operations, including risks associated with: (i) foreign currency fluctuations and devaluations; (ii) political, social, security and economic instability in foreign countries; (iii) changes in and compliance with local laws and regulations or uncertainty regarding the interpretation and/or application of applicable laws, including export and import control laws, sanctions regulations, tax laws, labour laws, employee benefits, currency restrictions and other requirements; (iv) differences in tax regimes and potentially adverse tax consequences of operating in foreign countries or unfavourable or arbitrary tax enforcement; (v) customizing products for foreign countries; (vi) legal uncertainties regarding liability, export and import restrictions, tariffs and other trade barriers; (vii) changes in governmental regulations regarding currency or price controls, profit repatriation, labour, or health and safety matters; (viii) hiring qualified foreign employees; and (viii) difficulty in accounts receivable collection and longer collection periods. Accordingly, as the Corporation begins to operate internationally, the Corporation's exposure to risks involved with operating in foreign countries will be increased, which could have a material adverse effect on the Corporation's business, financial condition and results of operations.
52 |
2018 Annual Information Form |
Expansion into Foreign Jurisdictions
The Corporation's expansion into jurisdictions outside of Canada is subject to risks. In addition, in jurisdictions outside of Canada, there can be no assurance that any market for the Corporation's products will develop. The Corporation may face new or unexpected risks or significantly increase its exposure to one or more existing risk factors, including economic instability, changes in laws and regulations, and the effects of competition. These factors may limit the Corporation's ability to successfully expand its operations into such jurisdictions and could have a material adverse effect on the Corporation's business, financial condition and results of operations.
The Corporation Relies on International Advisors and Consultants
The legal and regulatory requirements in the foreign countries in which the Corporation operates with respect to the cultivation and sale of cannabis, banking system and controls, as well as local business culture and practices are different from those in Canada. The officers and Directors of the Corporation must rely, to a great extent, on the Corporation's local management team and employees as well as legal counsel and local consultants retained by the Corporation in order to keep abreast of material legal, regulatory and governmental developments as they pertain to and affect the Corporation's business operations, and to assist the Corporation with its governmental relations. The Corporation also relies on the advice of local experts and professionals in connection with current and new regulations that develop in respect of the cultivation and sale of cannabis as well as in respect of banking, financing, labour, litigation and tax matters in these jurisdictions. Any developments or changes in such legal, regulatory or governmental requirements or in local business practices are beyond the control of the Corporation. The impact of any such changes could have a material adverse effect on the Corporation's business, financial condition and results of operations.
The Corporation May Expand into Other Geographic Areas, Which Could Increase the Corporation's Operational, Regulatory and Other Risks
The Corporation may in the future expand into other geographic areas, which could increase the Corporation's operational, regulatory, compliance, reputational and foreign exchange rate risks. The failure of the Corporation's operating infrastructure to support such expansion could result in operational failures and regulatory fines or sanctions. In addition, to the extent the Corporation attempts to enter into the cannabis market in a developing country, these risks may be exacerbated and there may be additional risks with such emerging economies, such as hyperinflation, price controls, property seizures, war, terrorism, expropriation, nationalism, social and labour unrest, organized crime, corruption and fraud and restrictions on the acquisition or lease of properties. Future international expansion could require the Corporation to incur a number of up-front expenses, including those associated with obtaining regulatory approvals, as well as additional ongoing expenses, including those associated with infrastructure, staff and regulatory compliance. The Corporation may not be able to successfully identify suitable acquisition and expansion opportunities or integrate such operations successfully with the Corporation's existing operations.
The Corporation May Be Responsible for Corruption and Anti-Bribery Law Violations
The Corporation's business is subject to Canadian laws which generally prohibit companies and employees from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. In addition, the Corporation is subject to the anti-bribery laws of any other countries in which it conducts business now or in the future. The Corporation's employees or other agents may, without its knowledge and despite its efforts, engage in prohibited conduct under the Corporation's policies and procedures and anti-bribery laws for which the Corporation may be held responsible. The Corporation's policies mandate compliance with these anti-corruption and anti-bribery laws. However, there can be no assurance that the Corporation's internal control policies and procedures will always protect it from recklessness, fraudulent behaviour, dishonesty or other inappropriate acts committed by its affiliates, employees, contractors or agents. If the Corporation's employees or other agents are found to have engaged in such practices, the Corporation could suffer severe penalties and other consequences that may have a material adverse effect on its business, financial condition and results of operations.
53 |
2018 Annual Information Form |
Forward-Looking Statements, Future-Oriented Financial Information, and Financial Outlooks May Prove Inaccurate
Investors are cautioned not to place undue reliance on forward-looking statements, future-oriented financial information and financial outlooks. By their nature, forward-looking statements, future-oriented financial information and financial outlooks involve numerous assumptions, known and unknown risks and uncertainties, of both a general and specific nature, that could cause actual results to differ materially from those suggested by the forward-looking statements or contribute to the possibility that predictions, forecasts or projections will prove to be materially inaccurate.
Risk Factors Related the Common Shares
The Corporation Is Subject to Risks Related to Additional Regulatory Burden and Controls Over Financial Reporting
The Corporation is subject to the continuous and timely disclosure requirements of Canadian securities laws and the rules, regulations and policies of the TSX-V. These rules, regulations and policies relate to, among other things, corporate governance, continuous disclosure and financial reporting standards. The Corporation has made, and will continue to make, changes in these and other areas. However, there is no assurance that these and other measures that it may take will be sufficient to allow the Corporation to satisfy its obligations as a public company on a timely basis. In addition, compliance with reporting and other requirements applicable to public companies create additional costs for the Corporation and require the time and attention of management of the Corporation. The Corporation cannot predict the amount of the additional costs that the Corporation may incur, the timing of such costs or the impact that management's attention to these matters will have on the Corporation's business.
Publication of Inaccurate or Unfavourable Research and Reports
The trading market for the Common Shares relies in part on the research and reports that securities analysts and other third parties choose to publish about the Corporation. The Corporation will not control these analysts or other third parties. The price of the Common Shares could decline if one or more securities analysts downgrade the Common Shares or if one or more securities analysts or other third parties publish inaccurate or unfavourable research about the Corporation or cease publishing reports about the Corporation. If one or more analysts cease coverage of the Corporation or fail to regularly publish reports on the Corporation, the Corporation could lose visibility in the financial markets, which in turn could cause the Corporation's share price or trading volume to decline.
Price Volatility of the Common Shares
The market price of the Common Shares may be subject to wide price fluctuations in response to many factors, including variations in the operating results of the Corporation and its subsidiaries, divergence in financial results from analysts' expectations, changes in earnings estimates by stock market analysts, changes in the business prospects for the Corporation and its subsidiaries or others in the cannabis industry, general economic conditions, legislative changes, community support for the cannabis industry and other events and factors outside of the Corporation's control, including
54 |
2018 Annual Information Form |
Financial markets have recently experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of companies and that have often been unrelated to the operating performance, underlying asset values or prospects of such companies. Accordingly, the market price of the Common Shares may decline even if the Corporation's operating results, underlying asset values or prospects have not changed. Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed to be other than temporary, which may result in impairment losses. There can be no assurance that continuing fluctuations in price and volume will not occur. If such increased levels of volatility and market turmoil continue, the Corporation's operations could be adversely impacted, and the trading price of the Common Shares may be materially adversely affected.
Decreases in the Value of the Corporation's Assets Could Lead to Impairments in the Future
Potential impairment of intangible assets may significantly impact the Corporation's profitability. Intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate the carrying amount of an asset exceeds its recoverable amount. If an impairment exists, the Corporation would be required to take an impairment charge with respect to the impaired asset. Events giving rise to impairment are difficult to predict and are an inherent risk. As a result of the significance of intangible assets, should such an impairment of intangible assets occur, it could have a material adverse effect on the Corporation's business, financial condition and results of operations.
Dilution
The Corporation may sell additional Common Shares or other securities that are convertible, exercisable or exchangeable into Common Shares in subsequent offerings or may issue additional Common Shares or other securities to finance future acquisitions. The Corporation cannot predict the size or nature of future sales or issuances of securities or the effect, if any, that such future sales and issuances will have on the market price of the Common Shares. Sales or issuances of substantial numbers of Common Shares or other securities that are convertible, exercisable or exchangeable into Common Shares, or the perception that such sales or issuances could occur, may adversely affect prevailing market prices of the Common Shares. With any additional sale or issuance of Common Shares or other securities that are convertible or exchangeable into Common Shares, investors will suffer dilution to their voting power and economic interest in the Corporation. Furthermore, to the extent holders of the Corporation's stock options or other convertible securities convert or exercise their securities and sell the Common Shares they receive, the trading price of the Common Shares may decrease due to the additional amount of Common Shares available in the market.
Control by Majority Shareholders and the Corporation's Governance
A holder of a substantial amount of the Common Shares may be able to exercise a controlling influence on the Corporation, which may affect the Corporation's governance and operations. For so long as such shareholders maintain their interest in the Corporation, such shareholders may be able to exercise a controlling influence over the business and affairs of the Corporation and the Corporation, the selection of senior management, the acquisition or disposition of the Corporation's assets, access to capital markets, the payment of dividends and any change of control of the Corporation, such as a merger or take-over. The effect of this control may be to limit the price that investors are willing to pay for the Common Shares. In addition, a sale of the Common Shares by such shareholders, or the perception of the market that a sale may occur, may adversely affect the market price of the Common Shares.
55 |
2018 Annual Information Form |
As of March 11, 2019: (i) Tom Flow beneficially owns, or controls or directs, directly or indirectly, a total of 26,025,000 Common Shares, representing approximately 18.4% of the equity of the Corporation on a fully diluted basis; and (ii) Steven Klein, through Core Flow Canada Holdings Inc., beneficially owns, or controls or directs, directly or indirectly, a total of 7,893,054 Common Shares and 41,598,000 Flowr ULC Class A Shares that are convertible into Common Shares, representing approximately 5.5% of the equity of the Corporation on a fully diluted basis.
Corporation Does Not Anticipate Paying Dividends in The Foreseeable Future
The Corporation has no earnings or dividend record, and does not anticipate paying any dividends on the Common Shares in the foreseeable future. Dividends paid by the Corporation would be subject to tax and, potentially, withholdings for non-residents of Canada.
56 |
2018 Annual Information Form |
ADDITIONAL INFORMATION
Additional information including Directors' and officers' remuneration and indebtedness, the executive compensation for named executive officers of the Corporation, principal holders of the Corporation's securities, interests of insiders in material transactions, as applicable, and securities authorized for issuance under equity compensation plans will be contained in the Corporation's management information circular for its most recent annual meeting of securityholders that involved the election of Directors.
Additional financial information is provided in the Corporation's financial statements and management's discussion and analysis for the year ended December 31, 2018. A copy of this Annual Information Form, the management information circular, financial statements and management's discussion and analysis may be obtained upon request from the Corporation and those documents and other information in respect of the Corporation are also available on SEDAR at www.sedar.com.
57 |
2018 Annual Information Form |
APPENDIX "A" GLOSSARY OF TERMS
In addition to terms defined elsewhere in this Annual Information Form, the following are defined terms used in this Annual Information Form:
ABCA |
means the Business Corporations Act (Alberta). |
Ace Valley |
has the meaning ascribed to that term under the heading "Description of the Business - Recreational Market" in this Annual Information Form. |
ACMPR |
means the Access to Cannabis for Medical Purposes Regulations to the CDSA. |
Annual Information Form |
means this annual information form dated, April 3, 2019. |
Amalgamation Agreement |
means the amalgamation agreement dated August 27, 2018, among Needle, Flowr Privateco and Needle Subco, as amended by an amending agreement dated September 10, 2018. |
APS |
has the meaning ascribed to that term under the heading "Regulatory Framework - Australia". |
Board |
means the board of directors of the Corporation. |
Business Combination |
means the series of transactions, as detailed in the Business Combination Agreement, through which the businesses of Flowr Privateco and Needle were combined. |
Business Combination Agreement |
means the business combination agreement dated August 27, 2018, among Needle, Flowr Privateco and Needle Subco, as amended by an amending agreement dated September 10, 2018. |
Cannabis Act |
means the Cannabis Act (Canada). |
Cannabis Regulations |
has the meaning ascribed to that term under the heading "Description of the Business - The Facility" in this Annual Information Form. |
Cannatech |
has the meaning ascribed to that term under the heading "General Development of the Business - Company History" in this Annual Information Form. |
CBD |
means cannabidiol. |
CDSA |
means the Controlled Drugs and Substances Act (Canada). |
Common Shares |
means the common shares in the capital of the Corporation. |
Consolidation |
means the consolidation of the Needle Shares on the basis of one (1) post-consolidation Needle Share for every thirteen (13) pre-consolidation Needle Shares completed on September 20, 2018. |
Corporation or Flowr |
means The Flowr Corporation, and unless the context otherwise requires, includes each of the subsidiaries of The Flowr Corporation. |
Director |
means a member of the Board. |
The Flowr Corporation 2018 |
Annual Information Form |
DL 15/93 |
has the meaning ascribed to that term under the heading "Regulatory Framework - Portugal". |
DSUs |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
DSU Participant |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
DSU Termination Date |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
EBITDA |
means income adjusted for net interest expense, income tax expense, depreciation and amortization. |
Extension Period |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
Filing Statement |
means the filing statement of the Corporation dated September 19, 2018. |
Final Vesting Date |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
Flowco US Partners |
means, together, Core Flow Canada Holdings Inc. and APMJ Canada Holdings Inc. |
Flowr Class A Shares |
means the Class A preferred shares in the capital of Flowr Privateco. |
Flowr Common Shares |
means the common shares in the capital of Flowr Privateco. |
Flowr Forest |
has the meaning ascribed to that term under the heading "Description of Capital Structure - General Description of the Business" in this Annual Information Form. |
Flowr Okanagan |
has the meaning ascribed to that term under the heading "General Development of the Business - Company History" in this Annual Information Form. |
Flowr Privateco |
has the meaning ascribed to that term under the heading "Corporate Structure - Name, Address and Incorporation" in this Annual Information Form. |
Flowr ULC |
has the meaning ascribed to that term under the heading "General Development of the Business - Company History" in this Annual Information Form. |
Flowr ULC Class A Shares |
has the meaning ascribed to that term under the heading "General Development of the Business - Company History" in this Annual Information Form. |
The Flowr Corporation 2018 |
Annual Information Form |
Flowr ULC Common Shares |
means the common shares in the capital of Flowr ULC. |
forward-looking statements |
has the meaning ascribed to that term under the heading "Cautionary Note Regarding Forward-Looking Information" in this Annual Information Form. |
GMP |
means the ICH good manufacturing practices standards. |
Hawthorne |
has the meaning ascribed to that term under the heading "Description of the Business - Cultivars" in this Annual Information Form. |
Hawthorne Agreement |
means the Amended and Restated Agreement between Flowr ULC, Flowr Okanagan and Hawthorne, dated December 14, 2018 relating to a research and development facility to be constructed at the Kelowna Campus. |
Holigen |
has the meaning ascribed to that term under the heading "Description of the Business - Recent Events" in this Annual Information Form. |
Holigen Agreement |
means the share purchase and subscription agreement between Holigen, Holigen Limited and the Corporation dated as of December 19, 2018. |
ICH |
means the International Council for Harmonisation. |
IFRS |
means the International Financial Reporting Standards as issued by the International Accounting Standards Board. |
INFARMED |
has the meaning ascribed to that term under the heading "Regulatory Framework - Portugal". |
IRS |
means the Internal Revenue Service of the United States of America. |
ITA |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
K1 Facility |
has the meaning ascribed to that term under the heading "Description of the Business - The Facility" in this Annual Information Form. |
K2 Facility |
has the meaning ascribed to that term under the heading "Description of the Business - The Facility" in this Annual Information Form. |
Kelowna Campus |
has the meaning ascribed to that term under the heading "Description of the Business - The Facility" in this Annual Information Form. |
Law 33/2018 |
has the meaning ascribed to that term under the heading "Regulatory Framework - Portugal". |
Lease |
means the lease dated December 1, 2016, between 0954717 B.C. Ltd. and Cannatech Plant Systems Inc. with respect to the property known for municipal purposes as 9590 McCarthy Road, in the City of Kelowna, British Columbia. |
License |
has the meaning ascribed to that term under the heading "Description of the Business - The Facility" in this Annual Information Form. |
The Flowr Corporation 2018 |
Annual Information Form |
LTIP |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
MI 61-101 |
has the meaning ascribed to that term under the heading "Related Parties" in this Annual Information Form. |
Minister |
means the Minister of Border Security and Organized Crime Reduction. |
Narcotics Act |
has the meaning ascribed to that term under the heading "Regulatory Framework - Australia". |
Needle |
has the meaning ascribed to that term under the heading "Corporate Structure - Name, Address and Incorporation" in this Annual Information Form. |
Needle Shares |
means the common shares in the capital of Needle prior to the closing of the Qualifying Transaction. |
Needle Subco |
has the meaning ascribed to that term under the heading "Corporate Structure - Name, Address and Incorporation" in this Annual Information Form. |
NI 52-110 |
means National Instrument 52-110 Audit Committees |
NLC |
has the meaning ascribed to that term under the heading "Regulatory Framework - Canada - Provincial Regulatory Framework". |
OBCA |
means the Business Corporations Act (Ontario). |
OCRS |
has the meaning ascribed to that term under the heading "Regulatory Framework - Canada - Provincial Regulatory Framework". |
OCS |
means the Ontario Cannabis Store, a subsidiary of the Liquor Control Board of Ontario. |
ODC |
has the meaning ascribed to that term under the heading "Regulatory Framework - Australia". |
Options |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Stock Option Plan" in this Annual Information Form. |
Preferred Shares |
has the meaning ascribed to that term under the heading "Description of Capital Structure". |
Qualifying Transaction |
has the meaning ascribed to that term under the heading "Corporate Structure - Name, Address and Incorporation" in this Annual Information Form. |
RD 61/94 |
has the meaning ascribed to that term under the heading "Regulatory Framework - Portugal". |
RSUs |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
The Flowr Corporation 2018 |
Annual Information Form |
RSU Participant |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
RTO Financing |
has the meaning ascribed to that term under the heading "Equity Transactions". |
SAS |
has the meaning ascribed to that term under the heading "Regulatory Framework - Australia". |
SEC |
means the Securities and Exchange Commission of the United States of America. |
SEDAR |
means the System for Electronic Document Analysis and Retrieval. |
Share Exchange Agreement |
means the share exchange agreement among Flowr Privateco, Flowr ULC, Needle and the Flowco US Partners dated as at the closing of the Business Combination, which sets out the rights of the Flowco US Partners to exchange their Flowr ULC Class A Shares for Common Shares, for no additional consideration, and the mechanism by which additional Flowr ULC Common Shares will be issued to the Corporation in the event that Flowr issues additional Common Shares. |
Shoppers |
means Shoppers Drug Mart Inc. |
SOP |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Stock Option Plan" in this Annual Information Form. |
Subscription Receipt |
means a subscription receipt exchangeable for a Flowr Common Share which was issued by Flowr Privateco pursuant to a private placement completed on August 28, 2018. |
TGA |
has the meaning ascribed to that term under the heading "Regulatory Framework - Australia". |
THC |
means tetrahydrocannabinol. |
TSX-V |
means the TSX Venture Exchange. |
Units |
has the meaning ascribed to that term under the heading "Description of Capital Structure - Long Term Incentive Plan" in this Annual Information Form. |
The Flowr Corporation 2018 |
Annual Information Form |
APPENDIX "B" AUDIT COMMITTEE CHARTER
The Flowr Corporation 2018 |
Annual Information Form |
THE FLOWR CORPORATION
Audit Committee Charter
Audit Committee
Charter |
THE FLOWR CORPORATION
AUDIT COMMITTEE CHARTER
1. Purpose
The Audit Committee (the Committee) is a standing committee of the Board of Directors (the Board) of The Flowr Corporation (the Corporation) appointed as required by (i) National Instrument 52-110 - Audit Committees (NI 52-110) (ii) Rule 5605 of the NASDAQ Stock Market Rules (including Rule 5605(c)(2)(A)) (Rule 5605); and (iii) Rule 10A-3 of the United States Securities Exchange Act of 1934, as amended (Rule 10A-3). The purpose of the Committee is to oversee the accounting and financial reporting processes of the Corporation and the audits of the financial statements of the Company, and to assist the Board in fulfilling its oversight responsibilities for (i) the integrity of the Corporations financial statements, (ii) the process for identifying the Corporations principal financial risks and the control systems in place to monitor them; (iii) the Corporations compliance with legal and regulatory requirements, and (iv) the qualifications and independence of the auditor of the Corporation (the external auditor).
2. Authority
The Committee has authority to conduct or authorize investigations into any matter within its scope of responsibility. It is empowered to:
(a) |
Recommend to the Board the public accounting firm to be nominated for appointment by the Corporations shareholders as the independent external auditor |
| |
(b) |
Be directly responsible for the appointment, compensation, retention and oversight of the work of the external auditor engaged for the purpose of preparing or issuing an auditors report or performing other audit, review or attest services for the Corporation, subject to the appointment of the Corporations external auditor by the Corporations shareholders, as described above The external auditor will report directly to the Committee. |
| |
(c) |
Resolve any disagreements between management and the external auditor regarding financial reporting. |
| |
(d) |
Pre-approve permitted non- audit services performed by the Corporations external auditor. |
| |
(e) |
Retain independent counsel, accountants, or others to advise the Committee or assist in its duties and to set and pay their applicable compensation. |
| |
(f) |
Meet with the Corporations officers, external auditor or outside counsel, as necessary and communicate directly with the Corporations shareholders. |
| |
(g) |
Delegate authority, to the extent permitted by applicable law, to one or more designated members of the Committee, including the authority to pre- approve all permitted non-audit services, provided that such decisions are reported to the full Committee at its next scheduled meeting. |
| |
(h) |
Take such other actions as are authorized by this Charter or by other Corporation policies approved by the Board. |
3. Composition
(a) |
The Committee must consist of at least three directors, as determined by resolution of the Board from time to time. |
(b) |
No member of the Committee can have participated in the preparation of the Corporations or any of its subsidiaries financial statements at any time during the past three years. |
(c) |
The Board, or any committee delegated by the Board, will recommend to the Board applicable directors for appointment to the Committee and the Chair of the Committee. |
(d) |
If and whenever a vacancy exists on the Committee, the remaining members may exercise all of its powers so long as there continue to be at least three members on the Committee. If at any time a vacancy exists on the Committee that the Board is required to fill, the Board may appoint a new member to fill such vacancy by ordinary resolution of the Board. |
(e) |
Subject to the exemptions contemplated by NI 52- 110, Rule 10A-3 and Rule 5605, each member of the Committee shall be independent, pursuant to the requirements of NI 52 -110, Rule 10A-3 and Rule 5605. |
(f) |
Each Committee member must be financially literate as defined in NI 52-110 and must be able to read and understand fundamental financial statements, including a company's balance sheet, income statement, and cash flow statement . |
(g) |
At least one member of the Committee must be an audit committee financial expert under Item 407 of Regulation S-K or otherwise have past employment experience in finance or accounting, requisite professional certification in accounting or other comparable experience or background which results in the individuals financial sophistication. |
(h) |
The Board or the Committee may, from time to time, establish policies limiting the number of committees which Committee members may be appointed to. |
4. Meetings
(a) |
The Committee must meet at least four times per year, and at least annually, privately, with each of management and the external auditor. |
(b) |
The greater of two members or 50% of the members of the Committee shall constitute a quorum. All resolutions of the Committee shall be made by a majority of its members present at a meeting duly called and held. All Committee members are expected to attend each meeting, in person or by telephone or video conference. Any decision or determination of the Committee reduced to writing and signed by all of the members of the Committee shall be fully as effective as if it had been made at a meeting duly called and held. |
(c) |
The Committee may invite such officers, directors and employees of the Corporation as it deems necessary or advisable from time to time to attend meetings of the Committee and assist in the discussion and consideration of the duties of the Committee. |
(d) |
The time at which and place where the meetings of the Committee shall be held and the calling of meetings and the procedure in all things at such meetings shall be determined by the Committee. Following a Committee meeting, the Committee Chair shall report on the Committees activities to the Board at the next Board meeting. The Committee must keep and approve minutes of its meetings in which shall be recorded all action taken by it, which minutes must be made available to the Board as soon as practicable after each meeting of the Committee. |
5. Responsibilities
The Committee must:
(a) |
Review significant accounting and reporting issues and understand their impact on the financial statements, including but not limited to: | |
(i) |
complex or unusual transactions and highly judgmental areas; | |
(ii) |
major issues regarding accounting principles and financial statement presentation, including any significant changes in the Corporations selection or application of accounting principles; | |
(iii) |
any significant variances with comparative reporting periods; and | |
(iv) |
the effect of regulatory and accounting initiatives, as well as off-balance sheet structures, on the financial statements of the Corporation. | |
(b) |
Review analyses prepared by management and/or the external auditor relating to significant financial reporting issues and judgments made in connection with the preparation of the financial statements, including analyses of the effects of the selection or application of the Corporations accounting principles. | |
(c) |
Review compliance with covenants under any loan agreements. | |
(d) |
Review disclosure requirements for commitments and contingencies. | |
(e) |
Review with management and the external auditor the results of the audit, including any difficulties encountered. This review will include any restrictions on the scope of the external auditors activities or on access to requested information, any significant disagreements with management, and adjustments raised by external auditors, whether or not included in the financial reports. | |
(f) |
Review and discuss the annual audited financial statements and quarterly financial statements with management and the external auditor, including the Corporations disclosures under Managements Discussion and Analysis of Financial Condition and Results of Operations (MD&A), including the discussion of critical accounting estimates included therein. | |
(g) |
Review and recommend to the Board for approval, prior to public disclosure, the annual and quarterly financial statements, MD&A and annual and interim profit or loss press releases. | |
(h) |
Review disclosures made by the Chief Executive Officer and the Chief Financial Officer during the certification process about significant deficiencies or material weakness in the design or operation of internal controls or any fraud that involves management or other employees who have a significant role in the Corporations internal controls and, if applicable, understand the basis upon which the certifying officers concluded that any particular deficiency or combination of deficiencies did or did not constitute a material weakness. |
(i) |
Review and recommend to the Board for approval, prior to public disclosure, financial information and earnings guidance provided externally, including to analysts and rating agencies if applicable. This review may be general (i.e., the types of information to be disclosed and the type of presentations to be made). |
(j) |
Satisfy itself that adequate procedures are in place, and periodically assess the adequacy of those procedures, for the review of any public disclosure of financial information extracted or derived from the financial statements, other than the statements themselves, the MD&A or the press releases referred to above. |
(k) |
Review and oversee all related party transactions for potential conflict of interest situations on an ongoing basis. The term "related party transactions" shall refer to transactions that would be required to be disclosed to the U.S. Securities and Exchange Commission pursuant to Form 20 -F, Item 7.B., notwithstanding that the Corporation may file its annual reports on a different form. |
(l) |
Annually review and assess the Corporations policies in effect from time to time, including its Timely Disclosure, Confidentiality and Insider Trading Policy and make recommendations to the Board. |
6. Internal Control
The Committee shall also:
(a) |
Consider the effectiveness of the Corporations system for internal control over financial reporting, including information technology security and control. |
(b) |
Review the scope of the external auditors review of internal control over financial reporting, and obtain reports on significant findings and recommendations, together with managements responses. |
(c) |
Review the external auditors management letters and managements responses to such letters. |
(d) |
As requested by the Board, discuss with management and the external auditor the Corporations identifiable risks arising from any financial, operational or other deficiencies, the adequacy and effectiveness of the Corporations accounting and financial controls relating thereto, and the steps management has taken to monitor and control identified risks. |
(e) |
Annually review the Corporations disclosure controls and procedures, including any significant deficiencies in, or material non- compliance with same, and the steps management has taken to monitor and control such deficiencies or instances of non-compliance. |
7. External Audit
The Committee shall also:
(a) |
Review the external auditors proposed audit scope and approach. | |
|
| |
(b) |
Review the performance of the external auditor. Annually review the report of the external auditor on matters required to be communicated to the Committee under Section 5135 (auditors responsibility to consider fraud) and Section 5751 (communications with those having oversight responsibility for the financial reporting process-independence) of the Canadian Institute of Chartered Accountants handbook and Rule 5605(c) (ensuring independence of external auditor). | |
|
| |
(c) |
Report any conclusions with respect to the external auditor to the Board. | |
|
| |
(d) |
Establish and periodically assess the Corporations hiring policies for partners, employees and former partners and employees of the current or prior external auditor. | |
|
| |
(e) |
At least once per year, meet privately with the external auditor to discuss any matters that the Committee or the external auditor believes should be discussed privately. | |
|
| |
(f) |
Review and pre- approve, in accordance with NI 52-110 and Rule 2-01(c)(7) of Regulation S-X, any non- audit services, provided by the Corporations external auditor, taking into consideration whether the delivery of non-audit services will interfere with the independence of the auditors. The pre-approval of non-audit services may be further delegated to one or more independent members of the Committee, provided that said pre-approval is presented to the Committee at its first scheduled meeting following such approval. The pre-approval requirement is satisfied with respect to the provision of de minimis non-audit services if: | |
|
| |
(i) |
the aggregate amount of all such non-audit services provided to the Corporation which were not pre- approved constitutes not more than 5% of the total amount of fees paid by the Corporation and its subsidiaries to the external auditor during the fiscal year in which the non- audit services are provided; | |
|
| |
(ii) |
the services were not recognized by the Corporation or its subsidiaries, at the time of the engagement, to be non-audit services; and | |
|
| |
(iii) |
the services are promptly brought to the attention of the Committee and approved, prior to the completion of the audit, by the Committee or by one or more members of the Committee to whom authority to grant such approvals has been delegated by the Committee. | |
|
| |
(g) |
The Committee may from time to time establish specific pre-approval policies and procedures in accordance with NI 52-110. | |
|
| |
(h) |
The Committee shall be responsible for assuring the regular rotation of the lead audit partner of Companys external auditor and considering regular rotation of the accounting firm serving as Companys external auditor. |
(i) |
The Committee shall be responsible for obtaining and reviewing on a periodic basis, and at least annually, a formal written statement from the external auditor delineating all relationships between the external auditor and Company . The Committee is responsible for discussing with the external auditor any disclosed relationships or services that may impact the objectivity and independence of the external auditor and for taking or recommending that the Board take appropriate action in response to the external auditors report to satisfy itself of the external auditors independence. |
8. Compliance
The Committee shall also:
(a) |
Annually review the effectiveness of the Corporations system of monitoring compliance with laws and regulations and the results of managements investigation and follow-up (including disciplinary action) of any instances of non- compliance. |
(b) |
Establish and periodically assess the adequacy of procedures for: (i) the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls, or auditing matters; and (ii) the confidential, anonymous submission by employees regarding questionable accounting or auditing matters. |
(c) |
Review findings of any examinations by regulatory agencies, and any external auditors observations made regarding those findings. |
(d) |
Review the process for communicating the Code of Business Conduct and Ethics to Corporation personnel, and for monitoring compliance therewith. |
9. Reporting Responsibilities
The Committee shall also:
(a) |
Report to the Board about Committee activities and issues that arise with respect to the quality or integrity of the Corporations financial statements, the Corporations compliance with legal or regulatory requirements, the performance and independence of the Corporations external auditor and internal controls over financial reporting. |
(b) |
Review any other reports the Corporation issues that relate to Committee responsibilities. |
(c) |
Liaise with the external auditor and the Board to ensure that any material issues that have arisen related to compliance and governance have been addressed and that appropriate actions have been identified and undertaken to mitigate the issues identified. |
(d) |
The Committee shall at least annually evaluate its own performance and the contents of this Charter, and recommend to the Board such changes to the Charter as the Committee deems appropriate. |
10. Other responsibilities
The Committee shall also:
(a) |
Discuss with management the Corporations major polices with respect to risk assessment and risk management. |
(b) |
Perform other activities related to this Charter as requested by the Board. |
(c) |
Institute and oversee special investigations as required with respect to the discharge of the Committees duties hereunder. |
(d) |
Ensure appropriate disclosure of this Charter as may be required by applicable law. |
11. Funding
The Corporation shall provide for appropriate funding, as determined by the Committee, for payment of:
(a) |
Compensation to the external auditor; |
(b) |
Compensation to any counsel and advisers employed by the Committee pursuant to the terms of this Charter; and |
(c) |
Ordinary administrative expenses of Committee that are necessary or appropriate in carrying out its duties. |
Managements Discussion and Analysis | |
For the Three and Twelve Months Ended December 31, 2018 and 2017 |
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Managements Discussion and Analysis
The following Managements Discussion and Analysis of Financial Condition and Results of Operations (MD&A) of The Flowr Corporation, formerly The Needle Capital Corp., (the Company) provides a discussion and analysis of the financial condition and results of operations to enable a reader to assess material changes in the financial condition of the Company between December 31, 2017 and December 31, 2018, and results of operations for the three and twelve months ended December 31, 2018, ( "Q4 2018" and YTD 2018, respectively) and for the three and twelve months ended December 31, 2017, ("Q4 2017" and YTD 2017, respectively). The MD&A should be read in conjunction with Flowrs audited consolidated financial statements for the year ended December 31, 2018 and 2017 (the Financial Statements). In this MD&A, references to Company or Flowr, as defined below, are references to The Flowr Corporation and its subsidiaries, as applicable. To the extent applicable, updated information contained in this MD&A supersedes older information contained in previously filed continuous disclosure documents.
This MD&A is dated as of April 3, 2019.
The Financial Statements (and the financial information contained in this MD&A) were prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). The Financial Statements and this MD&A have been reviewed and approved by the Companys Board of Directors (the Board of Directors or the Board). The Financial Statements include the accounts of the Company and its primary subsidiaries, The Flowr Canada Holdings ULC and The Flowr Group (Okanagan) Inc.
All amounts in this MD&A are expressed in Canadian dollars (CAD) except per share data and unless otherwise indicated. All amounts in tables are expressed in thousands of CAD, unless otherwise indicated.
Non-IFRS Measures
This MD&A contains certain financial performance measures that are not defined by IFRS; and are used by management to assess the financial and operational performance of the Company. These include but are not limited to adjusted EBITDA (defined below).
As there are no standardized methods of calculating non-IFRS measures, the Companys approaches may differ from those used by other companies in the industry and may not be comparable as a result. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered independently or in substitution for measures prepared in accordance with IFRS.
Additional information relating to the Company, including the Companys Annual Information Form dated April 3, 2019 (the AIF),is available on SEDAR at www.sedar.com.
This MD&A contains forward-looking information within the meaning of Canadian securities legislation (see Forward-looking Information below for a full discussion on the nature of forward-looking information). Information regarding the adequacy of cash resources to carry out the Companys operations and capital projects or the need for future financing is forward-looking information. All forward-looking information, including information not specifically identified herein, is made subject to cautionary language at the end of this MD&A. Readers are advised to refer to the cautionary language included at the end of this MD&A under the heading "Forward-looking Information" when reading any forward-looking information. This MD&A is prepared in accordance with Form 51-102F1 and has been approved by the Companys Board of Directors prior to its release.
Company Overview
The Company was incorporated under the Business Corporations Act (Alberta) on June 1, 2016. In connection with the completion of the Qualifying Transaction (as defined below), the Company continued from the Business Corporations Act (Alberta) to the Business Corporations Act (Ontario) on September 25, 2018. The head office of the Company is located at 461 King Street West, Suite 200, Toronto, Ontario, M5V 1K4. The Companys shares are listed on the TSX Venture Exchange (the Exchange) under the symbol FLWR.
1
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
The Company, formerly known as The Needle Capital Corp., was previously classified as a Capital Pool Company as defined in Policy 2.4 of the Exchange. The principal business of the Company was to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein by completing a purchase transaction. The purpose of such an acquisition was to satisfy the related conditions of a qualifying transaction under the Exchange rules (the Qualifying Transaction).
On September 21, 2018, the Company completed its Qualifying Transaction pursuant to a business combination agreement between the Company, 2652253 Ontario Inc. and a private corporation called The Flowr Corporation (Flowr PrivateCo) (the Business Combination Agreement). As a part of the Qualifying Transaction, the Company changed its name to The Flowr Corporation and consolidated its 7,679,997 common shares on a 13:1 basis to 590,769 common shares. In connection with the Qualifying Transaction, Flowr PrivateCo exchanged its shares for all of the issued and outstanding shares of the Company with the former shareholders of Flowr PrivateCo receiving a total of 85,692,095 post-consolidation common shares. Immediately following the closing of the Qualifying Transaction, the Company had a total of 86,282,864 issued and outstanding common shares, where the shareholders of Flowr PrivateCo owned 99.3% of the common shares the Company, and as a result, the transaction is considered a reverse acquisition of the Company by Flowr PrivateCo. The transaction has been accounted for as a listing expense in the consolidated statements of loss in the amount of $1,802,830 based on the fair value of equity instruments issued by the Company to the shareholders, option holders and warrant holders of The Needle Capital Corp and other professional fees incurred net of cash acquired from The Needle Capital Corp. Flowr PrivateCo is considered to be the acquirer and the Company is considered to be the acquiree. Accordingly, the discussion in this MD&A is a continuation of the operations of Flowr PrivateCo, hereinafter referred to as Flowr.
Prior to December 1, 2017, the business of Flowr was originally undertaken solely by Cannatech Plant Systems Inc., a British Columbia corporation (Cannatech). On December 1, 2017, a reorganization was completed (the Reorganization). The Reorganization resulted in: the limited partners of Flowco Services LP and Flowco Investments LP becoming shareholders of Flowr and Flowr having one direct subsidiary, The Flowr Canada Holdings ULC, a British Columbia corporation (Flowr ULC), and one indirect subsidiary, The Flowr Group (Okanagan) Inc., formerly known as Cannatech (Flowr Okanagan).
Flowr owns 100% of the issued and outstanding Flowr ULC common shares and two US shareholders own 100% of the issued and outstanding Flowr ULC Class A Shares. The Flowr ULC Class A Shares are exchangeable for common shares of Company at the sole option and discretion of the holders on a one-for-one basis and at no cost to the holder.
Flowrs interest in Flowr Okanagan is held through Flowr ULC, which owns 100% of the issued and outstanding shares in Flowr Okanagan.
2
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Flowr Okanagan is a license holder of (i) standard cultivation, (ii) standard processing and (iii) sale for medical purpose licences issued under the Cannabis Act and Cannabis Regulations and operates what is expected to be an 85,000 square foot GMP designed cultivation facility in Kelowna, British Columbia (Kelowna 1). Over time, Flowr will build out additional facilities and sites adjacent to Kelowna 1 (the Kelowna Campus) and Flowr has begun acquiring properties and rights, as described below. Flowr is focused on producing high-yield, high-quality cannabis for patients and consumers throughout Canada. Flowr also prioritizes research and development to breed specific cannabis varieties to identify unique characteristics and ultimately work to improve Flowrs final products. On August 10, 2018, Flowr Okanagan was granted by Health Canada the sales license for medical cannabis. For a summary of the regulatory framework relating to the Companys operations, please refer to the Companys AIF.
Overall Performance
Highlights of YTD 2018 and as of the Date of this Report
Financial Summary
In thousands of CAD dollars (except where noted), | Three months ended | Year ended | ||||||||||
December 31, | December 31, | |||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Grams produced | 259,091 | | 617,859 | | ||||||||
Grams sold | 405,584 | | 405,584 | | ||||||||
Net revenue | 2,870 | | 2,870 | | ||||||||
Net loss | 6,059 | 1,887 | 17,907 | 2,805 | ||||||||
Capital Expenditures | 4,051 | 6,305 | 15,124 | 9,296 |
During YTD 2018 and to the date of this MD&A, the following highlights the Companys significant events:
| Financing and Investing Activities The Company completed the following financing and investing activities in 2018: |
o |
On January 9, 2018, Flowr completed a non-brokered financing of 15,000,000 Flowr Class A Shares at a price of $1.00 per share, for aggregate gross proceeds of $15,000,000 with gross proceeds of $815,000 received in Q1 2018 and the balance received at the end of FY 2017. (These shares were converted into common shares of the Company as a result of the Qualifying Transaction). | |
| ||
o |
On July 18, 2018, Flowr completed a non-brokered financing of 5,309,361 Flowr common shares at a price of $2.60 per share, for aggregate gross proceeds of $13,804,339 (These shares were converted into common shares of the Company as a result of the Qualifying Transaction). | |
| ||
(each a Non-Brokered Financing and together the Non-Brokered Financings). | ||
| ||
o |
As a part of the Qualifying Transaction, Flowr completed a brokered and non-brokered financing (together the RTO Financing) issuing 13,807,734 common shares for gross proceeds of $35,900,108. (These shares were converted into common shares of the Company as a result of the Qualifying Transaction). |
3
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
o |
On October 10, 2018, through a strategic alliance with Ace Valley a brand of cannabis created by the team behind Ace Hill Beer (Ace Hill), the Company invested $750,000 in exchange for common shares of Ace Hill. The investment in Ace Hill has been recorded in investments at fair value in the Consolidated Statements of Financial Position as of December 31, 2018. | |
o |
On November 19, 2018, the Company entered into a binding term sheet (the Term Sheet) with Holigen Holdings Limited (Holigen), pursuant to which the Company agreed to lend $6,000,000 to Holigen. The proceeds received from Flowr are being used by Holigen to purchase land and obtain certain cannabis related licenses in certain jurisdictions, including Portugal. As of December 31, 2018, $6,000,000 has been advanced to Holigen. Flowr has the right to convert all debt owing under the loan facility into the same class of shares held by the shareholders of Holigen, that would result in a 4.8% equity interest in Holigen upon additional terms and conditions being met. | |
The Companys Filing Statement dated September 19, 2018 included information related to the Companys use of proceeds from the RTO Financing. As a result of the foregoing, the Company has committed $6,000,000 from the RTO Financing to advance this loan to Holigen. | ||
On December 19, 2018, the Company entered into a share purchase and subscription agreement (the SPSA) which effectively exercises the Companys option to convert the loan receivable into shares of Holigen. In addition, on December 19, 2018, the Company entered into a license agreement with Holigen, whereby the Company agreed to provide certain intellectual property to Holigen to accelerate the completion of Holigens construction and licensing projects. The closing of the acquisition of the 19.8% equity interest with Holigen is subject to certain closing conditions. |
| Corporate Matters The Company made the following changes during the fiscal year and to the date of this MD&A: |
o |
On January 8, 2018, Flowr Okanagan filed a notice of alteration to change its name from Cannatech Plant Systems Inc. to The Flowr Group (Okanagan) Inc. | |
o |
On February 12, 2018, Flowr ULC filed a notice of alteration to change its name from The Flowr Cannabis ULC to The Flowr Canada Holdings ULC. | |
o |
On September 4, 2018, Flowr appointed Vinay Tolia as Chief Executive Officer (Co-CEO) of the Company. Prior to Mr. Tolias appointment, Thomas Flow, President and Founder of the Company assumed the position of CEO following Mr. Anthony Giorgis departure from the organization in June 2018. | |
o |
On September 26, 2018, the Company began trading on the Exchange under the symbol FLWR, following the completion of the Qualifying Transaction. In addition, the directors and officers of the legacy entity became the directors and officers of the Company. | |
o |
On October 26, 2018, David Towill resigned as a director of the Company. | |
o |
On November 9, 2018, Flowr appointed Thomas Flow, President and Founder of the Company as co- CEO with Vinay Tolia, and announced the departure of David Ralston, the Companys former Chief Operating Officer. | |
o |
On December 28, 2018, Karen Basian, Maurice Levesque and Dr. J. Andre de Barros Teixeira were elected by shareholders of the Company to sit on the Companys Board of Directors. Ms. Basian brings over 25 years of experience in the consumer products, financial services and technology sectors, while Dr. Teixeira has an extensive background as a consultant in the areas of innovation, business development, multiculturalism in business, global development, motivation, story telling, ideation, and as a mentor of CEOs and executives. Mr. Levesque has 30 years of experience in the Canadian financial industry and is recognized for his broad knowledge, skills and experience in the venture capital industry, financial services industry and for his leadership skills in new business formation and development. |
4
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
o |
On December 28, 2018, the shareholders of the Company approved the Companys Long-Term Incentive Plan (LTIP), which was subsequently approved by the TSX-V on January 16, 2019. Under the terms of the LTIP the Board or a committee on behalf of the Board may grant units, which may be either restricted share units (RSUs) or deferred share units (DSUs) to officers, directors, employees or consultants of the Corporation. The maximum number of common shares which may be reserved and set aside for issue under the LTIP in respect of awards of DSUs to DSU participants and for payments in respect of awards of RSUs to RSU participants, shall not exceed 10% of the total issued and outstanding common shares of the Company, including the 44,100,000 convertible Flowr ULC Class A Shares. There are no RSUs or DSUs issued and outstanding as at the date of this MD&A. | |
o |
On February 5, 2019, Flowr submitted an application to list its common shares on The NASDAQ Capital Market (NASDAQ) and has filed a Form-40F Registration statement with the U.S. Securities Exchange Commission. A trading date will be made public once all regulatory formalities are satisfied. | |
o |
On March 6, 2019, the Company promoted Jason Broome to the role of Chief Research and Innovation Officer. Mr. Broome previously served as Senior Vice President of Operations. |
| Operating Activities In keeping with the Companys objective of advancing and optimizing Kelowna 1, the following progress at the Companys operations has been made: |
o |
The interior of Kelowna 1 continues to be under construction which is being completed in stages. In 2018, Flowr operated in approximately 16,000 square feet of the finished structure of Kelowna 1 while construction of the remaining portion of the interior is completed. | |
o |
On April 23, 2018, Flowr began the harvest of its first crop of cannabis in Kelowna 1. | |
o |
On January 24, 2019, Flowr Okanagan received approval from Health Canada to open additional grow rooms in Kelowna 1 that is under construction. | |
o |
In February 2019, another stage of construction was completed resulting in 6 additional grow rooms, similar in size to existing grow rooms, with 4 available for use and propagated with plants. Flowr expects to complete construction of Kelowna 1 by the end of the third quarter of 2019. The Companys anticipates spending $18.3M to complete Kelowna 1 in 2019, which would bring the total capital cost of Kelowna 1 to $33.8 million. The revised timeline of the completion of Kelowna 1 was due to steel supply delivery delays, change in scope to improve optimization of grow rooms and the decision to manage all construction activity internally. |
|
Growth Activities1 Flowr has undertaken the following activities to support the future growth of the Company: |
1The following statements constitute forward-looking information related to possible events and conditions and may involve unknown risks, assumptions and uncertainties that may cause actual events to differ materially. Please refer to the forward-looking information section of the MD&A.
5
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
o | In anticipation of the phased construction of the Kelowna Campus, Flowr has purchased, or has entered into agreements to purchase, several parcels of land near or adjacent to Kelowna 1, as follows: |
|
On June 29, 2017, Flowr purchased 0.53 acres of land located directly south and adjacent to Kelowna 1 (the June 29 Parcel); | |
| ||
|
On February 28, 2018, Flowr purchased 1.942 acres of land located directly to the north and adjacent to Kelowna 1 (the February 28 Parcel); | |
| ||
|
On March 2, 2018, Flowr purchased 0.53 acres of land located directly south and adjacent to the June 29 Parcel. Combined with the June 29 Parcel, the total land parcels will be utilized for a research and development facility (R&D Facility) in partnership with Hawthorne (as defined below) dedicated to advancing cannabis cultivation techniques and systems; | |
| ||
|
On June 7, 2018, Flowr entered into a purchase and sale agreement to purchase 17.6 acres of land located across the road to the east of Kelowna 1, subject to Flowrs satisfaction as to the feasibility of the land for the intended use, zoning and permitting. On February 12, 2019, the purchase and sale agreement closed and Flowr took title over the property. The agreement also provides Flowr with a right of first refusal to purchase two additional parcels of land located adjacent to the 17.6 acres of land. Specifically, the right of first refusal provides Flowr with the right to purchase one 10-acre parcel of land and another 9.4-acre parcel of land subject to agreed terms and conditions. Flowr intends to use these properties for greenhouse and outdoor production of cannabis and extraction of such other form factors (the Flowr Forest). Upon finalizing site design, floor plans and corresponding activities to be conducted at the Flowr Forest, the Company will initiate its licensing process with Health Canada. The Company expects to obtain the relevant licenses from Health Canada in 2019. The anticipated capital spending on Flowr Forest is $5.7 million in 2019; | |
| ||
|
Flowr is planning to begin planting the Flowr Forest upon receipt of Health Canada and other required approvals. The products cultivated from the Flowr Forest will be used for extraction in developing edibles and concentrates; | |
| ||
|
On August 31, 2018, Flowr purchased two (2) acres of land located directly north and adjacent to the February 28 Parcel. Combined with the February 28 Parcel, the total land parcels are intended to be used towards the Companys second cultivation facility (Kelowna 2). The Company is currently in the initial planning stages and would require additional sources of financing to move forward with the project. |
o | During YTD 2018, Flowr applied for two patents: |
| US Patent Application No. 15/912,377 Apparatus for Transporting Hanging Crops; and | |
| US Patent Application No. 15/912,356 Apparatus for Sorting of Crop Components |
o | On January 25, 2018 Flowr entered into an agreement with Hawthorne Gardening Company (Hawthorne), a subsidiary of The Scotts Miracle Gro Company, to construct and operate the R&D Facility. | |
o | On October 11, 2018, executives from Flowr and The Scotts Miracle Gro Company, Hawthorne and elected officials from surrounding communities, celebrated the ground breaking of the R&D Facility. |
6
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
o |
On March 1, 2019, Flowr hired celebrated Canadian Chef Ryan Reed to develop signature edible cannabis products for the Flowr brand. Flowr expects that customers will be able to purchase these unique, gourmet products once launched following the anticipated legalization of edibles and infused products in Q4 2019. |
| Key Distribution Channels The following activities occurred during FY 2018 and up to the date of this MD&A: |
o |
In FY 2018, the majority of the Company sales were to the adult-use recreational markets in Canada. In 2019, the Company anticipates increasing its share in the medicinal market with the signing of a supply agreement with Shoppers Drug Mart (Shoppers). | |
o |
On July 11, 2018, the B.C. Liquor Distribution Board, the retailer and distributor of non-medical cannabis for the province of British Columbia, entered into memorandums of understanding with 32 Licenced Producers which included Flowr Okanagan to form its initial wholesale product assortment to cater to the B.C. market. The supply agreement was ratified on October 1, 2018. | |
o |
On August 10, 2018, Flowr was granted by Health Canada, an amendment to remove the restrictions on its ACMPR licence and in the process, the Company obtained its sales licence to sell cannabis to the Canadian medical and adult-use recreational market. | |
o |
On August 20, 2018, the Ontario Cannabis Store announced that it had entered into supply agreements with 26 Licensed Producers including Flowr Okanagan. | |
o |
On October 17, 2018, Flowr fulfilled its initial sales orders with the provinces of British Columbia, Ontario and Nova Scotia in relation to the commencement of the recreational cannabis market in Canada. | |
o |
On January 9, 2019, Flowr Okanagan entered into an agreement with Shoppers, whereby Shoppers will be the direct-to-patient online provider of the Companys FlowrRx products in Canada. FlowrRx products became available on the Shoppers ecommerce site on March 18, 2019. FlowrRx products were previously available online to patients registered via the Company website and through select clinics. | |
o |
On January 29, 2019, Flowrs premium cannabis products became available for purchase in Manitoba through licensed private retailers. | |
o |
On January 31, 2019, Flowr announced that it will be begin selling a wide selection of cannabis cultivars, in both high-quality seed and clone form in the second quarter of 2019. Flowr believes that there is an opportunity to sell select cultivars in four key markets (i) Canadian Licence holders seeking high quality genetics (ii) Micro-Cultivators a new Health Canada subclass that can operate small craft cultivation facilities (iii) Export to international markets and (iv) individual consumers that purchase through provincial or licensed private retailers for personal use. No cultivar supply agreements or commitments have been entered into as of the date of this MD&A. |
Outlook
Management believes that Kelowna 1 which is designed to GMP standards, provides it with a significant competitive advantage over other Licenced Producers. The staff at Flowr have decades of combined experience both in (1) designing and building cannabis cultivation facilities and (2) performing the actual cultivation of high quality cannabis plants. To realize its objectives, the Companys strategy includes the following activities:
| Differentiate itself from other Licensed Producers by providing high quality cannabis products. |
7
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
| Pursue and maintain Good Manufacturing Practices certificates. | |
| Enforce quality assurance protocols that will be among the most rigorous in the industry. |
Key Financial Results and Operational Highlights
The following table summarizes the Companys key financial and operational results:
In thousands of CAD dollars, | Three months ended | Year ended | ||||||||||
(except loss per share and grams produced) | December 31, | December 31, | ||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Grams produced* | 259,091 | | 617,859 | | ||||||||
Grams sold | 405,584 | | 405,584 | | ||||||||
Net revenue | 2,870 | | 2,870 | | ||||||||
Gross profit (loss) before fair value adjustments | 252 | (104 | ) | (390 | ) | (258 | ) | |||||
SG&A | 4,286 | 1,412 | 8,531 | 2,289 | ||||||||
Share-based compensation | 3,356 | 602 | 7,208 | 602 | ||||||||
Listing expense | | | 1,803 | | ||||||||
Net loss | 6,059 | 1,887 | 17,907 | 2,805 | ||||||||
Loss per share (basic and diluted) | (0.10 | ) | (0.04 | ) | (0.22 | ) | (0.05 | ) | ||||
Cash used in investing activities | (10,609 | ) | (5,116 | ) | (21,670 | ) | (8,132 | ) | ||||
Cash from financing activities | 2,267 | 13,614 | 51,296 | 17,363 |
*Grams produced refers to the grams of dried cannabis harvested from plants in the period. The Company calculates grams produced based on the final recorded weight of dried harvested buds that have completed the drying stage net of any weight loss during the drying process for the period.
Construction of Facility
Construction of Kelowna 1 is progressing. For FY 2018, Flowr operated 4 grow rooms and it is expected that when Kelowna 1 is fully completed in 2019 it will have 20 grow rooms. As of the date of this MD&A, the Company has a total of 10 grow rooms ready for use, of which 8 grow rooms are propagated with plants. Flowr anticipates having a total of 10 grow rooms operational in the summer of 2019. Upon completion of the final stages of construction, an additional 10 grow rooms will become available. Flowr anticipates all 20 grow rooms to be operational in Q4 2019.
As of December 31, 2018, the Company spent approximately $15.5 million on the development of Kelowna 1.
Results of Operations
Three Months Ended December 31, 2018, and December 31, 2017
Net loss in Q4 2018 totalled $6,059,002 which was $4,171,257 higher than the net loss in Q4 2017. The increase is mainly driven by the ramp up of the activities of the Company in 2018 with the commencement of the cultivation operations, harvests and sales in January 2018, April 2018 and October 2018, respectively. Key costs contributing to a higher net loss in Q4 2018 were cost of sales, selling, general and administrative expenses and share-based compensation partially offset by unrealized gains on changes in fair value of biological assets.
8
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Cost of sales for Q4 2018 was $2,618,889 compared to $103,509 in Q4 2017. The increase in cost of sales is largely attributable to the expensing of capitalized inventory costs, as product was sold in Q4-2018. In 2017 costs were expensed directly to cost of sales as cultivation had not yet commenced.
Selling, general and administrative expenditures, consisting primarily of salaries and professional fees, were $4,286,622 in Q4 2018 compared to $1,411,933 in Q4 2017. Share-based compensation was $3,356,823 in Q4 2018 compared to $601,536 in Q4 2017. Share-based compensation expense in Q4 2018 resulted from the issuance of stock options in the latter half of 2018 primarily to officers and directors of the Company.
Twelve Months Ended December 31, 2018, and December 31, 2017
The Company incurred a net loss of $17,907,188 during YTD 2018 compared to a net loss of $2,805,335 during YTD 2017 resulting in an increased loss of $15,101,853. The higher loss in YTD 2018 was driven by the ramp up of the activities of the Company with the commencement of the cultivation operations in January 2018. The following were the key expenditures that contributed to the higher loss during YTD 2018 period with selling, general and administrative costs being the most significant:
| Cost of sales were $3,260,799 in YTD 2018 compared to $258,038 in YTD 2017. The increase in cost of sales is primarily due to expensing inventory sold in 2018 and due to initial non-recurring costs incurred during the ramp up of operating activities in 2018. | |
| Selling, general and administrative costs of $8,531,402 in YTD 2018 were higher by $6,242,857 compared to $2,288,545 costs in YTD 2017 primarily due to increases in employee headcount and professional fees as result of the growing workforce and operations in 2018. | |
| Research and development costs were $321,824 in YTD 2018 compared to a $nil amount in YTD 2017. | |
| Share-based compensation was $7,208,273 compared to $601,536 in YTD 2017. The options generally vest equally over a 36-month period for executive optionees or vest over 3 equal tranches on the 15th, 27th, and 39th month from the date of grant for options. All options expire 5 years from the date of the grant. | |
| Listing expense was $1,802,830 compared to a $nil amount in YTD 2017. | |
| Unrealized losses on changes in fair value of biological assets in YTD 2018 were $420,410 compared to a $nil amount in YTD 2017. |
9
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Adjusted EBITDA (Non-IFRS Measure)
Adjusted EBITDA is net loss, plus (minus) income taxes (recovery), plus (minus) interest income (expense), net, plus depreciation and amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on biological assets and inventory sold, plus listing expense costs and plus (minus) loss (gain) on investments. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash used by operations.
In thousands of CAD dollars | Three months ended | Year ended | ||||||||||
December 31, | December 31, | |||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Net loss | (6,059 | ) | (1,887 | ) | (17,907 | ) | (2,805 | ) | ||||
Depreciation and amortization | 620 | | 640 | | ||||||||
Unrealized (gains) losses on fair value adjustments of | ||||||||||||
biological assets | (165 | ) | | 420 | | |||||||
Fair value adjustments on inventory sold | (500 | ) | | (500 | ) | | ||||||
Share-based compensation | 3,356 | 602 | 7,208 | 602 | ||||||||
Listing expense | | | 1,803 | | ||||||||
Net gains on valuation of warrant investment | (489 | ) | (224 | ) | (153 | ) | (336 | ) | ||||
Interest (income) expense | (104 | ) | | (102 | ) | 1 | ||||||
Adjusted EBITDA | (3,341 | ) | (1,509 | ) | (8,591 | ) | (2,538 | ) |
Adjusted EBITDA losses were higher for the three and twelve months ended December 31, 2018 compared to 2017 by $1,832,000 and $6,053,000, respectively, due to the ramp up of cultivation, operating activities and sales in 2018.
Cash used in Investing and from Financing activities
The cash used in investing activities for the three and twelve months ended December 31, 2018 was $10,608,771 and $21,669,702 respectively, compared to $5,115,778 and $8,131,902 respectively in 2017. The increase in investing activities are primarily due to the continuing of the construction activities to complete Kelowna 1. Management anticipates the construction of Kelowna 1 to be completed at the end of the third quarter 2019.
Net cash provided from financing activities for the three months ended December 31, 2018 was $2,266,896 compared to $13,613,168 in 2017. The decrease from the prior quarter is largely due to the Non-Brokered Financings completed in Q4 2017 with the Company receiving gross proceeds of $13,748,032 in December 2017. Net cash provided from financing activities for the twelve months ended December 31, 2018 was $51,296,267 compared to $17,362,578 respectively in 2017. The increase in financing activities in 2018 is due to the capital raises completed in 2018.
Total Assets and Liabilities
In thousands of CAD dollars | December 31, 2018 | December 31, 2017 | December 31, 2016 | ||||||
Total assets | 67,133 | 21,502 | 4,358 | ||||||
Current liabilities | 6,283 | 1,956 | 409 | ||||||
Non-current liabilities | 1,304 | | |
Total assets as at December 31, 2018 increased by a net of $45,631,383 from the end of FY 2017. The change is largely attributed to the increase in cash and cash equivalents of $19,939,484 due to the financings in 2018 and property, plant & equipment of $14,046,780 primarily in relation to the construction of Kelowna 1. Amounts receivable increased by $2,165,570 as a result of the commencement of sales in Q4-2018. In addition, biological assets and inventory increased by $497,102 and $1,398,943, respectively as a result of plants and finished goods inventory resulting from commencement of cultivating activities in 2018.
10
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Summary of Quarterly Results
In thousands of CAD dollars | Q4-2018 | Q3-2018 | Q2-2018 | Q1-2018 | Q4-2017 | Q3-2017 | Q2-2017 | Q1-2017 | ||||||||||||||||
Net revenue | 2,870 | | | | | | | | ||||||||||||||||
Net Loss | (6,059 | ) | (5,633 | ) | (3,633 | ) | (2,582 | ) | (1,888 | ) | (467 | ) | (233 | ) | (217 | ) | ||||||||
Net Loss attributable to: | ||||||||||||||||||||||||
Common shareholders | (5,515 | ) | (5,420 | ) | (2,724 | ) | (1,742 | ) | (1,442 | ) | (249 | ) | (110 | ) | (108 | ) | ||||||||
Non-controlling interest | (544 | ) | (213 | ) | (909 | ) | (840 | ) | (446 | ) | (218 | ) | (123 | ) | (109 | ) | ||||||||
Basic and diluted loss per share attributable to common shareholders of the Company |
(0.07 | ) | (0.08 | ) | (0.04 | ) | (0.03 | ) | (0.04 | ) | (0.01 | ) | | |
Liquidity and Capital Resources
Liquidity
The main sources of liquidity are the Companys cash and cash equivalents and equity issuances. As at December 31, 2018, cash and cash equivalents were $27,689,183 compared to $7,749,699 at December 31, 2017.
On January 9, 2018, Flowr completed a Non-Brokered Financing of 15,000,000 Flowr Class A Shares at a price of $1.00 per share, for aggregate gross proceeds of $15,000,000. The financing closed in two tranches, as follows:
o | On December 28, 2017, 14,185,000 Flowr Class A shares were issued for aggregate gross proceeds of $14,185,000; and | |
o | On January 9, 2018, 815,000 Flowr Class A shares were issued for aggregate gross proceeds of $815,000. |
On July 18, 2018, Flowr completed a Non-Brokered Financing of 5,309,361 Flowr common shares at a price of $2.60 per share, for aggregate gross proceeds of $13,804,339. The Non-Brokered Financing closed on a rolling basis in five tranches, as follows:
o | On April 11, 2018, 3,310,330 Flowr common shares were issued for aggregate gross proceeds of $8,606,858; | |
o | On April 23, 2018, 970,232 Flowr common shares were issued for aggregate gross proceeds of $2,522,603; | |
o | On May 28, 2018, 84,382 Flowr common shares were issued for aggregate gross proceeds of $219,393; | |
o | On July 12, 2018, 896,151 Flowr common shares were issued for aggregate gross proceeds of $2,329,993; | |
o | On July 18, 2018, 48,266 Flowr common shares were issued for aggregate gross proceeds of $125,492. |
On September 21, 2018, Flowr completed the RTO Financing of 13,807,734 Flowr common shares at a price of $2.60 per share, for aggregate proceeds of $35,900,108. In relation to the RTO financing, the Company issued 441,720 broker warrants exercisable at $2.60, expiring 2 years from the date of grant.
Working Capital
As at December 31, 2018, the Company had working capital of $27,178,500 (December 31, 2017 $6,767,797), calculated as total current assets less total current liabilities. The increase in working capital of $20,410,703 is mostly due to the financing transactions completed during YTD 2018 offset by capital spending related to the construction of Kelowna 1.
11
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Contractual Obligations
The Companys contractual obligations for the year ended December 31, 2018 are set out below:
Contractual Obligations | Less than 1 | ||||||||
In thousands of CAD dollars | Total | year | 1-2 years | ||||||
Trade and other payables | 4,605 | 4,605 | | ||||||
Due to related parties | 63 | 63 | | ||||||
Deferred revenue | 1,328 | 1,328 | | ||||||
Debt | 1,592 | 288 | 1,304 | ||||||
Total contractual obligations | 7,588 | 6,284 | 1,304 |
Commitments and Contingencies
Future minimum payments as at December 31, 2018, under agreements to which the Company is a party are as follows:
In thousands of CAD dollars | Less than 1 year | 1- 3 years | 3- 5 years | Over 5 years | Total | ||||||||||
Purchase obligations | 2,002 | | | | 2,002 | ||||||||||
Lease commitments | 455 | 990 | 565 | 5,854 | 7,864 |
The Company expects to meet its contractual obligations and commitments with its available cash and cash equivalents.
On January 25, 2018, Hawthorne and Flowr entered into an agreement to construct the R&D Facility and to provide certain R&D services upon completion of the R&D facility. The agreement was amended effective December 14, 2018. Under the amended agreement, Flowr Okanagan received a design and construction fee of $1,500,000 which is initially recorded as deferred revenue in the consolidated statements of financial position. The revenue is recognized as design and construction income in the consolidated statements of loss over the period of time the services are rendered. Hawthorne will also finance all approved development expenses through a loan to Flowr Okanagan to a maximum loan amount of $11,500,000 (the Hawthorne Loan). The funds will be advanced to Flowr on a monthly basis based on the expected expenditures to be incurred for the month. On the opening date of the R&D Facility, the Hawthorne Loan will become payable through an agreed upon payment schedule and will commence to accrue interest at rate a of 4%. The Hawthorne Loan will be fully repaid over 20 years from the opening date of the R&D Facility.
As of December 31, 2018, Hawthorne advanced $1,591,536 to Flowr Okanagan under the Hawthorne Loan.
As a part of the arrangement, once the R&D Facility is operational, Hawthorne will pay Flowr a monthly management fee and a monthly SR&ED service fee which can be offset against the monthly loan and interest repayments.
As of December 31, 2018, if the contract were to terminate under certain circumstances, the Company could be required to pay 100% of all costs and expenses loaned by Hawthorne and $1,500,000 in liquidated damages.
Off-Balance Sheet Arrangements
There are no off-balance sheet arrangements as at December 31, 2018.
12
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Transactions with Related Parties
The Companys related parties as defined by International Accounting Standard 24 "Related Party Disclosures" (IAS 24), include the Companys subsidiaries, executive and non-executive directors, senior officers and key management personnel. Transactions with related parties are measured at fair value, which in all cases are equivalent to the exchange amounts being the amount of consideration established and agreed upon by the related parties. All related party transactions entered into by the Company are in the normal course of business and have been approved by the Board of Directors of the Company and/or shareholders of the Company as required.
Key management personnel are defined as directors and senior officers of the Company.
Transactions with related parties during YTD 2018 and YTD 2017 are listed below:
(a) |
Compensation of Key Management Personnel: |
In thousands of CAD dollars | Year Ended December 31, | |||||
2018 | 2017 | |||||
Salaries and benefits | 1,805 | 439 | ||||
Share-based compensation | 6,697 | 575 | ||||
Total | 8,502 | 1,014 |
(b) | Transactions with employees, shareholders and officers |
As at December 31, 2018, the following related party amounts were included in (a) prepaid expenses and other assets (b) loan receivable (c) due to related parties (d) property, plant and equipment (e) accounts payable and accrued liabilities were as follows:
In thousands of CAD dollars | For the Year Ended, | ||||||
December 31, 2018 | December 31, 2017 | ||||||
(a) | Amounts in
relation to reimbursable expenses due from a corporation whose principal is a director and officer of Flowr |
| 96 | ||||
(b) | Loan to shareholder and employee
of Flowr bearing interest at 1% per annum |
| 25 | ||||
(c) | i) Shareholder advance payable to a director and officer of Flowr | | 25 | ||||
ii) Reimbursable expenses due to a corporation with directors and officers in common with Flowr | 63 | 3 | |||||
(d) | Fees paid to a
company for the construction of Facility whose principal is an employee and shareholder of Flowr(1 |
2,211 | 5,928 | ||||
(e) | Amounts due to a construction
company whose principal is an employee and shareholder of Flowr(1 |
82 | 1,104 |
1The Company engaged Maddocks Construction Ltd. (Maddocks) as one of the primary contractors involved with its capital projects (mainly Kelowna 1 and the R&D Facility). The principal of Maddocks in not an officer or director of the Company.
13
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Included in general and administrative expense are amounts paid to shareholders or to companies whose principals are either a shareholder, director or officer of Flowr as follows:
In thousands of CAD dollars | For the Year Ended December 31, | |||||
2018 | 2017 | |||||
Consulting and administration fees | 95 | 51 | ||||
Rental fees | 21 | 19 | ||||
Total | 116 | 70 |
The Company and its subsidiaries are considered related parties under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (MI 61-101) as a result of Core Flow Canada Holdings Inc.s deemed beneficial ownership by it of the common shares of the Company underlying the Flowr ULC Class A Shares it holds, and also on the basis that Core Flow Holdings Canada Inc. is controlled by Steve Klein (a director of the Company).
As a result, the Company does not benefit from the exemption of the application of the related party transaction rules in section 5.1 of MI 61-101 for transactions with Flowr ULC or Flowr Okanagan on the basis that i) it is not a downstream transaction, because Core Flow Canada Holdings Inc. is a related party of the Company and Core Flow Canada Holdings Inc. has more than 5% of the voting rights in Flowr ULC; and ii) neither Flowr ULC or Flowr Okanagan are wholly owned subsidiaries of the Company.
The Company does from time to time enter into related party transactions with Flowr ULC and Flowr Okanagan primarily related to cash management transactions, intercompany loans and the issuances of shares from the Flowr ULC to the Company in accordance with the share exchange agreement dated August 20, 2018 among the Company and Flowr ULC and certain US shareholders of the Company.
Financial Instruments
The following table outlines the Companys financial instruments as of December 31, 2018. The carrying value of these financial instruments approximate their fair values as at December 31, 2018.
In thousands of CAD dollars | Fair Value at | ||||||||
December 31, 2018 | Basis of Measurement | Financial Instruments | |||||||
Financial Assets | |||||||||
Cash and cash equivalents | 27,689 | Carrying value | Amortized cost | ||||||
Amounts receivable | 2,963 | Carrying value | Amortized cost | ||||||
Deposits recoverable | 361 | Carrying value | Amortized cost | ||||||
Investment in private securities - shares | 750 | Fair value | FVOCI | ||||||
Investment in private securities - warrants | 489 | Fair value | FVPL | ||||||
Convertible loan receivable | 6,000 | Fair value | FVPL | ||||||
Financial Liabilities | |||||||||
Accounts payable and accrued liabilities | 4,605 | Carrying value | Amortized cost | ||||||
Due to related parties | 63 | Carrying value | Amortized cost | ||||||
Debt | 1,592 | Carrying value | Amortized cost |
Amortized cost The carrying values of all the financial assets and liabilities measured at amortized cost approximate their fair values.
FVPL Investments intended for sale and non-hedging derivative instruments (such as warrants) that are recognized at fair value and changes in fair value are recognized in other expenses (income) in the consolidated statement of loss.
14
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Investments private securities Warrants
(i) |
Plant Properties Warrants |
On December 31, 2018, the Companys 1,500,000 warrants in Plant Properties were terminated. Each warrant was exercisable into one common share of Plant Properties any time prior to June 13, 2019, at an exercise price of $0.50 per common share. For the year ended December 31, 2018, the Company recognized a realized loss on Plant Properties warrants of $335,571 (2017 unrealized gain $207,194) in other income in the Consolidated Statements of Loss.
(ii) |
Seven Leaf Warrants |
On December 31, 2018, the Company was granted 2,500,000 warrants in Seven Leaf. Each warrant is exercisable into one common share of Seven Leaf any time prior to December 31, 2020, at an exercise price of $0.50 per common share. Seven Leaf has two directors in common with Flowr. For the year ended December 31, 2018, the Company recognized a gain on issuance of the warrants of $488,695 (2017 nil) in other income in the Consolidated Statements of Loss.
Convertible loan receivable
On the November 19, 2018, the Company entered into the Term Sheet with Holigen, pursuant to which the Company agreed to lend $6,000,000 to Holigen. The proceeds received from Flowr are being used by Holigen to purchase land and obtain certain cannabis related licenses in certain jurisdictions including Portugal. As of December 31, 2018, $6,000,000 has been advanced to Holigen. Flowr has the right to convert all debt owing under the loan facility into the same class of shares held by the shareholders of Holigen, that would result in a 4.8% ownership interest in Holigen (the Conversion Option).
On December 19, 2018, the Company entered into the SPSA with Holigen which effectively exercises the Companys Conversion Option and provides the Company with an additional 15% equity interest in Holigen, for an aggregate 19.8% ownership interest. The Company provided Holigen with certain intellectual property to accelerate the completion of Holigens construction and licensing projects. The closing of the acquisition of the 19.8% ownership interest of Holigen is subject to various legal, administrative and approval conditions. As the Conversion Option has been exercised prior to the outside date of January 31, 2019 under the loan facility, interest will not accrue on the loan balance. However, in the event that the acquisition of the 19.8% interest in Holigen does not close, the entire outstanding loan balance and related interest will become payable on February 1, 2020. Interest under the loan facility would be calculated at 8% per annum from the first advance made under the loan.
The Conversion Option represents a call option to the Company and is included in the fair value of the loan. There existed an insignificant difference in fair value between the initial recognition date of November 19, 2018 and the reporting date of December 31, 2018, and accordingly the transaction price approximated the fair value of the note. The value of the Conversion Option of the loan is $487,474 as of December 31, 2018.
FVOCI Investments not held for trading and non-hedging derivative instruments that are recognized at fair value and changes in fair value are recognized in other comprehensive income.
Investments private securities Shares
On October 10, 2018, the Company acquired 319,149 shares of Ace Hill at a cost of $750,000. As Ace Hill is not a listed public company, the valuation of the shares at the time of issuance was based on a discounted projected cash flow model. As of December 31, 2018, the Company re-assessed the fair value of the shares based on the projected cash flow model and concluded there were no significant changes in fair value. As of December 31, 2018, the cost of the investment approximated the fair value. No adjustments in fair value were reported through other comprehensive income in the Financial Statements.
15
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Risk Management
The Companys exposure to financial instruments includes, but is not limited to, the following risks:
Market risk
Market risk is the risk that the future cash flows or the fair value of a financial instrument will fluctuate because of changes in market conditions. The Company operates in an industry regulated by Health Canada and applicable legislation in Canada. Changes in legislation could have a significant impact on the Companys operations.
Credit Risk
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Companys credit risk is primarily associated with liquid financial assets. The Company limits exposure to credit risk on liquid financial assets by holding cash and cash equivalents at highly-rated financial institutions. As at December 31, 2018, the Company had a convertible loan receivable of $6,000,000 (2017 Nil) and amounts receivable of $2,963,115 (December 31, 2017 - $797,545). The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. The Company is not significantly exposed to credit risk as the accounts receivables are primarily due from provincial government organizations and overall amounts receivable and convertible loan receivables comprise 13.4% (December 31, 2017 3.8%) of the Companys total assets.
Liquidity Risk
Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company manages the liquidity risk inherent in these financial obligations by regularly monitoring actual cash flows to annual budget which forecast cash needs and expected cash availability to meet future obligations.
The Company will need to raise additional capital through equity issuances or debt financing in order to advance strategic initiatives under consideration or commence new capital projects.
Capital Risk Management
The Company considers its capital to be its equity. The Companys objective for capital management is to: (i) maintain sufficient levels of liquidity to fund and support its capital projects and operating activities and; (ii) maintain a strong financial position to ensure it has ready access to debt and equity markets to supplement free cash flow being invested in its growth projects. The Company monitors its financial position and the potential impact of adverse market conditions on an ongoing basis. The Company manages its capital structure and adjusts it based on prevailing market conditions and according to its business plan. The Companys funding strategy is to maintain a capital structure comprised primarily of equity sourced from equity offerings and net earnings generated from its operations, accompanied with financing through debt.
16
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Significant Changes in Accounting Policies
The Company has changed its accounting policy with respect to production costs related to biological assets. Prior to this change, the Company expensed any costs related to production of biological assets. The Company now capitalizes production costs related to biological assets and recognizes the expenses in cost of sales as the inventory is sold. Non-recurring start-up costs are expensed directly through cost of sales. Shipping and fulfillment charges and any related depreciation are expensed to cost of goods sold in the period in which the costs are incurred. The Company also revised its presentation in the consolidated statement of loss to separate fair value adjustments for both biological assets and inventory sold in the period. The Company believes that the revised policy and presentation provides more relevant financial information to the users of the Financial Statements.
The amended policy is as follows:
(a) |
Biological assets |
While the Companys biological assets, consisting of cannabis plants, are within the scope of IAS 41 Agriculture, the direct and indirect costs of biological assets are determined using an approach similar to the capitalization criteria outlined in IAS 2 Inventories. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs, grow consumables, utilities, facilities costs including an allocation of overhead costs related to production facility, quality and testing costs, and production related depreciation. Capitalized costs are subsequently recorded within cost of sales in the consolidated statements of loss in the period that the related product is sold.
The Company measures biological assets, at fair value less cost to sell up to the point of harvest. Unrealized gains or losses arising from the changes in fair value less cost to sell during the period are separately recorded in the consolidated statement of loss for the related period. Cost to sell includes post harvest production costs and fulfilment costs.
The Company commenced cultivating cannabis in January 2018. Biological assets were measured at a fair value of nil in reporting periods prior to the Company obtaining its sales license on August 10, 2018, as management could not reasonably assess the likelihood of obtaining the sales license from Health Canada at the time. As a result, all capitalized costs related to biological assets were expensed through changes in fair in value of biological assets.
(b) |
Inventory |
Inventory of harvested bulk cannabis and finished goods are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour related costs, consumables, packaging supplies, facilities costs including an allocation of overhead costs related to production facility, quality and testing costs, and related depreciation. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Supplies and consumables are valued at the lower of costs and net realizable value, with cost determined based on an average cost basis.
The changes in accounting policy has been applied retrospectively. As there were no biological assets and cannabis inventory in 2017, comparatives were not impacted by this change in policy. However, the presentation of production costs in 2017 is now captured as cost in sales in the comparative period.
The Company also adopted IFRS 9, Financial Instruments effective January 1, 2018. The adoption has no material impact on the Financial Statements. More details are available in the Financial statements.
17
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Future Accounting Standards and Pronouncements
The following new standard IFRS 16 is not yet effective for the year ended December 31, 2018 and has not been applied when preparing the Financial Statements.
The Companys assessment of IFRS 16 is set out below.
IFRS 16, Leases
IFRS 16, issued in January 2017, replaces IAS 17, Leases. IFRS 16 results in most leases being reported on the statement of financial position for lessees, eliminating the distinction between a finance lease and an operating lease. The standard is expected to impact the accounting for the Companys operating leases, which are currently reflected in the consolidated statements of loss and in the Companys disclosure in respect of future commitments. Under IFRS 16, all operating leases, except for short term and low value leases, are expected to be accounted for as finance leases. As a result, the leased assets and the associated obligations are recognized in the consolidated statements of financial position. The leased assets will be depreciated over the shorter of the estimated useful life of the asset and the lease term. The lease payments are apportioned between finance charges and a reduction of the lease liability. The current operating lease expense will be replaced with a depreciation charge on the leased assets and a finance charge on the lease liability, which are in aggregate expected to result in a higher total periodic expense in the earlier periods of the lease.
IFRS 16 is effective for annual periods beginning on or after January 1, 2019. The Company has reviewed all leases to determine and document the expected changes associated with the adoption of IFRS 16. Upon adoption of IFRS 16, all existing operating leases with a term greater than 1 year, will be recognized as a leased asset and the associated obligation will be recorded.
Share Capital Information
As at the date of this MD&A, the following number of common shares of the Company and other securities of the Company exercisable for common shares of the Company are outstanding (on a post-consolidation basis):
Securities | Common shares on exercise | ||
Common shares | 86,895,352 | ||
Flowr ULC Class A shares (convertible into common shares)* | 44,100,000 | ||
Warrants | 258,270 | ||
Stock options | 10,374,280 | ||
Fully diluted share capital | 141,627,902 |
*The Flowr ULC Class A Shares are issued and outstanding in the Flowr ULC and convertible into common shares of the Company at the election of the holder and no cost to the holder.
Disclosure Controls and Procedures
Management has established processes to provide them sufficient knowledge to support representations that they have exercised reasonable diligence that (i) the consolidated financial statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of and for the periods presented by the consolidated financial statements; and (ii) the consolidated financial statements fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented.
In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), the Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures ("DC&P") and internal control over financial reporting ("ICFR"), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of:
18
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers accounting policies.
The issuers certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in the certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost-effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.
Forward-looking Information, Risks and Uncertainties
Certain statements contained in this MDA constitute forward-looking information and forward looking statements within the meaning of applicable Canadian and United States securities laws (collectively, forward-looking information), which are based upon the Companys current internal expectations, estimates, projections, assumptions and beliefs. Statements concerning the Companys objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and the business, operations, future financial performance and condition of the Company is forward-looking information. The words believe, expect, anticipate, estimate, intend, may, will, would and similar expressions, including the negative and grammatical variations of such expressions, are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. In addition, this MD&A, may contain forward-looking information attributed to third-party industry sources.
By their nature, forward-looking information involves numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts and projections that constitute forward-looking information will not occur. Such forward-looking information in this MD&A speak only as of the date of this MD&A. Forward-looking information in this MD&A includes, but is not limited to, statements with respect to:
| the expected size, capacity and completion of Kelowna 1, and the timing of completion thereof; | |
| the additional grow rooms of Kelowna 1 and the timing of completion and operation thereof; | |
| the construction of additional facilities on the Kelowna Campus; | |
| Flowr seeking to acquire additional properties, and its ability to do so; | |
| the expectation that the Companys common shares will commence trading on the NASDAQ; | |
| the R&D Facility advancing cannabis cultivation techniques and systems; | |
| Flowr using certain properties in the Flowr Forest for greenhouse production and extraction; | |
| licensing with respect to the Companys property and facilities; | |
| timing of obtaining licenses for the Flowr Forest; | |
| Flowr planting the Flowr Forest and the timing thereof; |
19
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
| the timing of selling other form factors and the source of cannabis for such form factors; | |
| capital spending relating to the Companys projects, including Kelowna 1 and the Flowr Forest; | |
| Kelowna 2 and the completion thereof; | |
| the plans for Kelowna 2 and financing thereof; | |
| customers being able to purchase unique gourmet products as a result of the hiring of Chef Ryan Reed, and the timing of the availability of such products; | |
| the Shoppers supply agreement increasing sales for Flowr; | |
| Flowr selling cannabis cultivars, and the timing of the commencement of such sales; | |
| the markets that Flowr believes it can sell cannabis cultivars in; | |
| the advantages that Flowr believes it has with Kelowna 1 and its strategies with respect to growing premium cannabis, attaining certain manufacturing certifications and enforcing certain protocols; | |
| the performance of the Companys business and operations; | |
| the Companys capital expenditure programs; | |
| the future development of the Company, its growth strategy and the timing thereof; | |
| the acquisition strategy of the Company; | |
| the estimated future contractual obligations of the Company; | |
| the Companys future liquidity and financial capacity; | |
| the Companys ability to satisfy its financial obligations in future periods; | |
| the supply and demand for cannabis products and services similar to the Companys products and services; | |
| cost and/or pricing of the Companys products; | |
| expectations regarding the Companys ability to raise capital; | |
| the Companys treatment under government regulatory and taxation regimes; | |
| the closing of the acquisition of the 19.8% ownership interest in Holigen; and | |
| the Companys net sales of all or any one of its products. |
With respect to the forward-looking information contained in this MD&A, the Company has made certain assumptions and such forward-looking information is subject to certain risks, including, without limitation, the following risks and assumptions:
| the timing of completion of the Facility and the additional grow rooms; | |
| the expected capacity of the Facility; | |
| the ability of Flowr to complete construction of additional facilities on the Kelowna Campus; | |
| Flowr being able to acquire additional properties; | |
| the Companys common shares being approved for trading on the NASDAQ; | |
| the R&D Facility being capable of advancing cannabis cultivation techniques and systems; |
20
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
|
the Flowr Forest enabling Flowr to produce cannabis in greenhouses and Flowr being able to extract cannabis for other form factors; | |
|
Flowr being able to plant the Flowr Forest and the timing thereof; | |
|
Flowr receiving licenses and approvals for future and/or planned projects, including the Flowr Forest and Kelowna 2; | |
|
Flowr being able to sell other form factors and the timing thereof; | |
|
Chef Ryan Reed and Flowr being able to create unique and gourmet products, customers purchasing such products and the timing of the availability of such products; | |
|
the Shoppers supply agreement actually increasing sales for Flowr; | |
|
Flowr being able to sell cannabis cultivars, and the timing of the commencement of such sales; | |
|
the markets that Flowr believes it can sell cannabis cultivars in actually forming and those markets purchasing | |
such products from Flowr; | ||
|
the Facility and Flowrs strategies with respect to growing premium cannabis, attaining certain manufacturing certifications and enforcing certain protocols providing it with the competitive advantage that Flowr believes it has over other licensed producers; | |
|
the ability to develop and market future products; | |
|
timing to launch new products; | |
|
cost to develop and/or manufacture products; | |
|
operating cost estimates and yield trends for the Company; | |
|
inventory levels; | |
|
pricing for the Companys products; | |
|
future market demand/trends; | |
|
gross profitability for products; | |
|
the ability of the Company to comply with its contractual obligations, including, without limitation, its obligations under debt arrangements, as applicable; | |
|
the successful sale of products to third parties on terms favorable to the Company; | |
|
the ability of the Company to maintain key strategic alliances, and licencing and partnering arrangements, now and in the future; | |
|
the ability of the Company to complete construction of its facilities on time or at all; | |
|
any delay in the construction and/or licencing of the facilities of the Company not being material; | |
|
the ability of the Company to maintain its distribution networks and distribute its products effectively; | |
|
the general regulatory environment in which the Company operates, including the areas of taxation, environmental protection, consumer safety and health regulation; | |
|
the timely receipt of any required regulatory approvals; | |
|
the general economic, financial, market and political conditions impacting the industry in which the Company operates; |
21
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
| the tax treatment of the Company and the materiality of legal proceedings; | |
| the ability of the Company to achieve or increase profitability, fund its operations with existing capital, and/or raise additional capital to fund future acquisitions and/or development, including construction and licencing of the facilities of the Company; | |
| the ability of the Company to acquire any necessary technology, products or businesses and effectively integrate such acquisitions; | |
| reliance on third party suppliers to supply the Company with products required for its business on favourable terms; | |
| the ability of the Company to generate sufficient cash flow from operations; | |
| the availability of raw materials and finished products necessary for the Companys products; | |
| the impact of increasing competition; | |
| the ability of the Company to obtain and retain qualified staff, equipment and services in a timely and efficient manner; | |
| the ability of the Company to maintain and enforce the protection afforded by trade secrets or other intellectual property rights; | |
| the ability of the Company to conduct operations in a safe, efficient and effective manner; | |
| the results of continuing and future safety and efficacy studies by industry and government agencies related to the Companys products; and | |
| the ability of the Company to successfully market its products and services. |
Forward-looking information contained in this MD&A is based on the key assumptions described herein. Readers are cautioned that such assumptions, although considered reasonable by the Company, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided in this MD&A as a result of numerous known and unknown risks and uncertainties and other factors. The Company cannot guarantee future results.
Risks related to forward-looking information include those risks referenced herein and in the Companys other filings with the Canadian Securities Regulators. Some of the risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking information contained in this MD&A include, but are not limited to, the risk factors described above and included under the heading Risk Factors in the Annual Information Form.
Forward-looking information contained in this MD&A is based on the Companys current plans, expectations, estimates, projections, beliefs and opinions and the assumptions relating to those plans, expectations, estimates, projections, beliefs and opinions may change. Management has included the summary of assumptions and risks related to forward-looking information included in this MD&A for the purpose of assisting the reader in understanding managements current views regarding those future outcomes. Readers are cautioned that this information may not be appropriate for other purposes. Readers are cautioned that the lists of assumptions and risk factors contained herein are not exhaustive. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of the forward-looking information contained herein.
Such forward-looking information is made as of the date of this MD&A and the Company disclaims any intention or obligation to update publicly any such forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
All of the forward-looking information made in this MD&A are expressly qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company.
22
MANAGEMENTS DISCUSSION & ANALYSIS For the Three and Twelve Months Ended December 31, 2018 |
Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking information in this MD&A, and, accordingly, investors should not place undue reliance on any such forward-looking information. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for the Companys management to predict all of such factors, or changes in such factors, or to assess in advance the impact of each such factors on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information contained in this MD&A.
Other Disclosures
Trademarks
This MD&A includes trademarks that are protected under applicable intellectual property laws and are the property of the Company or its affiliates or licensors. Solely for convenience, the trademarks of the Company or its affiliates and/or licensors referred to in this MD&A may appear with or without the ® or symbol, but such references or the absence thereof are not intended to indicate, in any way, that the Company or its affiliates or licensors will not assert, to the fullest extent under applicable law, their respective rights to these trademarks. Any other trademarks used in this MD&A are the property of their respective owners.
Market Data
This MD&A contains certain statistical data, market research and industry forecasts that were obtained, unless otherwise indicated, from independent industry and government publications and reports or are based on estimates derived from such publications and reports and managements knowledge of, and experience in, the markets in which the Company operates. Industry and government publications and reports generally indicate that they have obtained their information from sources believed to be reliable, but do not guarantee the accuracy and completeness of their information. While the Company believes this data to be reliable, market and industry data is subject to variation and cannot be verified due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. The Company has not independently verified the accuracy or completeness of such information contained herein. In addition, projections, assumptions and estimates of the Companys future performance and the future performance of the industry in which the Company operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described under the heading Risk Factors in the Annual Information Form.
23
Form 52-109F1 - AIF |
Certification of Annual Filings |
In Connection with Voluntarily Filed AIF |
This Certificate is being filed on the same date that The Flowr Corporation (the issuer) has voluntarily filed an AIF.
I, Alexander Dann, Chief Financial Officer of issuer, certify the following:
1. |
Review: I have reviewed the AIF, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the annual filings) of issuer for the financial year ended December 31, 2018. |
2. |
No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the annual filings. |
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the annual filings. |
Date: April 4, 2019
Alexander Dann
Alexander Dann
Chief Financial Officer
NOTE TO READER | |
In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of | |
i) | controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and |
ii) | a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers GAAP. |
The issuers certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52- 109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation. | |
1
Form 52-109F1 - AIF |
Certification of Annual Filings |
In Connection with Voluntarily Filed AIF |
This Certificate is being filed on the same date that The Flowr Corporation (the issuer) has voluntarily filed an AIF.
I, Vinay Tolia, Co- Chief Executive Officer of issuer, certify the following:
1. |
Review: I have reviewed the AIF, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the annual filings) of issuer for the financial year ended December 31, 2018. |
2. |
No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the annual filings. |
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the annual filings. |
Date: April 4, 2019
Vinay Tolia
Vinay Tolia
Co- Chief Executive Officer
NOTE TO READER | |
In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of | |
i) | controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and |
ii) | a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers GAAP. |
The issuers certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52- 109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation. | |
1
Consolidated Financial Statements
For the years ended
December 31, 2018 and 2017
(in
Canadian dollars
1
Independent Auditor's Report |
To the Shareholders of The Flowr Corporation:
Opinion
We have audited the consolidated financial statements of The Flowr Corporation and its subsidiaries (the "Company"), which comprise the consolidated statements of financial position as at December 31, 2018 and December 31, 2017, and the consolidated statements of loss, changes in shareholders’ equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.
In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at December 31, 2018 and December 31, 2017, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.
Basis for Opinion
We conducted our audits in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audits of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Other Information
Management is responsible for the other information. The other information comprises Management’s Discussion & Analysis.
Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
In connection with our audits of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audits or otherwise appears to be materially misstated. We obtained Management’s Discussion and Analysis prior to the date of this auditor’s report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the consolidated financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
Those charged with governance are responsible for overseeing the Company’s financial reporting process.
Auditor's Responsibilities for the Audit of the Consolidated Financial Statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.
As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audits and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
The engagement partner on the audit resulting in this independent auditor's report is Sandra Alison Solecki.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
As at December 31, 2018 and 2017 |
(in Canadian dollars) |
December 31, 2018 | December 31, 2017 | ||||||||
ASSETS | Notes | ||||||||
Current Assets | |||||||||
Cash and cash equivalents | 27,689,183 | 7,749,699 | |||||||
Amounts receivable | 4 | 2,963,115 | 797,545 | ||||||
Prepaids and other current assets | 5, 15 | 913,468 | 152,013 | ||||||
Inventory | 6 | 1,398,943 | | ||||||
Biological assets | 7 | 497,102 | | ||||||
Loan receivable | 15 | | 25,000 | ||||||
33,461,811 | 8,724,257 | ||||||||
Non-Current Assets | |||||||||
Investments at fair value | 8 | 1,238,695 | 335,571 | ||||||
Property, plant and equipment | 9 | 23,326,017 | 9,279,237 | ||||||
Intangible assets | 10 | 3,056,728 | 3,112,803 | ||||||
Convertible loan receivable | 11 | 6,000,000 | | ||||||
Other long-term assets | 12 | 50,000 | 50,000 | ||||||
33,671,440 | 12,777,611 | ||||||||
TOTAL ASSETS | 67,133,251 | 21,501,868 | |||||||
LIABILITIES | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 13,15 | 4,604,727 | 1,928,898 | ||||||
Due to related parties | 15 | 63,217 | 27,562 | ||||||
Deferred revenue | 14 | 1,327,865 | | ||||||
Current portion of long-term debt | 14 | 287,502 | | ||||||
6,283,311 | 1,956,460 | ||||||||
Non-Current Liabilities | |||||||||
Long-term debt | 14 | 1,304,034 | | ||||||
TOTAL LIABILITIES | 7,587,345 | 1,956,460 | |||||||
SHAREHOLDERS' EQUITY | |||||||||
Share capital | 21 | 70,002,237 | 18,116,920 | ||||||
Other reserves | 18, 22 | (15,719,745 | ) | 601,536 | |||||
Deficit | (16,532,564 | ) | (1,131,266 | ) | |||||
Equity attributable to common shareholders of the Company | 37,749,928 | 17,587,190 | |||||||
Non-controlling interests | 26 | 21,795,978 | 1,958,218 | ||||||
TOTAL EQUITY | 59,545,906 | 19,545,408 | |||||||
TOTAL LIABILITIES AND EQUITY | 67,133,251 | 21,501,868 | |||||||
The accompanying notes are an integral part of the consolidated financial statements |
Approved by the Board of Directors | |||
Steve Klein (signed) | Karen Basian (signed) | ||
Director | Director |
THE FLOWR CORPORATION | 1 |
CONSOLIDATED STATEMENTS OF LOSS |
For the years ended December 31, 2018 and 2017 |
(in Canadian dollars, except per share amounts) |
Year ended | |||||||||
December 31, | |||||||||
2018 | 2017 | ||||||||
Notes | |||||||||
Revenue | 17 | 2,870,408 | | ||||||
Cost of sales | 3,260,799 | 258,038 | |||||||
Gross loss before fair value adjustments | (390,391 | ) | (258,038 | ) | |||||
Fair value adjustments on inventory sold | (499,793 | ) | | ||||||
Unrealized loss on changes in fair value of biological assets | 7 | 420,410 | | ||||||
(311,008 | ) | (258,038 | ) | ||||||
Selling and marketing | 1,266,320 | 29,400 | |||||||
General and administrative | 15 | 7,265,082 | 2,259,145 | ||||||
Research and development | 321,824 | | |||||||
Share-based compensation | 18 | 7,208,273 | 601,536 | ||||||
Listing expense | 3(a) | 1,802,830 | | ||||||
Design and construction income | 14 | (172,135 | ) | | |||||
Depreciation and amortization | 174,446 | | |||||||
Other income | 19 | (270,460 | ) | (342,784 | ) | ||||
Loss before income taxes | (17,907,188 | ) | (2,805,335 | ) | |||||
Net loss | (17,907,188 | ) | (2,805,335 | ) | |||||
Net loss attributable to: | |||||||||
Common shareholders of the Company | (15,401,298 | ) | (1,908,684 | ) | |||||
Non-controlling interests | 26 | (2,505,890 | ) | (896,651 | ) | ||||
Net loss | (17,907,188 | ) | (2,805,335 | ) | |||||
Loss per share attributable to common shareholders of the Company | |||||||||
-Basic | 23 | (0.22 | ) | (0.05 | ) | ||||
-Diluted | 23 | (0.22 | ) | (0.05 | ) |
The accompanying notes are an integral part of the consolidated financial statements
THE FLOWR CORPORATION | 2 |
CONSOLIDATED STATEMENTS OF CASH FLOWS |
For the years ended December 31, 2018 and 2017 |
(in Canadian dollars) |
Year ended | |||||||||
December 31, | |||||||||
2018 | 2017 | ||||||||
Notes | |||||||||
OPERATING ACTIVITIES | |||||||||
Net loss | (17,907,188 | ) | (2,805,335 | ) | |||||
Items not affecting cash and other adjustments | 24 | 9,918,097 | 345,295 | ||||||
Changes in non-cash working capital | 24 | (1,697,990 | ) | (136,291 | ) | ||||
Cash used in operating activities | (9,687,081 | ) | (2,596,331 | ) | |||||
INVESTING ACTIVITIES | |||||||||
Investments | 8 | (750,000 | ) | | |||||
Advance paid for private company investment | 12 | | (50,000 | ) | |||||
Loan advances | 11 | (6,000,000 | ) | (25,000 | ) | ||||
Expenditures on property, plant and equipment | (14,691,091 | ) | (8,040,595 | ) | |||||
Expenditures on intangible assets | (228,611 | ) | (16,307 | ) | |||||
Cash used in investing activities | (21,669,702 | ) | (8,131,902 | ) | |||||
FINANCING ACTIVITIES | |||||||||
Proceeds from shares issued | 21 | 51,064,925 | 13,748,032 | ||||||
Share issuance costs | 21 | (1,487,627 | ) | (134,791 | ) | ||||
Loan proceeds | 14 | 1,616,536 | | ||||||
Capital contributions to Partnership | 2.1(c) | | 3,750,000 | ||||||
Interest (paid) received | 102,433 | (663 | ) | ||||||
Cash provided from financing activities | 51,296,267 | 17,362,578 | |||||||
Increase in cash and cash equivalents | 19,939,484 | 6,634,345 | |||||||
Cash and cash equivalents, beginning of year | 7,749,699 | 1,115,354 | |||||||
Cash and cash equivalents, end of year | 27,689,183 | 7,749,699 |
The accompanying notes are an integral part of the consolidated financial statements
THE FLOWR CORPORATION | 3 |
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY |
For the years ended December 31, 2018 and 2017 |
(in Canadian dollars, expect for number of shares) |
Share Capital | Other reserves | |||||||||||||||||||||||||||||
Number of | Share | Partnership | Warrants | Contributed | Flowr ULC share | Non-controlling | ||||||||||||||||||||||||
shares | Capital | Interest | (note 22) | Surplus (note 18) | issuances | Interest (note 26) | Deficit | Total | ||||||||||||||||||||||
Notes | ||||||||||||||||||||||||||||||
Balance at January 1, 2017 | | | 1,692,010 | | | | 2,256,988 | | 3,948,998 | |||||||||||||||||||||
Net loss for the 11 months ended November 30, 2017 | | | (777,418 | ) | | | | (757,732 | ) | | (1,535,150 | ) | ||||||||||||||||||
Contributions into Partnership as of November 30, 2017 | | | 1,912,495 | | | | 1,837,505 | | 3,750,000 | |||||||||||||||||||||
Transfer of Partnership Interest to Flowr - the Reorganization | 2.1(c) | 35,775,000 | 2,827,087 | (2,827,087 | ) | | | | | | | |||||||||||||||||||
Issuance of shares for 20% acquisition of Flowr Okanagan | 3 | 10,000,000 | 1,239,624 | | | | | (1,239,624 | ) | | | |||||||||||||||||||
Equity Financing Dec 2017, net of share issue costs of $134,791 | 21 | 14,185,000 | 14,050,209 | | | | | | | 14,050,209 | ||||||||||||||||||||
Share-based compensation | 18 | | | | | 601,536 | | | | 601,536 | ||||||||||||||||||||
Net loss for the 1 month ended December 31, 2017 | | | | | | | (138,919 | ) | (1,131,266 | ) | (1,270,185 | ) | ||||||||||||||||||
Balance at December 31, 2017 | 59,960,000 | 18,116,920 | | | 601,536 | | 1,958,218 | (1,131,266 | ) | 19,545,408 | ||||||||||||||||||||
Equity financing Jan 2018, net of share issue costs of $30,037 | 815,000 | 784,963 | | | | | | | 784,963 | |||||||||||||||||||||
Financing Q2-Q3 2018,net of share issue costs of $59,220 | 5,309,361 | 13,745,119 | | | | | | | 13,745,119 | |||||||||||||||||||||
Share-based compensation | 18 | | | | | 7,208,273 | | | | 7,208,273 | ||||||||||||||||||||
Shares issued from exercise of stock options | 18 | 6,205,961 | 43,380 | | | | | | | 43,380 | ||||||||||||||||||||
Transferred from contributed surplus on exercise of options | | 1,770,846 | | | (1,770,846 | ) | | | | | ||||||||||||||||||||
RTO Financing, net of share issue cash costs of $1,398,369 & Broker warrants | 21 | 13,807,734 | 33,972,701 | | 529,038 | | | | | 34,501,739 | ||||||||||||||||||||
Amalgamation with Needle Capital Corp. | 3(a) | 590,769 | 1,535,999 | | 34,937 | 38,349 | | | | 1,609,285 | ||||||||||||||||||||
Shares issued from exercise of warrants | 22 | 11,481 | 14,927 | | | | | | | 14,927 | ||||||||||||||||||||
Valuation transferred from warrants on exercise | 22 | | 17,382 | | (17,382 | ) | | | | | | |||||||||||||||||||
Other changes in non-controlling interest | 26 | | | | | | (22,343,650 | ) | 22,343,650 | | | |||||||||||||||||||
Net loss for the year ended December 31, 2018 | | | | | | | (2,505,890 | ) | (15,401,298 | ) | (17,907,188 | ) | ||||||||||||||||||
Balance at December 31, 2018 | 86,700,306 | 70,002,237 | | 546,593 | 6,077,312 | (22,343,650 | ) | 21,795,978 | (16,532,564 | ) | 59,545,906 |
The accompanying notes are an integral part of the consolidated financial statements
THE FLOWR CORPORATION | 4 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years ended December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
1. |
CORPORATE INFORMATION |
The Flowr Corporation, formerly known as The Needle Capital Corp. (the Company), is a publicly traded, cannabis cultivation company that was incorporated under the Business Corporations Act (Alberta) (ABCA) on June 1, 2016. On September 25, 2018, the Company continued from the ABCA to the Business Corporations Act (Ontario) as part of the completion of the Qualifying Transaction (defined below). The Head Office of the Company is located at 461 King Street West, Suite 200, Toronto, Ontario, M5V 1K4. The principal activity of the Company is the production and sale of premium cannabis in Canada, with a focus on the natural science of cannabis. In December 2017, through its subsidiary The Flowr Group (Okanagan) Inc. (Flowr Okanagan), formerly Cannatech Plant Systems Inc., the Company received its license from Health Canada to operate as a licensed producer, under the provisions of Access to Cannabis for Medical Purposes Regulations. On August 10, 2018, Flowr Okanagan received its sales license from Health Canada, allowing the Company to sell to the Canadian medical market and to the adult-use recreational (recreational) market post legalization on October 17, 2018. The Companys common shares are listed on the TSX Venture Exchange (the Exchange), under the trading symbol FLWR.
The Company, was previously classified as a Capital Pool Company (CPC) as defined in Policy 2.4 of the Exchange. The principal business of the Company as a CPC was to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein by completing a purchase transaction. The purpose of such an acquisition was to satisfy the related conditions of a qualifying transaction under the Exchange rules (Qualifying Transaction).
On September 21, 2018, the Company completed its Qualifying Transaction pursuant to a business combination agreement between the Company, 2652253 Ontario Inc. and a private corporation called The Flowr Corporation (Flowr PrivateCo) the (Business Combination Agreement). As a part of the Qualifying Transaction, the Company changed its name from The Needle Capital Corp. to The Flowr Corporation and consolidated its 7,679,997 common shares on a 13:1 basis to 590,769 common shares. In connection with the Qualifying Transaction, Flowr PrivateCo exchanged its shares for all of the issued and outstanding shares of the Company with the former shareholders of Flowr PrivateCo receiving a total of 85,692,095 post-consolidation common shares. Immediately following closing of the Qualifying Transaction, the Company had a total of 86,282,864 issued and outstanding common shares.
Upon closing of the Qualifying Transaction, the shareholders of Flowr PrivateCo owned 99.3% of the common shares of the Company, and as a result, the Qualifying Transaction is considered a reverse acquisition of the Company by Flowr PrivateCo (RTO). For accounting purposes, Flowr PrivateCo is considered to be the acquirer and the Company is considered to be the acquiree. Accordingly, these consolidated financial statements are a continuation of the consolidated financial statements of Flowr PrivateCo, henceforth referred to as Flowr as applicable (note 3(a)).
On December 1, 2017, FlowCo Services LP and FlowCo Investments LP collectively FlowCo, legal entities under common control, completed a corporate reorganization (the Reorganization). Prior to the Reorganization, Flowr PrivateCo and a new subsidiary called The Flowr Canada Holdings ULC (Flowr ULC) were incorporated. As a result of the Reorganization, all assets and liabilities held in FlowCo including its 80% ownership of Flowr Okanagan were rolled into the Flowr ULC and a resulting non-controlling interest in the Flowr ULC was established. (note 2.1(c)) .
As at December 31, 2018, Flowrs consolidated financial statements include Flowr and its subsidiary companies (collectively, the Company). Flowrs principal subsidiaries include, a 66.3% (December 31, 2017 - 57.6%) ownership of Flowr ULC, which owns, 100% of Flowr Okanagan.
THE FLOWR CORPORATION | 5 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
2.1 |
BASIS OF PREPARATION |
(a) |
Statement of compliance |
The Companys consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB) and Interpretations of the International Financial Reporting Interpretations Committee (IFRIC) which the Canadian Accounting Standards Board has approved for incorporation into Part I of the Chartered Professional Accountants of Canada Handbook Accounting. These consolidated financial statements were approved by the Board of Directors on April 3, 2019.
(b) |
Basis of measurement |
These consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments (note 2.2) that are measured at fair value.
(c) |
Corporate reorganization |
On December 1, 2016, 80% of the outstanding shares of Cannatech Plant Systems Inc. (now operating as Flowr Okanagan) were acquired by FlowCo (note 3). On December 1, 2017, FIowCo completed the Reorganization, whereby the net assets of each FlowCo entity were rolled over into Flowr ULC in exchange for 35,775,000 common shares and 44,100,000 class A preferred shares of Flowr ULC. The holders of the 35,775,000 Flowr ULC common shares were immediately exchanged for 35,775,000 common shares in Flowr. The Flowr ULC class A preferred shares provide the shareholders thereof with a right to exchange these shares for common shares of the Company at any point in time. As the right to exchange was not exercised as a part of the Reorganization, a 49.1% non-controlling interest in Flowr ULC was established on the close of the Reorganization. In the event that the Company issues additional common shares, a corresponding amount of Flowr ULC common shares are required to be issued from Flowr ULC to the Company.
Concurrently on December 1, 2017, Flowr acquired the remaining 20% ownership of Cannatech Plant Systems Inc. in exchange for 10,000,000 common shares of Flowr. The 20% ownership interest was then acquired by Flowr ULC in exchange for common shares of Flowr ULC, resulting in Flowr ULC owning a 100% interest in Cannatech Plant Systems Inc.
The consolidated financial statements are prepared under the name of The Flowr Corporation based on the post-Reorganization structure as of December 31, 2017 and are a continuation of the consolidated financial statements of FlowCo.
(d) |
Basis of consolidation |
Subsidiaries are entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.
The Company uses the acquisition method of accounting to account for business combinations. The fair value of the acquisition of a subsidiary is based on the fair value of the assets acquired, the liabilities assumed, and the fair value of the consideration. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values on the acquisition date. The excess, if any, of the consideration over the fair value of the identifiable net assets acquired is recorded as goodwill.
THE FLOWR CORPORATION | 6 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
For acquisitions that do not meet the definition of a business under IFRS, the Company follows International Accounting Standard (IAS) 16 and IAS 38 guidelines for asset acquisition, where the consideration paid is allocated to assets acquired based on fair values on the acquisition date and transactions costs are capitalized and allocated to the assets acquired.
Subsidiaries are fully consolidated from the date on which control is acquired by the Company and they are deconsolidated from the date that control ceases. The financial statements of the subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies. All inter-company balances, revenues and expenses and earnings and losses resulting from inter-company transactions are eliminated on consolidation.
Non-controlling interests in the net assets of consolidated subsidiaries are a separate component of the Companys equity. Non-controlling interests consist of the non-controlling interests on the date of the original acquisition plus the non-controlling interests share of changes in equity since the date of acquisition. Changes in the Companys interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.
(e) |
Critical accounting estimates and judgments |
The preparation of the Companys consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities and contingent liabilities on the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are evaluated and are based on managements experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates.
The significant areas of estimation and/or judgment considered by management in preparing the consolidated financial statements include, but are not limited to:
| Biological assets (note 2.2(a)(i)); | |
| Revenue recognition (note 2.2(b)); | |
| Fair value of certain financial instruments (note 2.2(c)); | |
| Property, plant and equipment (note 2.3(c)); | |
| Intangible assets (note 2.3(d)); | |
| Share-based compensation (note 2.3(k)); | |
| Deferred income tax assets and liabilities (note 2.3(l)) |
(f) |
Presentation and functional currency |
These consolidated financial statements are presented in Canadian dollars, which is also the functional currency of the Company and its subsidiaries.
THE FLOWR CORPORATION | 7 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
2.2 |
CHANGES IN ACCOUNTING POLICES |
(a) On July 1, 2018, the Company changed its accounting policy with respect to production costs related to biological assets. Prior to this change, the Company expensed any costs related to the production of biological assets. The Company now capitalizes production costs related to biological assets and recognizes the expense in cost of sales as the inventory is sold. This change in policy will more accurately reflect the true costs of production related to the revenues earned in the period. Non-recurring start-up costs are expensed directly through cost of sales. Fulfillment charges and any related depreciation are expensed to cost of goods sold in the period in which the costs are incurred. The Company also revised its presentation in the consolidated statement of loss to separate fair value adjustments for both biological assets and inventory sold in the period. The amended policy is as follows:
(i) |
Biological assets |
While the Companys biological assets, consisting of cannabis plants, are within the scope of IAS 41 Agriculture, the direct and indirect costs of biological assets are determined using an approach similar to the capitalization criteria outlined in IAS 2 Inventories. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs, grow consumables, utilities, facilities costs including an allocation of overhead costs related to production facility, quality and testing costs, and production related depreciation. Capitalized costs are subsequently recorded within cost of sales in the consolidated statements of loss in the period that the related product is sold.
The Company measures biological assets, at fair value less cost to sell up to the point of harvest. Unrealized gains or losses arising from the changes in fair value less cost to sell during the period are separately recorded in the consolidated statement of loss for the related period. Cost to sell includes post harvest production costs and fulfilment costs.
The Company commenced cultivating cannabis in January 2018. Biological assets were measured at a fair value of nil in reporting periods prior to the Company obtaining its sales license on August 10, 2018. All capitalized costs related to biological assets were expensed through changes in fair value of biological assets.
(ii) |
Inventory |
Inventory of harvested bulk cannabis and finished goods are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour related costs, consumables, packaging supplies, facilities costs including an allocation of overhead costs related to production facility, quality and testing costs, and related depreciation. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Supplies and consumables are valued at the lower of costs and net realizable value, with cost determined based on an average cost basis.
The change in accounting policy has been applied retrospectively. As there were no biological assets and cannabis inventory in 2017, comparatives were not impacted by this change in policy. However, the presentation of production costs in 2017 is now captured as cost of sales in the comparative period.
THE FLOWR CORPORATION | 8 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
The change in policy noted in (i) and (ii) above will impact the previously reported periods in 2018. The following table summarize the effects of the change described above for the six months ended June 30, 2018.
Condensed interim consolidated statement of loss | As previously | As | |||||||
For the six months ended June 30, 2018 | reported | Adjustments | Restated | ||||||
Cost of sales (formerly Production costs) | 1,747,849 | (847,100 | ) | 900,7491 | |||||
Unrealized losses on changes in fair value of biological assets | | 847,100 | 847,100 |
1 Included in cost of sales was an impairment of $169,157 in inventory to net realizable value of $Nil as the Company did not have the ability to sell cannabis at the time. |
Condensed interim consolidated statement of cash flows | As previously | As | |||||||
For the six months ended June 30, 2018 | reported | Adjustments | Restated | ||||||
Items not affecting cash | 2,003,177 | 1,014,257 | 3,017,434 | ||||||
Changes in non-cash working capital | 913,234 | (1,014,257 | ) | (101,023 | ) |
(b) |
Revenue recognition |
The Company adopted IFRS 15, Revenue from Contracts with Customers, in the fourth quarter of 2018 upon commencement of cannabis sales. Revenue from the sale of cannabis is recognized when control has been transferred, which is considered to occur when products have been delivered to the location specified in the sales contract and accepted by the customer. Revenue is measured based on the consideration specified in the contract taking into account any variation that may result from rights of return.
The Company is required to remit excise tax to the Canada Revenue Agency on the sale of medical and recreational cannabis in Canada. The Company becomes liable for these excise duties when cannabis products are delivered to the customer. In accordance with IFRS 15, revenue presented on the Consolidated Statements of Loss, represents revenue from the sale of goods less applicable excise tax.
Design and construction income relating to construction services are recognized over a period of time as performance obligations are completed.
Significant areas of judgement include (i) identifying the customer under the definition of IFRS 15 (ii) estimating returns on product sold and, (iii) assessment of whether control has passed to the customer based on criteria established in IFRS 15.
(c) |
Financial instruments |
Effective January 1, 2018, the Company adopted IFRS 9, Financial Instruments. In accordance with the transitional provisions, the Company adopted the standard retrospectively without restating comparatives as the change did not impact the opening balances.
THE FLOWR CORPORATION | 9 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
IFRS 9 replaces IAS 39, Financial Instruments: Recognition and Measurement. IFRS 9 introduces new requirements for the classification, measurement and impairment of financial assets and hedge accounting. It establishes two primary measurement categories for financial assets: (i) amortized cost and (ii) fair value either through profit or loss (FVPL) or through other comprehensive income (FVOCI); establishes criteria for the classification of financial assets within each measurement category based on business model and cash flow characteristics; and eliminates the existing held for trading, held to maturity, available for sale, loans and receivable and other financial liabilities categories. IFRS 9 also introduces a new expected credit loss model for the purpose of assessing the impairment of financial assets.
The following table shows the previous classification under IAS 39 and the new classification under IFRS 9 for the Companys financial instruments:
Financial Instrument Classification | ||||||
Under IAS 39 | Under IFRS 9 | |||||
Financial assets | ||||||
Cash | Loans and receivables | Amortized cost | ||||
Amounts receivable | Loans and receivables | Amortized cost | ||||
Deposits recoverable | Loans and receivables | Amortized cost | ||||
Loan receivable | Loans and receivables | Amortized cost | ||||
Plant Properties warrants | Held for trading | FVPL | ||||
Financial liabilities | ||||||
Accounts payable and accrued liabilities | Other financial liabilities | Amortized cost | ||||
Due to related parties | Other financial liabilities | Amortized cost |
The following are the Companys new accounting policies for financial instruments under IFRS 9:
Financial assets and liabilities
Financial assets
Non-derivative financial assets within the IFRS 9 are classified as financial assets at fair value (either through FVOCI or through FVPL), and financial assets at amortized costs as appropriate. The Company determines the classification of its financial assets at initial recognition based on the Companys business model and contractual terms of cash flows.
All financial assets are recognized initially at fair value plus, in the case of investments not at FVPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instrument.
Where the fair values of financial assets recorded on the consolidated statement of financial position cannot be derived from active markets, they are determined using a variety of valuation techniques. The inputs to these models are derived from observable market data where possible, but where observable market data are not available, judgment is required to establish fair values.
THE FLOWR CORPORATION | 10 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Financial assets at FVPL
Financial assets measured at FVPL include financial assets management intends to sell and any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial assets measured at FVPL are carried at fair value in the consolidated statements of financial position with changes in fair value recognized in other income or expense in the consolidated statements of earnings (loss). The Companys investment in Plant Properties Corp. (Plant Properties) warrants and Seven Leaf Venture Corp (Seven Leaf) warrants are classified as financial assets at FVPL.
Financial assets at FVOCI
Financial assets measured at FVOCI are non-derivative financial assets that are not held for trading and the Company has made an irrevocable election at the time of initial recognition to measure the assets at FVOCI. The Companys investment in Ace Hill Beer Company (Ace Hill) is classified as FVOCI.
After initial measurement, investments measured at FVOCI are subsequently measured at fair value with unrealized gains or losses recognized in other comprehensive income or loss in the consolidated statements of comprehensive income (loss). When the investment is sold, the cumulative gain or loss remains in accumulated other comprehensive income or loss and is not reclassified to profit or loss.
Derecognition
A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the asset.
Impairment of financial assets
The impairment model under IFRS 9 is applicable to financial assets measured at amortized cost where any expected future credit losses are provided for, irrespective of whether a loss event has occurred as at the reporting date. The Companys only financial assets subject to impairment are amounts receivable and convertible loan receivable, which are measured at amortized cost. The Company has elected to apply the simplified approach to impairment as permitted by IFRS 9, which requires the expected lifetime loss to be recognized at the time of initial recognition of the receivable. An impairment loss is reversed in subsequent periods if the amount of the expected loss decreases and the decrease can be objectively related to an event occurring after the initial impairment was recognized. The Company has measured the lifetime expected credit losses taking into consideration historical credit loss experience and financial factors specific to debtors and other relevant factors.
Financial liabilities
Non-derivative financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVPL. The Companys financial liabilities include accounts payable and accrued liabilities, amounts due to related parties and debt which are each measured at amortized cost.
All financial liabilities are recognized initially at fair value and in the case of loans and borrowings, net of directly attributable transaction costs.
THE FLOWR CORPORATION | 11 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Financial liabilities at amortized cost
After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate (EIR) method. Amortized cost is calculated by taking into account any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. The EIR amortization is included in finance cost in the consolidated statements of earnings (loss).
Derecognition
A financial liability is derecognized when the obligation under the liability is discharged, cancelled or expires with any associated gains or losses reported in other income or expense in the consolidated statements of earnings (loss).
2.3 |
SIGNIFICANT ACCOUNTING POLICIES |
(a) |
Cash and cash equivalents |
Cash and cash equivalents comprise cash deposits and/or other highly rated and liquid securities with an original maturity of less than three months.
(b) |
Foreign currency |
Foreign currency transactions
Monetary assets and liabilities denominated in foreign currencies are translated into Canadian dollars at exchange rates on the reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are translated at the exchange rates on the dates that their fair values are determined. Non-monetary assets and liabilities denominated in foreign currencies that are measured at historical cost are translated at the exchange rates on the dates of the transactions. Income and expense items are translated at the exchange rate on the dates of the transactions. Exchange gains and losses resulting from the translation of these amounts are included in net loss.
(c) |
Property, plant and equipment |
Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment charges.
The initial cost of property, plant and equipment comprises its purchase price or construction cost and any costs directly attributable to bringing it to a working condition for its intended use. The purchase price or construction cost is the aggregate amount of cash consideration paid and the fair value of any other consideration given to acquire the asset. Where an item of property, plant and equipment is comprised of significant components with different useful lives, the components are accounted for as separate items of property, plant and equipment.
Depreciation
For all property, plant and equipment, depreciation is based on the estimated useful life of the asset on a straight-line basis starting from the date it is available for use.
THE FLOWR CORPORATION | 12 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
The estimated useful lives for the current and comparative years are as follows:
Estimated useful life | |||
Asset Category | (Years) | ||
Leasehold improvements | Term of TFGOK facility lease | ||
Production equipment | 5-10 years | ||
Mechanical equipment | 5-10 years | ||
Electrical equipment | 5-10 years | ||
Office equipment and furniture | 5 years | ||
Computer and IT equipment | 3-5 years |
Construction-in-progress includes property, plant and equipment in the course of construction and is carried at cost less any recognized impairment charge. These assets are reclassified to the appropriate category of property, plant and equipment and depreciation of these assets commences when they are completed and ready for their intended use.
An item of property, plant and equipment, including any significant part initially recognized, is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in net loss when the asset is derecognized.
The residual values, useful lives and methods of depreciation of all assets are reviewed at each financial year end and are adjusted prospectively, if appropriate. Significant judgment is involved in the determination of estimated residual values and useful lives and no assurance can be given that actual residual values and useful lives will not differ significantly from current estimates.
(d) |
Intangible assets |
Intangible assets include costs related to obtaining Health Canada licenses. Intangible assets acquired separately are measured upon initial recognition at cost, which comprises the purchase price plus any costs directly attributable to the preparation of the asset for its intended use. Intangible assets acquired through business combinations or asset acquisitions are initially recognized at fair value as at the date of acquisition. Subsequent to initial recognition, intangible assets are carried at cost less accumulated amortization and any accumulated impairment charges.
All intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:
Estimated useful life | |||
Asset Category | (Years) | ||
Health Canada license | Term of TFGOK facility lease | ||
Website development | 2 years | ||
Software | 3 years |
Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the intangible assets require the use of estimates and assumptions and are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense attributable to an intangible asset is recognized in the consolidated statements of loss in the expense category consistent with the function of the intangible asset.
THE FLOWR CORPORATION | 13 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
The gain or loss arising from the derecognition of an intangible asset is measured as the difference between the net disposal proceeds and the carrying amount of the asset and is recognized in net loss when the asset is derecognized.
(e) |
Impairment of non-financial assets |
The carrying value of property, plant and equipment and intangible assets are assessed for impairment at each statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. Events or changes in circumstances which may indicate impairment include: a significant change to the Companys operations, significant decline in performance, or a change in market conditions which adversely affect the Company. The recoverable amount is determined as the higher of the fair value less costs of disposal (FVLCD) and its value in use based on discounted cash flows.
For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs to sell, and its value in use. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the recoverable amount. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded.
(f) |
Provisions and contingencies |
General
Provisions are recognized when: a) the Company has a present obligation (legal or constructive) as a result of a past event; and b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made for the amount of the obligation. If the effect of the time value of money is material, provisions are discounted using a current pre-tax discount rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision as a result of the passage of time is recognized in finance cost in the consolidated statements of loss.
A contingent liability is not recognized in the case where no reliable estimate can be made; however, disclosure is required unless the possibility of an outflow of resources embodying economic benefits is remote. By its nature, a contingent liability will only be resolved when one or more future events occur or fail to occur. The assessment of a contingent liability inherently involves the exercise of significant judgment and estimates of the outcome of future events.
(g) |
Offsetting of financial instruments |
Financial assets and financial liabilities are offset if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the assets and settle the liabilities simultaneously.
THE FLOWR CORPORATION | 14 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
(h) |
Deferred revenue |
Deferred revenue is recognized in the consolidated statements of financial position when a cash prepayment is received from one or more customers prior to the sale of product or delivery of service. Revenue is subsequently recognized in the consolidated statements of loss when the sale occurs, which generally occurs when control has been transferred or in the case of services, when the services have been rendered.
(i) |
Leases |
The determination of whether an arrangement is, or contains, a lease is based on the substance of the agreement on the inception date.
Finance leases
Finance leases which transfer substantially all the risks and rewards incidental to ownership of the leased item to the Company as a lessee, are capitalized at the inception of the lease at the fair value of the leased asset, or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and the reduction of the lease liability. Finance charges are recognized in finance cost in the consolidated statements of loss.
Capitalized leased assets are depreciated over the shorter of the estimated useful life of the asset and the lease term, if there is no reasonable certainty that the Company will obtain ownership by the end of the term of the lease. As of December 31, 2018, the Company did not have any finance leases.
Operating leases
Leases that do not transfer substantially all the risks and rewards incidental to ownership to the Company as a lessee are classified as operating leases. Operating lease payments are recognized as an expense in the consolidated statements of loss on a straight-line basis over the lease term.
(j) |
Research and development |
Research costs are expensed as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized in profit or loss as incurred. To date, no development costs have been capitalized.
(k) |
Share-based compensation |
The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Companys estimate of equity instruments that will eventually vest. Stock options are measured on the date of grant by reference to the fair value determined using a Black-Scholes valuation model, further details of which are given in note 18. The value is recognized as share-based compensation expense in the consolidated statements of loss and an increase to contributed surplus in the consolidated statements of changes in shareholders equity over the period in which the performance and/or service conditions are fulfilled.
For share-based payments granted to non-employees the compensation expense is measured at the fair value of the goods and services received except where the fair value cannot be estimated in which case it is measured at the fair value of the equity instruments granted.
THE FLOWR CORPORATION | 15 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Consideration paid by employees or non-employees on the exercise of stock options is recorded as share capital and the related share-based compensation is transferred from contributed surplus to share capital.
The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.
(l) |
Income taxes |
Current income tax
Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities on the taxable loss or income for the period. The tax rates and tax laws used to compute the amount are those enacted or substantively enacted by the end of the reporting period.
Current income tax assets and current income tax liabilities are only offset if a legally enforceable right exists to offset the amounts and the Company intends to settle on a net basis or to realize the asset and settle the liability simultaneously.
Deferred income tax
Deferred income tax is provided using the balance sheet method on temporary differences on the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred income tax liabilities are recognized for all taxable temporary differences. Deferred income tax assets are recognized for all deductible temporary differences, and the carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable income will be generated in future periods to utilize these deductible temporary differences.
The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient future taxable income will be generated to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are reassessed at the end of each reporting period and are recognized to the extent that it has become probable that future taxable income will be generated to allow the deferred income tax asset to be recovered.
Deferred income tax assets and liabilities are measured at the tax rates that are expected to be in effect in the period when the asset is expected to be realized or the liability is expected to be settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred income tax assets and liabilities are offset if a legally enforceable right exists to offset current income tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.
Judgment is required in determining whether deferred income tax assets and liabilities are recognized on the consolidated statements of financial position. Deferred income tax assets, including those arising from unutilized tax losses, require management to assess the likelihood that the Company will generate future taxable income in order to utilize the deferred income tax assets. Estimates of future taxable income are based on forecasted cash flows from operations or other activities. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred income tax assets recorded on the reporting date could be impacted.
THE FLOWR CORPORATION | 16 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
(m) |
Earnings per share |
Basic earnings per share is computed by dividing the net earnings available to common shareholders by the weighted average number of shares outstanding during the reporting period.
Diluted earnings per share reflects the potential dilution that could occur if additional common shares are assumed to be issued under securities that entitle their holders to obtain common shares in the future. The number of additional shares for inclusion in diluted earnings per share is determined using the treasury stock method, whereby stock options and warrants, whose exercise price is less than the average market price of the Companys common shares, are assumed to be exercised at the beginning of the period with proceeds based on the average market price for the period. The incremental number of common shares issued under stock options is included in the calculation of diluted earnings per share.
2.3 |
NEW STANDARDS NOT YET ADOPTED |
IFRS 16, Leases
IFRS 16, issued in January 2016, replaces IAS 17. Leases IFRS 16 results in most leases being reported on the statement of financial position for lessees, eliminating the distinction between a finance lease and an operating lease. The standard is expected to impact the accounting for the Companys operating leases, which are currently reflected in the consolidated statements of loss and in the Companys disclosure in respect of future commitments. Under IFRS 16, all operating leases, except for short term and low value leases, are expected to be accounted for as finance leases. As a result, the leased assets and the associated obligations are recognized in the consolidated statements of financial position. The leased assets will be depreciated over the shorter of the estimated useful life of the asset and the lease term. The lease payments are apportioned between finance charges and a reduction of the lease liability. The current operating lease expense will be replaced with a depreciation charge on the leased assets and a finance charge on the lease liability, which are in aggregate expected to result in a higher total periodic expense in the earlier periods of the lease.
IFRS 16 is effective for annual periods beginning on or after January 1, 2019. The Company has reviewed all leases to determine and document the expected changes associated with the adoption of IFRS 16. Upon adoption of IFRS 16, all existing operating leases with a term greater than 1 year, will be recognized as a leased asset and the associated obligation will be recorded.
3. |
SIGNIFICANT TRANSACTIONS |
(a) |
Reverse Acquisition |
On September 21, 2018, the Company, then operating as The Needle Capital Corp. (Needle) completed its Qualifying Transaction, pursuant to the Business Combination Agreement. Through the Qualifying Transaction, Needle acquired all the issued and outstanding common shares of Flowr PrivateCo through a three-cornered amalgamation, whereby Flowr amalgamated with 2652253 Ontario Inc., a subsidiary of Needle into a newly formed entity. On January 1, 2019, the amalgamated entity was amalgamated into The Flowr Corporation. The resulting legal entities are The Flowr Corporation, Flowr ULC and Flowr Okanagan.
THE FLOWR CORPORATION | 17 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
The Qualifying Transaction was a reverse acquisition of Needle and has been accounted for under IFRS 2, Share-based Payments. As a result, the transaction has been accounted for at the fair value of equity instruments issued by the Company to the option holders, warrant holders and shareholders of Needle holding such equity instruments as of the date of the Qualifying Transaction. The difference between the fair value of equity instruments issued and the net assets acquired has been recognized as a listing expense in the consolidated statements of loss for the year ended December 31, 2018. Additional legal and professional fees of $402,610 were incurred to complete the transaction.
The following table represents the fair value of the net assets acquired and the total consideration transferred upon closing of the Qualifying Transaction:
Fair value of shares issued (590,769 shares) | 1,535,999 | ||
Fair value of warrants issued (23,077 warrants) | 34,937 | ||
Fair value of options issued (18,461 options) | 38,349 | ||
Total consideration transferred | 1,609,285 | ||
Net assets acquired (Cash) | 209,065 | ||
Excess attributed to cost of listing | 1,400,220 | ||
Legal and other professional fees | 402,610 | ||
Listing expense | 1,802,830 |
The warrants and options were valued using the Black-Scholes pricing model. The inputs used in the measurement of the fair value of the option and warrants granted were as follows:
Options | Warrants | |||||
Risk free interest rate | 2.33 | % | 2.02 | % | ||
Expected life in years | 5 | 1 | ||||
Expected volatility | 90 | % | 90 | % | ||
Dividends per share | | |
(b) |
Acquisition of Cannatech Plant Systems (now operating as Flowr Okanagan) |
On December 1, 2016, Flowr acquired an 80% ownership in Cannatech Plant Systems Inc., now operating as The Flowr Group (Okanagan) Inc. Total consideration paid to acquire the net assets of Flowr Okanagan amounted to $2,536,804 which includes transaction costs of $136,804.
On December 1, 2017, through the Reorganization (note 2.1(c)), Flowr acquired the remaining 20% ownership in Flowr Okanagan in exchange for 10,000,000 common shares of Flowr. The 20% ownership interest was then acquired by Flowr ULC from Flowr in exchange for common shares of Flowr ULC, resulting in Flowr ULC owning a 100% interest in Flowr Okanagan. As this does not result in a change of control, the acquired assets and liabilities remain at their carrying values. The fair value of consideration paid was comparable to the carrying value of the assets acquired.
THE FLOWR CORPORATION | 18 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
4. |
AMOUNTS RECEIVABLE |
December 31, | December 31, | |||||
2018 | 2017 | |||||
Accounts receivable | 2,507,577 | 41,386 | ||||
GST HST receivable | 455,538 | 268,991 | ||||
Subscription receivable | | 487,168 | ||||
2,963,115 | 797,545 |
5. |
PREPAIDS AND OTHER CURRENT ASSETS |
December 31, | December 31, | |||||
2018 | 2017 | |||||
Prepaid expenses | 552,948 | 56,122 | ||||
Deposits recoverable | 360,520 | | ||||
Due from related parties (note 15) | | 95,891 | ||||
913,468 | 152,013 |
6. |
INVENTORY |
Capitalized | Biological asset fair | Carrying | |||||||
costs | valuation adjustment | value | |||||||
Harvested cannabis | |||||||||
Work in process | 945,211 | 40,776 | 985,987 | ||||||
Finished goods | 199,650 | (68,256 | ) | 131,394 | |||||
1,144,861 | (27,480 | ) | 1,117,381 | ||||||
Supplies and consumables | 281,562 | | 281,562 | ||||||
Balance as at December 31, 2018 | 1,426,423 | (27,480 | ) | 1,398,943 |
During the year ended December 31, 2018, there was no impairment of inventory.
For the year ended December 31, 2018, the Company capitalized $254,942 (2017 nil) of depreciation and amortization to harvested cannabis inventory and expensed $465,844 (2017 nil) capitalized inventory costs to cost of sales.
THE FLOWR CORPORATION | 19 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
7. |
BIOLOGICAL ASSETS |
Biological assets consist of cannabis of plants. The changes in the carrying value of biological assets are as follows:
Balance at December 31, 2017 | | ||
Production costs capitalized | 2,652,926 | ||
Changes in fair value less cost to sell due to biological transformation | (420,410 | ) | |
Transferred to inventory upon harvest | (1,735,414 | ) | |
Balance as at December 31, 2018 | 497,102 |
The Company measures its biological assets at their fair value less costs to sell. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Companys method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
The following table quantifies each significant unobservable input, and provides the impact a 10% increase/decrease in each input would have on the fair value of biological assets:
As at December 31, 2018 | |||||||||
Assumptions: | Input | 10% change | |||||||
(i) | Weighted average of expected loss of plants until harvest (a) | 16% | $ | 6,428 | |||||
(ii) | Expected yields for cannabis plants | 13.46 | |||||||
(average grams per plant) | grams dry flower | ||||||||
4.11 | |||||||||
grams dry trim | $ | 49,710 | |||||||
(iii) | Weighted average number of growing weeks completed as a percentage of total growing weeks as at year end | 50% | $ | 49,710 | |||||
(iv) | Estimated selling price (per gram) (b) | $ | 6.98 | ||||||
for dry flower | |||||||||
$ | 0.88 | ||||||||
for dry trim | $ | 82,035 | |||||||
(v) | After harvest cost to complete and sell (per gram) | $ | 2.73 | $ | 35,854 | ||||
(vi) | Reasonable margin on after harvest costs to complete and sell (per gram) | $ | 0.25 | $ | 3,259 |
(a) |
Weighted average of expected loss of plants until harvest represents loss via plants that do not survive to the point of harvest. It does not include any financial loss on a surviving plant. |
THE FLOWR CORPORATION | 20 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
(b) |
The estimated selling price (per gram) represents the average contractual sales price for the Companys various strains sold as recreational products or expected selling price in recreational and medical market for strains with no contractual sales price. |
The Company obtained its sales license in August 2018. Prior to obtaining its sales license, the fair value of biological assets was determined to be nil.
These estimates are subject to volatility in market prices and a number of uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.
The Company estimates the harvest yields for medical cannabis at various stages of growth. As of December 31, 2018, it is expected that the Companys cannabis plants biological assets will yield approximately 239,406 grams of dry cannabis and 73,115 grams of dry trim when harvested.
The Companys estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the gain or loss on biological assets in future periods.
For the year December 31, 2018, the Company capitalized $104,586 (2017 - nil) of depreciation and amortization expense to biological assets.
8. |
FINANCIAL INSTRUMENTS |
Set out below is a comparison, by category, of the carrying amounts of the Companys financial instruments that are recognized in the consolidated statements of financial position:
The carrying values of all the financial assets and liabilities measured at amortized cost approximate their fair values as at December 31, 2018 and December 31, 2017.
Carrying Amount | |||||||||
Financial Instrument | December 31, | December 31, | |||||||
Classification | 2018 | 2017 | |||||||
Financial assets | |||||||||
Cash | Amortized cost | 27,689,183 | 7,749,699 | ||||||
Amounts receivable | Amortized cost | 2,963,115 | 797,545 | ||||||
Deposits recoverable | Amortized cost | 360,520 | | ||||||
Loan receivable | Amortized cost | | 25,000 | ||||||
Investment in private securities - shares | FVOCI | 750,000 | | ||||||
Investment in private securities - warrants | FVPL | 488,695 | 335,571 | ||||||
Convertible loan receivable | FVPL | 6,000,000 | | ||||||
Financial liabilities | |||||||||
Accounts payable and accrued liabilities | Amortized cost | 4,604,727 | 1,928,898 | ||||||
Due to related parties | Amortized cost | 63,217 | 27,562 | ||||||
Debt | Amortized cost | 1,591,536 | |
THE FLOWR CORPORATION | 21 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Investments private securities Shares
On October 10, 2018, the Company acquired 319,149 shares of Ace Hill at a cost of $750,000. As Ace Hill is not a listed public company, the valuation of the shares at the time of issuance was based on a discounted projected cash flow model. As of December 31, 2018, the Company re-assessed the fair value of the shares based on the projected cash flow model and concluded there were no significant changes in fair value. As of December 31, 2018, the cost of the investment approximated the fair value. No adjustments in fair value were reported through other comprehensive income.
Investments private securities Warrants
(i) |
Plant Properties Warrants |
On December 31, 2018, the Companys 1,500,000 warrants in Plant Properties were terminated. Each warrant was exercisable into one common share of Plant Properties any time prior to June 13, 2019, at an exercise price of $0.50 per common share. For the year ended December 31, 2018, the Company recognized a realized loss on Plant Properties warrants of $335,571 (2017 unrealized gain $207,194) in other income (note 19) in the Consolidated Statements of Loss.
(ii) |
Seven Leaf Warrants |
On December 31, 2018, the Company was granted 2,500,000 warrants in Seven Leaf. Each warrant is exercisable into one common share of Seven Leaf any time prior to December 31, 2020, at an exercise price of $0.50 per common share. Seven Leaf has two directors in common with Flowr. For the year ended December 31, 2018, the Company recognized a gain on issuance of the warrants of $488,695 (2017 nil) in other income (note 19).
The inputs used in the measurement of the fair value at the time the investments in warrants were granted and subsequently re-measured were as follows:
December 31, | December 31, | |||||
2018 | 2017 | |||||
Investment in warrants | ||||||
Risk free interest rate | 1.6% - 1.86% | 0.91% - 1.66% | ||||
Expected exercise period in years | 0.70 - 2 | 1.45 - 2 | ||||
Expected volatility | 70% - 97% | 97% | ||||
Dividends per share | | |
Fair value hierarchy
The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:
| Level 1: based on quoted (unadjusted) prices in active markets for identical assets or liabilities; | |
| Level 2: based on inputs which have a significant effect on fair value that are observable, either directly or indirectly from market data; and | |
| Level 3: based on inputs which have a significant effect on fair value that are not observable from market data. |
THE FLOWR CORPORATION | 22 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
The investments in privately held securities have been classified as Level 3 in the fair value hierarchy as at December 31, 2018 and December 31, 2017.
During the years ended December 31, 2018 and 2017, there were no transfers between Level 1 and Level 2 fair value measurements, and no transfers into or out of Level 3 fair value measurements.
The following table reconciles Level 3 fair value measurements from January 1, 2017 to December 31, 2018:
Balance as at January 1, 2017 | | ||
Grant date fair value included in net loss | 128,377 | ||
Unrealized gains included in net loss | 207,194 | ||
Balance as at December 31, 2017 | 335,571 | ||
Investment in Ace Hill | 750,000 | ||
Convertible loan receivable (note 11) | 6,000,000 | ||
Realized loss Plant Properties warrants included in net loss (note 19) | (335,571 | ) | |
Unrealized gain on Seven Leaf warrants included in net loss (note 19) | 488,695 | ||
Balance as of December 31, 2018 | 7,238,695 |
9. |
PROPERTY, PLANT AND EQUIPMENT |
Balance as at | Balance as at | ||||||||
January 1, | December 31, | ||||||||
2018 | Additions | 2018 | |||||||
Cost: | |||||||||
Land | 1,380,500 | 4,370,836 | 5,751,336 | ||||||
Leasehold improvements | 2,577,059 | 338,269 | 2,915,328 | ||||||
Construction-in-progress | 998,657 | 8,804,923 | 9,803,580 | ||||||
Production equipment | 271,072 | 356,018 | 627,090 | ||||||
Mechanical equipment | 2,909,727 | 561,963 | 3,471,690 | ||||||
Electrical equipment | 1,067,794 | 206,034 | 1,273,828 | ||||||
Office equipment and furniture | 25,173 | 69,728 | 94,901 | ||||||
Computer and IT equipment | 49,255 | 187,375 | 236,630 | ||||||
Total cost | 9,279,237 | 14,895,146 | 24,174,383 | ||||||
Accumulated depreciation: | |||||||||
Leasehold improvements | | 111,299 | 111,299 | ||||||
Production equipment | | 43,218 | 43,218 | ||||||
Mechanical equipment | | 481,288 | 481,288 | ||||||
Electrical equipment | | 176,617 | 176,617 | ||||||
Office equipment and furniture | | 7,870 | 7,870 | ||||||
Computer and IT equipment | | 28,074 | 28,074 | ||||||
Total accumulated depreciation | | 848,366 | 848,366 | ||||||
Net book value | 9,279,237 | 23,326,017 |
THE FLOWR CORPORATION | 23 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Balance as at | Balance as at | ||||||||
January 1, | December 31, | ||||||||
2017 | Additions | 2017 | |||||||
Cost: | |||||||||
Land | | 1,380,500 | 1,380,500 | ||||||
Leasehold improvements | | 2,577,059 | 2,577,059 | ||||||
Construction-in-progress | | 998,657 | 998,657 | ||||||
Production equipment | | 271,072 | 271,072 | ||||||
Mechanical equipment | | 2,909,727 | 2,909,727 | ||||||
Electrical equipment | | 1,067,794 | 1,067,794 | ||||||
Office equipment and furniture | | 25,173 | 25,173 | ||||||
Computer and IT equipment | | 49,255 | 49,255 | ||||||
Balance as at December 31, 2017 | | 9,279,237 | 9,279,237 | ||||||
Accumulated depreciation | |||||||||
Balance as at December 31, 2017 | | | | ||||||
Net book value December 31, 2017 | | 9,279,237 |
As the majority of property plant, and equipment additions were acquired in December 2017 or became available for use in 2018, no depreciation expense was recognized during the year ended December 31, 2017.
10. |
INTANGIBLE ASSETS |
Balance as at | Balance as at | ||||||||
January 1, | December 31, | ||||||||
2018 | Additions | 2018 | |||||||
Cost: | |||||||||
Software | 15,507 | 9,681 | 25,188 | ||||||
Website development | | 218,930 | 218,930 | ||||||
License | 3,175,964 | | 3,175,964 | ||||||
Total cost | 3,191,471 | 228,611 | 3,420,082 | ||||||
Accumulated amortization: | |||||||||
Software | | 5,499 | 5,499 | ||||||
Website development | | 145,953 | 145,953 | ||||||
License | 78,668 | 133,234 | 211,902 | ||||||
Total accumulated amortization | 78,668 | 284,686 | 363,354 | ||||||
Net book value | 3,112,803 | 3,056,728 |
Capitalized license costs relates to costs incurred by the Company to acquire its licenses from Health Canada.
THE FLOWR CORPORATION | 24 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Balance as at | Balance as at | ||||||||
January 1, | December 31, | ||||||||
2017 | Additions | 2017 | |||||||
Cost: | |||||||||
Software | | 15,507 | 15,507 | ||||||
License | 3,175,164 | 800 | 3,175,964 | ||||||
Total cost | 3,175,164 | 16,307 | 3,191,471 | ||||||
Accumulated amortization: | |||||||||
License | | 78,668 | 78,668 | ||||||
Total accumulated amortization | | 78,668 | 78,668 | ||||||
Net book value | 3,175,164 | 3,112,803 |
11. |
CONVERTIBLE LOAN RECEIVABLE |
On the November 19, 2018, the Company entered into a binding term sheet with Holigen Holdings Limited (Holigen), pursuant to which the Company agreed to lend $6,000,000 to Holigen. The proceeds received from Flowr are being used by Holigen to purchase land and obtain certain cannabis related licenses in certain jurisdictions including Portugal. As of December 31, 2018, $6,000,000 has been advanced to Holigen. Flowr has the right to convert all debt owing under the loan facility into the same class of shares held by the shareholders of Holigen, that would result in a 4.8% ownership interest in Holigen (the Conversion Option).
On December 19, 2018, the Company signed a share purchase and share subscription agreement (the SPSA) with Holigen which effectively exercises the Companys Conversion Option and provides the Company with an additional 15% ownership interest in Holigen, for an aggregate ownership interest of 19.8% . The Company also provided Holigen with certain intellectual property to accelerate the completion of Holigens construction and licensing projects. The closing of the acquisition of the 19.8% ownership interest of Holigen is subject to various legal, administrative and approval conditions. As the Conversion Option has been exercised prior to the outside date of January 31, 2019 under the loan facility, interest will not accrue on the loan balance. However, in the event that the acquisition of the 19.8% interest in Holigen does not close, the entire outstanding loan balance and related interest will become payable on February 1, 2020 and interest under the loan facility would be calculated at 8% per annum from the first advance made under the loan.
The Conversion Option represents a call option to the Company and is included in the fair value of the loan. There existed an insignificant difference in fair value between the initial recognition date of November 19, 2018 and the reporting date of December 31, 2018, and accordingly the transaction price approximated the fair value of the note. The value of the Conversion Option of the loan is $487,474 as of December 31, 2018. The convertible loan receivable has been classified as a Level 3 in the fair value hierarchy (note 8).
12. |
OTHER LONG-TERM ASSETS |
Other long-term assets consist of a $50,000 advance payment made to Inplanta Biotechnology (Inplanta), to acquire shares in Inplanta.
THE FLOWR CORPORATION | 25 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
13. |
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES |
December 31, | December 31, | |||||
2018 | 2017 | |||||
Accounts payable (note 15) | 2,782,502 | 1,638,256 | ||||
Accrued liabilities | 1,472,422 | 290,642 | ||||
GST/HST, PST, and excise tax payable | 349,803 | | ||||
4,604,727 | 1,928,898 |
14. |
DEBT |
On January 25, 2018, Hawthorne Canada Limited (Hawthorne) and Flowr entered into an agreement to construct a research and development (R&D) facility and provide certain R&D services upon completion of the R&D facility. The agreement was amended effective December 14, 2018. Under the amended agreement, Flowr Okanagan received a design and construction fee of $1,500,000 which is initially recorded as deferred revenue in the consolidated statements of financial position. The revenue is recognized as design and construction income in the consolidated statements of loss over the period of time the services are rendered. Hawthorne will also finance all approved development expenses through a loan to Flowr Okanagan to a maximum loan amount of $11,500,000 (the Hawthorne Loan). The funds will be advanced to Flowr on a monthly basis based on the expected expenditures to be incurred for the month. On the opening date of the R&D facility, the Hawthorne Loan will become payable through an agreed upon payment schedule and will commence to accrue interest at rate of 4%. The Hawthorne Loan will be fully repaid over 20 years from the opening date of the R&D Facility.
As of December 31, 2018, Hawthorne advanced $1,591,536 to Flowr Okanagan under the Hawthorne Loan.
As a part of the arrangement, once the R&D facility is operational, Hawthorne will pay Flowr a monthly management fee and a monthly SR&ED service fee which can be offset against the monthly loan and interest repayments.
As of December 31, 2018, if the contract were to terminate under certain circumstances, the Company could be required to pay 100% of all costs and expenses loaned by Hawthorne and $1,500,000 in liquidated damages.
THE FLOWR CORPORATION | 26 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
15. |
RELATED PARTY TRANSACTIONS |
As at December 31, 2018 and December 31, 2017 related party amounts included in (a) prepaid expenses and other current assets (b) loan receivable (c) due to related parties (d) property plant and equipment and (e) accounts payable and accrued liabilities were as follows:
December 31, | December 31, | |||||
2018 | 2017 | |||||
(a) Amounts in relation to reimbursable expenses due from a corporation whose principal is a director and officer of Flowr | | 95,891 | ||||
(b) Loan to shareholder and employee of Flowr bearing interest at 1% per annum | | 25,000 | ||||
(c) Reimbursable expenses due
to a corporation with directors and officers (i) in common with Flowr |
63,217 | 2,562 | ||||
(ii) Shareholder advance payable to a director and officer of Flowr | | 25,000 | ||||
(d) Fees paid to a company for the construction of the Kelowna facility whose principal is an employee and shareholder of Flowr | 2,210,578 | 5,927,526 | ||||
(e) Amounts due to a construction company whose principal is an employee and shareholder of Flowr | 82,252 | 1,103,639 |
Included in general and administrative expense are amounts paid to shareholders or to companies whose principals are either a shareholder, director or officer of the Company as follows:
Year ended | ||||||
December 31, | ||||||
General and administrative | 2018 | 2017 | ||||
Consulting and administration fees | 95,454 | 50,890 | ||||
Rental fees | 21,000 | 19,250 | ||||
116,454 | 70,140 |
Refer to Notes 8 and 25.
All the above transactions are in the normal course of operations and are measured at the exchange amounts, being the amounts agreed to by the parties.
THE FLOWR CORPORATION | 27 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
16. |
KEY MANAGEMENT REMUNERATION |
The Companys related parties includes its key management. Key management includes directors, the Chief Executive Officers (Co-CEOs) and the executive officers reporting directly to the Co-CEOs.
The remuneration of the key management of the Company recognized in the consolidated statements of loss for the year ended December 31, 2018 and 2017 were as follows:
Year ended | ||||||
December 31, | December 31, | |||||
2018 | 2017 | |||||
Salaries and short-term benefits | 1,805,008 | 439,366 | ||||
Share-based compensation | 6,696,797 | 574,977 | ||||
Total renumeration | 8,501,805 | 1,014,343 |
17. |
REVENUE |
Year ended | ||||||
December 31, | ||||||
2018 | 2017 | |||||
Gross revenue | 3,269,977 | | ||||
Excise tax | 399,569 | | ||||
2,870,408 | |
18. |
SHARE-BASED COMPENSATION |
Stock options
The Company has established a stock option plan (SOP) for the directors, selected employees and consultants. Pursuant to the SOP, the exercise price of the option cannot be less than the closing price of Flowrs common shares on the trading date preceding the day the option is granted, subject to permitted discounts pursuant to the rules of the Exchange. The maximum number of common shares reserved for issuance under the SOP is 10% of the total issued and outstanding common shares of the Company including the 44,100,000 convertible Flowr ULC Class A Preferred Shares (note 2.1(c)).
During the year ended December 31, 2018, the Company granted 8,053,991 (2017 - 10,125,000) stock options at a fair value of $16,388,192 (2017 - $2,835,000). The estimated value of the options granted will be recognized as an expense in the consolidated statements of loss and an addition to contributed surplus in the consolidated statements of changes in shareholders equity over the vesting period. The options generally vest over 3 to 3.5 years from the grant date. The Company recorded stock option expenses of $7,208,273 (2017 $601,536) for the year ended December 31, 2018.
THE FLOWR CORPORATION | 28 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
As at December 31, 2018, there was $10,750,492 of share-based compensation cost remaining to be charged to net earnings in future periods relating to stock option grants. The fair value of options granted was estimated using the Black-Scholes option pricing model. Due to limited historical data, the expected volatility is estimated based on the volatility of comparable publicly traded companies. The inputs used in the measurement of the fair values at the time the options were granted were as follows:
2018 | 2017 | |||||
Five year risk free interest rate | 2.11 - 2.45% | 1.65% | ||||
Expected life in years | 5.00 | 5.00 | ||||
Expected volatility | 86% - 90% | 75.0% | ||||
Dividends per share | | |
The following is a stock option continuity for the years indicated:
Weighted | ||||||
average | ||||||
Number of | exercise price | |||||
options | per share $ | |||||
Balance as at January 1, 2017 | | | ||||
Options granted | 10,125,000 | 0.05 | ||||
Options forfeited | | | ||||
Options expired | | | ||||
Balance as at December 31, 2017 | 10,125,000 | 0.05 | ||||
Options granted | 8,418,991 | 2.70 | ||||
Options exercised | (6,205,961 | ) | 0.05 | |||
Options forfeited | (1,740,750 | ) | 0.23 | |||
Options expired | | | ||||
Balance as at December 31, 2018 | 10,597,280 | 2.13 |
The following lists the options outstanding and exercisable as at December 31, 2018:
Options outstanding | Options exercisable | ||||||||||||||||
Weighted | Weighted | Weighted | |||||||||||||||
Number of | average | average | Number of | average | |||||||||||||
Range of exercise | options | remaining | exercise price | options | exercise price | ||||||||||||
prices per share | outstanding | years | per share $ | exercisable | per share $ | ||||||||||||
$ | 0.05 | 2,318,750 | 3.92 | 0.05 | 375,000 | 0.05 | |||||||||||
2.60 | 7,913,530 | 4.70 | 2.60 | 375,158 | 2.60 | ||||||||||||
3.43 - 3.60 | 40,000 | 4.83 | 3.52 | | | ||||||||||||
5.24 | 325,000 | 4.76 | 5.24 | 9,028 | 5.24 | ||||||||||||
$ | 0.05 -2.60 | 10,597,280 | 4.54 | 2.13 | 759,186 | 1.37 |
THE FLOWR CORPORATION | 29 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
19. |
OTHER INCOME |
Year ended | ||||||
December 31, | ||||||
2018 | 2017 | |||||
Acquisition of warrants investments | (488,695 | ) | (128,377 | ) | ||
Loss (gain) on warrants investment valuation | 335,571 | (207,194 | ) | |||
Interest (income) expense, net | (102,433 | ) | 662 | |||
Other income | (14,903 | ) | (7,875 | ) | ||
(270,460 | ) | (342,784 | ) |
20. |
INCOME TAXES |
The major items causing the Companys effective income tax rate of nil to differ from the combined federal and provincial enacted rate of 26.75% (2017-CCPC1 rate 13.81%) were as follows:
2018 | 2017 | |||||
Losses before income taxes | (17,907,188 | ) | (2,805,335 | ) | ||
Combined Canadian federal and provincial statutory income tax rates (2017- CCPC1 ) | 26.75% | 13.81% | ||||
Expected income tax recovery | (4,790,000 | ) | (387,000 | ) | ||
Share based compensation expense and Non-deductible | 2,326,240 | 87,000 | ||||
Losses allocated to former Partnership members | | 210,000 | ||||
Share issue costs recorded through equity | (397,940 | ) | (4,000 | ) | ||
Other | 15,880 | | ||||
Tax rate changes and other adjustments | (165,140 | ) | (2,000 | ) | ||
Change in tax benefit not recognized | 3,010,960 | 96,000 | ||||
Income tax expense | | |
1 |
Canadian controlled private corporation |
Deferred income tax (assets) and liabilities have been recognized in respect of the following (deductible) taxable temporary differences:
2018 | 2017 | |||||
Investments at fair value | 130,000 | 44,000 | ||||
Biological assets | 22,000 | | ||||
Non-capital loss carry-forwards | (152,000 | ) | (44,000 | ) | ||
Net deferred income tax liabilities | | |
THE FLOWR CORPORATION | 30 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intention to offset.
Deferred income tax assets have not been recognized in respect of the following deductible temporary differences:
2018 | 2017 | |||||
Non-capital loss carry-forwards | 8,820,120 | 1,054,000 | ||||
Share issue costs | 1,593,060 | 108,000 | ||||
Other temporary differences | 1,301,150 | 12,000 | ||||
Total deferred income tax assets | 11,714,330 | 1,174,000 |
The Company has a total of $9.4 million in non-capital losses of which $1.1M will expire from 2032 to 2037 and $8.3M will expire in 2038.
21. |
SHARE CAPITAL |
The authorized capital of the Company consists of an unlimited number of common shares and an unlimited number of preferred shares issuable in series. As of December 31, 2018, the Company had 86,700,306 common shares issued and outstanding and no issued and outstanding preferred shares. The Flowr ULC preferred class A shares (note 2.1 (c)) are convertible into common shares of the Company.
(a) |
Financings |
In December 2017, Flowr completed a private placement where 14,185,000 class A preferred shares were issued at a price of $1.00 per share, for total proceeds of $14,185,000 of which $487,168 was included in amounts receivable and $50,200 was oversubscribed and included in accounts payable as of December 31, 2017. Total share issuance costs were $134,791. In January 2018, the remaining tranche of 815,000 class A preferred shares were issued at a price of $1.00 per share for gross proceeds of $815,000, and related share issuance costs were $30,037. Total gross proceeds received from both tranches amounted to $15,000,000.
In the second and third quarters of 2018, Flowr closed a private placement in a series of five tranches as noted in the table below. Total share issuance costs related to this financing were $59,220.
Closing | Shares | Gross | |||||||
Tranche | date | issued | proceeds $ | ||||||
1 | 11-Apr-18 | 3,310,330 | 8,606,858 | ||||||
2 | 23-Apr-18 | 970,232 | 2,522,603 | ||||||
3 | 28-May-18 | 84,382 | 219,393 | ||||||
4 | 11-Jul-18 | 896,151 | 2,329,993 | ||||||
5 | 18-Jul-18 | 48,266 | 125,492 | ||||||
TOTAL | 5,309,361 | 13,804,339 |
THE FLOWR CORPORATION | 31 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
(b) |
Refer to note 3(a) for shares issued in the Qualifying Transaction classified as a listing expense. As a part of the Qualifying Transaction, Flowr completed a concurrent RTO Financing issuing 13,807,734 common shares for gross proceeds of $35,900,108. In relation to the RTO financing the Company incurred $1,927,407 in share issuance costs, of which $529,038 relate to broker warrants issued (note 22). |
All the above noted shares issuances were exchanged for common shares of the Company in connection with the closing of the Qualifying Transaction.
22. |
WARRANTS |
The following lists the warrants outstanding and exercisable as at December 31, 2018:
Weighted | ||||||
average | ||||||
Number of | exercise price | |||||
warrants | per share $ | |||||
Balance as at December 31, 2017 | | | ||||
Warrants granted | 464,797 | 2.60 | ||||
Warrants exercised | (11,481 | ) | 1.30 | |||
Warrants expired | | | ||||
Balance as at December 31, 2018 | 453,316 | 2.57 |
The following is a warrant continuity for the year:
Number of | ||||||
warrants | Value $ | |||||
Balance as at December 31, 2017 | | | ||||
Granted in relation to RTO | 23,077 | 34,937 | ||||
Broker warrant -RTO Financing | 441,720 | 529,038 | ||||
Warrants exercised | (11,481 | ) | (17,382 | ) | ||
Balance as at December 31, 2018 | 453,316 | 546,593 |
The fair value of warrants granted was estimated using the Black-Scholes option pricing model. Due to limited historical data, the expected volatility is estimated based on the volatility of comparable publicly traded companies. The inputs used in the measurement of the fair values at the time the warrants were granted were as follows:
2018 | |||
Five year risk free interest rate | 2.02 - 2.81% | ||
Expected life in years | 1 - 2 | ||
Expected volatility | 90.0% | ||
Dividends per share | - |
THE FLOWR CORPORATION | 32 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
23. |
LOSS PER SHARE |
Year ended | ||||||
December 31, | ||||||
2018 | 2017(1) | |||||
Net loss attributable to common shareholders | (15,401,298 | ) | (1,908,684 | ) | ||
Basic and diluted weighted average number of common shares outstanding | 71,335,830 | 37,673,616 | ||||
Basic and diluted loss per share | (0.22 | ) | (0.05 | ) |
(1) |
The 2017 basic weighted average common shares is a reflection of the common shares issued from the Reorganization in exchange for the partnership interest. |
24. |
SUPPLEMENTARY CASH FLOW INFORMATION |
(a) |
Items not affecting cash and other adjustments: |
Year ended | ||||||
December 31, | ||||||
2018 | 2017 | |||||
Depreciation and amortization | 1,133,052 | 78,668 | ||||
Unrealized gain resulting from fair valuation of biological assets | (79,383 | ) | | |||
Share-based compensation expense | 7,208,273 | 601,536 | ||||
Gain on investments in warrants | (153,124 | ) | (335,571 | ) | ||
Listing expense | 1,911,710 | | ||||
Other, net | (102,431 | ) | 662 | |||
Items not affecting cash and other adjustments | 9,918,097 | 345,295 |
(b) |
Changes in non-cash working capital: |
Year ended | ||||||
December 31, | ||||||
2018 | 2017 | |||||
Increase in amounts receivable | (2,652,739 | ) | (293,569 | ) | ||
Increase in other current assets | (761,455 | ) | (101,579 | ) | ||
Increase in inventories | (899,150 | ) | | |||
Increase in biological assets | (917,512 | ) | | |||
Increase in accounts payable and accrued liabilities | 2,169,347 | 603,269 | ||||
Increase in deferred revenue | 1,327,865 | | ||||
Increase (decrease) in amounts due to related parties | 35,654 | (344,412 | ) | |||
Changes in non-cash working capital | (1,697,990 | ) | (136,291 | ) |
THE FLOWR CORPORATION | 33 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
25. |
COMMITMENTS |
Contractual obligations
The Company had the following minimum future contractual obligations as at December 31, 2018:
up to 1 year | 1 - 3 years | 3 - 5 years | over 5 years | Total | |||||||||||
Purchase obligations | 2,001,735 | 2,001,735 | |||||||||||||
Operating lease obligations (i) | 454,550 | 990,285 | 565,473 | 5,853,244 | 7,863,552 | ||||||||||
Total Commitments | 2,456,285 | 990,285 | 565,473 | 5,853,244 | 9,865,287 |
(i) |
Included in operating leases, is the Flowr Okanagan facility operating lease. This lease cost has been capitalized to biological assets and inventory in 2018. The lease is payable to 0954717 B.C. LTD. whose principal owners are also shareholders of Flowr. The total remaining commitment for this lease is $7,564,123, of which $273,258 is due within one year. |
Refer to note 14 for additional contractual commitments.
26. |
NON-CONTROLLING INTEREST |
Set out below is summarized financial information reported by Flowr ULC and its subsidiaries that have been incorporated into these consolidated financial statements. All of the financial information is presented before any intercompany eliminations with its parent company (Flowr).
The following table summarizes the consolidated financial position for Flowr ULC as at December 31, 2018 and 2017:
Year ended | ||||||
December 31, | ||||||
2018 | 2017 | |||||
Current assets | 31,540,775 | 11,047,419 | ||||
Non-current assets | 42,161,662 | 12,856,280 | ||||
Current liabilities | (5,695,615 | ) | (4,055,775 | ) | ||
Non-current liabilities | (3,304,034 | ) | | |||
Consolidated net assets | 64,702,788 | 19,847,924 |
THE FLOWR CORPORATION | 34 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
The following tables summarizes Flowr ULCs consolidated net loss for the years ended December 31, 2018 and 2017:
Year ended | ||||||
December 31, | ||||||
2018 | 2017 | |||||
Revenue | 2,870,408 | | ||||
Expenses | (10,302,860 | ) | (2,114,743 | ) | ||
Consolidated net loss | (7,432,452 | ) | (2,114,743 | ) |
Other changes in non-controlling interest as reported in the statement of changes in shareholders equity is attributable to the shares issued by Flowr ULC to the Company as required whenever the Company issues common shares, as established through the Reorganization (note 2.1(c) ).
27. |
FINANCIAL RISK MANAGEMENT |
The Companys principal financial liabilities comprise of accounts payable and accrued liabilities, amounts due to related parties and debt. The main purpose of these financial instruments is to assist with the management of the Companys short term and long-term cash flow requirements. The Company has various financial assets, such as cash and cash equivalents, and amounts receivable, which arise directly from its operations.
The main risks that could adversely affect the Companys financial assets, liabilities or future cash flows are market risk, liquidity risk and credit risk. Management reviews each of these risks and establishes policies for managing them as summarized below.
Market risk
Market risk is the risk that the future cash flows or the fair value of a financial instrument will fluctuate because of changes in market conditions. The Company operates in an industry regulated by Health Canada. Changes in legislation could have a significant impact on the Companys operations.
Credit risk
The exposure to credit risk arises through the potential failure of a customer or another third party to meet its contractual obligations to the Company. As at December 31, 2018, the Company had a convertible loan receivable of $6,000,000 (2017 Nil) and amounts receivable of $2,963,115 (December 31, 2017 - $797,545). The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. The Company is not significantly exposed to credit risk as the accounts receivables are primarily due from provincial government organizations and overall amounts receivable and convertible loan receivables comprise 13.4% (December 31, 2017 3.8%) of the Companys total assets.
THE FLOWR CORPORATION | 35 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
Liquidity risk
The Company relies on the cash flows generated from its operations and its ability to raise debt and equity from the capital markets to fund its operating, investment and liquidity needs. To reduce these risks, the Company: (i) prepares regular cash flow forecasts to monitor its capital requirements and available liquidity (ii) strives to maintain a prudent capital structure that is comprised primarily of equity financing; and (iii) targets a minimum level of liquidity comprised of surplus cash balances to avoid having to raise additional capital at times when the costs or terms would be regarded as unfavourable.
Capital management
The Company considers its capital to be its equity. The Companys objective for capital management is to: (i) maintain sufficient levels of liquidity to fund and support its capital projects and operating activities; (ii) maintain a strong financial position to ensure it has ready access to debt and equity markets to supplement free cash flow being invested in its growth projects. The Company monitors its financial position and the potential impact of adverse market conditions on an ongoing basis. The Company manages its capital structure and makes adjustments to it based on prevailing market conditions and according to its business plan. The Companys funding strategy is to maintain a capital structure comprised primarily of equity sourced from equity offerings and net earnings generated from its operations accompanied with financing through debt.
Its time s, you too!
28. |
EXPENSE BY NATURE |
The operating costs, including cost of sales, selling and marketing, general and administrative expenses and research and development costs, as reported in the consolidated statements of loss, have been regrouped by the nature of the expenses as follows:
Year ended | ||||||
December 31, | ||||||
2018 | 2017 | |||||
Salaries and benefits | 5,027,924 | 1,474,236 | ||||
Professional fees | 2,303,497 | 449,441 | ||||
Production costs | 1,708,266 | 258,038 | ||||
General and administrative | 1,124,625 | 221,833 | ||||
Travel | 868,725 | 113,635 | ||||
Selling and marketing | 607,619 | | ||||
Depreciation and amortization | 465,844 | 29,400 | ||||
Research and development | 7,525 | | ||||
Total operating expenses | 12,114,025 | 2,546,583 |
THE FLOWR CORPORATION | 36 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
For the years December 31, 2018 and 2017 |
(in Canadian dollars, unless otherwise indicated) |
29. |
OPERATING SEGMENT INFORMATION |
Operating segments are components of an entity whose operating results are regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance and for which separate financial information is available.
The Company primarily operates in one reportable operating segment, being a licensed producer operating in Canada. As the operations comprise a single reporting segment, amounts disclosed in the consolidated financial statements also represent segment amounts.
30. |
SUBSEQUENT EVENTS |
(a) |
Long-Term Incentive Plan |
On December 28, 2018, the shareholders of the Company approved the Companys Long-Term Incentive Plan (LTIP), which was subsequently approved by the TSX-V on January 16, 2019. Under the terms of the LTIP, the Board of Directors (the Board) or a committee on behalf of the Board may grant units, which may be either restricted share units (RSUs) or deferred share units (DSUs) to officers, directors, employees or consultants of the Company. The maximum number of common shares which may be reserved and set aside for issue under the LTIP in respect of awards of DSUs to DSU participants and for payments in respect of awards of RSUs to RSU participants, shall not exceed 10% of the total issued and outstanding common shares of the Company, including 44,100,000 convertible Flowr ULC class A preferred shares, at the time of approval of the LTIP (being 13,057,421 common shares of the Company). There are no RSUs or DSUs issued and outstanding as at the date of approval of these Consolidated Financial Statements.
THE FLOWR CORPORATION | 37 |
UNDERTAKING
To: Canadian Securities Administrators (except in Manitoba, Québec, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland, Northwest Territories, Yukon and Nunavut)
In connection with Application No. 2018/0743 by The Flowr Corporation under section 1(11) of the Securities Act (Ontario), and in accordance with Section 6.1 and Section 6.4 of National Policy 41-201 - Income Trusts and Other Indirect Offerings, the undersigned hereby undertakes, in complying with its reporting issuer obligations, and for as long as the undersigned is a reporting issuer and The Flowr Group (Okanagan) Inc. ("Flowr Okanagan") would be treated as an operating entity if the undersigned were an income trust, that:
the undersigned will treat The Flowr Canada Holdings ULC ("Flowr ULC") and Flowr Okanagan as subsidiaries of the undersigned; however, if generally accepted accounting principles ("GAAP") used by the undersigned prohibit the consolidation of the financial information of Flowr ULC and Flowr Okanagan and the undersigned, then for as long as Flowr ULC and Flowr Okanagan represent significant assets of the undersigned, the undersigned will provide shareholders with separate audited annual financial statements and interim financial reports and management's discussion and analysis for Flowr ULC and Flowr Okanagan, prepared in accordance with the same GAAP as the undersigned's financial statements and interim financial reports and in accordance with National Instrument 51-102 - Continuous Disclosure Obligations, or its successor;
for so long as Flowr ULC and Flowr Okanagan represent significant assets of the undersigned, then the undersigned will take the appropriate measures to direct each person who would be an "insider" (as defined in the Securities Act (Ontario)) of either Flowr ULC or Flowr Okanagan or a "person or company in a special relationship" (as defined in the Securities Act (Ontario)) with either Flowr ULC or Flowr Okanagan, if either Flowr ULC or Flowr Okanagan was a reporting issuer, as applicable, to comply with statutory prohibitions against insider trading under applicable Canadian securities laws;
for so long as Flowr ULC and Flowr Okanagan represent significant assets of the undersigned, then the undersigned will take the appropriate measures to direct each person who would be a "reporting insider" (as that term is defined in National Instrument 55-104 - Insider Reporting Requirements and Exemptions ("NI 55-104")) of either Flowr ULC or Flowr Okanagan, if either Flowr ULC or Flowr Okanagan was a reporting issuer, as applicable, to file insider reports about trades in the securities of the undersigned (including securities which are exchangeable into securities of the undersigned); and
the undersigned will annually certify as to its compliance with the above undertakings and file the certificate on SEDAR concurrently with the filing of its annual financial statements.
For the purposes of undertaking 3 above, please refer to the list of "reporting insiders" of the undersigned provided to the Ontario Securities Commission in connection with Application No. 2018/0743 by The Flowr Corporation under section 1(11) of the Securities Act (Ontario), which represent the directors and, as applicable, the Chief Executive Officers, Chief Financial Officer, Chief Medical and Policy Officer, President, Vice President and Secretary, General Counsel and Corporate Secretary and Chief Research and Innovation Officer of the undersigned, Flowr ULC, Flowr Okanagan and Core Flow Holdings Canada Inc., respectively and, with respect to each of Flowr ULC and Core Flow Holdings Canada Inc., Significant Shareholders (as that term is defined in NI 55-104).
[Remainder of page intentionally left blank. Signature page follows.]
Date: April 22, 2019
The Flowr Corporation
By: /s/ Francesco Tallarico
Name: Francesco Tallarico
Title: General Counsel & Corporate Secretary
Flowr Provides Corporate Update |
Announces C$15 Million Private Placement Led By Management and the Board; Adds Seasoned Board Member, Don Duet, and Head of Capital Markets, Thierry Elmaleh |
Toronto, Ontario April 29, 2019 (GLOBE NEWSWIRE) The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (Flowr or the Company), a Canadian Licensed Producer and global leader in premium cannabis R&D and innovation, today provided a corporate update on various matters. Details are as follows:
Private Placement
Flowr intends to complete a non-brokered private placement of up to 2,400,000 common shares of Flowr at a price of C$6.25 per common share for aggregate gross proceeds of up to C$15 million (the Private Placement).
The Company expects to use the proceeds of the Private Placement for general working capital purposes, including for the funding of construction of certain operations of Holigen Holdings Limited (Holigen). Holigen is a European-based cannabis company in the process of developing large-scale GMP-compliant cultivation facilities in Portugal and Australia that are expected to provide medical cannabis products, ingredients, and plants and seeds to markets globally.
Investors participating in the Private Placement, and investing an aggregate of approximately C$3,600,000, include Flowr CEO Vinay Tolia, Chairman, Steve Klein, through Core Flow Canada Holdings Inc. (Core Flow), as well as individual members of Flowrs Board of Directors (Board), including new Board member Don Duet. The participation of Flowrs senior management team and Board members demonstrates their long-term commitment to Flowrs corporate strategy and business model. Closing of the Private Placement is expected to occur on or about May 10, 2019, but is at the discretion of the Company (the Closing Date). The Company will announce the outcome of the Private Placement after closing in a subsequent press release. As of the date of this press release, management and Board members currently own or exercise control over 60% of the securities interests of Flowr (taking into account the Companys 87,045,352 issued and outstanding common shares and 43,950,000 securities held by certain shareholders in a subsidiary of the Company that are convertible into common shares of Flowr for no additional consideration).
Through leading each round of financing for the Company, Core Flow has a strong conviction in Flowrs edge in designing and constructing highly efficient facilities and producing high quality cannabis products, said Steve Klein. Moreover, Flowr is building a company, from its management team to cultivators, that I believe is second to none."
Pricing of the Private Placement was determined by the Board based on the closing price for the common shares on the date prior to announcement of the Private Placement and in compliance with regulatory policies. All common shares issued under the Private Placement will be delivered from Canada and are subject to a hold period expiring four months and one day from the Closing Date.
The Private Placement is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.
The common shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Holigen Investment
Portugal
Through its investment, Flowr is supporting Holigen’s proposed €45 million investment in Portugal to produce medicinal cannabis outdoors and generate 200 jobs over the next four years. Holigen’s first installation in Portugal is under construction in Sintra, with 21,500 square feet for cultivation, processing, GMP manufacturing and R&D operations. Holigen has been granted a cultivation license for its Sintra indoor facility which now has mother plants growing and in development. In addition, the GMP extraction and packaging areas in the Sintra facility have been completed and the extraction equipment is in place and undergoing testing. The GMP manufacturing inspection for Sintra’s indoor facility is scheduled and expected to occur in June 2019.
In addition, this year, Holigen expects to initiate the installation of one of the largest outdoor cannabis cultivation facilities for cannabis sativa (THC) in the world in Aljustrel, Portugal, which will have a combined production, transformation and R&D area of more than 7,000,000 square feet. Holigen’s Aljustrel site is now security fenced and is expected to be ready for inspection by the Portuguese authorities in May 2019. This project has been designated a Project of National Interest by the Portuguese government, which ensures special handling and prioritization by government agencies and access to low cost financing.
Australia
In Australia, Holigen has been licensed by the Office of Drug Control (ODC) to cultivate and manufacture medicinal cannabis products, and was granted Good Manufacturing Practice (GMP) by the Therapeutic Goods Administration for labelling, secondary packaging and release for supply in November 2018. Holigen is on track to have its full manufacturing facility in Australia inspected to Good Manufacturing Practice (GMP) later this year.
Subject to available financing, Phase 1 construction at the Australian facility is expected to be finalized in the second half of this year in preparation for an ODC inspection, and Phase 2 construction is expected be completed by August 2019. Upon completion of construction, inspections, permitting and licensing, Holigen expects to start manufacturing in Australia by the end of this year.
As Holigen continues to progress through its licensing process in Portugal and Australia, it has also been granted cannabis clone import permits from Flowr as well as seed, tissue culture and seedling import permits in Europe and Australia.
Holigen, through partnerships it has and is developing, has access to pharmaceutical distribution in over 35 countries across Europe and the southern hemisphere (excluding South America), including a distribution partner that has approximately 170 client wholesale and distribution outlets and is experienced in international importing and exporting of certain medicines.
Holigen also has a highly skilled team in place with extensive experience in the pharmaceutical, distribution and construction industry, including senior engineers in the opiate industry (cultivation and extraction), senior GMP specialists, senior regulatory pharmacists experienced in dealing with European regulations and pharmacopeia, and senior construction executives.
Further to the announcement made by the Company on December 20, 2018, Flowr is in the process of closing its 19.8% interest in Holigen and is evaluating a further acquisition and/or investment into Holigen. The Company provides no assurances that a transaction with Holigen will be completed as proposed or at all.
Board and Management Update
Flowr also announced changes to its Board of Directors and the addition of Thierry Elmaleh, as Head of Capital Markets.
Current Board member Rishi Shah has stepped down as Lead Independent Director, and current Board member Karen Basian will replace him in the role. Don Duet, former Partner, Head of Global Technology Division, Goldman Sachs, will be filling Mr. Shah’s Board seat, and will join the Audit Committee, Nominating and Corporate Governance Committee and Human Resources and Compensation Committee, the latter of which he will Chair. Additionally, Tom Flow has decided to transition from his role as Co-CEO and Board member to the position of Founder and Managing Partner, enabling him to better focus his time on Flowr’s operations (including the ramp up of Holigen’s business), as the Company continues to focus on scaling its operations globally.
“I can speak for the entire Board of Directors in expressing our gratitude to Rishi and Tom for their many valuable contributions to our company’s governance. We believe that Don’s appointment highlights our continued focus on governance and assembling a Board with diverse skillsets. We are also excited to have Tom back in a role that better utilizes his passion and expertise on our global operational initiatives, as we pursue our goal of growing cannabis of the highest possible quality,” said Mr. Tolia.
Mr. Tolia continued, “with the addition of Thierry on our team, we also believe we are well positioned to continue executing on our capital markets strategy, as Flowr grows and gains additional exposure to the investment community.”
About New Board Member and Head of Capital Markets
Don Duet – Over his nearly 30-year career at Goldman Sachs, Mr. Duet ran the bank’s Technology Division, helping lead investments in emerging companies including Square, Docker and Barefoot Networks. Mr. Duet currently serves as Senior Advisor to McKinsey & Company and as an Advisory Board Member to Centana Growth Partners, a growth equity firm. He graduated from Marist College with a degree in Computer Science.
Thierry Elmaleh – Mr. Elmaleh brings 15 years of progressively more senior leadership experience in capital markets to Flowr. Most recently, Mr. Elmaleh was a Managing Director in the Trading Products division at BMO Capital Markets, which was the first Canadian Schedule 1 Bank to provide investment banking services to the cannabis sector. Prior to joining BMO, Mr. Elmaleh led the buildout of Susquehanna’s US equity and derivatives business in Canada, was a Vice President in Institutional Equity Sales at Bank of America Merrill Lynch & began his career as an investment banking analyst at TD Securities. Mr. Elmaleh has an MBA from the Rotman School of Management at the University of Toronto and a BA in Economics from McGill University.
Grant of Equity Incentives
In addition, Flowr also announced today that the Board has approved the granting of an aggregate of 615,000 incentive stock options (the “Options”) and aggregate of 100,000 restricted share units (the “RSUs”) to certain officers of the Company. The Options are exercisable at a price of CAD$5.93 per share for a period of five years. The Options will vest either: (i) in equal proportion on a monthly basis over a period of thirty-six months, with the first monthly vesting to occur on March 31, 2019, with each subsequent vesting to occur on each of the following thirty-five (35) subsequent one (1) month anniversaries of that date; or (ii) as to thirty-three and one-third percent (331/3%) on each anniversary of the date of commencement of employment for the applicable officer. The RSUs will vest as to thirty-three and one-third percent (331/3%) on each anniversary of the date of commencement of employment for the applicable officer.
About The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and sales license granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own growing systems. Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Vinay Tolia
CEO and Director
Forward-Looking Information
This press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr, Holigen and their respective businesses, which may include, but are not limited to: the Private Placement, including the size of the Private Placement, dilution, use of proceeds, closing date and required approvals, statements with respect to Core Flow’s conviction in Flowr’s edge in designing and constructing highly efficient facilities and producing high quality cannabis products, Core Flow’s views on Flowr building a company that is second to none, the transactions described herein, statements with respect to Holigen developing large-scale GMP compliant cultivation facilities that will provide medical cannabis products, ingredients, plants and seeds to markets globally, Holigen’s markets, Holigen having the ability to raise and invest €45 million into Portugal, Holigen producing cannabis outdoors and generating 200 jobs over the next four years, the production capacity of Holigen, the scale of Holigen, including with respect to Holigen having one of the largest outdoor cultivation facilities for cannabis sativa, the status of Holigen’s licensing and inspection process, including the timing of receipt of all required licenses and the timing of all inspection, the partnerships Holigen is forming with distributors globally, including the partnership with the distributor described herein, Holigen’s facilities, Holigen seeking to have GMP compliant facilities, the dates for inspections and final granting of licenses for Holigen’s facilities and properties, the completion and operational dates for Holigen’s facilities and properties, including the timing thereof, the production capacity of such facilities and properties, the extraction of dried flower at Holigen’s facilities, the designation of Holigen’s Portuguese projects being a Project of National Interest, which allows special handling and prioritization by government agencies and access to low cost financing, the completion of construction of Holigen’s facilities in Australia, including each phase of completion and the timing thereof, the timing in which Holigen expects to begin manufacturing products in each of its facilities, the closing of Flowr’s 19.8% interest in Holigen, including the timing thereof, the Company evaluating a further acquisition and/or investment into Holigen, the Company continuing to focus on scaling its operations globally and pursuing its goal of growing cannabis at the highest possible quality, Mr. Duet’s and Mr. Elmaleh’s appointment, including the appointment of Mr. Duet highlighting Flow’s focus on governance and diverse skillsets, Mr. Elmaleh’s enabling Flowr to be better positioned to execute on its capital markets strategy, Flowr’s investment in research and development along with its sense of craftsmanship and spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use market and addresses specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as “potential”, “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of Flowr’s management and are based on assumptions and subject to risks and uncertainties. Although Flowr’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.
The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks relating to the failure to obtain regulatory approvals, the failure to complete the transactions described herein, including as a result of certain conditions not being satisfied, the failure to complete the Private Placement or a reduction in the amount of the Private Placement, which could result in lack of funds available to Flowr for further development and/or result in Flowr having to raise capital by alternative means on less favourable terms, the dilution to shareholders as a result of the Private Placement, Flowr not using the proceeds of the Private Placement as described herein, the closing of the Private Placement being delayed, Flowr not having an edge in designing and constructing highly efficient facilities and producing high quality cannabis products, which could result in Flowr losing a competitive advantage over its peers, Flowr not building a company that is second to none, Holigen’s inability to develop large-scale GMP compliant cultivation facilities that will provide medical cannabis products, ingredients, plants and seeds to markets globally, which could have a significant impact on Flowr’s investment in Holigen, Holigen not having access to the markets described herein, Holigen not being able to raise and invest €45 million into Portugal, which would significantly delay Holigen’s business plans, and materially impact Flowr’s investment in Holigen, Holigen being unable to produce jobs at the scale described herein, which would materially impact its status with as a Project of National Interest and materially affect Holigen’s ability to grow, the production capacity and scale of Holigen being significantly less than projected herein, competitors having larger facilities and sites than Holigen, which could create an oversupply of the markets that Holigen is targeting, Holigen failing to obtain the licenses and permits described herein or being delayed in obtaining them, which could materially impact the timing of operations, business, financial condition and Flowr’s investment in Holigen, the inspections described herein not being completed or being delayed, which could materially impact the timing of operations, business, financial condition and Flowr’s investment in Holigen, Holigen not being able to form the partnerships described herein with distributors globally, Holigen’s partnership with the distributor described herein being terminated, risks associated with Holigen’s facilities, Holigen not completing its facilities and properties, or being delayed in completing them, which could have a martial adverse impact the timing of operations, business, financial condition and Flowr’s investment in Holigen, Holigen’s projects not being designated or losing status as a Project of National Interest, which would impact or result in the loss of the special handling and prioritization by government agencies and access to low cost financing for these projects, Flowr’s not closing its 19.8% interest in Holigen, which would result in a loss of Flowr’s investment in Holigen, the Company not completing a further acquisition and/or investment into Holigen, the Company not being able to scale its operations globally and not being able to pursue its goal of growing cannabis at the highest possible quality, which could materially impact Flowr’s business, financial condition and operations, Mr. Duet not bringing a set of diverse skills and/or governance skills to Flowr, Mr. Elmaleh’s not enabling Flowr to be better positioned to execute on its capital markets strategy, risks relating to the use of Flowr’s or Holigen’s products, risks relating to the markets in which Flowr and Holigen operate and/or distribute their respective products, possible failure to realize the anticipated benefits of the transactions described herein, the reliance on information provided by Holigen about its business and plans, the inability of Holigen to complete its licensing process or construct its facilities or properties as a result of a lack of funding, the cost of production of Holigen being more than expected, resulting in lower earnings, Holigen not having one of the largest cultivation facilities, or competitors being able to construct and operate comparable facilities and properties, Portugal and Flowr failing to provide Holigen with the climate, workforce and cultivation expertise, as applicable, to produce one of the lowest cost cultivation operations, Holigen not being able to export low-cost cannabis and not having direct access to EU markets and global markets, which would materially impact revenues and earnings, Flowr’s industry leading cultivation expertise and partnership with Holigen not enabling Flowr to gain exposure to the European and Australian markets, Holigen not being able to construct and license GMP compliant facilities, which could impact the ability to sell products where such compliance is required, the combination of Holigen and Flowr failing to create a worldwide leader in production, the production capacity of such facilities and properties not being achieved, which could materially impact the value of Holigen, the inability to extract dried flower at Holigen’s facilities, the relationship between Flowr and Holigen failing to create a leading cannabis franchise in Europe and Australia, Holigen’s inability to develop medical cannabis brands, leveraging its distribution partnerships, or evaluating alternative product lines, the partnership between Flowr and Holigen not benefiting Holigen in executing on the licenses it holds and is obtaining, Holigen failing to participate in the Australian government’s export strategy or being delayed in participating in such opportunity, Holigen and Flowr not being in a unique position to act as a true medical cannabis multinational, Holigen’s inability to grow the amount of cannabis described herein, which could adversely impact revenues, the fact that the facilities described herein may not include all the elements described in this press release, which could adversely impact the partnership described herein, Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities described herein or otherwise, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Flowr requiring additional financing from time to time in order to continue its operations or assist Holigen with its licensing and construction projects, and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Company’s business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowr’s products to be high quality, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowr’s securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements, possible failure to realize the anticipated benefits of partnership arrangements, product launches (including, without limitation, unsuccessful product launches), the inability to launch products, Flowr not being able to provide premium quality cannabis that appeals to the adult-use market and addresses specific patient needs in the medicinal market, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks asso ciated with growth and competition (including, without limitation, with respect to Flowr’s and Holigen’s products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowr’s filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr.
Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
CONTACT INFORMATION: |
U.S. MEDIA: |
Tim Streeb, ICR |
1-646-677-1800 |
tim.streeb@icrinc.com |
CANADIAN MEDIA: |
Rebecca Brown, Crowns Agency |
1-647-456-5599 |
rebecca@crowns.agency |
INVESTOR RELATIONS: |
Raphael Gross, ICR |
1-203-682-8253 |
raphael.gross@icrinc.com |
Bram Judd |
The Flowr Corporation |
1-647-483-7065 ext. 1520 |
bram@flowr.ca |
AMENDED & RESTATED SHARE PURCHASE AND SUBSCRIPTION AGREEMENT
This AMENDED & RESTATED SHARE PURCHASE AND SUBSCRIPTION AGREEMENT is dated as of May 8, 2019 among Holigen Holdings Limited, a company incorporated under the laws of Malta with a company registration number C87034 and having its registered address at Lara Buildings, Level I, Guzeppi Calleja Street, Iklin, IKL 1264, Malta (the Company), Holigen Limited, a private limited liability company incorporated under the laws of Malta with company registration number C87049 and having its registered address at Lara Buildings, Level 1, Guzeppi Calleja Street, Iklin, IKL 1264, Malta (Holigen Sub), The Flowr Corporation, a corporation incorporated under the laws of the Province of Ontario (Flowr), DFT Trading Limited, a corporation existing under the laws of Malta (Pauric Holdco), DFT Holdings Limited, a corporation existing under the laws of Malta (Pauric Topco) and Pauric Duffy, an individual residing in the City of Sintra, Portugal.
WHEREAS, Pauric Holdco wishes to sell to Flowr, and Flowr wishes to purchase from Pauric Holdco, ordinary shares of the Company (the Purchased Shares), on the terms and conditions set forth herein; and
WHEREAS, Pauric Holdco is a wholly-owned subsidiary of Pauric Topco and Pauric Topco is wholly-owned by Pauric Duffy; and
WHEREAS, Flowr wishes to subscribe for, and the Company wishes to issue to Flowr, ordinary shares of the Company (the Subscription Shares), on the terms and conditions set out herein; and
WHEREAS, after giving effect to the sale of the Purchased Shares and the subscription for the Subscription Shares, Flowr would own 19.8% of the outstanding shares of the Company on a fully diluted basis; and
WHEREAS, this Agreement amends and restates a share purchase and subscription agreement among the Company, Holigen Sub and Flowr dated December 19, 2018 (the 2018 Agreement).
THIS AGREEMENT WITNESSES that, in consideration of the mutual covenants and agreements herein contained and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the parties hereto covenant and agree as follows:
ARTICLE 1
INTERPRETATION
1.1 Defined Terms. Unless otherwise defined or the context otherwise specifies or requires, capitalized terms shall have the respective meanings set out in Schedule A.
1.2 Usages. References to this agreement, the agreement, hereof, herein, hereto and like references refer to this Amended and Restated Share Purchase and Subscription Agreement and not to any particular Article, Section or other subdivision of this Agreement.
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 2 -
Any references herein to any agreements or documents shall mean such agreements or documents as amended, supplemented or otherwise modified from time to time in accordance with the terms hereof and thereof.
1.3 Plural and Singular. Where the context so requires, words importing the singular number shall include the plural and vice versa.
1.4 Headings. The division of this Agreement into Articles and Sections and the insertion of headings in this Agreement are for convenience of reference only and shall not affect the construction or interpretation of this Agreement.
1.5 Schedules. The schedules attached to this Agreement form an integral part of this Agreement for all purposes of it.
1.6 Applicable Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.
1.7 Time of the Essence. Time shall in all respects be of the essence of this Agreement.
1.8 Non-Business Days. Whenever any action to be taken hereunder shall be stated to be required to be taken on a day other than a Business Day, such action shall be taken on the next succeeding Business Day.
1.9 Meaning of Include. The words include, includes and including, when used in this Agreement, shall be deemed to be followed by the phrase without limitation.
1.10 Rule of Construction. This Agreement has been negotiated by each party with the benefit of legal representation, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not apply to the construction or interpretation of this Agreement.
ARTICLE 2 | Redacted: Commercially | |
SHARE PURCHASE AND SALE | sensitive information |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 3 -
2.2 Purchase Price. The aggregate Purchase Price shall be satisfied on the Closing Date by a cheque or bank draft (in each case, of immediately available funds) of such amount as directed by Pauric Holdco in writing. At the option of Flowr, such cheque or bank draft may be for the Canadian dollar equivalent of the aggregate Purchase Price, based on the Bank of Canada exchange rate on the Business Day prior to the Closing Date.
ARTICLE 3
SHARE SUBSCRIPTION
3.1 Subscription. Subject to the terms and conditions hereof, immediately following the completion of the Purchase and Sale contemplated in Article 2, Flowr irrevocably subscribes for and agrees to purchase on the Closing Date from the Company, and the Company hereby irrevocably agrees to issue to Flowr, such number of Subscription Shares (the Subscription) that when combined with the Purchased Shares acquired pursuant to the Purchase and Sale would result in Flowr owning 19.8% of the issued and outstanding Shares in the capital of the Company on a fully-diluted basis and the aggregate purchase price for such Subscription Shares acquired by Flowr shall be an amount equal to $6,000,000 (the Subscription Price) . The parties hereto acknowledge that the Subscription is subject to: (a) receipt of all necessary Official Body approvals, and (b) certain other terms and conditions as set forth herein.
3.2 Subscription Price. It is acknowledged that the Subscription Shares shall be issued for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Company, being the full settlement by Flowr of a debt owing to it by the Company, in the amount of the Euro equivalent of $6,000,000 (based on the Bank of Canada exchange rate on the Closing Date) owing by the Company to Flowr as more particularly described in the Term Sheet. For avoidance of doubt, the parties hereto acknowledge payment by Flowr of funds in the amount of $6,000,000 and that, upon delivery of the Subscription Shares pursuant to Section 4.3(a)(ii)(C), such debt shall be fully settled.
ARTICLE 4
CLOSING
4.1 Closing. Subject to the terms and conditions herein, the closing of each of the Purchase and Sale and the Subscription will occur on the second (2nd) Business Day following the satisfaction or waiver of the closing conditions set out in Section 4.3 or such other date as determined by the parties hereto (the Closing Date). The closing of the Purchase and Sale and the Subscription shall occur in succession on the Closing Date, unless otherwise agreed to by the parties hereto. Until the Closing occurs, the Term Sheet shall remain in full force and effect and unamended. Prior to Closing, the Company shall deliver to Flowr a certificate of an officer of the Company certifying the issued and outstanding Shares and other securities of the Company, any rights to acquire Shares or any other securities of the Company and list of holders of Shares and rights to acquire Shares. Following receipt by Flowr of the deliverable in the foregoing sentence, Flowr shall deliver to Pauric Holdco and the Company a calculation of the Purchased Shares and Subscription Shares to be acquired by Flowr and the applicable Purchase Price and Subscription Price.
Amended and Restated Share Purchase and Subscription Agreement - Holigen
(a) |
The necessary documents to obtain a valid stamp duty exemption determination in terms of the Duty on Documents and Transfers Act (Chapter 364 of the Laws of Malta), which shall remain in full force and effect as of the Closing Date. | |
(b) |
In respect of the Subscription, to the extent required under applicable law and/or by an Official Body: |
(i) |
the necessary documents to amend the Companys memorandum of articles to (A) increase the authorised share capital of the Company to allow for the issue of the Subscription Shares, and (B) provide for the appointment right set out in Section 6.3, and such amendments to the memorandum of articles to be mutually agreed upon by the Parties, acting reasonably; | |
(ii) |
a Section 73 report on the valuation of the applicable Subscription Shares and the Subscription Price being paid therefor; and | |
(iii) |
a copy of this Agreement wherein it is agreed to issue such Subscription Shares. |
4.3 Closing Deliverables.
(a) |
The obligations of Flowr to complete the transactions contemplated by this Agreement shall be subject to the satisfaction, on or before the Closing Date, of the following conditions precedent, each of which is for Flowrs exclusive benefit and may be waived, in whole or in part, by Flowr in its sole discretion: |
(i) |
In respect of the Purchase and Sale, delivery of: |
(A) |
evidence of confirmation of approval or consent from the applicable Official Body in respect of the filings required to be made pursuant to Section 4.2, to the satisfaction of Flowr; | |
(B) |
evidence of the written approval issued by the board of directors of the Company with respect to the Purchase and Sale in accordance with the terms of the memorandum and articles of association of the Company; | |
(C) |
share certificates representing the Purchased Shares, free and clear of all Liens, issued by the Company in the name of Flowr, together with evidence satisfactory to Flowr that Flowr has been entered upon the books of the Company as the holder of the Purchased Shares (and the share certificate or certificates representing the Purchased Shares in the name of Pauric Holdco marked as cancelled); |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 5 -
(D) |
evidence satisfactory to Flowr, acting reasonably, that the Company has obtained a full and complete exemption from any requirement to pay a stamp duty in connection with the transactions contemplated herein pursuant to the laws of Malta; | |
(E) |
waiver of pre-emptive rights letter, in form satisfactory to Flowr, acting reasonably, pursuant to which each of the Shareholders waives any and all pre-emptive rights pursuant to the memorandum and articles of association of the Company or otherwise pursuant to applicable law in relation to the transfer of the Purchased Shares; and | |
(F) |
evidence satisfactory to Flowr, acting reasonably, of the board appointment provided for in Section 6.3. |
(ii) |
In respect of the Subscription, delivery of: |
(A) |
evidence of confirmation of approval or consent from the applicable Official Body in respect of the filings required to be made pursuant to Section 4.2, to the satisfaction of Flowr; | |
(B) |
an acknowledgment from the Company that the Subscription Price has been duly satisfied and evidence, satisfactory to Flowr, of the termination of the Term Sheet; and | |
(C) |
share certificates representing the Subscription Shares together with evidence satisfactory to Flowr that Flowr has been entered upon the books of the Company as the holder of the Subscription Shares. |
(iii) |
In respect of the Purchase and Sale and the Subscription, delivery of: |
(A) |
evidence of any other confirmations of approval or consents from the applicable Official Body required in respect of the Purchase and Sale and the Subscription, including approval of the TSX Venture Exchange, if required; | |
(B) |
certificate of an officer of the Company certifying the issued and outstanding Shares and other securities of the Company, any rights to acquire Shares or any other securities of the Company and list of holders of Shares and rights to acquire Shares (or a bringdown certificate in respect of the certificate delivered by the Company pursuant to Section 4.1 certifying that such certificate delivered pursuant to Section 4.1 is true and correct as at the time of Closing); |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 6 -
(C) |
evidence of the register of members and directors of the Company duly updated to reflect the transactions contemplated by this Agreement; and | |
(D) |
a certificate of status, compliance, good standing or like certificate with respect to the Company issued by the appropriate Official Body. |
(b) |
The obligations of Pauric Holdco to complete the transactions contemplated by this Agreement shall be subject to the satisfaction, on or before the Closing Date, of the following condition precedent, which is for Pauric Holdcos exclusive benefit and may be waived, in whole or in part, by Pauric Holdco in its sole discretion: in respect of the Purchase and Sale, delivery of a cheque or bank draft contemplated by Section 2.2. | |
(c) |
The obligations of the Company to complete the transactions contemplated by this Agreement shall be subject to the satisfaction, on or before the Closing Date, of the following condition precedent, which is for the Companys exclusive benefit and may be waived, in whole or in part, by the Company in its sole discretion: in respect of the Subscription, delivery of evidence, satisfactory to the Company, of the termination of the Term Sheet. |
4.4 Post-Closing Filings. Within fourteen (14) Business Days of the Closing Date, the Company covenants to file with the applicable Official Body and use its reasonable commercial efforts to have registered promptly by such Official Body:
(a) |
In respect of the Purchase and Sale, the requisite statutory forms (Form T and Form BO2). | |
(b) |
In respect of the Subscription: |
(i) |
the requisite statutory forms (Form H and Form BO2); and | |
(ii) |
an extract of the resolution of the Shareholders approving the issuance of the Subscription Shares. |
ARTICLE 5
REPRESENTATIONS AND WARRANTIES
5.1 Representations and Warranties. To induce Flowr to enter into this Agreement, the Company, Pauric Holdco, Pauric Topco and Pauric Duffy, as applicable, hereby represent and warrant to Flowr, on a joint and several basis, as at the date hereof and as of the Closing Date, as follows and acknowledge and confirm that Flowr is relying upon such representations and warranties in entering into this Agreement:
(a) |
Status and Power. Each of the Company, Pauric Holdco and Pauric Topco is a company duly incorporated and validly subsisting under the laws of its jurisdiction of incorporation or formation. Each of the Company, Pauric Holdco and Pauric Topco is duly qualified, registered or licensed in all jurisdictions where such qualification, registration or licensing is required and has all requisite capacity, power and authority to own, hold under licence or lease its properties, to carry on its business as now conducted and to otherwise enter into, and carry out the transactions contemplated by, this Agreement. Pauric Duffy is of the full age of majority and has the legal capacity and competence to enter into and perform his obligations under this Agreement. |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 7 -
(b) |
Authorization and Enforcement. All necessary action, corporate (in the case of the Company, Pauric Holdco and Pauric Topco) or otherwise, has been taken to authorize the execution, delivery and performance by each of the Company, Pauric Holdco, Pauric Topco and Pauric Duffy of this Agreement. Each of the Company, Pauric Holdco, Pauric Topco and Pauric Duffy has duly executed and delivered this Agreement and the Subscription Shares will be duly and validly authorized and issued as fully paid and non- assessable ordinary shares in the capital of the Company. This Agreement is a legal, valid and binding obligation of each of the Company, Pauric Holdco, Pauric Topco and Pauric Duffy, enforceable against such Person by the other parties hereto in accordance with its terms, subject to the laws of general application affecting creditors rights and the discretion of the court in awarding equitable remedies. | |
(c) |
Compliance with Other Instruments. The execution, delivery and performance by each of the Company, Pauric Holdco, Pauric Topco and Pauric Duffy of this Agreement, and the consummation of the transactions contemplated herein (i) do not conflict with, result in any breach or violation of, or constitute a default under the terms, conditions or provisions of, (A) in the case of the Company, Pauric Holdco and Pauric Topco, the memorandum and articles of association, articles of incorporation or by-laws of, or any unanimous shareholder agreement or declaration relating to such Person or (B) any applicable law binding on or applicable to the Company, Pauric Holdco, Pauric Topco or Pauric Duffy or to which such Persons property is subject or any agreement, lease, licence, permit or other instrument to which such Person is a party or is otherwise bound or by which such Person benefits or to which any of such Persons property is subject and (ii) do not require the consent or approval of any Official Body or any other Person which has not been obtained and provided to Flowr or is otherwise expressly provided for herein. | |
(d) |
Consents, Approvals, etc. Except as expressly provided for herein, no consents, approvals, acknowledgements, undertakings, non-disturbance agreements, directions or other documents or instruments which have not already been provided to Flowr are required to be entered into by any Person to implement the transactions contemplated by this Agreement. | |
(e) |
Issuance of Shares. The Subscription Shares have been duly authorized and, when issued, delivered and paid for in the manner set forth in this Agreement, will be validly issued, fully paid and non- assessable. The issuance of the Subscription Shares has been approved by the Shareholder. |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 8 -
(f) |
Capital and Subsidiaries. |
(i) |
The statements in the preamble to this Agreement with respect to the Shares of the Company and the ownership of Pauric Holdco and Pauric Topco are true and correct and all necessary filings with Official Bodies have been made in respect of such Share holdings. | |
(ii) |
There is no unanimous shareholder agreement or declaration with respect any Holigen Entity. | |
(iii) |
There are no outstanding warrants, options or other agreements which require or may require the issuance of any Shares of any Holigen Entity, there are no outstanding debt or securities convertible into Shares of any Holigen Entity and there are no Shares of any Holigen Entity allotted for issuance, in each case to a Person other than a Holigen Entity or Flowr. | |
(iv) |
No Holigen Entity is a partner in any limited or general partnership, a member of any unlimited liability company or a party to any joint venture. There are no Subsidiaries of the Company other than as set out in Schedule B. | |
(v) |
The authorized and issued capital of each Subsidiary of the Company is set forth in Schedule B. All of the issued Shares of each Holigen Entity have been or will be issued as fully paid and non-assessable. |
(g) |
Foreign Assets Control Regulations. Neither the execution and delivery of this Agreement nor the Companys or Pauric Holdcos use of the proceeds hereunder will violate the Trading with the Enemy Act, as amended, or any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order relating thereto. Without limiting the foregoing, neither Pauric Holdco nor the Holigen Entities (a) is or will become a Person whose property or interests in property are blocked pursuant to Section 1 of Executive Order 13224 of September 23, 2001 Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism (66 Fed. Reg. 49079 (2001)) or (b) engages or will engage in any dealings or transactions, or be otherwise associated, with any such Person. Each of the Company and Pauric Holdco is in compliance, in all material respects, with the Title III of Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (USA Patriot Act of 2001). | |
(h) |
Sanctions and Anti-Corruption Legislation. No part of the proceeds from the Purchase and Sale or the Subscription herein will be used, directly or indirectly, for any payment to any governmental official or employee, political party, official of a political party, candidate for political office or anyone else acting in an official party capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of any applicable Anti-Corruption Legislation. Neither the Holigen Entities nor Pauric Holdco (i) is a Sanctioned Person, (ii) owns assets in Sanctioned Countries, or (iii) derives operating income from investments in, or transactions with Sanctioned Persons or Sanctioned Countries. Neither the Company nor Pauric Holdco has and nor will it use the proceeds of the Purchase and Sale or the Subscription herein to fund any operations in, finance any investments or activities in or make any payments in violation of any Sanctions or to a Sanctioned Person or a Sanctioned Country that is in violation of any restrictions. |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 9 -
(i) |
Anti-Money Laundering Legislation. The Holigen Entities have adopted and maintain adequate procedures and controls to ensure that they are in compliance with all AML Legislation. Pauric Holdco is in compliance with AML Legislation. | |
(j) |
Solvency. Each of the Company and Pauric Holdco is Solvent. | |
(k) |
No Material Adverse Change. Since December 31, 2017, there has been no Material Adverse Change. |
5.2 Survival of Representations and Warranties. All of the representations and warranties contained in Section 5.1 shall survive the execution and delivery of this Agreement.
ARTICLE 6
COVENANTS
6.1 Ordinary Course. Each of the Company and Pauric Holdco shall use reasonable best efforts to cause each Holigen Entity to, except as expressly consented to by Flowr in writing, conduct the business of such Person in the ordinary course of business until the Outside Date. For certainty, no Holigen Entity (including the Company) shall (i) make any changes to its corporate structure, board composition or Share capital without the prior written consent of Flowr, and (ii) engage in the cannabis business (A) in any jurisdiction in which such business is not governed by a regulatory framework, or (B) in the United States.
6.2 Post-Closing Covenants of the Company. From and after the completion of the Purchase and Sale, the Company and Pauric Holdco each covenant, agree and undertake to not allow the Company to issue, sell or encumber its Shares (or securities convertible or exercisable into or exchangeable for Shares) or the Shares (or securities convertible or exercisable into or exchangeable for Shares) in the capital of Holigen Sub, RPK and/or TCann and to not allow the Company, Holigen Sub, RPK and/or TCann to sell or encumber any of their respective Intellectual Property or to sell all or substantially all of their respective assets and to not permit any of their respective shareholders to transfer or otherwise encumber any Shares or other securities convertible or exercisable into or exchangeable for Shares owned by them without the unanimous approval of the board of directors of the Company, provided that:
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 11 -
written consent of the board of directors of the Company, it being understood that Flowrs nominee on the board of directors shall be excluded from voting for such consent. In the event that the board of directors of the Company has notified Flowr that it desires to approve a sale of the Shares of the Company to a third party, then Flowr shall have the option, in its sole discretion, to agree to transfer its Shares to such third party.
6.4 Pre-Emptive Rights. After the Outside Date, if any Shares of the Company, or securities convertible into or exchangeable directly or indirectly for shares in the capital of the Company (including any newly created class or series) (collectively referred to in this Section as Additional Securities), are to be issued, the Company shall first offer such Additional Securities to those holders of its Shares (the Eligible Shareholders) by notice given to them of the Companys intention to issue Additional Securities and the number and purchase price of such Additional Securities to be so issued. Each of the Eligible Shareholders may purchase its Pro Rata Share (as such term is defined below) of the Additional Securities so offered. Each Eligible Shareholders Pro Rata Share of the Additional Securities shall be equal to the total number of Additional Securities so offered, multiplied by the quotient of X/Y, where X is equal to the number of Shares that the Eligible Shareholder holds, and Y is equal to the aggregate number of Shares held by all of the Eligible Shareholders. Each Eligible Shareholder shall have ten (10) Business Days from the date such notice is given to give a notice to the Company of such Eligible Shareholders intention to purchase all or any of the Additional Securities to which it is entitled and shall indicate in such notice the maximum number of Additional Securities that such Eligible Shareholder is willing to purchase (which number may be up to its Pro Rata Share). If no such notice is given by an Eligible Shareholder within such ten (10) Business Day period, such Eligible Shareholder shall be deemed to have rejected the offer to purchase such Additional Securities. The transaction of purchase and sale by the Company to the Eligible Shareholders shall be completed on the date specified by the board of directors of the Company. Any Additional Securities not taken up by the Eligible Shareholders may be issued within sixty (60) days of such Additional Securities having been first offered to the Eligible Shareholders, at not less than the price and on terms no more favourable than the terms offered to the Eligible Shareholders, to such Persons as the directors of the Company determine, provided that such Persons agree to be bound by the terms of Sections 6.4, 6.5, and 6.6 of this Agreement.
6.5 Tag-Along. After the Outside Date, if any Shareholder (the Selling Party) receives a bona fide written offer (the Third Party Offer) to purchase all or any of the Shares then held by the Selling Party, then, prior to the acceptance of the Third Party Offer, the Selling Party shall notify all of the other Shareholders (the Remaining Shareholders) of such proposed sale and the terms of such proposed sale and the Selling Party shall obtain from the party making the Third Party Offer (the Third Party) a bona fide offer (the Tag-Along Offer) addressed to each of the Remaining Shareholders, on terms and conditions at least as favourable as those contained in the Third Party Offer, to purchase from each Remaining Shareholder: (i) that number of Shares that is the same portion of the total number of Shares which the Remaining Shareholder holds, as the number of Shares proposed to be sold by the Selling Party pursuant to the Third Party Offer bears to the total number of Shares then held by the Selling Party, or (ii) if the Third Party Offer relates to a limited number of Shares only, such limited number of Shares multiplied by the quotient of X/Y, where X is equal to the total number of Shares then held by the Remaining Shareholder and Y is equal to the sum of the limited number of Shares to which the Third Party Offer relates plus the number of Shares that all Remaining Shareholders desiring to participate in the proposed sale hold and, in the case of a sale of Shares by any Remaining Shareholder(s) under this Section 6.5, the number of Shares to be sold by the Selling Party shall be reduced in order to accommodate the number of Shares to be sold by the Remaining Shareholder(s).
Amended and Restated Share Purchase and Subscription Agreement - Holigen
Redacted: Commercially sensitive | ||
- 12 - | information |
The Selling Party shall deliver the Tag-Along Offer to the Remaining Shareholders, together with a copy of the Third Party Offer. The Tag-Along Offer shall be irrevocable and shall be open for acceptance by the Remaining Shareholders for thirty (30) days after the delivery thereof to the last of the Remaining Shareholders. If, within such thirty (30) day period, a Remaining Shareholder does not provide the Selling Party with notice of such Remaining Shareholders intent to accept or reject the Tag-Along Offer, such Remaining Shareholder shall be deemed to have rejected the Tag-Along Offer.
The price per share for any Shares in respect of which a tag-along right under this Section 6.5 is exercised will be equal to the price per Share set out in the Third Party Offer.
6.6 Drag-Along. After the Outside Date, if:
then, upon being notified by the Company or such third party offeror of the names of the Shareholders who have irrevocably accepted or otherwise approved such offer and the number of Shares in respect of which they have irrevocably accepted, or otherwise approved, the Sale Transaction, each Shareholder: (I.) shall, if the Sale Transaction involves a sale or other tender of Shares, sell all of the Shares held by such Shareholder to the third party offeror pursuant to the terms of the Sale Transaction in accordance with the offer upon the terms and at the price contained in the offer; (II.) shall vote in favour of (for the purposes of any approval acquired by applicable law, the memorandum of articles, this Agreement or otherwise), and otherwise act (including, without limitation, by executing and delivering when required all documents and instruments), to approve the Sale Transaction and any continuance, reorganization or recapitalization or any other change to the memorandum of articles and this Agreement that is necessary to implement the Sale Transaction, as applicable; and (III.) shall provide such reasonable representations, warranties, indemnities, covenants, escrow agreements and other agreements as may be required by the third party offeror pursuant to such Sale Transaction. To the extent permitted by law, each Shareholder hereby expressly waives any right to dissent or appraisal under applicable laws with respect to the transactions or approvals referred to in this Section 6.6.
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 13 -
Notwithstanding the foregoing, no Shareholder is required to comply with the terms of this Section 6.6 if:
(c) |
the liability of such Shareholder under the purchase agreement for the Sale Transaction (including, without limitation, liability for a breach of representation or warranty or for a claim under an indemnity) exceeds with respect to such Shareholder the lesser of such Shareholders (A.) pro rata share of any claim; and (B.) the purchase price payable to such Shareholder; or | |
(d) |
the Sale Transaction is conditioned on any requirement by a third party offeror that would unreasonably prevent or restrict such Shareholders ability to make investments in any business. |
ARTICLE 7
MISCELLANEOUS
7.1 Counterparts. This Agreement may be executed in one or more counterparts (including counterparts by facsimile or electronic transmissions in portable document format), each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute one and the same instrument.
7.2 Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto and supersede any prior agreements, representations and understandings, both written and verbal, in respect of the subject matter hereof. For certainty, this Agreement amends and restates the 2018 Agreement in its entirety, and any terms of the 2018 Agreement which conflict with the terms hereof are of no further force or effect.
7.3 Binding Effect. The provisions of this Agreement shall be binding upon and accrue to the benefit of the parties hereto and their respective heirs, legal representatives, successors and permitted assigns.
7.4 Further Assurances. Each of the parties hereto shall, from time to time and at all times hereafter, upon every reasonable request of another party, make, do, execute, and deliver or cause to be made, done, executed and delivered all such further acts, deeds, assurances and things as may reasonably be necessary for more effectually implementing and carrying out the terms of this Agreement.
7.5 Forum Selection and Consent to Jurisdiction. Any legal action or proceeding with respect to this Agreement may be brought in the courts of the Province of Ontario and, by
Amended and Restated Share Purchase and Subscription Agreement - Holigen
- 14 -
execution and delivery of this Agreement, the parties hereby accept for themselves and in respect of their property, generally and unconditionally, the non-exclusive jurisdiction of the aforesaid courts. The parties hereto hereby expressly and irrevocably submits to the jurisdiction of the courts of the Province of Ontario for the purpose of any such litigation as set forth above and irrevocably agrees to be bound by any judgment rendered thereby in connection with such litigation.
[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
Amended and Restated Share Purchase and Subscription Agreement - Holigen
IN WITNESS WHEREOF the parties hereto have executed this Agreement
HOLIGEN LIMITED | HOLIGEN HOLDINGS LIMITED | |
Lara Buildings, Level 1 | ||
Guzeppi Calleja Street | ||
Iklin, IKL 1264 | ||
Malta | ||
Attention: | Pauric Duffy | |
Email: | [Redacted :Personal Information] |
By: | Pauric Duffy | |
Name: Pauric Duffy | ||
Title: Director | ||
By: | Peter Comerford | |
Name: Peter Comerford | ||
Title: Director |
HOLIGEN LIMITED | HOLIGEN LIMITED | |
Lara Buildings, Level 1 | ||
Guzeppi Calleja Street | ||
Iklin, IKL 1264 | ||
Malta | ||
Attention: | Pauric Duffy | |
Email: | [Redacted :Personal Information] |
By: | Pauric Duffy | |
Name: Pauric Duffy | ||
Title: Director | ||
By: | Peter Comerford | |
Name: Peter Comerford | ||
Title: Director |
DFT TRADING LIMITED | DFT TRADING LIMITED | |
Lara Buildings, Level 1 | ||
Guzeppi Calleja Street | ||
Iklin, IKL 1264 | ||
Malta | ||
Attention: | Pauric Duffy | |
Email: | [Redacted :Personal Information] |
By: | Pauric Duffy | |
Name: Pauric Duffy | ||
Title: Director |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
DFT HOLDINGS LIMITED | DFT HOLDINGS LIMITED | |
Lara Buildings, Level 1 | ||
Guzeppi Calleja Street | ||
Iklin, IKL 1264 | ||
Malta | ||
Attention: | Pauric Duffy | |
Email: | [Redacted :Personal Information] | |
By: Pauric
Duffy
|
Name: Pauric Duffy | ||
Title: Director |
Inès Viola | Pauric Duffy | |
Witness | PAURIC DUFFY |
THE FLOWR CORPORATION | THE FLOWR CORPORATION | |
201-100 Allstate Pkwy | ||
Markham, ON L3R 6H3 | ||
Attention: | General Counsel and Corporate | |
Secretary | ||
Email: | Francesco@flowr.ca |
By: | Francesco Tallarico | |
Name: Francesco Tallarico | ||
Title: General Counsel & Corporate Secretary | ||
By: | ||
Name: | ||
Title: |
Amended and Restated Share Purchase and Subscription Agreement - Holigen
A-1
SCHEDULE A
DEFINED TERMS
€ shall means Euros.
$ shall mean Canadian dollars.
2018 Agreement has the meaning given to such term in the recitals.
Agreement means this Amended and Restated Share Purchase and Subscription Agreement.
AML Legislation means (i) Part II.1 of the Criminal Code (Canada) and the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), including any guidelines or orders thereunder, (ii) the USA Patriot Act, or (iii) any other applicable anti-money laundering, anti-terrorist financing and economic sanction laws of Canada, the United States of America or any other applicable jurisdiction (collectively, including any guidelines or orders thereunder).
Anti-Corruption Legislation means any laws, rules and regulations of any jurisdiction applicable from time to time to any of the Holigen Entities concerning bribery or corruption, including the Corruption of Foreign Public Officials Act (Canada), S.C. 1998, c. 34, the Foreign Corrupt Practices Act of 1977, 15 U.S.C. §§ 78dd-1 et seq. and the United Kingdoms Bribery Act 2010 (c. 23).
Business Day means any day, other than Saturday and Sunday, on which banks generally are open for business in Toronto, Ontario and Valletta, Malta.
Closing Date has the meaning given to such term in Section 4.1.
Company has the meaning given to such term in the recitals.
Holigen Entities means collectively with the Company (i) Holigen Sub, (ii) RPK Biopharma, Unipessoal Lda., a corporation existing under the laws of Portugal, (iii) GreyCan Pty Ltd., a corporation existing under the laws of Australia, and (iv) TCann Pty Ltd., a corporation existing under the laws of Australia.
Holigen Sub has the meaning given to such term in the recitals.
Intellectual Property means all issued patents and patent applications, industrial design registrations, trade-marks, registrations and applications therefor, trade secrets, know-how, designs, trade-names and styles, logos, copyright registrations and applications therefor, all of the foregoing owned by or licensed to any of the Holigen Entities and used in or necessary to the operation of its business and which Intellectual Property includes all Intellectual Property necessary (including genetics) to progress, according to the budget and plans laid out for, the Sintra, Aljustrel and Australia facilities, all of which has commercial value to the Holigen Entities.
Amended and Restated Share Purchase and Subscription Agreement - Holigen
Redacted: Commercially sensitive | ||
A-2 | information |
Lien means any mortgage, charge, pledge, privilege, hypothec, security interest, assignment, lien (statutory or otherwise), easement, encroachment, option, title retention agreement, adverse claim, interest, preference, priority, proxy, right of first refusal or first offer, transfer restriction (other than restrictions under applicable securities laws) or arrangement, conditional sale, deemed or statutory trust, restrictive covenant or other encumbrance of any nature which, in substance, secures payment or performance of an obligation.
Material Adverse Change means any change of circumstances or any event which would have a material adverse effect (or a series of adverse effects, none of which is material in and of itself but which, cumulatively, result in a material adverse effect) on (i) the business, property, assets, liabilities, conditions (financial or otherwise) or prospects of the Holigen Entities individually or in the aggregate; or (ii) the ability of any of the Company, Pauric Holdco, Pauric Topco or Pauric Duffy to perform such Persons obligations under this Agreement.
OFAC means the U.S. Department of the Treasurys Office of Foreign Assets Control.
OFAC Lists shall mean, collectively, the List of Specially Designated Nationals and Blocked persons maintained by OFAC, as amended from time to time, or any similar lists issued by OFAC.
Official Body means any national government or government of any political subdivision thereof, or any parliament, legislature, council, agency, authority, board, central bank, monetary authority, commission, department, agency or instrumentality thereof, or any court, tribunal, grand jury, mediator or arbitrator, whether foreign or domestic, in each case having jurisdiction in the relevant circumstances.
Pauric Holdco has the meaning given to such term in the recitals. Pauric Topco has the meaning given to such term in the recitals.
Person means any natural person, corporation, firm, partnership, joint venture, joint stock company, incorporated or unincorporated association, government, governmental agency or any other entity, whether acting in an individual, fiduciary or other capacity.
Public Offering means a transaction (whether by way of initial public offering, reverse takeover, qualifying transaction, or a similar transaction) that will result in the equity securities of the Company being listed on a recognized exchange (as defined in National Instrument 51-102 Continuous Disclosure Obligations).
Sanctioned Country means any country or territory, to the extent that such country or territory itself is subject (or becomes the subject) of Sanctions.
Sanctioned Person means (i) any person that is a designated target of any applicable legislation, regulations, orders, economic or trade sanctions or restrictive measures adopted, administered or enforced by the United Nations Security Council, OFAC (including any persons subject to country-specific or activity-specific sanctions administered by OFAC and any persons named on any OFAC Lists), the U.S. Department of Commerce Bureau of Industry and Security, the U.S. Department of State or pursuant to any other law, rules, regulations or other official acts of the United States, the Parliament of Canada, the European Union, and/or any present or future member state thereof and/or the United Kingdoms Her Majestys Treasury or other relevant sanctions authority which governs transactions in controlled goods or technologies or dealings with countries, entities, organizations or individuals subject to such legislation, regulations, orders, economic or trade sanctions or restrictive measures (each of the foregoing, collectively, Sanctions) or (ii) any person owned or controlled directly or indirectly by any person which is a designated target of Sanctions. As of the date hereof, certain information regarding Sanctioned Persons issued by the United States can be found (i) on the website of the United States Department of Treasury at www.treas.gov/ofac/, or (ii)(A) an agency of the government of a Sanctioned Country, (B) an organization controlled by a Sanctioned Country, or (C) a person resident in a Sanctioned Country, to the extent subject to a sanctions program administered by OFAC.
Amended and Restated Share Purchase and Subscription Agreement - Holigen
A-3
Shareholder means a holder of Shares of the Company and Shareholders means more than one Shareholder.
Shares, as applied to the shares of any corporation or other entity, means the shares or other ownership interests of every class whether now or hereafter authorized, regardless of whether such shares or other ownership interests shall be limited to a fixed sum or percentage with respect to the rights of the holders thereof to participate in dividends and in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding-up of such corporation or other entity.
Solvent means at any time (i) such person is not for any reasons unable to meet its obligations as they generally become due, (ii) such person has not ceased paying its current obligations in the ordinary course of business as they generally become due, and (iii) the aggregate property of such person is, at a fair valuation, sufficient, or, if disposed of at a fairly conducted sale under legal process, would be sufficient, to enable payment of all of its obligations, due and accruing due.
Subscription Shares has the meaning given to such term in the recitals.
Subsidiary means, with respect to any Person, any corporation, company or other similar business entity of which more than fifty per cent (50%) of the outstanding Shares or other equity interests (in the case of Persons other than corporations) having ordinary voting power to elect a majority of the board of directors or the equivalent thereof of such corporation, company or similar business entity (irrespective of whether at the time Shares of any other class or classes of the Shares of such corporation, company or similar business entity shall or might have voting power upon the occurrence of any contingency) is at the time directly or indirectly owned by such Person, by such Person and one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person.
Term Sheet means the binding term sheet between the Company and Flowr dated November 19, 2018, pursuant to which Flowr agreed to lend up to $6,000,000 to the Company.
Amended and Restated Share Purchase and Subscription Agreement - Holigen
B-1
SCHEDULE B
SUBSIDIARIES
HOLIGEN LIMITED, a corporation duly incorporated under the laws of Malta and having its principal place of business at Triq, Guzeppi Calleja, IKL 1262, Iklin (Holigen Sub)
RPK BIOPHARMA, UNIPESSOAL, LDA., a corporation duly incorporated under the laws of Portugal and having its principal place of business at Rua do Campo de Futebol 330 2oESQ, 2785- 609 São Domingos de Rana, Portugal (RPK)
TCANN PTY LTD., a corporation duly incorporated under the laws of Australia and having its principal place of business at 9-15 Chilvers Road, Thornleigh, NSW 2120, Australia (TCANN)
GREYCAN PTY LTD., a corporation duly incorporated under the laws of Australia and having its principal place of business at Level1, 241 Denison Street, Broadmeadow NSW 2292, Australia (GREYCAN)
Amended and Restated Share Purchase and Subscription Agreement - Holigen
C-1
Redacted: Commercially sensitive information
Amended and Restated Share Purchase and Subscription Agreement - Holigen
The Flowr Corporation Completes Private Placement
for Approximately C$13.5 Million
Announces First Quarter
2019 Conference Call and Webcast
Toronto, Ontario May 10, 2019 The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (Flowr or the Company), a Canadian Licensed Producer and global leader in premium cannabis R&D, innovation, and cultivation, is pleased to announce that, further to its news release dated April 29, 2019, it has completed a non-brokered private placement of 2,165,547 common shares at a price of C$6.25 per common share for aggregate gross proceeds of approximately C$13.5 million (the Private Placement).
All securities issued under the Private Placement are subject to the customary four-month hold period and may not be traded before September 11, 2019. In addition, common shares issued to subscribers in the United States will be subject to a hold period under the U.S. Securities Act of 1933, as amended (the "1933 Act") and can only be resold in strict compliance with the applicable exemptions from the registration requirements of the 1933 Act.
Flowr insiders subscribed for a total of approximately C$3.6 million or 578,618 common shares.
The net proceeds from the Private Placement will be used for general working capital purposes and administration expenditures, including for the funding of construction of certain operations of Holigen Holdings Limited.
The Private Placement remains subject to the final acceptance of the TSX Venture Exchange. Flowr intends to file a material change report with respect to the private placement within 10 days of the closing.
The common shares have not been and will not be registered under 1933 Act, or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the 1933 Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
In addition, Flowr also announced today that the Board has approved the granting of an aggregate of 60,000 incentive stock options (the Options) to certain directors of the Company. The Options are exercisable at a price of C$5.70 per share for a period of five years. The Options will vest as to thirty-three and one-third percent (331/3%) on each anniversary of the date of the appointment to the Board of the applicable director.
Release of First Quarter 2019 Results
Flowr also announced today that it will release its first quarter 2019 results before the opening of the financial markets on Friday, May 17, 2019. The Company will also host a conference call and webcast to review these results at 8:30 a.m. Eastern Time. A question-and-answer session will follow.
Toll Free: 1-877-705-6003
Toll/International:
1-201-493-6725
Webcast: flowr.ca/investors
A telephonic replay of the call will be available later that same day beginning at 11:30 a.m. Eastern Time through midnight on Friday, May 31, 2019. To listen to the archived call, dial Toll Free 1-844-512-2921 or Toll/International 1-412-317-6671 and enter replay pin number 13690749, or access the webcast replay via Flowrs website.
About The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and sales license granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own growing systems. Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Vinay Tolia
CEO and Director
Forward-Looking Information
This press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr and its business, which may include, but are not limited to: statements with respect to the release date of Flowr's financial results, the Private Placement, including the receipt of final approval from the TSX Venture Exchange, Flowrs intention to file a material change report, the use of proceeds from the Private Placement, Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and address specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as plans, is expected, expects, scheduled, intends, contemplates, anticipates, believes, proposes or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results may, could, would, might or will be taken, occur or be achieved. Such statements are based on the current expectations of Flowrs management and are based on assumptions and subject to risks and uncertainties. Although Flowrs management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks associated with a delay in releasing Flowrs financial statements (which could result in a violation of applicable laws), Flowr not receiving TSX Venture Exchange final approval for the Private Placement, which could impact the ability of Flowr to close the Private Placement or require Flowr to amend the terms of the Private Placement, Flowr failing to file a material change report within 10 days of closing, Flowr not using the proceeds of the Private Placement as described herein, or the use of the proceeds not advancing Flowrs or Holigens business, Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities or otherwise, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Flowr requiring additional financing from time to time in order to continue its operations and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Companys business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowrs products to be high quality, the inability of Flowrs products to appeal to the adult-use recreational market and address specific patient needs in the medicinal market, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowrs securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowrs products to treat certain conditions, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements, possible failure to realize the anticipated benefits of partnership arrangements, product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowrs products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowrs filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
CONTACT INFORMATION:
MEDIA: |
Sean Griffin |
Vice President, Communications & Public Relations |
(877) 356-9726 ext. 1526 |
sean.griffin@flowr.ca |
INVESTORS: |
Thierry Elmaleh |
Head of Capital Markets |
(877) 356-9726 ext. 1520 |
thierry@flowr.ca |
Form 51-102F3
Material Change Report
Item 1 | Name and Address of Company |
The Flowr Corporation | |
461 King Street W., Floor 2 | |
Toronto, Ontario | |
M5V 1K4 | |
Item 2 | Date of Material Change |
May 10, 2019 | |
Item 3 | News Release |
A news release in respect of the closing of the Private Placement (as defined below) was disseminated by The Flowr Corporation (Flowr or the Company) over GlobeNewswire on May 10, 2019. | |
Item 4 | Summary of Material Change |
On May 10, 2019, Flowr completed a non-brokered private placement of 2,165,547 common shares at a price of C$6.25 per common share for aggregate gross proceeds of approximately C$13.5 million. | |
Item 5 | Full Description of Material Change |
5.1 | Full Description of Material Change |
On May 10, 2019, Flowr completed a non-brokered private placement of 2,165,547 common shares at a price of C$6.25 per common share for aggregate gross proceeds of approximately C$13.5 million (the Private Placement). All securities issued under the Private Placement are subject to the customary four-month hold period and may not be traded before September 11, 2019. In addition, common shares issued to subscribers in the United States will be subject to a hold period under the U.S. Securities Act of 1933, as amended (the 1933 Act) and can only be resold in strict compliance with the applicable exemptions from the registration requirements of the 1933 Act. Flowr insiders subscribed for a total of approximately C$3.6 million or 578,618 common shares. | |
The net proceeds from the Private Placement will be used for general working capital purposes and administration expenditures, including for the funding of construction of certain operations of Holigen Holdings Limited. | |
As of the date of this material change report, the Private Placement remains subject to the final acceptance of the TSX Venture Exchange. |
- 1 -
5.2 | Disclosure for Restructuring Transactions |
Not applicable. | |
Item 6 | Reliance on subsection 7.1(2) of National Instrument 51-102 |
Not applicable. | |
Item 7 | Omitted Information |
Not applicable. | |
Item 8 | Executive Officer |
Alexander Dann | |
Chief Financial Officer | |
877- 356- 9726 | |
Item 9 | Date of Report |
May 14, 2019 |
- 2 -
Forward-Looking Information
This material change report includes forward-looking information within the meaning of Canadian securities laws regarding Flowr and its business, which may include, but are not limited to: statements with respect the Private Placement, including the receipt of final approval from the TSX Venture Exchange, the use of proceeds from the Private Placement, Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and address specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as plans, is expected, expects, scheduled, intends, contemplates, anticipates, believes, proposes or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results may, could, would, might or will be taken, occur or be achieved. Such statements are based on the current expectations of Flowrs management and are based on assumptions and subject to risks and uncertainties. Although Flowrs management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this material change report may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks associated with Flowr not receiving TSX Venture Exchange final approval for the Private Placement, which could impact the ability of Flowr to close the Private Placement or require Flowr to amend the terms of the Private Placement, Flowr not using the proceeds of the Private Placement as described herein, or the use of the proceeds not advancing Flowrs or Holigens business, Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities or otherwise, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Flowr requiring additional financing from time to time in order to continue its operations and such financing may not be available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Companys business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowrs products to be high quality, the inability of Flowrs products to appeal to the adult-use recreational market and address specific patient needs in the medicinal market, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowrs securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowrs products to treat certain conditions, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements, possible failure to realize the anticipated benefits of partnership arrangements, product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowrs products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowrs filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
- 3 -
The Flowr Corporation Announces Results for the First
Quarter 2019
Company to Host Conference Call and Webcast Today at 8:30
A.M. ET
Toronto, Ontario May 17, 2019 The Flowr Corporation (TSXV: FLWR; OTC: FLWPF) ("Flowr" or the "Company"), herein announces its financial and operational results for the first quarter ended March 31, 2019.
Select highlights from the first quarter of 2019 include:
An additional four grow rooms were propagated as construction of the purpose-built, indoor cultivation facility, Kelowna 1, is on track to be completed in the third quarter of 2019; | |||
10 of a planned 20 rooms are licensed and ready for use with 8 rooms propagated with plants; | |||
Production increased 8% quarter over quarter as process optimizations resulted in higher yields from core strains and cultivation activities ramp up in tandem with construction; | |||
Production in the quarter excludes the four new grow rooms as their first harvest occurred in the second quarter; | |||
Consumer demand for Flowrs premium dried flower was strong and average net realized price per gram was $7.70, a 9% quarter over quarter increase; and | |||
Gross revenue of approximately $1.8 million and net revenue of approximately $1.6 million, which excludes approximately $250,000 of design and construction fees from Hawthorne Canada Limited in relation to construction of the R&D facility on the Kelowna Campus. |
The following table summarizes the Companys key financial and operational results:
In thousands of Canadian dollars, | Three months ended | ||||||||
(except loss per share and grams produced) | March 31 | December 31 | |||||||
2019 | 2018 | 2018 | |||||||
Grams produced* | 279,760 | - | 259,091 | ||||||
Grams sold | 211,195 | - | 405,584** | ||||||
Average net realized price per gram | 7.70 | - | 7.08 | ||||||
Net revenue | 1,626 | - | 2,870 | ||||||
Gross profit (loss) before fair value adjustments | 114 | (656 | ) | 252 | |||||
Selling, General and Administrative expense | 3,701 | 1,214 | 4,286 | ||||||
Share-based compensation | 2,103 | 386 | 3,356 | ||||||
Net loss | (5,850 | ) | (2,582 | ) | (6,059 | ) | |||
Loss per share (basic and diluted) | (0.06 | ) | (0.03 | ) | (0.10 | ) | |||
Cash used in investing activities | (12,645 | ) | (5,098 | ) | (10,609 | ) | |||
Cash from financing activities | 2,110 | 783 | 2,267 |
*Grams produced refers to the grams of dried cannabis harvested
from plants in the period. The Company calculates grams produced based on the
final recorded weight of dried harvested buds that have completed the drying
stage net of any weight loss during the drying process for the period.
**
Includes the sale of inventory produced in prior quarters of 2018.
Management Commentary
Vinay Tolia, Flowrs Chief Executive Officer commented: "Our team in Kelowna is doing a tremendous job balancing our construction schedule, propagating and harvesting from rooms as they come online, and refining our cultivation process as we dial in our facility. We doubled the number of rooms available for propagation during the quarter and began harvesting from some of the additional rooms in the second quarter. At the same time, we continued to optimize processes and delivered improved yields compared to last quarter."
All results are reported in Canadian dollars unless otherwise stated.
Mr. Tolia continued, "Bottlenecks in processing and packaging persisted during the quarter as we work from a temporary setup during construction. We are implementing improvements to reduce the impact of this situation and ultimately expect to increase the level of automation involved in these processes when our facility is completed later this year. Our March run-rate was closer to where we expect to be. We exited the quarter on a positive and accelerating trend."
Operational Results for the Three Months Ended March 31, 2019
Kelowna 1
In the first quarter, the Company continued to advance construction of its purpose-built, indoor cultivation facility, Kelowna 1, at the same time as it ramped up production.
The Company produced approximately 280 kilograms of cannabis in the first quarter, compared to 259 kilograms in the fourth quarter of 2018.
By the end of the first quarter, 10 of a planned total 20 rooms were licensed and ready for use, with plants propagated in eight (8) of these rooms.
First quarter production does not reflect the addition of four (4) rooms during the quarter. These rooms were propagated during the quarter and the increased production capacity is expected to be realized beginning in the second quarter of 2019. The approximate 8% quarter over quarter production increase reflects the Companys continued optimization efforts as the facility advances to full capacity.
The Company is currently processing and packaging product in a temporary area as the permanent packaging site is currently under construction. The challenges associated with processing and packing in a temporary area continued to impact sales during the quarter. Improvements, including adding shifts, were made to the current process and the Company expects to add automation as part of the move to the permanent processing and packaging area later this year.
The Company spent approximately $4.4 million on construction activities at Kelowna 1 in the first quarter. The total budget for the project is $33.8 million, $18.3 million of which is anticipated to be spent in 2019.
Construction remains on track to be completed by the end of the third quarter of 2019, with all 20 grow rooms anticipated to be propagated in the fourth quarter of 2019.
Flowr Forest
In the first quarter, the Company advanced preparation work for Flowr Forest, the greenhouse and outdoor production project adjacent to Kelowna 1. The perimeter is now fenced, and security is in place for the site, which is envisaged to include 42 greenhouses, each approximately 4,500 square feet, pending Health Canada approval.
Research and Development ("R&D") Facility
In 2018, Flowr was selected as the R&D partner of choice for Hawthorne Canada Limited, a subsidiary of The Scotts Miracle-Gro Company. Together with Hawthorne Canada, Flowr is creating a cannabis cultivation R&D facility, which is located adjacent to Kelowna 1. Construction remains on track for completion in the third quarter of 2019, with operational timing pending Health Canada approval.
Holigen Holdings Limited ("Holigen")
The Company entered into an agreement to acquire a 19.8% interest in Holigen a European-based cannabis company in the process of developing large-scale cannabis cultivation facilities and Good Manufacturing Process (GMP) compliant production facilities that are expected to provide finished medical cannabis products, pharmaceutical ingredients, and plants and seeds to medical cannabis markets globally. As disclosed in the Companys April 29, 2019, press release, Flowr is evaluating a further acquisition and/or investment into Holigen. The Company provides no assurances that any transaction with Holigen will be completed as proposed or at all.
During the first quarter, work continued at Holigens Aljustrel facility in Portugal, an over seven million square foot outdoor growing operation with an expected annual capacity of over 500,000 kilograms. Phase 1 of the project is fenced and security monitored and is expected to be operational by mid-2019, pending final approval by authorities. The initial phase has an expected 968,800 square feet of growing space and an expected annual capacity of 77,500 kilograms.
NASDAQ Listing
As previously disclosed, the Company submitted an application to list its common shares on the NASDAQ Capital Market ("NASDAQ") and subsequently has been in contact with the exchange. The submission is progressing through the approval process and the Company will provide a trading date once all regulatory formalities are satisfied.
Financial Results for the Three Months Ended March 31, 2019
During the first quarter, the Company generated gross revenue of approximately $1.8 million and net revenue of approximately $1.6 million, both of which excludes an approximate $250,000 of design and construction fees from Hawthorne Canada Limited in relation to construction of the R&D facility on the Kelowna Campus.
The Company sold approximately 211 kilograms of premium cannabis products in the first quarter, at an average net realized price per gram of $7.70. A comparison of quarter over quarter sales may not be indicative as fourth quarter 2018 included the sale of inventory produced in prior quarters of 2018. Flowr believes it must grow its own product to deliver the quality that its customers expect and does not source material from third parties.
Net loss in the first quarter of 2019 was approximately $5.8 million. Key costs contributing to a net loss in the quarter were cost of sales, selling, general and administrative expenses and share-based compensation, partially offset by unrealized gains on changes in fair value of biological assets.
Cost of sales for the first quarter was approximately $1.5, including the expensing of capitalized inventory costs, as product was sold in the first quarter of 2019.
Selling, general and administrative expenditures, consisting primarily of salaries and professional fees, were approximately $3.7 million and share-based compensation was approximately $2.1 million in the first quarter of 2019. These amounts reflect the expansion across all functional areas to support the increasing production platform of the Kelowna Campus.
Adjusted EBITDA (Non-IFRS Measure)
Adjusted EBITDA is net loss, plus (minus) income taxes (recovery), plus (minus) interest income (expense), net, plus depreciation and amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on biological assets and inventory sold, plus listing expense costs and plus (minus) loss (gain) on investments. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash used by operations.
In thousands of CAD dollars | Three months ended | |||||
March 31, | ||||||
2019 | 2018 | |||||
Net loss | (5,850 | ) | (2,582 | ) | ||
Depreciation and amortization | 469 | 175 | ||||
Unrealized (gains) losses on fair value adjustments | (206 | ) | 210 | |||
of biological assets | ||||||
Fair value adjustments on inventory sold | (42 | ) | - | |||
Share-based compensation | 2,103 | 386 | ||||
Unrealized loss on valuation of warrant | 351 | 27 | ||||
investment | ||||||
Interest (income) expense | 40 | 2 | ||||
Adjusted EBITDA | (3,135 | ) | (1,782 | ) |
Adjusted EBITDA losses were higher for the three months ended March 31, 2019 compared to 2018 by $1,353,000, due to the ramp up of cultivation and operating activities in 2019.
For a full discussion of Flowrs operational and financial results, please refer to the Companys first quarter 2019 Managements Discussion & Analysis and Financial Statements, which have been filed on SEDAR.
Management Update
The Company is also pleased to announce that Ashley Thomson (nee Dalziel) has joined Flowr as Chief People Officer. In this new role, Ms. Thomson will be the driving force behind Flowrs culture and employee experience. She will be responsible to build and support world-class teams and create environments that inspire people's best work. Ms. Thomson will be an instrumental business partner in Flowrs growth through the creation and execution of best-in-class strategies to ensure that Flowr is attracting, developing and maximizing high-quality talent to fuel the expansion of the brand and address skill set gaps created through rapid growth.
Ms. Thomson served as the Chief People Officer of Freshii Inc. from May 2, 2017 to May 3, 2019, and previously as Vice President of People Culture at Freshii Inc. from February 1, 2016 to May 2, 2017. Prior to joining Freshii, Ms. Thomson held a number of positions at Lululemon Athletica Inc. from October 2006 to January 2016, where she served as the Global Manager of Recruiting and Talent. Ms. Thomson holds a B.A. in Psychology from the University of British Columbia and holds a Master of Counseling Psychology from the City University of Seattle.
Conference Call and Webcast
Flowr will host a conference call and webcast today at 8:30 a.m. Eastern Time. A question-and-answer session will follow.
Toll Free: 1-877-705-6003 |
Toll/International: 1-201-493-6725 |
Webcast: flowr.ca/investors |
A replay of the call will be available later that same day beginning at 11:30 a.m. Eastern Time through midnight on Friday, May 31, 2019. To listen to the archived call, dial Toll Free 1-844-512-2921 or Toll/International 1-412-317-6671 and enter replay pin number 13690749, or access the webcast replay via Flowrs website.
To access webcast information, please visit www.flowr.ca/investors
About The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and sales license granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own growing systems. Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Vinay
Tolia
CEO and Director
Non-IFRS Financial Measures
This press release makes reference to certain measures that are not recognized measures under International Financial Reporting Standards ("IFRS"). These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS, and are therefore unlikely to be comparable to similar measures presented by other companies. When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure. These measures are provided as additional information to complement those IFRS measures by providing further understanding of the Companys results of operations from managements perspective. Accordingly, they should not be considered in isolation nor as a substitute to the Companys financial information reported under IFRS. Management uses non-IFRS measures such as Adjusted EBITDA to provide investors with supplemental information of the Companys operating performance and thus highlight trends in the Companys core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, to assess its ability to meet future debt service requirements, in making capital expenditures, and to consider the businesss working capital requirements. Readers are cautioned that the non-IFRS measures contained herein may not be appropriate for any other purpose.
Forward-Looking Information
This press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr and its business, which may include, but are not limited to: statements with respect to the completion of Kelowna 1 in the third quarter of 2019, the number of planned rooms that will be licensed and used at Kelowna 1, the ramping up of cultivation activities in tandem with construction, Flowr continuing to optimize processes, Flowr implementing improvements to reduce bottlenecks in processing, Flowr increasing levels of automation in the future as part of its move to a permanent processing and packaging area, expectations for the Companys run-rate, Flowr being on a positive and accelerating trend, Flowr realizing increased production capacity, the total budget for the construction of Kelowna 1 and the amount anticipated to be spent in 2019, the anticipated timeline for all grow rooms at Kelowna 1 to be propagated, preparation work for Flowr Forest, the timeline for completing the R&D facility, Health Canada approvals for the R&D facility, Ms. Thomson building and supporting world-class teams and creating environments that inspire people's best work, Ms. Thomson creating and executing best-in-class strategies to ensure that Flowr is attracting, developing and maximizing high-quality talent to fuel the expansion of the brand and address skill set gaps created through rapid growth, statements with respect to Holigen, including the closing of the acquisition of a 19.8% interest in Holigen, Flowrs evaluation of a further acquisition and/or investment in Holigen, facilities Holigen is proposing to complete, the products it proposes to produce and sell, and the markets it proposes to operate and distribute its products in, Holigen developing large-scale cannabis cultivation facilities and GMP compliant facilities, Holigens facilities providing finished medical cannabis products, pharmaceutical ingredients, and plants and seeds to medical cannabis markets globally, expected timelines for Holigens Aljustrel facility becoming operational, the expected square footage of growing space and expected annual capacity of the initial phase of Holigens Aljustrel facility, Holigen potentially being among the lowest cost producers in the world, Flowr intending to use the Flowr Forest for greenhouse and outdoor production of cannabis and extraction of such other form factors, the Company initiating its licensing process with Health Canada and obtaining its license for Flowr Forest, the Company planning to begin construction and growing the Flowr Forest in 2019 and beyond, the products cultivated from the Flowr Forest being used for extraction in developing edibles and concentrates, the number of greenhouses, size of greenhouses, and size of the outdoor grow at the Flowr Forest, the Company intending to develop Kelowna 2, the planned size of Kelowna 2 and the number of grow rooms expected in Kelowna 2, Flowr only getting started with its planned operations and strategic direction, Flowrs design and cultivation expertise and superior IP know-how enabling it to grow high quality cannabis on a large scale at industry leading yields, Flowrs operational efficiency improving with the completion of the Kelowna 1 facility, Flowr having 20 grow rooms fully constructed in the third quarter of 2019, the completion of the Kelowna 1 facility enabling Flowr to begin to capitalize on strategic growth opportunities, the number of kilograms of capacity on an annualized basis, the completion and timing of completion of the Kelowna 1 facility, the additional grow rooms that will become available upon completion of the Kelowna 1 facility, the listing of the Companys common shares on the NASDAQ, the timing and progress thereof and trading of the common shares being approved for listing, Flowrs belief that it must grow its own product to deliver the quality its customers expect, Flowr not sourcing material from third parties, Flowr being well positioned to complete its facilities build-out and ramp-up production in 2019 and capitalize on its strategic growth opportunities globally, Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeal to the adult-use recreational market and address specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of Flowrs management and are based on assumptions and subject to risks and uncertainties. Although Flowrs management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including, but not limited to, Flowr deciding to use third party products to supplement any supply shortage, which could impact Flowrs brand and/or its ability to sell premium product, other licensed producers selling third party product at a lower cost that is premium and directly competes with Flowrs products, Flowr being delayed in closing the acquisition of a 19.8% interest in Holigen or such acquisition not being completed, Flowr not completing a further investment into and/or acquisition of Holigen, which could materially impac t Flowrs strategy to expand globally, Holigen being unable to complete construction of its proposed facilities or being unable to get the required licenses to operate such facilities, Holigen not being able to produce and/or sell the products described herein or in the markets it proposes to sell such products, Holigen not being among the lowest cost producers in the world, resulting in decreased margins, higher costs and additional financing requirements, Holigen not developing large-scale cannabis cultivation and GMP compliant facilities, Holigen not meeting expected timelines, or expectations for growing space or expectations for annual capacity, the inability of Flowr to use the Flowr Forest for greenhouse and outdoor production of cannabis and extraction of such other form factors, as result of the inability to receive required approvals and licenses, which could have a material adverse impact on Flowrs results of operations, financial condition and business, the number of greenhouses, size of greenhouses and/or size of outdoor production being materially less than the numbers described herein, which could materially adversely impact the products to be cultivated and produced out of the Flowr Forest and the Companys forecasts, the Company failing to initiate its licensing process with Health Canada and/or being unable to obtain its Health Canada license for the Flowr Forest, the Company being delayed in initiating its licensing process or Health Canada not approving the license for the Flowr Forest, which could have a material adverse impact on its financial condition, results of operations and business, the Company being delayed in constructing the Flowr Forest or not being able to construct or plant the Flowr Forest at all for any reason, including as a result of not receiving required approvals or due to weather conditions, which could have a material adverse impact on Flowrs financial condition, results of operations, business, and/or ability to compete in the other form factor markets, the products cultivated from the Flowr Forest not being used or the inability to use such products for extraction in developing edibles and concentrates, any delay in the timing that edibles and concentrates are expected to be legally sold in Canada, which could materially adversely impact Flowrs future cash-flows and forecasts, Flowr not being in a position to launch cannabis oils and vape technologies in 2019 or not launching them at all, which could have a material adverse impact on Flowr financial results, operations and financial condition, including losing competitive advantages over other licensed producers, the Company not being able to construct the Kelowna 2 facility, which would reduce Flowrs capacity and have an impact on future financial results, Kelowna 2 being smaller and/or containing fewer grow rooms, which could materially reduce the Companys future planned capacity and forecasts, Flowr not being well positioned to execute on its planned operational and strategic direction, the inability of Flowrs design and cultivation expertise and superior IP know-how enabling it to grow high quality cannabis on a large scale at industry leading yields, Flowrs operational efficiency not improving as a result of the completion of the Kelowna 1 facility, Flowr failing to complete the 20 grow rooms or such rooms not being fully operational on the timing described herein, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the completion of the Kelowna 1 facility not allowing Flowr to begin to capitalize on strategic growth opportunities, Flowr not achieving or producing the number of kilograms of capacity on an annualized basis as set forth herein, which could have a material adverse effect on Flowrs business, financial condition and results of operations, Flowr not being able to or being delayed in selling a wide selection of cannabis cultivars in both seed and clone form in 2019, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the Companys cultivation process not enabling it to produce high quality clones, Flowr not being able to produce the anticipated number of clones or at all on annualized basis upon completion of the Kelowna 1 facility, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the clones that Flowr produces not being incremental to the Companys cultivation process and in excess of what it needs for its retail and medical production, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the Kelowna 1 facility not being completed or completed in time or on the timeline contained herein, the Kelowna 1 facility not having the anticipated number of licensed and/or operational grow rooms, the additional grow rooms that will become available upon completion of the Kelowna 1 facility not becoming available on time or at all, which could have a material adverse impact on Flowrs business, financial condition and results of operations, cultivation activities not ramping up in tandem with construction, Flowr being unable to optimize process and reduce bottlenecks in processing, Flowr not completing the R&D facility on the timeline herein, any delay or inability to obtain Health Canada approvals for the R&D facility, the listing of the Companys common shares on the NASDAQ not being approved or further delayed, which could impact the liquidity of the Companys common shares or cause a significant decline in the price of the common shares, Ms. Thomson not being able to build and support world-class teams and create environments that inspire people's best work, Ms. Thomson not being able to create and execute best-in-class strategies to ensure that Flowr attracts, develops and maximizes high-quality talent to fuel the expansion of the brand and address skill set gaps created through rapid growth, the steps taken by Flowr not preparing it financially and/or operationally for the recreational use market and/or to execute on its business strategy, Flowr not completing the build out and/or ramp-up of production in 2019, which could materially adversely impact Flowrs financial condition, results of operations and business, Flowr not being able to execute on growth strategies, including international opportunities, which could adversely impact Flowrs growth and future prospects, Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities or otherwise, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Flowr requiring additional financing from time to time in order to continue its operations or expand domestically or globally and such financing not being available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Companys business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowrs products to be high quality, the inability of Flowrs products to appeal to the adult-use recreational market and address specific patient needs in the medicinal market, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowrs securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowrs products to treat certain conditions, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements (including the Hawthorne partnership), possible failure to realize the anticipated benefits of partnership arrangements (including the Hawthorne partnership), product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and co mpetition (including, without limitation, with respect to Flowrs products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowrs filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
CONTACT INFORMATION:
MEDIA: |
Sean Griffin |
Vice President, Communications & Public Relations |
(877) 356-9726 ext. 1526 |
sean.griffin@flowr.ca |
INVESTORS: |
Thierry Elmaleh |
Head of Capital Markets |
(877) 356-9726 ext. 1528 |
thierry@flowr.ca |
Head of Capital Markets |
(877) 356-9726 ext. 1528 |
thierry@flowr.ca |
Managements Discussion and Analysis
For the
Three Months Ended March 31, 2019 and 2018
Managements Discussion and Analysis
The following Managements Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") of The Flowr Corporation, formerly The Needle Capital Corp., (the "Company") provides a discussion and analysis of the financial condition and results of operations to enable a reader to assess material changes in the financial condition of the Company between December 31, 2018 and March 31, 2019, and results of operations for the three months ended March 31, 2019, ( "Q1 2019" and "YTD 2019", respectively) and for the three months ended March 31, 2018, ("Q1 2018" and "YTD 2018", respectively). The MD&A should be read in conjunction with Flowrs unaudited condensed interim consolidated financial statements for the three months ended March 31, 2019 (the "Financial Statements") and audited consolidated financial statements for the year ended December 31, 2018 ("FY 2018"). In this MD&A, references to "Company" or "Flowr", as defined below, are references to The Flowr Corporation and its subsidiaries, as applicable. To the extent applicable, updated information contained in this MD&A supersedes older information contained in previously filed continuous disclosure documents.
This MD&A is dated as of May 16, 2019.
The Financial Statements (and the financial information contained in this MD&A) were prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). The Financial Statements and this MD&A have been reviewed and approved by the Companys Board of Directors (the "Board of Directors" or the "Board"). The Financial Statements include the accounts of the Company and its primary subsidiaries, The Flowr Canada Holdings ULC and The Flowr Group (Okanagan) Inc.
All amounts in this MD&A are expressed in Canadian dollars ("CAD") except per share data and unless otherwise indicated. All amounts in tables are expressed in thousands of CAD, unless otherwise indicated.
Non-IFRS Measures
This MD&A contains certain financial performance measures that are not defined by IFRS, and are used by management to assess the financial and operational performance of the Company. These include but are not limited to adjusted EBITDA (defined below).
As there are no standardized methods of calculating non-IFRS measures, the Companys approaches may differ from those used by other companies in the industry and may not be comparable as a result. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered independently or in substitution for measures prepared in accordance with IFRS.
Additional information relating to the Company, including the Companys Annual Information Form dated April 3, 2019 (the "AIF"),is available on SEDAR at www.sedar.com.
This MD&A contains forward-looking information within the meaning of Canadian securities legislation (see "Forward-looking Information, Risks and Uncertainties" below for a full discussion on the nature of forward-looking information). Information regarding the adequacy of cash resources to carry out the Companys operations and capital projects or the need for future financing is forward-looking information. All forward-looking information, Risks and Uncertainties, including information not specifically identified herein, is made subject to cautionary language at the end of this MD&A. Readers are advised to refer to the cautionary language included at the end of this MD&A under the heading "Forward-looking Information" when reading any forward-looking information. This MD&A is prepared in accordance with Form 51-102F1 and has been approved by the Companys Board of Directors prior to its release.
1
Company Overview
The Company was incorporated under the Business Corporations Act (Alberta) on June 1, 2016. In connection with the completion of the Qualifying Transaction (as defined below), the Company continued from the Business Corporations Act (Alberta) to the Business Corporations Act (Ontario) on September 25, 2018. The head office of the Company is located at 461 King Street West, Suite 200, Toronto, Ontario, M5V 1K4. The Companys shares are listed on the TSX Venture Exchange (the "Exchange") under the symbol "FLWR".
The Company, formerly known as The Needle Capital Corp., was previously classified as a Capital Pool Company as defined in Policy 2.4 of the Exchange. The principal business of the Company was to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein by completing a purchase transaction. The purpose of such an acquisition was to satisfy the related conditions of a qualifying transaction under the Exchange rules (the "Qualifying Transaction").
On September 21, 2018, the Company completed its Qualifying Transaction pursuant to a business combination agreement between the Company, 2652253 Ontario Inc. and a private corporation called The Flowr Corporation ("Flowr PrivateCo") (the "Business Combination Agreement"). As a part of the Qualifying Transaction, the Company changed its name to "The Flowr Corporation" and consolidated its 7,679,997 common shares on a 13:1 basis to 590,769 common shares. In connection with the Qualifying Transaction, Flowr PrivateCo exchanged its shares for all of the issued and outstanding shares of the Company with the former shareholders of Flowr PrivateCo receiving a total of 85,692,095 post-consolidation common shares. Immediately following the closing of the Qualifying Transaction, the Company had a total of 86,282,864 issued and outstanding common shares, where the shareholders of Flowr PrivateCo owned 99.3% of the common shares of the Company, and as a result, the transaction is considered a reverse acquisition of the Company by Flowr PrivateCo. The transaction has been accounted for as a listing expense in the FY 2018 consolidated statements of loss in the amount of $1,802,830 based on the fair value of equity instruments issued by the Company to the shareholders, option holders and warrant holders of The Needle Capital Corp and other professional fees incurred net of cash acquired from The Needle Capital Corp. Flowr PrivateCo is considered to be the acquirer and the Company is considered to be the acquiree. Accordingly, the discussion in this MD&A is a continuation of the operations of Flowr PrivateCo, hereinafter referred to as Flowr or the Company, as applicable.
As at March 31, 2019, Flowrs principal subsidiaries include, a 66.3% (December 31, 2018 66.3%) ownership of The Flowr Canada Holdings ULC, a British Columbia corporation ("Flowr ULC"), which owns, 100% of The Flowr Group (Okanagan) Inc., ("Flowr Okanagan").
Flowr owns 100% of the issued and outstanding Flowr ULC common shares and two US shareholders own 100% of the issued and outstanding Flowr ULC class A shares. The Flowr ULC class A shares are exchangeable for common shares of Company at the sole option and discretion of the holders on a one-for-one basis and at no cost to the holder.
2
Flowr Okanagan is a license holder of (i) standard cultivation, (ii) standard processing and (iii) sale licence issued under the Cannabis Act and Cannabis Regulations and operates what is expected to be an 85,000 square foot GMP designed cultivation facility in Kelowna, British Columbia ("Kelowna 1"). Over time, Flowr will build out additional facilities and sites adjacent to Kelowna 1 (the "Kelowna Campus") and Flowr has begun acquiring properties and rights, as described below. Flowr is focused on producing high-yield, high-quality cannabis for patients and consumers throughout Canada. Flowr also prioritizes research and development to breed specific cannabis varieties to identify unique characteristics and ultimately work to improve Flowrs final products. For a summary of the regulatory framework relating to the Companys operations, please refer to the Companys AIF.
Overall Performance
Highlights of YTD 2019 and as of the Date of this Report
Financial Summary
In thousands of CAD dollars (except where noted), | Three months ended | |||||
March 31, | ||||||
2019 | 2018 | |||||
Grams produced | 279,760 | | ||||
Grams sold | 211,195 | | ||||
Net revenue | 1,626 | | ||||
Net loss | 5,850 | 2,582 | ||||
Capital Expenditures(1) | 21,779 | 4,447 |
(1) |
Capital expenditures includes $10.3 million capital lease additions as a result of transition to IFRS 16. |
During YTD 2019 and to the date of this MD&A, the following highlights the Companys significant events:
|
Financing and Investing Activities The Company completed the following financing and investing activities in 2019: | ||
|
On May 10, 2019, the Company closed a non-brokered private placement of 2,165,547 common shares at a price of C$6.25 per common share for aggregate gross proceeds of $13,534,669 (the "Private Placement"). The net proceeds from the Private Placement will be used for general working capital purposes and administration expenditures, including for the funding of construction of certain operations of Holigen Holdings Limited ("Holigen"). The private placement remains subject to final acceptance of the Exchance. | ||
|
On November 19, 2018, the Company entered into a binding term sheet (the "Term Sheet") with Holigen, pursuant to which the Company agreed to lend $6,000,000 to Holigen. The proceeds received from Flowr are being used by Holigen to purchase land and obtain certain cannabis related licenses in certain jurisdictions, including Portugal. As of March 31, 2019, $6,000,000 has been advanced to Holigen. Flowr has the right to convert all debt owing under the loan facility into the same class of shares held by the shareholders of Holigen, that would result in a 4.8% equity interest in Holigen upon additional terms and conditions being met. | ||
The Companys Filing Statement dated September 19, 2018 included information related to the Companys use of proceeds from its $35.9 million financing completed concurrently with the closing of the Qualifying Transaction (the "RTO Financing"). As a result of the foregoing, the Company had committed $6,000,000 from the RTO Financing to advance this loan to Holigen. |
3
|
On December 19, 2018, the Company entered into a share purchase and subscription agreement, as amended and restated on May 8, 2019 (the "SPSA") which effectively exercises the Companys option to convert the loan receivable into 4.8% shares of the shares of Holigen and the purchase of by the Company of an additional 15% interest in Holigen. In addition, on December 19, 2018, the Company entered into a license agreement with Holigen, whereby the Company agreed to provide certain intellectual property to Holigen to accelerate the completion of Holigens construction and licensing projects. The closing of the acquisition of the 19.8% equity interest with Holigen is subject to certain closing conditions. |
||
|
On October 10, 2018, through a strategic alliance with Ace Valley a brand of cannabis created by the team behind Ace Hill Beer ("Ace Hill"), the Company invested $750,000 in exchange for common shares of Ace Hill. The investment in Ace Hill has been recorded in investments at fair value in the Consolidated Statements of Financial Position as of March 31, 2019. | ||
|
Corporate Matters The Company made the following changes during the period ended March 31, 2019 and to the date of this MD&A: | ||
|
In May 2019, the Company hired Ashley Thomson as Chief People Officer. In this new role, Ms. Thomson will be the driving force behind Flowrs culture and employee experience. She will be responsible to build and support world-class teams and create environments that inspire people's best work. Ms. Thomson will be an instrumental business partner in Flowrs growth through the creation and execution of best-in-class strategies to ensure that Flowr is attracting, developing and maximizing high-quality talent to fuel the expansion of the brand and address skill set gaps created through increasing growth. | ||
|
On March 6, 2019, the Company promoted Jason Broome to the role of Chief Research and Innovation Officer. Mr. Broome previously served as Senior Vice President of Operations. | ||
|
On March 1, 2019, Flowr hired celebrated Canadian Chef Ryan Reed to develop signature edible cannabis products for the Flowr brand. Flowr expects that customers will be able to purchase these unique, gourmet products once launched following the anticipated legalization of edibles and infused products in Q4 2019. | ||
|
On February 5, 2019, Flowr submitted an application to list its common shares on The NASDAQ Capital Market ("NASDAQ") and has filed a Form-40F Registration statement with the U.S. Securities Exchange Commission. A trading date will be made public once all regulatory formalities are satisfied. |
4
|
On December 28, 2018, the shareholders of the Company approved the Companys Long-Term Incentive Plan ("LTIP"), which was subsequently approved by the TSX-V on January 16, 2019. Under the terms of the LTIP the Board or a committee on behalf of the Board may grant units, which may be either restricted share units ("RSUs") or deferred share units ("DSUs") to officers, directors, employees or consultants of the Corporation. The maximum number of common shares which may be reserved and set aside for issue under the LTIP in respect of awards of DSUs to DSU participants and for payments in respect of awards of RSUs to RSU participants, shall not exceed 10% of the total issued and outstanding common shares of the Company, including the 44,100,000 convertible Flowr ULC class A preferred shares. As at the date of this MD&A 197,250 RSUs were issued and outstanding. | ||
|
Operating Activities In keeping with the Companys objective of advancing and optimizing Kelowna 1, the following progress at the Companys operations has been made: | ||
|
The Company continued to advance construction at Kelowna 1 as scheduled. Construction is on track to be completed by the end of the third quarter of 2019. The Company spent $4.4 million on construction activities at Kelowna 1 in the first quarter of 2019. The total budget for the project is $33.8 million, $18.3 million of which is anticipated to be spent in 2019. | ||
|
A total of 10 grow rooms, similar in size, are now completed at Kelowna 1, and in the first quarter of 2019 eight of these rooms are propagated with plants. | ||
|
On January 24, 2019, Flowr Okanagan received approval from Health Canada to open additional grow rooms in Kelowna 1. | ||
|
Growth Activities1 Flowr has undertaken the following activities to support the future growth of the Company: |
1The following statements constitute forward-looking information related to possible events and conditions and may involve unknown risks, assumptions and uncertainties that may cause actual events to differ materially. Please refer to the forward-looking information, Risk and Uncertainties section of the MD&A.
|
In anticipation of the phased construction of the Kelowna Campus, Flowr has purchased, or has entered into agreements to purchase, several parcels of land near or adjacent to Kelowna 1, as follows: | ||
|
On June 29, 2017, Flowr purchased 0.53 acres of land located directly south and adjacent to Kelowna 1 (the "June 29 Parcel"); | ||
|
On February 28, 2018, Flowr purchased 1.942 acres of land located directly to the north and adjacent to Kelowna 1 (the "February 28 Parcel"); | ||
|
On March 2, 2018, Flowr purchased 0.53 acres of land located directly south and adjacent to the June 29 Parcel. Combined with the June 29 Parcel, the total land parcels will be utilized for a research and development facility ("R&D Facility") in partnership with Hawthorne (as defined below) dedicated to advancing cannabis cultivation techniques and systems. The Company spent a total of $4 million on the construction of the R&D Facility as of March 31, 2019 of which $3.5 million has been financed through a loan from Hawthorne with the remainder to be received through loan advances in Q2 2019; | ||
|
On June 7, 2018, Flowr entered into a purchase and sale agreement to purchase 17.6 acres of land located across the road to the east of Kelowna 1, subject to Flowrs satisfaction as to the feasibility of the land for the intended use, zoning and permitting. On February 12, 2019, the purchase and sale agreement closed and Flowr took title over the property. The agreement also provides Flowr with a right of first refusal to purchase two additional parcels of land located adjacent to the 17.6 acres of land. Specifically, the right of first refusal provides Flowr with the right to purchase one 10-acre parcel of land and another 9.4-acre parcel of land subject to agreed terms and conditions. Flowr intends to use these properties for greenhouse and outdoor production of cannabis and extraction of such other form factors (the "Flowr Forest"). Upon finalizing site design, floor plans and corresponding activities to be conducted at the Flowr Forest, the Company will initiate its licensing process with Health Canada. The Company expects to obtain the relevant licenses from Health Canada in 2019. The anticipated capital spending on Flowr Forest is $5.7 million in 2019 of which $3.2 million was spent in Q1 2019; |
5
|
Flowr is planning to begin planting the Flowr Forest upon receipt of Health Canada and other required approvals. The products cultivated from the Flowr Forest will be used for extraction in developing edibles and concentrates; | |||
|
On August 31, 2018, Flowr purchased two (2) acres of land located directly north and adjacent to the February 28 Parcel. Combined with the February 28 Parcel, the total land parcels are intended to be used towards the Companys second cultivation facility ("Kelowna 2"). The Company is currently in the initial planning stages and would require additional sources of financing to move forward with the project. | |||
|
During YTD 2018, Flowr applied for two patents: | |||
|
US Patent Application No. 15/912,377 Apparatus for Transporting Hanging Crops; and | |||
|
US Patent Application No. 15/912,356 Apparatus for Sorting of Crop Components | |||
|
On January 25, 2018 Flowr entered into an agreement with Hawthorne Gardening Company ("Hawthorne"), a subsidiary of The Scotts Miracle Gro Company, to construct and operate the R&D Facility. | |||
|
Key Distribution Channels The following activities occurred during the first quarter of 2019 and up to the date of this MD&A: | |||
|
On January 31, 2019, Flowr announced that it will be begin selling a wide selection of cannabis cultivars, in both high-quality seed and clone form in the second quarter of 2019. Flowr believes that there is an opportunity to sell select cultivars in four key markets (i) Canadian Licence holders seeking high quality genetics (ii) Micro-Cultivators a new Health Canada subclass that can operate small craft cultivation facilities (iii) Export to international markets and (iv) individual consumers that purchase through provincial or licensed private retailers for personal use. No cultivar supply agreements or commitments have been entered into as of the date of this MD&A. | |||
|
On January 29, 2019, Flowrs premium cannabis products became available for purchase in Manitoba through licensed private retailers. | |||
|
On January 9, 2019, Flowr Okanagan entered into an agreement with Shoppers Drug Mart ("Shoppers"), whereby Shoppers will be the direct-to-patient online provider of the Companys FlowrRx products in Canada. FlowrRx products became available on the Shoppers ecommerce site on March 18, 2019. FlowrRx products were previously available online to patients registered via the Company website and through select clinics. |
6
Outlook
Management believes that Kelowna 1 which is designed to GMP standards, provides it with a significant competitive advantage over other Licenced Producers. The staff at Flowr have decades of combined experience both in (1) designing and building cannabis cultivation facilities and (2) performing the actual cultivation of high quality cannabis plants. To realize its objectives, the Companys strategy includes the following activities:
Differentiate itself from other Licensed Producers by providing high quality cannabis products.
Pursue and maintain Good Manufacturing Practices certificates.
Enforce quality assurance protocols that will be among the most rigorous in the industry.
Key Financial Results and Operational Highlights
The following table summarizes the Companys key financial and operational results:
In thousands of CAD dollars, | Three months ended | |||||
(except loss per share and grams produced) | March 31, | |||||
2019 | 2018 | |||||
Grams produced* | 279,760 | | ||||
Grams sold | 211,195 | | ||||
Net revenue | 1,626 | | ||||
Gross profit (loss) before fair value adjustments | 114 | (656 | ) | |||
SG&A | 3,701 | 1,214 | ||||
Share-based compensation | 2,103 | 386 | ||||
Net loss | 5,850 | 2,582 | ||||
Loss per share (basic and diluted) | (0.06 | ) | (0.03 | ) | ||
Cash used in investing activities | (12,645 | ) | (5,098 | ) | ||
Cash from financing activities | 2,110 | 783 |
*Grams produced refers to the grams of dried cannabis harvested from plants in the period. The Company calculates grams produced based on the final recorded weight of dried harvested buds that have completed the drying stage net of any weight loss during the drying process for the period.
7
Construction of Facility
Construction of Kelowna 1 is progressing. For FY 2018, Flowr operated 4 grow rooms and it is expected that when Kelowna 1 is fully completed in 2019 it will have 20 grow rooms. As of the date of this MD&A, the Company has a total of 10 grow rooms ready for use, of which 8 grow rooms are propagated with plants. Flowr anticipates having a total of 10 grow rooms operational in the summer of 2019. Upon completion of the final stages of construction, an additional 10 grow rooms will become available. Flowr anticipates all 20 grow rooms to be operational in Q4 2019.
As of March 31, 2019, the Company spent approximately $19.4 million on the development of Kelowna 1.
Results of Operations
Three Months Ended March 31, 2019, and March 31, 2018
Net loss in Q1 2019 totalled $5,849,669 which was $3,267,391 higher than the net loss in Q1 2018. The increase is mainly driven by the ramp up of the activities of the Company in 2019 partially offset by sales in Q1 2019. Key costs contributing to a higher net loss in Q1 2019 were cost of sales, selling, general and administrative expenses and share-based compensation partially offset by unrealized gains on changes in fair value of biological assets.
Cost of sales for Q1 2019 was $1,512,114 compared to $656,157 in Q1 2018. The increase in cost of sales is largely attributable to the expensing of capitalized inventory costs, as product was sold in Q1-2019. In Q1 2018 start-up costs were expensed directly to cost of sales.
Selling, general and administrative expenditures, consisting primarily of salaries and professional fees, were $3,701,182 in Q1 2019 compared to $1,214,114 in Q1 2018. Share-based compensation was $2,103,109 in Q1 2019 compared to $385,824 in Q1 2018.
8
Adjusted EBITDA (Non-IFRS Measure)
Adjusted EBITDA is net loss, plus (minus) income taxes (recovery), plus (minus) interest income (expense), net, plus depreciation and amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on biological assets and inventory sold, plus listing expense costs and plus (minus) loss (gain) on investments. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash used by operations.
In thousands of CAD dollars | Three months ended | |||||
March 31, | ||||||
2019 | 2018 | |||||
Net loss | (5,850 | ) | (2,582 | ) | ||
Depreciation and amortization | 469 | 175 | ||||
Unrealized (gains) losses on fair value adjustments of biological assets | (206 | ) | 210 | |||
Fair value adjustments on inventory sold | (42 | ) | | |||
Share-based compensation | 2,103 | 386 | ||||
Unrealized loss on valuation of warrant investment | 351 | 27 | ||||
Interest expense | 40 | 2 | ||||
Adjusted EBITDA | (3,135 | ) | (1,782 | ) |
Adjusted EBITDA losses were higher for the three months ended March 31, 2019 compared to 2018 by $1,353,000, due to the ramp up of cultivation and operating activities in 2019.
Cash used in Investing and from Financing activities
The cash used in investing activities for the three months ended March 31, 2019 was $12,644,657 compared to $5,098,268 in 2018. The increase in investing activities are primarily due to the continuing of the construction activities to complete Kelowna 1. Management anticipates the construction of Kelowna 1 to be completed at the end of the third quarter 2019.
Net cash provided from financing activities for the three months ended March 31, 2019 was $2,109,574 compared to $783,442 in 2018. The increase from the prior quarter is largely due to loan advances received from Hawthorne in relation to construction of the R&D Facility.
Total Assets and Liabilities
In thousands of CAD dollars | March 31, 2019 | December 31, 2018 | December 31, 2017 | ||||||
Total assets | 77,404 | 67,133 | 21,502 | ||||||
Current liabilities | 9,094 | 6,283 | 1,956 | ||||||
Non-current liabilities | 12,154 | 1,304 | |
Total assets as at March 31, 2019 increased by a net of $10,270,768 from the end of FY 2018. The change is largely attributed to the increase in property, plant & equipment of $21,020,834 primarily in relation to the construction of Kelowna 1 and recognition of capital leases upon transition to IFRS 16, Leases, partially offset by a decrease in cash and cash equivalents of $11,396,117 mainly due to capital spending. Total liabilities increased by $13,660,579, of which $9,805,275 of the increase related to capital leases obligations recognized on transition to IFRS 16.
9
Summary of Quarterly Results
In thousands of CAD dollars | Q1-2019 | Q4-2018 | Q3-2018 | Q2-2018 | Q1-2018 | Q4-2017 | Q3-2017 | Q2-2017 | ||||||||||||||||
Net revenue | 1,626 | 2,870 | | | | | | | ||||||||||||||||
Net Loss | (5,850 | ) | (6,059 | ) | (5,633 | ) | (3,633 | ) | (2,582 | ) | (1,888 | ) | (467 | ) | (233 | ) | ||||||||
Net Loss attributable to: | ||||||||||||||||||||||||
Common shareholders | (5,045 | ) | (5,515 | ) | (5,420 | ) | (2,724 | ) | (1,742 | ) | (1,442 | ) | (249 | ) | (110 | ) | ||||||||
Non-controlling interest | (805 | ) | (544 | ) | (213 | ) | (909 | ) | (840 | ) | (446 | ) | (218 | ) | (123 | ) | ||||||||
Basic and diluted loss per share attributable to common shareholders of the Company | (0.06 | ) | (0.07 | ) | (0.08 | ) | (0.04 | ) | (0.03 | ) | (0.04 | ) | (0.01 | ) | |
Liquidity and Capital Resources
Liquidity
The main sources of liquidity are the Companys cash and cash equivalents, debt, capital lease obligations and equity issuances. As at March 31, 2019, cash and cash equivalents were $16,293,066 compared to $27,689,183 at December 31, 2018 and total debt was $3,471,536 compared to $1,591,536 at December 31, 2018.
On May 10, 2019, the Company completed the Private Placement of 2,165,547 common shares at price of $6.25 per common shares for aggregate proceeds of $13,534,669.
On September 21, 2018, Flowr completed the RTO Financing of 13,807,734 Flowr common shares at a price of $2.60 per share (the "Second Non-Brokered Financing"), for aggregate proceeds of $35,900,108. In relation to the RTO financing, the Company issued 441,720 broker warrants exercisable at $2.60, expiring 2 years from the date of grant.
On July 18, 2018, Flowr completed a non-brokered financing of 5,309,361 Flowr common shares at a price of $2.60 per share, for aggregate gross proceeds of $13,804,339. The Second Non-Brokered Financing closed on a rolling basis in five tranches, as follows:
On April 11, 2018, 3,310,330 Flowr common shares were issued for aggregate gross proceeds of $8,606,858;
On April 23, 2018, 970,232 Flowr common shares were issued for aggregate gross proceeds of $2,522,603;
On May 28, 2018, 84,382 Flowr common shares were issued for aggregate gross proceeds of $219,393;
On July 12, 2018, 896,151 Flowr common shares were issued for aggregate gross proceeds of $2,329,993;
On July 18, 2018, 48,266 Flowr common shares were issued for aggregate gross proceeds of $125,492.
On January 9, 2018, Flowr completed a non-brokered financing of 15,000,000 Flowr Class A Shares at a price of $1.00 per share (the "First Non-Brokered Financing"), for aggregate gross proceeds of $15,000,000. The First Non-Brokered Financing closed in two tranches, as follows:
On December 28, 2018, 14,185,000 Flowr Class A Shares were issued for aggregate gross proceeds of $14,185,000; and
On January 9, 2018, 815,000 Flowr Class A Shares were issued for aggregate gross proceeds of $815,000.
10
Working Capital
As at March 31, 2019, the Company had working capital of $13,988,482 (December 31, 2018 $27,178,500), calculated as total current assets less total current liabilities. The decrease in working capital of $13,190,018 is primarily due to the capital spending related to the construction of Kelowna 1.
Contractual Obligations
The Companys contractual obligations for the period ended March 31, 2019 are set out below:
Contractual Obligations | Less than 1 | |||||||||||
In thousands of CAD dollars | Total | year | 1-2 years | After 2 years | ||||||||
Trade and other payables | 6,805 | 6,805 | | | ||||||||
Due to related parties | 51 | 51 | | | ||||||||
Deferred revenue | 1,115 | 1,115 | | | ||||||||
Debt | 3,472 | 335 | 1,150 | 1,987 | ||||||||
Total contractual obligations | 11,443 | 8,306 | 1,150 | 1,987 |
Commitments and Contingencies
Future minimum payments as at March 31, 2019, under agreements to which the Company is a party are as follows:
In thousands of CAD dollars | Less than 1 year | 1- 3 years | 3- 5 years | Over 5 years | Total | ||||||||||
Purchase obligations | 11,636 | | | | 11,636 | ||||||||||
Capital lease obligations | 1,345 | 3,740 | 2,686 | 8,683 | 16,454 | ||||||||||
Operating lease obligations | 2 | 2 | | | 4 |
The Company expects to meet its contractual obligations and commitments with its available cash and cash equivalents.
On January 25, 2018, Hawthorne and Flowr entered into an agreement to construct the R&D Facility and to provide certain R&D services upon completion of the R&D facility. The agreement was amended effective December 14, 2018. Under the amended agreement, Flowr Okanagan received a design and construction fee of $1,500,000 which is initially recorded as deferred revenue in the consolidated statements of financial position. The revenue is recognized as design and construction income in the consolidated statements of loss over the period of time the construction and design services are rendered. Hawthorne will also finance all approved development expenses through a loan to Flowr Okanagan to a maximum loan amount of $11,500,000 (the "Hawthorne Loan"). The funds will be advanced to Flowr on a monthly basis based on the expected expenditures to be incurred for the month. On the opening date of the R&D Facility, the Hawthorne Loan will become payable through an agreed upon payment schedule and will commence to accrue interest at a rate of 4%. The Hawthorne Loan will be fully repaid over 20 years from the opening date of the R&D Facility.
As of March 31, 2019, Hawthorne advanced $3,471,536 to Flowr Okanagan under the Hawthorne Loan.
As a part of the arrangement, once the R&D Facility is operational, Hawthorne will pay Flowr a monthly management fee and a monthly SR&ED service fee which can be offset against the monthly loan and interest repayments.
As of March 31, 2019, if the contract were to terminate under certain circumstances, the Company could be required to pay 100% of all costs and expenses loaned by Hawthorne and $1,500,000 in liquidated damages.
11
Off-Balance Sheet Arrangements
There are no off-balance sheet arrangements as at March 31, 2019.
Transactions with Related Parties
The Companys related parties as defined by International Accounting Standard 24 "Related Party Disclosures" (IAS 24), include the Companys subsidiaries, executive and non-executive directors, senior officers and key management personnel. Transactions with related parties are measured at fair value, which in all cases are equivalent to the exchange amounts being the amount of consideration established and agreed upon by the related parties. All related party transactions entered into by the Company are in the normal course of business and have been approved by the Board of Directors of the Company and/or shareholders of the Company as required.
Key management personnel are defined as directors and senior officers of the Company.
Transactions with related parties during YTD 2018 and YTD 2018 are listed below:
(a) Compensation of Key Management Personnel:
In thousands of CAD dollars | Three Months Ended March 31, | |||||
2019 | 2018 | |||||
Salaries and benefits | 441 | 265 | ||||
Share-based compensation | 1,970 | 336 | ||||
Total | 2,411 | 601 |
(b) Transactions with employees, shareholders and officers
As at March 31, 2019, the following related party amounts were included in (a) prepaid expenses and other assets (b) loan receivable (c) due to related parties (d) property, plant and equipment (e) accounts payable and accrued liabilities were as follows:
In thousands of CAD dollars | For the Period Ended | ||||||||
March 31, 2019 | December 31, 2018 | ||||||||
(c) | Reimbursable expenses due to a corporation with directors and officers in common with Flowr | 51 | 63 | ||||||
(d) | Fees paid to a company for the construction of Kelowna 1 whose principal is an employee and shareholder of Flowr(1) | 434 | 2,211 | ||||||
(e) | Amounts due to a construction company whose principal is an employee and shareholder of Flowr(1) | 163 | 82 |
1The Company engaged Maddocks Construction Ltd. ("Maddocks") as one of the primary contractors involved with its capital projects (mainly Kelowna 1 and the R&D Facility). The principal of Maddocks is not an officer or director of the Company.
12
Included in general and administrative expense are amounts paid to shareholders or to companies whose principals are either a shareholder, director or officer of Flowr as follows:
In thousands of CAD dollars | For the Period Ended March 31, | |||||
2019 | 2018 | |||||
Consulting and administration fees | | 61 | ||||
Rental fees | 5 | 5 | ||||
Total | 5 | 66 |
The Company and its subsidiaries are considered related parties under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101") as a result of Core Flow Canada Holdings Inc.s deemed beneficial ownership by it of the common shares of the Company underlying the Flowr ULC class A preferred shares it holds, and also on the basis that Core Flow Holdings Canada Inc. is controlled by Steve Klein (a director of the Company).
As a result, the Company does not benefit from the exemption of the application of the related party transaction rules in section 5.1 of MI 61-101 for transactions with Flowr ULC or Flowr Okanagan on the basis that i) it is not a downstream transaction, because Core Flow Canada Holdings Inc. is a related party of the Company and Core Flow Canada Holdings Inc. has more than 5% of the voting rights in Flowr ULC; and ii) neither Flowr ULC or Flowr Okanagan are wholly owned subsidiaries of the Company.
The Company does from time to time enter into related party transactions with Flowr ULC and Flowr Okanagan primarily related to cash management transactions, intercompany loans and the issuances of shares from the Flowr ULC to the Company in accordance with the share exchange agreement dated August 2018 among the Company and Flowr ULC and certain US shareholders of the Company.
Financial Instruments
The following table outlines the Companys financial instruments as of March 31, 2019. The carrying value of these financial instruments approximate their fair values as at March 31, 2019.
In thousands of CAD dollars | Fair Value at | ||||||||
March 31, 2019 | Basis of Measurement | Financial Instruments | |||||||
Financial Assets | |||||||||
Cash and cash equivalents | 16,293 | Carrying value | Amortized cost | ||||||
Amounts receivable | 3,164 | Carrying value | Amortized cost | ||||||
Deposits recoverable | 443 | Carrying value | Amortized cost | ||||||
Investment in private securities - shares | 602 | Fair value | FVOCI | ||||||
Investment in private securities - warrants | 138 | Fair value | FVPL | ||||||
Convertible loan receivable | 6,000 | Fair value | FVPL | ||||||
Financial Liabilities | |||||||||
Accounts payable and accrued liabilities | 6,805 | Carrying value | Amortized cost | ||||||
Due to related parties | 51 | Carrying value | Amortized cost | ||||||
Lease obligations | 9,805 | Carrying value | Amortized cost | ||||||
Debt | 3,472 | Carrying value | Amortized cost |
13
Amortized cost The carrying values of all the financial assets and liabilities measured at amortized cost approximate their fair values.
FVPL Investments intended for sale and non-hedging derivative instruments (such as warrants) that are recognized at fair value and changes in fair value are recognized in other expenses (income) in the consolidated statement of loss.
Investments private securities Warrants
Seven Leaf Warrants
On December 31, 2018, the Company was granted 2,500,000 warrants in Seven Leaf. Each warrant is exercisable into one common share of Seven Leaf any time prior to December 31, 2020, at an exercise price of $0.50 per common share. Seven Leaf has two directors in common with Flowr. For the period ended March 31, 2019, the Company recognized an unrealized loss of $350,698 (2018 nil) in other expense in the condensed interim consolidated statements of loss.
Convertible loan receivable
On the November 19, 2018, the Company entered into the Term Sheet with Holigen, pursuant to which the Company agreed to lend $6,000,000 to Holigen. The proceeds received from Flowr are being used by Holigen to purchase land and obtain certain cannabis related licenses in certain jurisdictions, including Portugal. As of March 31, 2019, $6,000,000 has been advanced to Holigen. Flowr has the right to convert all debt owing under the loan facility into the same class of shares held by the shareholders of Holigen, that would result in a 4.8% ownership interest in Holigen (the "Conversion Option").
On December 19, 2018, the Company entered into the SPSA, which was amended and restated on May 8, 2019, with Holigen which effectively exercises the Companys Conversion Option and provides the Company with an additional 15% equity interest in Holigen, for an aggregate 19.8% ownership interest. The Company provided Holigen with certain intellectual property to accelerate the completion of Holigens construction and licensing projects. The closing of the acquisition of the 19.8% ownership interest of Holigen is subject to various legal, administrative and approval conditions. As the Conversion Option has been exercised prior to the outside date of January 31, 2019 under the loan facility, interest will not accrue on the loan balance. However, in the event that the acquisition of the 19.8% interest in Holigen does not close, the entire outstanding loan balance and related interest will become payable on February 1, 2020. Interest under the loan facility would be calculated at 8% per annum from the first advance made under the loan.
The Conversion Option represents a call option to the Company and is included in the fair value of the loan. There existed an insignificant difference in fair value between the initial recognition date of November 19, 2018 and the reporting date of March 31, 2019, and accordingly the transaction price approximated the fair value of the loan. The value of the Conversion Option of the loan is $162,367 as of March 31, 2019.
FVOCI Investments not held for trading and non-hedging derivative instruments that are recognized at fair value and changes in fair value are recognized in other comprehensive income.
Investments private securities Shares
On October 10, 2018, the Company acquired 319,149 shares of Ace Hill at a cost of $750,000. As Ace Hill is not a listed public company, the valuation of the shares at the time of issuance was based on a discounted projected cash flow model. The Company re-assessed the fair value of the shares based on equity issuances in the period. For the period ended March 31, 2019 the Company recorded unrealized losses of $148,089 (2018 nil) through other comprehensive income.
14
Risk Management
The Companys exposure to financial instruments includes, but is not limited to, the following risks:
Market risk
Market risk is the risk that the future cash flows or the fair value of a financial instrument will fluctuate because of changes in market conditions. The Company operates in an industry regulated by Health Canada and applicable legislation in Canada. Changes in legislation could have a significant impact on the Companys operations.
Credit Risk
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Companys credit risk is primarily associated with liquid financial assets. The Company limits exposure to credit risk on liquid financial assets by holding cash and cash equivalents at highly-rated financial institutions. As at March 31, 2019, the Company had a convertible loan receivable of $6,000,000 (December 31, 2018 $6,000,000) and amounts receivable of $3,163,838 (December 31, 2018 - $2,963,115). The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. The Company is not significantly exposed to credit risk as the accounts receivables are primarily due from provincial government organizations and overall amounts receivable and convertible loan receivables comprise 11.8% (December 31, 2018 13.4%) of the Companys total assets.
Liquidity Risk
Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company manages the liquidity risk inherent in these financial obligations by regularly monitoring actual cash flows to annual budget which forecast cash needs and expected cash availability to meet future obligations.
The Company will need to raise additional capital through equity issuances or debt financing in order to advance strategic initiatives under consideration or commence new capital projects.
Capital Risk Management
The Company considers its capital to be its equity. The Companys objective for capital management is to: (i) maintain sufficient levels of liquidity to fund and support its capital projects and operating activities; and (ii) maintain a strong financial position to ensure it has ready access to debt and equity markets to supplement free cash flow being invested in its growth projects. The Company monitors its financial position and the potential impact of adverse market conditions on an ongoing basis. The Company manages its capital structure and adjusts it based on prevailing market conditions and according to its business plan. The Companys funding strategy is to maintain a capital structure comprised primarily of equity sourced from equity offerings and net earnings generated from its operations, accompanied with financing through debt.
15
Significant Changes in Accounting Policies
In Q3 2018, the Company has changed its accounting policy with respect
to production costs related to biological assets. Prior to this change, the
Company expensed any costs related to production of biological assets. The
Company now capitalizes production costs related to biological assets and
recognizes the expenses in cost of sales as the inventory is sold. Non-recurring
start-up costs are expensed directly through cost of sales. Shipping and
fulfillment charges and any related depreciation are expensed to cost of goods
sold in the period in which the costs are incurred. The Company also revised its
presentation in the consolidated statement of loss to separate fair value
adjustments for both biological assets and inventory sold in the period. The
Company believes that the revised policy and presentation provides more relevant
financial information to the users of the Financial Statements.
The amended policy is as follows:
(i) Biological assets
While the Companys biological assets, consisting of cannabis plants, are within the scope of IAS 41 Agriculture, the direct and indirect costs of biological assets are determined using an approach similar to the capitalization criteria outlined in IAS 2 Inventories. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs, grow consumables, utilities, facilities costs including an allocation of overhead costs related to production facility, quality and testing costs, and production related depreciation. Capitalized costs are subsequently recorded within cost of sales in the consolidated statements of loss in the period that the related product is sold.
The Company measures biological assets, at fair value less cost to sell up to the point of harvest. Unrealized gains or losses arising from the changes in fair value less cost to sell during the period are separately recorded in the consolidated statement of loss for the related period. Cost to sell includes post harvest production costs and fulfilment costs.
The Company commenced cultivating cannabis in January 2018. Biological assets were measured at a fair value of nil in reporting periods prior to the Company obtaining its sales license on August 10, 2018, as management could not reasonably assess the likelihood of obtaining the sales license from Health Canada at the time. As a result, all capitalized costs related to biological assets were expensed through changes in fair in value of biological assets.
(ii) Inventory
Inventory of harvested bulk cannabis and finished goods are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour related costs, consumables, packaging supplies, facilities costs including an allocation of overhead costs related to production facility, quality and testing costs, and related depreciation. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Supplies and consumables are valued at the lower of cost and net realizable value, with cost determined based on an average cost basis.
The changes in accounting policy have been applied retrospectively. The presentation of production costs in Q1 2018 is now captured as cost in sales in the comparative period.
16
(b) IFRS 16, Leases
Effective January 1, 2019, the Company adopted IFRS 16, Leases, replacing IAS 17, which resulted in changes in accounting policies as described below. In accordance with the transitional provisions in the standard, IFRS 16 was adopted retrospectively without restating comparatives, with the cumulative impact adjusted in the opening balances as at January 1, 2019. The Company also utilized certain practical expedient elections whereby (i) there is no need to reassess whether an existing contract is a lease, or contains an embedded lease if previously determined under IAS 17, (ii) short term and low value leases are treated as operating leases, and (iii) there is no need to reassess the previous assessments in respect of onerous contracts that confirmed there were no existing onerous lease contracts. Under IFRS 16, most leases are now recognized on the balance sheet for lessees, essentially eliminating the distinction between a finance lease and an operating lease under IAS 17, where operating leases were reflected in the consolidated statements of earnings (loss). As a result, as at January 1, 2019, the Company recognized lease obligations and leased assets under existing operating leases of $10,317,064, with no impact on total shareholders equity. Each lease obligation was measured at the present value of the remaining lease payments, discounted using the Companys estimated incremental borrowing rate of 5.8% . Leased assets were recognized as right-of-use assets in property, plant and equipment and were measured at the amount equal to the lease obligations. Leases previously classified as finance leases and recognized in the carrying amounts of the Companys lease obligations and leased assets are now recognized in the carrying amounts of the lease obligations and the right-of-use assets as at January 1, 2019.
The following are the Companys new accounting policies for its leases under IFRS 16:
The determination of whether an arrangement is, or contains, a lease is based on the substance of the agreement on the inception date.
As a lessee, the Company recognizes a lease obligation and a right-of-use asset in the consolidated statements of financial position on a present-value basis at the date when the leased asset is available for use. Each lease payment is apportioned between a finance charge and a reduction of the lease obligation. Finance charges are recognized in finance cost in the consolidated statements of earnings (loss). The right of-use asset is included in property, plant and equipment and is depreciated over the shorter of its estimated useful life and the lease term on a straight-line basis.
Lease obligations are initially measured at the net present value of the following lease payments:
Lease payments are discounted using the interest rate implicit in the lease, or if this rate cannot be determined, the Companys incremental borrowing rate. Right-of-use assets are initially measured at cost comprising the following:
Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated statements of earnings (loss). Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise primarily small equipment.
17
Sublease
In February 2019, the Company entered into a sublease agreement, which is classified as a finance lease under IFRS 16 by reference to the right of use asset generated through the Companys primary lease obligation ("Head Lease"). Upon entering into the sublease arrangement, the right of use asset generated from the Head Lease is derecognized and a receivable related to the net investment in lease is generated based on the net present value of cash flows to be received from the sublease. As of March 31, 2019, the Company had $182,709 receivable due from its net investment in the sublease. Upon entering into the sublease agreement, the Company was required to established a letter of credit with the lessor in the amount of the Companys total remaining lease payments, which has been reflected as restricted cash in other current and long term assets.
Share Capital Information
As at the date of this MD&A, the following number of common shares of the Company and other securities of the Company exercisable for common shares of the Company are outstanding (on a post-consolidation basis):
Securities | Common shares on exercise | ||
Common shares | 89,210,899 | ||
Flowr ULC class A preferred shares (convertible into common shares)* | 43,950,000 | ||
Warrants | 258,270 | ||
Stock options | 12,051,780 | ||
Restricted share units | 197,250 | ||
Fully diluted share capital | 145,668,199 |
*The Flowr ULC class A preferred shares are issued and outstanding in the Flowr ULC and convertible into common shares of the Company at the election of the holder and no cost to the holder.
Disclosure Controls and Procedures
Management has established processes to provide them sufficient knowledge to support representations that they have exercised reasonable diligence that (i) the consolidated financial statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of and for the periods presented by the consolidated financial statements; and (ii) the consolidated financial statements fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented.
In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), the Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures ("DC&P") and internal control over financial reporting ("ICFR"), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of:
i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
18
ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers accounting policies.
The issuers certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in the certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost-effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.
Forward-looking Information, Risks and Uncertainties
Certain statements contained in this MDA constitute "forward-looking information" and "forward looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "forward-looking information"), which are based upon the Companys current internal expectations, estimates, projections, assumptions and beliefs. Statements concerning the Companys objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and the business, operations, future financial performance and condition of the Company is forward-looking information. The words "believe", "expect", "anticipate", "estimate", "intend", "may", "will", "would" and similar expressions, including the negative and grammatical variations of such expressions, are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. In addition, this MD&A, may contain forward-looking information attributed to third-party industry sources.
By their nature, forward-looking information involves numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts and projections that constitute forward-looking information will not occur. Such forward-looking information in this MD&A speak only as of the date of this MD&A. Forward-looking information in this MD&A includes, but is not limited to, statements with respect to:
the expected size, capacity and completion of Kelowna 1, Kelowna 2 and the timing of completion thereof;
the additional grow rooms of Kelowna 1 and the timing of completion and operation thereof;
the construction of additional facilities on the Kelowna Campus;
Flowr seeking to acquire additional properties, and its ability to do so;
the expectation that the Companys common shares will commence trading on the NASDAQ;
the R&D Facility advancing cannabis cultivation techniques and systems;
Flowr using certain properties in the Flowr Forest for greenhouse production and extraction;
licensing with respect to the Companys property and facilities;
timing of obtaining licenses for the Flowr Forest;
Flowr planting the Flowr Forest and the timing thereof;
the timing of selling other form factors and the source of cannabis for such form factors;
capital spending relating to the Companys projects, including Kelowna 1, the R&D Facility and the Flowr Forest;
19
Kelowna 2 and the completion thereof;
the plans for Kelowna 2 and financing thereof;
customers being able to purchase unique gourmet products as a result of the hiring of Chef Ryan Reed, and the timing of the availability of such products;
the experience and skill set of Flowrs management, including Ashley Thomson;
Ms. Thomson being an instrumental partner in Flowrs growth, through creation of best in class strategies;
the Shoppers supply agreement increasing sales for Flowr;
Ms. Thomson or Flowrs ability to attract high quality talent to fuel expansion and address skill set gaps;
Flowr selling cannabis cultivars, and the timing of the commencement of such sales;
the markets that Flowr believes it can sell cannabis cultivars in;
the advantages that Flowr believes it has with Kelowna 1 and its strategies with respect to growing premium cannabis, attaining certain GMP and manufacturing certifications and enforcing certain protocols;
the performance of the Companys business and operations;
the Companys capital expenditure programs;
the future development of the Company, its growth strategy and the timing thereof;
the acquisition strategy of the Company;
the estimated future contractual obligations of the Company;
the Companys future liquidity and financial capacity;
the Companys ability to satisfy its financial obligations in future periods;
the supply and demand for cannabis products and services similar to the Companys products and services;
cost and/or pricing of the Companys products;
expectations regarding the Companys ability to raise capital;
the Companys treatment under government regulatory and taxation regimes;
the use of proceeds from financings completed by the Company;
the closing of the acquisition of the 19.8% ownership interest in Holigen; and
the Companys net sales of all or any one of its products.
With respect to the forward-looking information contained in this MD&A, the Company has made certain assumptions and such forward-looking information is subject to certain risks, including, without limitation, the following risks and assumptions:
the timing of completion of the Facility and the additional grow rooms;
the expected capacity of the Facility;
the ability of Flowr to complete construction of additional facilities on the Kelowna Campus;
20
Flowr being able to acquire additional properties;
the Companys common shares being approved for trading on the NASDAQ;
the R&D Facility being capable of advancing cannabis cultivation techniques and systems;
the Flowr Forest enabling Flowr to produce cannabis in greenhouses and Flowr being able to extract cannabis for other form factors;
Flowr being able to plant the Flowr Forest and the timing thereof;
Flowr receiving licenses and approvals for future and/or planned projects, including the Flowr Forest and Kelowna 2;
Flowr being able to sell other form factors and the timing thereof;
Chef Ryan Reed and Flowr being able to create unique and gourmet products, customers purchasing such products and the timing of the availability of such products;
Flowr and/or Ms. Thomson being able to attract high quality talent and Ms. Thomson proving to be instrumental in Flows growth;
the Shoppers supply agreement actually increasing sales for Flowr;
Flowr being able to sell cannabis cultivars, and the timing of the commencement of such sales;
the markets that Flowr believes it can sell cannabis cultivars in actually forming and those markets purchasing such products from Flowr;
Kelowna 1 and Flowrs strategies with respect to growing premium cannabis, attaining certain manufacturing certifications and enforcing certain protocols providing it with the competitive advantage that Flowr believes it has over other licensed producers;
the ability to develop and market future products;
timing to launch new products;
cost to develop and/or manufacture products;
operating cost estimates and yield trends for the Company;
inventory levels;
pricing for the Companys products;
future market demand/trends;
gross profitability for products;
the ability of the Company to comply with its contractual obligations, including, without limitation, its obligations under debt arrangements, as applicable;
the successful sale of products to third parties on terms favorable to the Company;
the ability of the Company to maintain key strategic alliances, and licensing and partnering arrangements, now and in the future;
the ability of the Company to complete construction of its facilities on time, at all or on budget;
21
any delay in the construction and/or licensing of the facilities of the Company not being material;
the ability of the Company to maintain its distribution networks and distribute its products effectively;
the general regulatory environment in which the Company operates, including the areas of taxation, environmental protection, consumer safety and health regulation;
the timely receipt of any required regulatory approvals;
the general economic, financial, market and political conditions impacting the industry in which the Company operates;
the tax treatment of the Company and the materiality of legal proceedings;
the ability of the Company to achieve or increase profitability, fund its operations with existing capital, and/or raise additional capital to fund future acquisitions and/or development, including construction and licensing of the facilities of the Company;
the ability of the Company to acquire any necessary technology, products or businesses and effectively integrate such acquisitions;
reliance on third party suppliers to supply the Company with products required for its business on favourable terms;
the ability of the Company to generate sufficient cash flow from operations;
the availability of raw materials and finished products necessary for the Companys products;
the impact of increasing competition;
the ability of the Company to obtain and retain qualified staff, equipment and services in a timely and efficient manner;
the ability of the Company to maintain and enforce the protection afforded by trade secrets or other intellectual property rights;
the ability of the Company to conduct operations in a safe, efficient and effective manner;
the results of continuing and future safety and efficacy studies by industry and government agencies related to the Companys products; and
the ability of the Company to successfully market its products and services.
Forward-looking information contained in this MD&A is based on the key assumptions described herein. Readers are cautioned that such assumptions, although considered reasonable by the Company, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided in this MD&A as a result of numerous known and unknown risks and uncertainties and other factors. The Company cannot guarantee future results.
Risks related to forward-looking information include those risks referenced herein and in the Companys other filings with the Canadian Securities Regulators. Some of the risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking information contained in this MD&A include, but are not limited to, the risk factors described above and included under the heading "Risk Factors" in the Annual Information Form.
Forward-looking information contained in this MD&A is based on the Companys current plans, expectations, estimates, projections, beliefs and opinions and the assumptions relating to those plans, expectations, estimates, projections, beliefs and opinions may change. Management has included the summary of assumptions and risks related to forward-looking information included in this MD&A for the purpose of assisting the reader in understanding managements current views regarding those future outcomes. Readers are cautioned that this information may not be appropriate for other purposes. Readers are cautioned that the lists of assumptions and risk factors contained herein are not exhaustive. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of the forward-looking information contained herein.
22
Such forward-looking information is made as of the date of this MD&A and the Company disclaims any intention or obligation to update publicly any such forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
All of the forward-looking information made in this MD&A are expressly qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company.
Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking information in this MD&A, and, accordingly, investors should not place undue reliance on any such forward-looking information. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for the Companys management to predict all of such factors, or changes in such factors, or to assess in advance the impact of each such factors on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information contained in this MD&A.
Other Disclosures
Trademarks
This MD&A includes trademarks that are protected under applicable intellectual property laws and are the property of the Company or its affiliates or licensors. Solely for convenience, the trademarks of the Company or its affiliates and/or licensors referred to in this MD&A may appear with or without the ® or symbol, but such references or the absence thereof are not intended to indicate, in any way, that the Company or its affiliates or licensors will not assert, to the fullest extent under applicable law, their respective rights to these trademarks. Any other trademarks used in this MD&A are the property of their respective owners.
Market Data
This MD&A contains certain statistical data, market research and industry forecasts that were obtained, unless otherwise indicated, from independent industry and government publications and reports or are based on estimates derived from such publications and reports and managements knowledge of, and experience in, the markets in which the Company operates. Industry and government publications and reports generally indicate that they have obtained their information from sources believed to be reliable, but do not guarantee the accuracy and completeness of their information. While the Company believes this data to be reliable, market and industry data is subject to variation and cannot be verified due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. The Company has not independently verified the accuracy or completeness of such information contained herein. In addition, projections, assumptions and estimates of the Companys future performance and the future performance of the industry in which the Company operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described under the heading "Risk Factors" above and in the Annual Information Form.
23
Form 52-109FV2 |
Certification of Interim Filings |
Venture Issuer Basic Certificate |
I, Alexander Dann, Chief Financial Officer of The Flowr Corporation, certify the following:
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of The Flowr Corporation (the "issuer") for the interim period ended March 31, 2019. |
2. |
No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings. |
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings. |
Date: May 17, 2019 | |
"Alexander Dann" | |
Alexander Dann | |
Chief Financial Officer |
NOTE TO READER | |
In contrast to the certificate required for non-venture issuers under National Instrument 52- 109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of | |
i) | controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and |
ii) | a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers GAAP. |
The issuers certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52- 109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation. |
Form 52-109FV2 |
Certification of Interim Filings |
Venture Issuer Basic Certificate |
I, Vinay Tolia, Chief Executive Officer of The Flowr Corporation, certify the following:
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of The Flowr Corporation (the "issuer") for the interim period ended March 31, 2019. |
2. |
No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings. |
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings. |
Date: May 17, 2019 | |
"Vinay Tolia" | |
Vinay Tolia | |
Chief Executive Officer |
NOTE TO READER | |
In contrast to the certificate required for non-venture issuers under National Instrument 52- 109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of | |
i) | controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and |
ii) | a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers GAAP. |
The issuers certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52- 109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation. |
Condensed Interim Consolidated Financial Statements
For the periods ended
March 31, 2019 and 2018
(in Canadian dollars)
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
As at March 31, 2019 and December 31, 2018 |
(unaudited, in Canadian dollars) |
March 31, 2019 | December 31, 2018 | |||||||
ASSETS | Notes | |||||||
Current Assets | ||||||||
Cash and cash equivalents | 16,293,066 | 27,689,183 | ||||||
Amounts receivable | 4 | 3,163,838 | 2,963,115 | |||||
Prepaids and other receivables | 5 | 905,440 | 913,468 | |||||
Inventory | 6 | 1,886,578 | 1,398,943 | |||||
Biological assets | 7 | 833,103 | 497,102 | |||||
23,082,025 | 33,461,811 | |||||||
Non-Current Assets | ||||||||
Investments at fair value | 8 | 739,909 | 1,238,695 | |||||
Property, plant and equipment | 9 | 44,346,851 | 23,326,017 | |||||
Intangible assets | 10 | 3,001,147 | 3,056,728 | |||||
Convertible loan receivable | 8,11 | 6,000,000 | 6,000,000 | |||||
Other long-term assets | 12 | 234,087 | 50,000 | |||||
54,321,994 | 33,671,440 | |||||||
TOTAL ASSETS | 77,404,019 | 67,133,251 | ||||||
LIABILITIES | ||||||||
Current Liabilities | ||||||||
Accounts payable and accrued liabilities | 13,15 | 6,805,011 | 4,604,727 | |||||
Due to related parties | 15 | 51,212 | 63,217 | |||||
Deferred revenue | 14 | 1,114,881 | 1,327,865 | |||||
Short-term lease obligations | 2.2 (b) | 787,020 | | |||||
Current portion of long-term debt | 14 | 335,419 | 287,502 | |||||
9,093,543 | 6,283,311 | |||||||
Non-Current Liabilities | ||||||||
Long-term debt | 14 | 3,136,117 | 1,304,034 | |||||
Lease obligations | 2.2 (b) | 9,018,255 | | |||||
12,154,372 | 1,304,034 | |||||||
TOTAL LIABILITIES | 21,247,915 | 7,587,345 | ||||||
SHAREHOLDERS' EQUITY | ||||||||
Share capital | 20 | 70,737,936 | 70,002,237 | |||||
Other reserves | 18, 21 | (14,062,322 | ) | (15,719,745 | ) | |||
Deficit | (21,576,844 | ) | (16,532,564 | ) | ||||
Accumulated other comprehensive loss | (148,089 | ) | | |||||
Equity attributable to common shareholders of the Company | 34,950,681 | 37,749,928 | ||||||
Non-controlling interests | 21,205,423 | 21,795,978 | ||||||
TOTAL EQUITY | 56,156,104 | 59,545,906 | ||||||
TOTAL LIABILITIES AND EQUITY | 77,404,019 | 67,133,251 |
The accompanying notes are an integral part of the condensed interim consolidated financial statements
Approved by the Board of Directors
Steve Klein (signed) | Director | Karen Basian (signed) | Director |
THE FLOWR CORPORATION 1
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars) |
Three months ended | ||||||||
March 31, | ||||||||
2019 | 2018 | |||||||
Notes | ||||||||
Revenue | 17 | 1,625,694 | | |||||
Cost of sales | 1,512,114 | 656,157 | ||||||
Gross profit (loss) before fair value adjustments | 113,580 | (656,157 | ) | |||||
Fair value adjustments on inventory sold | (42,237 | ) | | |||||
Unrealized (gain) loss on changes in fair value of biological assets | 7 | (206,180 | ) | 210,358 | ||||
361,997 | (866,515 | ) | ||||||
Selling and marketing | 25,843 | 123,756 | ||||||
General and administrative | 15 | 3,675,339 | 1,090,358 | |||||
Research and development | 59 | 78,729 | ||||||
Share-based compensation | 18 | 2,103,109 | 385,824 | |||||
Design and construction income | 14 | (249,875 | ) | | ||||
Depreciation and amortization | 260,901 | 8,201 | ||||||
Finance costs | 98,634 | | ||||||
Other expense | 19 | 297,656 | 28,895 | |||||
Loss before income taxes | (5,849,669 | ) | (2,582,278 | ) | ||||
Net loss | (5,849,669 | ) | (2,582,278 | ) | ||||
Net loss attributable to: | ||||||||
Common shareholders of the Company | (5,044,280 | ) | (1,741,979 | ) | ||||
Non-controlling interests | (805,389 | ) | (840,299 | ) | ||||
Net loss | (5,849,669 | ) | (2,582,278 | ) | ||||
Loss per share attributable to common shareholders of the Company | ||||||||
-Basic | 22 | (0.06 | ) | (0.03 | ) | |||
-Diluted | 22 | (0.06 | ) | (0.03 | ) |
The accompanying notes are an integral part of the condensed interim consolidated financial statements
THE FLOWR CORPORATION 2
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars) |
Three months ended | |||||||||
March 31, | |||||||||
2019 | 2018 | ||||||||
Notes | |||||||||
OPERATING ACTIVITIES | |||||||||
Net loss | (5,849,669 | ) | (2,582,278 | ) | |||||
Items not affecting cash and other adjustments | 23 | 2,764,616 | 850,190 | ||||||
Changes in non-cash working capital | 23 | 2,224,019 | 210,358 | ||||||
Cash used in operating activities | (861,034 | ) | (1,521,730 | ) | |||||
INVESTING ACTIVITIES | |||||||||
Expenditures on property, plant and equipment | (12,592,157 | ) | (4,987,550 | ) | |||||
Expenditures on intangible assets | (52,500 | ) | (110,718 | ) | |||||
Cash used in investing activities | (12,644,657 | ) | (5,098,268 | ) | |||||
FINANCING ACTIVITIES | |||||||||
Proceeds from shares issued | 20 | 500,482 | 815,000 | ||||||
Share issuance costs | 20 | | (30,037 | ) | |||||
Loan proceeds | 14 | 1,880,000 | | ||||||
Finance lease obligations | (88,611 | ) | | ||||||
Increase in restricted cash | (246,456 | ) | | ||||||
Finance lease income | 5,591 | | |||||||
Interest received (paid) | 58,568 | (1,521 | ) | ||||||
Cash provided from financing activities | 2,109,574 | 783,442 | |||||||
Increase in cash and cash equivalents | (11,396,117 | ) | (5,836,556 | ) | |||||
Cash and cash equivalents, beginning of period | 27,689,183 | 7,749,699 | |||||||
Cash and cash equivalents, end of period | 16,293,066 | 1,913,143 |
The accompanying notes are an integral part of the condensed interim consolidated financial statements
THE FLOWR CORPORATION 3
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, expect for number of shares) |
Share Capital | Other reserves | |||||||||||||||||||||||||||||
Number of | Share | Warrants | Contributed | Flowr ULC share | Accumulated other | Non-controlling | ||||||||||||||||||||||||
shares | Capital | (note 22) | Surplus (note 18) | issuances | Comprehensive loss | Interest (note 26) | Deficit | Total | ||||||||||||||||||||||
Notes | ||||||||||||||||||||||||||||||
Balance at January 1, 2018 | 59,960,000 | 18,116,920 | | 601,536 | | | 1,958,218 | (1,131,266 | ) | 19,545,408 | ||||||||||||||||||||
Equity financing Jan 2018, net of share issue costs of $30,037 | 815,000 | 784,963 | | | | | | | 784,963 | |||||||||||||||||||||
Share-based compensation | 18 | | | | 385,824 | | | | | 385,824 | ||||||||||||||||||||
Net loss for the period ended March 31, 2018 | | | | | | | (840,299 | ) | (1,741,979 | ) | (2,582,278 | ) | ||||||||||||||||||
Balance at March 31, 2018 | 60,775,000 | 18,901,883 | | 987,360 | | | 1,117,919 | (2,873,245 | ) | 18,133,917 | ||||||||||||||||||||
Balance at January 1, 2019 | 86,700,306 | 70,002,237 | 546,593 | 6,077,312 | (22,343,650 | ) | | 21,795,978 | (16,532,564 | ) | 59,545,906 | |||||||||||||||||||
Share-based compensation | 18 | | | | 2,103,109 | | | | | 2,103,109 | ||||||||||||||||||||
Shares issued from exercise of warrants | 21 | 195,046 | 735,699 | (235,217 | ) | | | | | | 500,482 | |||||||||||||||||||
Other changes in non- controlling interest | | | | | (210,469 | ) | | 214,834 | 4,365 | |||||||||||||||||||||
Loss on investments held at fair value | | | | | | (148,089 | ) | | | (148,089 | ) | |||||||||||||||||||
Net loss for the period ended March 31, 2019 | | | | | | | (805,389 | ) | (5,044,280 | ) | (5,849,669 | ) | ||||||||||||||||||
Balance at March 31, 2019 | 86,895,352 | 70,737,936 | 311,376 | 8,180,421 | (22,554,119 | ) | (148,089 | ) | 21,205,423 | (21,576,844 | ) | 56,156,104 |
The accompanying notes are an integral part of the condensed interim consolidated financial statements
THE FLOWR CORPORATION 4
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
1. |
CORPORATE INFORMATION |
The Flowr Corporation, formerly known as The Needle Capital Corp. (the "Company"), is a publicly traded, cannabis cultivation company that was incorporated under the Business Corporations Act (Alberta) ("ABCA") on June 1, 2016. On September 25, 2018, the Company continued from the ABCA to the Business Corporations Act (Ontario) as part of the completion of the Qualifying Transaction (defined below). The Head Office of the Company is located at 461 King Street West, Suite 200, Toronto, Ontario, M5V 1K4. The principal activity of the Company is the production and sale of premium cannabis in Canada, with a focus on the natural science of cannabis. In December 2017, through its subsidiary The Flowr Group (Okanagan) Inc. ("Flowr Okanagan"), formerly Cannatech Plant Systems Inc., the Company received its license from Health Canada to operate as a licensed producer, under the provisions of Access to Cannabis for Medical Purposes Regulations. On August 10, 2018, Flowr Okanagan received its sales license from Health Canada, allowing the Company to sell to the Canadian medical market and to the adult-use recreational ("recreational") market post legalization on October 17, 2018. The Companys common shares are listed on the TSX Venture Exchange (the "Exchange"), under the trading symbol "FLWR".
The Company, was previously classified as a Capital Pool Company ("CPC") as defined in Policy 2.4 of the Exchange. The principal business of the Company as a CPC was to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein by completing a purchase transaction. The purpose of such an acquisition was to satisfy the related conditions of a qualifying transaction under the Exchange rules ("Qualifying Transaction").
On September 21, 2018, the Company completed its Qualifying Transaction pursuant to a business combination agreement between the Company, 2652253 Ontario Inc. and a private corporation called The Flowr Corporation ("Flowr PrivateCo") (the "Business Combination Agreement"). As a part of the Qualifying Transaction, the Company changed its name from "The Needle Capital Corp." to "The Flowr Corporation" and consolidated its 7,679,997 common shares on a 13:1 basis to 590,769 common shares. In connection with the Qualifying Transaction, Flowr PrivateCo exchanged its shares for all of the issued and outstanding shares of the Company with the former shareholders of Flowr PrivateCo receiving a total of 85,692,095 post-consolidation common shares.
Upon closing of the Qualifying Transaction, the shareholders of Flowr PrivateCo owned 99.3% of the common shares of the Company, and as a result, the Qualifying Transaction is considered a reverse acquisition of the Company by Flowr PrivateCo ("RTO"). For accounting purposes, Flowr PrivateCo is considered to be the acquirer and the Company is considered to be the acquiree. Accordingly, these condensed interim consolidated financial statements are a continuation of the condensed interim consolidated financial statements of Flowr PrivateCo, henceforth referred to as Flowr as applicable (note 3(a)).
As at March 31, 2019, Flowrs condensed interim consolidated financial statements include Flowr and its subsidiary companies (collectively, the "Company"). Flowrs principal subsidiaries include, a 66.3% (December 31, 2018 66.3%) ownership of Flowr ULC, which owns, 100% of Flowr Okanagan.
2.1 |
BASIS OF PREPARATION |
(a) |
Statement of compliance |
The Companys condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC") which the Canadian Accounting Standards Board has approved for incorporation into Part I of the Chartered Professional Accountants of Canada Handbook Accounting applicable to the preparation of interim financial statements, including International Accounting Standard ("IAS") 34, Interim Financial Reporting.
THE FLOWR CORPORATION 5
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
These condensed interim consolidated financial statements do not include all of the information required for full financial statements and should be read in conjunction with the Companys annual consolidated financial statements for the year ended December 31, 2018, which have been prepared in accordance with IFRS. The accounting policies applied in these condensed interim consolidated financial statements are consistent with those applied in the preparation of the Companys annual consolidated financial statements for the year ended December 31, 2018, except for the changes in accounting policies as described below in note 2.2. These condensed interim consolidated financial statements were approved by the Board of Directors on May 16, 2019.
(b) |
Basis of measurement |
These consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments that are measured at fair value.
(c) |
Basis of consolidation |
Subsidiaries are entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.
The Company uses the acquisition method of accounting to account for business combinations. The fair value of the acquisition of a subsidiary is based on the fair value of the assets acquired, the liabilities assumed, and the fair value of the consideration. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values on the acquisition date. The excess, if any, of the consideration over the fair value of the identifiable net assets acquired is recorded as goodwill.
For acquisitions that do not meet the definition of a business under IFRS, the Company follows International Accounting Standard ("IAS") 16 and IAS 38 guidelines for asset acquisition, where the consideration paid is allocated to assets acquired based on fair values on the acquisition date and transactions costs are capitalized and allocated to the assets acquired.
Subsidiaries are fully consolidated from the date on which control is acquired by the Company and they are deconsolidated from the date that control ceases. The financial statements of the subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies. All inter-company balances, revenues and expenses and earnings and losses resulting from inter-company transactions are eliminated on consolidation.
Non-controlling interests in the net assets of consolidated subsidiaries are a separate component of the Companys equity. Non-controlling interests consist of the non-controlling interests on the date of the original acquisition plus the non-controlling interests share of changes in equity since the date of acquisition. Changes in the Companys interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.
THE FLOWR CORPORATION 6
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
(e) |
Critical accounting estimates and judgments |
The preparation of the Companys consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities and contingent liabilities on the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are evaluated and are based on managements experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates.
Accounting estimates and judgements applied in these condensed interim consolidated financial statements are consistent with those applied in the preparation of the Companys annual consolidated financial statements for the year ended December 31, 2018, except as described below in note 2.2.
(f) |
Presentation and functional currency |
These consolidated financial statements are presented in Canadian dollars, which is also the functional currency of the Company and its subsidiaries.
2.2 |
CHANGES IN ACCOUNTING POLICES |
(a) On July 1, 2018, the Company changed its accounting policy with respect to production costs related to biological assets. Prior to this change, the Company expensed any costs related to the production of biological assets. The Company now capitalizes production costs related to biological assets and recognizes the expense in cost of sales as the inventory is sold. This change in policy will more accurately reflect the true costs of production related to the revenues earned in the period. Non-recurring start-up costs are expensed directly through cost of sales. Fulfillment charges and any related depreciation are expensed to cost of goods sold in the period in which the costs are incurred. The Company also revised its presentation in the consolidated statement of loss to separate fair value adjustments for both biological assets and inventory sold in the period. The amended policy is as follows:
(i) |
Biological assets |
While the Companys biological assets, consisting of cannabis plants, are within the scope of IAS 41 Agriculture, the direct and indirect costs of biological assets are determined using an approach similar to the capitalization criteria outlined in IAS 2 Inventories. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs, grow consumables, utilities, facilities costs including an allocation of overhead costs related to production facility, quality and testing costs, and production related depreciation. Capitalized costs are subsequently recorded within cost of sales in the consolidated statements of loss in the period that the related product is sold.
The Company measures biological assets, at fair value less cost to sell up to the point of harvest. Unrealized gains or losses arising from the changes in fair value less cost to sell during the period are separately recorded in the consolidated statement of loss for the related period. Cost to sell includes post harvest production costs and fulfilment costs.
The Company commenced cultivating cannabis in January 2018. Biological assets were measured at a fair value of nil in reporting periods prior to the Company obtaining its sales license on August 10, 2018. All capitalized costs related to biological assets were expensed through changes in fair value of biological assets.
THE FLOWR CORPORATION 7
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
(ii) |
Inventory |
Inventory of harvested bulk cannabis and finished goods are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour related costs, consumables, packaging supplies, facilities costs, including an allocation of overhead costs related to production facility, quality and testing costs, and related depreciation. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Supplies and consumables are valued at the lower of cost and net realizable value, with cost determined based on an average cost basis.
The change in accounting policy has been applied retrospectively. The presentation of production costs in 2018 is now captured as cost of sales in the comparative period.
The change in policy noted in (i) and (ii) above will impact the previously reported periods in 2018. The following table summarizes the effects of the change described above for the three months ended March 31, 2018.
Condensed interim consolidated statement of loss | As previously | As | |||||||
For the three months ended March 31, 2018 | reported | Adjustments | Restated | ||||||
Cost of sales (formerly Production costs) | 866,515 | (210,358 | ) | 656,157 | |||||
Unrealized losses on changes in fair value of biological assets | | 210,358 | 210,358 |
Condensed interim consolidated statement of cash flows | As previously | As | |||||||
For the three months ended March 31, 2018 | reported | Adjustments | Restated | ||||||
Items not affecting cash | 639,832 | 210,358 | 850,190 | ||||||
Changes in non-cash working capital | 358,870 | (210,358 | ) | 148,512 |
THE FLOWR CORPORATION 8
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
(b) |
IFRS 16, Leases |
Effective January 1, 2019, the Company adopted IFRS 16, Leases, replacing IAS 17, which resulted in changes in accounting policies as described below. In accordance with the transitional provisions in the standard, IFRS 16 was adopted retrospectively without restating comparatives, with the cumulative impact adjusted in the opening balances as at January 1, 2019. The Company also utilized certain practical expedient elections whereby (i) there is no need to reassess whether an existing contract is a lease, or contains an embedded lease if previously determined under IAS 17, (ii) short term and low value leases are treated as operating leases, and (iii) there is no need to reassess the previous assessments in respect of onerous contracts that confirmed there were no existing onerous lease contracts. Under IFRS 16, most leases are now recognized on the balance sheet for lessees, essentially eliminating the distinction between a finance lease and an operating lease under IAS 17, where operating leases were reflected in the consolidated statements of earnings (loss). As a result, as at January 1, 2019, the Company recognized lease obligations and leased assets under existing operating leases of $10,317,064, with no impact on total shareholders equity. Each lease obligation was measured at the present value of the remaining lease payments, discounted using the Companys estimated weighted average incremental borrowing rate of 6.2% . Leased assets were recognized as right-of-use assets in property, plant and equipment and were measured at the amount equal to the lease obligations. Leases previously classified as finance leases and recognized in the carrying amounts of the Companys lease obligations and leased assets are now recognized in the carrying amounts of the lease obligations and the right-of-use assets as at January 1, 2019.
The following are the Companys new accounting policies for its leases under IFRS 16:
The determination of whether an arrangement is, or contains, a lease is based on the substance of the agreement on the inception date.
As a lessee, the Company recognizes a lease obligation and a right-of-use asset in the consolidated statements of financial position on a present-value basis at the date when the leased asset is available for use. Each lease payment is apportioned between a finance charge and a reduction of the lease obligation. Finance charges are recognized in finance cost in the consolidated statements of earnings (loss). The right of-use asset is included in property, plant and equipment and is depreciated over the shorter of its estimated useful life and the lease term on a straight-line basis.
Lease obligations are initially measured at the net present value of the following lease payments:
Lease payments are discounted using the interest rate implicit in the lease, or if this rate cannot be determined, the Companys incremental borrowing rate. Right-of-use assets are initially measured at cost comprising the following:
Payments associated with short-term leases and leases of low-value assets are recognized on a straightline basis as an expense in the consolidated statements of earnings (loss). Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise primarily small equipment.
THE FLOWR CORPORATION 9
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
Sublease
In February 2019, the Company entered into a sublease agreement, which is classified as a finance lease under IFRS 16 by reference to the right of use asset generated through the Companys primary lease obligation ("Head Lease"). Upon entering into the sublease arrangement, the right of use asset generated from the Head Lease is derecognized and a receivable related to the net investment in lease is generated based on the net present value of cash flows to be received from the sublease. As of March 31, 2019, the Company had $182,709 receivable due from its net investment in the sublease. Upon entering into the sublease agreement, the Company was required to established a letter of credit with the lessor in the amount of the Companys total remaining lease payments, which has been reflected as restricted cash in other current and long term assets.
3. | SIGNIFICANT TRANSACTIONS |
(a) | Reverse Acquisition |
On September 21, 2018, the Company, then operating as The Needle Capital Corp. ("Needle") completed its Qualifying Transaction, pursuant to the Business Combination Agreement. Through the Qualifying Transaction, Needle acquired all the issued and outstanding common shares of Flowr PrivateCo through a three-cornered amalgamation, whereby Flowr amalgamated with 2652253 Ontario Inc., a subsidiary of Needle into a newly formed entity. On January 1, 2019, the amalgamated entity was amalgamated into The Flowr Corporation. The resulting legal entities are The Flowr Corporation, Flowr ULC and Flowr Okanagan.
The Qualifying Transaction was a reverse acquisition of Needle and has been accounted for under IFRS 2, Share-based Payments. As a result, the transaction has been accounted for at the fair value of equity instruments issued by the Company to the option holders, warrant holders and shareholders of Needle holding such equity instruments as of the date of the Qualifying Transaction. The difference between the fair value of equity instruments issued and the net assets acquired has been recognized as a listing expense in the consolidated statements of loss for the year ended December 31, 2018. Total legal and professional fees of $402,610 were incurred in 2018 to complete the transaction.
4. |
AMOUNTS RECEIVABLE |
March 31, | December 31, | |||||
2019 | 2018 | |||||
Accounts receivable | 2,546,745 | 2,507,577 | ||||
GST/HST receivable | 504,081 | 455,538 | ||||
Net investment in lease | 113,012 | | ||||
3,163,838 | 2,963,115 |
THE FLOWR CORPORATION 10
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
5. |
PREPAIDS AND OTHER RECEIVABLES |
March 31, | December 31, | |||||
2019 | 2018 | |||||
Prepaid expenses | 308,156 | 552,948 | ||||
Deposits recoverable | 442,718 | 360,520 | ||||
Current portion of restricted cash (note 2.2(b)) | 154,566 | | ||||
905,440 | 913,468 |
6. |
INVENTORY |
Biological asset fair | |||||||||
Capitalized costs | valuation adjustment | Carrying value | |||||||
Harvested cannabis | |||||||||
Work in process | 890,843 | 151,093 | 1,041,936 | ||||||
Finished goods | 517,924 | (35,841 | ) | 482,083 | |||||
1,408,767 | 115,252 | 1,524,019 | |||||||
Supplies and consumables | 362,559 | | 362,559 | ||||||
Balance as at March 31, 2019 | 1,771,326 | 115,252 | 1,886,578 |
Biological asset fair | |||||||||
Capitalized costs | valuation adjustment | Carrying value | |||||||
Harvested cannabis | |||||||||
Work in process | 945,211 | 40,776 | 985,987 | ||||||
Finished goods | 199,650 | (68,256 | ) | 131,394 | |||||
1,144,861 | (27,480 | ) | 1,117,381 | ||||||
Supplies and consumables | 281,562 | | 281,562 | ||||||
Balance as at December 31, 2018 | 1,426,423 | (27,480 | ) | 1,398,943 |
For the period ended March 31, 2019, the Company capitalized $34,621 (2018 nil) of depreciation and amortization expense to harvested cannabis inventory. Total capitalized depreciation of $208,536 (2018 nil) was expensed to cost of sales in the period.
THE FLOWR CORPORATION 11
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
7. |
BIOLOGICAL ASSETS |
Biological assets consist of cannabis plants. The changes in the carrying value of biological assets are as follows:
Balance at December 31, 2017 | | ||
Production costs capitalized | 2,652,926 | ||
Changes in fair value less cost to sell due to biological transformation | (420,410 | ) | |
Transferred to inventory upon harvest | (1,735,414 | ) | |
Balance at December 31, 2018 | 497,102 | ||
Production costs capitalized | 931,921 | ||
Changes in fair value less cost to sell due to biological transformation | 206,180 | ||
Transferred to inventory upon harvest | (802,100 | ) | |
Balance as at March 31, 2019 | 833,103 |
The Company measures its biological assets at their fair value less costs to sell. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Companys method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
The following table quantifies each significant unobservable input, and provides the impact a 10% increase/decrease in each input would have on the fair value of biological assets:
Assumptions: |
As at March 31, 2019 | As at December 31, 2018 | ||
Input | 10% change | Input | 10% change | |
(i) Weighted average of expected loss of plants until harvest (a) | 15 % | $ 6,713 | 16 % | $ 6,428 |
(ii) Expected yields for cannabis plants (average grams per plant) (b) | 10.51 - 22.09 grams dry flower |
$ 83,310 | 10.36 - 18.10 grams dry flower |
$ 49,710 |
(iii)Weighted average number of growing weeks completed as a percentage of total growing weeks as at year end | 42 % | $ 83,310 | 50 % | $ 49,710 |
(iv)Estimated selling price (per gram) (c)
|
$ 7.18 for dry flower $ 0.88 for dry trim |
$ 180,185 |
$ 6.98 for dry flower $ 0.88 for dry trim |
$ 82,035 |
(v) After harvest cost to complete and sell (per gram) | $ 4.07 | $ 96,875 | $ 2.73 | $ 35,854 |
(vi)Reasonable margin on after harvest costs to complete and sell (per gram) | $ 0.37 | $ 8,807 | $ 0.25 | $ 3,259 |
(a) |
Weighted average of expected loss of plants until harvest represents loss via plants that do not survive to the point of harvest. It does not include any financial loss on a surviving plant. |
THE FLOWR CORPORATION 12
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
(b) |
Expected average yields for cannabis plants vary based on the mix of strains existing at each reporting date. The expected average grams of dry flower from plants as of March 31, 2019 is 14.09 grams (December 31, 2018 13.46 grams). The expected average grams of trim from plants as of March 31, 2019 is 4.26 grams (December 31, 2018 4.11). |
(c) |
The estimated selling price (per gram) represents the average contractual sales price for the Companys various strains sold as recreational products or expected selling price in recreational and medical market for strains with no contractual sales price. |
The Company obtained its sales license in August 2018. Prior to obtaining its sales license, the fair value of biological assets was determined to be nil.
These estimates are subject to volatility in market prices and a number of uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.
The Company estimates the harvest yields for cannabis at various stages of growth. As of March 31, 2019, it is expected that the Companys cannabis plants biological assets will yield approximately 527,711 grams of dry cannabis and 187,777 grams of dry trim when harvested.
The Companys estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the gain or loss on biological assets in future periods.
For the period ended March 31, 2019, the Company capitalized $159,666 (2018 - nil) of depreciation and amortization expense to biological assets.
THE FLOWR CORPORATION 13
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
8. |
FINANCIAL INSTRUMENTS |
Set out below is a comparison, by category, of the carrying amounts of the Companys financial instruments that are recognized in the consolidated statements of financial position.
The carrying values of all the financial assets and liabilities measured at amortized cost approximate their fair values as at March 31, 2019 and December 31, 2018.
Carrying Amount | |||||||||
Financial Instrument | March 31, | December 31, | |||||||
Classification | 2019 | 2018 | |||||||
Financial assets | |||||||||
Cash | Amortized cost | 16,293,066 | 27,689,183 | ||||||
Amounts receivable | Amortized cost | 3,163,838 | 2,963,115 | ||||||
Deposits recoverable | Amortized cost | 442,718 | 360,520 | ||||||
Investment in private securities - shares | FVOCI | 601,911 | 750,000 | ||||||
Investment in private securities - warrants | FVPL | 137,998 | 488,695 | ||||||
Convertible loan receivable | FVPL | 6,000,000 | 6,000,000 | ||||||
Financial liabilities | |||||||||
Accounts payable and accrued liabilities | Amortized cost | 6,805,011 | 4,604,727 | ||||||
Due to related parties | Amortized cost | 51,212 | 63,217 | ||||||
Lease obligations | Amortized cost | 9,805,275 | | ||||||
Debt | Amortized cost | 3,471,536 | 1,591,536 |
Investments private securities Shares
On October 10, 2018, the Company acquired 319,149 shares of Ace Hill Beer ("Ace Hill") at a cost of $750,000. As Ace Hill is not a listed public company, the valuation of the shares at the time of issuance was based on a discounted projected cash flow model. For the period ended March 31, 2019, the Company recorded unrealized losses of $148,089 (2018 nil) through other comprehensive income.
Investments private securities Warrants
(i) Plant Properties Warrants
On December 31, 2018, the Companys 1,500,000 warrants in Plant Properties were terminated. Each warrant was exercisable into one common share of Plant Properties any time prior to June 13, 2019, at an exercise price of $0.50 per common share. For the period ended March 31, 2018, the Company recognized an unrealized loss on Plant Properties warrants of $27,373 in other expense (note 19) in the Consolidated Statements of Loss.
THE FLOWR CORPORATION 14
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
(ii) Seven Leaf Warrants
On December 31, 2018, the Company was granted 2,500,000 warrants in Seven Leaf. Each warrant is exercisable into one common share of Seven Leaf any time prior to December 31, 2020, at an exercise price of $0.50 per common share. Seven Leaf has two directors in common with Flowr. For the period ended March 31, 2019, the Company recognized an unrealized loss of $350,698 (2018 nil) in other expense (note 19).
The inputs used in the measurement of the fair value at the time the investments in warrants were granted and subsequently re-measured were as follows:
March 31, | December 31, | |||||
2019 | 2018 | |||||
Investment in warrants | ||||||
Risk free interest rate | 1.55% | 1.60% - 1.86% | ||||
Expected exercise period in years | 1.76 | 0.70 - 2.00 | ||||
Expected volatility | 80% | 70% - 97% | ||||
Dividends per share | | |
Fair value hierarchy
The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:
The investments in privately held securities have been classified as Level 3 in the fair value hierarchy as at March 31, 2019 and December 31, 2018.
During the period ended March 31, 2019 and year ended December 31, 2018, there were no transfers between Level 1 and Level 2 fair value measurements, and no transfers into or out of Level 3 fair value measurements.
The following table reconciles Level 3 fair value measurements from January 1, 2018 to March 31, 2019:
Balance as at January 1, 2018 | 335,571 | ||
Investment in Ace Hill | 750,000 | ||
Convertible loan receivable | 6,000,000 | ||
Realized loss on Plant Properties warrants included in net loss | (335,571 | ) | |
Unrealized gain on Seven Leaf warrants included in net loss | 488,695 | ||
Balance as at December 31, 2018 | 7,238,695 | ||
Unrealized loss on investments through OCI | (148,089 | ) | |
Unrealized loss on warrant investments included in net loss (note 19) | (350,698 | ) | |
Balance as of March 31, 2019 | 6,739,908 |
THE FLOWR CORPORATION 15
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
9. |
PROPERTY PLANT AND EQUIPMENT |
Balance as at | Balance as at | ||||||||||||||
January 1, | March 31, | ||||||||||||||
2019 | Additions | Disposals | Transfers | 2019 | |||||||||||
Cost: | |||||||||||||||
Land | 5,751,336 | 3,118,009 | | | 8,869,345 | ||||||||||
Capital leases | | 10,317,064 | 227,622 | | 10,089,442 | ||||||||||
Leasehold improvements | 2,915,328 | 27,915 | | 1,360,497 | 4,303,740 | ||||||||||
Construction-in-progress | 9,803,580 | 7,816,183 | | (5,446,037 | ) | 12,173,723 | |||||||||
Production equipment | 627,090 | 158,211 | | 391,708 | 1,177,009 | ||||||||||
Mechanical equipment | 3,471,690 | 135,056 | | 2,961,222 | 6,567,968 | ||||||||||
Electrical equipment | 1,273,828 | 9,750 | | 732,610 | 2,016,188 | ||||||||||
Office equipment and furniture | 94,901 | 118,729 | | | 213,630 | ||||||||||
Computer and IT equipment | 236,630 | 25,760 | | | 262,390 | ||||||||||
Total cost | 24,174,383 | 21,726,677 | 227,622 | | 45,673,435 | ||||||||||
Accumulated depreciation: | |||||||||||||||
Capital lease | | 208,561 | 27,130 | | 181,431 | ||||||||||
Leasehold improvements | 111,299 | 29,887 | | | 141,186 | ||||||||||
Production equipment | 43,218 | 33,759 | | | 76,977 | ||||||||||
Mechanical equipment | 481,288 | 163,210 | | | 644,498 | ||||||||||
Electrical equipment | 176,617 | 51,492 | | | 228,109 | ||||||||||
Office equipment and furniture | 7,870 | 6,563 | | | 14,433 | ||||||||||
Computer and IT equipment | 28,074 | 11,876 | | | 39,950 | ||||||||||
Total accumulated depreciation | 848,366 | 505,348 | 27,130 | | 1,326,584 | ||||||||||
Net book value | 23,326,017 | 44,346,851 |
As of March 31, 2019, capital leases included in property, plant and equipment consists of the Flowr Okanagan facility lease and the Companys head office lease Refer to note 2.2(b) and note 24.
THE FLOWR CORPORATION 16
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
Balance as at | Balance as at | ||||||||
January 1, | December 31, | ||||||||
2018 | Additions | 2018 | |||||||
Cost: | |||||||||
Land | 1,380,500 | 4,370,836 | 5,751,336 | ||||||
Leasehold improvements | 2,577,059 | 338,269 | 2,915,328 | ||||||
Construction-in-progress | 998,657 | 8,804,923 | 9,803,580 | ||||||
Production equipment | 271,072 | 356,018 | 627,090 | ||||||
Mechanical equipment | 2,909,727 | 561,963 | 3,471,690 | ||||||
Electrical equipment | 1,067,794 | 206,034 | 1,273,828 | ||||||
Office equipment and furniture | 25,173 | 69,728 | 94,901 | ||||||
Computer and IT equipment | 49,255 | 187,375 | 236,630 | ||||||
Total cost | 9,279,237 | 14,895,146 | 24,174,383 | ||||||
Accumulated depreciation | |||||||||
Leasehold improvements | | 111,299 | 111,299 | ||||||
Production equipment | | 43,218 | 43,218 | ||||||
Mechanical equipment | | 481,288 | 481,288 | ||||||
Electrical equipment | | 176,617 | 176,617 | ||||||
Office equipment and furniture | | 7,870 | 7,870 | ||||||
Computer and IT equipment | | 28,074 | 28,074 | ||||||
Total accumulated depreciation | | 848,366 | 848,366 | ||||||
Net book value | 9,279,237 | 23,326,017 |
10. |
INTANGIBLE ASSETS |
Balance as at | Balance as at | ||||||||
January 1, | March 31, | ||||||||
2019 | Additions | 2019 | |||||||
Cost: | |||||||||
Software | 25,188 | | 25,188 | ||||||
Website development | 218,930 | 52,500 | 271,430 | ||||||
License | 3,175,964 | | 3,175,964 | ||||||
Total cost | 3,420,082 | 52,500 | 3,472,582 | ||||||
Accumulated amortization: | |||||||||
Software | 5,499 | 2,070 | 7,569 | ||||||
Website development | 145,953 | 72,977 | 218,930 | ||||||
License | 211,902 | 33,034 | 244,936 | ||||||
Total accumulated amortization | 363,354 | 108,081 | 471,435 | ||||||
Net book value | 3,056,728 | 3,001,147 |
THE FLOWR CORPORATION 17
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
Capitalized license costs relates to costs incurred by the Company to acquire its licenses from Health Canada.
Balance as at | Balance as at | ||||||||
January 1, | December 31, | ||||||||
2018 | Additions | 2018 | |||||||
Cost: | |||||||||
Software | 15,507 | 9,681 | 25,188 | ||||||
Website development | | 218,930 | 218,930 | ||||||
License | 3,175,164 | | 3,175,964 | ||||||
Total cost | 3,190,671 | 228,611 | 3,420,082 | ||||||
Accumulated amortization: | |||||||||
Software | | 5,499 | 5,499 | ||||||
Website development | | 145,953 | 145,953 | ||||||
License | 78,668 | 133,234 | 211,902 | ||||||
Total accumulated amortization | 78,668 | 284,686 | 363,354 | ||||||
Net book value | 3,112,003 | 3,056,728 |
11. |
CONVERTIBLE LOAN RECEIVABLE |
On November 19, 2018, the Company entered into a binding term sheet with Holigen Holdings Limited ("Holigen"), pursuant to which the Company agreed to lend $6,000,000 to Holigen. The proceeds are being used by Holigen to purchase land and obtain certain cannabis related licenses in certain jurisdictions, including Portugal. As of March 31, 2019, $6,000,000 has been advanced to Holigen. Flowr has the right to convert all debt owing under the loan facility into the same class of shares held by the shareholders of Holigen, that would result in a 4.8% ownership interest in Holigen (the "Conversion Option").
On December 19, 2018, the Company signed a share purchase and share subscription agreement, as amended and restated on May 8, 2019 (the "SPSA") with Holigen which effectively exercises the Companys Conversion Option and provides the Company with an additional 15% ownership interest in Holigen, for an aggregate ownership interest of 19.8% . The Company also provided Holigen with certain intellectual property to accelerate the completion of Holigens construction and licensing projects. The closing of the acquisition of the 19.8% ownership interest of Holigen is subject to various legal, administrative and approval conditions. As the Conversion Option has been exercised prior to the outside date of January 31, 2019 under the loan facility, interest will not accrue on the loan balance. However, in the event that the acquisition of the 19.8% interest in Holigen does not close, the entire outstanding loan balance and related interest will become payable on February 1, 2020 and interest under the loan facility would be calculated at 8% per annum from the first advance made under the loan.
The Conversion Option represents a call option to the Company and is included in the fair value of the loan. There existed an insignificant difference in fair value between the initial recognition date of November 19, 2018 and the reporting date of March 31, 2019, and accordingly the transaction price approximated the fair value of the loan. The value of the Conversion Option of the loan is $162,367 as of March 31, 2019. The convertible loan receivable has been classified as a Level 3 in the fair value hierarchy (note 8).
THE FLOWR CORPORATION 18
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
12. |
OTHER LONG-TERM ASSETS |
March 31, | December 31, | |||||
2019 | 2018 | |||||
Long term portion of net investment in lease | 69,697 | | ||||
Restricted cash (note 2.2(b)) | 91,890 | | ||||
Advances | 72,500 | 50,000 | ||||
234,087 | 50,000 |
Advances include a $50,000 advance payment made to Inplanta Biotechnology ("Inplanta"), to acquire shares in Inplanta.
13. |
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES |
March 31, | December 31, | |
2019 | 2018 | |
Accounts payable (note 15) | 6,157,499 | 2,782,502 |
Accrued liabilities | 404,850 | 1,472,422 |
GST/HST, PST, and excise tax payable | 242,662 | 349,803 |
6,805,011 | 4,604,727 |
14. |
DEBT |
On January 25, 2018, Hawthorne Canada Limited ("Hawthorne") and Flowr entered into an agreement to construct a research and development ("R&D") facility and provide certain R&D services upon completion of the R&D facility. The agreement was amended effective December 14, 2018. Under the amended agreement, Flowr Okanagan received a design and construction fee of $1,500,000, which was initially recorded as deferred revenue in the consolidated statements of financial position. The revenue is recognized as design and construction income in the consolidated statements of loss over the period of time the construction and design services are rendered. For the three months ended March 31, 2019, $249,875 was recognized as design and construction income in the condensed interim consolidated statement of loss. Hawthorne will also finance all approved development expenses through a loan to Flowr Okanagan to a maximum loan amount of $11,500,000 (the "Hawthorne Loan"). The funds will be advanced to Flowr on a monthly basis based on the expected expenditures to be incurred for the month. On the opening date of the R&D facility, the Hawthorne Loan will become payable through an agreed upon payment schedule and will commence to accrue interest at a rate of 4%. The Hawthorne Loan will be fully repaid over 20 years from the opening date of the R&D facility.
As of March 31, 2019, Hawthorne advanced $3,471,535 to Flowr Okanagan under the Hawthorne Loan.
As a part of the arrangement, once the R&D facility is operational, Hawthorne will pay Flowr a monthly management fee and a monthly SR&ED service fee which can be offset against the monthly loan and interest repayments.
As of March 31, 2019, if the contract were to terminate under certain circumstances, the Company could be required to pay 100% of all costs and expenses loaned by Hawthorne and $1,500,000 in liquidated damages.
THE FLOWR CORPORATION 19
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
15. |
RELATED PARTY TRANSACTIONS |
As at March 31, 2019 and December 31, 2018 related party amounts included in (a) due to related parties (b) property plant and equipment and (c) accounts payable and accrued liabilities were as follows:
March 31, | December 31, | |||||
2019 | 2018 | |||||
(a) Reimbursable expenses due to a corporation with directors and officers in common with Flowr | 51,212 | 63,217 | ||||
(b) Fees paid to a company for the construction of the Kelowna facility whose principal is an employee and shareholder of Flowr | 433,686 | 2,210,578 | ||||
(c) Amounts due to a construction company whose principal is an employee and shareholder of Flowr | 163,312 | 82,252 |
Included in general and administrative expense are amounts paid to shareholders or to companies whose principals are either a shareholder, director or officer of the Company as follows:
Three months ended | ||||||
March 31, | ||||||
General and administrative | 2019 | 2018 | ||||
Consulting and administration fees | | 60,700 | ||||
Rental fees | 5,250 | 5,250 | ||||
5,250 | 65,950 |
Refer to Notes 8 and 24.
All the above transactions are in the normal course of operations and are measured at the exchange amounts, being the amounts agreed to by the parties.
16. |
KEY MANAGEMENT REMUNERATION |
The Companys related parties includes its key management. Key management includes directors, the Chief Executive Officers ("Co-CEOs") and the executive officers reporting directly to the Co-CEOs.
The remuneration of the key management of the Company recognized in the consolidated statements of loss for the period ended March 31, 2019 and 2018 were as follows:
Three months ended | ||||||
March 31, | March 31, | |||||
2019 | 2018 | |||||
Salaries and short-term benefits | 440,526 | 265,185 | ||||
Share-based compensation | 1,969,990 | 336,196 | ||||
Total renumeration | 2,410,516 | 601,381 |
THE FLOWR CORPORATION 20
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
17. |
REVENUE |
Three months ended | ||||||
March 31, | ||||||
2019 | 2018 | |||||
Gross revenue | 1,811,500 | | ||||
Excise tax | 185,806 | | ||||
1,625,694 | |
18. |
SHARE-BASED COMPENSATION |
a) |
Stock options |
The Company has established a stock option plan ("SOP") for the directors, selected employees and consultants. Pursuant to the SOP, the exercise price of the option cannot be less than the closing price of Flowrs common shares on the trading date preceding the day the option is granted, subject to permitted discounts pursuant to the rules of the Exchange. The maximum number of common shares reserved for issuance under the SOP is 10% of the total issued and outstanding common shares of the Company including the 44,100,000 convertible Flowr ULC Class A Preferred Shares (note 2.1(c)) .
During the year ended December 31, 2018 the Company granted 8,418,991 stock options at a fair value of $16,388,192. The estimated value of the options granted will be recognized as an expense in the consolidated statements of loss and an addition to contributed surplus in the consolidated statements of changes in shareholders equity over the vesting period.
The options generally vest over 3 to 3.5 years from the grant date. The Company recorded stock option expenses of $2,103,109 (2018 $385,824) for the period ended March 31, 2019.
As at March 31, 2019, there was $9,394,839 of share-based compensation cost remaining to be charged to net earnings in future periods relating to stock option grants. The fair value of options granted was estimated using the Black-Scholes option pricing model. Due to limited historical data, the expected volatility is estimated based on the volatility of comparable publicly traded companies. The inputs used in the measurement of the fair values at the time the options were granted were as follows:
2018 | |||
Five year risk free interest rate | 2.11 - 2.45 % | ||
Expected life in years | 5.00 | ||
Expected volatility | 86% - 90 % | ||
Dividends per share | |
THE FLOWR CORPORATION 21
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
The following is a stock option continuity for the periods indicated:
Weighted | ||||||
average | ||||||
Number of | exercise price | |||||
options | per share $ | |||||
Balance as at January 1, 2018 | 10,125,000 | 0.05 | ||||
Options granted | 8,418,991 | 0.01 | ||||
Options exercised | (6,205,961 | ) | 0.05 | |||
Options forfeited | (1,740,750 | ) | 0.23 | |||
Options expired | | | ||||
Balance as at December 31, 2018 | 10,597,280 | 2.13 | ||||
Options granted | | | ||||
Options exercised | | | ||||
Options forfeited | (273,000 | ) | 0.35 | |||
Options expired | | | ||||
Balance as at March 31, 2019 | 10,324,280 | 2.11 |
The following lists the options outstanding and exercisable as at March 31, 2019:
Options outstanding | Options exercisable | ||||||||||||||
Weighted | Weighted | Weighted | |||||||||||||
Number of | average | average | Number of | average | |||||||||||
Range of exercise | options | remaining | exercise price | options | exercise price | ||||||||||
prices per share | outstanding | years | per share $ | exercisable | per share $ | ||||||||||
$ 0.05 | 2,318,750 | 3.67 | 0.05 | 375,000 | 0.05 | ||||||||||
2.60 | 7,640,530 | 4.61 | 2.60 | 375,158 | 2.60 | ||||||||||
3.43 - 3.60 | 40,000 | 4.59 | 3.52 | | | ||||||||||
5.24 | 325,000 | 4.51 | 5.24 | 36,112 | 5.24 | ||||||||||
$ 0.05 - 5.24 | 10,324,280 | 4.40 | 2.11 | 786,270 | 1.51 |
b) |
Long-term incentive plan ("LTIP") |
On December 28, 2018, the shareholders of the Company approved the Companys LTIP, which was subsequently approved by the Exchange on January 16, 2019. Under the terms of the LTIP, the Board of Directors (the "Board") or a committee on behalf of the Board may grant units, which may be either restricted share units ("RSUs") or deferred share units ("DSUs") to officers, directors, employees or consultants of the Company. The maximum number of common shares which may be reserved and set aside for issue under the LTIP in respect of awards of DSUs to DSU participants and for payments in respect of awards of RSUs to RSU participants, shall not exceed 10% of the total issued and outstanding common shares of the Company, including 44,100,000 convertible Flowr ULC Class A Preferred Shares, at the time of approval of the LTIP (being 13,057,421 common shares of the Company). There are no RSUs or DSUs issued and outstanding as of March 31, 2019. On May 9, 2019, the Board approved an amendment to the LTIP, which permits RSU participants to defer their settlement of an RSU award that has vested, within a period of 5 years from the vesting date.
THE FLOWR CORPORATION 22
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
19. |
OTHER EXPENSE |
Three months ended | ||||||
March 31, | ||||||
2019 | 2018 | |||||
Loss on warrants investment valuation | 350,698 | 27,373 | ||||
Interest (income) expense, net | (58,568 | ) | 1,522 | |||
Other expense | 5,526 | | ||||
297,656 | 28,895 |
20. |
SHARE CAPITAL |
The authorized capital of the Company consists of an unlimited number of common shares and an unlimited number of preferred shares issuable in series. As of March 31, 2019, the Company had 86,895,352 common shares issued and outstanding and no issued and outstanding preferred shares. The Flowr ULC preferred class A shares (note 2.1 (c)) are convertible into common shares of the Company.
In December 2017 through a corporate reorganization, Flowr ULC issued 44,100,000 class A preferred shares which provide the shareholders thereof with a right to exchange these shares for common shares of the Company at any point in time. In the event that the Company issues additional common shares, a corresponding amount of Flowr ULC common shares are required to be issued from Flowr ULC to the Company. As of March 31, 2019, none of the class A preferred shares have been converted into shares of the Company.
(a) |
Financings |
In January 2018, the remaining tranche of 815,000 class A preferred shares were issued at a price of $1.00 per share for gross proceeds of $815,000, and related share issuance costs were $30,037. | |
In the second and third quarters of 2018, Flowr closed a private placement in a series of five tranches as noted in the table below. Total share issuance costs related to this financing were $59,220. |
Closing | Shares | Gross | |||||||
Tranche | date | issued | proceeds $ | ||||||
1 | 11-Apr-18 | 3,310,330 | 8,606,858 | ||||||
2 | 23-Apr-18 | 970,232 | 2,522,603 | ||||||
3 | 28-May-18 | 84,382 | 219,393 | ||||||
4 | 11-Jul-18 | 896,151 | 2,329,993 | ||||||
5 | 18-Jul-18 | 48,266 | 125,492 | ||||||
TOTAL | 5,309,361 | 13,804,339 |
THE FLOWR CORPORATION 23
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
(b) |
Refer to note 3(a) for shares issued in the Qualifying Transaction classified as a listing expense. As a part of the Qualifying Transaction, Flowr completed a concurrent RTO Financing issuing 13,807,734 common shares for gross proceeds of $35,900,108. In relation to the RTO financing the Company incurred $1,927,407 in share issuance costs, of which $529,038 relate to broker warrants issued (note 21). |
All the above noted shares issuances were exchanged for common shares of the Company in connection with the closing of the Qualifying Transaction.
21. |
WARRANTS |
The following lists the warrants outstanding and exercisable as at March 31, 2019:
Weighted | ||||||
average | ||||||
Number of | exercise price | |||||
warrants | per share $ | |||||
Balance as at December 31, 2018 | 453,316 | 2.57 | ||||
Warrants exercised | (195,046 | ) | 1.21 | |||
Balance as at March 31, 2019 | 258,270 | 2.57 |
The following is a warrant continuity for the period:
Number of | ||||||
warrants | Value $ | |||||
Balance as at December 31, 2018 | 453,316 | 546,593 | ||||
Warrants exercised | (195,046 | ) | (235,217 | ) | ||
Balance as at March 31, 2019 | 258,270 | 311,376 |
The fair value of warrants granted was estimated using the Black-Scholes option pricing model. Due to limited historical data, the expected volatility is estimated based on the volatility of comparable publicly traded companies. The inputs used in the measurement of the fair values at the time the warrants were granted were as follows:
2018 | |||
Five year risk free interest rate | 2.02 - 2.81% | ||
Expected life in years | 1 - 2 | ||
Expected volatility | 90.0% | ||
Dividends per share | - |
THE FLOWR CORPORATION 24
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
22. |
LOSS PER SHARE |
Three months ended | ||||||
March 31, | ||||||
2019 | 2018 | |||||
Net loss attributable to common shareholders | (5,044,280 | ) | (1,741,979 | ) | ||
Basic and diluted weighted average number of common shares outstanding | 86,799,052 | 60,693,500 | ||||
Basic and diluted loss per share | (0.06 | ) | (0.03 | ) |
23. |
SUPPLEMENTARY CASH FLOW INFORMATION |
(a) |
Items not affecting cash and other adjustments: |
Three months ended | ||||||
March 31, | ||||||
2019 | 2018 | |||||
Depreciation and amortization | 613,429 | 225,113 | ||||
Unrealized gain resulting from fair valuation of biological assets | (248,417 | ) | 210,358 | |||
Share-based compensation expense | 2,103,109 | 385,824 | ||||
Unrealized losses on investments | 350,698 | 27,373 | ||||
Other, net | (54,203 | ) | 1,522 | |||
Items not affecting cash and other adjustments | 2,764,616 | 850,190 |
(b) |
Changes in non-cash working capital: |
Three months ended | ||||||
March 31, | ||||||
2019 | 2018 | |||||
(Increase) decrease in amounts receivable | (88,617 | ) | 483,323 | |||
(Increase) decrease in other current assets | 140,094 | (5,410 | ) | |||
Increase in inventories | (445,398 | ) | | |||
Increase in biological assets | (129,821 | ) | (148,512 | ) | ||
Increase (decrease) in accounts payable and accrued liabilities | 2,972,750 | (165,360 | ) | |||
Increase in deferred revenue | (212,984 | ) | | |||
(Decrease) increase in amounts due to related parties | (12,005 | ) | 46,317 | |||
Changes in non-cash working capital | 2,224,019 | 210,358 |
THE FLOWR CORPORATION 25
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
24. |
COMMITMENTS |
Contractual obligations
The Company had the following minimum future contractual obligations as at March 31, 2019:
up to 1 year | 1 - 3 years | 3 - 5 years | over 5 years | Total | |||||||||||
Purchase obligations | 11,635,886 | 11,635,886 | |||||||||||||
Capital lease obligations | 1,345,169 | 3,739,783 | 2,686,178 | 8,682,617 | 16,453,747 | ||||||||||
Operating lease obligations (i) | 2,037 | 1,702 | | | 3,739 | ||||||||||
Total Commitments | 12,983,092 | 3,741,485 | 2,686,178 | 8,682,617 | 28,093,372 |
(i) |
Included in capital leases, is the Flowr Okanagan facility operating lease. The lease is payable to 0954717 B.C. LTD. whose principal owners are also shareholders of Flowr. The total remaining commitment for this lease is $9,541,442, of which $273,258 is due within one year. |
Refer to note 14 for additional contractual commitments.
25. |
FINANCIAL RISK MANAGEMENT |
The Companys principal financial liabilities comprise of accounts payable and accrued liabilities, amounts due to related parties, capital lease obligations and debt. The main purpose of these financial instruments is to assist with the management of the Companys short term and long-term cash flow requirements. The Company has various financial assets, such as cash and cash equivalents, and amounts receivable, which arise directly from its operations.
The main risks that could adversely affect the Companys financial assets, liabilities or future cash flows are market risk, liquidity risk and credit risk. Management reviews each of these risks and establishes policies for managing them as summarized below.
Market risk
Market risk is the risk that the future cash flows or the fair value of a financial instrument will fluctuate because of changes in market conditions. The Company operates in an industry regulated by Health Canada. Changes in legislation could have a significant impact on the Companys operations.
Credit risk
The exposure to credit risk arises through the potential failure of a customer or another third party to meet its contractual obligations to the Company. As at March 31, 2019, the Company had a convertible loan receivable of $6,000,000 (December 31, 2018 $6,000,000) and amounts receivable of $3,163,838 (December 31, 2018 - $2,963,115). The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. The Company is not significantly exposed to credit risk as the accounts receivables are primarily due from provincial government organizations and overall amounts receivable and convertible loan receivables comprise 11.8% (December 31, 2018 13.4% ) of the Companys total assets.
THE FLOWR CORPORATION 26
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
Liquidity risk
The Company relies on the cash flows generated from its operations and its ability to raise debt and equity from the capital markets to fund its operating, investment and liquidity needs. To reduce these risks, the Company: (i) prepares regular cash flow forecasts to monitor its capital requirements and available liquidity (ii) strives to maintain a prudent capital structure that is comprised primarily of equity financing; and (iii) targets a minimum level of liquidity comprised of surplus cash balances to avoid having to raise additional capital at times when the costs or terms would be regarded as unfavourable.
Capital management
The Company considers its capital to be its equity. The Companys objective for capital management is to: (i) maintain sufficient levels of liquidity to fund and support its capital projects and operating activities; (ii) maintain a strong financial position to ensure it has ready access to debt and equity markets to supplement free cash flow being invested in its growth projects. The Company monitors its financial position and the potential impact of adverse market conditions on an ongoing basis. The Company manages its capital structure and makes adjustments to it based on prevailing market conditions and according to its business plan. The Companys funding strategy is to maintain a capital structure comprised primarily of equity sourced from equity offerings and net earnings generated from its operations accompanied with financing through debt.
26. |
EXPENSE BY NATURE |
The operating costs, including cost of sales, selling and marketing, general and administrative expenses and research and development costs, as reported in the consolidated statements of loss, have been regrouped by the nature of the expenses as follows:
Three months ended | ||||||
March 31, | ||||||
2019 | 2018 | |||||
Salaries and benefits | 1,713,683 | 830,701 | ||||
Professional fees | 1,218,210 | 113,065 | ||||
Production costs | 993,885 | 331,141 | ||||
General and administrative | 928,720 | 407,789 | ||||
Travel | 125,249 | 32,038 | ||||
Selling and marketing | 25,013 | 59,614 | ||||
Depreciation and amortization | 208,536 | 174,652 | ||||
Research and development | 59 | | ||||
Total operating expenses | 5,213,355 | 1,949,000 |
THE FLOWR CORPORATION 27
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
For the three months ended March 31, 2019 and 2018 |
(unaudited, in Canadian dollars, unless otherwise indicated) |
27. |
OPERATING SEGMENT INFORMATION |
Operating segments are components of an entity whose operating results are regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance and for which separate financial information is available.
The Company primarily operates in one reportable operating segment, being a licensed producer operating in Canada. As the operations comprise a single reporting segment, amounts disclosed in the condensed interim consolidated financial statements also represent segment amounts.
28. |
SUBSEQUENT EVENTS |
(a) Issuance of stock options and restricted share units
The Company granted 1,727,500 stock options to certain employees and directors of the Company, which are exercisable into one common share at a price ranging from $5.70 -$5.93 over a term of 5 years. The Company also granted 197,250 restricted share units to employees and officers of the Company that vest evenly over a term of 3 years from the grant date.
(b) Private placement
On May 10, 2019, the Company closed a non-brokered private placement of 2,165,547 common shares at a price of C$6.25 per common share for aggregate gross proceeds of $13,534,669. The private placement remains subject to final acceptance of the Exchange.
THE FLOWR CORPORATION 28
THE FLOWR CORPORATION |
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS |
to be held on June 11, 2019 |
NOTICE IS HEREBY GIVEN that the Annual General and Special Meeting (the "Meeting") of the holders ("Shareholders") of common shares ("Common Shares") of The Flowr Corporation ("Flowr" or the "Corporation") will be held at 10:00 a.m. (EST) on June 11, 2019 for the following purposes:
1. |
to receive the consolidated financial statements of the Corporation, for the year ended December 31, 2018, including the auditors report thereon (the "Financial Statements"); |
2. |
to elect directors of the Corporation (the " Directors") who will serve until the end of the next annual meeting of Shareholders or until their successors are elected or appointed; |
3. |
to re-appoint the auditor of the Corporation for the ensuing year and to authorize the Directors to fix the remuneration to be paid to the auditor; |
4. |
to consider and, if deemed advisable, pass, with or without variation, an ordinary resolution to approve the Corporations stock option plan, as amended (the "SOP"), as more particularly described in the attached Circular (the full text of the SOP and the proposed ordinary resolution are attached to the Circular as Appendix "A" and Appendix "B", respectively); |
5. |
to consider and, if deemed advisable, to pass, with or without variation, a special resolution approving the amendment of the articles of the Corporation to change the place of the registered office of the Corporation from 201-100 Allstate Pkwy, Markham, Ontario, L3R 6H3 to 461 King Street West, Floor 2, Toronto, Ontario M5V 1K4 (the "Registered Office Resolution") (the full text of the Registered Office Resolution is attached to the Circular as Appendix "D"); and |
6. |
to transact such further and other business as may properly come before the Meeting or the reconvening of any adjournment or postponement thereof. |
Additional information on the above matters can be found in the management information circular dated May 9, 2019 (the "Circular") under the heading "Business of the Meeting".
The board of directors of the Corporation (the "Board") has fixed the close of business on May 10, 2019 as the record date (the "Record Date") for the determination of Shareholders entitled to notice of and to vote at the Meeting and at any adjournment or postponement thereof.
The Circular, this notice of Meeting (the "Notice"), the form of proxy and the voting instruction form (collectively, the "Meeting Materials") are being mailed to Shareholders of record as at the Record Date and are available online under the Corporations profile on the System for Electronic Document Analysis and Retrieval ("SEDAR"), at www.sedar.com. Shareholders are reminded to review the Meeting Materials before voting.
Whether or not you expect to attend the Meeting, you are encouraged to promptly complete and sign the enclosed form of proxy and return it for receipt by no later than 10:00 a.m. (EST) on June 7, 2019. If you receive more than one proxy form because you own Common Shares registered in different names or addresses, each proxy form should be completed and returned.
If you are a Non-Registered Shareholder (as defined in the Circular under the heading "Non-Registered Shareholders"), accompanying this Notice is a voting instruction form for your use. If you receive these materials through your broker or another intermediary, please complete and sign the materials in accordance with the instructions provided to you by such broker or other intermediary.
3
Dated this 9th day of May, 2019.
BY ORDER OF THE BOARD OF DIRECTORS OF | |||
THE FLOWR CORPORATION | |||
By: | <Signed> "Steve Klein" | ||
Name: | Steve Klein | ||
Title: | Chairman and Chief Strategy Officer |
4
NOTICE OF MEETING AND |
MANAGEMENT INFORMATION CIRCULAR |
FOR THE ANNUAL GENERAL AND SPECIAL MEETING OF |
SHAREHOLDERS OF |
THE FLOWR CORPORATION |
THIS MANAGEMENT INFORMATION CIRCULAR IS FURNISHED IN CONNECTION WITH THE SOLICITATION BY THE MANAGEMENT OF THE FLOWR CORPORATION OF PROXIES TO BE VOTED AT THE ANNUAL GENERAL AND SPECIAL MEETING OF ALL SHAREHOLDERS.
To be held at the offices of Fasken Martineau DuMoulin LLP, 333 Bay Street, Suite 2400, Bay Adelaide Centre, Toronto, Ontario, M5H 2T6 on June 11, 2019 at 10:00 a.m. (EST)
May 9, 2019
These materials are important and require your immediate attention. They require Shareholders to make important decisions. If you are in doubt as to how to deal with these materials or the matters they describe, please contact your financial, legal, tax or other professional advisors. |
May 9, 2019
Dear Shareholders,
On behalf of The Flowr Corporation ("Flowr" or the "Corporation"), it is with great pleasure that we invite you to attend our annual general and special meeting of shareholders to be held at 10:00 a.m. (EST) on June 11, 2019. Your participation at this meeting is very important and we encourage you to review the attached information circular (the "Circular"), which includes information for the holders of Flowrs common shares.
We encourage you to vote on the matters set out in this Circular by following the proxy instructions set out herein and returning your proxy or voting instruction form (as applicable) by the applicable deadline. Our aim is to provide shareholders with the information needed to cast informed votes.
This past year has been incredibly eventful for the Corporation. The fourth quarter of 2018 marked a major milestone for Flowr, as the Corporation launched its medicinal and recreational sales channels after receiving licenses in August 2018, and sold nearly 406 kilograms of premium cannabis, despite having only 20% of its grow rooms in Kelowna 1 operational during the quarter itself. As of today, Flowr has 10 grow rooms in Kelowna 1 licensed for use and the Corporation expects to have all 20 grow rooms fully constructed in the third quarter of 2019. As a global leader in the premium cannabis industry, Flowrs design and cultivation expertise along with its superior IP know-how enables the Corporation to grow high quality cannabis on a large scale at what the Corporation believes will be industry-leading yields. Once the Kelowna 1 facility is completed, the Corporations operational efficiency will only improve. Completion of Kelowna 1 should enable Flowr to begin capitalizing on strategic growth opportunities for medicinal and recreational use with approximately 10,000 kilograms of capacity for premium cannabis flower on an annualized basis.
As the year progresses, we are focussed on the continued build out of our Kelowna Campus, including the construction of the Hawthorne R&D Facility, our second facility and the Flowr Forest, and international expansion, including with respect to our strategic investment in Holigen.
Most importantly, I would like to thank Flowrs shareholders. Flowrs success is driven by your support and we are sincerely grateful to each of you for having chosen to accompany us on this journey. We look forward to building on our past accomplishments with your continued support.
Yours truly,
<Signed> "Steve Klein" | |
Steve Klein | |
Chairman and Chief Strategy Officer | |
The Flowr Corporation |
THE FLOWR CORPORATION |
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS |
to be held on June 11, 2019 |
NOTICE IS HEREBY GIVEN that the Annual General and Special Meeting (the "Meeting") of the holders ("Shareholders") of common shares ("Common Shares") of The Flowr Corporation ("Flowr" or the "Corporation") will be held at 10:00 a.m. (EST) on June 11, 2019 for the following purposes:
1. |
to receive the consolidated financial statements of the Corporation, for the year ended December 31, 2018, including the auditors report thereon (the "Financial Statements"); |
2. |
to elect directors of the Corporation (the "Directors") who will serve until the end of the next annual meeting of Shareholders or until their successors are elected or appointed; |
3. |
to re-appoint the auditor of the Corporation for the ensuing year and to authorize the Directors to fix the remuneration to be paid to the auditor; |
4. |
to consider and, if deemed advisable, pass, with or without variation, an ordinary resolution to approve the Corporations stock option plan, as amended (the "SOP"), as more particularly described in the attached Circular (the full text of the SOP and the proposed ordinary resolution are attached to the Circular as Appendix "A" and Appendix "B", respectively); |
5. |
to consider and, if deemed advisable, to pass, with or without variation, a special resolution approving the amendment of the articles of the Corporation to change the place of the registered office of the Corporation from 201-100 Allstate Pkwy, Markham, Ontario, L3R 6H3 to 461 King Street West, Floor 2, Toronto, Ontario M5V 1K4 (the "Registered Office Resolution") (the full text of the Registered Office Resolution is attached to the Circular as |
Appendix "D"); and | |
6. |
to transact such further and other business as may properly come before the Meeting or the reconvening of any adjournment or postponement thereof. |
Additional information on the above matters can be found in the management information circular dated May 9, 2019 (the "Circular") under the heading "Business of the Meeting".
The board of directors of the Corporation (the "Board") has fixed the close of business on May 10, 2019 as the record date (the "Record Date") for the determination of Shareholders entitled to notice of and to vote at the Meeting and at any adjournment or postponement thereof.
The Circular, this notice of Meeting (the "Notice"), the form of proxy and the voting instruction form (collectively, the "Meeting Materials") are being mailed to Shareholders of record as at the Record Date and are available online under the Corporations profile on the System for Electronic Document Analysis and Retrieval ("SEDAR"), at www.sedar.com. Shareholders are reminded to review the Meeting Materials before voting.
Whether or not you expect to attend the Meeting, you are encouraged to promptly complete and sign the enclosed form of proxy and return it for receipt by no later than 10:00 a.m. (EST) on June 7, 2019. If you receive more than one proxy form because you own Common Shares registered in different names or addresses, each proxy form should be completed and returned.
If you are a Non-Registered Shareholder (as defined in the Circular under the heading "Non-Registered Shareholders"), accompanying this Notice is a voting instruction form for your use. If you receive these materials through your broker or another intermediary, please complete and sign the materials in accordance with the instructions provided to you by such broker or other intermediary.
3
Dated this 9th day of May, 2019.
BY ORDER OF THE BOARD OF DIRECTORS OF | |||
THE FLOWR CORPORATION | |||
By: | <Signed> "Steve Klein" | ||
Name: | Steve Klein | ||
Title: | Chairman and Chief Strategy Officer |
4
MANAGEMENT INFORMATION CIRCULAR |
This Circular is furnished to Shareholders in connection with the solicitation of proxies by and on behalf of the management of the Corporation for use at the Meeting and any adjournment or postponement thereof, for the purposes set forth in the attached Notice.
The Meeting Materials are being mailed on or about May 21, 2019 to Shareholders of record as at the Record Date. The Corporation will bear all costs associated with the preparation and mailing of the Meeting Materials, as well as the cost of the solicitation of proxies. The solicitation will be primarily by mail and telephone; however, officers and regular employees of the Corporation may also directly solicit proxies (but not for additional compensation), personally, by facsimile or by other means of electronic transmission. Banks, brokerage houses and other custodians and nominees or fiduciaries will be requested to forward proxy solicitation material to their principals and to obtain authorizations for the execution of proxies and will be reimbursed for their reasonable expenses in doing so.
All information contained in this Circular is given as of May 9, 2019 unless otherwise specifically stated. Certain capitalized terms used but not defined herein have the meanings given to them in the Notice of Annual General and Special Meeting of Shareholders delivered with this Circular.
Currency
Except where otherwise indicated, all dollar amounts set forth in this Circular are in Canadian ("CAD") dollars, the presentation currency used by the Corporation in reporting its consolidated financial results.
GENERAL PROXY MATTERS
Voting in Person at the Meeting
A registered holder of Common Shares ("Registered Shareholder"), their proxy or a beneficial owner who has appointed itself to represent it at the Meeting, will appear on a list of Shareholders prepared by Computershare Investor Services Inc. ("Computershare"), the registrar and transfer agent for purposes of the Meeting. To vote in person at the Meeting each Registered Shareholder or appointee will be required to register for the Meeting by identifying himself/herself/itself at the registration desk. Non-Registered Shareholders (as defined in this Circular under the heading "Non-Registered Shareholders") must appoint themselves as a proxyholder to vote in person at the Meeting.
Solicitation of Proxies
The information contained in this Circular is furnished to Shareholders in connection with the solicitation of proxies to be used at the Meeting. The solicitation of proxies by this Circular is being made by or on behalf of the management of the Corporation and the total cost of the solicitation will be borne by the Corporation. The solicitation of proxies will be primarily by mail and telephone, but may also be in person, fax or oral communication without special compensation being paid to officers or employees of the Corporation. Banks, brokerage houses and other custodians and nominees or fiduciaries will be requested to forward proxy solicitation material to their principals or beneficial owners and to obtain authorizations for the execution of proxies. The Corporation will reimburse these banks, brokerage houses and other custodians and nominees or fiduciaries for the reasonable costs incurred in obtaining authorization to execute forms of proxy from their principals or beneficial owners.
Appointment of Proxies
The persons named in the enclosed form of proxy are Directors and/or officers of the Corporation. Each Shareholder has the right to appoint a person, other than the persons designated by management in the form of proxy, to represent the Shareholder at the Meeting. A Shareholder giving a proxy can strike out the names of the management designees printed in the accompanying proxy form and insert the name of another designated person in the space provided, or the Shareholder may complete another form of proxy. A proxy designee need not be a Shareholder of the Corporation.
Those Shareholders who wish to be represented at the Meeting by proxy must complete and deliver a proper form of proxy to Computershare either in person, or by mail or courier, to Computershare Investor Services Inc. 8th Floor, 100 University Ave, Toronto ON M5J 2Y1, by fax at 1-866-249-7775 (toll free) or (416) 263-9524 (local) or via the Internet at www.investorvote.com.
5
The form of proxy must be deposited with Computershare by no later than 10:00 a.m. (EST) on June 7, 2019, or if the Meeting is adjourned or postponed, not less than 48 hours, excluding Saturdays, Sundays and statutory holidays, preceding the time of reconvening such adjourned or postponed Meeting before the commencement of the reconvening of such adjourned or postponed Meeting.
If a Shareholder who has completed a form of proxy attends the Meeting in person, any votes cast by such Shareholder on a poll will be counted and the completed form of proxy will be disregarded.
Non-Registered Shareholders
The information set forth in this section is of importance to many Shareholders, as a substantial number of Shareholders do not hold Common Shares in their own name. Shareholders who hold their Common Shares through brokers, intermediaries, trustees or other persons, or who otherwise do not hold their Common Shares in their own name (referred to in this Circular as "Non-Registered Shareholders") should note that only proxies deposited by Registered Shareholders (that is, Shareholders whose names appear on the records maintained by the registrar and transfer agent or nominee for the Common Shares as registered holders of Common Shares) will be recognized and acted upon at the Meeting. If Common Shares are listed in an account statement provided to a Non-Registered Shareholder by a broker, those Common Shares will, in all likelihood, not be registered in the Shareholders name. Such Common Shares will more likely be registered under the name of the Shareholders broker or an agent of that broker. In Canada, the vast majority of such shares are registered under the name of CDS & Co. (the registration name for CDS Clearing and Depository Services Inc., which acts as nominee for many Canadian brokerage firms). Common Shares held by brokers (or their agents or nominees) on behalf of a brokers client can only be voted at the direction of the Non-Registered Shareholder. Without specific instructions, brokers (or their agents and nominees) are prohibited from voting shares for the brokers clients. Subject to the following discussion in relation to NOBOs (as defined below), the Corporation does not know for whose benefit the Common Shares registered in the name of CDS & Co., a broker or another agent or nominee, are held.
There are two categories of Non-Registered Shareholders for the purposes of applicable securities regulatory policy in relation to the mechanism of dissemination to Non-Registered Shareholders of proxy-related materials and other securityholder materials and the request for voting instructions from such Non-Registered Shareholders. Non-objecting beneficial owners ("NOBOs") of Common Shares are Non-Registered Shareholders who have advised their intermediary (such as brokers or their agents or nominees) that they do not object to their intermediary disclosing share ownership information to the Corporation, consisting of their name, address, e-mail address, securities holdings and preferred language of communication. Securities legislation restricts the use of that information to matters strictly relating to the affairs of the Corporation. Objecting beneficial owners ("OBOs") of Common Shares are Non-Registered Shareholders who have advised their intermediary that they object to their intermediary disclosing such share ownership information to the Corporation.
National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer ("NI 54-101") permits the Corporation, in its discretion, to obtain a list of its NOBOs from intermediaries and use such NOBO list for the purpose of distributing the Meeting Materials directly to, and seeking voting instructions directly from, such NOBOs. As a result, the Corporation is entitled to deliver Meeting Materials to Non-Registered Shareholders in two manners: (a) directly to NOBOs and indirectly through intermediaries to OBOs; or (b) indirectly to all Non-Registered Shareholders through intermediaries. In accordance with the requirements of NI 54-101, the Corporation is sending the Meeting Materials directly to NOBOs and indirectly through intermediaries to OBOs. The Corporation will pay the fees and expenses of intermediaries for their services in delivering Meeting Materials to OBOs in accordance with NI 54-101.
The Corporation has used a NOBO list to send the Meeting Materials directly to NOBOs whose names appear on that list. If the transfer agent, Computershare, has sent these materials directly to a NOBO, such NOBOs name and address and information about its holdings of Common Shares have been obtained from the intermediary holding such shares on the NOBOs behalf in accordance with applicable securities regulatory requirements. As a result, such NOBO of the Corporation can expect to receive a voting instruction form from the Corporations transfer agent. NOBOs should complete and return the voting instruction form to Computershare in the envelope provided. In addition, Internet voting is available. Instructions in respect of the procedure for Internet voting can be found in the voting instruction form. Computershare will tabulate the results of voting instruction forms received from NOBOs and will provide appropriate instructions at the Meeting with respect to the Common Shares represented by such voting instruction forms.
6
Applicable securities regulatory policy requires intermediaries, on receipt of Meeting Materials that seek voting instructions from Non-Registered Shareholders indirectly, to seek voting instructions from Non-Registered Shareholders in advance of shareholders meetings on Form 54-101F7 Request for Voting Instructions Made by Intermediary ("Form 54-101F7"). Every intermediary/broker has its own mailing procedures and provides its own return instructions, which should be carefully followed by Non-Registered Shareholders in order to ensure that their Common Shares are voted at the Meeting or the reconvening of or any adjournment(s) or postponement(s) thereof. Often, the form of proxy supplied to a Non-Registered Shareholder by its broker is identical to the form of proxy provided to Registered Shareholders; however, its purpose is limited to instructing the Registered Shareholder how to vote on behalf of the Non-Registered Shareholder. Non-Registered Shareholders who wish to vote at the Meeting should be appointed as their own representatives at the Meeting in accordance with the directions of their intermediaries and Form 54-101F7. Non-Registered Shareholders can also write the name of someone else whom they wish to vote on their behalf at the Meeting. Unless prohibited by law, the person whose name is written in the space provided in Form 54-101F7 will have full authority to present matters to the Meeting and vote on all matters that are presented at the Meeting, even if those matters are not set out in Form 54-101F7 or this Circular. The majority of brokers now delegate responsibility for obtaining instructions from clients to Broadridge Financial Solutions, Inc. ("Broadridge"). Broadridge typically mails a voting instruction form in lieu of the form of proxy. Non-Registered Shareholders are requested to complete and return the voting instruction form to Broadridge by mail or facsimile. Broadridge will then provide aggregate voting instructions to Computershare, which tabulates the results and provides appropriate instructions respecting the voting of Common Shares to be represented at the Meeting or the reconvening of any adjournment(s) or postponement(s) thereof. By choosing to send the Meeting Materials to NOBOs directly, the Corporation (and not the intermediary holding Common Shares on your behalf) has assumed responsibility for (i) delivering these materials to you; and (ii) executing your proper voting instructions. Please return your voting instructions as specified in the request for voting instructions.
All references to Shareholders in this Circular and the accompanying instrument of proxy and Notice are to Registered Shareholders unless specifically stated otherwise.
Revocation
A Registered Shareholder who has given a proxy may revoke the proxy:
1. |
by completing and signing a form of proxy bearing a later date and depositing it with Computershare as described above; |
2. |
by depositing an instrument in writing executed by the Shareholder or by the Shareholders attorney authorized in writing or by electronic signature at the registered office of the Corporation addressed to Steve Klein, Chairman of the Board of Directors, at any time up to and including the close of business on the last business day preceding the day of the Meeting, or the reconvening of any adjournment or postponement of the Meeting, at which the proxy is to be used or by delivering such instrument to the Chairman of the Meeting prior to the commencement of the Meeting on the day of the Meeting or the reconvening of any adjournment or postponement of the Meeting (which instrument should be sent by facsimile to the Corporation at 1-855-265-5402 marked for the attention of Steve Klein, Chairman of the Board of Directors); or |
3. |
in any other manner permitted by law. |
A Non-Registered Shareholder may revoke a voting instruction form or a waiver of the right to receive Meeting Materials and to vote, which has been provided to an intermediary, at any time by written notice to the intermediary.
Voting of Proxies
The Common Shares represented by any valid proxy in favour of the management designees named in the accompanying form of proxy will be voted for or withheld from voting in accordance with the specific instructions made by the Shareholder on any ballot that may be called for with respect to the election of Directors, the re-appointment of the auditor of the Corporation and authorization of the Directors to fix such auditors remuneration, approving the SOP, approving the Registered Office Resolution and if a Shareholder specifies a choice with respect to any matter to be acted upon, the Common Shares will be voted accordingly. In the absence of any such specific instructions, such Common Shares will be voted by the designated persons named by management in the accompanying form of proxy:
1. |
FOR the election of the Directors named in this Circular; |
2. |
FOR the re-appointment of MNP, LLP as auditor of the Corporation and the authorization of the Directors to fix such auditors remuneration; |
7
3. |
FOR the approval of the SOP; and |
4. |
FOR the approval of the Registered Office Resolution. |
The accompanying form of proxy confers discretionary authority upon the persons named therein with respect to amendments or variations to matters identified in the Notice and with respect to such other business or matters which may properly come before the Meeting or the reconvening of any adjournment(s) or postponement(s) thereof. As of the date of this Circular, the Corporation is not aware of any such amendments or variations or any other matters to be addressed at the Meeting.
Record Date
The Record Date for determining Shareholders entitled to receive notice of and vote at the Meeting is May 10, 2019. Shareholders of record as at the close of business on such date are entitled to participate in and vote at the Meeting, or the reconvening of any adjournment(s) or postponement(s) thereof, in the manner and subject to the procedures described in this Circular.
Voting Shares and Quorum
As of the Record Date, there were 87,045,352 Common Shares issued and outstanding. Shareholders of record on May 10, 2019 are entitled to receive notice of and vote at the Meeting. Each Common Share entitles the holder thereof to one vote at the Meeting.
Pursuant the by-laws of the Corporation, a quorum for the transaction of business at any meeting of Shareholders shall be at least two persons present in person or represented by proxy holding not less than 10% of the outstanding shares of the Corporation entitled to vote at the meeting.
Principal Shareholders
To the knowledge of the Directors and executive officers of the Corporation, the only persons or companies that beneficially own, or control or direct, directly or indirectly, voting securities carrying 10% or more of the voting rights attached to any class of issued and outstanding voting securities of the Corporation as at May 9, 2019 are:
(i) |
Thomas Flow Investments Inc., governed by the laws of Canada and owned by Thomas Flow (an employee of the Corporation). Thomas Flow Investments Inc. owns 26,025,000 of the Common Shares, which is 19.9% of the total issued and outstanding interests in Flowr;(1)(2) and | |
(ii) |
Core Flow Canada Holdings Inc., governed by the laws of the State of New York and controlled by Steve Klein (a Director and Chief Strategy Officer of the Corporation). Core Flow Canada Holdings Inc. owns 7,821,0144 of the Common Shares and 41,598,000 class A preferred shares of The Flowr Canada Holdings ULC (which are exchangeable at no additional consideration for Common Shares on a one for one basis at any time), which is 37.7% of the total issued and outstanding interests in Flowr(2). |
Notes:
(1) |
Thomas Flow also has the right to purchase, or direct the sale of, securities of the Corporation from Michael Thompson, William Street, Craig Main, and Jason Broome, in the event that any of the foregoing individuals cease to be employed by the Corporation before the date that is three |
(3) years from the date of such individuals start of employment with the Corporation. Such right has been exercised in respect of certain shares held by Mark DAngela. | |
(2) |
For the purposes of calculating the percentage of the total issued and outstanding interests in Flowr, the number of Common Shares held by either Thomas Flow Investments Inc. or Core Flow Canada Holdings Inc., as applicable, has been divided by a denominator which includes all of the issued and outstanding Common Shares and all of the issued and outstanding class A preferred shares of The Flowr Canada Holdings ULC (which are exchangeable at no additional consideration for Common Shares on a one for one basis at any time) but does not include any Common Shares that would be issued and outstanding upon the exercise or vesting, as applicable, of any issued and outstanding Options (as defined herein), RSUs (as defined herein) or warrants. |
(3) |
The information above has been furnished by the entities/individuals listed above. |
8
(4) |
On April 29, 2019, the Corporation announced it intended to complete a non-brokered private placement of up to 2,400,000 Common Shares. As of the date of this Circular, the private placement has not closed. It is anticipated that Core Flow Canada Holdings Inc. will subscribe for 432,000 Common Shares under the private placement. |
THE CORPORATION
The Flowr Corporation was incorporated pursuant to the provisions of the Business Corporations Act (Alberta) on June 1, 2016, under the name "The Needle Capital Corp" ("Needle"). The Corporation completed its initial public offering on September 15, 2017, and was listed on the TSX Venture Exchange ("TSX-V") as a capital pool company until it completed its qualifying transaction on September 21, 2018 (the "Qualifying Transaction"). On September 20, 2018, and prior to the completion of the Qualifying Transaction, the Corporation changed its name to "The Flowr Corporation" and completed a consolidation of its share capital on a basis of one post-consolidation Common Share for every thirteen (13) common shares existing immediately before the consolidation. On September 25, 2018, the Corporation continued from the Business Corporations Act (Alberta) to the Business Corporations Act (Ontario). The Common Shares were listed for trading on the TSX-V under the symbol "FLWR" on September 26, 2018.
Prior to the completion of the Qualifying Transaction, the Corporation did not own any assets other than cash and had not conducted any active business operations. Since its incorporation and prior to the Qualifying Transaction, the principal activities of the Corporation consisted of the financing through its initial public offering. As a result of the Qualifying Transaction, the Corporation has become a vertically integrated cannabis company focused on growing high-quality cannabis. As at December 31, 2018, the Corporation had 121 employees (78 full-time and 43 part-time).
The head office of Flowr is located at 461 King Street West, Floor 2, Toronto, Ontario M5V 1K4. The registered office of the Corporation is located at 100 Allstate Parkway, Suite 201, Markham, Ontario L3R 6H3. The Corporation will change the location of its registered office to its head office address upon approval of the Registered Office Resolution at the Meeting.
BUSINESS OF THE MEETING
The Meeting will be constituted as an annual general and special meeting of Shareholders.
At the Meeting, Shareholders will be asked to consider and vote on: (a) the election of the Directors who will serve until the end of the next annual meeting of Shareholders, or until their successors are elected or appointed; (b) the re-appointment of MNP, LLP as auditor of the Corporation and the authorization of the Directors to fix such auditors remuneration (c) the approval of the SOP; (d) the approval of the Registered Office Resolution; and (e) such further and other business as may properly come before the Meeting or the reconvening of any adjournment(s) or postponement(s) thereof.
Interests of Certain Persons or Companies in the Matters to be Acted Upon
As of the date of this Circular, there were 87,045,352 Common Shares issued and outstanding. As at the date of this Circular, Tom Flow, the current Directors and NEOs (as defined in this Circular under the heading "Compensation Discussion and Analysis") of the Corporation, and their associates or affiliates, as a group, beneficially owned, directly or indirectly, or exercised control or direction over, an aggregate of 36,475,463 Common Shares representing approximately 41.9% of the issued and outstanding Common Shares on a non-diluted basis. Any ownership of Common Shares as of the date of this Circular by former Directors and NEOs is not within the knowledge of the Corporation and has not been included in the preceding amounts or percentages.
None of the principal holders of Common Shares or any Director, proposed nominee for election as a Director or executive officer of the Corporation, as the case may be, or any associate or affiliate of any of the foregoing persons, since the beginning of the Corporations last financial year, has any material interest in any proposed matter to be acted upon, other than the election of Directors, that materially affected or will materially affect the Corporation or any of its affiliates.
PRESENTATION OF FINANCIAL STATEMENTS
Management, on behalf of the Board, will submit the Financial Statements to the Shareholders at the Meeting, but no vote by the Shareholders with respect thereto is required or proposed to be taken in respect of the Financial Statements.
The Financial Statements placed before Shareholders will be mailed to requesting Registered Shareholders, as well as requesting Non-Registered Shareholders on or about May 17, 2019 and are also available under the Corporations profile on SEDAR at www.sedar.com.
9
ELECTION OF DIRECTORS
Under the articles of the Corporation, the Board is to consist of a minimum of three (3) and a maximum of fifteen (15) Directors. Pursuant to the special resolution passed by Shareholders at the special meeting of Shareholders held on December 28, 2018, the Board is empowered to determine the number of Directors from time to time by resolution of the Board. The number of Directors to be elected at the Meeting is eight (8). Pursuant to the OBCA, each nominee may be elected by a plurality of the votes cast by Shareholders present in person or represented by proxy.
In the absence of any instructions to the contrary, management of the Corporation proposes to nominate and the Common Shares represented by proxies received by management will be voted FOR the approval of the election as Directors of each of the proposed nominees whose names are set forth under the heading "Director Nominees of The Flowr Corporation". |
Management does not contemplate that any of the proposed nominees will be unable to serve as a Director but, if that should occur for any reason prior to the Meeting, the Common Shares represented by properly executed proxies given in favour of such nominee(s) may be voted by the persons designated by management of the Corporation in the enclosed form of proxy, in their discretion, in favour of another nominee selected by the Board. Each Director elected will hold office until the next annual meeting of Shareholders, or until their respective successors are elected or appointed in accordance with applicable law and the Corporations by-laws.
RE-APPOINTMENT OF AUDITOR
At the Meeting, Shareholders will be asked to re-appoint MNP, LLP, Chartered Professional Accountants, 50 Burnhamthorpe Road West, Suite 900, Mississauga, Ontario L5B 3C2 ("MNP"), as the auditor of the Corporation to hold office until the close of the next annual meeting of Shareholders, based on the recommendation of the Audit Committee and the Board. MNP LLP, Calgary, Alberta was first appointed auditors of Needle on November 3, 2016 and MNP, Mississauga, Ontario were appointed auditors of the Corporation on January 24, 2018.
The persons named in the accompanying form of proxy will, in the absence of specifications or instructions to withhold from voting on the form of proxy, vote FOR the re-appointment of MNP as the auditor of the Corporation to hold office until the next annual meeting of Shareholders and to authorize the Directors to fix such auditors remuneration. |
If a majority of the Common Shares represented at the Meeting are withheld from voting for the appointment of MNP as the auditors of the Corporation, the Board will appoint another firm of chartered accountants based upon the recommendation of the Corporations Audit Committee.
A summary of the external auditor service fees and billings paid or payable to MNP, in respect of the fiscal years ended December 31, 2018 and December 31, 2017, is set out below:
Firm |
Fiscal
Year |
Audit Fees |
Audit-Related Fees
|
Tax Fees |
All Other Fees |
Total |
MNP LLP |
20171 | $51,000 | $7,500 | $27,000 | $110,501 | $196,001 |
2018 | $81,000 | $38,500 | $27,000 | $21,950 | $162,450 |
Notes:
(1) |
These are the fees incurred by Needle prior to the completion of the Qualifying Transaction and also include fees incurred by The Flowr Corporation, the private corporation that completed the Qualifying Transaction with Needle, as MNP LLP acted as auditor for both entities. |
10
STOCK OPTION PLAN
The TSX-V requires that listed issuers obtain shareholder approval every year for security based compensation arrangements that do not have a fixed maximum aggregate of securities issuable. As described in more detail below, the SOP is being put forth for approval by Shareholders at the Meeting.
The SOP was first approved by the TSX-V in connection with the Qualifying Transaction. Effective as of November 26, 2018, the SOP was amended. Such amendment was of a "house-keeping" nature to address certain United States securities laws matters, to reflect the adoption of the Corporations Long-Term Incentive Plan, as amended effective May 9, 2019 ("LTIP") and to make certain administrative changes to reflect the total number of securities that may be issued pursuant to the SOP. The SOP, as amended, was approved by Shareholders at the special meeting of Shareholders held on December 28, 2018, and approved by the TSX-V on January 16, 2019.
Summary of Stock Option Plan
The following is a summary of the principal provisions of the SOP and is qualified in its entirety by the full text of the SOP which is attached as Appendix "A" hereto.
Stock options ("Options") to purchase Common Shares may be granted to full-time and part-time employees of the Corporation or its subsidiaries, and directors, officers, consultants or advisors of the Corporation or its subsidiaries; provided, however, that a consultant or advisor shall not be an eligible participant of the SOP unless such consultant or advisor is an individual that provides bona fide services to the Corporation and such services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for Corporations securities.
Pursuant to the SOP, the exercise price of any Option cannot be less than the market price of the Common Shares at the time the Option is granted. Market price is deemed to be the closing price of the Common Shares on the TSX-V on the last trading day immediately preceding the day upon which the Option is granted, subject to any discounts that may be granted in accordance with the policies of the TSX-V. Options shall vest on the dates specified in the option agreement between the Corporation and the participant optionee. The exercise period of the Options cannot exceed ten (10) years. In the event that a participant ceases to be eligible under the SOP due to death or incapacity, Options that are exercisable will terminate 180 days after the date at which a participant ceases to be eligible, or in the case of retirement, 120 days after the date at which a participant ceases to be eligible. Subject to the provisions of any employment contracts as it relates to exercise and vesting conditions, where a participant is terminated without good cause, the Options that are exercisable at the termination date will be exercisable until the earlier of (i) 30 days after that date, (ii) the date determined by the Board and (iii) the date at which the Option expires pursuant to the SOP. Where a participant is terminated by reason of good cause or resignation, any Options held by the participant will expire immediately and are cancelled at such time as may be determined by the Board.
The Board may grant Options, in accordance with the SOP, at any time they deem to be appropriate. The maximum number of Common Shares reserved for issuance under the SOP shall not exceed, in the aggregate, 10% of the issued and outstanding (a) Common Shares and (b) class A preferred shares in the capital of The Flowr Canada Holdings ULC ("Flowr ULC"), a subsidiary of the Corporation (which are exchangeable for Common Shares at any time at the option of the holder), from time to time, provided that the Board shall have the right, from time to time, to increase such percentage subject to the approval of Shareholders and such regulatory authorities, stock exchanges or over-the-counter markets having jurisdiction over the affairs of the Corporation. For purposes of clarity, the maximum number of Shares reserved and set aside for issue under the SOP and under LTIP shall not exceed 20% of the Common Shares and Flowr ULC class A preferred shares.
The maximum number of Common Shares reserved for issuance in any 12 month period to any individual employee, officer, director, consultant or advisor shall not exceed 5% of the issued and outstanding Common Shares and Flowr ULC class A preferred shares, and to any consultant or person providing investor relation activities shall not exceed 2% of the issued and outstanding Common Shares and Flowr ULC class A preferred shares. The aggregate number of Common Shares that can be granted to insiders of the Corporation as a group shall not exceed 10% of the issued and outstanding Common Shares and Flowr ULC class A preferred shares.
Common Shares that were the subject of Options that have expired, been surrendered, lapsed, cancelled or terminated shall thereupon no longer be in reserve and may once again be subject to an Option granted under the SOP, effectively resulting in a replenishing of the number of Options available for grant under the SOP.
11
A resolution will be placed before the Shareholders to approve the SOP. This approval will be effective for one year from the date of the Meeting. If approval is not obtained at the Meeting, Options which have not been allocated as of June 11, 2019 and Options which are outstanding as of June 11, 2019 and are subsequently cancelled, terminated or exercised will not be available for a new grant of Options. Previously allocated Options will continue to be unaffected by the approval or disapproval of the resolution.
The SOP benefits Shareholders by enabling the Corporation to attract and retain personnel of the highest calibre by rewarding them for their contribution to the generation of Shareholder value, and aligning the interests of the Corporations Directors and officers with those of Shareholders. Accordingly, the Board recommends that Shareholders vote FOR the approval of the SOP.
Approval Required
The full text of the SOP, as well as the proposed ordinary resolution approving the SOP, are attached to this Circular as Appendix "A" and Appendix "B", respectively.
The persons named in the accompanying form of proxy will, in the absence of specifications or instructions to withhold from voting on the form of proxy, vote FOR the approval of the SOP. |
As at May 9, 2019, the current Directors and NEOs (as defined in this Circular under the heading "Compensation Discussion and Analysis") of the Corporation, as a group, beneficially own, directly or indirectly, or exercise control or direction over an aggregate of 29,154,667 Common Shares (44,639,610 Common Shares if all Options held by them are exercised and all Flowr ULC class A preferred shares held by them are converted into Common Shares), representing approximately 33.5% of the current outstanding Common Shares on a non-diluted basis (approximately 32.2% of the current outstanding Common Shares on a non-diluted basis if all Options held by them are exercised and all Flowr ULC class A preferred shares held by them are converted into Common Shares and no other Options or other convertible securities of the Corporation are exercised or converted, as applicable) and approximately 20.3% of the Common Shares on a fully diluted basis, excluding the exercise of all Options and Flowr ULC class A preferred shares held by the Directors and NEOs (approximately 31.1% of the current outstanding Common Shares on a fully diluted basis if all Options held by them are exercised and all Flowr ULC class A preferred shares held by them have been converted and all other outstanding Options and other convertible securities of the Corporation are exercised or converted, as applicable). Any ownership of Common Shares as of the date of this Circular by former Directors and NEOs is not within the knowledge of the Corporation and has not been included in the preceding amounts or percentages.
As at the date of this Circular, there were 12,051,780 outstanding Options to purchase 12,051,780 Common Shares under the SOP with a weighted average exercise price of $2.66. There were also future grants of Options approved by the Board to purchase 785,000 Common Shares with such Options to be granted to the applicable employee on either the start date of employment or the expiry of the Corporations current blackout period for trading in securities.
Under the SOP, as of May 9, 2019, 6,205,961 Options have been granted and have been exercised; 2,013,750 Options have been granted and have expired; 12,051,780 Options are outstanding; 785,000 Options have been approved for granting subject to either, for the applicable employee, the commencement of employment or the expiry of the Corporations current blackout period for trading in securities; and 262,755 Options remain available for future granting.
Options granted since inception of the SOP and either exercised or outstanding | 20,271,491 | ||
Options granted subject to Shareholder approval | - | ||
Options granted subject to the expiry of the Corporations current blackout period for trading in | 35,000 | ||
securities | |||
Options granted subject to the commencement of employment for new employees | 750,000 | ||
Total | 21,056,491 | ||
Options exercised since inception of the SOP | 6,205,961 | ||
Options outstanding | 12,051,780 | ||
Options cancelled | 2,013,750 | ||
Options approved for future granting | 785,000 | ||
Options available for future granting | 262,755 | ||
Total | 21,319,246 |
12
LONG TERM INCENTIVE PLAN
As part of an ongoing review of the Corporations compensation strategies, effective as of November 26, 2018 the Board approved the LTIP, a copy of which is attached hereto as Appendix "C" to this Circular. The LTIP was approved by Shareholders at the special meeting of Shareholders held on December 28, 2018. On May 9, 2019 the Board approved certain amendments to the LTIP of a housekeeping nature in order to permit RSU Participants (as defined below) to elect to defer the payment in respect of an award of RSUs when it becomes payable on the applicable vesting date. Any such deferral by an RSU Participant may be for a period of no longer than 5 years from the date of the applicable RSU award agreement. A copy of the LTIP, including the amendments described herein, is attached as Appendix "C" hereto. Pursuant to the terms of the LTIP, Shareholder approval is not required for such amendment to the LTIP.
Under the terms of the LTIP the Board or, if authorized by the Board, a committee of the Board may grant units ("Units"), which may be either restricted share units ("RSUs") or deferred share units ("DSUs") to officers, Directors, employees or consultants of the Corporation; provided, however, that a consultant or advisor shall not be an eligible participant of the LTIP unless such consultant or advisor is an individual that provides bona fide services to the Corporation and such services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the Corporations securities. The purpose of the LTIP is to advance the interests of the Corporation: (a) through the motivation, attraction and retention of key employees and Directors of the Corporation; (b) by aligning the interests of eligible participants with the interests of Shareholders generally; and (c) by furnishing eligible participants with an additional incentive in their efforts on behalf of the Corporation.
As of the date of this Circular:
there are 197,250 RSUs issued and outstanding;
there are no DSUs issued and outstanding;
there are 290,000 RSUs granted subject to the expiry of the Corporations current blackout period for trading in securities; and
there are 575,000 RSUs granted subject to the commencement of employment for new employees.
Summary of the Long Term Incentive Plan
The following is a summary of the principal provisions of the LTIP and is qualified in its entirety by the full text of the LTIP which is attached as Appendix "C" hereto.
Pursuant to the terms of the LTIP each Unit represents the right to receive one Common Share. Participation in the LTIP is voluntary and, if an eligible participant agrees to participate, the grant of Units is evidenced by an agreement between the Corporation and the participant. The interest of any participant in any Unit may not be transferred or assigned except by testamentary disposition or in accordance with the laws governing the devolution of property upon death.
The maximum number of Common Shares which may be reserved and set aside for issue under the LTIP in respect of awards of DSUs to DSU participants and for payments in respect of awards of RSUs to RSU participants, shall not exceed 10% of the (a) Common Shares and (b) class A preferred shares in the capital of Flowr ULC (which are exchangeable for Common Shares at any time at the option of the holder) (being a fixed number of 13,057,421 Common Shares as reserved with the TSX-V), provided that the Board shall have the right, from time to time, to increase such number of Common Shares subject to the approval of Shareholders and such regulatory authorities, stock exchanges or over-the-counter markets having jurisdiction over the affairs of the Corporation. For purposes of clarity, the maximum number of Common Shares reserved and set aside for issue under the LTIP and under the SOP shall not exceed 20% of the Common Shares and Flowr ULC class A preferred shares. Common Shares that were the subject of awards that have expired, been surrendered, lapsed, cancelled or terminated shall thereupon no longer be in reserve and may once again be subject to an award granted under the LTIP, effectively resulting in a replenishing of the number of RSUs and DSUs available for grant under the LTIP.
The LTIP, together with all other previously established or proposed security based compensation arrangements of the Corporation, including the SOP, may not result in:
13
1. |
the number of Common Shares reserved for issuance to insiders at any time exceeding 10% of the issued and outstanding Common Shares and Flowr ULC class A preferred shares; |
2. |
the issuance to insiders of the Corporation of a number of Common Shares exceeding, within a one year period, 10% of the issued and outstanding Common Shares and Flowr ULC class A preferred shares; or |
3. |
the issuance to any one insider of the Corporation, within a one year period, of a number of Common Shares exceeding 5% of the issued and outstanding Common Shares and Flowr ULC class A preferred shares. |
Restricted Share Units
An officer, Director, employee or consultant of the Corporation who has been designated by the Corporation for participation in the LTIP and who agrees to participate in the LTIP is an eligible participant to receive RSUs under the LTIP (an "RSU Participant").
Unless otherwise set forth in an award agreement, an RSU will vest as to 33 1/3% on each of the first, second and third anniversary dates of the grant date, provided that, unless otherwise provided under the applicable award agreement, all RSUs granted under a particular award shall vest on or before December 31st of the calendar year which is 3 years following the calendar year in which the service was performed in respect of which the particular award was made (the "Final Vesting Date"), provided further that all payments under a particular award of a U.S. taxpayer shall be made on or before December 31st of the year in which the scheduled RSU vesting date (determined without regard to Section 3.2.2 of the LTIP) occurs or, if later, by the date that is two and one-half (2 ½) months after such scheduled RSU vesting date. In the event that a vesting date occurs within a blackout period or within 5 business days thereafter, the vesting date shall be 10 business days after the blackout period ends (the "Extension Period"). If an additional blackout period is subsequently imposed during the Extension Period, then the Extension Period will commence following the end of such additional blackout period. Despite the foregoing, and unless otherwise provided under the applicable award agreement, a vesting date will not be extended beyond the Final Vesting Date.
On each vesting date, unless the decision has already been made in the award agreement, on the RSU vesting date, the Corporation decides, in its sole discretion, whether to make all payments in respect of vested RSUs to the RSU Participant in cash, Common Shares issued from treasury or a combination thereof based on the fair market value of the Common Shares as at such date. For the purposes of the LTIP, the fair market value of a Common Share is the weighted average trading price of the Common Shares on the TSX-V for the 5 trading days immediately preceding the vesting date for a RSU or DSU Termination Date (as defined below) in respect of DSUs, as applicable.
If an RSU Participant ceases to be an eligible participant under the LTIP due to termination with cause or voluntary termination by the RSU Participant, all unvested RSUs previously credited to the participants account are terminated and forfeited as of the termination date. If an RSU Participant ceases to be an eligible participant under the LTIP due to termination without cause, death, total or permanent long-term disability or retirement, any unvested RSUs previously credited to the participants account will continue to vest in accordance with their terms or, at the discretion of the Board, be terminated and forfeited as of the termination date, subject to the provisions of any RSU Participants employment contract. In the event the Corporation pays a dividend on the Common Shares subsequent to the granting of an RSU award, the number of RSUs relating to such award shall be increased to reflect the amount of the dividend.
Deferred Share Units
A Director of the Corporation who has been designated by the Corporation for participation in the LTIP and who agrees to participate in the LTIP is an eligible participant to receive DSUs under the LTIP (a "DSU Participant").
All DSUs awarded to a DSU Participant vest on the date on which the DSU Participant ceases to be a Director of the Corporation (the "DSU Termination Date"). Notwithstanding the foregoing, any payments under a particular award of a U.S. taxpayer shall be made as soon as practicable following a DSU Termination Date in accordance with the LTIP, but in no case later than December 31st of the year in which such DSU Termination Date occurs or, if later, by the date that is two and one-half (2 ½) months after such DSU Termination Date.
On the DSU Termination Date, payment in respect of a DSU Participants DSUs becomes payable and the Corporation decides, in its sole discretion, whether to make the payment in cash, Common Shares issued from treasury or a combination thereof based on the fair market value of the Common Shares as at the DSU Termination Date.
14
In the event the Corporation pays a dividend on the Common Shares subsequent to the granting of a DSU award, the number of DSUs relating to such award shall be increased to reflect the amount of the dividend.
Amendments
The Corporation retains the right without the approval of Shareholders:
1. |
to amend the LTIP or any RSUs or DSUs to: | |
(i) |
make amendments of a grammatical, typographical, clerical and administrative nature and any amendments required by a regulatory authority or to comply or conform with applicable laws; | |
(ii) |
change vesting provisions of the LTIP or any RSUs or DSUs; | |
(iii) |
make any other amendments of a non-material nature; | |
(iv) |
make amendments to the definition of "DSU Participant" and/or "RSU Participant" or the eligibility requirements of participating in the LTIP, where such amendment would not have the potential of broadening or increasing insider participation; | |
(v) |
make amendments to the manner in which eligible participants may elect to participate in the LTIP; | |
(vi) |
make any amendments to the provisions concerning the effect of the termination of a participants employment or services on such participants status under the LTIP; or | |
(vii) |
make any amendment which is intended to facilitate the administration of the LTIP; or | |
2. |
to suspend, terminate or discontinue the terms and conditions of the LTIP and the RSUs and DSUs granted under the LTIP by resolution of the Board, provided that: | |
(i) |
no such amendment to the LTIP shall cause the LTIP in respect of RSUs to cease to be a plan described in paragraph (k) of the definition of "salary deferral arrangement" in subsection 248(1) of the Income Tax Act (Canada) (the "ITA") or any successor to such provision; | |
(ii) |
no such amendment to the LTIP shall cause the LTIP in respect of DSUs to cease to be a plan described in regulation 6801(d) of the ITA or any successor to such provision; and | |
(iii) |
any amendment shall be subject to the prior consent of any applicable regulatory bodies, including the TSX-V, as may be required. |
Any amendment to the LTIP which changes the vesting provisions of the LTIP or any RSUs or DSUs, or any suspension, termination or discontinuance of the terms and conditions of the LTIP and the RSUs and DSUs granted under the LTIP, shall take effect only with respect to awards granted after the effective date of such amendment, provided that it may apply to any outstanding award with the mutual consent of the Corporation and the participants to whom such awards have been granted.
Any amendment to the LTIP other than as described above shall require the approval of Shareholders given by the affirmative vote of a simple majority of the Common Shares (or, where required, "disinterested" Shareholder approval) represented at a meeting of Shareholders at which a motion to approve the LTIP or an amendment to the LTIP is presented. Specific amendments requiring Shareholder approval include:
1. |
to increase the number of Common Shares reserved under the LTIP; |
2. |
to change the definition of RSU Participants or DSU Participants or the eligibility requirements of participating in the LTIP, where such amendment would have the potential of broadening or increasing insider participation; |
3. |
the extension of any right of a participant under the LTIP beyond the date on which such right would originally have expired; |
15
4. |
to permit RSUs or DSUs to be transferred other than by testamentary disposition or in accordance with the laws governing the devolution of property in the event of death; |
5. |
to permit awards other than RSUs and DSUs under the LTIP; and |
6. |
to amend the amendment provisions of the LTIP so as to increase the ability of the Board to amend the LTIP without Shareholder approval. |
In accordance with the policies of the TSX-V, to the extent that the Corporation grants RSUs or DSUs to eligible participants under the LTIP, which are agreed to be settled in cash on the grant date, such RSUs and DSUs will not reduce the pool of securities available for grant under the LTIP.
APPROVAL OF REGISTERED OFFICE RESOLUTION
At the Meeting, the Shareholders will be asked to consider, and if deemed advisable, confirm, ratify and approve by special resolution the Registered Office Resolution, a copy of which is attached hereto as Appendix "D".
Approval Required
The proposed special resolution approving the amendment of the articles of the Corporation to change the place of the registered office of the Corporation from 201-100 Allstate Pkwy, Markham, Ontario, L3R 6H3 to 461 King Street West, Floor 2, Toronto, Ontario M5V 1K4 is attached to this Circular as Appendix "D". The vote required to pass the Registered Office Resolution is at least two-thirds (662/3%) of the votes cast by the Shareholders present in person or represented by proxy at the Shareholders Meeting and entitled to vote on such resolution.
The persons named in the accompanying form of proxy will, in the absence of specifications or instructions to withhold from voting on the form of proxy, vote FOR the approval of the Registered Office Resolution. |
DIRECTOR NOMINEES OF THE FLOWR CORPORATION
Under the articles of the Corporation, the Board is to consist of a minimum of three (3) and a maximum of fifteen (15) Directors. Pursuant to the special resolution passed by Shareholders at the special meeting of Shareholders held December 28, 2018, the Board is empowered to determine the number of Directors from time to time by resolution of the Board. The number of Directors to be elected at the Meeting is eight (8). Pursuant to the OBCA, each nominee may be elected by a plurality of the votes cast by Shareholders present or represented by proxy.
The Board has approved the nomination of the following eight (8) individuals for election as Directors. Voting for the election of the eight (8) nominee Directors will be conducted on an individual basis. All of the nominees for election at the Meeting are currently Directors. All nominees have agreed to stand for election.
The following disclosure sets out, as at the date of this Circular, (a) the names of nominees for election as Directors, and their residency, (b) all major offices and positions with the Corporation each now holds, (c) each nominees principal occupation, business or employment, (d) the period of time during which each has been a Director, (e) the current equity ownership consisting of Common Shares beneficially owned, directly or indirectly, or controlled or directed, and options or other exchangeable securities credited to each nominee, and (f) other current public board memberships and committees.
Common Shares beneficially owned, controlled or directed, directly or indirectly, as at May 9, 2019 is based upon information furnished to the Corporation by each individual Director or nominee.
Management does not contemplate that any of the nominees will be unable to serve as a Director. If, as a result of circumstances not now contemplated, any nominee is unable to serve as a Director, the proxy will be voted for the election of such other person or persons as the Board may select. Each Director elected will hold office until the next annual meeting of Shareholders, or until their respective successors are elected or appointed in accordance with applicable law and the Corporations by-laws.
16
17
18
19
20
Notes to the above Director Bios:
(1) |
Independent Director for purposes of National Instrument 58-101 Disclosure of Corporate Governance Practices ("NI 58-101"). |
(2) |
Member of the Audit Committee. If elected, it is proposed that Ms. Basian will Chair the Audit Committee, and Messrs. Duet and Levesque will be the other members of the Audit Committee. |
(3) |
The information as to country and province or state or residence, and principal occupation, not being within the knowledge of the Corporation, has been furnished by the respective nominees. |
(4) |
Each Director listed will hold his or her position as a Director of the Corporation until the next annual meeting of Shareholders or until his or her respective successor is elected or appointed in accordance with applicable laws and the Corporations by-laws. |
(5) |
Securities beneficially owned, controlled or directed, directly or indirectly, as at May 9, 2019, is based upon information furnished to the Corporation by each individual Director or nominee. |
(6) |
Member of the Human Resources & Compensation Committee. If elected, it is proposed that Mr. Duet will Chair the Human Resources & Compensation Committee, and Ms. Basian and Mr. Levesque will be the other members of the Human Resources & Compensation Committee. |
(7) |
Mr. Klein is also a principal of Core Flow Canada Holdings Inc., which holds an aggregate of 49,419,014 Common Shares and class A preferred shares of a subsidiary of the Corporation. This figure includes the securities, other than Options, held by Messrs. Klein, Miller and Tolia disclosed above. |
(8) |
Member of the Nominating & Corporate Governance Committee. If elected, it is proposed that Mr. Levesque will Chair the Nominating & Corporate Governance Committee, and Ms. Basian and Mr. Duet will be the other members of the Nominating & Corporate Governance Committee. |
(9) |
On April 29, 2019, the Corporation announced it intended to complete a non-brokered private placement of up to 2,400,000 Common Shares. As of the date of this Circular, the private placement has not closed. It is anticipated that (i) Core Flow Canada Holdings Inc. will subscribe for 432,000 Common shares under the private placement, (ii) Vinay Tolia will subscribe for 40,000 Common Shares under the private placement and (iii) Don Duet, through a family trust, will subscribe for 106,618 Common Shares under the private placement. |
(10) |
Dr. de Barros Teixeira is independent with respect to the Corporation pursuant to NI 58-101. Dr. de Barros Teixeira is retained as a consultant by Holigen Holdings Limited. The Corporation has entered into an agreement to acquire an 19.8% interest in Holigen Holdings Limited. |
21
STATEMENT OF BOARD OF DIRECTOR COMPENSATION |
Compensation arrangement for non-executive members of the Board are designed to align with the competitive market to attract qualified and experienced directors. The Human Resources & Compensation Committee and the Board approved for fiscal 2019 a Director compensation package based on the following key pillars:
Board compensation should
be competitive to attract skilled and experience directors. |
Compensation is set at a level that will attract experienced and skilled candidates and retain current Directors. The Corporation recognizes that there is significant competition for qualified directors and that directors must select their directorships wisely due to board limit restrictions being imposed by institutional shareholders. |
Board compensation
should align the interests of Directors with those of the Shareholders. |
The overall compensation package, including a mix of both cash and equity components should align Directors interests with those of Shareholders. |
Board compensation should be fair and reasonable. | The Corporation recognizes that Directors need to be compensated fairly for their time and effort. The Corporation seeks to reward Directors reasonably, reflecting the complexities, risks, skill set and value associated with being on the Board. |
The Corporation has implemented a fixed fee Director compensation structure, under which additional fees are not provided to Directors on a meeting-by-meeting basis. The Corporation has adopted the fixed fee approach based on the following:
Transparency to the Board, Shareholders and management.
Meeting attendance and preparation is expected, not rewarded.
Compensating for the role holistically, not the number of meetings held in a year.
Under the fixed fee model, in 2019 the Corporation will compensate specifically for the role and responsibilities of each individual Director. This will be broken out by retainers for service on the Board and individual committees. Director compensation will have two components: cash retainers and equity-based awards.
Cash Retainer | An annual fixed Board retainer to be paid to non-executive Directors establishes the competitive foundation of the Director compensation program. Committee retainers are granted for both the committee chair as well as committee members and serve as additional compensation for the time and expertise required to serve on the different committees. For 2019, the Lead Independent Director will receive a premium on the cash retainer to account for increased responsibilities. |
Equity Award | An annual equity grant in the form of Options, RSUs or DSUs is made to non- executive Directors to align their interests with the interests of Shareholders, to reinforce longer-term business performance and to remain market competitive. |
Prior to the closing of the Qualifying Transaction, the former Board members, being Douglas Osrow, Robb McNaughton and Daniel Lanskey received options to purchase Common Shares of the Corporation.
Outlined in the table below is the 2019 Director compensation pay structure that has been implemented by the Board. The Board currently has three committees, being the Audit Committee, the Human Resources & Compensation Committee ("HRCC") and the Nominating and Corporate Governance Committee ("NCGC").
22
Based on the recommendation of the HRCC, the Board approved compensation for Directors in 2019 as detailed in the table below:
2019 | ||
Fee Description | Equity | |
Cash Retainer | Retainer | |
Lead Independent Director | $45,000 | 15,000 Options |
Non-Executive Director 1 | $35,000 | 15,000 Options |
Audit Committee Chair | $15,000 | - |
Audit Committee Member2 | $2,500 | - |
HRCC Chair | $3,500 | - |
HRCC Member3 | $1,750 | - |
NCGC Chair | $3,500 | - |
NCGC Member4 | $1,750 | - |
Notes: | |
_______________________________ | |
1 | Other than the Lead Independent Director. |
2 | Other than the Audit Committee Chair. |
3 | Other than the HRCC Chair. |
4 | Other than the NCGC Chair. |
Director Summary Compensation Table
The table below sets out a summary of total compensation applicable to each non-executive member of the Board for the 2018 and 2017 fiscal year, excluding compensation related to the issuance of securities. The Corporation may also reimburse Directors for out-of-pocket expenses for, among other matters, attending meetings.
Name and Position1 |
Year |
Salary, consulting fee, retainer or commission ($) |
Bonus ($) |
Committee or meeting fees ($) |
Value of perquisites ($) |
Value of all other compensation ($) |
Total compensation ($) |
Karen Basian Lead Independent Director |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - | |
Don Duet(2) Independent Director |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - | |
Maurice Levesque Independent Director |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - | |
J. André de Barros Teixeira Independent Director |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - | |
David Miller Director and former General Counsel |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - | |
David Towill3 Former Director |
2018 | - | - | - | - | - | - |
2017 | $10,890 | - | - | - | - | $10,890 | |
Rishi Shah4 Former Director |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | ||
Douglas Osrow5 Former Director |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - | |
Robb McNaughton5 Former Director |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
23
Notes:
________________________________
1 |
Steve Klein, Vinay Tolia and Dr. Lyle Oberg are officers of the Corporation, and Daniel Lanskey was an officer of the Corporation until September 21, 2018. Thomas Flow was a Director and an officer of the Corporation until April 29, 2019. The compensation information for the foregoing individuals is set forth under the heading "Statement of Executive Compensation - Summary Compensation Table". Mr. Klein is not an employee of the |
Corporation, but provides services as Chief Strategy Officer. | |
2 |
Don Duet was appointed to the Board on April 29, 2019. |
3 |
David Towill ceased to be a Director effective October 26, 2018. |
4 |
Rishi Shah ceased to be a Director effective April 29, 2019. |
5 |
Each of Messrs. Osrow, McNaughton and Lanskey ceased being Directors on September 21, 2018 in connection with the completion of the Qualifying Transaction. |
Stock Options and Other Compensation Securities
The following table discloses all compensation securities granted or issued to each Director in the year ended December 31, 2018, other than Directors who serve as NEOs.
Name and Position1 |
Type of security compensation |
Number of compensation securities, number of underlying securities, and percentage of class |
Date of Issue or Grant |
Issue, conversion or exercise price ($) |
Closing price of security or underlying security on date of grant ($) |
Closing price of security or underlying security at year end ($) |
Expiry Date |
David Towill2 Former Director |
- |
- |
- |
- |
- |
- |
- |
Rishi Shah3 Former Director |
- |
- |
- |
- |
- |
- |
- |
Douglas Osrow4 Former Director |
- |
- |
- |
- |
- |
- |
- |
Robb McNaughton4 Former Director |
- |
- |
- |
- |
- |
- |
- |
David Miller Director and former General Counsel |
Options |
1,050,000 |
August 24, 2018 |
$2.60 |
$2.60 |
$4.39 |
August 24, 2023 |
Karen Basian5 Lead Independent Director |
- |
- |
- |
- |
- |
- |
- |
Don Duet5,6 Independent Director |
- |
- |
- |
- |
- |
- |
- |
Maurice Levesque5
Independent Director |
- |
- |
- |
- |
- |
- |
- |
J. André de Barros5 Teixeira Independent Director |
- |
- |
- |
- |
- |
- |
- |
Notes:
__________________________________
1 |
Steve Klein, Vinay Tolia and Dr. Lyle Oberg are officers of the Corporation, and Daniel Lanskey was an officer of the Corporation until September 21, 2018. Thomas Flow was a Director and an officer of the Corporation until April 29, 2019. The compensation information for the foregoing individuals is set forth under the heading "Statement of Executive Compensation - Summary Compensation Table". Mr. Klein is not an employee of the Corporation, but provides services as Chief Strategy Officer. |
2 |
David Towill ceased to be a Director effective October 26, 2018. |
3 |
Rishi Shah ceased to be a Director effective April 29, 2019. |
4 |
Each of Messrs. Osrow, McNaughton and Lanskey ceased being Directors on September 21, 2018 in connection with the completion of the Qualifying Transaction. |
5 |
Each of Ms. Basian and Messrs. Duet, Levesque and de Barros Teixeira were granted 15,000 Options on May 2, 2019. |
6 |
Don Duet was appointed to the Board on April 29, 2019. |
24
Exercise of Compensation Securities by Directors
The following table sets out each exercise by a Director of compensation securities during 2018.
Name and
Position1 |
Type of
compensation security |
Number of
underlying securities exercised |
Exercise Price per security ($) |
Date of
exercise |
Closing price per
security on date of exercise ($) |
Difference between
exercise price and closing price on date of exercise ($) |
Total
value on exercise date ($) |
David Towill2 | - | - | - | - | - | - | - |
Rishi Shah3 | - | - | - | - | - | - | - |
Douglas Osrow4
|
Options |
240,000 |
0.10 |
September 20, 2018 |
0.15 |
0.05 |
12,000 |
Robb McNaughton4
|
Options |
240,000 |
0.10 |
September 20, 2018 |
0.15 |
0.05 |
12,000 |
David Miller | - | - | - | - | - | - | - |
Karen Basian | - | - | - | - | - | - | - |
Don Duet5 | - | - | - | - | - | - | - |
Maurice Levesque | - | - | - | - | - | - | - |
J. André de
Barros Teixeira |
- |
- |
- |
- |
- |
- |
- |
Notes:
1 |
Steve Klein, Vinay Tolia and Dr. Lyle Oberg are officers of the Corporation, and Daniel Lanskey was an officer of the Corporation until September 21, 2018. Thomas Flow was a Director and an officer of the Corporation until April 29, 2019. The compensation information for the foregoing individuals is set forth under the heading "Statement of Executive Compensation - Summary Compensation Table". Mr. Klein is not an employee of the Corporation, but provides services as Chief Strategy Officer. |
2 |
David Towill ceased to be a Director effective October 26, 2018. |
3 |
Rishi Shah ceased to be a Director effective April 29, 2019. |
4 |
Each of Messrs. Osrow, McNaughton and Lanskey ceased being Directors on September 21, 2018 in connection with the completion of the Qualifying Transaction. All Options held by Messrs. Osrow and McNaughton were exercised prior to the closing of the Qualifying Transaction. |
5 |
Don Duet was appointed to the Board on April 29, 2019. |
Interest of Informed Persons in Material Transactions
Other than as disclosed below, since the commencement of the Corporations most recently completed financial year, the Corporation did not have any transactions, or any proposed transactions, with any "informed person" (as defined in applicable securities laws), or any proposed Director of the Corporation, or any associate or affiliate of any informed person or proposed Director, who has a material interest or had a material interest, direct or indirect, which has materially affected or would materially affect the Corporation or any of its subsidiaries.
Corporate Cease Trade Orders or Bankruptcies
Except as disclosed below, to the knowledge of the Corporation none of the persons proposed for election as Directors nor any personal holding company owned or controlled by any of them: (a) are, as at the date of this Circular, or have been, within the 10 years before the date of this Circular, a director, chief executive officer or chief financial officer of any company that: (i) was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant company access to any exemption under securities legislation that was in effect for a period of more than 30 consecutive days (an "Order") that was issued while the proposed Director was acting in the capacity as director, chief executive officer or chief financial officer; or (ii) was subject to an Order that was issued after the proposed Director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer; (b) are, as at the date of this Circular, or have been within 10 years before the date of this Circular, a director or executive officer of any company that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or (c) have, within the 10 years before the date of this Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of that person.
Mr. Levesque has been the President and a director of Knightswood Financial Corp. ("KFC") since December 1996. KFC was a publicly listed company on the TSX-V until mid 2017, and prior to December 1998 was known as First Venture Developments Ltd. Trading in the shares of KFC was halted on June 11, 2001, pending clarification of the companys affairs. On July 20, 2001, trading in the securities of KFC resumed under the "Inactive" designation pending completion of the review of the companys reorganization as per Canadian Venture Exchange (now the TSX-V) Policy 2.6. This review resulted in KFC no longer being deemed inactive as per Policy 2.6.
Penalties and Sanctions
Other than as disclosed herein, to the knowledge of the Corporation none of the persons proposed for election as Directors nor any personal holding company owned or controlled by any of them: (a) has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or (b) has been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable securityholder in deciding whether to vote for the proposed Director.
Messrs. Klein and Miller are former members of the board of directors of CNC Development, Ltd. ("CNC"). During the tenure of Messrs. Klein and Miller, CNC exhausted its liquidity and was unable to pay the necessary accounting and legal fees to fulfill its requirements as a publicly listed company in the United States to file periodic reports with the SEC. Trading in the shares of CNC was suspended and the SEC took administrative action to delist CNC in 2013.
Indebtedness of Directors, Officers and Employees
None of the Directors, executive officers or nominees for election as Directors or their respective associates is, or at any time since the beginning of the most recently completed fiscal year has been, indebted to the Corporation or any of its subsidiaries or is, or has been since the beginning of the most recently completed fiscal year, indebted to another entity where the Corporation or any of its subsidiaries provided a guarantee, support agreement, letter of credit or other similar arrangement in connection with such debt. There was no indebtedness as at May 9, 2019 to the Corporation or any of its subsidiaries, excluding routine indebtedness, owing by present and former officers, present Directors or nominees for election as Directors, or employees of the Corporation and any of its subsidiaries.
26
COMPENSATION DISCUSSION AND ANALYSIS |
STATEMENT OF EXECUTIVE COMPENSATION
The following discussion provides information about the Corporations proposed philosophy, objectives and processes regarding compensation for its executive officers. Compensation for the Corporations Chief Executive Officer, Chief Financial Officer and the next three (3) most highly compensated executive officers (collectively, the "NEOs") is determined by the Board. The HRCC provides recommendations to the Board with respect to executive compensation based on advice obtained from the Boards compensation consultants. The Corporations executive compensation predominantly based on prevailing industry compensation practices for companies of comparable size and industry and the Corporations performance in achieving certain goals.
It will be the responsibility of the Board, on the recommendation of the HRCC, as a whole to make decisions regarding executive compensation matters. The Corporations compensation program supports its commitment to delivering strong performance for Shareholders. The Corporations overall objective of its compensation philosophy is the attraction, motivation and retention of quality, experienced people to achieve the Corporations strategic objectives and to align the interests of its executive officers and employees with the long-term interests of Shareholders.
It is currently contemplated that executive compensation will be comprised of the following components: (i) base salary, (ii) bonus and (iii) equity incentives. Together, these components are designed to address the key objectives of the Corporations compensation program.
For the purposes of this Circular:
"CEO" of the Corporation means each individual who served as Chief Executive Officer of the Corporation or acted in a similar capacity for any part of the most recently completed financial year;
"CFO" of the Corporation means each individual who served as Chief Financial Officer of the Corporation or acted in a similar capacity for any part of the most recently completed financial year; and
"Named Executive Officers" or "NEOs" means (i) CEO, (ii) CFO, (iii) each of the three (3) most highly compensated executive officers of the Corporation, including any subsidiary of the Corporation, or the three (3) most highly compensated individuals acting in a similar capacity, other than the CEO and CFO, at the end of the most recently completed financial year whose total compensation was, individually, more than $150,000; and (iv) each individual who would be a NEO under paragraph (iii) but for the fact that the individual was neither an executive officer of the Corporation or a subsidiary of the Corporation, nor acting in a similar capacity, at the end of that financial year.
Named Executive Officers for 2018
During the financial year ended December 31, 2018, the Corporation had the following NEOs:
Vinay Tolia | Co-Chief Executive Officer |
Alexander Dann | Chief Financial Officer |
Lyle Oberg | Chief Policy and Medical Officer |
Steve Klein | Chief Strategy Officer |
Daniel Lanskey | Former President, Chief Executive Officer and Chief Financial Officer |
Thomas Flow | Former Co-Chief Executive Officer |
Anthony Giorgi | Former Chief Executive Officer |
David Ralston | Former Chief Operating Officer |
Daniel Lanskey ceased to be an officer of the Corporation on September 21, 2018 upon completion of the Qualifying Transaction.
On September 21, 2018, the Needle Capital Corp. completed its Qualifying Transaction with The Flowr Corporation. Upon completion of the Qualifying Transaction and as at December 31, 2018, Vinay Tolia and Thomas Flow were the co-Chief Executive Officers of the Corporation, Alex Dann was the Chief Financial Officer of the Corporation, Dr. Lyle Oberg was the Chief Policy and Medical Officer of the Corporation and Steve Klein was the Chief Strategy Officer of the Corporation. Mr. Klein is not an employee of the Corporation, but provides services as Chief Strategy Officer. Mr. Flow stepped down as a Director and Co-CEO on April 29, 2019. Anthony Giorgi was the former CEO of The Flowr Corporation, the private corporation that existed prior to the completion of the Qualifying Transaction and that completed the Qualifying Transaction with the Corporation, and ceased to hold that position on June 21, 2018. David Ralston was the Chief Operating Officer of the Corporation and ceased to hold that position on November 9, 2018.
27
The summary compensation table provides for compensation paid to the co-Chief Executive Officers (as at December 31, 2018), Chief Financial Officer and NEOs for the calendar year ended December 31, 2018 and 2017, despite that these individuals were not executive officers of the Corporation for the financial year ended December 31, 2017. Such compensation was paid to these individuals by The Flowr Corporation, a private corporation, prior to the completion of the Qualifying Transaction.
Compensation Risk
The Board assesses the potential risks relating to the Corporations policies and practices for its employees, including those related to the Corporations executive compensation program. The Board considers the Corporations compensation policies and practices, identifies potential risks and considers mitigating factors. Periodically, and going forward at least annually, the Board and the HRCC will review and discuss with management the relationship between the Corporations compensation policies and practices and its risk management, including the extent to which those policies and practices create risks for the Corporation. Based on this assessment, the Board determined that the Corporations policies and practices do not encourage excessive or unnecessary risk taking and are not reasonably likely to have a material adverse effect on the Corporation.
Clawback Policy
The Corporation intends on adopting a Clawback Policy in fiscal 2019, which will provide the Board and HRCC with discretion to recover certain incentive compensation received or realized by a senior executive officer, if there is an incidence of misconduct resulting in the need for the Corporation to publicly issue an accounting restatement of all or a portion of its interim or annual financial statements. It is proposed that misconduct will be characterized as gross negligence, intentional misconduct or fraud engaged in by the applicable executive which resulted in the financial restatement by the Corporation.
Independent Compensation Consultants
The Corporation has engaged independent compensation consultants, Willis Towers Watson, to provide the Board and management with compensation advice for compensation structures to be implemented for the calendar year 2019.
Compensation Benchmarking and Comparator Group
For the calendar year 2017 and 2018, the Corporation did not have a comparator group, as the Corporation was a capital pool company with no operations.
Upon completion of the Qualifying Transaction, the Board and management of the Corporation engaged Willis Towers Watson to assist the Corporation with selecting a comparator group and to complete benchmarking for the Corporations 2019 compensation structure.
28
For 2019, Willis Towers Watson has identified the following peer group for the Corporation, which the Board has approved.
2019 Peer Group | |
Cronos Group Inc. | HEXO Corp. |
CannTrust Holdings Inc. | The Supreme Cannabis Company, Inc. |
Jamieson Wellness Inc. | Andrew Peller Limited |
Namaste Technologies Inc. | Corby Spirit and Wine Limited |
Eastwood Bio-Medical Canada Inc. | Village Farms International, Inc. |
Brick Brewing Co. Limited |
Components of Executive Compensation
Base Salaries
The base salary component is intended to provide a fixed level of pay that reflects each NEOs primary duties and responsibilities. While base salaries are an important element of executive officer compensation, the size and stage of the Corporation prevents the Corporation from paying base salaries which are comparable to those of larger companies in the similar industry and, accordingly, performance-based compensation elements are an integral component of the executive compensation package. In setting base compensation levels for executive officers, consideration will be given to objective factors such as level of responsibility, experience and expertise as well as subjective factors such as leadership. For 2019, the Board and management of the Corporation will be reviewing base salaries with the advice of Willis Towers Watson, and may adjust salaries based on the 2019 comparator group and the growth of the Corporation.
Bonus
The Corporation does not currently have a bonus plan and intends to implement a bonus structure, with the advice of Willis Towers Watson, for its employees in 2019 based on the 2019 comparator group. Notwithstanding the foregoing, the Corporation may grant cash bonuses to reflect contributions made by certain employees to the Corporations development and success. In fiscal 2018, the Board approved a cash bonus of $500,000 to Tom Flow in recognition of his significant contribution to the Corporation, with such amount paid in calendar year 2019.
Long-Term Incentives
Long-term incentives in the form of Options, RSUs and/or DSUs are determined by considering overall corporate performance as well as the performance of the individual employee. The role of the long-term incentive is to align an executives and Directors performance with the long-term performance of the Corporation and to provide an additional incentive for executives and Directors to enhance shareholder value. The Board generally adheres to the following principles, as applicable, in connection with grants of Options, RSUs and/or DSUs:
Options, RSUs and/or DSUs are generally granted, at the discretion of the Board, upon initial employment and annually. In certain circumstances, the Board may grant Options, RSUs and/or DSUs to employees and Directors based on certain corporate achievements throughout a calendar year;
previous grants and existing equity ownership levels are taken into account when considering further grants of Options, RSUs and/or DSUs;
Options granted as part of the long-term incentive program generally carry a five year life and vest in equal proportions over a three (3) year period for employees and executive officers. Previous grants to certain executive officers of the Corporation vest on a monthly basis over a period of thirty-six (36) months;
RSUs granted as part of the long-term incentive program generally carry a three year life and vest in equal proportions over a three (3) year period for employees and executive officers with the ability for the grantee to elect to defer the payment in respect of an award of RSUs when it becomes payable on the applicable vesting date. Any such deferral by an RSU Participant may be for a period of no longer than five (5) years from the date of the applicable RSU award agreement;
29
the Option price is determined by the Board or the committee of the Board authorized to grant Options, provided that such price shall not be lower than the closing price of the Common Shares on the TSX-V on the business day prior to the date the Option is granted or such other price as is permitted pursuant to the rules and regulations of the TSX-V;
RSUs track the share price of the Common Shares, as no exercise price is applicable with respect to RSUs; and
it is expected that the Corporations compensation strategy and overall program will continue to evolve and be reviewed in the future. It is anticipated that DSUs will also be become part of the long-term compensation package for Directors. The Corporation continues to work with its compensation advisors to complete a compensation structure for long-term incentives that will include RSUs and DSUs.
Long-Term Incentive Grants for 2018 Compensation
Details of all equity awards to the NEOs for the fiscal year 2018 are provided in the table below, as well as the value of such awards as of December 31, 2018.
Named Executive Officer (Position)
|
Option Grant
(Number of Options) |
Value ($) on
12/31/2018 |
Vinay Tolia (CEO) | 3,635,530 | 6,507,599 |
Steve Klein (Chief Strategy Officer) | 1,200,000 | 2,148,000 |
Notes: | |
1 | Mr. Klein is not an employee of the Corporation, but provides services as Chief Strategy Officer. |
Benefits and Perquisites
The Corporation offers limited benefits and perquisites, aligned with market competitive practice. Details of the benefits and perquisites provided to the NEOs are disclosed in the "Value of all other compensation" column of the 2018 summary compensation table set forth in this Circular, including: health and dental coverage, various company-paid insurance plans, including life insurance, and paid vacation.
In general, the Corporation will only provide a specific perquisite when it provides competitive value and promotes retention of executives. The limited perquisites the Corporation provides to its NEOs may include a cellular telephone and computer equipment, commuting and parking expenses, reasonable legal, accounting and other professional fees, housing allowances under special circumstances, reimbursement of certain tax related expenses, as well as payment of certain professional dues that are related directly to the performance of the executives functions.
30
SUMMARY COMPENSATION TABLE |
The following table sets forth a summary of all compensation, other than compensation related to the issuance of securities, earned during the two most recently completed fiscal years ended December 31, 2018 and 2017 for the NEOs of the Corporation.
Name and Position |
Year |
Salary, consulting fee, retainer or commission ($) |
Bonus7 ($) |
Committee or meeting fees ($) |
Value of perquisites ($) |
Value of all other compensation ($) |
Total compensation1 ($) |
Anthony Giorgi2
Former Chief Executive Officer of The Flowr Corporation, a private corporation |
2018 | 128,969 | - | - | - | 120,688 | 249,384 |
2017 | 80,109 | - | - | - | - | 80,109 | |
Thomas Flow3
Former Executive Director and Co-Chief Executive Officer |
2018 | 240,000 | - | - | - | 1,262 | 241,262 |
2017 | 201,169 | - | - | - | - | 201,169 | |
Vinay Tolia3
Executive Director and Chief Executive Officer |
2018 | 90,000 | - | - | - | 115 | 90,115 |
2017 | - | - | - | - | - | - | |
David Ralston4
Former Chief Operating Officer |
2018 | 194,677 | - | - | - | 134,595 | 329,272 |
2017 | 44,553 | - | - | - | - | 44,553 | |
Alex Dann Chief Financial Officer |
2018 | 200,000 | - | - | - | 1,377 | 201,377 |
2017 | 33,442 | - | - | - | - | 33,442 | |
Dr. Lyle Oberg3
Executive Director and Chief Policy and Medical Officer |
2018 | 176,666 | - | - | - | 1,135 | 177,801 |
2017 | 80,098 | - | - | - | - | 80,095 | |
Daniel Lanskey5
Former Chief Executive Officer, Chief Financial Officer and President |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - | |
Steven Klein6
Executive Director and Chief Strategy Officer |
2018 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
Notes: | |
1 |
Security based award disclosure is not included in this table. Compensation is based on amounts received on employment start date. |
2 |
Mr. Giorgi was the Chief Executive Officer of The Flowr Corporation, a private corporation, prior to the closing of the Qualifying Transaction, and ceased to hold that position on June 21, 2018. The Flowr Corporation completed the Qualifying Transaction with the Corporation, to become the resulting public entity on September 21, 2018. Mr. Giorgis compensation includes severance amounts totalling $120,000.00. |
3 |
All compensation paid to Messrs. Flow, Tolia and Oberg were paid in their role as officers of the Corporation, and not as a Director. Mr. Tolia became the Chief Executive Officer of the Corporation on August 15, 2018 and a Director on October 26, 2018. Mr. Klein is not an employee of the Corporation, but provides services as Chief Strategy Officer. Mr. Flow was previously the President of the Corporation, and held the Chief Executive Officer position on an interim basis from June 2018 to August 2018. On November 9, 2018, Mr. Flow was named Co-CEO of the Corporation. On April 29, 2019, Mr. Flow stepped down as a Director and Co-CEO. |
4 |
Mr. Ralston was the Chief Operating Officer of the Corporation until November 9, 2018. |
5 |
Mr. Lanskey was a Director, President, Chief Executive Officer and Chief Financial Officer of the Corporation until completion of the Qualifying Transaction and ceased to hold such positions on September 21, 2018. |
6 |
Mr. Klein is not an employee of the Corporation, but provides services as Chief Strategy Officer. |
31
7 |
In fiscal 2018, the Board approved a cash bonus of $500,000 to Tom Flow in recognition of his significant contribution to the Corporation. The bonus was not paid until fiscal 2019 and, as such, is not reflected in the table above. |
INCENTIVE PLAN AWARDS |
Stock Options and Other Compensation Securities
The following table discloses all compensation securities granted or issued to each NEO in the year ended December 31, 2018.
Name and Position |
Type of security compensation |
Number of compensation securities, number of underlying securities, and percentage of class |
Date of Issue or Grant |
Issue, conversion or exercise price ($) |
Closing price of security or underlying security on date of grant ($) |
Closing price of security or underlying security at year end ($) |
Expiry Date |
Thomas Flow1 Former Executive Director and Co- CEO |
- |
- |
- |
- |
- |
- |
- |
Vinay Tolia1 Executive Director and CEO |
Options |
3,635,530 |
August 24, 2018 |
2.60 |
2.60 |
4.39 |
August 24, 2023 |
Anthony Giorgi2 Former CEO of The Flowr Corporation |
- |
- |
- |
- |
- |
- |
- |
David Ralston3 Former Chief Operating Officer |
- |
- |
- |
- |
- |
- |
- |
Alex Dann4 CFO |
- |
- |
- |
- |
- |
- |
- |
Dr. Lyle Oberg1, 5
Executive Director and Chief Medical and Policy Officer |
- |
- |
- |
- |
- |
- |
- |
Daniel Lanskey6 Former President, CEO and CFO |
- |
- |
- |
- |
- |
- |
- |
Steve Klein Executive Director and Chief Strategy Officer |
Options |
1,200,000 |
August 24, 2018 |
2.60 |
2.60 |
4.39 |
August 24, 2023 |
Notes: | |
________________________________ | |
1 |
All compensation paid to Messrs. Flow, Tolia and Oberg were paid in their role as officers of the Corporation, and not as a Director. Mr. Klein was granted Options in connection with his contribution to the development of the Corporations business and the closing of the Qualifying Transa ction. Mr. Klein is not an employee of the Corporation, but provides services as Chief Strategy Officer. Mr. Tolia became the Chief Executive Officer of the Corporation on August 15, 2018 and a Director on October 26, 2018. Mr. Flow was previously the President of the Corporation, and held the Chief Executive Officer position on an interim basis from June 2018 to August 2018. On November 9, 2018, Mr. Flow was named Co-CEO of the Corporation. On April 29, 2019, Mr. Flow stepped down as a Director and Co-CEO. |
32
2 |
Mr. Giorgi ceased to be employed by The Flowr Corporation on June 21, 2018. All vested Options that Mr. Giorgi held have been exercised and no Options remain outstanding as at the date of this Circular. |
3 |
Mr. Ralston ceased to be employed by the Corporation on November 9, 2018. All vested Options that Mr. Ralston held have been exercised and no Options remain outstanding as at the date of this Circular. |
4 |
Mr. Dann held 1,181,250 Options to acquire 1,181,250 Common Shares as at December 31, 2018. The Options held by Mr. Dann have an exercise price of $0.05, vest on a monthly basis and expire on October 30, 2022. |
5 |
Dr. Oberg held 618,750 Options to acquire 618,750 Common Shares as at December 31, 2018. The Options held by Dr. Oberg have an exercise price of $0.05, vest on a monthly basis and expire on October 30, 2022. |
6 |
Mr. Lanskey ceased to be an officer of the Corporation on September 21, 2018 in connection with the closing of the Qualifying Transaction. All vested options held by Mr. Lanskey have been exercised and no options remain outstanding as at the date of this Circular. |
Exercise of Compensation Securities by NEOs
The following table sets out each exercise by an NEO of compensation securities during 2018.
Name and Position
|
Type of compensation security |
Number of underlying securities exercised |
Exercise Price per security ($) |
Date of exercise |
Closing price per security on date of exercise(1) ($) |
Difference between exercise price and closing price on date of exercise ($) |
Total value on exercise date ($) |
Thomas Flow
Former Executive Director and Co-CEO |
Options |
2,550,000 |
0.000001 |
August 1, 2018 |
2.60 |
2.60 |
6,629,997 |
Vinay Tolia Executive Director and CEO |
- |
- |
- |
- |
- |
- |
- |
Anthony Giorgi Former CEO of The Flowr Corporation |
Options |
900,000 |
0.000001 |
May- August, 2018 |
2.60 |
2.60 |
2,339,999 |
Options |
100,000 |
0.05 |
October 2018 |
2.60 |
2.55 |
255,000 | |
David Ralston Former Chief Operating Officer |
Options |
506,250 |
0.000001 |
May- August, 2018 |
2.60 |
2.60 |
1,316,249 |
Options |
225,000 |
0.05 |
December 10, 2018 |
3.18 |
3.13 |
704,250 | |
Alex Dann CFO |
Options |
393,750 |
0.000001 |
May- August, 2018 |
2.60 |
2.60 |
1,023,750 |
Dr. Lyle Oberg Executive Director and Chief Policy and Medical Officer |
Options |
1,181,250 |
0.000001 |
May- August, 2018 |
2.60 |
2.60 |
3,071,249 |
Daniel Lanskey Former President, CEO and CFO |
Options |
18,461 |
1.30 |
October 18, 2018 |
4.97 |
3.67 |
67,752 |
Steve Klein Director and Chief Strategy Officer |
- |
- |
- |
- |
- |
- |
-
|
Notes: | |
(1) | For the exercise of Options prior to the completion of the Qualifying Transaction, the closing price on the date of exercise is based on the pricing of the Corporations recently completed financings at the time of the exercise. |
33
Equity Compensation Plan Information
The following table sets out the equity compensation plan information as at May 9, 2019:
Plan Category |
Number of securities to be issued upon exercise of outstanding options, warrants and rights3 (a) |
Weighted-average exercise price of outstanding options, warrants and rights (b) |
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)1 |
Equity compensation plans approved by Shareholders (SOP)2 |
12,051,780 |
$2.66 |
262,755 |
Equity compensation plans approved by Shareholders (LTIP) |
197,270 |
N/A |
12,095,171 |
Warrants | 258,270 | $2.57 | N/A |
Total | 12,507,300 | $2.66 | 12,357,926 |
Notes: | |
________________________________ | |
1 |
Pursuant to the terms of the LTIP and the SOP, the total number of Common Shares which may be issued under both equity incentive plans, in the aggregate amount, is equal to twenty per cent (20%) of the issued and outstanding Common Shares and class A preferred shares in the capital of Flowr ULC at any given time. The figures in column (c) above include securities that are issuable under the LTIP. |
2 |
In connection with the Meeting, Shareholders are being asked to approve an ordinary resolution to approve the SOP. |
3 |
The Corporation also has 258,270 broker warrants issued and outstanding. Such broker warrants were issued in connection with the closing of the Qualifying Transaction and also includes warrants issued by The Needle Capital Corp. These broker warrants are included in column (a) above. |
PENSION PLAN BENEFITS AND DEFERRED COMPENSATION PLANS |
The Corporation does not have a pension plan, defined benefit plan or any retirement savings programs for NEOs or other employees of the Corporation, and does not have a deferred compensation plan for NEOs or other employees of the Corporation. Pursuant to the terms of the LTIP, as amended, an RSU Participant may elect to defer the payment in respect of an award of RSUs when it becomes payable on the applicable vesting date. Any such deferral by an RSU Participant may be for a period of no longer than 5 years from the date of the applicable RSU award agreement.
TERMINATION AND CHANGE OF CONTROL BENEFITS |
Other than Steve Klein who has not received any compensation in his role as Chief Strategy Officer as he is not an employee of the Corporation, and other than the Options as described herein, the Corporation or one of its subsidiaries has entered into employment agreements with each of the NEOs who are currently employed by the Corporation or such subsidiary under which each NEO has agreed to continue to serve the Corporation in his current office and perform the duties of such office in accordance with the terms set out in their employment agreements. Under the terms of each of the executive employment agreements, each executive has made commitments in favour of the Corporation including non-competition and non-solicitation covenants (which survive termination of an NEOs termination in certain circumstances, as applicable, for periods of 6 to 24 months per the terms of each NEOs employment agreement), as well as non-disclosure covenants (which survive the termination of an NEOs employment).
In the event of termination of an NEOs employment, other than for cause (as defined in the applicable employment agreements), the Corporation will provide such executive with working notice or severance pay or a combination of notice and severance. The following section outlines the significant terms of each of the NEOs employment agreements.
In addition, under certain circumstances, and pursuant to applicable employment standards legislation, earned bonuses may also be payable upon termination.
Executive Employment Agreements
As at December 31, 2018, Mr. Flow was party to an employment agreement with a subsidiary of the Corporation dated December 1, 2016, the terms of which form the basis for the disclosure contained herein with respect to Mr. Flows entitlements on a termination or a change of control (the "Flow Agreement"). The Board has approved the terms of a new employment agreement with a subsidiary of the Corporation, following Mr. Flows transition to Managing Partner and his stepping down as a Director and Co-CEO on April 29, 2019. As at the date of this Circular, Mr. Flow and the Corporation have not entered into the new employment agreement. Mr. Tolia is party to an employment agreement with a subsidiary of the Corporation dated August 15, 2018, which continues for an indefinite term, unless earlier terminated. Mr. Dann is party to an employment agreement with a subsidiary of the Corporation dated October 10, 2017, which continues for an indefinite term, unless earlier terminated. Dr. Oberg is party to an employment agreement with a subsidiary of the Corporation dated September 21, 2017, which continues for an indefinite term, unless earlier terminated. Mr. Ralston was party to an employment agreement with a subsidiary of the Corporation dated November 22, 2017. Effective November 9, 2018, Mr. Ralstons employment with the Corporation ceased. Mr. Giorgi was party to an employment agreement dated September 25, 2017 which was an agreement with a subsidiary of The Flowr Corporation prior to completion of the Qualifying Transaction. Effective June 21, 2018, Mr. Giorgis employment with The Flowr Corporation ceased.
In connection with his termination, Mr. Ralston was provided with an aggregate severance payment of approximately $133,333, and a total of 112,500 Options vested in accordance with the terms of his severance agreement. In connection with his termination, Mr. Giorgi was provided with an aggregate severance payment of $100,000, and a total of 150,000 Options vested in accordance with the terms of his severance agreement.
As indicated above, Mr. Klein does not have an employment agreement with the Corporation and received no compensation for his services other than the granting of Options disclosed herein. In addition, this section of the Circular does not provide any disclosure as it relates to Mr. Lanskey, who was a former director and officer of the capital pool company, The Needle Capital Corp., and ceased to hold such positions upon completion of the Qualifying Transaction.
35
Termination upon Notice
Each of Messrs. Tolia, Dann and Oberg may terminate his employment agreement upon providing the Corporation with not less than four (4) weeks written notice. The Corporation retains the right (at its option) to accelerate the termination date set out in the written notice by notifying the executive that the Corporation will pay him an aggregate amount equal to:
TOLIA | DANN | OBERG | |
Base salary through to last day of notice period | Yes | Yes | Yes |
Business expenses which have not been reimbursed | Yes | Yes | Yes |
Value of unused vacation | Yes | Yes | Yes |
Participation in benefit plan during notice period | Yes | Yes | Yes |
The Flow Agreement did not provide for a notice period upon Mr. Flow resigning. However, the Flow Agreement provided that Mr. Flow was entitled to resign on notice in the event that his salary was unpaid for four (4) consecutive months, or any failure to pay his regular salary or part thereof was not cured within four (4) months of the date of such failure.
Termination Without Cause
In the case that the Corporation terminates the NEOs employment agreement without cause (as defined in each NEOs respective employment agreement, as applicable), the NEO shall be entitled to receive:
FLOW | TOLIA | DANN | OBERG | |
Base salary payment |
6 months and no less than min. under applicable employment standards legislation |
Notice as required by applicable employment standards legislation and twenty six (26) weeks |
12 months |
Notice as required by applicable employment standards legislation and three (3) weeks |
Annual pro rata bonus payment up to date of termination |
N/A |
N/A |
Pro Rata (if prior annualized bonus paid) |
N/A |
Business expenses which have not been reimbursed |
Yes |
Yes |
Yes |
Yes |
Value of unused vacation | Yes | Yes | Yes | Yes |
Continued benefits |
N/A |
N/A |
Notice as required by
applicable employment standards legislation |
N/A |
Unvested Options |
N/A |
If
certain market caps achieved, vesting accelerated: $1billion market cap, 1/3 unvested will vest; $2 billion market cap, 2/3 unvested will vest; and $3 billion market cap, all vest. |
N/A |
N/A |
36
Termination for Cause
In the case that an NEO employment agreement is terminated for cause (as defined in each NEOs employment agreement, as applicable), the NEOs employment with the Corporation shall end immediately and the NEO shall be entitled to:
FLOW | TOLIA | DANN | OBERG | |
Base salary up to the date of termination | Yes | Yes | Yes | Yes |
Business expenses which have not been reimbursed | Yes | Yes | Yes | Yes |
Value of unused vacation | Yes | Yes | Yes | Yes |
Any benefits to which he is entitled to and which are unpaid as of the date of termination | Yes | Yes | Yes | Yes |
Termination Due to Death
Upon termination due to death, Mr. Flow would have been entitled to payment of base salary and benefits through the date of such termination. The other employment agreements with NEOs do not contemplate termination due to death.
Termination Due to Disability
Upon termination due to disability, Mr. Flow would have been entitled to payment of three (3) months base salary and benefits for such three (3) month period. The other employment agreements with NEOs do not contemplate termination due to disability.
Change of Control
The employment agreement entered into between the applicable subsidiary of the Corporation and Mr. Dann contains stock option acceleration provisions upon a change of control. In particular, upon a change of control, all unvested Options granted to Mr. Dann shall vest and become immediately exercisable, notwithstanding any contingent vesting provision to which such Options may have otherwise been subject.
SOP and LTIP Change of Control Provisions
SOP Trigger Event
Except as provided for in certain NEO employment agreements, in the case of a potential or actual Trigger Event (as defined in the SOP) the Board may, in its discretion, without the necessity or requirement for the agreement of any optionholder, but subject always to the prior written approval of the TSX-V: (i) accelerate, conditionally or otherwise, on such terms as it sees fit, the vesting date of any option; (ii) permit the conditional exercise of any option, on such terms as it sees fit; (iii) otherwise amend or modify the terms of the option, including for greater certainty permitting optionholders to exercise any option, to assist the optionholder to tender the underlying shares to, or participate in, the actual or potential Trigger Event or to obtain the advantage of holding the underlying shares during such Trigger Event; and (iv) terminate, following the successful completion of such Trigger Event, on such terms as it sees fit, the options not exercised prior to the successful completion of such Trigger Event.
In the event that: (i) an actual or potential Trigger Event is not completed within the time specified therein; or (ii) all of the shares subject to an option that were tendered by an optionholder in connection with an actual or potential Trigger Event are not taken up or paid for by the offeror in respect thereof, then the Board may, in its discretion, without the necessity or requirement for the agreement of any optionholder, permit the shares received upon such exercise, or in the case of subparagraph (ii) above the shares that are not taken up and paid for, to be returned by the optionholder to the Corporation and reinstated as authorized but unissued shares and, with respect to such returned shares, the related options may be reinstated as if they had not been exercised and the terms for such options becoming vested will be reinstated pursuant to the SOP. If any shares are returned to the Corporation, the Corporation will immediately refund the exercise price to the optionholder for such shares.
37
LTIP Change of Control
Except as provided for in certain executive employment agreements, in the case of a Change of Control (as defined in the LTIP), at the sole discretion of the Board, the Corporation: (i) shall determine the adjustment price, if any, to the number and type of Common Shares (or other securities or other property) that thereafter shall be made subject of and issuable as payment under outstanding RSUs or DSUs; (ii) shall determine the number and type of shares (or other securities or other property) subject to and issuable as payment under outstanding RSUs or DSUs; (iii) shall determine the acquisition price with respect to the settlement or payment of any outstanding RSUs or DSUs; provided, however that the number of Common Shares covered by any RSUs or DSUs or to which such RSUs or DSUs relate shall always be a whole number; and (iv) may convert or exchange for or into any other security or any other property or cash, any outstanding RSUs or DSUs that are still capable of being exercised, upon giving to any such RSU or DSU participant to whom such RSUs or DSUs have been granted at least thirty (30) days written notice of its intention to convert or exchange such RSUs or DSUs and, during such notice period, the RSUs and DSUs may be exercised by any such holder of RSUs or DSUs without regard to any vesting conditions attached thereto, and on the expiry of such period of notice, the unexercised portion of the RSUs or DSUs shall lapse and be cancelled.
In addition to the foregoing, the Board or any company which is or would be the successor to the Corporation or which may issue securities in exchange for Common Shares upon the occurrence of a Change of Control may offer any RSU or DSU holder the opportunity to obtain new or replacement awards for securities into which the Common Shares are changed or are convertible or exchangeable, on a basis proportionate to the number of Common Shares issuable under the outstanding RSUs and DSUs.
The Board may also, in its sole discretion, cancel any or all outstanding RSUs or DSUs and pay to the holders of any such RSUs or DSUs, in cash, the value of such RSUs and DSUs based upon the price per Common Shares received or to be received by other Shareholders in the event of a Change of Control.
Estimated Incremental Payment on Change of Control and/or Termination
The following table provides details regarding the estimated incremental payments by the Corporation to the NEOs indicated below under the above-described agreements in the event of: (i) termination upon notice; (ii) termination without cause; (iii) termination with cause; (iv) termination upon death; (v) termination upon disability; (vi) termination upon change of control (as defined in the applicable employment agreements of the NEOs); and (vii) Trigger Event under the SOP, assuming, in each case, that the event took place on December 31, 2018. For purposes of the table below, Change of Control under the LTIP has not been included, as no RSUs and/or DSUs were issued and outstanding as at December 31, 2018.
Event | |||||||
Termination Upon Notice |
Termination without Cause |
Termination with Cause |
Termination Upon Death |
Termination Upon Disability |
Change of Control |
Trigger Event1 | |
Thomas Flow2 Severance Deferred Compensation Other Benefits Total |
- - - - |
$120,000 - - $120,000 |
- - - - |
- - - - |
$60,000 - $345 $60,345 |
- - - - |
- - - - |
Vinay Tolia Severance Deferred Compensation Other Benefits Total |
- - - - |
$120,000 - - $120,000 |
- - - - |
- - - - |
- - - - |
- - - - |
$5,784,534 - - $5,784,534 |
Alex Dann Severance Deferred Compensation Other Benefits Total |
- - - - |
$200,000 - $115 $200,115 |
- - - - |
- - - - |
- - - - |
- - - - |
$4,367,125 - - $4,367,125 |
38
Event | |||||||
Termination Upon Notice |
Termination without Cause |
Termination with Cause |
Termination Upon Death |
Termination Upon Disability |
Change of Control |
Trigger Event1 | |
Dr. Lyle Oberg Severance Deferred Compensation Other Benefits Total |
- - - - |
$16,667 - - $16,667 |
- - - - |
- - - - |
- - - - |
- - - - |
$2,197,125 - - $2,197,125 |
Steve Klein Severance Deferred Compensation Other Benefits Total |
- - - - |
- - - - |
- - - - |
- - - - |
- - - - |
- - - - |
$1,909,330 - - $1,909,334 |
Notes: | |
____________________________________ | |
1 | The figures in this table assume payment of cash consideration for unvested Options held by the optionees in the event of a Trigger Event, using the closing price of the Common Shares on December 31, 2018 of $4.39. |
2 | As at the date of this Circular, Mr. Flow and the Corporation have not entered into a new employment agreement. |
39
STATEMENT OF CORPORATE GOVERNANCE PRACTICES |
Board of Directors
The Board is currently comprised of eight (8) Directors. If all of the Director nominees are successfully elected, the Board will consist of four (4) independent Directors. In order to facilitate the exercise of independent judgement in carrying out its responsibilities, the Board will continue to hold in camera meetings of independent Directors after certain meetings of the Board (in particular, meetings relating to the review and approval of quarterly and annual financial statements). The Board has concluded that four (4) of the proposed Directors (being Ms. Basian and Messrs. Duet, Levesque and de Barros Teixeira) are independent from management of the Corporation for the purposes of NI 58-101. Messrs. Tolia, Oberg, Klein and Miller are not considered independent because they are or were previously officers of the Corporation. Mr. Klein was not an employee of the Corporation, but provided services in his capacity as Chief Strategy Officer.
Karen Basian is currently the Lead Independent Director of the Board and, if elected, and is expected to be named Lead Independent Director subsequent to the Meeting. The Lead Independent Director responsibilities include leadership of the Board and its efficient and independent organization and operation.
Summary of Director Qualifications and Expertise
The NCGC annually conducts a self-assessment of the Boards performance, an assessment of Board members and its committees, with each committee assessing its members, and to recommend to the Board nominees for appointment of new Directors to fill vacancies or meet additional needs of the Board. Through the Board evaluation process and ongoing monitoring of the needs of the Corporation, desired expertise and skill sets are identified and individuals that possess the required experience and skills are contacted by the Corporation. Prospective new Director nominees are intended to be interviewed by the Chair of the NCGC, the Lead Independent Director, Chairman and the CEO and considered by the entire NCGC for recommendations to the Board as potential nominee Directors.
The matrix below illustrates the mix of experience, knowledge and understanding possessed by the members of the Board in the categories that are relevant to the Corporation that enable the Board to better carry out its fiduciary responsibilities.
STEVE KLEIN |
DAVID MILLER |
VINAY TOLIA |
DR. LYLE OBERG |
KAREN BASIAN |
DR. J. ANDRÉ DE BARROS TEIXEIRA |
MAURICE LEVESQUE |
DON DUET | |
Accounting | x | x | x | x | ||||
Corporate Finance / M&A | x | x | x | x | x | x | ||
Executive Leadership | x | x | x | x | x | x | x | |
Economics / Business | x | x | x | x | x | x | x | x |
Financial Literacy | x | x | x | x | x | x | x | x |
Governance | x | x | x | x | x | |||
Government / Regulatory | x | x | x | |||||
HR & Compensation | x | x | x | |||||
Industry Experience | x | x | x | x | x | |||
International Business | x | x | x | x | ||||
Legal | x | x | ||||||
Risk Management | x | x | x | |||||
Strategic Planning | x | x | x | x | x | x | x | x |
Mandate of the Board of Directors
The Board does not have a written mandate. The duties and responsibilities of the Board are to supervise the management of the business and affairs of the Corporation, and to act with a view towards the best interests of the Corporation. The Board is responsible for the oversight and review of:
40
the strategic planning process of the Corporation;
identifying the principal risks of the Corporations business and ensuring the implementation of appropriate systems to manage these risks;
succession planning, including appointing, training and monitoring senior management;
a communications policy for the Corporation to facilitate communications with investors and other interested parties; and
the integrity of the Corporations internal control and management information systems.
The Board discharges its responsibilities directly and through its committees, currently consisting of the Audit Committee, the HRCC and the NCGC.
The Board and the Chief Executive Officer have not developed a written position description for the Chief Executive Officer position. The Chief Executive Officer reports to and is subject to the general direction of the Board pursuant to the executive employment agreement between the Corporation and Mr. Tolia. The Chief Executive Officers duties include overseeing the day-to-day operations of the Corporation, strategic planning and business development.
The Board has developed formal charters for each Committee. Copies of the Committee charters are located on the Corporations website at www.flowr.ca, which are not incorporated by reference into this Circular.
Meetings of the Board of Directors
The Board meets at least once each quarter, with additional meetings held when appropriate. Meetings of the Board may be held in person and by teleconference or other electronic means, as needed to discharge its responsibilities. Independent Directors meet in camera without non-independent Directors or management present on an as-needed basis (particularly with respect to meetings related to the review and approval of quarterly and annual financial statements). Board members are expected to attend all Board meetings and meetings of committees on which they serve.
The following table provides the record of attendance of each member of the Board for all meetings of the Board and each committee, which were held since the completion of the Qualifying Transaction on September 21, 2018, but does not include matters approved by way of written resolution. The HRCC and NCGC were first constituted on December 28, 2018 but no meetings of either committee were held in 2018.
Director1 |
Board
Meetings2 |
Audit
Committee Meetings |
Overall
| |||
# | % | # | % | # | % | |
David Towill3 | N/A | N/A | N/A | N/A | N/A | N/A |
Steve Klein4 | 2/2 | 100 | 1/1 | 100 | 3/3 | 100 |
David Miller5 | 1/2 | 50 | 1/1 | 100 | 2/3 | 66 |
Thomas Flow | 2/2 | 100 | N/A | N/A | 2/2 | 100 |
Dr. Lyle Oberg | 2/2 | 100 | N/A | N/A | 2/2 | 100 |
Vinay Tolia6 | 2/2 | 100 | N/A | N/A | 2/2 | 100 |
Rishi Shah7 | 2/2 | 100 | 1/1 | 100 | 3/3 | 100 |
Karen Basian | 1/1 | 100 | N/A | N/A | 1/1 | 100 |
Donald Duet8 | N/A | N/A | N/A | N/A | N/A | N/A |
Maurice Levesque | 1/1 | 100 | N/A | N/A | 1/1 | 100 |
J. André de Barros Teixeira | 0/1 | 0 | N/A | N/A | 01 | 0 |
Notes: | |
________________________________ | |
1 |
The table above provides information for board and committee attendance subsequent to the completion of the Qualifying Transaction, as it provides a more accurate description of the activities of the Board subsequent to the closing of the Qualifying Transaction. |
41
2 |
This table does not reflect matters passed by the Board by way of written resolution, and does not include meetings of the HRCC and NCGC as the first meetings of those committees occurred in 2019. |
3 |
Attendance records for Mr. Towills participation in Board and Audit Committee meetings relate only to the period prior to Mr. Towills resignation as a Director on October 26, 2018. Mr. Towill was a member of the Audit Committee until October 26, 2018. No meetings of the Audit Committee and Board were held in 2018 prior to October 26, 2018. |
4 |
Mr. Klein was a member of the Audit Committee from October 26, 2018 until December 28, 2018. Attendance records for Mr. Kleins participation in |
Audit Committee meetings relate only to the period between October 26, 2018 and December 28, 2018. | |
5 |
Mr. Miller was a member of the Audit Committee from September 21, 2018 until December 28, 2018. Attendance records for Mr. Millers participation in Audit Committee meetings relate only to the period between September 21, 2018 and December 28, 2018. |
6 |
Mr. Tolia was appointed to the Board on October 26, 2018. Attendance records for Mr. Tolias participation in Board meetings relate only to the period subsequent to October 26, 2018. |
7 |
Mr. Shah was the Audit Committee Chair from October 26, 2018 until December 28, 2018. Attendance records for Mr. Shahs participation in Audit Committee meetings relate only to the period between September 21, 2018 and December 28, 2018. Mr. Shah stepped down from the Board on April 29, 2019. |
8 |
Mr. Duet was appointed to the Board on April 29, 2019. |
Board Renewal and Term Limits
The Corporation has not adopted a formal policy on Director term limits. It has been the Corporations practice to elect Directors on an annual basis to hold office until a successor is appointed or until the conclusion of the next annual meeting of Shareholders. Management believes that the current approach allows the Corporation to undergo Board renewal as necessary. In addition, the Corporation relies on its current Director nominee selection process, in addition to the Corporations various policies (as described below), when selecting Director nominees for election to the Board on an annual basis.
Independence of the Board
For the purposes of NI 58-101, an "independent director" is a director who has no direct or indirect material relationship with the Corporation. A "material relationship" is in turn defined as a relationship which could, in the view of the Board, be reasonably expected to interfere with such members independent judgment. In determining whether a particular Director is an "independent director" or a "non-independent director", the Board considers the factual circumstances of each Director in the context of these guidelines.
The Board is currently comprised of eight (8) members, four of which are "independent directors" for the purposes of NI 58-101. The independent Directors are Karen Basian, Don Duet, Maurice Levesque and J. André de Barros Teixeira. Messrs. Klein, Miller, Tolia and Oberg are not independent for the purposes of NI 58-101 due to being, or having been, a member of the Corporations management team. Mr. Klein is not an employee of the Corporation, but provided services as the Chief Strategy Officer.
Chairman and Lead Independent Director
The roles of the Chairman and CEO are separated. In addition, Karen Basian is the Lead Independent Director of the board and subsequent to the Meeting it is expected that the Board will re-appoint Ms. Basian as Lead Independent Director. The Lead Independent Director is independent and with the assistance of the Chairman is responsible for the management, development and effective functioning of the Board and provides leadership in every aspect of its work. The Lead Independent Directors key responsibilities include setting the Board meeting agenda in consultation with the Chairman and CEO and chairing all Board meetings with the Chairman. In the absence of the Lead Independent Director, one of the other independent Directors will assume the responsibilities of the Lead Independent Director. The Lead Independent Director will provide leadership to the Directors and ensures the Board is independent from management. The Lead Independent Director and each committee can also engage outside consultants without consulting management. This helps ensure they receive independent advice as they feel necessary.
Committee Composition
There are currently three standing committees of the Board: (a) the Audit Committee, (b) the HRCC, and (c) the NCGC. All three committees are comprised solely of independent Directors.
Committee chairs are responsible for the effective organization and operation of the relevant committee he or she chairs and is required to provide leadership in discharging the mandate set out in the committee charter. The chair also acts as primary liaison between the relevant committee and the Corporations management where necessary. The chair of each committee reports directly to the Board.
42
The Board intends to review the composition of the Audit Committee, HRCC and the NCGC subsequent to the Meeting. Any changes in membership of the committees will be disclosed by the Corporation at the appropriate time.
Succession Planning
The NCGC and HRCC (with the advice of the Chairman and CEO) have primary oversight of succession planning for senior management, the performance of the CEO, and the CEOs assessments of the other senior officers. The Board, as a whole, conducts reviews of succession options relating to senior management positions as required.
The independent Directors are expected to participate in the assessment of the CEOs performance every year. The Board approves all NEO appointments.
Selection of New Board Members
The NCGC considers candidates for Board membership who are suggested by members of the committee, other Board members, members of management and Shareholders as well as outside consultants retained specifically for the purpose of identifying Board candidates. Once the NCGC has identified prospective nominees for directorship, the Board is responsible for selecting such candidates. The NCGC seeks to identify Director candidates with solid business and other appropriate experience and expertise, having regard to the nature of the Corporations business and the current composition of the Board, and commitment to devoting the time and attention necessary to fulfill their duties to the Corporation.
The NCGC considers the following general factors in evaluating a prospective candidate to the Board, which include (i) the extent to which the candidate will enhance the objective of having Directors with diverse viewpoints, and (ii) backgrounds, experience, expertise, skills and other demographics of Director candidates. The Corporation believes that the backgrounds and qualifications of its Directors, considered as a group, should provide a mix of skills, experience, and knowledge, which will ensure that the Board is able to continue to fulfill its responsibilities. The NCGC also considers the independence of Directors and proposed Directors. The Corporation has not adopted a formal policy on term limits for its Directors, as it believes the process used by the NCGC in selecting appropriate nominees for election to the Board on an annual basis will ensure that the Board undergoes regular renewal, as necessary.
Assessments and Performance Reviews
The Board, on an annual basis, receives a recommendation from the NCGC for assessing the performance and effectiveness of the Board, its committees and the individual Directors. In order to facilitate this, the NCGC is responsible for developing and recommending to the Board a process for assessing criteria that considers the solicitation and receipt of comments from any Directors and the competencies and skills each Director is expected to bring to the Board.
Each individual committee and the Board, in the assessment process to be overseen by the NCGC (as described above), assesses its own performance and that of the individual Directors of which each is comprised, as well as each committees own respective charter.
Orientation and Education
The NCGC is expected to develop, recommend and oversee the Boards orientation program for new Directors. This program will be designed to assist new Directors to understand the role of the Board and its committees, the contribution individual Directors are expected to make to the Corporation (including the commitment of time and energy that the Corporation expects) and the nature and operation of the Corporations business. In addition, new Directors are oriented to the roles of the Board, individual Directors and the business and affairs of the Corporation through discussions with the Corporations management and the incumbent Directors and by periodic presentations from senior management on major business, industry and competitive issues. Management, along with Board advisors, provide information to the Board and its committees as necessary to keep the Directors up-to-date with corporate governance requirements and best practices, the Corporation and its business and the environment in which it operates, as well as developments concerning the responsibilities of Directors.
The Board currently does not provide continuing education for its Directors. The Directors are encouraged to attend industry and governance related education sessions independently to ensure they are abreast of emerging trends impacting the Corporation. By using a Board composed of experienced professionals with a wide range of financial and industry expertise, the Corporation ensures that the Board operates effectively and efficiently.
43
Code of Business Conduct and Ethics
The Board has adopted a written Code of Business Conduct and Ethics ("Code"). The Code is applicable to all Directors, officers and employees of the Corporation, as well as consultants and contract workers who perform work on behalf of the Corporation. The Code constitutes written standards that are designed to promote integrity and to deter wrongdoing. In particular, the Code addresses the following issues:
compliance with laws, rules and regulations | protection and proper use of corporate assets and opportunities |
conflicts of interest | confidentiality of company information |
fair dealing | disclosure matters |
reporting of any breaches of company policies and applicable laws |
Interested parties may request a copy of the Code by writing to the Chief Financial Officer, at 461 King Street W., Floor 2, Toronto, Ontario M5V 1K4 or may obtain a copy under the Corporations profile on SEDAR, online at www.sedar.com.
In keeping with the reporting requirements contained within the Code, employees are encouraged to report any instance of non-compliance with the Code to the CEO or CFO and in certain instances the Audit Committee. The Board periodically reviews the Corporations policies, including the Code and may revise and update the Code on an annual basis. All new Directors, officers and employees of the Corporation and any subsidiaries, as well as consultants and contract workers who perform work on behalf of the Corporation, are advised of the Code and its importance.
The Corporation is governed by the provisions of the OBCA. Pursuant to the OBCA, a Director or officer of the Corporation must disclose in writing or by requesting that it be entered in the minutes of meetings of the Board, the nature and extent of any interest that he or she has in a material contract or material transaction, whether made or proposed, with the Corporation, if the Director or officer: (a) is a party to the contract or transaction; (b) is a director or an officer, or an individual acting in a similar capacity, of a party to the contract or transaction; or (c) has a material interest in a party to the contract or transaction. The interested Director cannot vote on any resolution to approve the contract or transaction, subject to certain limited exceptions.
Committees of the Board
Audit Committee
The Audit Committee is currently comprised of three Directors, Ms. Basian (Chair), and Messrs. Duet and Levesque. All members of the Audit Committee are financially literate for purposes of National Instrument 52-110 Audit Committees ("NI 52-110"). Each of Ms. Basian and Messrs. Duet and Levesque are independent for purposes of NI 52-110. If elected at the Meeting, it is expected that Ms. Basian (as Chair) and Messrs. Duet and Levesque will be appointed to the Audit Committee.
The responsibilities and operation of the Audit Committee are set out in the Corporations Audit Committee Charter, the text of which is included as Appendix "E" hereto.
The relevant education and experience of each member of the Audit Committee, and proposed members of the Audit Committee subsequent to the Meeting, is provided above, under the heading "Director Nominees of The Flowr Corporation".
The Audit Committee has the authority to pre-approve non-audit services which may be required from time to time, as set forth in the Audit Committee charter.
In accordance with NI 52-110, the Audit Committee will, from time to time, implement and oversee procedures for the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls or auditing matters and the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters. In this regard, the Corporation has established a reporting policy, which is contained within the Code.
44
A summary of the external auditor service fees and billings paid or payable to the Corporations external auditors in respect of the last two fiscal years ended December 31 is set out below:
Fiscal Year | Audit Fees | Audit-Related | Tax Fees | All Other Fees | Total | ||||||||||
Fees | |||||||||||||||
2018 | $ | 81,000 | $ | 38,500 | $ | 27,000 | $ | 21,950 | $ | 162,450 | |||||
20171 | $ | 51,000 | $ | 7,500 | $ | 27,000 | $ | 110,501 | $ | 196,001 |
Notes: | |
____________________________ | |
1 | These are the fees incurred by The Needle Capital Corp. prior to the completion of the Qualifying Transaction and also include fees incurred by The Flowr Corporation, the private corporation, that completed the Qualifying Transaction with The Needle Capital Corp., as MNP LLP acted as auditor for both entities. |
Nominating and Corporate Governance Committee
The NCGC is comprised of three Directors, Ms. Basian and Messrs. Duet and Levesque (Chair). The relevant education and experience of each proposed member of the NCGC is provided above, under the heading "Director Nominees of The Flowr Corporation". If elected at the Meeting, Ms. Basian and Messrs. Duet and Levesque (as Chair) will be appointed to the NCGC, and therefore the NCGC will be comprised of all independent Directors for the purposes of NI 58-101.
The NCGC oversees the Corporations approach to corporate governance matters. A copy of the NCGCs Charter is located on the Corporations website at www.flowr.ca, which is not incorporated by reference herein.
The mandate of the NCGC includes:
Any recommendation made by the NCGC will be presented to the Board for approval to ensure additional oversight of the process.
Human Resources and Compensation Committee
The HRCC is comprised of three Directors, Ms. Basian and Messrs. Duet (Chair) and Levesque. If elected at the Meeting, Ms. Basian and Messrs. Duet (as Chair) and Levesque will be appointed to the HRCC, and therefore the HRCC will be comprised of all independent Directors for the purposes of NI 58-101.
The members of the HRCC will be appointed annually by the Board, and each member of the HRCC will serve at the pleasure of the Board until the member resigns, is removed, or ceases to be a member of the Board. In addition to the education and experience of each member of the HRCC provided above, under the heading "Director Nominees of The Flowr Corporation", the members of the HRCC have the following (i) direct experience relevant to their responsibilities on the HRCC in determining executive compensation and (ii) skills and experience that enable the HRCC to make decisions on the suitability of the Corporations compensation policies and practices:
Ms. Basian: as CFO and SVP Operations at 724 Solutions (SVNX:TO) Ms. Basian led Human Resources. She is also currently the Chairman of the Human Resources & Compensation Committee of goeasy (GSY:TO);
Mr. Duet: is currently the CEO and Founder of Concourse, where matters relating to executive compensation are overseen by Mr. Duet. Mr. Duet was also formerly an executive and Board member of Vapor.io, where Mr. Duet was involved in compensation related matters and decision making. In addition, during his tenure with Goldman Sachs, Mr. Duet gain key insights into compensation related matters at both the regional and global level.; and
45
Although the HRCC is comprised entirely of independent Directors, any recommendations of the HRCC must be approved by the Board to ensure an objective process for determining the compensation of its Directors and NEOs.
A copy of the HRCC Charter is located on the Corporations website at www.flowr.ca, which is not incorporated by reference herein. To fulfil its responsibilities and duties in developing the Corporations approach to compensation issues, the HRCC shall:
Review and approve corporate goals and objectives relevant to compensation of the CEO and evaluate the performance of the CEO in light of these corporate goals and objectives.
Review corporate goals and objectives relevant to compensation of the NEOs (other than the CEO), and other direct reports of the CEO as approved by the CEO and receive a report annually from the CEO of the performance those NEOs and other direct reports against such corporate goals and objectives.
Ensure that the Corporations security-based compensation plans and all amendments to such plans which require the approval of the Shareholders are approved by the Board and by Shareholders, as may be required.
Approve and evaluate performance measures for executive incentive plans.
Review any proposed disclosure of executive compensation. Without limiting the foregoing, annually review any report on executive compensation (including any discussion or analysis thereof) and recommend to the Board that it be included in the Corporations annual report, management information circular or other documents prepared for an annual meeting of Shareholders.
Position Descriptions
The Board has not developed written position descriptions for the Chairman, the Lead Independent Director or the chairs of the committees of the Board. The responsibilities of the Chairman and the Lead Independent Director include leadership of the Board and its efficient organization and operation.
Each committee chair is responsible for the effective organization and operation of the relevant committee he or she chairs and is required to provide leadership in discharging the mandate set out in the committee charter. The chair also acts as primary liaison between the relevant committee and the Corporations management where necessary. The chair of each committee reports directly to the Board.
Timely Disclosure, Confidentiality and Insider Trading Policy
The Board has adopted a Timely Disclosure, Confidentiality and Insider Trading Policy designed to promote consistent disclosure practices aimed at informative, timely and broadly disseminated disclosure of material information to the public in accordance with all applicable legal and regulatory requirements. It is applicable to all persons in a special relationship with the Corporation. The Timely Disclosure, Confidentiality and Insider Trading Policy prohibits selective disclosure of material information regarding the Corporation or its business. In addition, the Timely Disclosure, Confidentiality and Insider Trading Policy addresses securities trading matters, and provides for trading blackout periods and quiet periods.
Directors and Officers Liability Insurance
The Corporation annually renews and purchases insurance coverage for Directors and Officers liability. The current term (September 20, 2018 to September 20, 2019) premium of approximately $136,500 covers Directors and officers liability for an aggregate limit as set forth in the policy. The policy provides for deductibles ranging from $nil to $25,000 depending upon the nature of the claim. There is no deductible for any claim made by a Director or officer when indemnification has not been granted. This premium is paid entirely by the Corporation.
The Corporation indemnifies Directors and officers of the Corporation ("Indemnified Persons") for the full amount of any cost reasonably incurred by an Indemnified Person in connection with any proceeding that may be made or asserted against or affect an Indemnified Person or in which an Indemnified Person is required by law to participate or in which an Indemnified Person participates at the request of the Corporation if it relates to, arises from or is based on an Indemnified Persons service in an indemnified capacity.
46
AUDITOR
Flowrs current auditors are MNP, LLP, Chartered Professional Accountants, 50 Burnhamthorpe Road West, Suite 900, Mississauga, Ontario L5B 3C2. MNP LLP, Calgary, Alberta was first appointed auditors of The Needle Capital Corp. on November 3, 2016 and MNP, Mississauga, Ontario were appointed auditors of The Flowr Corporation, the private corporation that completed the Qualifying Transaction with The Needle Capital Corp., on January 24, 2018.
MANAGEMENT CONTRACTS
The management functions of the Corporation are not to any substantial degree performed other than by the Directors and officers of the Corporation.
ADDITIONAL INFORMATION
Additional information relating to the Corporation is available under the Corporations profile on SEDAR, online at www.sedar.com. Financial information relating to the Corporation is provided in the Financial Statements and the accompanying managements discussion and analysis for the Corporations most recently completed financial year. Copies of the Financial Statements and the related managements discussion and analysis for the most recently completed financial year are available to anyone, upon request to the Chief Financial Officer of the Corporation at 461 King Street W., Floor 2, Toronto, Ontario M5V 1K4, and without charge to Shareholders, and are also available under the Corporations profile on SEDAR, online at www.sedar.com.
47
DIRECTORS APPROVAL
The contents of this Circular and its sending to Shareholders have been approved by the Board.
Dated this 9th day of May, 2019.
BY ORDER OF THE BOARD OF DIRECTORS OF | |||
THE FLOWR CORPORATION | |||
By: | <Signed> "Steve Klein" | ||
Name: | Steve Klein | ||
Title: | Chairman and Chief Strategy Officer |
48
APPENDIX "A" - STOCK OPTION PLAN, AS AMENDED
AMENDED AND RESTATED
STOCK OPTION PLAN
The Flowr Corporation (the "Corporation") hereby adopts this Amended and Restated Stock Option Plan (the "Plan") for Eligible Participants of the Corporation and its Subsidiaries.
ARTICLE 1
PURPOSE
The purpose of the Plan is to attract, retain and motivate Eligible Participants, and to advance the interest of the Corporation and its Subsidiaries by affording such Eligible Participants with the opportunity through share options to acquire an increased proprietary interest in the Corporation.
ARTICLE 2
INTERPRETATION
2.1 |
Definitions | |
In this Plan, the following terms have the following meanings: | ||
(a) |
"Applicable Laws" means the requirements relating to the establishment and operation of stock option plans and the issue and/or transfer of shares under any applicable securities and other laws or any order, policy, by-law, rule or regulation of any regulatory body or stock exchange (including but not limited to the TSXV) having jurisdiction or authority over the securities of the Corporation or its Subsidiaries or the Plan, in any country or jurisdiction in which Options are granted to Optionees and/or in which Optionees reside at the date of exercise of their Options; | |
(b) |
"Blackout Period" means the blackout period of the Corporation pursuant to the Corporations policies during which the trading of Shares is prohibited; | |
(c) |
"Board" means the Board of Directors of the Corporation; | |
(d) |
"Business Day" means any day other than a Saturday or Sunday on which banks are open for business in the city of Toronto, Ontario; | |
(e) |
"Cause" means (i) any act or omission of the Optionee which, pursuant to Applicable Laws constitutes a serious reason for termination of employment or services; or (ii) as specified in such Optionees employment or services agreement with the Corporation or a Subsidiary; | |
(f) |
"Eligible Participant" means (subject to any Applicable Laws) a full-time or part- time employee of the Corporation or a Subsidiary, director, officer, consultant or advisor of the Corporation or a Subsidiary (for so long as such Person holds any such position, excluding any period of statutory, contractual or reasonable notice of termination of employment or deemed employment), and the Corporation and the Eligible Participant are responsible for ensuring and confirming that the Eligible Participant is a bona fide Eligible Participant; provided, however, that a consultant or advisor shall not be an Eligible Participant unless such consultant or advisor is an individual that provides bona fide services to the Corporation and such services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for Corporations securities. |
- 2 -
(g) |
"Flowr ULC Shares" means the class A preferred shares in the capital of The Flowr Canada Holdings ULC, a subsidiary of the Corporation, exchangeable for Class B preferred shares in the capital of the Corporation (or following completion of the Transaction, common shares in the capital of The Needle Capital Corp.) at any time at the option of the holder; | ||
(h) |
"Good Reason" means any of the following that results in the Optionees voluntary resignation of employment or services within 30 days of the occurrence thereof: (a) a reduction by the Corporation of at least 20% in the Optionees annual base salary or other annual remuneration, or (b) a breach by the Corporation of any material obligation under any employment or services agreement with an Optionee, as applicable, that remains not remedied 10 days after the Optionee provides written notice thereof to the Corporation, or (c) a change by the Corporation in the Optionees principal work or services location more than 100 kilometers; provided, that in no event will the Optionee be deemed to have resigned for Good Reason unless: (i) the action described in the preceding clause (a) or (c), as applicable, was performed without the consent of the Optionee; (ii) the Optionee has given written notice to the Corporation stating that he/she is invoking a "Resignation for Good Reason," stating the specific circumstances the Optionee claims to constitute Good Reason; and (iii) the Corporation fails to reasonably cure such circumstances within 10 days following receipt of such notice; | ||
(i) |
"Incapacity" means any medical condition whatsoever (including physical or mental illness) which leads to the Optionees absence from his job function for a continuous period of six months without the Optionee being able to resume functions on a full time basis at the expiration of such period and which, in light of the position held by the Optionee, the Board determines would cause undue hardship to the Corporation which cannot be accommodated; and unsuccessful attempts to return to work for periods of less than 15 days shall not interrupt the calculation of such six month period; | ||
(j) |
"Insider" has the meaning ascribed thereto pursuant to the rules and regulations of the TSXV; | ||
(k) |
"Market Price" means: | ||
(i) |
the closing price of the Shares on the TSXV or such other stock exchange on which the Shares may then be listed and primarily traded on the Business Day prior to the date the Option is granted or prior to the date of the applicable event for which pricing is required herein, as applicable, or such other price as is permitted pursuant to the rules and regulations of the TSXV or such other stock exchange on which the Shares may then be listed and primarily traded; or |
- 3 -
(ii) |
if the Shares or any other security in respect of which a determination of Market Price is being made are not listed on any stock exchange, the Market Price shall be determined by the Board, acting reasonably and in good faith, which determination shall be conclusive; | ||
(l) |
"Option" means the right to purchase Shares granted under the Plan pursuant to the terms and conditions of an Option Certificate; | ||
(m) |
"Optionee" means an Eligible Participant who holds Options granted under the Plan pursuant to an Option Certificate; | ||
(n) |
"Option Certificate" means the certificate issued by the Corporation evidencing the grant of an Option to an Eligible Participant and the terms and conditions of such Option substantially in the form of Schedule 4.4 hereto; | ||
(o) |
"Option Price" means the purchase price per Optioned Share determined in accordance with Section 5.1; | ||
(p) |
"Optioned Shares" means the Shares which may be purchased by an Optionee pursuant to an Option; | ||
(q) |
"Person" means a natural person, partnership, limited partnership, limited liability partnership, a corporation, joint stock company, trust, estate, unincorporated association, joint venture or other entity or governmental entity, and pronouns have a similarly extended meaning; | ||
(r) |
"Plan" means this Amended and Restated Stock Option Plan; | ||
(s) |
"Shareholder" means a holder of Shares; | ||
(t) |
"Shares" means the common shares in the capital of the Corporation or, in the event of any adjustment contemplated by Section 3.2, the shares or other securities in the capital of the Corporation or other Person to which an Optionee may be entitled upon the exercise of any Options pursuant to such adjustment; | ||
(u) |
"Subsidiary" has the meaning set forth in the Business Corporations Act (Ontario); | ||
(v) |
"Termination Date" means the date on which an Optionee ceases to be an Eligible Participant as a result of a termination of employment or services with the Corporation or a Subsidiary for any reason, including death, Incapacity, retirement, resignation (with or without Good Reason) or Cause. For the purposes of the Plan, an Optionees employment with, or provision of services to, the Corporation or a Subsidiary shall be considered to have terminated, (i) in the case of death, retirement, resignation (with or without Good Reason) or Cause, effective on the last day of the Optionees actual and active employment with, or provision of services to, the Corporation or a Subsidiary whether such day is selected by agreement with the individual, unilaterally by the Corporation or the Subsidiary and whether with or without advance notice to the Optionee, or (ii) in the case of an Incapacity of the Optionee, the effective date of termination as specified in the written notice from the Corporation or its Subsidiary to such Optionee. For the avoidance of doubt, no period of notice or pay in lieu of notice that is given or that ought to have been given under applicable laws in respect of such termination of employment that follows or is in respect of a period after the Optionees last day of actual and active employment shall be considered as extending the Optionees period of employment for the purposes of determining his entitlement under the Plan; |
- 4 -
(w) |
"Transaction" means the series of transactions through which the businesses of The Flowr Corporation and The Needle Capital Corp. will be combined pursuant to the business combination agreement dated August 27, 2018 between the Corporation and The Needle Capital Corp.; | |
(x) |
"Trigger Event" means: (a) the sale by the Corporation of all or substantially all of its assets; (b) the acceptance by the Shareholders, representing in the aggregate fifty percent (50%) or more of all of the issued Shares, of any offer, whether by way of a takeover bid or otherwise, for all or any of the outstanding Shares; (c) the acquisition, by whatever means, by a person (or two or more persons who, in such acquisition, have acted jointly or in concert or intend to exercise jointly or in concert any voting rights attaching to the Shares acquired), directly or indirectly, of beneficial ownership of such number of Shares or rights to Shares, which together with such persons then- owned Shares and rights to Shares, if any, represent (assuming the full exercise of such rights) fifty percent (50%) or more of the combined voting rights attached to the then-outstanding Shares; (d) the entering into of any agreement by the Corporation to merge, consolidate, restructure, amalgamate, initiate an arrangement or be absorbed by, into or with another corporation; (e) the passing of a resolution by the Board or Shareholders to substantially liquidate the assets of the Corporation or wind up the Corporations business or significantly rearrange its affairs in one or more transactions or series of transactions or the commencement of proceedings for such a liquidation, winding-up or re-arrangement (except where such re- arrangement is part of a bona fide reorganization of the Corporation in circumstances where the business of the Corporation is continued and the shareholdings remain substantially the same following the re-arrangement); or (f) the circumstance in which individuals who were members of the Board immediately prior to a meeting of the Shareholders involving a contest for the election of directors no longer constitute a majority of the Board following such election; and | |
(y) |
"TSXV" means the TSX Venture Exchange, or any primary successor exchange on which the Shares are posted for trading. |
2.2 |
Gender and Number |
Any reference in this Plan to gender shall include all genders and words importing the singular number only shall include the plural and vice versa. |
- 5 -
2.3 |
Headings |
The division of the Plan into subsections and clauses and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation of the plan. | |
2.4 |
Schedules |
The schedules and appendices to the Plan form an integral part of the Plan and any reference to the "Plan" herein shall include reference to such schedules and appendices, as applicable. |
ARTICLE 3
SHARES RESERVED FOR ISSUANCE
3.1 |
Maximum Shares Reserved |
Subject to adjustment as provided under Section 3.2, the maximum number of Shares issuable upon the exercise of all Options granted under the Plan shall not exceed, in the aggregate, 10% of the issued and outstanding a) common shares of the Corporation and b) Flowr ULC Shares, from time to time. For purposes of clarity, the maximum number of Shares reserved and set aside for issue under this Plan and under Flowrs long-term incentive plan shall not exceed 20% of the Shares and Flowr ULC Shares. Options shall not be granted under the Plan for a number of Shares in excess of the maximum number of Shares reserved for issuance. Notwithstanding the foregoing, and subject to Applicable Law, if any Option expires or otherwise terminates for any reason without having been exercised in full, the number of Shares in respect of the Option that has expired or terminated shall again be available for issuance under the Plan. | |
3.2 |
Adjustment of Options |
The existence of any Options does not affect in any way the right or power of the Corporation or its shareholders to make, authorize or determine any adjustment, recapitalization, reorganization or any other change in the Corporations capital structure or its business, or any amalgamation, combination, merger or consolidation involving the Corporation, to create or issue any bonds, debentures, shares or other securities of the Corporation or to determine the rights and conditions attaching thereto, to effect the dissolution or liquidation of the Corporation or any sale or transfer of all or any part of its assets or business, or to effect any other corporate act or proceeding, whether of a similar character or otherwise, whether or not any such action referred to in this section would have an adverse effect on this Plan or any Option granted hereunder. | |
If there is a change in the outstanding Shares by reason of any stock dividend or split, recapitalization, reclassification, amalgamation, consolidation, combination or exchange of shares, or other corporate change, the Board shall make, subject where required to the prior approval of the TSXV, appropriate substitution or adjustment in (a) the number or kind of Shares or other securities reserved for issuance pursuant to the Plan, and (b) the number and kind of Shares or other securities subject to unexercised Options theretofore granted and in the exercise price of such securities. |
- 6 -
No fractional Shares shall be issued upon the exercise of an Option. If, as a result of any adjustment under this Section 3.2 an Optionee would be entitled to a fractional Share, the Optionee shall have the right to acquire only the adjusted number of full Shares rounded down to the next full Share and no payment or other adjustment shall be made with respect to the fractional Shares so disregarded.
ARTICLE 4
GRANT OF OPTIONS
4.1 |
Grant of Options |
The Corporation may grant to any Eligible Participants designated by the Board one or more Options at an Option Price over such whole number of Optioned Shares as the Board decides. | |
4.2 |
Period for granting Options |
Subject to Applicable Law, Options may be granted at any time that the Board thinks appropriate except that no Option shall be granted after the termination of the Plan or at any time when any Eligible Participant is prohibited from being granted an Option under any dealing restrictions contained in any Applicable Laws to which the Corporation and/or the Eligible Participant is subject. | |
4.3 |
Approvals and Consents |
The grant of an Option will be subject to obtaining any approval or consent required under the provisions of any Applicable Laws. | |
4.4 |
Option Certificate |
Each Option granted by the Board shall be evidenced by an Option Certificate between the Optionee and the Corporation substantially in the form attached as Schedule 4.4 with such amendments as are approved by the Board, or such other form as may be acceptable to the Board, which shall be subject to the terms and conditions of the Plan and to such other terms and conditions as set out in the Option Certificate as the Board may deem appropriate. | |
4.5 |
Options Personal to Optionee |
An Option is personal to the Optionee to whom it is granted. Except to the extent specifically authorized by the Board or contemplated herein, an Option, part of an Option or any rights in respect of an Option may not be sold, transferred, assigned, pledged, hypothecated, charged or otherwise encumbered or disposed of. Option(s) held by an Optionee may be transmitted to the administrator, liquidator or executor of the Optionees estate. Options shall not be assignable or transferable by the Optionee, whether voluntarily or by operation of law, except by will or by the laws of succession of the domicile of the deceased Optionee. | |
4.6 |
Disclaimer of Options |
An Optionee may disclaim an Option, in whole or in part, in writing to the Corporation within 30 days after the Date of Grant. No consideration will be paid for the disclaimer of an Option. To the extent that an Option is disclaimed it will be deemed never to have been granted. |
- 7 -
4.7 |
Listing Conditions | |
Each Option is subject to the requirement that, if at any time counsel to the Corporation shall determine that the listing, registration or qualification of the Optioned Shares upon any securities exchange or under any Applicable Law, or the consent or approval of any securities exchange or any governmental or regulatory body, is necessary as a condition of, or in connection with, the exercise of such Option or the issuance or purchase of Optioned Shares thereunder, such Option may not be accepted or exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained on conditions acceptable to the Board. Furthermore, as a condition of receiving any Option, the Optionee agrees to comply with all Applicable Laws and agrees to furnish to the Corporation all information and undertakings as may be required to permit compliance with such Applicable Laws. Nothing herein shall be deemed to require the Corporation to apply for or to obtain such listing, registration, qualification, consent or approval. | ||
4.8 |
Limitations on Option Grants | |
Notwithstanding any other provision of this Plan, unless disinterested Shareholder approval is obtained in accordance with the policies of the TSXV, the aggregate number of Options: | ||
(a) |
granted to any one Eligible Participant in a 12 month period shall not exceed 5% of the issued and outstanding Shares and Flowr ULC Shares; | |
(b) |
granted to any one Eligible Participant that is a consultant of the Corporation or a Subsidiary in a 12 month period shall not exceed 2% of the issued and outstanding Shares and Flowr ULC Shares; | |
(c) |
granted to all Persons retained to provide investors relations activities in a 12 month period shall not exceed 2% of the issued and outstanding Shares and Flowr ULC Shares; | |
(d) |
granted to all Persons retained to provide investors relations activities will contain vesting provisions such that vesting occurs over at least 12 months with no more than 1\4 of the options vesting in any 3 month period; and | |
(e) |
granted to the Insiders of the Corporation as a group shall not exceed 10% percent of the issued and outstanding Shares and Flowr ULC Shares. | |
4.9 |
Hold Period | |
All Options granted hereunder may be subject to and legended with a four month hold period commencing on the date the Options were granted pursuant to the rules of the Exchange and applicable securities laws. Without limiting the generality of the foregoing, in the event that Options are granted to officers or directors, or at a discount to Market Price as permitted by the TSXV, the following legend will appear on the Option Certificate: |
- 8 -
WITHOUT PRIOR WRITTEN APPROVAL OF TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL [INSERT DATE THAT IS FOUR MONTHS AND A DAY FROM THE GRANT DATE]
ARTICLE 5
OPTION PRICE
5.1 |
Option Price |
The Option Price per Optioned Share at the time any Option is granted shall be a price not lower than the Market Price per Share as determined by the Board, or such lower price permitted by the policies of the TSXV. |
ARTICLE 6
TERMS OF OPTION CERTIFICATE
6.1 |
Option Certificate | |
Unless otherwise modified by the Board generally or in regard to specific Options, and subject to any Applicable Law, each Option Certificate shall have the following terms: | ||
(a) |
Subject to Article 12, the term of any Option shall not be greater than 10 years from the date of the grant; | |
(b) |
Options shall be exercisable if vested in accordance with Section 7.1, except as otherwise provided herein or in the Option Certificate; | |
(c) |
to the extent the right to purchase Optioned Shares has vested, Options shall be exercisable in accordance with Section 8.1, except as otherwise provided herein or in the Option Certificate; | |
(d) |
an Option Certificate may not be assigned or transferred by any Optionee and shall be exercisable only by the Optionee, subject to Sections 9.1(a) and 4.6, with respect to the death of an Optionee; and | |
(e) |
the exercise of any Option will be contingent upon receipt by the Corporation of payment of the full Option Price of such Optioned Shares. |
- 9 -
ARTICLE 7
VESTING
7.1 |
Vesting Specified in the Option Certificate |
Except as otherwise set forth in this Plan, an Optionees right to purchase the Optioned Shares shall vest on such dates and only in respect of such number of Optioned Shares as specified in the relevant Option Certificate. |
ARTICLE 8
EXERCISE OF OPTIONS
8.1 |
Exercise of Options | |
Options shall be exercisable at any time and from time to time as specified in the Option Certificate as to all or any lesser number of the Optioned Shares in respect of which the Optionees right to purchase Optioned Shares has vested. | ||
8.2 |
Manner of Exercise | |
Options that have vested shall be exercised by written notice to the Corporation in the manner provided in Section 14.1 and in the form required by the Corporation, if any, specifying the number of Optioned Shares in respect of which such Option is then being exercised (the "Notice") and such notice shall be accompanied by a certified cheque, bank draft, or wire transfer in respect of the then applicable Option Price per Optioned Share being exercised. | ||
8.3 |
Issuance of Shares | |
Subject to Section 8.4, following the exercise of the Option, the Corporation shall take all actions reasonably necessary to issue such Optioned Shares to the Optionee. | ||
8.4 |
Obligation to Issue Shares | |
The Corporations obligation to issue Optioned Shares to an Optionee pursuant to the exercise of an Option may be subject to: | ||
(a) |
completion of such registration or other qualifications of such Optioned Shares or obtaining approval of such governmental authority or stock exchange as the Corporation shall determine to be necessary or advisable in connection with the authorization, issuance or sale of the Optioned Shares; | |
(b) |
the receipt of full payment for the Optioned Shares; | |
(c) |
the admission of such Optioned Shares to listing on any stock exchange on which the Shares may be listed or proposed to be listed; and | |
(d) |
the receipt from the Optionee of such representations, agreements and undertakings as to future dealings in such Optioned Shares as may be necessary to comply with Applicable Laws. |
- 10 -
ARTICLE 9
TERMINATION OF EMPLOYMENT OR SERVICE OF
OPTIONEE
9.1 |
Termination Event | ||
(a) |
Unless otherwise provided hereunder or in the Option Certificate or as otherwise determined by the Board in its sole discretion, in the event of termination as a result of retirement, Incapacity or death of an Optionee, the Optionee (or the administrator, executor or liquidator of the Optionees estate): | ||
(i) |
may exercise any Options to the extent that the Options were exercisable at the Termination Date and the right to exercise such Options terminates on the earlier of: (i) in the case of Optionees death or Incapacity, the date that is 180 days after the Termination Date, and in the case of Optionees retirement, the date that is 120 days after the Termination Date; (ii) the date on which the particular Option expires pursuant to this Plan; and (iii) the date determined by the Board in the event of a Trigger Event, provided that if an Optionee (or his legal representative) does not exercise his Options on or prior to such date, such Options shall immediately expire and are cancelled on such date. Any Options held by the Optionee that were not exercisable at the Termination Date immediately expire and are cancelled on such date; and | ||
(ii) |
such Optionees eligibility to receive further grants of Options under the Plan ceases as of the Termination Date. | ||
(b) |
Unless otherwise provided hereunder or in the Option Certificate, or as otherwise determined by the Board in its sole discretion, in the event of termination without Cause or resignation for Good Reason (whether such termination occurs with or without any or adequate reasonable notice, or with or without any or adequate compensation in lieu of such reasonable notice), then any Options held by Optionee that are exercisable at the Termination Date, continue to be exercisable by Optionee until the earlier of: (i) the date that is 30 days after the Termination Date; and (ii) the date on which the particular Option expires pursuant to this Plan; and (iii) the date determined by the Board in the event of a Trigger Event, provided that if an Optionee does not exercise his Options on or prior to such date, such Options shall immediately expire and are cancelled on such date. Any Options held by Optionee that are not exercisable at the Termination Date immediately expire and are cancelled on the Termination Date. | ||
(c) |
Unless otherwise provided hereunder or in the Option Certificate, in the event of Termination by reason of (i) Cause or (ii) resignation by Optionee, other than for Good Reason, then any Options held by the Optionee, whether or not exercisable at the Termination Date, immediately expire and are cancelled on such date or at a time as may be determined by the Board, in its sole discretion. | ||
(d) |
In no event can an Optionees Options be exercisable after the date that is one year after the Termination Date. |
- 11 -
ARTICLE 10
SHAREHOLDER RIGHTS
10.1 |
Shareholder Rights |
An Optionee shall have no rights whatsoever as a shareholder in respect of any of the Optioned Shares (including any right to vote or to receive dividends or other distributions therefrom), unless and only to the extent that the Optionee shall from time to time duly exercise an Option and become a Shareholder. |
ARTICLE 11
TRIGGER EVENT
11.1 |
Trigger Event | |
(a) |
Notwithstanding any other provision of this Plan, in the event of an actual or potential Trigger Event, the Board may, in its discretion, without the necessity or requirement for the agreement of any Eligible Participant, but subject always to the prior written approval of the TSXV: (i) accelerate, conditionally or otherwise, on such terms as it sees fit, the vesting date of any Option; (ii) permit the conditional exercise of any Option, on such terms as it sees fit; (iii) otherwise amend or modify the terms of the Option, including for greater certainty permitting Eligible Participants to exercise any Option, to assist the Eligible Participants to tender the underlying Shares to, or participate in, the actual or potential Trigger Event or to obtain the advantage of holding the underlying Shares during such Trigger Event; and (iv) terminate, following the successful completion of such Trigger Event, on such terms as it sees fit, the Options not exercised prior to the successful completion of such Trigger Event. The determination of the Board in respect of any such Trigger Event shall for the purposes of this Plan be final, conclusive and binding. | |
(b) |
Notwithstanding any other provision of this Plan, in the event that: (i) an actual or potential Trigger Event is not completed within the time specified therein; or (ii) all of the Shares subject to an Option that were tendered by an Eligible Participant in connection with an actual or potential Trigger Event are not taken up or paid for by the offeror in respect thereof, then the Board may, in its discretion, without the necessity or requirement for the agreement of any Eligible Participant, permit the Shares received upon such exercise, or in the case of subparagraph (ii) above the Shares that are not taken up and paid for, to be returned by the Eligible Participant to the Corporation and reinstated as authorized but unissued Shares and, with respect to such returned Shares, the related Options may be reinstated as if they had not been exercised and the terms for such Options becoming vested will be reinstated pursuant to this Section 11.1. If any Shares are returned to the Corporation under this Section 11.1, the Corporation will immediately refund the exercise price to the Eligible Participants for such Shares |
- 12 -
ARTICLE 12
BLACKOUT PERIODS
12.1 |
Blackout Periods | ||
(a) |
The expiration of the term of an Option will be the later of a date set out in the Option Certificate or a date after such expiration date should such date fall within or immediately after a Blackout Period, if applicable, provided that: | ||
(i) |
the Blackout Period is formally self-imposed by the Corporation as a result of the bona fide existence of undisclosed material information; | ||
(ii) |
the Blackout Period must expire upon the general disclosure of the undisclosed material information and the period of time provided to exercise the Option after the lifting of the Blackout Period cannot be more than 10 Business Days; | ||
(iii) |
the foregoing extension will not be permitted where the Eligible Participant or the Corporation is subject to a cease trade order in respect of the Corporations securities; and | ||
(iv) |
all Eligible Participants under the Plan are eligible for the extension, under the same terms and conditions. | ||
(b) |
For certainty, if a Blackout Period is in effect, this means that the maximum term of an Option that would otherwise expire during such Blackout Period is 10 years, plus the length of the Blackout Period, plus 10 Business Days. |
ARTICLE 13
TERMS AND CONDITIONS OF OPTIONS GRANTED
TO U.S. PARTICIPANTS
13.1 |
This Article 13 applies only to U.S. Participants. In this Article 13, the following words and phrases shall have the following meanings: | |
(a) |
"Code" means the U.S. Internal Revenue Code of 1986, as amended. | |
(b) |
"Disability" means, with respect to any U.S. Participant, that such U.S. Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted, or can be expected to last, for a continuous period of not less than 12 months. The preceding definition of the term "Disability" is intended to comply with, and will be interpreted consistently with, sections 22(e)(3) and 422(c)(6) of the Code. | |
(c) |
"Fair Market Value" means (i) the closing price of the Shares on the TSXV or such other stock exchange on which the Shares may then be listed and primarily traded on the Business Day prior to the date the Option is granted or prior to the date of the applicable event for which pricing is required herein, as applicable; or (ii) if the Shares are not listed on any stock exchange, Fair Market Value shall be determined by the Board, acting reasonably and in good faith and in accordance with the principles under section 409A of the Code and applicable guidance thereunder. |
- 13 -
(d) |
"Grant Date" means, for purposes of Articles 13 and 14, the date on which the grant of an Option becomes effective by the Corporation completing the actions necessary to grant the Option and creating a legally binding right in the Optionee, including specifying the Optionee, the number of Shares subject to the Option granted to such Optionee, and the Option Price of the Option. | |
(e) |
"Incentive Stock Option" means an Option that is intended to qualify as an "incentive stock option" pursuant to section 422 of the Code. | |
(f) |
"Non-qualified Stock Option" means an Option that is not an Incentive Stock Option. | |
(g) |
"Parent" means any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, if at the time of granting the option, each of the corporations other than the Corporation owns stock possessing 50% or more of the combined voting power of all classes of stock in one of the other corporations in such chain. The preceding definition of the term "Parent" is intended to comply with, and will be interpreted consistently with, section 424(f) of the Code. | |
(h) |
"Subsidiary" means any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, if at the time of granting the option, each corporation (other than the last corporation) in such chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. The preceding definition of the term "Subsidiary" is intended to comply with, and will be interpreted consistently with, section 424(f) of the Code. | |
(i) |
"U.S. Employee" means an Eligible Participant who is an employee of the Corporation (or of any Subsidiary) for purposes of section 422 of the Code. | |
(j) |
"U.S. Participant" means an Optionee who is a citizen of the United States or a resident of the United States, in each case as defined in section 7701(a)(30)(A) and section 7701(b)(1) of the Code, and such other Optionees to the extent their Options awarded under the Plan are subject to U.S. federal income tax under the Code. | |
(k) |
"10% Shareholder" means any Person who owns, taking into account the constructive ownership rules set forth in section 424(d) of the Code, more than 10% of the total combined voting power of all classes of stock of the Corporation (or of any Parent or Subsidiary). | |
13.1 |
Any adjustment, amendment or termination of outstanding Options granted to U.S. Participants will be undertaken in accordance with section 409A of the Code on a basis consistent with the regulations thereunder, to the extent applicable. | |
13.2 |
Except as otherwise provided in this Section 13.3, the Option Price will be not less than 100% of the Fair Market Value of a Share on the applicable Grant Date but (i) the Board may designate an Option Price below the Fair Market Value of a Share on the Grant Date if the Option is granted in substitution for a stock option previously granted by an entity that is acquired by or merged with the Corporation or a Subsidiary if the number of Shares covered by the Option and the Option Price are proportionately adjusted in a manner compliant with the Treasury Regulations issued under Section 409A of the Code; and (ii) the Board may grant an Option with the Option Price less than 100% of the Fair Market Value on the applicable Grant Date if such Option otherwise qualifies for exemption from Section 409A of the Code. |
- 14 -
13.3 |
Each Option Certificate with respect to an Option granted to a U.S. Participant shall specify whether the related Option is an Incentive Stock Option or a Non-qualified Stock Option. If no such specification is made in an Option Certificate, the related Option will be a Non- qualified Stock Option. | |
13.4 |
Notwithstanding any other provision of this Plan to the contrary, the aggregate number of Shares available for Incentive Stock Options shall not exceed 12,155,000 Shares, subject to adjustment pursuant to Section 3.2 of this Plan and in accordance with the requirements of sections 422 and 424 of the Code. | |
13.5 |
In addition to the other terms and conditions of this Plan (and notwithstanding any other term or condition of this Plan to the contrary), the following limitations and requirements will apply to an Incentive Stock Option: | |
(a) |
An Incentive Stock Option may be granted only to a U.S. Employee. | |
(b) |
The aggregate Fair Market Value of the Shares (determined as of the applicable Grant Date) with respect to which Incentive Stock Options are exercisable for the first time by any U.S. Participant during any calendar year (pursuant to this Plan and all other plans of the Corporation and of any Parent or Subsidiary) will not exceed US$ 100,000 or any other limitation subsequently set forth in section 422(d) of the Code. To the extent that such limitation is exceeded, the options in excess of such limitation will be treated as Non-qualified Stock Options. | |
(c) |
The Option Price payable upon exercise of an Incentive Stock Option will be not less than 100% of the Fair Market Value of a Share on the applicable Grant Date but the Option Price payable upon exercise of an Incentive Stock Option granted to a U.S. Participant who is a 10% Shareholder on the applicable Grant Date will be not less than 110% of the Fair Market Value of a Share on the applicable Grant Date. Notwithstanding the foregoing, the Board may designate an Option Price below Fair Market Value of a Share on the Grant Date (or 110% of the Fair Market Value on the Grant Date, as applicable) if the Option is granted in substitution for a stock option previously granted by an entity that is acquired by or merged with the Corporation or a Subsidiary if the number of Shares covered by the Option and the Option Price are proportionately adjusted in a manner compliant with the Treasury Regulations issued under section 424 of the Code. | |
(d) |
No Incentive Stock Option may be granted more than 10 years after the earlier of (i) the date on which the Board adopts the Plan (or the most recent amendment and restatement of the Plan as applicable) or (ii) the date on which the Shareholders approve the Plan (or the most recent amendment and restatement of the Plan as applicable). |
- 15 -
(e) |
An Incentive Stock Option will terminate and no longer be exercisable no later than the earlier of the term set by the Board and 10 years after the applicable Grant Date (or if the Optionee is a 10% Shareholder, five years after the applicable Grant Date). | |
(f) |
If a U.S. Participant has been granted an Incentive Stock Option and ceases to be a U.S. Employee, then, to retain its status as an Incentive Stock Option for U.S. federal tax purposes such Option must be exercised within the time limits set forth below. Failure to exercise such Incentive Stock Options within the following time limits will result in the Option ceasing to be an Incentive Stock Option. The limitations below are not intended to extend the term of an Option as set forth in the Plan or any applicable Option Certificate. The limitations below merely reflect the period during which an Option intended to be an Incentive Stock Option must be exercised (assuming it otherwise could be exercised during such period) in order retain Incentive Stock Option tax treatment. |
(i) |
To retain its Incentive Stock Option status, an Incentive Stock Option of a U.S. Participant who ceases to be a U.S. Employee due to Disability must be exercised (to the extent such Incentive Stock Option was exercisable on the date of termination due to Disability) by such U.S. Participant (or the U.S. Participants Guardian) within one year following the date of termination due to Disability (but in no event beyond the term of such Incentive Stock Option). | |
(ii) |
To retain its Incentive Stock Option status, an Incentive Stock Option of a U.S. Participant who ceases to be a U.S. Employee for any reason other than the death or Disability of such U.S. Participant, such Incentive Stock Option must be exercised (to the extent such Incentive Stock Option was exercisable on the date of termination) by such U.S. Participant within three months following the date of termination (but in no event beyond the term of such Incentive Stock Option). | |
(iii) |
An Incentive Stock Option of a U.S. Participant who ceases to be a U.S. Employee by reason of death can be exercised by the estate in accordance with the terms of the Plan and applicable Option Certificate during the period specified in the Plan or the applicable Option Certificate without loss of Incentive Stock Option treatment. |
For greater clarity, under no circumstances shall the above limitations with respect to the period of time in which an Incentive Stock Option must be exercised to retain its status as an Incentive Stock Option be construed to extend the time during which an Option may be exercised pursuant to its terms as set forth in the Plan or applicable Option Certificate
If an Incentive Stock Option ceases to be an Incentive Stock Option by virtue of failure to timely exercise the Option as described above, but the Option remains exercisable pursuant to its terms, the Option will be treated as a Non-qualified Stock Option and the provisions set forth in the Plan or the Option Certificate will apply with respect to the period during which the Option may be exercised.
- 16 -
For purposes of this Subsection 13.6(f), the employment of a U.S. Participant holding an Incentive Stock Option will not be considered interrupted or terminated upon (a) sick leave, military leave or any other leave of absence approved by the Corporation that does not exceed 90 days in the aggregate but if re-employment upon the expiration of any such leave is guaranteed by contract or applicable law, such 90 day limitation will not apply, or (b) a transfer from one office of the Corporation (or of any Parent or Subsidiary) to another office of the Corporation (or of any Parent or Subsidiary) or a transfer between the Corporation and any Parent or Subsidiary. | ||
(g) |
An Incentive Stock Option granted to a U.S. Participant may be exercised during such U.S. Participants lifetime only by such U.S. Participant. | |
(h) |
An Incentive Stock Option granted to a U.S. Participant may not be transferred, assigned, pledged, hypothecated or otherwise disposed of by such U.S. Participant, except by will or by the laws of descent and distribution. |
13.6 |
If this Plan is not approved by the Shareholders as required by Section 422 of the Code within 12 months after the date on which this Plan is adopted by the Board, any Incentive Stock Option granted under this Plan will automatically be deemed to be a Non-qualified Stock Option. |
ARTICLE 14
CALIFORNIA OPTIONS
Notwithstanding any other provision of this Plan, the provisions of this Article 14 shall apply to any Option granted or proposed to be granted to a resident of California, unless such Option is otherwise exempt from the applicable securities laws of California (a "California Option").
14.1 |
Maximum Grant and Exercise Periods |
A California Option may not be exercised more than 10 years after the Grant Date. No California Option shall be granted to such a Participant after ten years from the earlier of the date of adoption of the Plan by the Board or the date of shareholder approval. | |
14.2 |
Post-Termination Exercise Period |
Unless employment is terminated for cause as defined by applicable law, the terms of the Plan or Option Certificate or a contract of employment, the right to exercise a California Option in the event of termination of employment of the Optionee, to the extent that the Optionee is entitled to exercise on the date employment terminates, continues until at least the earlier of the expiration of the term of the California Option under the Plan or applicable Option Certificate or: |
- 17 -
(a) |
at least six months from the date of termination, if termination was caused by death or disability; or | |
(b) |
at least 30 days from the date of termination, if termination was caused by other than death or disability. |
14.3 |
Shareholder Approval. |
The Plan or any increase in the maximum aggregate number of common shares issuable thereunder as provided in Section 3.1 (the "Authorized Shares") shall be approved by a majority of the outstanding securities of the Corporation entitled to vote by the later of (a) a period beginning twelve (12) months before and ending twelve (12) months after the date of adoption thereof by the Board or (b) the first issuance of any security pursuant to the Plan in the State of California (within the meaning of Section 25008 of the California Corporations Code). Awards granted prior to security holder approval of the Plan or in excess of the Authorized Shares previously approved by the security holders shall become exercisable no earlier than the date of security holder approval of the Plan or such increase in the Authorized Shares, as the case may be, and such Awards shall be rescinded if such security holder approval is not received in the manner described in the preceding sentence. Notwithstanding the foregoing, a foreign private issuer, as defined by Rule 3b-4 of the Securities Exchange Act of 1934, as amended (17 C.F.R. 240.3b-4), shall not be required to comply with this section 14.3 provided that the aggregate number of persons in California granted options under all option plans and agreements and issued securities under all purchase and bonus plans and agreements does not exceed 35. |
ARTICLE 15
AMENDMENTS
15.1 |
Amendments to the Plan | ||
(a) |
Subject to Section 15.1(b), the Board reserves the right to amend or modify the Plan as follows at any time if and when it is deemed advisable in its absolute discretion, subject to the prior written approval of the TSXV and obtaining shareholder approval, if applicable, and each Optionee hereby consents to any such change. Such changes are: | ||
(i) |
minor changes of a "housekeeping nature" which includes amendments to eliminate any ambiguity or correct or supplement any provision contained herein which may be incorrect or incompatible with any other provision hereof; | ||
(ii) |
amending Options issued under the Plan, including with respect to the period for exercising options (provided that the period during which an option is exercisable does not exceed the time period set out in Section 6.1(a) (subject to Article 12) and that such option is not held by an Insider), vesting period, exercise method and frequency, Option Price (provided that such Option is not held by an Insider) and method of determining the Option Price, assignability and transfer and effect of termination of an Optionees employment or provision of services or cessation of an Optionees directorship; |
- 18 -
(iii) |
accelerating vesting or extending the expiration date of any Option, (provided that such option is not held by an Insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted; | ||
(iv) |
in order to enable the Corporation to consummate a Trigger Event; and | ||
(v) |
in order to comply with any requirements of all applicable regulatory authorities or stock exchange. | ||
(b) |
Subject to Applicable Law, the following amendments to the Plan or to Options issued pursuant to the Plan shall not be made without prior approval of the TSXV and approval of the Shareholders (such approval to exclude, in certain circumstances, the votes of Insiders in accordance with the rules of the TSXV): | ||
(i) |
changing the class of Eligible Participants eligible to participate under the Plan; | ||
(ii) |
a reduction in the Option Price of an Option held by an Insider of the Corporation; | ||
(iii) |
an extension of the term of an Option held by an Insider of the Corporation; | ||
(iv) |
an increase in the maximum number of Shares issuable pursuant to Options granted under this Plan; | ||
(v) |
the limitations under this Plan on the number of Options that may be granted to any one Person or any category of Persons; | ||
(vi) |
the maximum term of Options; and | ||
(vii) |
amendments to this Section 15.1. |
ARTICLE 16
GENERAL
16.1 |
Notice |
Any notice required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given if delivered by hand, mailed by first class mail, postage prepaid or by facsimile and addressed to the recipient, and if to the Corporation at its principal office and if to the Optionee, at the address indicated in the Option Certificate or at the Optionees last known address shown in the records of the Corporation or any Subsidiary. It is the responsibility of the Optionee to advise the Corporation of any change in address, and neither the Corporation nor any Subsidiary shall have any responsibility for any failure by the Optionee to do so. Any Optionee may change his, her or its address from time to time by notice in writing to the Corporation. The Corporation shall give written notice to each Optionee of any change of the Corporations address. Any such notice, if mailed, shall be deemed to have been received on the fifth business day next following the date of mailing, if delivered, on the date of delivery and, if sent by facsimile, on the day following receipt of the facsimile. |
- 19 -
16.2 |
Employment and Participation |
Nothing contained in the Plan nor any action taken pursuant to the Plan shall confer upon any Optionee any right with respect to employment, engagement to service or in continuance of employment, engagement or service with the Corporation or any of its Subsidiaries or interfere in any way with the right of the Corporation or any of its Subsidiaries to terminate an Optionees employment, engagement or service at any time or for any reason. The Plan does not give any Optionee any right to claim any benefit or compensation except to the extent specifically provided in the Plan. Nothing in the Plan or the Optionees opportunity to participate in the Plan shall be construed to provide the Optionee with any rights whatsoever to participate or continue to participate in the Plan, or to compensation or damages in lieu of continued participation or the right to participate in the Plan upon the Optionee ceasing to be an Eligible Participant for any reason whatsoever. | |
16.3 |
Tax Withholding |
The Corporation will withhold from any amount of cash payment (including from any type of employment income or other amounts otherwise payable to an Optionee) made to an Optionee who exercises or surrenders Options an amount sufficient to satisfy all federal, provincial, state and local withholding requirements in respect of income tax, social security, or similar amounts (the "withholding requirements"). | |
In the case of an Option pursuant to which Shares may be delivered and if no cash withholding is performed to satisfy the withholding requirements, the Board will either require that the Optionee or other appropriate person remit to the Corporation an amount sufficient to satisfy the withholding requirements, or make other arrangements satisfactory to the Board with regard to such requirements, prior to the delivery of any shares or removal of restrictions thereon, or may permit the Optionee or such other person to elect at such time and in such manner as the Board provides to have the Corporation hold back from the Shares to be delivered, or to deliver to the Corporation, Shares having a value calculated to satisfy the withholding requirement. The Board may make such Share withholding mandatory with respect to any Option at the time such Option is granted to an Optionee. | |
16.4 |
Termination or Suspension of the Plan |
The Board at any time may suspend or terminate the Plan. An Option may not be granted under the Plan while the Plan is suspended or after it is terminated. |
- 20 -
16.5 |
Administration | ||
(a) |
The Plan shall be administered by the Board, which shall be empowered to interpret the Plan from time to time and to adopt, amend and rescind rules and regulations for carrying out the Plan. Subject to Applicable Law and certain amendments for which shareholder approval is required, as set out herein, and the prior written approval of the TSXV, where applicable, the Board shall have the power to: | ||
(i) |
adopt rules and regulations for implementing the Plan; | ||
(ii) |
determine and designate from time to time those Persons who shall be eligible to participate in the Plan and to whom Options are to be granted, the number and type of Options to be granted to each such Optionee, the vesting conditions in connection therewith and, subject to Article 4 and Applicable Law, the Option Price; | ||
(iii) |
determine the time or times when, and the manner in which, each Option shall be exercisable and the duration of the exercise term; | ||
(iv) |
subject to Article 4 and Applicable Law, change the Option Price under an Option Certificate; | ||
(v) |
interpret and construe the provisions of the Plan; | ||
(vi) |
restrict or limit the Shares and the nature of such restrictions and limitations, if any; | ||
(vii) |
accelerate the exercisability or waive the termination of any Options, based on such factors as the Board may determine; | ||
(viii) |
make exceptions to the Plan in circumstances which the Board determines; | ||
(ix) |
delegate part or all of the authority, powers, discretion or obligations of the Board pursuant to this Plan to a committee of the Board; and | ||
(x) |
take such other steps as it or they determine to be necessary or desirable to give effect to the Plan. | ||
(b) |
Any decision or determination made or action taken by the Board arising out of or in connection with the interpretation and administration of the Plan shall be final and conclusive, and the interpretation and construction of any provision of the Plan by the Board shall be final and conclusive. | ||
(c) |
No member of the Board or any Person acting pursuant to authority delegated by it, shall be liable for any action or determination in connection with the Plan made or taken in good faith, and each member of the Board and each such Person shall be entitled to indemnification with respect to any such action or determination in the manner provided for by the Corporation. |
- 21 -
16.6 |
No Undertaking or Representation |
The Optionees, by participating in the Plan, shall be deemed to have accepted all risks associated with acquiring Shares pursuant to the Plan. The Corporation hereby informs each Optionee that the Options and the Optioned Shares are subject to Applicable Laws. The Corporation, its Subsidiaries and the Board make no undertaking, representation, warranty or guarantee as to the future value or price, or as to the continued listing on the TSXV or other market, of any Shares issued in accordance with the provisions of the Plan, and shall not be liable to any Optionee for any loss whatsoever resulting from that Optionees participation in the Plan or as a result of the amendment, suspension or termination of the Plan or any Option. | |
The Optionee (including, if applicable, his legal personal representative) shall have no legal or equitable rights, claims, or interest in any specific property or assets of the Corporation or its Subsidiaries. No assets of the Corporation or its Subsidiaries shall be held in any way as collateral security for the fulfillment of the obligations of the Corporation and/or its Subsidiaries, as applicable, under this Plan. Any and all of the Corporations, and if applicable Subsidiaries, assets shall be, and remain, the general unpledged, unrestricted assets of the Corporation and such Subsidiary. | |
16.7 |
Applicable Law |
This Plan and the provisions hereof shall be governed by and interpreted and enforced in accordance with the laws of the Province of Ontario, without recourse to conflict of laws rules, and the laws of Canada applicable thereto. | |
16.8 |
Other Employee Benefits |
The amount or value deemed to be or received by an Optionee as a result of the exercise of an Option or as a result of the sale of a Share received or purchased upon an exercise of an Option will not constitute compensation with respect to which any other employee benefits of that Optionee are determined including, without limitation, benefits under any bonus, pension, profit-sharing, insurance and salary continuation plan, nor will it be a basis to calculate any amount of termination or severance after the Optionees Termination Date. In the event that the employment of the Optionee is terminated by the Corporation either with or without Cause, and with or without reasonable notice, the Optionee shall have no rights to any particular grants which have been made to him other than as set forth in the Plan or other separate written agreement with the Optionee, and the Optionee will not be entitled to recover damages nor to be paid any benefits or to recover any compensation which the Optionee would or may otherwise have been entitled to under the Plan if the Optionee had remained actively employed by the Corporation. This Plan document and the Option Certificate represent the entire agreement between the Optionee and the Corporation with respect to any and all matters described in it. Neither the Optionee nor the Corporation relies upon or regards as material, any representations or any writing that has not been incorporated into the Plan or the Option Certificate or made part of the Plan or Option Certificate. |
- 22 -
16.9 |
Compliance with Applicable Law |
If any provision of the Plan or any Option contravenes any Applicable Law, then such provision may in the sole discretion of the Board be amended to the extent considered necessary or desirable to bring such provision into compliance therewith. | |
16.10 |
Severability |
If any provision of this Plan shall be determined by any court of competent jurisdiction to be illegal, invalid or unenforceable, that provision shall be severed from this Plan and the remaining provisions shall continue in full force and effect. | |
16.11 |
Entire Plan |
This Plan constitutes the entire stock option plan for Eligible Participants of the Corporation and its Subsidiaries and supersedes any prior stock option plans for such Eligible Participants. |
[Signature Page Follows]
EXECUTED and effective as of _________, 2019.
THE FLOWR CORPORATION | |
Per: Authorized Signing Officer |
APPENDIX "A" - STOCK OPTION PLAN, AS AMENDED |
SCHEDULE 4.4 |
FORM OF OPTION CERTIFICATE |
THE FLOWR CORPORATION |
AMENDED AND RESTATED |
STOCK OPTION PLAN |
STOCK OPTION PLAN |
OPTION CERTIFICATE |
(Non-U.S. Participant) |
This Certificate is issued pursuant to the provisions of the The Flowr Corporation (the "Corporation") stock option plan (the "Plan") and evidences that [name] is the holder (the "Optionee") of an option (the "Option") to purchase [number of shares] common shares (the "Shares") in the capital stock of the Corporation at a purchase price of CAD$[exercise price] per Share (the "Option Price").
The Plan provides for the granting of stock options that either (i) are intended to qualify as "Incentive Stock Options" within the meaning of Section 422 of the United States Internal Revenue Code of 1986, as amended (the "Code"), or (ii) do not qualify as Section 422 Stock Options ("Non-Qualified Stock Options"). This Option is intended to be a Non-Qualified Stock Option.
Subject to the provisions of the Plan and the Employment Agreement (as defined below):
(a) |
the effective date of the grant of the Option is [enter date] ("Effective Date"); | |
(b) |
the Option expires at 5:00 p.m. (EST) on [expiry date]; and | |
(c) |
All unvested Options to purchase Shares granted herein shall vest [enter vesting schedule]. |
To exercise Options, the Optionee must follow the exercise procedures established by the Corporation, as described in Article 8 of the Plan, substantially in the form attached as Appendix "A". Options may be exercised only to the extent they are vested. Payment of the Option Price for the Options may be made as provided in Article 8 of the Plan. Upon exercise of the Options, the Optionee understands that the Corporation may be required to withhold taxes.
The Option and any Shares issued on the exercise of the Option may be subject to escrow requirements, resale restrictions and may be subject to and legended with a four month hold period commencing on the date the Option was granted pursuant to the rules of the TSX Venture Exchange (the "Exchange") and applicable securities laws.
This Certificate and the Option evidenced hereby is not assignable, transferable or negotiable and is subject to the detailed terms and conditions contained in the Plan, the terms and conditions of which the Optionee hereby expressly agrees with the Corporation to be bound by. This Certificate is issued for convenience only and in the case of any dispute with regard to any matter in respect hereof, the provisions of the Plan and the records of the Corporation shall prevail.
All terms not otherwise defined in this Certificate shall have the meanings given to them under the Plan.
Dated this __________ day of _____________, 2019.
THE FLOWR CORPORATION
Per:
__________________________
Authorized Signatory
APPENDIX "A" |
THE FLOWR CORPORATION |
STOCK OPTION PLAN |
EXERCISE NOTICE |
TO: | THE FLOWR CORPORATION (the "Corporation") |
1. The undersigned (the "Optionee"), being the holder of an option (the "Option") to purchase ________________ common shares of the Corporation (the "Shares") at the exercise price of ______ per Share, hereby irrevocably gives notice, pursuant to the stock option plan of the Corporation (the "Plan"), of the exercise of the Option to acquire and hereby subscribes for ____________ of such Shares.
2. The Optionee tenders herewith a certified cheque or bank draft payable to the Corporation in an amount equal to the aggregate Option Price of the aforesaid Option, as exercised, and directs the Corporation to issue a share certificate evidencing said Shares in the name of the Optionee to be mailed to the Optionee at the following address:
___________________________________
___________________________________
___________________________________
___________________________________
3. By executing this Exercise Notice, the Optionee hereby confirms that the undersigned has read the Plan and agrees to be bound by the provisions of the Plan. All terms not otherwise defined in this Exercise Notice shall have the meanings given to them under the Plan or the attached Option Certificate.
4. The Optionee is resident in __________________ [name of state/province].
5. The undersigned Optionee hereby represents, warrants, acknowledges and agrees that the certificate(s) representing the Shares may be subject to and legended with a four month hold period commencing on the date the Options were granted pursuant to the rules of the Exchange and applicable securities laws.
DATED the ________day of ____________________, __________.
Signature of Optionee |
APPENDIX "B" RESOLUTION TO APPROVE STOCK OPTION PLAN |
ORDINARY RESOLUTION OF THE SHAREHOLDERS OF |
THE FLOWR CORPORATION |
TO APPROVE THE STOCK OPTION PLAN |
BE IT RESOLVED AS AN ORDINARY RESOLUTION OF THE SHAREHOLDERS THAT:
1. |
the stock option plan, as amended (the "SOP") of The Flowr Corporation (the "Corporation"), attached as Appendix "A" to the Corporations management information circular dated May 9, 2019 (the "Circular"), be and the same is hereby approved; |
2. |
the maximum number of common shares reserved for issuance under the SOP shall not exceed, in the aggregate, 10% of the issued and outstanding (a) common shares of the Corporation and (b) class A preferred shares in the capital of The Flowr Canada Holdings ULC, a subsidiary of the Corporation (which are exchangeable for common shares of the Corporation at any time at the option of the holder) from time to time, provided that the board of directors of the Corporation shall have the right, from time to time, to increase such number of common shares of the Corporation subject to the approval of shareholders of the Corporation and such regulatory authorities, stock exchanges or over-the-counter markets having jurisdiction over the affairs of the Corporation. For purposes of clarity, the maximum number of common shares reserved and set aside for issue under the SOP and under Flowrs long-term incentive plan shall not exceed 20% of the common shares of the Corporation and Flowr Canada Holdings ULC class A preferred shares; |
3. |
the board of directors of the Corporation be authorized to revoke this resolution before it is acted upon without requiring further approval of the shareholders of the Corporation in that regard; |
4. |
future shareholder approval of the SOP will be required on or before the first anniversary of the date of approval of this resolution; and |
5. |
any one director or officer of the Corporation be and is hereby authorized and directed, for and on behalf of the Corporation, to perform all such acts and deeds and things and execute, under the corporate seal of the Corporation or otherwise, deliver and file all documents and instruments and take such other actions as such director or officer may determine to be necessary or desirable to implement this resolution and the matters authorized hereby, such determination to be conclusively evidenced by the execution and delivery of any such documents or instruments and the taking of any such actions. |
APPENDIX "C" LONG TERM INCENTIVE PLAN
THE FLOWR CORPORATION LONG TERM INCENTIVE PLAN
ARTICLE 1
1.1 |
Purpose, Plan Definitions and Interpretation | ||
1.1.1 |
The purpose of this Plan (as defined below) is to advance the interests of Flowr (as defined below): | ||
(a) |
through the motivation, attraction and retention of key employees and directors of Flowr; (b) by | ||
aligning the interests of Participants (as defined below) with the interests of the shareholders of Flowr generally; and (c) by furnishing Participants with an additional incentive in their efforts on behalf of Flowr. | |||
1.1.2 |
In this Plan, the following terms have the following meanings: | ||
(a) |
"Account" means a Deferred Share Unit Account or a Restricted Share Unit Account, as applicable; | ||
(b) |
"Applicable Law" includes, without limitation, all applicable securities, corporate, tax and other laws, rules, regulations, instruments, notices, blanket orders, decision documents, statements, circulars, procedures and policies including, without limitation, the policies, rules and by-laws of the Exchange; | ||
(c) |
"Applicable Withholding Taxes" means any and all taxes and other source deductions or other amounts which Flowr is required by Applicable Law to withhold from any amounts paid or credited to a Participant under the Plan; | ||
(d) |
"Award" means an award of Deferred Share Units and/or Restricted Share Units under this Plan; | ||
(e) |
"Award Agreement" means the agreement in writing between Flowr and a Participant evidencing the terms and conditions under which an Award has been granted under this Plan; | ||
(f) |
"Beneficiary" means, subject to Applicable Law, any person designated by a Participant to receive any amount payable under the Plan in the event of a Participants death or, failing designation, the Participants estate; | ||
(g) |
"Blackout Period" means the period during which the relevant Participant is prohibited from trading in any securities of Flowr due to trading restrictions imposed by Flowr in accordance with its securities trading policies; | ||
(h) |
"Board" means the board of directors of Flowr; | ||
(i) |
"Change of Control" means the occurrence of any one or more of the following events: | ||
(i) |
any merger, business combination, consolidation, amalgamation, arrangement or similar transaction in which voting securities of Flowr possessing more than fifty percent (50%) of the total combined voting power of Flowrs outstanding voting securities are transferred to a person or group of persons acting jointly or in concert different from the persons holding those securities immediately prior to such transaction; | ||
(ii) |
any acquisition, directly or indirectly, by a person or group of persons acting jointly or in concert of beneficial ownership of voting securities of Flowr possessing more than fifty percent (50%) of the total combined voting power of Flowrs outstanding securities; | ||
(iii) |
a transaction or event that results in the directors of Flowr immediately prior to such transaction or event ceasing to constitute a majority of the Board following such transaction or event; |
(iv) |
any sale, transfer or other disposition of all or substantially all of the assets of Flowr in one or a series of related transactions; | |
(v) |
a liquidation, dissolution or winding-up of Flowr; or | |
(vi) |
any transaction or series of transactions involving Flowr or any of its affiliates that the Board in its discretion deems to be a Change of Control; |
provided however, that a Change of Control shall not be deemed to have occurred if such Change of Control results solely from the issuance, in connection with a bona fide financing or series of financings by Flowr, of voting securities of Flowr or any rights or entitlements to acquire voting securities of Flowr which are convertible into or exchangeable for voting securities. Notwithstanding the foregoing, the determination of "Change of Control" under any employment agreement between a Participant and Flowr shall be determined and administered separately from this Plan; | ||
(j) |
"Compensation Committee" means the Human Resources and Compensation Committee or similar committee of the Board, and if no such committee is in place, the Audit Committee of the Board; | |
(k) |
"Consultant" has the meaning given to it in the policies of the Exchange; | |
(l) |
"Date of Grant" of a Unit means the date such Unit is granted to a Participant under the Plan, as evidenced by an Award Agreement between Flowr and the Participant; | |
(m) |
"Deferred Share Unit" or "DSU" means a unit designated as a "Deferred Share Unit" representing the right to receive one Share in accordance with the terms set forth in the Plan; | |
(n) |
"Deferred Share Unit Account" has the meaning set forth in Section 4.1.1; | |
(o) |
"Disability" means, in respect of any Participant, the Participants inability, due to debilitating physical incapacity, to substantially perform his or her duties and responsibilities as an employee or director of Flowr for 90 consecutive days or a total of 180 days in any consecutive 12 - month period; | |
(p) |
"DSU Final Payment Date" means, with respect to a Deferred Share Unit granted to a DSU | |
Participant, December 31 of the calendar year following the calendar year in which the DSU Termination Date occurred; | ||
(q) |
"DSU Gross Payment" has the meaning set forth in Section 4.3.2(b)(i); | |
(r) |
"DSU Participant" means a director of Flowr who has been designated by Flowr for participation in the Plan and who has agreed to participate in the Plan and to whom Deferred Share Units have or will be granted hereunder; | |
(s) |
"DSU Termination Date" of a DSU Participant means, the day that the DSU Participant ceases to be a director of Flowr for any reason including, without limiting the generality of the foregoing, as a result of Retirement, death, voluntary or involuntary termination without cause, or permanent disability; | |
(t) |
"DSU Whole Shares" has the meaning set forth in Section 4.3.2(c)(i); | |
(u) |
"Eligible Person" means an officer, director, employee or Consultant of Flowr or any of its subsidiaries; provided, however, that a Consultant shall not be an Eligible Person unless such Consultant is an individual that provides bona fide services to Flowr and such services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for Flowrs securities; |
2
(v) |
"Exchange" means the TSX Venture Exchange or, if the Shares are not then listed and posted for trading on the TSX Venture Exchange, on such stock exchange in Canada or the United States on which such Shares are listed and posted for trading as may be selected for such purpose by the Board; | |
(w) |
"Extension Period" has the meaning set forth in Section 3.2.2; | |
(x) |
"Fair Market Value" means, with respect to a Share on any date, the weighted average trading price of the Shares on the Exchange for the five days on which Shares were traded immediately preceding that date; provided that if the Shares are not listed for trading on a stock exchange on such date, the Fair Market Value shall be the price per Share as the Board, acting in good faith, may determine; | |
(y) |
"Flowr" or the "Corporation" means The Flowr Corporation and, where the context requires it, includes its subsidiaries, affiliates, successors and assigns; | |
(z) |
"Flowr ULC Shares" means the class A preferred shares in the capital of The Flowr Canada | |
Holdings ULC, a subsidiary of Flowr, exchangeable for common shares in the capital of Flowr at any time at the option of the holder; | ||
(aa) |
"Insider" has the meaning given to that term in the Securities Act (Ontario), as amended from time to time, and shall include associates and affiliates of the Insider; | |
(bb) |
"ITA" means the Income Tax Act (Canada), R.S.C. 1985, c.1 (5th Supp.), including the regulations promulgated thereunder, as amended from time to time; | |
(cc) |
"Leave of Absence" means any period during which, pursuant to the prior written approval of Flowr or by reason of Disability, the Participant is considered to be on an approved leave of absence or on Disability and does not provide any services to Flowr; | |
(dd) |
"Outstanding Issue" is determined on the basis of the number of Shares and Flowr ULC Shares that are outstanding immediately prior to the Share issuance in question; | |
(ee) |
"Participant" means an RSU Participant or a DSU Participant, as applicable; | |
(ff) |
"Participant Information" has the meaning set forth in Section 6.6.4(b); | |
(gg) |
"Plan" means this Long Term Incentive Plan, as the same may be amended or varied from time to time; | |
(hh) |
"Restricted Share Unit" or "RSU" means a unit designated as a "Restricted Share Unit" representing the right to receive one Share in accordance with the terms set forth in the Plan; | |
(ii) |
"Restricted Share Unit Account" has the meaning set forth in Section 3.1.1; | |
(jj) |
"Retirement" means the normal retirement of the Participant from employment with or from appointment as a director of Flowr or the early retirement of the Participant pursuant to any applicable retirement plan of Flowr, all as determined by the Board, acting reasonably; | |
(kk) |
"RSU Final Vesting Date" means, with respect to a Restricted Share Unit granted to an RSU Participant, December 31 of the calendar year which is three (3) years after the calendar year in which the service was performed in respect of which the particular Award was made; | |
(ll) |
"RSU Gross Payment" has the meaning set forth in Section 3.3.2(b)(i); | |
(mm) |
"RSU Participant" means an Eligible Person who has been designated by Flowr for participation in the Plan and who has agreed to participate in the Plan and to whom Restricted Share Units have or will be granted hereunder; |
3
(nn) |
"RSU Participant Termination Date" of an RSU Participant means, where the Participants employment with or service to Flowr has been terminated, the Participants last day of active employment with or service to Flowr, regardless of the reason for the termination of employment or termination of services; | |
(oo) |
"RSU Vesting Date" means, with respect to a Restricted Share Unit granted to an RSU Participant, the date determined in accordance with Section 3.2; | |
(pp) |
"RSU Whole Shares" has the meaning set forth in Section 3.3.2(c)(i); | |
(qq) |
"Share" means a common share in the capital of Flowr; | |
(rr) |
"United States" means the United States of America, its territories and possessions, any state of the United States and the District of Columbia; | |
(ss) |
"Units" means Deferred Share Units and/or Restricted Share Units, as applicable; | |
(tt) |
"U.S. Person" has the meaning set forth in Rule 902(k) of Regulation S under the U.S. Securities Act and generally includes, but is not limited to, any natural person resident in the United States, any partnership or corporation organized under the laws of the United States and any estate or trust of which any executor, administrator or trustee is a U.S. Person; | |
(uu) |
"U.S. Securities Act" means the United States Securities Act of 1933, as amended; | |
(vv) |
"U.S. Taxpayer" means a Participant whose Award(s) under the Plan is subject to Section 409A of the United States Internal Revenue Code of 1986, as amended; | |
(ww) |
"Vested Deferred Share Units" has the meaning set forth in Section 4.2.1; | |
(xx) |
"Vested Restricted Share Units" has the meaning set forth in Section 3.2.4; and | |
(yy) |
"Vested Units" mean Vested Deferred Share Units and/or Vested Restricted Share Units, as applicable. |
In this Plan, unless the context requires otherwise, words importing the singular number may be construed to extend to and include the plural number, and words importing the plural number may be construed to extend to and include the singular number.
ARTICLE 2
GRANT OF UNITS
2.1 |
Grant of Units | |
2.1.1 |
Subject to the terms of the Plan, the Board may make grants of Deferred Share Units to DSU Participants and Restricted Share Units to RSU Participants in such number, at such times and on such terms and conditions, as the Board may, in its sole discretion, determine and thereafter Flowr shall provide an Award Agreement to each Participant; provided that: | |
(a) |
The maximum number of Shares which may be reserved and set aside for issue under this Plan in respect of Awards of Deferred Share Units to DSU Participants and for payments in respect of Awards of Restricted Share Units to RSU Participants shall not exceed, in the aggregate, 10% of the Shares and Flowr ULC Shares (being 13,057,421 Shares of the Corporation), provided that the Board shall have the right, from time to time, to increase such number subject to the approval of shareholders of the Corporation and such regulatory authorities, stock exchanges or over-the- counter markets having jurisdiction over the affairs of the Corporation. For purposes of clarity, the maximum number of Shares reserved and set aside for issue under this Plan and under Flowrs stock option plan shall not exceed 20% of the Shares and Flowr ULC Shares; |
4
(b) |
Shares that were the subject of Awards that have expired, been surrendered, lapsed, cancelled or terminated shall thereupon no longer be in reserve and may once again be subject to an Award granted under this Plan; and | ||
(c) |
under no circumstances shall this Plan, together with all of Flowrs other previously established or proposed stock options, restricted share units, deferred share units, stock option plans, employee stock purchase plans or any other compensation or incentive mechanisms involving the issuance or potential issuance of Shares, result, at any time, in: | ||
(i) |
the number of Shares reserved for issuance to Insiders at any time exceeding 10% of the Outstanding Issue; | ||
(i) |
the issuance to Insiders, within a one year period, of a number of Shares exceeding 10% of the Outstanding Issue; or | ||
(ii) |
the issuance to any one Insider, within a one year period, of a number of Shares exceeding 5% of the Outstanding Issue. | ||
2.1.2 |
Awards that are Restricted Share Units may only be granted to RSU Participants and Awards that are Deferred Share Units may only be granted to DSU Participants; provided that the participation in the Plan is voluntary. In determining the Participants to whom Awards may be granted and the number of Restricted Share Units and Deferred Share Units to be awarded pursuant to each Award, the Board may (but is not required to) take into account the following factors, as applicable: | ||
(a) |
compensation data for comparable benchmark positions among Flowrs competitors or companies in comparable industries; | ||
(b) |
the duties and seniority of the Participant; | ||
(c) |
the performance of the Participant in the prior year relative to the performance measures of Flowr for the relevant performance period; | ||
(d) |
individual and/or departmental contributions and potential contributions to the success of Flowr; and | ||
(e) |
such other factors as the Board shall deem relevant in connection with accomplishing the purposes of the Plan. | ||
2.1.3 |
The Board may at any time appoint the Compensation Committee to, among other things, interpret, administer and implement this Plan on behalf of the Board in accordance with such terms and conditions as the Board may prescribe, consistent with this Plan. The Board will take such steps that in its opinion are required to ensure that the Compensation Committee has the necessary authority to fulfill its functions under this Plan. | ||
2.1.4 |
All grants of Deferred Share Units and Restricted Share Units under this Plan will be evidenced by Award Agreements. Any one executive officer of Flowr is authorized and empowered to execute and deliver, for and on behalf of Flowr, an Award Agreement to each Participant. | ||
2.2 |
Forfeited Units | ||
2.2.1 |
For greater certainty, no Participant shall have any entitlement to receive any payment (whether in cash, Shares or otherwise) in respect of any Units which have been forfeited under this Plan, by way of damages, payment in lieu or otherwise. |
5
ARTICLE 3
RESTRICTED SHARE UNITS
3.1 |
Restricted Share Unit Grants and Accounts | |
3.1.1 |
An Account, to be known as a "Restricted Share Unit Account", shall be maintained by Flowr for each | |
RSU Participant that has been granted Restricted Share Units. On each Date of Grant, the Restricted Share Unit Account will be credited with the Restricted Share Units granted to an RSU Participant on that date. | ||
3.1.2 |
The establishment of the Plan in respect of Restricted Share Units shall be an unfunded obligation of Flowr. Neither the establishment of the Plan in respect of Restricted Share Units nor the grant of any Restricted Share Units or the setting aside of any funds by Flowr (if, in its sole discretion, it chooses to do so) shall be deemed to create a trust. Legal and equitable title to any funds set aside for the purposes of the Plan in respect of Restricted Share Units shall remain in Flowr and no RSU Participant shall have any security or other interest in such funds. Any funds so set aside shall remain subject to the claims of creditors of Flowr present or future. Amounts payable to any RSU Participant under the Plan in respect of Restricted Share Units shall be a general, unsecured obligation of Flowr. The right of the RSU Participant or Beneficiary to receive payment pursuant to the Plan in respect of Restricted Share Units shall be no greater than the right of other unsecured creditors of Flowr. | |
3.2 |
Vesting | |
3.2.1 |
Subject to Sections 3.2.2 and 3.2.3 and unless otherwise set forth in the applicable Award Agreement that specifies a different vesting date or dates, a Restricted Share Unit granted under this Plan shall vest on the dates set forth below, and in either case, each such date is a "Scheduled Vesting Date": | |
(a) |
as to 331/3% of the Restricted Share Units with respect to such Award, on the first anniversary of the Date of Grant; | |
(b) |
as to 331/3% of the Restricted Share Units with respect to such Award, on the second anniversary of the Date of Grant; | |
(c) |
as to 331/3% of the Restricted Share Units with respect to such Award, on the third anniversary of the Date of Grant; provided; however, that all Restricted Share Units granted under a particular Award shall vest on or before the RSU Final Vesting Date for such Restricted Share Units. | |
3.2.2 |
Subject to Section 3.2.3, in the event that a Scheduled Vesting Date for a Restricted Share Unit granted under this Plan occurs within a Blackout Period or within five business days after a Blackout Period, the RSU Vesting Date for such Restricted Share Unit shall be ten business days after the date the Blackout | |
Period ends (the "Extension Period"); provided that if an additional Blackout Period is subsequently imposed by Flowr during the Extension Period, then such Extension Period shall be deemed to commence following the end of such additional Blackout Period to enable the RSU Vesting Date for such Restricted Share Unit to be ten business days after the end of the last imposed Blackout Period. | ||
3.2.3 |
If any Applicable Law, including any law in respect of a Blackout Period, would apply at any particular time to prevent payment in respect of a Restricted Share Unit pursuant to Section 3.3.1 to be made on or before the RSU Final Vesting Date for such Restricted Share Unit, then, subject to Applicable Law, the RSU Vesting Date for such Restricted Share Unit will be accelerated by the Board to ensure that such payment is made on or before the RSU Final Vesting Date for such Restricted Share Unit. | |
3.2.4 |
All Restricted Share Units recorded in an RSU Participants Restricted Share Unit Account which have vested in accordance with this Plan and which have not been forfeited hereunder by the Participant on the | |
RSU Participant Termination Date are referred to herein as "Vested Restricted Share Units". | ||
3.2.5 |
For greater certainty, no RSU Participant nor any Beneficiary or other person claiming through an RSU Participant shall be entitled to any benefit hereunder in respect of any Restricted Share Units that are not Vested Restricted Share Units. |
6
3.2.6 |
Notwithstanding anything else herein contained, Flowr may, in its discretion, at any time permit the acceleration of vesting of any or all Restricted Share Units, all in the manner and on the terms as may be authorized by the Board. | ||
3.3 |
Payment in Respect of Restricted Share Units | ||
3.3.1 |
Payment in respect of an Award of a Restricted Share Unit granted to an RSU Participant shall become payable on each RSU Vesting Date for such Restricted Share Unit in accordance with Section 3.3.2; provided, however that, unless otherwise provided under the applicable Award Agreement, all payments under a particular Award shall be made on or before the RSU Final Vesting Date for such Restricted Share Unit, and provided further that all payments under a particular Award of a U.S. Taxpayer shall me made on or before December 31st of the year in which the Scheduled Vesting Date (determined without regard to Section 3.2.2) occurs or, if later, by the date that is two and one-half (2 ½) months after such Scheduled Vesting Date. | ||
3.3.2 |
On each RSU Vesting Date in respect of an Award of Restricted Share Units granted to an RSU Participant: | ||
(a) |
Unless the decision has already been made in the Award Agreement, on the RSU Vesting Date, Flowr shall decide, in its sole discretion, to make all payments in respect of an Award of a Restricted Share Unit to an RSU Participant in cash, in Shares issued from treasury, or in a combination of cash and Shares issued from treasury, in the manner described in this Section 3.3.2; | ||
(b) |
where Flowr decides to make all payments in respect of an Award of a Restricted Share Unit to an RSU Participant in cash, Flowr shall pay to the RSU Participant a cash amount equal to the amount by which: | ||
(i) |
the product that results by multiplying: (A) the number of Restricted Share Units credited to the RSU Participants Restricted Share Unit Account as at the RSU Vesting Date that are Vested Restricted Share Units; by (B) the Fair Market Value of a Share on the RSU Vesting Date (such amount referred to as the "RSU Gross Payment"); exceeds | ||
(ii) |
all Applicable Withholding Taxes in respect of such payment; | ||
(c) |
where Flowr decides to make all payments in respect of an Award of a Restricted Share Unit to an RSU Participant in Shares issued from treasury, Flowr shall: | ||
(i) |
determine the number of whole Shares that the RSU Participant has the right to receive under such Award (the "RSU Whole Shares") as the quotient (rounded down to the nearest whole number) obtained by dividing: (A) the RSU Gross Payment; by (B) the Fair Market Value of a Share determined on the RSU Vesting Date; and | ||
(ii) |
subject to Section 3.3.2(e), on the RSU Vesting Date, or such other date as set out in the Award Agreement, issue that number of Shares from treasury that is equal to the number of RSU Whole Shares determined under Section 3.3.2(c)(i); | ||
(d) |
where Flowr decides to make payments in respect of an Award of a Restricted Share Unit to an RSU Participant in a combination of cash and Shares issued from treasury, Flowr shall: | ||
(i) |
issue from treasury a number of Shares not to exceed the number that would be issued if Section 3.3.2(c) applied; and | ||
(ii) |
pay to the RSU Participant a cash amount equal to the amount by which the RSU Gross Payment exceeds the aggregate Fair Market Value on the date of issuance of the Shares issued from treasury, net of any Applicable Withholding Taxes; and |
7
(e) |
where Flowr decides to make any payments in respect of an Award of a Restricted Share Unit to an RSU Participant in Shares issued from treasury, Flowr shall have the right to withhold, or to require the RSU Participant to remit to Flowr in advance of the issue of such Shares, an amount sufficient to satisfy any Applicable Withholding Taxes. For greater certainty, Flowr may decide in its sole discretion to satisfy any Applicable Withholding Taxes by withholding from the Shares otherwise deliverable to the RSU Participant such number of Shares having a value, determined as of the date that the withholding tax obligation arises, equal to the amount of the total withholding tax obligation. | |
3.3.3 |
In the event of the acceleration of an Award of Restricted Share Units pursuant to Section 5.2.1(d), the payment provisions of this Section 3.3 shall apply. | |
3.4 |
Dividends Paid on Shares | |
3.4.1 |
Subject to Section 3.4.2, in the event Flowr pays a dividend on the Shares subsequent to the granting of an Award, the number of Restricted Share Units relating to such Award (that are not Vested Restricted Share Units) (the "Original RSU") shall be increased by an amount equal to: | |
(a) |
the product of: (i) the aggregate number of Original RSUs held by the RSU Participant on the record date for such dividend; and (ii) the per Share amount of such dividend (or, in the case of any dividend payable in property other than cash, the per Share fair market value of such property as determined by the Board), divided by | |
(b) |
the Fair Market Value of a Share calculated as of the date that is three days prior to the record date for the dividend. | |
3.4.2 |
In the event that Flowr pays a dividend on the Shares in additional Shares, the number of Original RSUs shall be increased by a number equal to the product of: (a) the aggregate number of Original RSUs held by the RSU Participant on the record date of such dividend; and (b) the number of Shares (including any fraction thereof) payable as a dividend on one Share, and in such circumstance the Participants Restricted Share Unit Account shall be credited to reflect such increase. | |
3.4.3 |
Additional RSUs credited pursuant to this Section 3.4 will become vested and will be settled and paid out at the same time as the underlying Original RSUs to which they relate. | |
3.5 |
Termination of Employment or Leave of Absence | |
3.5.1 |
Subject to Section 3.2.1 and the provisions of any applicable Award Agreement, upon the RSU Participant ceasing to be an Eligible Person due to involuntary termination with cause or voluntary termination by the | |
RSU Participant, all Restricted Share Units previously credited to such RSU Participants Restricted Share | ||
Unit Account which did not become Vested Restricted Share Units on or prior to the RSU Participant Termination Date shall be terminated and forfeited as of the RSU Participant Termination Date. | ||
3.5.2 |
Upon the RSU Participant ceasing to be an Eligible Person by reason of involuntary termination without cause, death, total or permanent long-term disability (as reasonably determined by the Board) or Retirement of the RSU Participant, any Restricted Share Units previously credited to such RSU Participants Restricted | |
Share Unit Account which did not become Vested Restricted Share Units on or prior to the RSU Participant Termination Date, shall continue to vest in accordance with their terms and pursuant to Section 3.2.1 or, at the sole discretion of the Board, be terminated and forfeited as of the RSU Participant Termination Date. | ||
3.5.3 |
Upon an RSU Participant commencing a Leave of Absence, unless otherwise determined by the Board in its sole discretion, any Restricted Share Units previously credited to such RSU Participants Restricted Share Unit Account shall continue to vest in accordance with their terms pursuant to Section 3.2.1. | |
3.5.4 |
If the relationship of the RSU Participant with Flowr is terminated for any reason prior to the vesting of the Restricted Share Units, whether or not such termination is with or without notice, adequate notice or legal notice or is with or without legal or just cause, the RSU Participants rights shall be strictly limited to those provided for in this Section 3.5, or as otherwise provided in the applicable Award Agreement between the RSU Participant and Flowr. Unless otherwise specifically agreed to in writing by Flowr, the RSU Participant shall have no claim to, or in respect of, any Restricted Share Units which may have or would have vested had due notice of termination of employment been given, nor shall the RSU Participant have any entitlement to damages or other compensation or any claim for wrongful termination or dismissal in respect of any Restricted Share Units or loss of profit or opportunity which may have or would have vested or accrued to the RSU Participant if such wrongful termination or dismissal had not occurred or if due notice of termination had been given. This provision shall be without prejudice to the RSU Participants rights to seek compensation for lost employment income or lost employment benefits (other than those accruing under or in respect of the Plan and any Restricted Share Units) in the event of any alleged wrongful termination or dismissal. |
8
ARTICLE 4
DEFERRED SHARE UNITS
4.1 |
Deferred Share Unit Grants and Accounts |
4.1.1 |
An Account, to be known as a "Deferred Share Unit Account", shall be maintained by Flowr for each DSU Participant that has been granted Deferred Share Units. On each Date of Grant, the Deferred Share Unit Account will be credited with the Deferred Share Units granted to a DSU Participant on that date. |
4.1.2 |
The establishment of the Plan in respect of Deferred Share Units shall be an unfunded obligation of Flowr. Neither the establishment of the Plan in respect of Deferred Share Units nor the grant of any Deferred Share Units or the setting aside of any funds by Flowr (if, in its sole discretion, it chooses to do so) shall be deemed to create a trust. Legal and equitable title to any funds set aside for the purposes of the Plan in respect of Deferred Share Units shall remain in Flowr and no DSU Participant shall have any security or other interest in such funds. Any funds so set aside shall remain subject to the claims of creditors of Flowr present or future. Amounts payable to any DSU Participant under the Plan in respect of Deferred Share Units shall be a general, unsecured obligation of Flowr. The right of the DSU Participant or Beneficiary to receive payment pursuant to the Plan in respect of Deferred Share Units shall be no greater than the right of other unsecured creditors of Flowr. |
4.2 |
Vesting |
4.2.1 |
All Deferred Share Units recorded in a DSU Participants Deferred Share Unit Account shall vest on the DSU Participants DSU Termination Date and shall be referred to herein as "Vested Deferred Share Units" as of that date, unless otherwise determined by the Board in its sole discretion. |
4.2.2 |
DSU Participants will not have any right to receive any benefit under the Plan in respect of a Deferred Share Unit until the DSU Termination Date. |
4.3 |
Payment in Respect of Deferred Share Units |
4.3.1 |
Payment in respect of an Award of a Deferred Share Unit granted to a DSU Participant shall become payable on the DSU Termination Date of the DSU Participant in the amount and in the manner referred to in Section 4.3.2. All payments to be made by Flowr in respect of a Deferred Share Unit in Shares issued from treasury shall occur on the DSU Termination Date and all payments to be made by Flowr in respect of a Deferred Share Unit in cash shall occur on or before the DSU Final Payment Date for such Deferred Share Unit. Notwithstanding the foregoing, any payment in respect to an award of a Deferred Share Unit granted to a U.S. Taxpayer shall be paid as soon as practicable following the DSU Termination Date in accordance with Schedule A hereto, but in no case later than December 31st of the year in which such DSU Termination Date occurs, or if later the date that is two and one-half (2 ½) months after such DSU Termination Date. |
4.3.2 |
On the DSU Termination Date in respect of an Award of Deferred Share Units granted to a DSU Participant: |
9
(a) |
Flowr shall decide, in its sole discretion, to make all payments in respect of an Award of a Deferred Share Unit to a DSU Participant in cash, in Shares issued from treasury, or in a combination of cash and Shares issued from treasury, in the manner described in this Section 4.3.2; | ||
(b) |
where Flowr decides to make all payments in respect of an Award of a Deferred Share Unit to a DSU Participant in cash, Flowr shall pay to the DSU Participant a cash amount equal to the amount by which: | ||
(i) |
the product that results by multiplying: (A) the number of Deferred Share Units credited to the DSU Participants Deferred Share Unit Account as at the DSU Termination Date that are Vested Deferred Share Units; by (B) the Fair Market Value of a Share on the | ||
DSU Termination Date (such amount referred to as the "DSU Gross Payment"); exceeds | |||
(ii) |
all Applicable Withholding Taxes in respect of such payment; | ||
(c) |
where Flowr decides to make all payments in respect of an Award of a Deferred Share Unit to a DSU Participant in Shares issued from treasury, Flowr shall: | ||
(i) |
determine the number of whole Shares that the DSU Participant has the right to receive under such Award (the "DSU Whole Shares") as the quotient (rounded down to the nearest whole number) obtained by dividing: (A) the DSU Gross Payment; by (B) the Fair Market Value of a Share determined on DSU Termination Date; and | ||
(ii) |
subject to Section 4.3.2(e), issue that number of Shares from treasury that is equal to the number of DSU Whole Shares determined under Section 4.3.2(c)(i); | ||
(d) |
where Flowr decides to make payments in respect of an Award of a Deferred Share Unit to a DSU Participant in a combination of cash and Shares issued from treasury, Flowr shall: | ||
(i) |
issue from treasury a number of Shares not to exceed the number that would be issued if Section 4.3.2(c) applied; and | ||
(ii) |
pay to the DSU Participant a cash amount equal to the amount by which the DSU Gross Payment exceeds the aggregate Fair Market Value on the date of issuance of the Shares issued from treasury, net of any Applicable Withholding Taxes; and | ||
(e) |
where Flowr decides to make any payments in respect of an Award of a Deferred Share Unit to a DSU Participant in Shares issued from treasury, Flowr shall have the right to withhold, or to require the DSU Participant to remit to Flowr in advance of the issuance of such Shares, an amount sufficient to satisfy any Applicable Withholding Taxes. For greater certainty, Flowr may decide in its sole discretion to satisfy any Applicable Withholding Taxes by withholding from the Shares otherwise deliverable to the DSU Participant such number of Shares having a value, determined as of the date that the withholding tax obligation arises, equal to the amount of the total withholding tax obligation. | ||
4.3.3 |
In the event of the acceleration of an Award of Deferred Share Units pursuant to Section 5.2.1(d), the payment provisions of this Section 4.3 shall apply. | ||
4.3.4 |
For greater certainty, no amount will be paid to, or in respect of, a DSU Participant under the Plan or pursuant to any other arrangement, and no other Deferred Share Units will be granted to such DSU Participant to compensate for a reduction in the fair market value of a Share, nor will any other form of benefit be conferred upon, or in respect of, a DSU Participant for such purpose. |
10
4.4 |
Dividends Paid on Shares | |
4.4.1 |
Subject to Section 4.4.2, in the event Flowr pays a dividend on the Shares subsequent to the granting of an Award, the number of Deferred Share Units relating to such Award (that are not Vested Deferred Share Units) (the "Original DSU") shall be increased by an amount equal to: | |
(a) |
the product of: (i) the aggregate number of Original DSUs held by the DSU Participant on the record date for such dividend; and : (ii) the per Share amount of such dividend (or, in the case of any dividend payable in property other than cash, the per Share fair market value of such property as determined by the Board); divided by | |
(b) |
the Fair Market Value of a Share calculated as of the date that is three days prior to the record date for the dividend. | |
(c) |
Additional DSUs credited pursuant to this Section 4.4 will be settled and paid out at the same time as the underlying Original DSUs to which they relate. | |
4.4.2 |
In the event that Flowr pays a dividend on the Shares in additional Shares, the number of Original DSUs shall be increased by a number equal to the product of: (a) the aggregate number of Original DSUs held by the DSU Participant on the record date of such dividend; and (b) the number of Shares (including any fraction thereof) payable as a dividend on one Share, and in such circumstance the Participants Deferred | |
Share Unit Account shall be credited to reflect such increase. |
ARTICLE 5
ADJUSTMENTS AND CHANGE OF
CONTROL
5.1 |
Adjustments | |
5.1.1 |
Appropriate adjustments to this Plan and to Awards shall be made, and shall be conclusively determined, by the Board to give effect to adjustments in the number of Shares resulting from subdivisions, consolidations, substitutions, reorganizations or reclassifications of the Shares, or changes in the capital of Flowr (including any such changes resulting from a Change of Control). Any dispute that arises at any time with respect to any such adjustment will be conclusively determined by the Board, and any such determination will be binding on Flowr, the Participant and all other affected parties. | |
5.2 |
Change of Control | |
5.2.1 |
In the event of a Change of Control or proposed Change of Control: | |
(a) |
the Board shall, in an appropriate and equitable manner, determine any adjustment to the number and type of Shares (or other securities or other property) that thereafter shall be made the subject of and issuable as payment under Awards; | |
(b) |
the Board shall, in an appropriate and equitable manner, determine the number and type of Shares (or other securities or other property) subject to and issuable as payment under outstanding Awards; | |
(c) |
the Board shall, in an appropriate and equitable manner, determine the acquisition price with respect to settlement or payment of any Award; provided, however, that the number of Shares covered by any Award or to which such Award relates shall always be a whole number; | |
(d) |
the Board shall, in its sole discretion, determine the manner in which all unvested Awards granted under this Plan will be treated including, without limitation, requiring the acceleration of the time for the vesting of such Awards by the Participants and the time for the expiry of such Awards; | |
(e) |
the Board or any company which is or would be the successor to Flowr or which may issue securities in exchange for Shares upon the occurrence of a Change of Control may offer any Participant the opportunity to obtain a new or replacement award for securities into which the Shares are changed or are convertible or exchangeable, on a basis proportionate to the number of Shares issuable under the Award (and otherwise substantially upon the terms of the Award being replaced, or upon terms no less favourable to the Participant) including, without limitation, the periods during which the Award may be exercised and expiry dates; and in such event, the Participant shall, if he or she accepts such offer, be deemed to have released his or her Award and such Award shall be deemed to have lapsed and be cancelled; and |
11
(f) |
the Board may convert or exchange for or into any other security or any other property or cash, any Award that is still capable of being exercised, upon giving to the Participant to whom such Award has been granted at least 30 days written notice of its intention to convert or exchange such Award, and during such period of notice, the Award, to the extent it has not been exercised, may be exercised by the Participant without regard to any vesting conditions attached thereto, and on the expiry of such period of notice, the unexercised portion of the Award shall lapse and be cancelled. |
Subsections (a) through (f) of this Section 5.2.1 may be utilized independently of, successively with, or in combination with each other and Section 5.1.1 and nothing therein contained shall be construed as limiting or affecting the ability of the Board to deal with Awards in any other manner. All determinations by the Board under this Article 5 will be final, binding and conclusive for all purposes. | |
5.2.2 |
The Board may, in its sole discretion, cancel any or all outstanding Awards and pay to the holders of any such Awards, in cash, the value of such Awards based upon the price per Share received or to be received by other shareholders of Flowr in the event of a Change of Control. |
5.2.3 |
The grant of any Awards under this Plan will in no way affect Flowrs right to adjust, reclassify, reorganize or otherwise change or exchange its capital or change its business structure, to complete a Change of Control or to merge, amalgamate, reorganize, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets or engage in any like transaction. |
5.2.4 |
No adjustment or substitution provided for in this Article 5 will require Flowr to issue a fractional share in respect of any Awards and the total substitution or adjustment with respect to each Award will be limited accordingly. |
ARTICLE 6
ADMINISTRATION
6.1 |
Administration |
6.1.1 |
The Plan shall be administered by Flowr in accordance with the provisions hereof. All costs and expenses of administering the Plan will be paid by Flowr. Flowr may, from time to time, establish administrative rules and regulations and prescribe forms or documents relating to the operation of the Plan as it may deem necessary to implement or further the purpose of the Plan and amend or repeal such rules and regulations or forms or documents. In administering the Plan, the Board or the Compensation Committee may seek recommendations from the Chairman, Chief Executive Officer or Chief Financial Officer of Flowr or such other advisors as they deem appropriate. The Board may also delegate to the Compensation Committee or any director, officer or employee of Flowr such duties and powers relating to the Plan as it may see fit. Flowr may also appoint or engage a trustee, custodian or administrator to administer or implement the Plan. |
6.1.2 |
Flowr shall keep or cause to be kept such records and accounts as may be necessary or appropriate in connection with the administration of the Plan and the discharge of its duties. At such times as Flowr shall determine, Flowr shall furnish the Participant with a statement setting forth the details of his or her Units including Date of Grant and the Vested Units held by each Participant. |
6.1.3 |
(a) Any notice, statement, certificate or other instrument required or permitted to be given to a Participant or any person claiming or deriving any rights through him or her shall be given by: |
12
(i) |
delivering it personally to the Participant or to the person claiming or deriving rights through him or her, as the case may be; | |
(ii) |
other than in the case of a delivery of Shares, sending it to the Participant via facsimile or similar means of electronic transmission to the facsimile or e-mail address which is maintained for the Participant in Flowrs personnel records; or | |
(iii) |
mailing it postage paid (provided that the postal service is then in operation) or delivering it to the address which is maintained for the Participant in Flowrs personnel records. |
(b) |
Any notice, statement, certificate or other instrument required or permitted to be given to Flowr shall be given by mailing it postage paid (provided that the postal service is then in operation), delivering it to Flowr at its principal address, or (other than in the case of a payment) sending it by means of facsimile or similar means of electronic transmission, to the attention of the Chief Financial Officer of Flowr. | |
(c) |
Any notice, statement, certificate or other instrument referred to in Section 6.1.3(a) or 6.1.3(b), if delivered, shall be deemed to have been given or delivered on the date on which it was delivered, if mailed (provided that the postal service is then in operation), shall be deemed to have been given or delivered on the third business day following the date on which it was mailed and if by facsimile or similar means of electronic transmission, on the next business day following transmission. |
6.2 |
Amendments |
6.2.1 |
Flowr retains the right without shareholder approval to: |
(a) |
amend the Plan or any Restricted Share Units or Deferred Share Units from time to time to | ||
(i) |
make amendments of a grammatical, typographical, clerical and administrative nature and any amendments required by a regulatory authority or to comply or conform with Applicable Laws, | ||
(ii) |
change vesting provisions of the Plan or any Restricted Share Units or Deferred Share Units, | ||
(iii) |
make any other amendments of a non-material nature, (iv) make amendments to the definition | ||
of "DSU Participant" and/or "RSU Participant" or the eligibility requirements of participating in this Plan, where such amendment would not have the potential of broadening or increasing Insider participation, (v) make amendments to the manner in which Participants may elect to participate in the Plan, (vi) make any amendments to the provisions concerning the effect of the termination of a Participants employment or services on such Participants status under this Plan, or (vii) make any amendment which is intended to facilitate the administration of this Plan; or | |||
(b) |
suspend, terminate or discontinue the terms and conditions of the Plan and the Restricted Share Units and Deferred Share Units granted hereunder by resolution of the Board, provided that: | ||
(i) |
no such amendment to the Plan shall cause the Plan in respect of Restricted Share Units to cease to be a plan described in paragraph (k) of the definition of "salary deferral arrangement" in subsection 248(1) of the ITA or any successor to such provision; | ||
(ii) |
no such amendment to the Plan shall cause the Plan in respect of Deferred Share Units to cease to be a plan described in regulation 6801(d) of the ITA or any successor to such provision; and | ||
(iii) |
any amendment shall be subject to the prior consent of any applicable regulatory bodies, including the Exchange, as may be required. |
6.2.2 |
Any amendment to the Plan made in accordance with Section 6.2.1(a)(ii) or 6.2.1(b) shall take effect only with respect to Awards granted after the effective date of such amendment, provided that it may apply to any outstanding Award with the mutual consent of Flowr and the Participants to whom such Awards have been granted. |
13
6.2.3 |
Any amendment to the Plan other than as described in Section 6.2.1 shall require the approval of the shareholders of Flowr given by the affirmative vote of a simple majority of the common shares (or, where required, "disinterested" shareholder approval) represented at a meeting of the shareholders of Flowr at which a motion to approve the Plan or an amendment to the Plan is presented. Specific amendments requiring shareholder approval include: | |
(a) |
to increase the number of Shares reserved under the Plan; | |
(b) |
to change the definition of RSU Participants or DSU Participants or the eligibility requirements of participating in this Plan, where such amendment would have the potential of broadening or increasing Insider participation; | |
(c) |
the extension of any right of a Participant under this Plan beyond the date on which such right would originally have expired; | |
(d) |
to permit RSUs or DSUs to be transferred other than by testamentary disposition or in accordance with the laws governing the devolution of property in the event of death; | |
(e) |
to permit awards other than RSUs and DSUs under the Plan; and | |
(f) |
to amend this Section 6.2.3 so as to increase the ability of the Board to amend the Plan without shareholder approval. | |
6.3 |
Currency | |
6.3.1 |
All payments and benefits under the Plan shall be determined and paid in the lawful currency of Canada. | |
6.4 |
Beneficiaries and Claims for Benefits | |
6.4.1 |
Subject to the requirements of Applicable Law, a Participant shall designate in writing a Beneficiary to receive any benefits that are payable under the Plan upon the death of such Participant. The Participant may, subject to Applicable Law, change such designation from time to time. Such designation or change shall be in such form and executed and filed in such manner as the Board may from time to time determine | |
6.5 |
Representations and Covenants of Participants | |
6.5.1 |
Each Award Agreement will contain representations and covenants of the Participant that: | |
(a) |
in respect of an RSU Participant, the RSU Participant is an Eligible Person; | |
(b) |
in respect of a DSU Participant, the DSU Participant is a director; | |
(c) |
the Participant has not been induced to enter into such Award Agreement by the expectation of employment or continued employment or appointment or continued appointment with Flowr; | |
(d) |
the Participant is aware that the grant of the Award is exempt from the obligation under applicable Canadian securities laws to file a prospectus qualifying the distribution of the Shares to be distributed thereunder under any applicable Canadian securities laws and that any Shares issued under the Plan or an Award may contain required restrictive legends; and | |
(e) |
upon vesting of an Award which is settled in Shares, the Participant or their legal representative, as the case may be, will prior to and upon any sale or disposition of any Shares received pursuant to an Award, comply with all Applicable Law. | |
6.6 |
General | |
6.6.1 |
The transfer of an employee among Flowr and its subsidiaries shall not be considered a termination of employment for the purposes of the Plan, so long as such Participant continues to be an Eligible Person. |
14
6.6.2 |
The determination by the Board of any question which may arise as to the interpretation or implementation of the Plan or any of the Units granted hereunder shall be final and binding on all Participants and other persons claiming or deriving rights through any of them. | |
6.6.3 |
The Plan shall enure to the benefit of and be binding upon Flowr and its successors and assigns. The interest of any Participant under the Plan in any Unit shall not be transferable or alienable by the Participant either by pledge, assignment or in any other manner whatsoever, otherwise than by testamentary disposition or in accordance with the laws governing the devolution of property in the event of death; and after the Participants lifetime shall enure to the benefit of and be binding upon the Participants Beneficiary. | |
6.6.4 |
(a) |
Flowrs grant of any Units hereunder is subject to compliance with Applicable Law. |
(b) |
As a condition of participating in the Plan, each Participant agrees to comply with all such Applicable Law and agrees to furnish to Flowr all information and undertakings as may be required to permit compliance with such Applicable Law. Each Participant shall provide the Board with all information (including personal information) the Board requires in order to administer the | |
Plan (the "Participant Information"). | ||
(c) |
Flowr may, without amending the Plan, modify the terms of Restricted Share Units and Deferred Share Units granted to Participants who provide services to Flowr from outside of Canada in order to comply with the Applicable Law of such foreign jurisdictions. Any such modification to the terms of Restricted Share Units or Deferred Share Units with respect to a particular Participant shall be reflected in the Award Agreement for such Participant. | |
(d) |
The terms of the Plan and Restricted Share Units and Deferred Share Units granted hereunder to Participants subject to taxation on employment income under the United States Internal Revenue Code of 1986, as amended, shall be determined by taking into consideration the provisions applicable to such persons as set forth in Schedule "A" hereto. | |
(e) |
The Board may from time to time transfer or provide access to Participant Information to a third party service provider for purposes of the administration of the Plan provided that such service providers will be provided with such information for the sole purpose of providing services to the Board in connection with the operation and administration of the Plan. The Board may also transfer and provide access to Participant Information to Flowr for purposes of preparing financial statements or other necessary reports and public filings and facilitating payment or reimbursement of Plan expenses. By participating in the Plan, each Participant acknowledges that Participant Information may be so provided and agrees and consents to its provision on the terms set forth herein. Flowr shall not disclose Participant Information except (i) as contemplated above in this Section 6.6.4(e) and in Section 6.6.8, (ii) in response to regulatory filings or other requirements for the information by a governmental authority or regulatory body, or (iii) for the purpose of complying with a subpoena, warrant or other order by a court, person or body having jurisdiction over Flowr to compel production of the information. | |
6.6.5 |
Nothing herein or otherwise shall be construed so as to confer on any Participant any rights as a shareholder of Flowr with respect to any Shares reserved for the purpose of any Award, including for greater certainty, no Award shall confer any entitlement as to dividends (except as set forth herein) or voting rights on a Participant. | |
6.6.6 |
Neither designation as a Participant nor the grant of any Units to any Participant entitles any Participant to any additional grant of any Units under the Plan. Neither the Plan nor any action taken hereunder shall interfere with the right of Flowr to terminate a Participants employment, if applicable, at any time. Neither any period of notice, if any, nor any payment in lieu thereof, upon termination of employment shall be considered as extending the period of employment for the purposes of the Plan. | |
6.6.7 |
Participation in the Plan shall be entirely voluntary and any decision not to participate shall not affect any persons relationship with Flowr. |
15
6.6.8 |
By participating in the Plan, the Participant agrees, acknowledges and consents to: | |
(a) |
the disclosure to Flowr and applicable directors, officers, employees, consultants, representatives and agents of Flowr, the Exchange and all tax, securities and other regulatory authorities of all Participant Information; and | |
(b) |
the collection, use and disclosure of such personal information by the persons described in (a) above of all Participant Information in accordance with their requirements, including the provision to third party service providers, from time to time. | |
6.6.9 |
Nothing contained in this Plan will restrict or limit or be deemed to restrict or limit the right or power of the Board in connection with any allotment and issuance of Shares which are not allotted and issued under this Plan including, without limitation, with respect to other compensation or incentive arrangements. | |
6.6.10 |
This Plan is established under the laws of the Province of Ontario and the rights of all parties and the construction of each and every provision of the Plan and any Units granted hereunder shall be construed according to the laws of the Province of Ontario. |
ARTICLE 7
UNITED STATES SECURITIES LAWS
7.1.1 |
Units shall not be granted under the Plan, and Shares shall not be issued with respect to such Units, unless the grant of the Units or the issuance of such Shares, respectively, shall comply with all relevant provisions of law, including, without limitation, any applicable state securities laws, the U.S. Securities Act, the rules and regulations thereunder and the requirements of any stock exchange or market upon which the Shares may then be listed or quoted. Any such issuance of Shares shall be further subject to the approval of counsel for Flowr with respect to such compliance, including the availability of an exemption from registration for the issuance and sale of such Shares. The inability of Flowr to obtain from any regulatory body the authority deemed by Flowr to be necessary for the lawful issuance and sale of any Shares under the Plan, or the unavailability of an exemption from registration for the issuance and sale of any Shares under the Plan, shall relieve Flowr of any liability with respect to the non-issuance or sale of such Shares. |
7.1.2 |
If the Shares issuable upon vesting of Units have not been registered under the U.S. Securities Act, as a condition to the grant of the Units and the issuance of such Shares, Flowr may require the Participant to represent and warrant in writing that the Units and Shares are being purchased only for investment and without any then present intention to sell or distribute such Units or Shares. At the option of Flowr, a stop - transfer order against such Shares may be placed on the shareholder register and records of Flowr, and a legend indicating that the Shares may not be pledged, sold or otherwise transferred unless an opinion of counsel is provided stating that such transfer is not in violation of any applicable law or regulation, may be stamped on the certificates representing such Shares in order to assure an exemption from registration. Flowr also may require such other documentation as may from time to time be necessary to comply with federal and state securities laws. Flowr has no obligation to undertake registration of Units or Shares to be issued under the Plan. |
16
Schedule A
Special Provisions Applicable to Participants Subject to Section 409A of the United States Internal Revenue Code
This schedule sets forth special provisions of the Plan that apply to Participants subject to section 409A of the United States Internal Revenue Code of 1986, as amended. Terms defined in the Plan and used herein shall have the meanings set forth in the Plan, as amended from time to time.
1. |
Definitions | |
1.1 |
In this Schedule, the following terms have the following meanings: | |
(a) |
"Code" means the United States Internal Revenue Code of 1986, as amended, and any applicable United States Treasury Regulations and other binding regulatory guidance thereunder; | |
(b) |
"Section 409A" means section 409A of the Code; | |
(c) |
"Separation From Service" shall mean the separation from service with Flowr within the meaning of U.S. Treas. Regs. § 1.409A-1(h). Whether a Separation From Service has occurred with respect to an employee of Flowr is determined based on whether the facts and circumstances indicate that Flowr and the Participant reasonably anticipated that no further services would be performed after a certain date or that the level of bona fide services the Participant would perform after such date (whether as an employee or independent contractor) would permanently decrease to no more than twenty percent (20%) of the average level of bona fide services performed (whether as an employee or an independent contractor) over the immediately preceding thirty six (36) month period (or the full period of services to Flowr if the Participant has been providing services to Flowr less than thirty six (36) months)). Separation from service shall not be deemed to occur while the Participant is on military leave, sick leave or other bona fide leave of absence if the period does not exceed six (6) months or, if longer, so long as the Participant retains a right to reemployment with Flowr under an applicable statute or by contract. For this purpose, a leave is bona fide only if, and so long as, there is a reasonable expectation that the Participant will return to perform services for Flowr. Notwithstanding the foregoing, a twenty-nine (29) month period of absence will be substituted for such six (6) month period if the leave is due to any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of no less than twelve (12) months and that causes the Participant to be unable to perform the duties of his or her position of employment. For this purpose, "Flowr" includes all entities that would be considered a single employer for purposes of U.S. Treasury Regulations; provided that, in applying those regulations, the language "at least 50 percent" shall be used instead of "at least 80 percent" each place it appears therein. Whether a Separation from Service has occurred with respect to a consultant (independent contractor) or a Director will be determined pursuant to of U.S. Treas. Regs. § 1.409A-1(h) and other applicable IRS guidance. In some instances a director may have a Separation From Service upon resignation as a director even if the director then becomes an officer or employee of Flowr; | |
(d) |
"Specified Employee" means a US Taxpayer who meets the definition of "specified employee" as defined in Section 409A(a)(2)(B)(i) of the Code; and | |
2. |
Compliance with Section 409A | |
2.1 |
Notwithstanding any provision of the Plan to the contrary, it is intended that any payments under the Plan either be exempt from or comply with Section 409A, and all provisions of the Plan shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. Each payment made in respect of Restricted Share Units and Deferred Share Units shall be deemed to be a separate payment for purposes of Section 409A. Each US Taxpayer is solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on or for the account of such US Taxpayer in connection with the Plan (including any taxes and penalties under Section 409A), and neither Flowr nor any of its subsidiaries shall have any obligation to indemnify or otherwise hold such US Taxpayer (or any beneficiary) harmless from any or all of such taxes or penalties. |
17
2.2 |
Solely to the extent required by Section 409A, any payment which is subject to Section 409A shall comply with the following: | |
(a) |
if a U.S. Taxpayer experiences a Separation from Service, such event will be treated as a DSU Termination Date and an RSU Participant Termination Date, as applicable, for purposes of payment Awards under the Plan. A payment which becomes payable on account of a DSU Termination Date or an RSU Participant Termination Date (for any reason, whether or not such termination is voluntary or involuntary, with or without notice, adequate notice or legal notice or is with or without legal or just cause or on account of Retirement, death or permanent disability) shall be payable by reason of such circumstance only if the circumstance is a Separation From Service. Generally, payments that become payable on account of a DSU Termination Date or an RSU Participant Termination Date (i.e. upon a U.S. Taxpayers Separation from Service) will be paid as soon as administratively feasible following such Separation from Service, but in any case by December 31st of the year in which such Separation from Service occurs, or, if later, the date that is two and one-half (2 ½) months after such Separation from Service, provided that if such payment has become payable on account of a Separation From Service of a U.S. Taxpayer who is determined to be a Specified Employee, such payment shall not be paid before the date which is six months after such Specified Employees Separation From Service (or, if earlier, the date of death of such Specified Employee). Following any applicable six month delay of payment, all such delayed payments shall be made to the Specified Employee in a lump sum on the earliest possible payment date; | |
(b) |
a payment which becomes payable on account of a Change of Control shall not be payable by reason of such circumstance unless the circumstance is a "change in ownership," change in effective control," or "change in ownership of a substantial portion of assets" as defined under Section 409A (hereinafter, a "409A Change of Control"); and | |
(c) |
Notwithstanding anything to the contrary in the Plan, including but not limited to Sections 3.2.6 and 5.2.1, a payment which is scheduled to become payable on account of an RSU Scheduled Vesting Date or other specified date shall not be accelerated on account of accelerated vesting or other intervening payment event unless such event itself qualifies as a Separation From Service, a 409A Change of Control or other payment event expressly permitted under Section 409A. | |
(d) |
Notwithstanding Article 5, Section 6.2 and any other provisions of the Plan, any adjustment or amendment of an outstanding Award, any acceleration of the time of payment with respect to an Award, any substitution of another award for an outstanding Award, and any termination of the Plan or an outstanding Award, will be available and will be undertaken only to the extent permitted under Section 409A. | |
(e) |
Section 6.6.1 of the Plan shall not apply to U.S. Taxpayers, and instead the following will apply. The transfer of an employee among Flowr and its subsidiaries or related entities shall not be considered a termination of employment for purposes of the Plan unless such transfer results in a termination of employment with all entities that would be considered a single employer for purposes of U.S. Treasury Regulations and thus results in a Separation from Service. | |
2.3 |
A US Taxpayer shall be required to pay to Flowr, and Flowr shall have the right and is hereby authorized to withhold, from any cash or other compensation payable under the Plan, or from any other compensation or amounts owing to the US Taxpayer, the amount of any required Applicable Withholding Taxes in respect of amounts paid under the Plan and to take such other action as may be necessary in the opinion of Flowr to satisfy all obligations for the payment of such withholding and taxes. |
18
3. |
Amendment of Schedule |
3.1 |
Notwithstanding Section 6.2 of the Plan, the Board shall retain the power and authority to amend or modify this schedule to the extent the Board in its sole discretion deems necessary or advisable to comply with any guidance issued under Section 409A. Such amendments may be made without the approval of any US Taxpayer. |
19
APPENDIX "D" REGISTERED OFFICE RESOLUTION
SPECIAL RESOLUTION OF THE SHAREHOLDERS OF
THE FLOWR
CORPORATION
TO APPROVE CHANGING THE PLACE OF THE REGISTERED OFFICE OF THE CORPORATION
BE IT RESOLVED AS AN SPECIAL RESOLUTION OF THE SHAREHOLDERS THAT:
1. |
the articles of The Flowr Corporation (the "Corporation") be and they are hereby amended to change the place in which the registered office of the Corporation is situated from 201-100 Allstate Pkwy, Markham, Ontario, L3R 6H3 to 461 King Street West, Floor 2, Toronto, Ontario M5V 1K4; |
2. |
any one director or officer be and is hereby authorized to send to the Director appointed under the OBCA articles of amendment of the Corporation in the prescribed form, and any one or more directors are hereby authorized to prepare, execute and file articles of amendment in the prescribed form in order to give effect to this special resolution, and to execute and deliver all such other deeds, documents and other writings and perform such other acts as may be necessary or desirable to give effect to this special resolution; |
3. |
notwithstanding the foregoing, the Directors of the Corporation are hereby authorized, without further approval of or notice, to revoke this special resolution; and |
4. |
any acts taken prior to the effective date of this resolution by any Director or officer of the Corporation in connection with the foregoing resolutions or the subject matter thereof are hereby approved, ratified, sanctioned and confirmed. |
APPENDIX "E" AUDIT COMMITTEE CHARTER |
THE FLOWR CORPORATION
Audit Committee Charter
Audit Committee Charter
THE FLOWR CORPORATION |
AUDIT COMMITTEE CHARTER |
1. Purpose
The Audit Committee (the "Committee") is a standing committee of the Board of Directors (the "Board") of The Flowr Corporation (the "Corporation") appointed as required by (i) National Instrument 52-110 - Audit Committees ("NI 52-110") (ii) Rule 5605 of the NASDAQ Stock Market Rules (including Rule 5605(c)(2)(A)) ("Rule 5605"); and (iii) Rule 10A-3 of the United States Securities Exchange Act of 1934, as amended ("Rule 10A-3"). The purpose of the Committee is to oversee the accounting and financial reporting processes of the Corporation and the audits of the financial statements of the Company, and to assist the Board in fulfilling its oversight responsibilities for (i) the integrity of the Corporations financial statements, (ii) the process for identifying the Corporations principal financial risks and the control systems in place to monitor them; (iii) the Corporations compliance with legal and regulatory requirements, and (iv) the qualifications and independence of the auditor of the Corporation (the "external auditor").
2. Authority
The Committee has authority to conduct or authorize investigations into any matter within its scope of responsibility. It is empowered to:
(a) |
Recommend to the Board the public accounting firm to be nominated for appointment by the Corporations shareholders as the independent external auditor |
(b) |
Be directly responsible for the appointment, compensation, retention and oversight of the work of the external auditor engaged for the purpose of preparing or issuing an auditors report or performing other audit, review or attest services for the Corporation, subject to the appointment of the Corporations external auditor by the Corporations shareholders, as described above.. The external auditor will report directly to the Committee. |
(c) |
Resolve any disagreements between management and the external auditor regarding financial reporting. |
(d) |
Pre-approve permitted non-audit services performed by the Corporations external auditor. |
(e) |
Retain independent counsel, accountants, or others to advise the Committee or assist in its duties and to set and pay their applicable compensation. |
(f) |
Meet with the Corporations officers, external auditor or outside counsel, as necessary and communicate directly with the Corporations shareholders. |
(g) |
Delegate authority, to the extent permitted by applicable law, to one or more designated members of the Committee, including the authority to pre-approve all permitted non-audit services, provided that such decisions are reported to the full Committee at its next scheduled meeting. |
(h) |
Take such other actions as are authorized by this Charter or by other Corporation policies approved by the Board. |
Audit Committee Charter |
3. Composition
(a) |
The Committee must consist of at least three directors, as determined by resolution of the Board from time to time. |
(b) |
No member of the Committee can have participated in the preparation of the Corporations or any of its subsidiaries financial statements at any time during the past three years. |
(c) |
The Board, or any committee delegated by the Board, will recommend to the Board applicable directors for appointment to the Committee and the Chair of the Committee. |
(d) |
If and whenever a vacancy exists on the Committee, the remaining members may exercise all of its powers so long as there continue to be at least three members on the Committee. If at any time a vacancy exists on the Committee that the Board is required to fill, the Board may appoint a new member to fill such vacancy by ordinary resolution of the Board. |
(e) |
Subject to the exemptions contemplated by NI 52-110, Rule 10A-3 and Rule 5605, each member of the Committee shall be independent, pursuant to the requirements of NI 52-110, Rule 10A-3 and Rule 5605. |
(f) |
Each Committee member must be financially literate as defined in NI 52-110 and must be able to read and understand fundamental financial statements, including a companys balance sheet, income statement, and cash flow statement. |
(g) |
At least one member of the Committee must be an "audit committee financial expert" under Item 407 of Regulation S-K or otherwise have past employment experience in finance or accounting, requisite professional certification in accounting or other comparable experience or background which results in the individuals financial sophistication. |
(h) |
The Board or the Committee may, from time to time, establish policies limiting the number of committees which Committee members may be appointed to. |
4. Meetings
(a) |
The Committee must meet at least four times per year, and at least annually, privately, with each of management and the external auditor. |
(b) |
The greater of two members or 50% of the members of the Committee shall constitute a quorum. All resolutions of the Committee shall be made by a majority of its members present at a meeting duly called and held. All Committee members are expected to attend each meeting, in person or by telephone or video conference. Any decision or determination of the Committee reduced to writing and signed by all of the members of the Committee shall be fully as effective as if it had been made at a meeting duly called and held. |
(c) |
The Committee may invite such officers, directors and employees of the Corporation as it deems necessary or advisable from time to time to attend meetings of the Committee and assist in the discussion and consideration of the duties of the Committee. |
Audit Committee Charter |
(d) |
The time at which and place where the meetings of the Committee shall be held and the calling of meetings and the procedure in all things at such meetings shall be determined by the Committee. Following a Committee meeting, the Committee Chair shall report on the Committees activities to the Board at the next Board meeting. The Committee must keep and approve minutes of its meetings in which shall be recorded all action taken by it, which minutes must be made available to the Board as soon as practicable after each meeting of the Committee. |
5. Responsibilities
The Committee must:
(a) |
Review significant accounting and reporting issues and understand their impact on the financial statements, including but not limited to: | |
(i) |
complex or unusual transactions and highly judgmental areas; | |
(ii) |
major issues regarding accounting principles and financial statement presentation, including any significant changes in the Corporations selection or application of accounting principles; | |
(iii) |
any significant variances with comparative reporting periods; and | |
(iv) |
the effect of regulatory and accounting initiatives, as well as off-balance sheet structures, on the financial statements of the Corporation. | |
(b) |
Review analyses prepared by management and/or the external auditor relating to significant financial reporting issues and judgments made in connection with the preparation of the financial statements, including analyses of the effects of the selection or application of the Corporations accounting principles. | |
(c) |
Review compliance with covenants under any loan agreements. | |
(d) |
Review disclosure requirements for commitments and contingencies. | |
(e) |
Review with management and the external auditor the results of the audit, including any difficulties encountered. This review will include any restrictions on the scope of the external auditors activities or on access to requested information, any significant disagreements with management, and adjustments raised by external auditors, whether or not included in the financial reports. | |
(f) |
Review and discuss the annual audited financial statements and quarterly financial statements with management and the external auditor, including the Corporations disclosures under "Managements Discussion and Analysis of Financial Condition and Results of Operations" ("MD&A"), including the discussion of critical accounting estimates included therein. | |
(g) |
Review and recommend to the Board for approval, prior to public disclosure, the annual and quarterly financial statements, MD&A and annual and interim profit or loss press releases. | |
(h) |
Review disclosures made by the Chief Executive Officer and the Chief Financial Officer during the certification process about significant deficiencies or material weakness in the design or operation of internal controls or any fraud that involves management or other employees who have a significant role in the Corporations internal controls and, if applicable, understand the basis upon which the certifying officers concluded that any particular deficiency or combination of deficiencies did or did not constitute a material weakness. |
Audit Committee Charter |
(i) |
Review and recommend to the Board for approval, prior to public disclosure, financial information and earnings guidance provided externally, including to analysts and rating agencies if applicable. This review may be general (i.e., the types of information to be disclosed and the type of presentations to be made). |
(j) |
Satisfy itself that adequate procedures are in place, and periodically assess the adequacy of those procedures, for the review of any public disclosure of financial information extracted or derived from the financial statements, other than the statements themselves, the MD&A or the press releases referred to above. |
(k) |
Review and oversee all related party transactions for potential conflict of interest situations on an ongoing basis. The term "related party transactions" shall refer to transactions that would be required to be disclosed to the U.S. Securities and Exchange Commission pursuant to Form 20-F, Item 7.B., notwithstanding that the Corporation may file its annual reports on a different form. |
(l) |
Annually review and assess the Corporations policies in effect from time to time, including its Timely Disclosure, Confidentiality and Insider Trading Policy and make recommendations to the Board. |
6. Internal Control
The Committee shall also:
(a) |
Consider the effectiveness of the Corporations system for internal control over financial reporting, including information technology security and control. |
(b) |
Review the scope of the external auditors review of internal control over financial reporting, and obtain reports on significant findings and recommendations, together with managements responses. |
(c) |
Review the external auditors management letters and managements responses to such letters. |
(d) |
As requested by the Board, discuss with management and the external auditor the Corporations identifiable risks arising from any financial, operational or other deficiencies, the adequacy and effectiveness of the Corporations accounting and financial controls relating thereto, and the steps management has taken to monitor and control identified risks. |
(e) |
Annually review the Corporations disclosure controls and procedures, including any significant deficiencies in, or material non-compliance with same, and the steps management has taken to monitor and control such deficiencies or instances of non-compliance. |
7. External Audit
The Committee shall also:
(a) |
Review the external auditors proposed audit scope and approach. |
Audit Committee Charter |
(b) |
Review the performance of the external auditor. Annually review the report of the external auditor on matters required to be communicated to the Committee under Section 5135 (auditors responsibility to consider fraud) and Section 5751 (communications with those having oversight responsibility for the financial reporting process-independence) of the Canadian Institute of Chartered Accountants handbook and Rule 5605(c) (ensuring independence of external auditor). | |
(c) |
Report any conclusions with respect to the external auditor to the Board. | |
(d) |
Establish and periodically assess the Corporations hiring policies for partners, employees and former partners and employees of the current or prior external auditor. | |
(e) |
At least once per year, meet privately with the external auditor to discuss any matters that the Committee or the external auditor believes should be discussed privately. | |
(f) |
Review and pre-approve, in accordance with NI 52-110 and Rule 2-01(c)(7) of Regulation S-X, any non-audit services, provided by the Corporations external auditor, taking into consideration whether the delivery of non-audit services will interfere with the independence of the auditors. The pre-approval of non-audit services may be further delegated to one or more independent members of the Committee, provided that said pre-approval is presented to the Committee at its first scheduled meeting following such approval. The pre-approval requirement is satisfied with respect to the provision of de minimis non-audit services if: | |
(i) |
the aggregate amount of all such non-audit services provided to the Corporation which were not pre-approved constitutes not more than 5% of the total amount of fees paid by the Corporation and its subsidiaries to the external auditor during the fiscal year in which the non-audit services are provided; | |
(ii) |
the services were not recognized by the Corporation or its subsidiaries, at the time of the engagement, to be non-audit services; and | |
(iii) |
the services are promptly brought to the attention of the Committee and approved, prior to the completion of the audit, by the Committee or by one or more members of the Committee to whom authority to grant such approvals has been delegated by the Committee. | |
(g) |
The Committee may from time to time establish specific pre-approval policies and procedures in accordance with NI 52-110. | |
(h) |
The Committee shall be responsible for assuring the regular rotation of the lead audit partner of Companys external auditor and considering regular rotation of the accounting firm serving as Companys external auditor. | |
(i) |
The Committee shall be responsible for obtaining and reviewing on a periodic basis, and at least annually, a formal written statement from the external auditor delineating all relationships between the external auditor and Company. The Committee is responsible for discussing with the external auditor any disclosed relationships or services that may impact the objectivity and independence of the external auditor and for taking or recommending that the Board take appropriate action in response to the external auditors report to satisfy itself of the external auditors independence. |
Audit Committee Charter |
8. Compliance
The Committee shall also:
(a) |
Annually review the effectiveness of the Corporations system of monitoring compliance with laws and regulations and the results of managements investigation and follow-up (including disciplinary action) of any instances of non- compliance. |
(b) |
Establish and periodically assess the adequacy of procedures for: (i) the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls, or auditing matters; and (ii) the confidential, anonymous submission by employees regarding questionable accounting or auditing matters. |
(c) |
Review findings of any examinations by regulatory agencies, and any external auditors observations made regarding those findings. |
(d) |
Review the process for communicating the Code of Business Conduct and Ethics to Corporation personnel, and for monitoring compliance therewith. |
9. Reporting Responsibilities
The Committee shall also:
(a) |
Report to the Board about Committee activities and issues that arise with respect to the quality or integrity of the Corporations financial statements, the Corporations compliance with legal or regulatory requirements, the performance and independence of the Corporations external auditor and internal controls over financial reporting. |
(b) |
Review any other reports the Corporation issues that relate to Committee responsibilities. |
(c) |
Liaise with the external auditor and the Board to ensure that any material issues that have arisen related to compliance and governance have been addressed and that appropriate actions have been identified and undertaken to mitigate the issues identified. |
(d) |
The Committee shall at least annually evaluate its own performance and the contents of this Charter, and recommend to the Board such changes to the Charter as the Committee deems appropriate. |
10. Other responsibilities
The Committee shall also:
(a) |
Discuss with management the Corporations major polices with respect to risk assessment and risk management. |
(b) |
Perform other activities related to this Charter as requested by the Board. |
Audit Committee Charter |
(c) |
Institute and oversee special investigations as required with respect to the discharge of the Committees duties hereunder. |
(d) |
Ensure appropriate disclosure of this Charter as may be required by applicable law. |
11. Funding
The Corporation shall provide for appropriate funding, as determined by the Committee, for payment of:
(a) |
Compensation to the external auditor; |
(b) |
Compensation to any counsel and advisers employed by the Committee pursuant to the terms of this Charter; and |
(c) |
Ordinary administrative expenses of Committee that are necessary or appropriate in carrying out its duties. |
Flowr Receives NASDAQ Listing Approval
Toronto, Ontario May 23, 2019 The Flowr Corporation (TSXV: FLWR; OTC: FLWPF) ("Flowr" or the "Company"), a Canadian Licensed Producer with an expanding global cannabis production platform, is pleased to announce that the Nasdaq Stock Market ("Nasdaq") has approved the Companys application to have its common shares listed on the Nasdaq Capital Market. A trading date will be announced by the Company upon the Companys Form 40-F registration statement becoming effective with the United States Securities and Exchange Commission. The common shares will be listed on the Nasdaq under the symbol "FLWR". The Company's common shares listed on the TSX Venture Exchange will continue to trade under the symbol FLWR.
"We have made tremendous progress against our strategic priorities in 2019, and the approval of our listing on the Nasdaq further enhances our capital markets objectives. This listing provides us with broader access to investors around the world and is a natural progression for Flowr," commented Vinay Tolia, Chief Executive Officer of Flowr. "Later this year we expect to complete construction of our purpose-built indoor cannabis facility, Kelowna 1, which will position us to pursue further expansion at our Kelowna Campus, while at the same time advancing our global plans through our announced partnership with Holigen Holdings Limited."
About The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and sales license granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own growing systems. Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.
For more information, visit flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of The Flowr Corporation:
Vinay Tolia
CEO and Director
CONTACT INFORMATION: |
MEDIA: |
Sean Griffin |
Vice President, Communications & Public Relations |
(877) 356-9726 ext. 1526 |
sean.griffin@flowr.ca |
INVESTORS: |
Thierry Elmaleh |
Head of Capital Markets |
(877) 356-9726 ext. 1528 |
thierry@flowr.ca |
Forward-Looking Information
This press release includes forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities laws regarding Flowr and its business, which may include, but are not limited to: Flowr expanding its global cannabis production platform, statements with respect to Holigen, including the closing of the acquisition of a 19.8% interest in Holigen, the completion of the Kelowna 1 facility enabling Flowr to begin to capitalize on strategic growth opportunities, the completion of Kelowna 1 positioning Flowr to pursue further expansion of its Kelowna Campus, the completion and timing of completion of the Kelowna 1 facility, the additional grow rooms that will become available upon completion of the Kelowna 1 facility, the listing of the Companys common shares on the NASDAQ, the timing thereof, the trading of the common shares being approved for listing, the approval of the Form 40-F registration statement by the United States Securities and Exchange Commission and the timing for such approval, Flowrs strategic priorities for 2019 and progress with respect thereto, Flowr further enhancing its capital market objectives, Flowr having broader access to investors, Flowr being well positioned to complete its facilities build-out and ramp-up production in 2019 and capitalize on its strategic growth opportunities globally, Flowrs investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeal to the adult-use recreational market and address specific patient needs in the medicinal market and other factors. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of Flowrs management and are based on assumptions and subject to risks and uncertainties. Although Flowrs management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including, but not limited to, Flowr being unable to expand its global cannabis production platform, Flowr being delayed in closing the acquisition of a 19.8% interest in Holigen or such acquisition not being completed, Flowrs operational efficiency not improving as a result of the completion of the Kelowna 1 facility, the completion of the Kelowna 1 facility not allowing Flowr to begin to capitalize on strategic growth opportunities, Flowr not achieving or producing the number of kilograms of capacity on an annualized basis as expected, which could have a material adverse effect on Flowrs business, financial condition and results of operations, Flowr not being able to or being delayed in selling a wide selection of cannabis cultivars in both seed and clone form in 2019, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the Companys cultivation process not enabling it to produce high quality clones, Flowr not being able to produce the number of clones expected or at all on annualized basis upon completion of the Kelowna 1 facility, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the clones that Flowr produces not being incremental to the Companys cultivation process and in excess of what it needs for its retail and medical production, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the Kelowna 1 facility not being completed or completed in time, the additional grow rooms that will become available upon completion of the Kelowna 1 facility not becoming available on time or at all, which could have a material adverse impact on Flowrs business, financial condition and results of operations, the listing of the Companys common shares on the NASDAQ being delayed, which could impact the liquidity of the Companys common shares or cause a significant decline in the price of the common shares, the SEC not bringing the Form 40-F registration statement effective, Flowr being unable to achieve its strategic priorities for 2019, the listing of the Companys common shares on NASDAQ not enhancing Flowrs capital market objectives and/or not providing greater access to investors, , Flowr not being able to execute on growth strategies, including international opportunities, which could adversely impact Flowrs growth and future prospects, Flowr not being able to sustain its competitive advantage in cultivation and being unable to remain at the forefront of industry innovation, whether as a result of failed construction of the facilities or otherwise, Flowr not being able to meet demand or fulfill purchase orders, which could materially impact revenues and its relationships with purchasers, Flowr requiring additional financing from time to time in order to continue its operations or expand domestically or globally and such financing not being available when needed or on terms and conditions acceptable to the Company, new laws or regulations adversely affecting the Companys business and results of operations, results of operation activities and development of projects, project cost overruns or unanticipated costs and expenses, the inability of Flowrs products to be high quality, the inability of Flowrs products to appeal to the adult-use recreational market and address specific patient needs in the medicinal market, the inability of Flowr to produce and distribute premium, high quality products, the inability to supply products or any delay in such supply, Flowrs securities, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, risks associated with the geographic markets in which Flowr operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Flowrs products to treat certain conditions, the cannabis industry and the regulation thereof, the failure to comply with applicable laws, risks relating to partnership arrangements (including the Hawthorne and Holigen partnerships), possible failure to realize the anticipated benefits of partnership arrangements (including the Hawthorne and Holigen partnerships), product launches (including, without limitation, unsuccessful product launches), the inability to launch products, the failure to obtain regulatory approvals, economic factors, market conditions, risks associated with the acquisition and/or launch of products, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Flowrs products), general economic and stock market conditions, risks and uncertainties detailed from time to time in Flowrs filings with the Canadian Securities Administrators and many other factors beyond the control of Flowr. Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
WK6M
M%JMG+;I,DC8=S&J&-@Y<9RNTC.>#VK*72;X+:QE8=MOJ+W60YRR$N?3K\X_(
MT3Z3?L6F2*V=X[MYDBE;*2(RX()QP?SH W+:YBNX!- ^Y"2,X(((.""#T((K
M%M-5N;^>2*&YBBNX;G9+:2)@B(/U&>22G.>16Q91/%; 2111,3DQQ?=7V!P,
M_7%95YIEQJ'V8W$$,=U!,KK=(V650V<#C.2.".G- &F=0MEG6$R' E:C_ &A SR(D4BRR1[ ^[.UBN>@]/2@"_1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C$*I)S@#/ S2T
M4 <]X=L%>WCGF2ZBF@N9G59-Z##,X'RGCHW7%1E)V+2"WG:&+4FEFC:)@73:
M<, 1\P!P>,]*WY+J&*>&!Y ))B1&O]X@$G] :FH YJ2QGELM2GMX64+Z8QPR
MI&P,1 B8@8&<<@Y!STYJ2'5K*:.XD65@+=@LH>-E*D\C@C)SD8]:S;S2[V;^
MTMB1?Z5W,T%]%;L[1'#
MI)M(.,\$;N?IVH Z*BHK=9E@1;B19)0/F9%V@GZ9.*Q1K5Q'>*)0DD#03RGR
MT/6,CA3_ !<'GCKTH WZ*PY=5NK?2AJ
=G60&X96D"RL Q&,< X[#ZX%5U\1V8MIY[B.>W6%48B1.6#CY=
MN,YSTQVJ[8ZA#?>
6$US%=>6UJZJ
M<#:!\I/5,,,Y]Z2W@
@##U
M%)3K.^&%YL20AX9(258 Y#H^/E*DY(SV]Z9I]N3>B*[L[K[5#<22"4C]VRL6
M^;=W^4XVGV_#I*C,T8+ N,I@-[$]!]?;W% ',0P%+72BVGS?Z->.)1Y'/*R
M''<9*\]*;=6N^"_C-E,P;58I4 MVP5_=[F''3AN:ZJ66.%0TKJBE@H+'').
M/Q)I] '(W'5EAMYXHC>P/"B0, ^!'G QR,J6SAC6[MC- ZREL$*&PPP/7MZ4 ;P P!VJ-8(5?>L48;.[(49SZUB0Z
MO>0Z'9W,L<4DDEIYQ8MC<=JD+@9.3DG.,#%32ZQ=M.\=K:1/MM$N@7E(R&W<
M<#K\OZT 7-8L7U&Q-LDB)F1')9=P(5@V,9]JLQ0QQ0B)8XU3&"JKA?RK-BUE
M[P8L+<2R"VCN=KOMR'SA0?7@\_2E;5YWN9H[:R>58)EBDYYR0I)';@,._.#0
M!?-G;%$0VT.U/N#8,+]/2G"WA$IE$,?F'@OM&3^-0ZHBOI=TK $>4Q_0USNE
MM/;P:=?JDL-E!IWFWCL.N.
&!F&0I).!
MD]NG)_(U'8:NGVB6VNYP9OM+PIMC..,$ D< X]3S0 B^'H(C;M!=74+PPK;E
MD< R1KT#<8_$ &I?[%@6]:XAFGA63'FPQM^[DP !D8XX '&,U974;1KA8%F!
M=F*+P=K,,Y4-T)QG/%5]3OY8;JTL;4+]INRV'896-5&68COV 'O0!=N81<
MV\D)=D$BE2RXS@_4&HK:PBM]-2P+-+"D0B_>8R5QC!P!VJG)>W%AJEK:W+":
M"Z#!) F&1U&<$#J",XX[=\UFR^(I3:SWD9F5([@P>4UG(0
G(Y/7GWJ6/1UB@6%+N?
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MMM)]I:X>6>6YB,+RR$;@AS\JX '/8?7-0MX>ADBN$FN[J4W%N+=V8J/E&<'
M@#GYC4MCK=M>132@2QK'*8OGB8;CDCCCDY!X&2.]7K>YBN4+0N& .UAT*GT(
M/(/L: *#Z)&;H7*7=U'*4"3,K@>E5_[1M?M2
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MP>Q-16NN:=>'$-RI_=>;\RE